{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "article 27953647  not found.\n",
      "article 27948541  not found.\n",
      "article 27943881  not found.\n",
      "article 27949797  not found.\n",
      "article 27955116  not found.\n",
      "article 27950623  not found.\n",
      "article 27945102  not found.\n",
      "clinical trial NCT02659670  not found.\n",
      "article 27198327  not found.\n"
     ]
    }
   ],
   "source": [
    "import articles.article_fetch as article_fetch\n",
    "import articles.articles_info as article_info\n",
    "from articles import article\n",
    "\n",
    "import clinical_trials.clinical_trial_fetch as ct_fetch\n",
    "import clinical_trials.clinical_trials_info as ct_info\n",
    "from clinical_trials import clinical_trial\n",
    "\n",
    "import csv\n",
    "import csv_data.csv as csv_data\n",
    "\n",
    "from dataframe import create_dataframe\n",
    "from dataframe import calculate_attributes\n",
    "\n",
    "from common_functions import common_functions\n",
    "\n",
    "import pandas as pd\n",
    "\n",
    "import importlib\n",
    "\n",
    "# I get the gold standard\n",
    "gold_standard = pd.read_csv('ClinicalPmidsALL.csv', encoding = 'ISO-8859-1', sep = ';')\n",
    "\n",
    "# Now I change the common answer from string to numerical\n",
    "csv_data.numerical_answers(gold_standard)\n",
    "\n",
    "# Let's correct data on csv (common answer sometimes is not correct)\n",
    "csv_data.correctData(gold_standard)\n",
    "\n",
    "# I get all the clinical trials ID and I get the articles in xml\n",
    "Clinical_trials = ct_fetch.get_xml_doms(gold_standard['CT'].tolist())\n",
    "\n",
    "# I get all the PMID and I get the articles in xml\n",
    "PubMed_id_string = list(map(str, gold_standard['PMID'].tolist())) # I get the PMID as list of strings\n",
    "PubMed_articles = article_fetch.fetch_many_articles(PubMed_id_string, local=True) # It takes time to fetch the articles\n",
    "\n",
    "# Let's map every clinical trial to every article (and remove the one that are not present) and common answer\n",
    "df = create_dataframe.get_base_dataframe(gold_standard, Clinical_trials, PubMed_articles)\n",
    "\n",
    "# standard, spacy or stanford\n",
    "ct_org_sample = 'standard'\n",
    "ar_org_sample = 'spacy'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "#lam = gold_standard['CT']\n",
    "#lam.index[lam == 'NCT00003204'].tolist()[0]\n",
    "\n",
    "ct_last_names, ct_first_name_initials, ct_first_names = ct_info.get_all_name_parts(df['CT'].tolist(), gold_standard)\n",
    "\n",
    "df['ct_last_name'], df['ct_first_name_initial'], df['ct_first_name'] = [ct_last_names, ct_first_name_initials, ct_first_names]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# print(sum(x is not None for x in ct_last_names))\n",
    "df = df.dropna().reset_index(drop = True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "ar_last_names, ar_first_name_initials, ar_first_names = article_info.get_all_name_parts(df['PubMed'].tolist(), gold_standard)\n",
    "\n",
    "df['ar_last_name'], df['ar_first_name_initial'], df['ar_first_name'] = [ar_last_names, ar_first_name_initials, ar_first_names]\n",
    "df.dropna().reset_index(drop = True)\n",
    "print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT00730210 doesn't have an organization.\n",
      "NCT02220283 doesn't have an organization.\n"
     ]
    }
   ],
   "source": [
    "# now that we have the base information, let's add other attributes\n",
    "\n",
    "# we get the organization of the principal investigator, so we don't need to pass his/her name\n",
    "ct_organization_names = ct_info.get_all_organization_names(df['CT'].tolist(), df['ct_last_name'].tolist(),\n",
    "                                                           df['ct_first_name_initial'].tolist(),\n",
    "                                                           sample=ct_org_sample)\n",
    "\n",
    "# Now we insert it in the dataframe\n",
    "if('ct_organization' not in df):\n",
    "    df.insert(6, 'ct_organization', ct_organization_names)\n",
    "    \n",
    "\n",
    "# I get the e-mails\n",
    "ct_mails = ct_info.get_all_mails(df['CT'].tolist(), df['ct_last_name'].tolist(), df['ct_first_name_initial'].tolist())\n",
    "\n",
    "if('ct_mail' not in df):\n",
    "    df.insert(7, 'ct_mail', ct_mails)\n",
    "    \n",
    "# I get the year\n",
    "ct_years = ct_info.get_all_years(df['CT'].tolist())\n",
    "    \n",
    "if('ct_year' not in df):\n",
    "    df.insert(8, 'ct_year', ct_years)\n",
    "    \n",
    "# I get the initials of the name\n",
    "ct_initials = ct_info.get_all_initials(df['ct_first_name'].tolist())\n",
    "\n",
    "if('ct_initials' not in df):\n",
    "    df.insert(9, 'ct_initials', ct_initials)\n",
    "    \n",
    "# I get the title\n",
    "ct_titles = ct_info.get_all_titles(df['CT'].tolist())\n",
    "\n",
    "if('ct_title' not in df):\n",
    "    df.insert(10, 'ct_title', ct_titles)\n",
    "    \n",
    "# I get the country and the city\n",
    "ct_countries, ct_cities = ct_info.get_all_countries_and_cities(df['CT'].tolist())\n",
    "\n",
    "if('ct_country' not in df):\n",
    "    df.insert(11, 'ct_country', ct_countries)\n",
    "    \n",
    "if('ct_city' not in df):\n",
    "    df.insert(12, 'ct_city', ct_cities)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "267\n"
     ]
    }
   ],
   "source": [
    "print(sum(x is not None for x in df['ct_mail']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "475\n",
      "126\n"
     ]
    }
   ],
   "source": [
    "# Let's add the same attributes for the articles\n",
    "\n",
    "ar_organization_names, ar_locations = article_info.get_all_organizations_locations(df['PubMed'].tolist(),\n",
    "                                                           df['ar_last_name'].tolist(),\n",
    "                                                           df['ar_first_name_initial'].tolist(),\n",
    "                                                           sample = ar_org_sample)\n",
    "df['ar_organization'] = ar_organization_names\n",
    "\n",
    "ar_mails = article_info.get_all_mails(df['PubMed'].tolist(), df['ar_last_name'].tolist(),\n",
    "                                      df['ar_first_name_initial'].tolist())\n",
    "df['ar_mail'] = ar_mails\n",
    "\n",
    "ar_years = article_info.get_all_years(df['PubMed'].tolist())\n",
    "\n",
    "df['ar_year'] = ar_years\n",
    "\n",
    "ar_initials = article_info.get_all_initials(df['ar_first_name'])\n",
    "\n",
    "df['ar_initials'] = ar_initials\n",
    "\n",
    "ar_titles = article_info.get_all_titles(df['PubMed'].tolist())\n",
    "\n",
    "df['ar_title'] = ar_titles\n",
    "df['ar_location'] = ar_locations\n",
    "\n",
    "print(sum(x is not None for x in ar_organization_names))\n",
    "print(sum(x is not None for x in ar_mails))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# I now calculate useful attributes for the classifiers\n",
    "first_name_equalities = calculate_attributes.get_string_arrays_similarity(df['ct_first_name'].tolist(),\n",
    "                                                                          df['ar_first_name'].tolist())\n",
    "organization_similarities, organization_type_equalities = calculate_attributes.get_organization_similarity_and_type_equality(df['ct_organization'].tolist(),\n",
    "                                                                             df['ar_organization'].tolist(),\n",
    "                                                                             ct_org_sample, ar_org_sample)\n",
    "email_equalities = calculate_attributes.get_arrays_equality(df['ct_mail'].tolist(), df['ar_mail'].tolist())\n",
    "year_differences = calculate_attributes.get_year_differences(df['ct_year'].tolist(), df['ar_year'].tolist())\n",
    "last_name_lengths = calculate_attributes.get_last_name_lengths(df['ct_last_name'].tolist())\n",
    "initials_equality = calculate_attributes.get_arrays_equality(df['ct_initials'].tolist(), df['ar_initials'].tolist())\n",
    "namespace_sizes = calculate_attributes.get_namespace_ambiguities(df['ct_last_name'].tolist(),\n",
    "                                                                 df['ct_first_name_initial'].tolist())\n",
    "country_equalities, city_equalities = calculate_attributes.get_location_equalities(df['ct_country'].tolist(),\n",
    "                                                                                   df['ct_city'].tolist(),\n",
    "                                                                                   df['ar_location'].tolist())\n",
    "jds_similarities, sts_similarities = calculate_attributes.get_all_jds_sts_similarities(df['CT'].tolist(),\n",
    "                                                                    df['PubMed'].tolist(), 4, 52,\n",
    "                                                                    'percentage_ranking')\n",
    "\n",
    "# Let's add the attributes to the data frame\n",
    "df['first_name_equality'], df['organization_similarity'] = [first_name_equalities, organization_similarities]\n",
    "df['email_equality'], df['year_difference'] = [email_equalities, year_differences]\n",
    "df['last_name_length'], df['initials_equality'] = [last_name_lengths, initials_equality]\n",
    "df['namespace_size'], df ['country_equality'] = [namespace_sizes, country_equalities]\n",
    "df['city_equality'], df['organization_type_equality'] = [city_equalities, organization_type_equalities]\n",
    "df['jds_similarity'], df['sts_similarity'] = [jds_similarities, sts_similarities]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"\\nimport numpy as np\\n\\nnp_array = np.array(df['namespace_size'].tolist())\\nstd = np_array.std()\\nmean = np_array.mean()\\nfor i in range(len(np_array)):\\n    np_array[i] = (np_array[i] - mean)/std\\n    \\ndf['namespace_size'] = np_array.tolist()\\n\\nnp_array = np.array(df['last_name_length'].tolist())\\nstd = np_array.std()\\nmean = np_array.mean()\\nfor i in range(len(np_array)):\\n    np_array[i] = (np_array[i] - mean)/std\\n    \\ndf['last_name_length'] = np_array.tolist()\\n\\nnp_array = np.array(df['year_difference'].tolist())\\nstd = np_array.std()\\nmean = np_array.mean()\\nfor i in range(len(np_array)):\\n    np_array[i] = (np_array[i] - mean)/std\\n    \\ndf['year_difference'] = np_array.tolist()\\n\""
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Now let's normalize and/or standardize the attributes that need this\n",
    "df['namespace_size'] = common_functions.normalize(df['namespace_size'])\n",
    "df['last_name_length'] = common_functions.normalize(df['last_name_length'])\n",
    "df['year_difference'] = common_functions.normalize(df['year_difference'])\n",
    "\n",
    "'''\n",
    "import numpy as np\n",
    "\n",
    "np_array = np.array(df['namespace_size'].tolist())\n",
    "std = np_array.std()\n",
    "mean = np_array.mean()\n",
    "for i in range(len(np_array)):\n",
    "    np_array[i] = (np_array[i] - mean)/std\n",
    "    \n",
    "df['namespace_size'] = np_array.tolist()\n",
    "\n",
    "np_array = np.array(df['last_name_length'].tolist())\n",
    "std = np_array.std()\n",
    "mean = np_array.mean()\n",
    "for i in range(len(np_array)):\n",
    "    np_array[i] = (np_array[i] - mean)/std\n",
    "    \n",
    "df['last_name_length'] = np_array.tolist()\n",
    "\n",
    "np_array = np.array(df['year_difference'].tolist())\n",
    "std = np_array.std()\n",
    "mean = np_array.mean()\n",
    "for i in range(len(np_array)):\n",
    "    np_array[i] = (np_array[i] - mean)/std\n",
    "    \n",
    "df['year_difference'] = np_array.tolist()\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Now we delete the ones we don't need in the classifier\n",
    "df_to_save = df.drop(['CT', 'PubMed', 'ct_last_name', 'ct_first_name_initial', 'ct_first_name',\n",
    "              'ct_organization', 'ct_mail', 'ct_year', 'ct_initials', 'ct_title', 'ct_country', 'ct_city', \n",
    "                'ar_last_name','ar_first_name_initial','ar_first_name','ar_organization', 'ar_mail', 'ar_initials',\n",
    "                      'ar_year', 'ar_title', 'ar_location'], axis = 1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Writing the dataframe to file\n",
    "import csv\n",
    "import codecs\n",
    "csv = df_to_save.to_csv(index=False)\n",
    "\n",
    "file = codecs.open(\"dataframe.csv\", \"w\", \"utf-8\")\n",
    "file.write(csv)\n",
    "file.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<module 'common_functions.common_functions' from 'C:\\\\Users\\\\Brescia\\\\Anaconda3\\\\Diploma\\\\common_functions\\\\common_functions.py'>"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "importlib.reload(article_info)\n",
    "importlib.reload(ct_info)\n",
    "importlib.reload(calculate_attributes)\n",
    "importlib.reload(clinical_trial)\n",
    "importlib.reload(common_functions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "CT                            <clinical_trials.clinical_trial.ClinicalTrial ...\n",
       "PubMed                        <articles.article.Article object at 0x0000014F...\n",
       "common_answer                                                                 0\n",
       "ct_last_name                                                               saba\n",
       "ct_first_name_initial                                                         s\n",
       "ct_first_name                                                           samir f\n",
       "ct_organization                                        University of Pittsburgh\n",
       "ct_mail                                                                    None\n",
       "ct_year                                                                    2005\n",
       "ct_initials                                                                  sf\n",
       "ct_title                          Genetic Predictors of Outcome in HCM Patients\n",
       "ct_country                                                      [United States]\n",
       "ct_city                                                            [Pittsburgh]\n",
       "ar_last_name                                                               saba\n",
       "ar_first_name_initial                                                         s\n",
       "ar_first_name                                                               s m\n",
       "ar_organization                              [Fakultät für Physik & Astronomie]\n",
       "ar_mail                                                                    None\n",
       "ar_year                                                                    2014\n",
       "ar_initials                                                                  sm\n",
       "ar_title                      Observation of high-energy astrophysical neutr...\n",
       "ar_location                                                   [Bochum, Germany]\n",
       "first_name_equality                                                    0.285714\n",
       "organization_similarity                                                   0.125\n",
       "email_equality                                                                0\n",
       "year_difference                                                        0.136364\n",
       "last_name_length                                                       0.117647\n",
       "initials_equality                                                             0\n",
       "namespace_size                                                       0.00421281\n",
       "country_equality                                                              0\n",
       "city_equality                                                                 0\n",
       "organization_type_equality                                                    0\n",
       "jds_similarity                                                                0\n",
       "sts_similarity                                                        0.0307845\n",
       "Name: 40, dtype: object"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.iloc[40]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CT</th>\n",
       "      <th>PubMed</th>\n",
       "      <th>common_answer</th>\n",
       "      <th>ct_last_name</th>\n",
       "      <th>ct_first_name_initial</th>\n",
       "      <th>ct_first_name</th>\n",
       "      <th>ct_organization</th>\n",
       "      <th>ct_mail</th>\n",
       "      <th>ct_year</th>\n",
       "      <th>ct_initials</th>\n",
       "      <th>...</th>\n",
       "      <th>email_equality</th>\n",
       "      <th>year_difference</th>\n",
       "      <th>last_name_length</th>\n",
       "      <th>initials_equality</th>\n",
       "      <th>namespace_size</th>\n",
       "      <th>country_equality</th>\n",
       "      <th>city_equality</th>\n",
       "      <th>organization_type_equality</th>\n",
       "      <th>jds_similarity</th>\n",
       "      <th>sts_similarity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>abdulkarim</td>\n",
       "      <td>b</td>\n",
       "      <td>bassam</td>\n",
       "      <td>AHS Cancer Control Alberta</td>\n",
       "      <td>None</td>\n",
       "      <td>2008</td>\n",
       "      <td>b</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.470588</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000627</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.629170</td>\n",
       "      <td>0.441395</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>gawin</td>\n",
       "      <td>f</td>\n",
       "      <td>frank</td>\n",
       "      <td>Friends Research Institute, Inc.</td>\n",
       "      <td>None</td>\n",
       "      <td>1999</td>\n",
       "      <td>f</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000534</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.217699</td>\n",
       "      <td>0.103129</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>deutsch</td>\n",
       "      <td>s</td>\n",
       "      <td>steven</td>\n",
       "      <td>Washington D.C. Veterans Affairs Medical Center</td>\n",
       "      <td>None</td>\n",
       "      <td>1999</td>\n",
       "      <td>s</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.181818</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.005065</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.034479</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>maisiak</td>\n",
       "      <td>r</td>\n",
       "      <td>richard s</td>\n",
       "      <td>University of Alabama at Birmingham</td>\n",
       "      <td>None</td>\n",
       "      <td>1999</td>\n",
       "      <td>rs</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000421</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.032278</td>\n",
       "      <td>0.028387</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>gorden</td>\n",
       "      <td>p</td>\n",
       "      <td>phillip</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>gordenp@extra.niddk.nih.gov</td>\n",
       "      <td>1999</td>\n",
       "      <td>p</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.196970</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.003333</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.661631</td>\n",
       "      <td>0.418099</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>hochster</td>\n",
       "      <td>h</td>\n",
       "      <td>howard</td>\n",
       "      <td>Eastern Cooperative Oncology Group</td>\n",
       "      <td>None</td>\n",
       "      <td>2000</td>\n",
       "      <td>h</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.121212</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001638</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.267082</td>\n",
       "      <td>0.374291</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>fabian</td>\n",
       "      <td>c</td>\n",
       "      <td>carol j</td>\n",
       "      <td>University of Kansas Medical Center</td>\n",
       "      <td>bkimler@kumc.edu</td>\n",
       "      <td>2000</td>\n",
       "      <td>cj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>0</td>\n",
       "      <td>0.002163</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.423678</td>\n",
       "      <td>0.374529</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>dematteo</td>\n",
       "      <td>r</td>\n",
       "      <td>ronald</td>\n",
       "      <td>American College of Surgeons</td>\n",
       "      <td>None</td>\n",
       "      <td>2001</td>\n",
       "      <td>r</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.227273</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.004512</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.140057</td>\n",
       "      <td>0.345120</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>klein</td>\n",
       "      <td>j</td>\n",
       "      <td>jonathan d</td>\n",
       "      <td>University of Rochester</td>\n",
       "      <td>None</td>\n",
       "      <td>2002</td>\n",
       "      <td>jd</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.181818</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>0</td>\n",
       "      <td>0.042269</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.035419</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>dispenzieri</td>\n",
       "      <td>a</td>\n",
       "      <td>angela</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>None</td>\n",
       "      <td>2002</td>\n",
       "      <td>a</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.529412</td>\n",
       "      <td>1</td>\n",
       "      <td>0.006422</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.545796</td>\n",
       "      <td>0.270666</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>fine</td>\n",
       "      <td>h</td>\n",
       "      <td>howard a</td>\n",
       "      <td>NCI, NIH</td>\n",
       "      <td>hfine@mail.nih.gov</td>\n",
       "      <td>2006</td>\n",
       "      <td>ha</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.003323</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.358494</td>\n",
       "      <td>0.393605</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>orban</td>\n",
       "      <td>t</td>\n",
       "      <td>tihamer</td>\n",
       "      <td>Joslin Diabetes Center</td>\n",
       "      <td>None</td>\n",
       "      <td>2003</td>\n",
       "      <td>t</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.075758</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001554</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.547160</td>\n",
       "      <td>0.300325</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>griffin</td>\n",
       "      <td>t</td>\n",
       "      <td>timothy</td>\n",
       "      <td>Children's Oncology Group</td>\n",
       "      <td>None</td>\n",
       "      <td>2003</td>\n",
       "      <td>t</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.007321</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.022982</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>palmer</td>\n",
       "      <td>j</td>\n",
       "      <td>jerry p</td>\n",
       "      <td>University of Washington</td>\n",
       "      <td>None</td>\n",
       "      <td>2003</td>\n",
       "      <td>jp</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.035013</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.660520</td>\n",
       "      <td>0.338614</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>grossi</td>\n",
       "      <td>s</td>\n",
       "      <td>sara g</td>\n",
       "      <td>University at Buffalo</td>\n",
       "      <td>None</td>\n",
       "      <td>2003</td>\n",
       "      <td>sg</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001826</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.255992</td>\n",
       "      <td>0.083915</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>goldbach-mansky</td>\n",
       "      <td>r</td>\n",
       "      <td>raphaela t</td>\n",
       "      <td>National Institute of Arthritis and Musculoske...</td>\n",
       "      <td>goldbacr@mail.nih.gov</td>\n",
       "      <td>2003</td>\n",
       "      <td>rt</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.764706</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001264</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.561897</td>\n",
       "      <td>0.147694</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>saltz</td>\n",
       "      <td>l</td>\n",
       "      <td>leonard</td>\n",
       "      <td>Memorial Sloan Kettering Cancer Center</td>\n",
       "      <td>None</td>\n",
       "      <td>2004</td>\n",
       "      <td>l</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.121212</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.003932</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.528708</td>\n",
       "      <td>0.379051</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>abrams</td>\n",
       "      <td>d</td>\n",
       "      <td>donald</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>None</td>\n",
       "      <td>2004</td>\n",
       "      <td>d</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.196970</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.007826</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.349422</td>\n",
       "      <td>0.255446</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>reid</td>\n",
       "      <td>t</td>\n",
       "      <td>tony</td>\n",
       "      <td>University of California, San Diego</td>\n",
       "      <td>None</td>\n",
       "      <td>2004</td>\n",
       "      <td>t</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.006750</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.270060</td>\n",
       "      <td>0.317719</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>hahn</td>\n",
       "      <td>s</td>\n",
       "      <td>stephen michael</td>\n",
       "      <td>Abramson Cancer Center of the University of Pe...</td>\n",
       "      <td>None</td>\n",
       "      <td>2004</td>\n",
       "      <td>sm</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.121212</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>0</td>\n",
       "      <td>0.021747</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.041148</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>penzak</td>\n",
       "      <td>s</td>\n",
       "      <td>scott r</td>\n",
       "      <td>National Institutes of Health (NIH)</td>\n",
       "      <td>spenzak@cc.nih.gov</td>\n",
       "      <td>2005</td>\n",
       "      <td>sr</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000964</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.347242</td>\n",
       "      <td>0.244992</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>shulan</td>\n",
       "      <td>m</td>\n",
       "      <td>mollie</td>\n",
       "      <td>Albany VA Medical Center Samuel S. Stratton, A...</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000047</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.311609</td>\n",
       "      <td>0.078577</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>nakayama</td>\n",
       "      <td>e</td>\n",
       "      <td>eiichi</td>\n",
       "      <td>Dept. of Immunology, Okayama University Schhol...</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>e</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.004615</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.494199</td>\n",
       "      <td>0.314358</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>butler</td>\n",
       "      <td>s</td>\n",
       "      <td>stephen f</td>\n",
       "      <td>Inflexxion, Inc.</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>sf</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.010551</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.277946</td>\n",
       "      <td>0.126575</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>blum</td>\n",
       "      <td>k</td>\n",
       "      <td>kristie</td>\n",
       "      <td>Ohio State University</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>k</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>0</td>\n",
       "      <td>0.005598</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.451701</td>\n",
       "      <td>0.390959</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>salmon</td>\n",
       "      <td>d</td>\n",
       "      <td>dominique</td>\n",
       "      <td>Hopital Cochin Paris. Centre des essais vaccin...</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>d</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.008491</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.346846</td>\n",
       "      <td>0.368623</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>braun</td>\n",
       "      <td>u</td>\n",
       "      <td>ursula k</td>\n",
       "      <td>Michael E DeBakey VA Medical Center</td>\n",
       "      <td>ubraun@bcm.edu</td>\n",
       "      <td>2005</td>\n",
       "      <td>uk</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.006450</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.066545</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>piketty</td>\n",
       "      <td>c</td>\n",
       "      <td>christophe</td>\n",
       "      <td>Hopital Européen Georges Pompidou Paris, servi...</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>c</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000871</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.103166</td>\n",
       "      <td>0.054459</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>perlis</td>\n",
       "      <td>m</td>\n",
       "      <td>michael</td>\n",
       "      <td>University of Rochester Sleep Research Lab</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.151515</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001283</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.365808</td>\n",
       "      <td>0.118721</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>kane</td>\n",
       "      <td>m</td>\n",
       "      <td>madeleine</td>\n",
       "      <td>Southwest Oncology Group</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.075758</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.009624</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.412692</td>\n",
       "      <td>0.387217</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1109</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>guo</td>\n",
       "      <td>x</td>\n",
       "      <td>xiaomao</td>\n",
       "      <td>Fudan University</td>\n",
       "      <td>guoxm1800@126.com</td>\n",
       "      <td>2017</td>\n",
       "      <td>x</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.058824</td>\n",
       "      <td>0</td>\n",
       "      <td>0.141167</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.046009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1110</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>lozano</td>\n",
       "      <td>a</td>\n",
       "      <td>andres m</td>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>am</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.008369</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.354118</td>\n",
       "      <td>0.272366</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1111</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>tang</td>\n",
       "      <td>j</td>\n",
       "      <td>jennifer</td>\n",
       "      <td>UNC-CH</td>\n",
       "      <td>jennifer_tang@med.unc.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>j</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.113409</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.045020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1112</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>fallowfield</td>\n",
       "      <td>j</td>\n",
       "      <td>jonathan a</td>\n",
       "      <td>MRC Centre for Inflammation Research, Queens M...</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>ja</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.529412</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000889</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.050919</td>\n",
       "      <td>0.337621</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1113</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>signorile</td>\n",
       "      <td>j</td>\n",
       "      <td>joseph f</td>\n",
       "      <td>University of Miami</td>\n",
       "      <td>jsignorile@miami.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>jf</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.411765</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000899</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.051682</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1114</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>horiuchi</td>\n",
       "      <td>a</td>\n",
       "      <td>akira</td>\n",
       "      <td>Showa Inan General Hospital</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>a</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.004980</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.144341</td>\n",
       "      <td>0.072914</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1115</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>protheroe</td>\n",
       "      <td>a</td>\n",
       "      <td>andrew s</td>\n",
       "      <td>Oxford University Hospitals NHS Trust</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>as</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.411765</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000861</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.035079</td>\n",
       "      <td>0.063594</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1116</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>elmunzer</td>\n",
       "      <td>b</td>\n",
       "      <td>b joseph</td>\n",
       "      <td>Medical University of South Carolina</td>\n",
       "      <td>elmunzer@musc.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>bj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001105</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.279356</td>\n",
       "      <td>0.308465</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1117</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>cheng</td>\n",
       "      <td>y</td>\n",
       "      <td>ya-jung</td>\n",
       "      <td>Anesthesiology Department, NTUH</td>\n",
       "      <td>chengyj@ntu.edu.tw</td>\n",
       "      <td>2017</td>\n",
       "      <td>yj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>0</td>\n",
       "      <td>0.134389</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.027651</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1118</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>gengoux</td>\n",
       "      <td>g</td>\n",
       "      <td>grace w</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>ggengoux@stanford.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>gw</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000084</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.410115</td>\n",
       "      <td>0.407291</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1119</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>iv</td>\n",
       "      <td>m</td>\n",
       "      <td>michael</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.212121</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000337</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.056941</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1120</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>yang</td>\n",
       "      <td>a</td>\n",
       "      <td>aiming</td>\n",
       "      <td>Peking Union Medical College Hospital</td>\n",
       "      <td>yangaiming@medmail.com.cn</td>\n",
       "      <td>2017</td>\n",
       "      <td>a</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.212121</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.027486</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.046088</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1121</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>nakamura</td>\n",
       "      <td>y</td>\n",
       "      <td>yukio</td>\n",
       "      <td>Shinshu University</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>y</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>0</td>\n",
       "      <td>0.107530</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.013447</td>\n",
       "      <td>0.058112</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1122</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>baumgartner</td>\n",
       "      <td>j</td>\n",
       "      <td>joy n</td>\n",
       "      <td>Duke University</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>jn</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.529412</td>\n",
       "      <td>0</td>\n",
       "      <td>0.006020</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.013691</td>\n",
       "      <td>0.092347</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1123</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>manconi</td>\n",
       "      <td>m</td>\n",
       "      <td>mauro</td>\n",
       "      <td>Ente Ospedaliero Cantonale, Bellinzona</td>\n",
       "      <td>mauro.manconi@eoc.ch</td>\n",
       "      <td>2017</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.151515</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.002078</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.113631</td>\n",
       "      <td>0.135808</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1124</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>jiang</td>\n",
       "      <td>x</td>\n",
       "      <td>xiongjing</td>\n",
       "      <td>Chinese Academy of Medical Sciences, Fuwai Hos...</td>\n",
       "      <td>None</td>\n",
       "      <td>2016</td>\n",
       "      <td>x</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.130316</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.253717</td>\n",
       "      <td>0.212852</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1125</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>berra</td>\n",
       "      <td>l</td>\n",
       "      <td>lorenzo</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>lberra@partners.org</td>\n",
       "      <td>2017</td>\n",
       "      <td>l</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000833</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.035512</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1126</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>king</td>\n",
       "      <td>r</td>\n",
       "      <td>rachel</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>rachel.king@ucsf.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>r</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>0</td>\n",
       "      <td>0.035678</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.505711</td>\n",
       "      <td>0.200758</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1127</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>slebos</td>\n",
       "      <td>d</td>\n",
       "      <td>dirk-jan</td>\n",
       "      <td>University Medical Center Groningen</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>dj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.121212</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001133</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.112041</td>\n",
       "      <td>0.025903</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1128</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>verkooijen</td>\n",
       "      <td>h</td>\n",
       "      <td>helena m</td>\n",
       "      <td>UMC Utrecht</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>hm</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.470588</td>\n",
       "      <td>1</td>\n",
       "      <td>0.002060</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0.118610</td>\n",
       "      <td>0.166400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1129</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>cox</td>\n",
       "      <td>d</td>\n",
       "      <td>daniel j</td>\n",
       "      <td>University of Virginia</td>\n",
       "      <td>None</td>\n",
       "      <td>2016</td>\n",
       "      <td>dj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.058824</td>\n",
       "      <td>0</td>\n",
       "      <td>0.025314</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.033265</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1130</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>kazakov</td>\n",
       "      <td>i</td>\n",
       "      <td>ivan</td>\n",
       "      <td>Moscow Clinical Scientific Center</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>i</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000964</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.438318</td>\n",
       "      <td>0.381960</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1131</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>levesque</td>\n",
       "      <td>s</td>\n",
       "      <td>sebastien</td>\n",
       "      <td>University Hospital of Poitiers, Department of...</td>\n",
       "      <td>sebastien.levesque@chu-poitiers.fr</td>\n",
       "      <td>2017</td>\n",
       "      <td>s</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001994</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.515409</td>\n",
       "      <td>0.430989</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1132</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>omran</td>\n",
       "      <td>e</td>\n",
       "      <td>eman</td>\n",
       "      <td>Cairo University</td>\n",
       "      <td>eman.omran@kasralaini.edu.eg</td>\n",
       "      <td>2017</td>\n",
       "      <td>e</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000243</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.010498</td>\n",
       "      <td>0.034285</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1133</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>rudroff</td>\n",
       "      <td>t</td>\n",
       "      <td>thorsten</td>\n",
       "      <td>University of Colorado, Denver</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>t</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000384</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.059204</td>\n",
       "      <td>0.098385</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1134</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>bedimo</td>\n",
       "      <td>r</td>\n",
       "      <td>roger</td>\n",
       "      <td>Dallas VAMC</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>r</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.196970</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000730</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.212359</td>\n",
       "      <td>0.306152</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1135</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>hallett</td>\n",
       "      <td>m</td>\n",
       "      <td>mark</td>\n",
       "      <td>National Institute of Neurological Disorders a...</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.075758</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.012517</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.237559</td>\n",
       "      <td>0.243547</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1136</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>brooke-wavell</td>\n",
       "      <td>k</td>\n",
       "      <td>katherine</td>\n",
       "      <td>Loughborough University</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>k</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.647059</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000374</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.625534</td>\n",
       "      <td>0.357658</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1137</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>percac-lima</td>\n",
       "      <td>s</td>\n",
       "      <td>sanja</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>s</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.529412</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000431</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.198631</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1138</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>huang</td>\n",
       "      <td>i</td>\n",
       "      <td>i-chan</td>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>referralinfo@stjude.org</td>\n",
       "      <td>2017</td>\n",
       "      <td>ic</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.005140</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.240913</td>\n",
       "      <td>0.221026</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1139 rows × 34 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                     CT  \\\n",
       "0     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "2     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "3     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "4     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "5     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "6     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "7     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "8     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "9     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "10    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "11    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "12    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "13    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "14    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "15    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "16    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "17    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "18    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "19    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "20    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "21    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "22    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "23    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "24    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "25    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "26    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "27    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "28    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "29    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "...                                                 ...   \n",
       "1109  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1110  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1111  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1112  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1113  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1114  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1115  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1116  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1117  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1118  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1119  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1120  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1121  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1122  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1123  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1124  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1125  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1126  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1127  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1128  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1129  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1130  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1131  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1132  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1133  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1134  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1135  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1136  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1137  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1138  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "\n",
       "                                                 PubMed  common_answer  \\\n",
       "0     <articles.article.Article object at 0x0000014F...              1   \n",
       "1     <articles.article.Article object at 0x0000014F...              1   \n",
       "2     <articles.article.Article object at 0x0000014F...              1   \n",
       "3     <articles.article.Article object at 0x0000014F...              1   \n",
       "4     <articles.article.Article object at 0x0000014F...              1   \n",
       "5     <articles.article.Article object at 0x0000014F...              1   \n",
       "6     <articles.article.Article object at 0x0000014F...              1   \n",
       "7     <articles.article.Article object at 0x0000014F...              1   \n",
       "8     <articles.article.Article object at 0x0000014F...              0   \n",
       "9     <articles.article.Article object at 0x0000014F...              1   \n",
       "10    <articles.article.Article object at 0x0000014F...              1   \n",
       "11    <articles.article.Article object at 0x0000014F...              1   \n",
       "12    <articles.article.Article object at 0x0000014F...              0   \n",
       "13    <articles.article.Article object at 0x0000014F...              1   \n",
       "14    <articles.article.Article object at 0x0000014F...              1   \n",
       "15    <articles.article.Article object at 0x0000014F...              1   \n",
       "16    <articles.article.Article object at 0x0000014F...              1   \n",
       "17    <articles.article.Article object at 0x0000014F...              1   \n",
       "18    <articles.article.Article object at 0x0000014F...              1   \n",
       "19    <articles.article.Article object at 0x0000014F...              0   \n",
       "20    <articles.article.Article object at 0x0000014F...              1   \n",
       "21    <articles.article.Article object at 0x0000014F...              1   \n",
       "22    <articles.article.Article object at 0x0000014F...              1   \n",
       "23    <articles.article.Article object at 0x0000014F...              1   \n",
       "24    <articles.article.Article object at 0x0000014F...              1   \n",
       "25    <articles.article.Article object at 0x0000014F...              1   \n",
       "26    <articles.article.Article object at 0x0000014F...              1   \n",
       "27    <articles.article.Article object at 0x0000014F...              1   \n",
       "28    <articles.article.Article object at 0x0000014F...              1   \n",
       "29    <articles.article.Article object at 0x0000014F...              1   \n",
       "...                                                 ...            ...   \n",
       "1109  <articles.article.Article object at 0x0000014F...              0   \n",
       "1110  <articles.article.Article object at 0x0000014F...              1   \n",
       "1111  <articles.article.Article object at 0x0000014F...              0   \n",
       "1112  <articles.article.Article object at 0x0000014F...              1   \n",
       "1113  <articles.article.Article object at 0x0000014F...              1   \n",
       "1114  <articles.article.Article object at 0x0000014F...              1   \n",
       "1115  <articles.article.Article object at 0x0000014F...              1   \n",
       "1116  <articles.article.Article object at 0x0000014F...              1   \n",
       "1117  <articles.article.Article object at 0x0000014F...              0   \n",
       "1118  <articles.article.Article object at 0x0000014F...              1   \n",
       "1119  <articles.article.Article object at 0x0000014F...              1   \n",
       "1120  <articles.article.Article object at 0x0000014F...              0   \n",
       "1121  <articles.article.Article object at 0x0000014F...              0   \n",
       "1122  <articles.article.Article object at 0x0000014F...              1   \n",
       "1123  <articles.article.Article object at 0x0000014F...              1   \n",
       "1124  <articles.article.Article object at 0x0000014F...              1   \n",
       "1125  <articles.article.Article object at 0x0000014F...              1   \n",
       "1126  <articles.article.Article object at 0x0000014F...              1   \n",
       "1127  <articles.article.Article object at 0x0000014F...              1   \n",
       "1128  <articles.article.Article object at 0x0000014F...              1   \n",
       "1129  <articles.article.Article object at 0x0000014F...              0   \n",
       "1130  <articles.article.Article object at 0x0000014F...              1   \n",
       "1131  <articles.article.Article object at 0x0000014F...              1   \n",
       "1132  <articles.article.Article object at 0x0000014F...              1   \n",
       "1133  <articles.article.Article object at 0x0000014F...              1   \n",
       "1134  <articles.article.Article object at 0x0000014F...              1   \n",
       "1135  <articles.article.Article object at 0x0000014F...              1   \n",
       "1136  <articles.article.Article object at 0x0000014F...              1   \n",
       "1137  <articles.article.Article object at 0x0000014F...              1   \n",
       "1138  <articles.article.Article object at 0x0000014F...              1   \n",
       "\n",
       "         ct_last_name ct_first_name_initial    ct_first_name  \\\n",
       "0          abdulkarim                     b           bassam   \n",
       "1               gawin                     f            frank   \n",
       "2             deutsch                     s           steven   \n",
       "3             maisiak                     r        richard s   \n",
       "4              gorden                     p          phillip   \n",
       "5            hochster                     h           howard   \n",
       "6              fabian                     c          carol j   \n",
       "7            dematteo                     r           ronald   \n",
       "8               klein                     j       jonathan d   \n",
       "9         dispenzieri                     a           angela   \n",
       "10               fine                     h         howard a   \n",
       "11              orban                     t          tihamer   \n",
       "12            griffin                     t          timothy   \n",
       "13             palmer                     j          jerry p   \n",
       "14             grossi                     s           sara g   \n",
       "15    goldbach-mansky                     r       raphaela t   \n",
       "16              saltz                     l          leonard   \n",
       "17             abrams                     d           donald   \n",
       "18               reid                     t             tony   \n",
       "19               hahn                     s  stephen michael   \n",
       "20             penzak                     s          scott r   \n",
       "21             shulan                     m           mollie   \n",
       "22           nakayama                     e           eiichi   \n",
       "23             butler                     s        stephen f   \n",
       "24               blum                     k          kristie   \n",
       "25             salmon                     d        dominique   \n",
       "26              braun                     u         ursula k   \n",
       "27            piketty                     c       christophe   \n",
       "28             perlis                     m          michael   \n",
       "29               kane                     m        madeleine   \n",
       "...               ...                   ...              ...   \n",
       "1109              guo                     x          xiaomao   \n",
       "1110           lozano                     a         andres m   \n",
       "1111             tang                     j         jennifer   \n",
       "1112      fallowfield                     j       jonathan a   \n",
       "1113        signorile                     j         joseph f   \n",
       "1114         horiuchi                     a            akira   \n",
       "1115        protheroe                     a         andrew s   \n",
       "1116         elmunzer                     b         b joseph   \n",
       "1117            cheng                     y          ya-jung   \n",
       "1118          gengoux                     g          grace w   \n",
       "1119               iv                     m          michael   \n",
       "1120             yang                     a           aiming   \n",
       "1121         nakamura                     y            yukio   \n",
       "1122      baumgartner                     j            joy n   \n",
       "1123          manconi                     m            mauro   \n",
       "1124            jiang                     x        xiongjing   \n",
       "1125            berra                     l          lorenzo   \n",
       "1126             king                     r           rachel   \n",
       "1127           slebos                     d         dirk-jan   \n",
       "1128       verkooijen                     h         helena m   \n",
       "1129              cox                     d         daniel j   \n",
       "1130          kazakov                     i             ivan   \n",
       "1131         levesque                     s        sebastien   \n",
       "1132            omran                     e             eman   \n",
       "1133          rudroff                     t         thorsten   \n",
       "1134           bedimo                     r            roger   \n",
       "1135          hallett                     m             mark   \n",
       "1136    brooke-wavell                     k        katherine   \n",
       "1137      percac-lima                     s            sanja   \n",
       "1138            huang                     i           i-chan   \n",
       "\n",
       "                                        ct_organization  \\\n",
       "0                            AHS Cancer Control Alberta   \n",
       "1                      Friends Research Institute, Inc.   \n",
       "2       Washington D.C. Veterans Affairs Medical Center   \n",
       "3                   University of Alabama at Birmingham   \n",
       "4     National Institute of Diabetes and Digestive a...   \n",
       "5                    Eastern Cooperative Oncology Group   \n",
       "6                   University of Kansas Medical Center   \n",
       "7                          American College of Surgeons   \n",
       "8                               University of Rochester   \n",
       "9                                           Mayo Clinic   \n",
       "10                                             NCI, NIH   \n",
       "11                               Joslin Diabetes Center   \n",
       "12                            Children's Oncology Group   \n",
       "13                             University of Washington   \n",
       "14                                University at Buffalo   \n",
       "15    National Institute of Arthritis and Musculoske...   \n",
       "16               Memorial Sloan Kettering Cancer Center   \n",
       "17              University of California, San Francisco   \n",
       "18                  University of California, San Diego   \n",
       "19    Abramson Cancer Center of the University of Pe...   \n",
       "20                  National Institutes of Health (NIH)   \n",
       "21    Albany VA Medical Center Samuel S. Stratton, A...   \n",
       "22    Dept. of Immunology, Okayama University Schhol...   \n",
       "23                                     Inflexxion, Inc.   \n",
       "24                                Ohio State University   \n",
       "25    Hopital Cochin Paris. Centre des essais vaccin...   \n",
       "26                  Michael E DeBakey VA Medical Center   \n",
       "27    Hopital Européen Georges Pompidou Paris, servi...   \n",
       "28           University of Rochester Sleep Research Lab   \n",
       "29                             Southwest Oncology Group   \n",
       "...                                                 ...   \n",
       "1109                                   Fudan University   \n",
       "1110                 University Health Network, Toronto   \n",
       "1111                                             UNC-CH   \n",
       "1112  MRC Centre for Inflammation Research, Queens M...   \n",
       "1113                                University of Miami   \n",
       "1114                        Showa Inan General Hospital   \n",
       "1115              Oxford University Hospitals NHS Trust   \n",
       "1116               Medical University of South Carolina   \n",
       "1117                    Anesthesiology Department, NTUH   \n",
       "1118                                Stanford University   \n",
       "1119                                Stanford University   \n",
       "1120              Peking Union Medical College Hospital   \n",
       "1121                                 Shinshu University   \n",
       "1122                                    Duke University   \n",
       "1123             Ente Ospedaliero Cantonale, Bellinzona   \n",
       "1124  Chinese Academy of Medical Sciences, Fuwai Hos...   \n",
       "1125                     Massachusetts General Hospital   \n",
       "1126            University of California, San Francisco   \n",
       "1127                University Medical Center Groningen   \n",
       "1128                                        UMC Utrecht   \n",
       "1129                             University of Virginia   \n",
       "1130                  Moscow Clinical Scientific Center   \n",
       "1131  University Hospital of Poitiers, Department of...   \n",
       "1132                                   Cairo University   \n",
       "1133                     University of Colorado, Denver   \n",
       "1134                                        Dallas VAMC   \n",
       "1135  National Institute of Neurological Disorders a...   \n",
       "1136                            Loughborough University   \n",
       "1137                     Massachusetts General Hospital   \n",
       "1138              St. Jude Children's Research Hospital   \n",
       "\n",
       "                                 ct_mail  ct_year ct_initials      ...        \\\n",
       "0                                   None     2008           b      ...         \n",
       "1                                   None     1999           f      ...         \n",
       "2                                   None     1999           s      ...         \n",
       "3                                   None     1999          rs      ...         \n",
       "4            gordenp@extra.niddk.nih.gov     1999           p      ...         \n",
       "5                                   None     2000           h      ...         \n",
       "6                       bkimler@kumc.edu     2000          cj      ...         \n",
       "7                                   None     2001           r      ...         \n",
       "8                                   None     2002          jd      ...         \n",
       "9                                   None     2002           a      ...         \n",
       "10                    hfine@mail.nih.gov     2006          ha      ...         \n",
       "11                                  None     2003           t      ...         \n",
       "12                                  None     2003           t      ...         \n",
       "13                                  None     2003          jp      ...         \n",
       "14                                  None     2003          sg      ...         \n",
       "15                 goldbacr@mail.nih.gov     2003          rt      ...         \n",
       "16                                  None     2004           l      ...         \n",
       "17                                  None     2004           d      ...         \n",
       "18                                  None     2004           t      ...         \n",
       "19                                  None     2004          sm      ...         \n",
       "20                    spenzak@cc.nih.gov     2005          sr      ...         \n",
       "21                                  None     2005           m      ...         \n",
       "22                                  None     2005           e      ...         \n",
       "23                                  None     2005          sf      ...         \n",
       "24                                  None     2005           k      ...         \n",
       "25                                  None     2005           d      ...         \n",
       "26                        ubraun@bcm.edu     2005          uk      ...         \n",
       "27                                  None     2005           c      ...         \n",
       "28                                  None     2005           m      ...         \n",
       "29                                  None     2005           m      ...         \n",
       "...                                  ...      ...         ...      ...         \n",
       "1109                   guoxm1800@126.com     2017           x      ...         \n",
       "1110                                None     2017          am      ...         \n",
       "1111           jennifer_tang@med.unc.edu     2017           j      ...         \n",
       "1112                                None     2017          ja      ...         \n",
       "1113                jsignorile@miami.edu     2017          jf      ...         \n",
       "1114                                None     2017           a      ...         \n",
       "1115                                None     2017          as      ...         \n",
       "1116                   elmunzer@musc.edu     2017          bj      ...         \n",
       "1117                  chengyj@ntu.edu.tw     2017          yj      ...         \n",
       "1118               ggengoux@stanford.edu     2017          gw      ...         \n",
       "1119                                None     2017           m      ...         \n",
       "1120           yangaiming@medmail.com.cn     2017           a      ...         \n",
       "1121                                None     2017           y      ...         \n",
       "1122                                None     2017          jn      ...         \n",
       "1123                mauro.manconi@eoc.ch     2017           m      ...         \n",
       "1124                                None     2016           x      ...         \n",
       "1125                 lberra@partners.org     2017           l      ...         \n",
       "1126                rachel.king@ucsf.edu     2017           r      ...         \n",
       "1127                                None     2017          dj      ...         \n",
       "1128                                None     2017          hm      ...         \n",
       "1129                                None     2016          dj      ...         \n",
       "1130                                None     2017           i      ...         \n",
       "1131  sebastien.levesque@chu-poitiers.fr     2017           s      ...         \n",
       "1132        eman.omran@kasralaini.edu.eg     2017           e      ...         \n",
       "1133                                None     2017           t      ...         \n",
       "1134                                None     2017           r      ...         \n",
       "1135                                None     2017           m      ...         \n",
       "1136                                None     2017           k      ...         \n",
       "1137                                None     2017           s      ...         \n",
       "1138             referralinfo@stjude.org     2017          ic      ...         \n",
       "\n",
       "     email_equality year_difference last_name_length initials_equality  \\\n",
       "0                 0        0.000000         0.470588                 1   \n",
       "1                 0        0.045455         0.176471                 1   \n",
       "2                 0        0.181818         0.294118                 1   \n",
       "3                 0        0.106061         0.294118                 1   \n",
       "4                 0        0.196970         0.235294                 1   \n",
       "5                 0        0.121212         0.352941                 1   \n",
       "6                 0        0.106061         0.235294                 0   \n",
       "7                 0        0.227273         0.352941                 1   \n",
       "8                 0        0.181818         0.176471                 0   \n",
       "9                 0        0.015152         0.529412                 1   \n",
       "10                0        0.060606         0.117647                 1   \n",
       "11                0        0.075758         0.176471                 1   \n",
       "12                0        0.030303         0.294118                 1   \n",
       "13                0        0.136364         0.235294                 1   \n",
       "14                0        0.030303         0.235294                 1   \n",
       "15                0        0.166667         0.764706                 1   \n",
       "16                0        0.121212         0.176471                 1   \n",
       "17                0        0.196970         0.235294                 1   \n",
       "18                0        0.136364         0.117647                 1   \n",
       "19                0        0.121212         0.117647                 0   \n",
       "20                0        0.045455         0.235294                 1   \n",
       "21                0        0.106061         0.235294                 1   \n",
       "22                0        0.136364         0.352941                 1   \n",
       "23                0        0.015152         0.235294                 1   \n",
       "24                0        0.136364         0.117647                 0   \n",
       "25                0        0.030303         0.235294                 1   \n",
       "26                1        0.090909         0.176471                 1   \n",
       "27                0        0.106061         0.294118                 1   \n",
       "28                0        0.151515         0.235294                 1   \n",
       "29                0        0.075758         0.117647                 1   \n",
       "...             ...             ...              ...               ...   \n",
       "1109              0        0.090909         0.058824                 0   \n",
       "1110              0        0.060606         0.235294                 1   \n",
       "1111              0        0.045455         0.117647                 1   \n",
       "1112              0        0.045455         0.529412                 1   \n",
       "1113              1        0.000000         0.411765                 0   \n",
       "1114              0        0.090909         0.352941                 1   \n",
       "1115              0        0.106061         0.411765                 1   \n",
       "1116              0        0.030303         0.352941                 1   \n",
       "1117              0        0.045455         0.176471                 0   \n",
       "1118              0        0.030303         0.294118                 0   \n",
       "1119              0        0.212121         0.000000                 1   \n",
       "1120              0        0.212121         0.117647                 1   \n",
       "1121              0        0.090909         0.352941                 0   \n",
       "1122              0        0.015152         0.529412                 0   \n",
       "1123              0        0.151515         0.294118                 1   \n",
       "1124              0        0.045455         0.176471                 1   \n",
       "1125              0        0.060606         0.176471                 1   \n",
       "1126              0        0.045455         0.117647                 0   \n",
       "1127              0        0.121212         0.235294                 1   \n",
       "1128              0        0.030303         0.470588                 1   \n",
       "1129              0        0.060606         0.058824                 0   \n",
       "1130              0        0.000000         0.294118                 1   \n",
       "1131              0        0.015152         0.352941                 1   \n",
       "1132              0        0.015152         0.176471                 1   \n",
       "1133              0        0.045455         0.294118                 1   \n",
       "1134              0        0.196970         0.235294                 1   \n",
       "1135              0        0.075758         0.294118                 1   \n",
       "1136              0        0.030303         0.647059                 1   \n",
       "1137              0        0.136364         0.529412                 1   \n",
       "1138              0        0.060606         0.176471                 1   \n",
       "\n",
       "     namespace_size country_equality city_equality organization_type_equality  \\\n",
       "0          0.000627                0             0                          0   \n",
       "1          0.000534                0             0                          0   \n",
       "2          0.005065                0             0                          0   \n",
       "3          0.000421                0             0                          0   \n",
       "4          0.003333                1             1                          1   \n",
       "5          0.001638                1             0                          0   \n",
       "6          0.002163                0             0                          0   \n",
       "7          0.004512                0             0                          0   \n",
       "8          0.042269                1             0                          1   \n",
       "9          0.006422                0             0                          0   \n",
       "10         0.003323                0             0                          0   \n",
       "11         0.001554                0             0                          0   \n",
       "12         0.007321                0             0                          0   \n",
       "13         0.035013                0             0                          0   \n",
       "14         0.001826                0             0                          0   \n",
       "15         0.001264                0             0                          0   \n",
       "16         0.003932                0             0                          0   \n",
       "17         0.007826                0             0                          0   \n",
       "18         0.006750                0             0                          0   \n",
       "19         0.021747                0             0                          0   \n",
       "20         0.000964                0             0                          0   \n",
       "21         0.000047                0             0                          0   \n",
       "22         0.004615                1             1                          1   \n",
       "23         0.010551                1             0                          1   \n",
       "24         0.005598                1             1                          1   \n",
       "25         0.008491                0             0                          0   \n",
       "26         0.006450                1             1                          0   \n",
       "27         0.000871                0             0                          0   \n",
       "28         0.001283                1             0                          1   \n",
       "29         0.009624                0             0                          0   \n",
       "...             ...              ...           ...                        ...   \n",
       "1109       0.141167                0             0                          0   \n",
       "1110       0.008369                0             0                          0   \n",
       "1111       0.113409                0             0                          0   \n",
       "1112       0.000889                0             0                          0   \n",
       "1113       0.000899                1             0                          1   \n",
       "1114       0.004980                1             1                          1   \n",
       "1115       0.000861                0             0                          0   \n",
       "1116       0.001105                1             1                          1   \n",
       "1117       0.134389                0             0                          0   \n",
       "1118       0.000084                0             0                          0   \n",
       "1119       0.000337                0             0                          0   \n",
       "1120       0.027486                0             0                          0   \n",
       "1121       0.107530                0             0                          0   \n",
       "1122       0.006020                0             0                          1   \n",
       "1123       0.002078                0             0                          0   \n",
       "1124       0.130316                0             0                          0   \n",
       "1125       0.000833                0             0                          0   \n",
       "1126       0.035678                0             0                          0   \n",
       "1127       0.001133                0             0                          0   \n",
       "1128       0.002060                1             1                          0   \n",
       "1129       0.025314                0             0                          0   \n",
       "1130       0.000964                1             1                          1   \n",
       "1131       0.001994                1             0                          0   \n",
       "1132       0.000243                0             0                          0   \n",
       "1133       0.000384                1             0                          1   \n",
       "1134       0.000730                1             0                          0   \n",
       "1135       0.012517                0             0                          0   \n",
       "1136       0.000374                1             0                          1   \n",
       "1137       0.000431                0             0                          0   \n",
       "1138       0.005140                1             1                          1   \n",
       "\n",
       "      jds_similarity sts_similarity  \n",
       "0           0.629170       0.441395  \n",
       "1           0.217699       0.103129  \n",
       "2           0.000000       0.034479  \n",
       "3           0.032278       0.028387  \n",
       "4           0.661631       0.418099  \n",
       "5           0.267082       0.374291  \n",
       "6           0.423678       0.374529  \n",
       "7           0.140057       0.345120  \n",
       "8           0.000000       0.035419  \n",
       "9           0.545796       0.270666  \n",
       "10          0.358494       0.393605  \n",
       "11          0.547160       0.300325  \n",
       "12          0.000000       0.022982  \n",
       "13          0.660520       0.338614  \n",
       "14          0.255992       0.083915  \n",
       "15          0.561897       0.147694  \n",
       "16          0.528708       0.379051  \n",
       "17          0.349422       0.255446  \n",
       "18          0.270060       0.317719  \n",
       "19          0.000000       0.041148  \n",
       "20          0.347242       0.244992  \n",
       "21          0.311609       0.078577  \n",
       "22          0.494199       0.314358  \n",
       "23          0.277946       0.126575  \n",
       "24          0.451701       0.390959  \n",
       "25          0.346846       0.368623  \n",
       "26          0.000000       0.066545  \n",
       "27          0.103166       0.054459  \n",
       "28          0.365808       0.118721  \n",
       "29          0.412692       0.387217  \n",
       "...              ...            ...  \n",
       "1109        0.000000       0.046009  \n",
       "1110        0.354118       0.272366  \n",
       "1111        0.000000       0.045020  \n",
       "1112        0.050919       0.337621  \n",
       "1113        0.000000       0.051682  \n",
       "1114        0.144341       0.072914  \n",
       "1115        0.035079       0.063594  \n",
       "1116        0.279356       0.308465  \n",
       "1117        0.000000       0.027651  \n",
       "1118        0.410115       0.407291  \n",
       "1119        0.000000       0.056941  \n",
       "1120        0.000000       0.046088  \n",
       "1121        0.013447       0.058112  \n",
       "1122        0.013691       0.092347  \n",
       "1123        0.113631       0.135808  \n",
       "1124        0.253717       0.212852  \n",
       "1125        0.000000       0.035512  \n",
       "1126        0.505711       0.200758  \n",
       "1127        0.112041       0.025903  \n",
       "1128        0.118610       0.166400  \n",
       "1129        0.000000       0.033265  \n",
       "1130        0.438318       0.381960  \n",
       "1131        0.515409       0.430989  \n",
       "1132        0.010498       0.034285  \n",
       "1133        0.059204       0.098385  \n",
       "1134        0.212359       0.306152  \n",
       "1135        0.237559       0.243547  \n",
       "1136        0.625534       0.357658  \n",
       "1137        0.000000       0.198631  \n",
       "1138        0.240913       0.221026  \n",
       "\n",
       "[1139 rows x 34 columns]"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "501\n"
     ]
    }
   ],
   "source": [
    "lista = df['CT'].tolist()\n",
    "a = df['ct_last_name'].tolist()\n",
    "b = df['ct_first_name_initial'].tolist()\n",
    "mails = df['ct_mail'].tolist()\n",
    "\n",
    "count = 0\n",
    "\n",
    "for i in range(len(lista)):\n",
    "    tags = lista[i].get_all_name_tags(a[i],b[i])\n",
    "    \n",
    "    for tag in tags:\n",
    "        if tag.email is not None or mails[i]:\n",
    "            #print(tag.email, mails[i])\n",
    "            count += 1\n",
    "        \n",
    "print(count)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Hong Kong Hong Kong \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Japan Japan \n",
      "\n",
      "United States United States \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "Japan Japan \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States Korea, Republic of \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Denmark Denmark \n",
      "\n",
      "United States United States \n",
      "\n",
      "United Kingdom United Kingdom \n",
      "\n",
      "United States United States \n",
      "\n",
      "Belgium Belgium \n",
      "\n",
      "United States United States \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Belgium Belgium \n",
      "\n",
      "United Kingdom United Kingdom \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Italy Italy \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Belgium Netherlands \n",
      "\n",
      "United States United States \n",
      "\n",
      "Norway Sweden \n",
      "\n",
      "Belgium Belgium \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Japan Japan \n",
      "\n",
      "Spain Spain \n",
      "\n",
      "Australia Australia \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "Ireland United Kingdom \n",
      "\n",
      "France France \n",
      "\n",
      "Hungary Hungary \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Japan Japan \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United Kingdom United Kingdom \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "China China \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Australia Germany \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Sweden Sweden \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "Sweden Sweden \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Sweden Sweden \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "France France \n",
      "\n",
      "United States United States \n",
      "\n",
      "France France \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Germany Germany \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "Israel Romania \n",
      "\n",
      "Thailand Thailand \n",
      "\n",
      "United States United States \n",
      "\n",
      "China China \n",
      "\n",
      "United States United States \n",
      "\n",
      "China China \n",
      "\n",
      "Netherlands Netherlands \n",
      "\n",
      "Belgium Belgium \n",
      "\n",
      "France France \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States Denmark \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "Italy Italy \n",
      "\n",
      "Denmark Denmark \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Brazil Brazil \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United Kingdom United Kingdom \n",
      "\n",
      "United States Netherlands \n",
      "\n",
      "United States New Zealand \n",
      "\n",
      "India India \n",
      "\n",
      "United States United States \n",
      "\n",
      "Brazil Brazil \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Spain Spain \n",
      "\n",
      "Taiwan Taiwan \n",
      "\n",
      "China China \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Ireland Ireland \n",
      "\n",
      "United States United States \n",
      "\n",
      "Belgium France \n",
      "\n",
      "Belgium Belgium \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "China China \n",
      "\n",
      "Austria Austria \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "France France \n",
      "\n",
      "United States United States \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Uganda Uganda \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Germany Netherlands \n",
      "\n",
      "United States United States \n",
      "\n",
      "United Kingdom United Kingdom \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Belgium Belgium \n",
      "\n",
      "United States United States \n",
      "\n",
      "China China \n",
      "\n",
      "United States United States \n",
      "\n",
      "Italy Romania \n",
      "\n",
      "United States United States \n",
      "\n",
      "France France \n",
      "\n",
      "Germany Germany \n",
      "\n",
      "United States France \n",
      "\n",
      "United States United States \n",
      "\n",
      "Spain Spain \n",
      "\n",
      "Turkey Turkey \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "China Germany \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Netherlands Netherlands \n",
      "\n",
      "United States United States \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "China China \n",
      "\n",
      "United States United States \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Japan Japan \n",
      "\n",
      "France France \n",
      "\n",
      "Canada Canada \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United Kingdom United Kingdom \n",
      "\n",
      "France France \n",
      "\n",
      "United States Honduras \n",
      "\n",
      "Spain Spain \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "Italy Italy \n",
      "\n",
      "United States United States \n",
      "\n",
      "Colombia Honduras \n",
      "\n",
      "China China \n",
      "\n",
      "United States United States \n",
      "\n",
      "France France \n",
      "\n",
      "France France \n",
      "\n",
      "France France \n",
      "\n",
      "Austria Austria \n",
      "\n",
      "France France \n",
      "\n",
      "China China \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "China China \n",
      "\n",
      "Germany Germany \n",
      "\n",
      "Hong Kong Hong Kong \n",
      "\n",
      "United States United States \n",
      "\n",
      "United States United States \n",
      "\n",
      "China China \n",
      "\n",
      "Belgium Belgium \n",
      "\n",
      "Austria Austria \n",
      "\n",
      "United States United States \n",
      "\n",
      "United Kingdom United Kingdom \n",
      "\n",
      "United States United States \n",
      "\n",
      "Netherlands Netherlands \n",
      "\n",
      "France France \n",
      "\n"
     ]
    }
   ],
   "source": [
    "lista = df['CT'].tolist()\n",
    "\n",
    "for i in range(len(lista)):\n",
    "    loc = lista[i].clinical_trial.findAll('location')\n",
    "    if len(loc) > 1:\n",
    "        print(loc[0].country.text, loc[1].country.text, '\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<overall_official>\n",
      "<last_name>Bassam Abdulkarim, MD, FRCPC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>AHS Cancer Control Alberta</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Frank Gawin, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Friends Research Institute, Inc.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steven Deutsch, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington D.C. Veterans Affairs Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard S. Maisiak, PhD, MSPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Alabama at Birmingham</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Phillip Gorden, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Howard Hochster</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Eastern Cooperative Oncology Group</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Carol J. Fabian, MD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>University of Kansas</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ronald DeMatteo</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>American College of Surgeons</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jonathan D. Klein, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Rochester</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Angela Dispenzieri</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Howard A Fine, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NCI, NIH</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tihamer Orban, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Joslin Diabetes Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Timothy Griffin</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Oncology Group</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jerry P Palmer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Washington</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sara G Grossi, DDS, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University at Buffalo</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Raphaela T Goldbach-Mansky, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Leonard Saltz</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Memorial Sloan Kettering Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Donald Abrams, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tony Reid, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Diego</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stephen Michael Hahn</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Scott R Penzak, Pharm.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institutes of Health (NIH)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mollie Shulan, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Albany VA Medical Center Samuel S. Stratton, Albany, NY</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eiichi Nakayama, MD., PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dept. of Immunology, Okayama University Schhol of Medicine and Dentistry</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stephen F Butler, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Inflexxion, Inc.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kristie Blum</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ohio State University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dominique Salmon, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hopital Cochin Paris. Centre des essais vaccinaux Cochin Pasteur</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ursula K. Braun, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Michael E DeBakey VA Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christophe Piketty, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hopital Européen Georges Pompidou Paris, service d'immunologie clinique</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Perlis, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Rochester Sleep Research Lab</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Madeleine Kane</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Southwest Oncology Group</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Renato S Procianoy, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Universidade Federal do Rio Grande do Sul-Hospital de Clínicas de Porto Alegre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gerardo Gonzalez, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yale University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Raul Mena, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>East Valley Hematology and Oncology Group</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregory Hammer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Patrick Kwan, FHKAM</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Chinese University of Hong Kong</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jennifer O Hagman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Health Sciences Center and The Children's Hospital, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David S Ludwig, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston Children’s Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alice Gottlieb, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rutgers, The State University of New Jersey</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christine Alvarez, MD, FRCSC, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of British Columbia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yeong-Shiau Pu, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Samir F. Saba, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pittsburgh</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jill S Halterman, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Rochester</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dan Iosifescu, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jalid Sehouli</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Charite University, Berlin, Germany</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Matthew Kulke, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dana-Farber Cancer Institute</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nikhil Munshi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dana-Farber Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joseph R Leventhal, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Northwestern University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tyng-Guey Wang, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University, School of Medicine, National Taiwan University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John Bantle, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pei-Fang Tang, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>M. R Bullock, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Virginia Commonwealth University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ronald M Salomon, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Vanderbilt University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard C Shelton, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Vanderbilt University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregg W Stone, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Columbia University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dan L. Longo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute on Aging (NIA)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Charles DeBattista</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gary Foster, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Temple University - Center for Obesity Research and Education</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kathryn Schmitz, PhD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Milton S. Hershey Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Vincent LM Esnault, MD PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>CHU de Nantes</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Vitaly Napadow, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Harvard University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Neil C Binkley, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Wisconsin, Madison</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Frederick Petty, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Creighton University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James M Mullin, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Main Line Health</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Maggie L Dylewski, MS,RD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shriners Hospitals for Children</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Laurence Klotz, MD, FRCSC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sunnybrook Health Sciences Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joseph Zohar, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Tel Aviv University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zohar Keidar, MD,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rambam Health Care Campus</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steve M Blevins, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Oklahoma</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Leslie Leve, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Oregon Social Learning Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Karina Davidson, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Columbia University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wayne Ray</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Vanderbilt University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Scott W. Powers, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mitchell Elkind, MD, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Columbia University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joachim Sieper, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Charité Campus Benjamin-Franklin, Rheumatology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard F. Davies, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Ottawa Heart Instittue</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Krista L Lanctot, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sunnybrook Health Sciences Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kevin F Gibson, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pittsburgh, Simmons Center for ILD</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marie A Badalamente, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dept. Orthopaedics, SUNY@Stony Brook, NY 11794</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stephanie Brister, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Toronto General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul Cales, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>CHU Angers, Service d'hépato-gastroentérologie, 49933 Angers Cedex 09</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lotte Lauritzen, Ph.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Human Nutrition, Royal Veterinary and Agricultural University, Denmark</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ilse Mombaerts, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Universitaire Ziekenhuizen Leuven</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steven Grant</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massey Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Masashi Fujii, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Surugadai Nihon University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Aaron S Fink, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Atlanta VA Medical and Rehab Center, Decatur, GA</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Carsten Bokemeyer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital Tuebingen (PI until 30Nov2004)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gen Yasuda, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yokohama City University Center Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sharon Compton, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Alberta</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jean-Pierre Lindenmayer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Manhattan Psychiatric Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Karlene Ball, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Alabama at Birmingham</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stephen J Brown, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>AIDS Research Alliance of West Hollywood</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Diana M Antoniucci, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Diana M Antoniucci, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marc J Semigran, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steven J. Lichtenstein, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Investigator / Contact</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard Aplenc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Oncology Group</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Grant Zhang, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Center For Integrative Medicine, University of Maryland</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Harriet Smith, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of New Mexico</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Said A. Ibrahim, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>VA Medical Center, Philadelphia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David Wang, DO</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>OSF Stroke Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fred Saad, MD, FRCS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Université de Montréal</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hsien-yuan Lane, MD,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dept. of Psychiatry, China Medical University Hospital, Taichung, Taiwan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sara Kindberg, PhD Student</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Aarhus University, Perinatal Epidemiological Unit</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Masunori Matsuzaki, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yamaguchi University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Andrea Harzstark</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California San Francisco Medical Center-Mount Zion</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Roberto Romero, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Laurence S Lim, MBBS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Singapore National Eye Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Bahadir M Gulluoglu, MD, FACS</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Marmara University School of Medicine, Department of General Surgery, Breast and Endocrine Surgery Unit</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Douglas Ross</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Maryland Greenebaum Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jane L Burns, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Washington and Children's Hospital and Regional Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christer Sinderby, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Michael's Hospital, Toronto</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nicoletta Aimonino Ricauda, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>San Giovanni Battista Hospital, Torino</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ian Roberts, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>London School of Hygiene and Tropical Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mindaugas Jievaltas, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Urology dep. of Kaunas University of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anna Durbin, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Center for Immunization Research, Johns Hopkins School of Public Health</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Donald H Lee, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>VUMC</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sunil Rao, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Martin Mohren, PD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Magdeburg, Department of Hematology and Oncology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Victor Hoffstein, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Health Network, Toronto</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anders Galloe, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Gentofte Hospital, Copenhagen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amit Oza</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Health Network-Princess Margaret Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Barbara J. Mason, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael K. Flynn, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Rochester</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Crystal A Gadegbeku, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan/Internal Medicine/Nephrology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ronald Levy, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Leisha A Emens, M.D.,Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Charlotte M Robroeks, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Maastricht University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hidefumi Aoyama, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hokkaido University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kristina M Cordasco, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, Los Angeles</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Niels Hoiby, Prof.M.D.DSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Clinical Microbiology, Rigshospitalet</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christian Seiler, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital Bern, Switzerland</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Chanita Hughes-Halbert, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pennsylvania</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lisa Neff, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rockefeller University</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John Wagner, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Thomas Jefferson University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael W. Otto, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Philip Gilbert, FDSRCS FRCS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Queen Victoria Hospital, East Grinstead</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michelle Keightley</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Toronto</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Berthold Amann, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Franziskus Hospital, Berlin Vascular Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>CEM Griffiths, Professor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Manchester Hope Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>anders mellemgaard, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dept of Oncology, herlev university hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sarah J Goodlin, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Patient-centered Education and Research</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Imaan Bayoumi</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>McMaster University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Linda A Hatfield, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Penn State University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sangeeta M Bhorade, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Chicago</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Moshe Phillip, Prof, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Schneider Children Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul R Germonpre</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Universiteit Antwerpen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nancy Ghanayem, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital and Health System Foundation, Wisconsin</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Timothy Baker, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Wisconsin, Madison</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Loren Rude, OD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>TLC</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Armin Ernst, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Beth Israel Deaconess Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amy D DiVasta, MD, MMSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston Children’s Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hartzell Schaff, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Heather M Phelps, DO</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Healthcare of Atlanta</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Irene Ghobrial, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dana-Farber Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Camilleri, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Graduate School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hendree Jones, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Glenn E Minah, DDS, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Biomedical Sciences, University of Maryland Dental School</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hendree E Jones, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Huay C Tan, FAMS FSCAI</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Heart Institute, National University Hospital of Singapore</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Olivier Grosgurin, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital, Geneva</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert Cavaliere</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ohio State University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lorenzo Cohen, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>M.D. Anderson Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yoon Woo Koh, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dept. of Otolaryngology-Head and Neck Surgery, Soonchunhyang University College of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amin Alousi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>M.D. Anderson Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Toshiro Fujita, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Professor, Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Razelle Kurzrock, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>M.D. Anderson Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anuja Jhingran, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>M.D. Anderson Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Edith Fleischmann, M.D., Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Anesthesiology, University of Vienna Medical School, Vienna, Austria</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John F Kragh, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>US Army Institute of Surgical Research</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jussara Marcondes-Machado, PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Botucatu School of Medicine - Unesp</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jaswinder K Ghuman, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Arizona</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David J Freeman, MSc, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Lawson Health Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michele M Gottschlich, PhD, RD, CNSD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shriners Hospital for Children</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Matthias Schwab, Prof, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steven W Bruch, MD, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Aalt Bast, Prof. Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Maastricht University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jonathan Friedberg, md</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Rochester</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Corey Cutler, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dana-Farber Cancer Institute</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Thomas Bandholm, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Gait Analysis Laboratory, Department of Orthopedic Surgery, Hvidovre University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Danielle Andrade, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>College of Physicians and Surgeons of Ontario</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dan V Iosifescu, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wing King Lee, Dr</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yaumatei Psychiatric Center, Kwai Chung Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yixing Jiang, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Penn State College of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>A. Marc Gillinov, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Cleveland Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul D. Brown, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yasuhide Yamada</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Cancer Center Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Klaus Rave, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Profil Institute for Metabolic Research</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nathan Fowler, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>M.D. Anderson Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Atreya Dash, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, Irvine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fuad Shihab, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Utah</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David Ring, MD PhD</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Mass General</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rhonda Bentley-Lewis, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey Wood, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, Los Angeles</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul G Harch, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>LSU School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul Chapman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Memorial Sloan Kettering Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alberto Chiappori, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Walter Kaye, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pittsburgh</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Frederic Baron, MD, PhD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>CHU-ULg</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sarbjit S Saini, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sonya Norman</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UCSD</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hans H Herfarth, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of North Carolina</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert H Carter, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Alabama at Birmingham</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Ramsay, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Baylor Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Teut Risler, Prof. Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Universitaetsklinikum Tuebingen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christiane M Erley, Prof. Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Joseph-Krankenhaus Berlin</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Bonnie J Brehm, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Cincinnati</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joseph V Pergolizzi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NEMA Research, Inc.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Elizabeth Miller, MB BS FFPHM FRCPath</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Public Health England</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Judith Korner, MD,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Columbia University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kingo Chida, MD,PhD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Hamamatsu University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sean P.F. Hughes, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Imperial College London</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joshua J Neumiller, PharmD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington State University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Antony J. Furlan, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Neurology; the Cleveland Clinic Foundation</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David Feiglin, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>SUNY Upstate MU</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Antonio R Mott, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Baylor College of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert Bissonnette, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Innovaderm Research Inc.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gordana Vlahovic, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ki Young , Na, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Internal Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John Joseph, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>CLINICAL TESTING CENTER of BEVERLY HILLS</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hany Z Aly, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>George Washington University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John K Amory</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Washington</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Belinda Mandrell, PhD, RN, PNP</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Jude Children's Research Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alberto Sanchez-Fueyo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Clinic Barcelona / IDIBAPS, Barcelona, Spain</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Scott Gerst, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Memorial Sloan Kettering Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Donna Bacchi, Md</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>State University of New York - Upstate Medical University</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amy Mackey, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Abington Memorial Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yuksel Peker, Assoc. Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Skaraborg Hospital, Sweden</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey Rubnitz, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Jude Children's Research Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Miguel Gus, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital de Clinicas de Porto Alegre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hal F Yee, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert CG Martin, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Louisville</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zei-Shung Huang, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NTUH</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fe-Lin L. Wu, MSCP,Ph D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Pharmacy, N.T.U.H.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alfredo Falcone, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Presidio Ospedaliero di Livorno</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Plamen D Penev, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Chicago</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Hill, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Foothills Medical Centre, University of Calgary</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lars Rejnmark, MD,DrMed</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey F. Geschwind, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Markus Zabel, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital of Goettingen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ole H Simonsen, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Northern Orthopaedic Division</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dawson Church, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Soul Medicine Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wasif A Khan, MBBS, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>International Centre for Diarrhoeal Disease Research, Bangladesh</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jana BA MacLeod, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Assistant Professor Of Surgery, Emory University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David Gomez-Almaguer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Universitario Dr. Jose E. Gonzalez</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lawrence Parish, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Paddington Testing Company</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Benjamin U Nwosu, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Massachusetts, Worcester</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Julie C Lowery, PhD MHSA</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>VA Ann Arbor Healthcare System, Ann Arbor, MI</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Colleen Loo, MBBS, FRANZCP. MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of NSW</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Shunji Matsuki, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kyushu Clinical Pharmacology Research Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kanti R Rai, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NSLIJ</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joyce Black, PhD, RN</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Nebraska</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Arnon Krongrad, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Krongrad Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ira Dunkel, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Memorial Sloan Kettering Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Usha Ramadhyani, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ochsner Health System</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ahmad H Awada, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Institute Jules Bordet</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeremty Brown, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>George Washington University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anthony Jerant, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, Davis</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter Leutscher, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Aarhus University Hospital, Dept. Infectious Diseases</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pesach Lichtenberg, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Herzog Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rory P Remmel, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Olle Korsgren, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Uppsala University Hospital, Sweden</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter Chung, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Health Network, Toronto</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Manal F Abdelmalek, M.D., MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Bart Keymeulen, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital Brussel</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Harold L Atkins, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ottawa Hospital Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David Anderson, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute on Aging (NIA)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael R Pranzatelli, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Pediatric Neuroinflammation Organization, Inc.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mauri Lepantalo, M.D., PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Vascular Surgery, Helsinki University Central Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Francois Nosten, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Malaria Research Unit, Thailand</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gisela Sjoegaard, Professor</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>University of Souther Denmark</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Chong-Xian Pan, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, Davis</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Maria K Hordinsky, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jie Wang, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>China Academy of Chinese Medical Sciences</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jennifer A Pryor, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eyal Banin, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hadassah Medical Organization</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael E. Hoffer, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>U.S. Military</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Margaret Powers, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>International Diabetes Center at Park Nicollet</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stefania Costi, Dr</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Modena and Reggio Emilia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Darren Sigal, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Staff Scripps Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Benoit Girard, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Anapharm</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>R Graham Barr, MD/DrPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Columbia University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Iyad S Saidi, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Metropolitan ENT and Facial Plastic Surgery</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tzong Hsi Lee, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Far Eastern Memorial Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eric S Hungness, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Northwestern University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Charles M Peniston, MD,FRCP</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Cardiac surgery-S.R.H.C</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ronald M Krauss, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital &amp; Research Center Oakland</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Thuan Dao, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Toronto</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tonya M Palermo, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Seattle Children's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christian Gerloff, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Neurology, University Hospital Hamburg-Eppendorf</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gary S Kitay, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Jacksonville Orthopedic Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Krassen Nedeltchev, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kantonsspital Aarau</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mona O. Bingham, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>LTC, Chief Nursing Research Services</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mark A Lumley, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Wayne State University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Naoki Ohmiya, M.D., Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Nagoya University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Antonio R. Pizarro,, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>SFBC Ft. Myers, Inc</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Calvo Rafael, Rn</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Susanna Hegewisch-Becker, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Onkologische Schwerpunktpraxis Eppendorf</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fredric A Hoffer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Seattle Children's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Junbo Ge</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shanghai Zhongshan Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>So Ran Hong, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Novum Pharmaceutical Research Services</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael A. Badurddoja, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Center for Neurosciences</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Annemarie L Lee, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Bayside Health</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yu-Chang Yeh, M.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Leorey N Saligan, C.R.N.P.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Nursing Research (NINR)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Cheryl Oncken, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UConn Health</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter Chung, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Health Network, Toronto</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Bruno Carneiro de Medeiros</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John R Knight, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston Children’s Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Daniel C Sadowski, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Royal Alexandra Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gareth Veal</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Newcastle Upon-Tyne</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Barbara Daly, PhD, RN</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Benoit Girard, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Anapharm</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>April Bleich, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Texas Southwestern Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pietro Renzulli, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Bern University Hospital, 3010 Bern, Switzerland</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Charles Ascher-Walsh, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mt Sinai School of Medicine, Dept Obstetrics and Gynecology</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Laurent MORTIER, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre Hospitalier Régional et Universitaire de LILLE</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Roderick Malone, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Clinical Research Center (Cincinnati)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alejandro Sanchez</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Río Carrión</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Melissa DelBello, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Cincinnati</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rema A Gupta, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rush University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregory Daniels, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Diego</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Beth A Malow, MD, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Vanderbilt University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter JH Jones, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Manitoba - Richardson Centre for Functional Foods and Nutraceuticals</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paola Papaldo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Regina Elena Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Susanne K. Kjaer, Professor MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Inst. of Cancer Epidemiology,Danish Cancer Society</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Karen E Hansen, MD, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Wisconsin, Madison</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Evan Yu</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>ECOG-ACRIN Cancer Research Group</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ki-Bae Seung, MD, PhD</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Seoul St. Mary's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kenya Nasu, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Toyohashi Heart Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ervin Epstein, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital &amp; Research Center Oakland</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Antonio Gil-Nagel, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Ruber Internacional La Masó 38, Mirasierra 28034 Madrid, Spain</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eliane C. Pereira, Master</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Tuiuti of Parana University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James P Steinberg, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Emory University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stella M. Davies, MBBSPhd MRCP</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David H McDermott, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sarah L Blair, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Diego</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James D Carlson, Pharm. D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>PRACS Institute, Ltd.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Philip Bejon, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Oxford Radcliffe Hospitals Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregory Austin, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard Ambinder, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Siegward M Elsas, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Oregon Health and Science University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Malcolm R Fraser, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Synergy Health Solutions</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eric M Reiman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Banner Alzheimer's Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stewart J Levine, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mark J. Manary, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John Kessler, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Northwestern Memorial Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kalpana P Padala, MD, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Nebraska</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yeong-Shiau Pu, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marina Reznik, MD, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Montefiore Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Efstratios Kolibianakis</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Unit for Human Reproduction</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sun U. Kwon, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Departement of Neurology, Asan Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gary V Heller, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hartford Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stanislaw Klek, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Jagiellonian University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alberto Sanchez Fueyo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Clinic Barcelona/IDIBAPS, University of Barcelona</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Maria Antonia Gómez-Mendieta</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Universitario La Paz</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jonathan Kaufman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Emory University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anil Bhansali, DM</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Postgraduate Institute of Medical Education and Research</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Heather Mertz, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Wake Forest University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ira Dunkel, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Memorial Sloan Kettering Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joseph J Cullen, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Iowa</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Britt Burton-Freeman, MS, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Illinois Institute of Technology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joel S. Perlmutter, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Benoit Girard, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Anapharm</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Doug Bremner, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Atlanta VA Medical and Rehab Center, Decatur</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nilofer Azad</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ib A Jacobsen, DMSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Odense University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Haibo Qiu, MD, Phd</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Southeast University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ron E Polk, Pharm.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Virginia Commonwealth University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eman Hammad, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Jordan/ Faculty of Pharmacy</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kenneth K Wang, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic Rochester MN</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Vaughn I Rickert, PsyD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Indiana University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dong-Tsamn Lin, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital,Taipei,Taiwan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mahmoud F Sakr, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Professor of Surgery, Faculty of Medicine, Alexandria University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Shao-Yi Cheng, MD, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John D Piette, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>VA Ann Arbor Healthcare System</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Elizabeth Reed</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Nebraska</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sonia A Duffy, PhD, RN</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christopher Attinger, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Georgetown Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Judith A. Long, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pennsylvania</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Heidi L Roth, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of North Carolina</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Constantine Manthous, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Bridgeport Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christian Breymann</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Zurich</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gaetano Morelli, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>MDS Pharma Services</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard B Schwab, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Diego</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Daniel Menendez, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Environmental Health Sciences (NIEHS)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lene Krenk, Doctor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rigshospitalet, Denmark</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amanda Newton, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Faculty of Medicine and Dentistry, University of Alberta</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joanne Kurtzberg, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeong-Yeon Hong, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Anesthesiology &amp; Pain Medicine, Severance Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marc Gunter, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Albert Einstein College of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>K. Luan Phan, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hiroyu Hatano, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James Eastham, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Memorial Sloan Kettering Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Aya Kamaya</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mohamad Al-Hosni, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Louis University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rita Mangione-Smith, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Seattle Children's Hospital/University of Washington</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Evelyn Attia, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>New York State Psychiatric Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rodica Pop-Busui, MD, Ph.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter Rechmann, DDS, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco, School of Dentistry</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jian Shi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shanghai Changzheng Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stefan Herrmann, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Erlangen-Nürnberg</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rebecca Landa, PhD, CCC-SLP</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sandrine Faivre</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hopital Beaujon</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gordon W. Peterson, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Neurology, Faculty Physicians and Surgeons of Loma Linda University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stephen McRae, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UT MD Anderson Cancer Center</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joseph Fay, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Baylor Health Care System</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kathleen T Brady, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Medical University of South Carolina</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Krittaecho Siripassorn, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Bamrasnaradura Infectious Diseases Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Chulani T Kappagoda, M.D., Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, Davis</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lars Klareskog, Professor</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Karolinska Institutet</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amit Oza</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Health Network-Princess Margaret Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rodrigo Jorge, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of São Paulo</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Oskar Hansson, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Lund University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ala' I Sharara, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>American University of Beirut Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Andrew Ko</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UCSF-Mount Zion</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard Finn</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Translational Oncology Research International</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>G. A. Rongen</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Radboud University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Takefumi Matuo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hyogo Prefectural AWAJI Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Matthew Graves, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Mississippi Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kartik Jhaveri, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Health Network, Toronto</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Bertil Lindahl, professor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Uppsala University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Brian K Auge, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>United States Naval Medical Center, San Diego</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tom Jaksic, M.D, Ph.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston Children’s Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Cay Anderson-Hanley, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Union College</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kimberly F Lairet, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>US Army Institute of Surgical Research</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregg W. Stone, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Columbia University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Karsten Knobloch, FACS, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hannover Medical School</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John R. Knight, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston Children’s Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mark Basik, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Segal Cancer Centre, Jewish General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ad Masclee, Prof. Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Head of dept</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Thomas C Bailey, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amir Hamrahian, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Cleveland Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>RIchard Ambinder, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregory Haugen, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cetero Research, San Antonio</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yuke Tian, M.D.</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hubert H. Fernandez, MD, FAAN</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Center for Neurological Restoration</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Naomi E Aronson, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Uniformed Services University of the Health Sciences</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert Noveck, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eric Simpson, MD, MCR</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Oregon Health &amp; Science University, Department of Dermatology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dr. Milos R Popovic, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Toronto Rehabilitation Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yves Gandon, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rennes University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Vincent Danel, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital, Grenoble</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Scott Roth, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Kentucky</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sven Mahner, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Medical Center Hamburg-Eppendorf, Department of Gynecology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David I Laibson, Ph.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Bureau of Economic Research</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lisa A Conboy, ScD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>New England School of Acupuncture</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dominick Shaw, Dr</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Nottingham</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Denise M McCarthy, MB FCARCSI</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cork Universtiy Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ioannis Pallikaris, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Crete</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Chantal P Bleeker-Rovers, MD PhD</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Radboud University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eric D Donnenfeld, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ophthalmic Consultants of Long Island</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert B Innis, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Mental Health (NIMH)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jens Funk, Prof. MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital Zurich, Ophtalmic Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christelle LEVY, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre François Baclesse</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ken Resnicow, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tavis S Campbell, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Calgary</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Damian A Borbolla, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Italiano de Buenos Aires</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steven Deeks, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Californa, San Francisco</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael A Mont, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sinai Hospital of Baltimore</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Minsoo Park</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Severance Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Geoffrey A Block, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Denver Nephrologists, PC</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Antigona Hasani, MD,MSC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Clinical Centre of Kosova</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yoshihisa Yamano, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Marianna University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tanir Allweis, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kaplan Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steve Burton, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pittsburgh</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amir Shafat</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Limerick</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>L Rankin, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Pharmaceutical Profiles, Ltd</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pavel A Bezdetko, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kharkov District Clinical Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David F Scott, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Spokane Joint Replacement Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey Infante, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>SCRI Development Innovations, LLC</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John P Miller, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Marrow Donor Program</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sandra Connolly, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Celerion</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Satoshi Kusuda, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Tokyo Women's Medical University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Azim Gangji, MD, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Joseph's Health Care London</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Olav Sletvold, MD,PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Neuroscience, Norwegian University of Science and Technology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Manish Shah, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Weill Medical College of Cornell University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michele Aubin, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Laval University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Roberta A Jong, FRCPC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sunnybrook Health Sciences Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>R. Graham Barr, M.D., Dr.PH.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Columbia University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Najib Ayas, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of British Columbia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Santiago Horgan, M.D., FACS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UCSD</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kun Ho Yoon</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Seoul St. Mary's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kenneth L Miller, PT, DPT</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Catholic Home Care</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lisa M Quinitiliani, PhD, RD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Deirdre D Dawson, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Baycrest centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Egbert Seidel, Prof.Dr.med.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Zentrum für Physikalische und Rehabilitative Medizin des Sophien- und Hufeland-Klinikums Weimar</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Laurel Northouse, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan School of Nursing</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eugenio A Maul, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Pontificia Universidad Catolica de Chile. Hospital Sotero del Rio.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lauren B Krupp, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stony Brook University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sriram Ramaswamy, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Veterans Affairs/NWIHCS</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Charles W Hogue, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tanios Bekaii-Saab</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ohio State University Comprehensive Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rebecca Wong, MB ChB</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Health Network, Princess Margaret Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Samuel Adler, Prof</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Given Imaging Ltd.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Supachai Rerks-Ngarm, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sergio Salerno, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Palermo</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Suzanne M Miller-Halegoua, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fox Chase Cancer Center</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Øivind ØK Klaastad, PhD, MD</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Oslo University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hiroto Inaba, MD,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Jude Children's Research Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ana Molina, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Memorial Sloan Kettering Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yuji Kiuchi, Professor</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Showa University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert D Galiano, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Northwestern University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Qingyu Xiu, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shanghai Changzheng Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Frederick Lansigan, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dartmouth-Hitchcock Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Susan Crowe, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hui Zhu, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Chengdu PLA General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nicholas Shaheen, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Coordinating/Study PI</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zhen Jun Wang, M.D.</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Beijing Chao Yang Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Josien Riphagen-Dalhuisen, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Medical Centre Groningen/ University of Groningen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gerhard Jahreis, Prof. Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Friedrich Schiller University Jena, Institute of Nutrition, Department of Nutritional Physiology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Victor H. Gonzalez, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Valley Retina Insitute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Denis Audet, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>PharmaNet</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Celeste Bello, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Trudy L. Robertson, MSN</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fraser Health Authority</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sabrina Houthoofd, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Universitaire Ziekenhuizen Leuven</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jean-Sebastien Roy, PT, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Laval University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jordi M Mones, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Institut de la Macula i de la Retina</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Katherine A Barsness, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lila Nachtigall, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rapid Medical Research of New York</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wei-Li Hsu, PT, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>MEIRAV BRAVERMAN, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>HaEmek Medical Center, Afula, Israel</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jens Overgaard, Prof., MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Danish Head and Neck Cancer Group</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Finn O Larsen, M.D. , Ph.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Unaffliated</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Frederic Anselme, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital, Rouen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ziva Novak Antolic, PhD, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Medical Centre Ljubljana</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marco Mielcarek</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert J Noveck, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul Devita, MSc, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The College of Health and Human Performance, Department of Exercise and Sport Science, Minges Coliseum Greenville, U.S.A.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Thomas R. Pieber, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Medical University of Graz</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Evelina Buinauskaite, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Lithuanian University of Health Sciences, Medical Academy, Department of Skin and Venereal Diseases</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ting Bao, MD, DABMA</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Maryland Marlene &amp; Stewart Greenebaum Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Glenn S. Murphy, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NorthShore University HealthSystem</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nimrod Adi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kaplan Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tracey A Rouault, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John Beyer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wai T Wong, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Eye Institute (NEI)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Akira Horiuchi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Showa Inan General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alejandro Interian, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Veteran Affairs, New Jersey</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Matthias Eikermann, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Andrew Skinner, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Paul's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ophir Klein, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>YULONG HE, PhD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Johan Olsson, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>KPL Good Food Practice AB</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>George Georges</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zeno Bisoffi, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre for Tropical Diseases, Negrar (Verona), Italy</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Quan D Nguyen, MD, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Wilmer Eye Institute - Johns Hopkins University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ronald Postuma, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Montreal General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David Simmons, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ascensia Diabetes Care</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pernille L Petersen, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>HOC, anesthesiology, Rigshospitalet, Copenhagen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Claire L Shovlin, PhD MA MB BChir FRCP</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Imperial College London</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eva J Kantelhardt, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Gynecology Martin Luther Univ Halle/Germany</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alireza Esteghamati, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Tehran University of Medical Sciences</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul Ridker, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Brigham and Women's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Elliot Israel, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Brigham and Women's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nicholas Moore, MD, PhD</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Université Victor Segalen Bordeaux 2</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Su Ying Low, BMBCh</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Singapore General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dustin A Heldman, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>CleveMed Inc. also dba Great Lakes NeuroTechnologies</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Simone A French, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Habib Habib, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Saint Michael's Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hélady S Pinheiro, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fundação IMEPEN</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stephane Cook, MD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>University Fribourg</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Erik Kubiak</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Orthopedic Surgery Operations</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Betty Ferrell</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>City of Hope Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hyman Hops, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Oregon Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Suchitra Krishnan-Sarin, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yale University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Maria Liza Lindenberg, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Cancer Institute (NCI)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kamlesh Khunti, MB BS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Leicester</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Shi Yuankai, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nilofer Azad</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>SKCCC at JHMI</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James White, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>London Health Sciences Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Manee Raksakietisak, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mahidol University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Scott S De Rossi, DMD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>GHSU</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ellen M Stein, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mija Yun</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>National Medical Center, Seoul</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Judith A. Long, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Haiyan Li, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Peking University Third Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Leonardo Calò, FESC MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Policlinico Casilino</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Simon J Brooker, DPhil</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>London School of Hygiene and Tropical Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Birgit Linnemann, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Goethe University Hospital, Division of Vascular Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Usha Ramakrishnan, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Emory University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Julie Dunn, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Poudre Valley Health System</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anurag Singh</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Roswell Park Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nelson M Oyesiku, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Emory University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ming-Chung Wang, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Chang Gung Memorial Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wang Weu</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Comprehensive Weight Management Center Taipei Medical University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kyung Sang Yu, Ph.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Seoul National University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Samuel T. Kuna, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Philadelphia VA Medical Center, Philadelphia, PA</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Karin Potthoff, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Center for Tumor Diseases, Heidelberg</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Diana Hernandez-Blanco, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Central \"Dr. Ignacio Morones Prieto\"</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zhao Xiang Bian, MD, Ph. D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>School of Chinese Medicine, Hong Kong Baptist University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gary Yang, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>gyang@llu.edu</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ronald G Crystal, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Weill Medical College of Cornell University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Subrat K Acharya, DM</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Neal D Barnard, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Physicians Committee for Responsible Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Matthias Schieker, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ludwig-Maximilians - University of Munich</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wei-Li Hsu, PT,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>School of physical therapy, National Taiwan University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Margherita Fontana, DDS, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dawn Bowers, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Florida- PHHP, CHP</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lionel Prin, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital, Lille</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nadjib Hammoudi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cardiology department - Pitié Salpêtrière Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hassan Arshad, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Roswell Park Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paulo R Menezes, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Sao Paulo</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter Choi, MBcHB PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Imperial College London</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kathryn J Stephens, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Nationwide Children's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Karen Miller, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kevin O. Hwang, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The University of Texas Health Science Center, Houston</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Timothy J Harris, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massey Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Howard A Liddle, EdD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Miami</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Oleg Shapiro, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>State University of New York - Upstate Medical University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christian Seiler, MD, Prof.</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>University Hospital Inselspital, Berne</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Guillermo Izquierdo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Section Chief of Neurology, University Hospital Virgen Macarena, Spain</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yu-Chang Yeh, M.D., Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Annalise Noelle Larson, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steven J Russell, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pierre-Emmanuel Bouet, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Université de Montréal</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Thomas B. Campbell, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yu Xin</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Beijing No.6 Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tijn Kool, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>IQ healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Heiner C Bucher, Prof Dr med</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amir Fathi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nilofer Azad</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard Barohn, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Kansas Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stephen M Perle, DC, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Bridgeport</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dr Mark A Glazebrook, MSc PhD Dip Sports Med MD,FRCS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Nova Scotia Health Authority</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Maria O'Sullivan, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Trinity College Dublin</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lars G Börjesson, Ass Prof</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Surgery, Sahlgrenska, Göteborg</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Farooq Naeem, MRCPsych,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Pakistan Association of Cognitive Therapists</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eric M Deshaies, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>SUNY Upstate Medical University Neurosurgery</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Patrick Couture, MD,FRCP,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Laval University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Raj Paspulati, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Case Comprehensive Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jason Kovacic, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Icahn School of Medicine at Mount Sinai</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Behrooz Rahimi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>MD, Departement of ophtalmology, Isfahan University of Medical Sciences, Isfahan, Iran</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John Christodouleas, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Klavs W Hansen, MD, dr.med.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Medical department, Diagnostic Center, Regional Hospital Silkeborg, Denmark</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amy Cyr, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alan E. Kazdin, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yale University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steven P Ringel, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nisha Acharya, MD, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>William L Bargar, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Orthopaedics, University of California at Davis</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amr M Elkhouli, ass prof</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>October 6 University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Erik Lunell, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Croel AB</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rubina Heptulla, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Montefiore Medical Center, Albert Einstein</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Maurice Laville, MD, PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de Néphrologie Bâtiment 3C, 3ème étage, Chemin du grand Revoyet 69495 PIERRE-BENITE</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zhao jiajun</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Shandong Province Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Arnaud Lemmers, MD,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Donna Johnston, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital of Eastern Ontario</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jacques Bergman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jean-Luc Ardilouze, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Clinical Research Center Étienne-Le Bel of the Sherbrooke University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Moishe Liberman, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Changsheng Ma, doctor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Beijing Anzhen Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rose Yang, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Cancer Institute (NCI)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard Greil, Prof.Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Universitätsklinik für Innere Medizin III, Salzburg</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rui Li, chief doctor</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Hand Sugery Department of the China-Japan Union Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jong Ho Lee, Ph.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yonsei University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marguerite L Bartholomew, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>John A Burns University of Hawaii School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rachel Freedman, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dana-Farber Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffery Feinstein, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford Hospital and Clinics and Lucile Packard Children's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Andrea H Kayo, PHD student</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Federal University of São Paulo</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ajay Gopal</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey M Miller, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>New York State Psychiatric Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pavani Chalasani</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Arizona</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alan R Mackie, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Quadram Institute Bioscience</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ning Ma, Doctor</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Beijing Tiantan Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Brian Clarke, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Staff Cardiologist and Clinical Assistant Professor, Division of Cardiology, QE II Health Science Centre, Dalhousie University and Capital District Health Authority</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stephen Ryder, Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Nottingham University Hospital NHS Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Roger Goldstein, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>West Park Healthcare Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marja L Mutanen, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Helsinki University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Adnan Bayram, Asst. Prof.</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>TC Erciyes University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anne Mathews, PhD, RD, LDN</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Florida</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jean-Marc LEGER, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hôpital de la Pitié Salpêtrière - Paris 75013</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Irene Sia, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christian P Fischer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rigshospitalet, Denmark</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gene Bowman, ND, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Oregon Health and Science University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Choi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UCSD and CLL Consortium</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Abraham G Kocheril, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Christie Clinc</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marcus Jonsson, PhD Student</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Region Örebro Län</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Donna Shelley, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NYU School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Chyi-Feng Jan, MD, MSc, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregory F Carolan, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Luke's University Hospital and Health Network</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tan X Hua</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Guangzhou 8th hospitol</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anne E McCarthy, MD, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Ottawa Hospital Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Liesbeth J Boersma, M.D., Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Maastro Clinic, The Netherlands</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amir Lerman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rick Haas, MD,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NKI</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mary Politi, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Washington University in St. Louis School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Georg Nilius, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Helios Klinik Hagen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>MinYoung Kim, M.D., Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>CHA University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey Burns, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Kansas Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Suzan M Shalaby, Ass.lecturer</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cairo University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marilyn S Nanney, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michelle Pezzani, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>El Camino Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sasha Gulati, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Olavs Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jacques Genest, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Research Institute of the McGill University Health Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>William A. Marston, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Division of Vascular Surgery, UNC at Chapel Hill</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lin Shen, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Peking Universtiy Cancer Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marina Caskey, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rockefeller Univesrity</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John Racadio, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Andrea Cercek, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Memorial Sloan Kettering Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jincheng Yang, Doctor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Diana M Gibb, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Medical Research Council</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wen-Shyong Liou, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Taichung Veteran General Hospital, Taiwan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Margit Janat-Amsbury, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Utah</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rasmus Bechshøft, Ph.d. stud</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Bispebjerg Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Elizabeth Maher, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UT Southwestern Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alessandra Bruns, Md, FRCPC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Université de Sherbrooke</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alain DIDIER, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hôpital Larrey, Toulouse, France</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Patrick Luyten, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>KULeuven, Belgium</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Emiliano Rodriguez, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fundacion Infosalud</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Grimley, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mark Agulnik, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Northwestern University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Clare Liddy, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Bruyere Research Institute, C. T. Lamont Primary Health Care Research Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Laura Murray, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul Walker, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Brody School of Medicine ar East Carolina University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Carlos J Roldan, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Texas</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Beom S Jeon, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Seoul National University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yu-Hsiang Chou, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NTUH Yun-Lin branch</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kwan-chee Allen Chan, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Chinese University of Hong Kong</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Timothy Bailey, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>AMCR Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jenny C Chang, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Methodist Hospital System</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Amita Avadhani, DNP</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Rutgers University and Saint Peters University Hospital</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nikolaus Marx, Univ.-Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Internal Medicine I, RWTH Aachen University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Carole Massabeau, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Institut Claudius Regaud, Toulouse (France)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paula S Lee, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>MOHSEN S ELALFY, PROF.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ain Shams University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Qifa Liu, MD.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Nanfang Hospital of Southern Medical University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard Mangwi Ayiasi, Masters</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Makerere University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tamara T Perry, MD,FAAP</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Arkansas</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Erik E Sørensen, PhD Nursing</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Clinical Nursing Research Unit, Aalborg University Hospital, Denmark</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Staffan K Berglund, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Umeå University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Raj Shah, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Blake K Scanlon, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>VA Palo Alto Health Care System, Palo Alto, CA</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ulrika Birgersdotter-Green, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Diego</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alejandro González-Ojeda, Ph.D., M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Instituto Mexicano del Seguro Social</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard R Anderson, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Adam O Hebb, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Colorado Neurological Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tine Tholstrup, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Nutrition, Exercise and Sports, University of Copenhagen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Shirley Owusu-Ofori, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Komfo Anokye Teaching Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Maria B Grant, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Alabama at Birmingham</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yin-Hsiu Chien, M.D., PhD.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rolando Espinosa, M. D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Rehabilitation</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert Middleton, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Royal Bournemouth Hospital NHS Foundation Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dwight Heron, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pittsburgh</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert Kirsner, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Miami</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nancy Lee</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NRG Oncology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fabio H Rossi, PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dante Pazzanese</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Maziar Lalezary, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Southern California Desert Retina Consultants</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Irene Hoesli, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital, Basel, Switzerland</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>E. Ray Dorsey, MD, MBA</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Rochester</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kristina Drott, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Lund University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Claude Schulman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Edith cavell clinic, Belgium</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jennifer Knox, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Princess Margaret Cancer Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joel Moss, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter E Morris, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Wake Forest University Health Sciences</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nong Yang, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hunan Province Tumor Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Burris R Duncan, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Arizona</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jinlin Hou, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Nanfang Hospital of Southern Medical University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Susan M James, MBA</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Savannas Forever Tanzania</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anselm Crombach, Dr</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Konstanz</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mihai Netea, Prof. Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Radboud University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter C Petersen, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Finsen Center, Rigshospitalet</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Cecilia Pascual-Garrido, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sira Bang, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Inje University Seoul Paik Hospital, Seoul, Korea</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nikolaj Raaber, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Central Denmark Region</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jong Ho Lee, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yonsei University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Deborah J Jones, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UNC Chapel Hill</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jennifer D Gottlieb, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston University</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard F. Schlenk, Prof. Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Universitätsklinikum Ulm, for the AML-SG group</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pedro Cahn, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fundacion Huesped</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hassan M Ali, Lecturer</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cairo University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Prapa Kanagaratnam, MBBChir PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Imperial College Healthcare NHS Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Chun-Fu Lai, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ionel Droc, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Emergency Clinic Center for The Army For the Cardiovascular Diseases</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ryan Hurt, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Douglas Naudie, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>London Health Sciences Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fay B Horak, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Oregon Health and Science University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rachel Patzer, PhD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Emory University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jacob Rosenberg, MD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Professor</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tae Hoon Ahn</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Gachon University Gil Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sharmin Ghaznavi, M.D., Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mark H Gotfried, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Pulmonary Associates, PA</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Federico Piccioni, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jean-Yves Blay, Pr</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre Léon Bérard, Lyon</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ann L. Horgas, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Florida</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jacques De Keyser, MD PhD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Universitair Ziekenhuis Brussel</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Niels H Secher, MD PHD Prof</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Rigshospitalet, University of Copenhagen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Dreher, Univ.-Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>RWTH Aachen University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James Ohr, DO</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Attending Physician, UPMC Hillman Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Domingo Hernandez, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Carlos Haya Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Taniga Kiatchai, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mahidol University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nancy R Rizzo, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>EPIC Research and Diagnostics</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jishnu Das, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>World Bank</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marina Daniele, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>London School of Hygiene and Tropical Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stuart Phillips, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>McMaster University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Brenda Fahy, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Florida</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Johan A Erasmus, MBChB</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Netcare Moot Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Damian E Dupuy, MD FACR</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Lifespan-Rhode Island Hospital, Rhode Island, USA</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Purwita Laksmi, MD,SpPD-KGer</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Division of Geriatrics, Department of Internal Medicine, Universitas Indonesia-Cipto Mangunkusumo General Hospital, Jakarta</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jonathan V Roth, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Albert Einstein Healthcare Network</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Georges Daccache, M.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital, Caen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Anne-Lise Fiant, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital of Caen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ahmed M Maged, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kasr Alainy medical school</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Li-Shiun Chen, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington University Asst Prof of Psychiatry</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregory A. Abel, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dana Faber Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Steven C Cramer, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, Irvine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gurjeet S Birdee, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Vanderbilt University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey Hull, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Richmond Vascular Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Audrey Marshall, MD</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Boston Children’s Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lisa R. Young, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Vanderbilt University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jamie Baydoun, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Emergency Medicine Physicians</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Volker Mai, PhD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Associate Professor</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jesper P. Hansen, MD</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>University of Copenhagen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David M Raffel, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Asch Muriel, PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>-Hôpital Robert Debré, Service de psychiatrie de l'enfant et de l'adolescent</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kamal Kishore, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Illinois Retina and Eye Associates</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>gurinder bains, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Loma Linda University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jayme Mancini, DO</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>New York Institute of Technology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jiayuan Sun, MD,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shanghai Chest Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Abrahim Al-Mamgani, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Netherlands Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Virender S Sangwan, MBBS, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>LV Prasad Eye Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nanette Santoro, MD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>John Cairney, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>McMaster University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Bohdan Nosyk, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Simon Fraser University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jennifer Czwornog, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christopher Halloran</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Liverpool</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hai Li</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Digestive Department of Renji Hospital,Shanghai Jiao Tong University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kelly Allison, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pennsylvania</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pejman Jabehdar Maralani, MD FRCPC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sunnybrook Health Sciences Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Charles A Leath</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NRG Oncology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Andreas Fritsche, Prof. Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital Tuebingen</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jason A Yoho, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mission Research, New Braunfels, TX</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marina Kremyanskaya, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Icahn School of Medicine at Mount Sinai</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David MacLeod, MB BS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke Anesthesiology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stefan Breitenstein, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kantonsspital Winterthur KSW</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ofir Frenkel, M.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sheba Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>David L. Katz, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yale-Griffin Prevention Research Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Daniel J Jackson, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Wisconsin, Madison</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michal Fried, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fauze Maluf-Filho, MD, PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cancer Institute of São Paulo</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sean PD MacBride-Stewart, MSc</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Dundee</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ailin Luo, MD.,PhD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alex Krist, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Virginia Commonwealth University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Shernan Holtan, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Afshan Hameed, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, Irvine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Madhur Garg</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Albert Einstein College of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yuji Kodama, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kodama Eye Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Cecilia Invitti, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Istituto Auxologico Italiano</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Weon Kim, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Kyunghee University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Catherine Lok, PU-PH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>CHU Amiens, Service de Dermatologie</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gregory D Zimet, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Indiana University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Natalia McInnes, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>McMaster University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Emerson C. Perin, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Texas Heart Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Reza Momenan, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Guy Jerusalem, Prof.</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>University of Liege</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Weimin Mao, MD.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Zhejiang Cancer Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Moishe Liberman, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre Hospitalier Universitaire de Montreal</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Beaussier Marc, PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Assistance publique hopitaux de Paris - APHP</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zhi Guo, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Tianjin Medical University Cancer Institue and Hospital</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Peter A LeWitt, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Henry Ford Hospital - West Bloomfield</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Vladimir M Kushnir, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tudor C Poerner, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Universitätsklinikum Jena</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ronen Rubinshtein, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Carmel Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Raymond Cross, MD, MS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Maryland</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>José Valber Meneses, MD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Federal University of Bahia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eric Larose, DVM, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sara Lazar, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mass. General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lorie G Richards, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Utah</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Asif Khan, MBBS, MRCSI</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>F. Joseph McClernon, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Patrice D. Cani, Professor</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>Université Catholique de Louvain</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yong Huo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Peking University First Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pete Kollbaum</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>CORL, Indiana University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Enrique Morales Ruiz, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Universitario 12 de Octubre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rick M Fairhurst, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Denise L Campbell-Scherer, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Alberta, Department of Family Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Helen Minnis</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Glasgow</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stuart Katz, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>New York University Medical School</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Laurent Mortier, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital, Lille</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>xiaobing Fu</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Chinee PLA General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James L Rudolph, MD, SM</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Providence VA Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey R Botkin, MD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Utah</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alan Chiem, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Olive View-UCA</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>martyn parker</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Peterborough hospital nhs trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marin Kollef, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Washington University School of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Santisteban Marta, Doctor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Staff of the department of Oncology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nicholas Christakis, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Yale University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Adalsteinn Gunnlaugsson, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Lund University Hospital, Department of Oncology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gabriel Olveira Fuster, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Regional Universitario de Málaga</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Vanja Giljača, M.D. PhD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>University Hospital Rijeka</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Artur Ludwin, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ludwin &amp; Ludwin Gynecology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jun Zhang, Master</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Xiamen University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ana M Rodriguez, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Texas Medical Branch (UTMB)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zeynep Eroglu, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Brent A. Bauer, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic in Rochester, MN</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>María L Evia-Viscarra</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Pediatric Endocrinology, Hospital Regional de Alta Especialidad del Bajío</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert Petrella, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Western University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hyongjin Jung, Dr. PhD.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Inje University Sangye Paik Hospital,</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Aki Sinkkonen, Docent</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Helsinki University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Fiore, MD, MPH, MBA</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Wisconsin, Madison</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Susanna Jernelöv, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Karolinska Institutet</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Rob Hinchliffe</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St George's, University of London</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Guangda Xiang, MD,PhD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Wuhan General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sheldon Yao, DO</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>NYITCOM</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lakshmanan Krishnamurti, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Emory University</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Linda Fleisher, PhD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital of Philadelphia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Glen E Foster, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of British Columbia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Meera Shah, MBChB</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jun Jun She, M.D.; PhD.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Roberto Bottino, Doctor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fondazione Poliambulanza Istituto Ospedaliero</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Richard Laing, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Boston University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ira Braunschweig</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Albert Einstein College of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Karen Basen-Engquist, PHD, BA, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>M.D. Anderson Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pramod K Mishra, Phd</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>GIPMER</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Abdiwahab Hashi, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Addis Ababa Univeristy</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Carlos David, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Lahey Hospital &amp; Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James McCarthy, Prof</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Q-Pharm Pty Ltd and QIMR Berghofer Medical Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Patricia FRANCO, MD PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Service d'exploration et pathologie du sommeil Hôpital Femme Mère Enfant, 59 bd Pinel 69677 BRON Cedex</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ashley Rosko, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ohio State University Comprehensive Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Doug Morgan, MD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer enter</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Johane Allard, MD, FRCPC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Health Network, Toronto</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yung-Tsan Wu, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Xiaodong Sun</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shanghai General Hospital, Shanghai Jiao Tong University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alexa Hollinger, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital, Basel, Switzerland</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yuankai Shi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ilya Nasrallah, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Pennsylvania</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Christopher J. Rhee, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Baylor College of Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Bernhard Schwartz, MSc</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>University of Applied Sciences Upper Austria</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sharon J Herring, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Temple University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ashraf Habib, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Beresford</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Alder Hey Children's NHS Foundation Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pradeep Bhandari, MBBS, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Portsmouth Hospitals NHS Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Shannon Morrison, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Faculty</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dustin Deming</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Wisconsin, Madison</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Elias F. Jarade, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Beirut Eye Specialist Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Charles Cunningham, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sunnybrook Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Arlette Da Silva, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre Oscar Lambret</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fabien Pelletier, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jing Wang, PhD, MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The University of Texas Health Science Center, Houston</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Emmanuel Haffen, Prof</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lisa Licitra, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Karin Kallander, MSc, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Malaria Consortium</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Fengchun Zhang</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Peking Union Medical College Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Matthew W Johnson, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Johns Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Emiliano Gogniat, PT</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospital Italiano de Buenos Aires</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Antje Koller, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Vienna, Faculty of Social Sciences, Institute of Nursing Science</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Susan Burden, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Wake Forest Baptist Health Eye Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Marc Lilot, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hospices Civils de Lyon Direction de la Recherche Clinique et de l'Innovation</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>VOGIN Guillaume, MD,PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Institut de Cancérologie de Lorraine</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Athena Zuppa, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital of Philadelphia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Gavin Murphy</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Leicester</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Petr Neuzil, Prof.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Na Homolce Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Bas Kietselaer, M.D. PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Maastricht UMC</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yongjun Fang, Ph.D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Nanjing Children's Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>lixin xie, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Chinese PLA General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Shelley R Sage</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>King's College London</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Victor G Carrion, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Carl Haas, MLS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Michigan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jianggang Song, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lars A Hagberg, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Region Örebro County</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yuan-Yang Cheng, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Physical Medicine and Rehabilitation</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hao Ying, PHD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shanghai First Maternity and Infant Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Denitza Blagev, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Intermountain Health Care, Inc.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jason A Roberts, Professor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Royal Brisbane and Womens Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Theodosia Kalfa, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Kathryn M Edwards, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Vanderbilt Vaccine Research Program</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Brian Fredman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Israel: Clalit Health bServices</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Keri McCrickerd, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Clinical Nutrition Research Centre</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eileen Connolly, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Assistant Professor Of Radiation Oncology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Norbert Avril, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Carrie Hruska, PhD R-D</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Edwin J Asturias, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Wei-Chieh Huang, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Topcon Medical Systems, Inc.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Lisa Isaac, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Hospital for Sick Children</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeong Hoon Yang</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Samsung Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Juhee Cho, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Samsung Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Tippi Mackenzie, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of California, San Francisco</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Idit Matot, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Tel-Aviv Sourasky Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>VITTORIO FRANCIOSI, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UO ONCOLOGIA MEDICA, AZIENDA OSPEDALIERO-UNIVERSITARIA, PARMA, ITALY</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Xingwu Zhong</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Matthew McRae, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>McMaster University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sylvain Boet, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Ottawa Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Pawel Majak, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Internal Medicine, Asthma and Alergology, Barlicki Hospital,</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joseph A Murray, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Mayo Clinic</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Raf Bisschops, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospitals Leuven, Dept. of Gastroenterology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ru Feng, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Hematology, Nanfang Hospital, Southern Medical University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yong Liu, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Department of Anesthesiology,Tongji Hospital,Wuhan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yan Zhao, Dr.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Peking Union Medical College Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Alice Ammerman, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of North Carolina, Chapel Hill</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>James R. Fricton, DDS</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>HealthPartners Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Abigail S. Caudle, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>M.D. Anderson Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Emily Miller, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Northwestern University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Reitan Ribeiro, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Erasto Gaertner Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yu Chi Huang, Bachelor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Study Principal Investigator ChangGungMH</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Seong Woo Jeon, Professor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Gastric Cancer Center, Kyungpook National University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Deanna L Gibson, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of British Columbia - Okanagan</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>AYong Yu, MD. PhD.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Wenzhou Medical University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ernest Seidman, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Research Institute of the MUHC</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Xichun Hu, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Fudan University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jeffrey Krischer, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of South Florida</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nadia Hansel, MD MPH</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Jonhs Hopkins University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul Marc, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of CA, Davis</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Noam Y. Harel, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>James J. Peters VAMC</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Clemens M Schiestl, PD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Children's University Hospital of Zurich</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Yik-wa Law, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The University of Hong Kong</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Elizabeth Chrischilles, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Iowa</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jenna Smith-Turchyn, PT, PhD(c)</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>McMaster University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Hazel Coop</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The Royal Wolverhampton NHS Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Stacey M. Anderson, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Virginia Center for Diabetes Technology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Zhigang Li, Master</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Shanghai Chest Hospital, Shanghai Jiao Tong University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joseph Bubalo</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>OHSU Knight Cancer Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Paul Kim, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UC San Diego</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eric Pujade-Lauraine, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Hôpital Hôtel-Dieu</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Janet E Pope, MD, MPH, FRCPC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Pope Research Corp.</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Herbert Resch, Prof. M.D.</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Paracelsus Medical University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Nathalie C. Zeitouni, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>The University of Arizona Cancer Center at Dignity Health St. Joseph's Hospital and Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Xiao-he Xiao</last_name>\n",
      "<role>Study Director</role>\n",
      "<affiliation>302 Military Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert Debernardo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cleveland Clinic, Case Comprehensive Cancer Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Shu-Wen Lin</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Taiwan University Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Derek Hanson, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jessica LaRose, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Virginia Commonwealth University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>He-Cheng Li, doctor</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Ruijin Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Francesco Madonna</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>CHU Bordeaux</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jennifer Tang, MD, MSRC</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>UNC-CH</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Jonathan A Fallowfield, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>MRC Centre for Inflammation Research, Queens Medical Research Institute</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joseph F Signorile, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Miami</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Akira Horiuchi, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Showa Inan General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Andrew S Protheroe, MBBS, PhD, MRCP, FRCP</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Oxford University Hospitals NHS Trust</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>B. Joseph Elmunzer</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Medical University of South Carolina</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Ya-Jung Cheng</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Anesthesiology Department, NTUH</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Grace W Gengoux, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Michael Iv</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Stanford University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Aiming Yang, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Peking Union Medical College Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Joy N Baumgartner, PhD, MSSW</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Duke University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mauro Manconi, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Sleep and Epilepsy Center, Neurocenter of Southern Switzerland, Ospedale Civico di Lugano, Ente Ospedaliero Cantonale</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Xiongjing Jiang, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Robert Kacmarek, RRT, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Dirk-Jan Slebos, MD PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>d.j.slebos@umcg.nl</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Helena M. Verkooijen, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Imaging Division, University Medical Center Utrecht, Utrecht</affiliation>\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Daniel J Cox, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Virginia</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mikhail Efanov, MD, PhD</last_name>\n",
      "<role>Study Chair</role>\n",
      "<affiliation>Moscow Clinical Scientific Center</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sebastien Levesque, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University Hospital of Poitiers, Department of Cardiology</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Eman Omran, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Cairo University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Thorsten Rudroff, Ph.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>University of Colorado, Denver</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Roger Bedimo, MD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Dallas VAMC</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Mark Hallett, M.D.</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Katherine Brooke-Wavel, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Loughborough University</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>Sanja Percac-Lima, MD, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>Massachusetts General Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n",
      "<overall_official>\n",
      "<last_name>I-Chan Huang, PhD</last_name>\n",
      "<role>Principal Investigator</role>\n",
      "<affiliation>St. Jude Children's Research Hospital</affiliation>\n",
      "</overall_official> \n",
      "\n"
     ]
    }
   ],
   "source": [
    "lista = df['CT'].tolist()\n",
    "\n",
    "for i in range(len(lista)):\n",
    "    loc = lista[i].clinical_trial.findAll('overall_official')\n",
    "    if len(loc) >= 1:\n",
    "        print(loc[0], '\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0.0 AHS Cancer Control Alberta \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Friends Research Institute, Inc. \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Washington D.C. Veterans Affairs Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Alabama at Birmingham \n",
      " None \n",
      "\n",
      "\n",
      "0.6111111111111112 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) \n",
      " ['Obesity Branch', 'National Institute of Diabetes and Digestive', 'National Institutes of Health'] \n",
      "\n",
      "\n",
      "0.32352941176470584 Eastern Cooperative Oncology Group \n",
      " ['Division of Medical Oncology', 'New York University School of Medicine', 'NYU Cancer Institute'] \n",
      "\n",
      "\n",
      "0.0 University of Kansas Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.37777777777777777 American College of Surgeons \n",
      " ['Columbia University College of Physicians and', 'Weill Cornell Medical College'] \n",
      "\n",
      "\n",
      "0.5 University of Rochester \n",
      " ['University of California, Irvine', 'CA'] \n",
      "\n",
      "\n",
      "0.0 Mayo Clinic \n",
      " None \n",
      "\n",
      "\n",
      "0.0 NCI, NIH \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Joslin Diabetes Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Children's Oncology Group \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Washington \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University at Buffalo \n",
      " None \n",
      "\n",
      "\n",
      "0.0 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Memorial Sloan Kettering Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of California, San Francisco \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of California, San Diego \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Abramson Cancer Center of the University of Pennsylvania \n",
      " None \n",
      "\n",
      "\n",
      "0.0 National Institutes of Health (NIH) \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Albany VA Medical Center Samuel S. Stratton, Albany, NY \n",
      " None \n",
      "\n",
      "\n",
      "0.36111111111111116 Dept. of Immunology, Okayama University Schhol of Medicine and Dentistry \n",
      " ['Faculty of Health and Welfare', 'Kawasaki University of Medical Welfare', 'Kurashiki'] \n",
      "\n",
      "\n",
      "0.9375 Inflexxion, Inc. \n",
      " ['Pain and Opioid Division', 'Inflexxion Inc.'] \n",
      "\n",
      "\n",
      "0.35593220338983056 Ohio State University \n",
      " ['Division of Hematology', 'The Ohio State University-James Comprehensive Cancer Center'] \n",
      "\n",
      "\n",
      "0.0 Hopital Cochin Paris. Centre des essais vaccinaux Cochin Pasteur \n",
      " None \n",
      "\n",
      "\n",
      "0.24590163934426235 Michael E DeBakey VA Medical Center \n",
      " ['Health Services Research and Development Center of Excellence'] \n",
      "\n",
      "\n",
      "0.0 Hopital Européen Georges Pompidou Paris, service d'immunologie clinique \n",
      " None \n",
      "\n",
      "\n",
      "0.4285714285714286 University of Rochester Sleep Research Lab \n",
      " ['Behavioral Sleep Medicine Program', 'Department of Psychiatry, University of Pennsylvania', 'Center for Sleep', 'Circadian Neurobiology', 'Department of Medicine', 'University of Pennsylvania', 'PA, USA,', 'School', 'Nursing, University of Pennsylvania'] \n",
      "\n",
      "\n",
      "0.0 Southwest Oncology Group \n",
      " None \n",
      "\n",
      "\n",
      "0.2564102564102564 Universidade Federal do Rio Grande do Sul-Hospital de Clínicas de Porto Alegre \n",
      " ['Department of Pediatrics', 'Universidade Federal'] \n",
      "\n",
      "\n",
      "0.0 Yale University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 East Valley Hematology and Oncology Group \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Stanford University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Chinese University of Hong Kong \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Colorado, Health Sciences Center and The Children's Hospital, Denver \n",
      " None \n",
      "\n",
      "\n",
      "0.4716981132075472 Boston Children’s Hospital \n",
      " [\"Division of Endocrinology, Boston Children's Hospital\"] \n",
      "\n",
      "\n",
      "0.2790697674418605 Rutgers, The State University of New Jersey \n",
      " ['Department of Dermatology', 'Tufts University School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 University of British Columbia \n",
      " None \n",
      "\n",
      "\n",
      "0.6304347826086957 National Taiwan University Hospital \n",
      " ['Department of Urology', 'National Taiwan University College of Medicine'] \n",
      "\n",
      "\n",
      "0.125 University of Pittsburgh \n",
      " ['Fakultät für Physik & Astronomie'] \n",
      "\n",
      "\n",
      "0.2804878048780488 University of Rochester \n",
      " ['Department of Pediatrics, University of Rochester School of Medicine and Dentistry'] \n",
      "\n",
      "\n",
      "0.06666666666666665 Massachusetts General Hospital \n",
      " ['Mount Sinai School of Medicine'] \n",
      "\n",
      "\n",
      "0.6388888888888888 Charite University, Berlin, Germany \n",
      " ['Department of Gynecology', 'Charité - University Medicine Berlin'] \n",
      "\n",
      "\n",
      "0.0 Dana-Farber Cancer Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Dana-Farber Cancer Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Northwestern University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 National Taiwan University, School of Medicine, National Taiwan University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Minnesota - Clinical and Translational Science Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.37142857142857144 National Taiwan University Hospital \n",
      " ['Department of Parasitology, College of Medicine', 'Chang Gung University', 'Tao-Yuan 33332'] \n",
      "\n",
      "\n",
      "0.0 Virginia Commonwealth University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Vanderbilt University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Vanderbilt University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Columbia University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 National Institute on Aging (NIA) \n",
      " None \n",
      "\n",
      "\n",
      "0.5 Stanford University \n",
      " ['Stanford University School of Medicine', 'Department of Psychiatry and Behavioral Sciences', 'Stanford'] \n",
      "\n",
      "\n",
      "0.0 Temple University - Center for Obesity Research and Education \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Milton S. Hershey Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.23076923076923073 CHU de Nantes \n",
      " ['Hôtel-Dieu'] \n",
      "\n",
      "\n",
      "0.0 Massachusetts General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Wisconsin, Madison \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Creighton University \n",
      " None \n",
      "\n",
      "\n",
      "0.2564102564102564 Main Line Health \n",
      " ['Lankenau Institute for Medical Research'] \n",
      "\n",
      "\n",
      "0.967741935483871 Shriners Hospitals for Children \n",
      " ['Shriners Hospital for Children'] \n",
      "\n",
      "\n",
      "0.1515151515151515 Sunnybrook Health Sciences Centre \n",
      " ['Department', 'Gebäude\\xa0A1'] \n",
      "\n",
      "\n",
      "0.9473684210526316 Tel Aviv University \n",
      " ['Division of Psychiatry', 'The State of Israel Ministry of Health', 'The Chaim Sheba Medical Center', 'Sackler Medical School', 'Tel-Aviv University'] \n",
      "\n",
      "\n",
      "0.0 Rambam Health Care Campus \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Oklahoma \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Oregon Social Learning Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Columbia University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Vanderbilt University Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Children's Hospital Medical Center, Cincinnati \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Columbia University \n",
      " None \n",
      "\n",
      "\n",
      "0.4347826086956522 Charité Campus Benjamin-Franklin, Rheumatology \n",
      " ['Medical Department I, Rheumatology', 'Charité University Medicine Berlin'] \n",
      "\n",
      "\n",
      "0.0 University of Ottawa Heart Instittue \n",
      " None \n",
      "\n",
      "\n",
      "0.9393939393939394 Sunnybrook Health Sciences Centre \n",
      " ['University of Toronto', 'Brain Sciences Research Program', 'Sunnybrook Health Sciences Center', 'Department of Psychiatry'] \n",
      "\n",
      "\n",
      "0.0 University of Pittsburgh \n",
      " None \n",
      "\n",
      "\n",
      "0.326530612244898 Dept. Orthopaedics, SUNY@Stony Brook, NY 11794 \n",
      " ['Department of Orthopaedics, Health Science Center', 'Stony Brook University Medical Center', 'Stony Brook'] \n",
      "\n",
      "\n",
      "0.0 Toronto General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.26086956521739135 CHU Angers, Service d'hépato-gastroentérologie, 49933 Angers Cedex 09 \n",
      " ['Department of Hepatology', 'University Hospital of Angers'] \n",
      "\n",
      "\n",
      "0.27380952380952384 Department of Human Nutrition, Royal Veterinary and Agricultural University, Denmark \n",
      " ['Department of Nutrition', 'Exercise', 'University of Copenhagen'] \n",
      "\n",
      "\n",
      "0.25 Universitaire Ziekenhuizen Leuven \n",
      " ['Department of Ophthalmology, University Hospitals Leuven'] \n",
      "\n",
      "\n",
      "0.0 Massey Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.2857142857142857 Surugadai Nihon University Hospital \n",
      " ['Department of Anesthesia', 'Intensive Care', 'Osaka Medical Center and Research Institute', 'Maternal and', 'Child Health'] \n",
      "\n",
      "\n",
      "0.0 Atlanta VA Medical and Rehab Center, Decatur, GA \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital Tuebingen (PI until 30Nov2004) \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Yokohama City University Center Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.2894736842105263 University of Alberta \n",
      " ['Lawrence Livermore National Laboratory', 'L-481,'] \n",
      "\n",
      "\n",
      "0.0 Manhattan Psychiatric Center \n",
      " None \n",
      "\n",
      "\n",
      "0.1428571428571429 University of Alabama at Birmingham \n",
      " ['Sturge-Weber Foundation', 'NJ'] \n",
      "\n",
      "\n",
      "0.0 AIDS Research Alliance of West Hollywood \n",
      " None \n",
      "\n",
      "\n",
      "0.6153846153846154 University of California, San Francisco \n",
      " ['Division of Endocrinology, Department of Medicine', 'University of California'] \n",
      "\n",
      "\n",
      "0.0 University of California, San Francisco \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Massachusetts General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.2727272727272727 Investigator / Contact \n",
      " ['University of Illinois at Peoria', 'University of Illinois'] \n",
      "\n",
      "\n",
      "0.0 Children's Oncology Group \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Center For Integrative Medicine, University of Maryland \n",
      " None \n",
      "\n",
      "\n",
      "0.1724137931034483 University of New Mexico \n",
      " [\"Department of Obstetrics and Gynecology and Women's Health\"] \n",
      "\n",
      "\n",
      "0.2222222222222222 VA Medical Center, Philadelphia \n",
      " ['University of Pennsylvania Perelman School of Medicine'] \n",
      "\n",
      "\n",
      "0.1333333333333333 OSF Stroke Center \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.045454545454545414 Université de Montréal \n",
      " ['Gulf Medical University', 'UAE'] \n",
      "\n",
      "\n",
      "0.0 Dept. of Psychiatry, China Medical University Hospital, Taichung, Taiwan \n",
      " None \n",
      "\n",
      "\n",
      "0.44897959183673475 Aarhus University, Perinatal Epidemiological Unit \n",
      " ['Perinatal Epidemiology Research Unit', 'Aarhus University Hospital'] \n",
      "\n",
      "\n",
      "0.0 Yamaguchi University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of California San Francisco Medical Center-Mount Zion \n",
      " None \n",
      "\n",
      "\n",
      "0.9080459770114943 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) \n",
      " ['Perinatology Research Branch', 'Program for Perinatal Research and Obstetrics, Division of Intramural Research', 'Eunice Kennedy Shriver National Institute of Child Health and Human Development', 'National Institutes of Health', 'MI', 'Department of Obstetrics and Gynecology', 'University of Michigan', 'MI', 'Department of Epidemiology and Biostatistics', 'Michigan State University', 'MI'] \n",
      "\n",
      "\n",
      "1.0 Singapore National Eye Centre \n",
      " ['Singapore Eye Research Institute', 'Singapore National Eye Centre'] \n",
      "\n",
      "\n",
      "0.0 Marmara University \n",
      " None \n",
      "\n",
      "\n",
      "0.17021276595744683 University of Maryland Greenebaum Cancer Center \n",
      " ['Bakewell Veterinary Clinic', 'Milford Farm', 'Mill Street'] \n",
      "\n",
      "\n",
      "0.26315789473684215 University of Washington and Children's Hospital and Regional Medical Center \n",
      " ['University of KwaZulu-Natal', 'Nelson R. Mandela School of Medicine', 'KwaZulu-Natal Department of Health'] \n",
      "\n",
      "\n",
      "0.14942528735632188 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) \n",
      " ['Department of Pediatrics'] \n",
      "\n",
      "\n",
      "0.0 San Giovanni Battista Hospital, Torino \n",
      " None \n",
      "\n",
      "\n",
      "0.9347826086956522 London School of Hygiene and Tropical Medicine \n",
      " ['Clinical Trials Unit', 'London School of Hygiene & Tropical Medicine'] \n",
      "\n",
      "\n",
      "0.0 Urology dep. of Kaunas University of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.11842105263157898 Center for Immunization Research, Johns Hopkins School of Public Health \n",
      " ['Institute of Health Policy, Management and Evaluation, University of Toronto'] \n",
      "\n",
      "\n",
      "0.16666666666666663 VUMC \n",
      " ['the Department of Radiology and Research Institute of Radiology', 'N.J.L.', 'M.S.C.', 'S.C.J.', 'C.-G.C.', 'S.J.K.', 'D.H.L.'] \n",
      "\n",
      "\n",
      "0.6111111111111112 Duke University \n",
      " ['Division of Radiation Biology and Toxicology, School of Life Sciences', 'Manipal University', 'Manipal', 'Karnataka'] \n",
      "\n",
      "\n",
      "0.20967741935483875 University of Magdeburg, Department of Hematology and Oncology \n",
      " ['Klinik', 'Hämatologie/Onkologie'] \n",
      "\n",
      "\n",
      "0.0 University Health Network, Toronto \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Gentofte Hospital, Copenhagen \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Health Network-Princess Margaret Hospital \n",
      " None \n",
      "\n",
      "\n",
      "1.0 The Scripps Research Institute \n",
      " ['Pearson Center', 'Alcoholism and Addiction Research', 'The Scripps Research Institute'] \n",
      "\n",
      "\n",
      "0.0 University of Rochester \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Michigan \n",
      " None \n",
      "\n",
      "\n",
      "0.5588235294117647 Stanford University \n",
      " ['Stanford University Medical Center', 'University of California Los Angeles Medical Center', 'CA', 'Indiana University Medical Center', 'Weill Medical College of Cornell University', 'University of Nebraska Medical Center', 'NE', 'Johns Hopkins University Oncology Center', 'British Columbia Cancer Agency Centre for Lymphoid Cancer', 'Toronto-Sunnybrook Regional Cancer Centre', 'Cross Cancer Institute', 'Washington University School of Medicine', 'MO', 'Oregon Health Science University', 'Rush University Medical Center', 'IL', 'University of Iowa Hospitals and Clinics', 'IA', 'Mayo Clinic', 'Dana-Farber Cancer Institute', 'Rocky Mountain Cancer Centers'] \n",
      "\n",
      "\n",
      "0.5581395348837209 Johns Hopkins University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Boston Children’s Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Mayo Clinic \n",
      " None \n",
      "\n",
      "\n",
      "0.65625 Children's Healthcare of Atlanta \n",
      " ['Sibley Heart Center Cardiology', \"Children's Healthcare\"] \n",
      "\n",
      "\n",
      "1.0 Dana-Farber Cancer Institute \n",
      " ['Department of Medical Oncology', 'Dana-Farber Cancer Institute', 'Harvard Medical School'] \n",
      "\n",
      "\n",
      "0.1875 Mayo Graduate School of Medicine \n",
      " ['Gastroenterology & Hepatology'] \n",
      "\n",
      "\n",
      "0.5581395348837209 Johns Hopkins University \n",
      " ['Johns Hopkins University School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 Department of Biomedical Sciences, University of Maryland Dental School \n",
      " None \n",
      "\n",
      "\n",
      "0.5581395348837209 Johns Hopkins University \n",
      " ['Johns Hopkins University School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 The Heart Institute, National University Hospital of Singapore \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital, Geneva \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Ohio State University \n",
      " ['Department of Neurology', 'Ohio State University'] \n",
      "\n",
      "\n",
      "0.0 M.D. Anderson Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Dept. of Otolaryngology-Head and Neck Surgery, Soonchunhyang University College of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 M.D. Anderson Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Tokyo University \n",
      " None \n",
      "\n",
      "\n",
      "0.3571428571428571 M.D. Anderson Cancer Center \n",
      " ['The Center for Personalized Cancer Therapy', 'University of California San Diego Moores Cancer Center'] \n",
      "\n",
      "\n",
      "0.0 M.D. Anderson Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Medical University of Vienna \n",
      " None \n",
      "\n",
      "\n",
      "0.95 US Army Institute of Surgical Research \n",
      " ['U.S. Army Institute of Surgical Research', 'Chambers Pass', 'JBSA'] \n",
      "\n",
      "\n",
      "0.4285714285714286 Botucatu School of Medicine - Unesp \n",
      " ['Department of Tropical Diseases', 'Botucatu Medical School', 'UNESP', 'Botucatu-SP'] \n",
      "\n",
      "\n",
      "0.0 University of Arizona \n",
      " None \n",
      "\n",
      "\n",
      "0.1875 Lawson Health Research Institute \n",
      " ['Department of Chemistry, Division of Chemical Biology', 'Medicinal Chemistry', 'Department of Pharmacology, University of North Carolina', 'Chapel Hill'] \n",
      "\n",
      "\n",
      "0.0 Shriners Hospitals for Children \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Robert Bosch Gesellschaft für Medizinische Forschung mbH \n",
      " None \n",
      "\n",
      "\n",
      "1.0 University of Michigan \n",
      " ['Department of Surgery', \"CS Mott Children's Hospital\", 'University of Michigan'] \n",
      "\n",
      "\n",
      "0.0 Maastricht University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Rochester \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Dana-Farber Cancer Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Gait Analysis Laboratory, Department of Orthopedic Surgery, Hvidovre University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 College of Physicians and Surgeons of Ontario \n",
      " None \n",
      "\n",
      "\n",
      "0.06666666666666665 Massachusetts General Hospital \n",
      " ['Mount Sinai School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 Yaumatei Psychiatric Center, Kwai Chung Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Penn State College of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 The Cleveland Clinic \n",
      " None \n",
      "\n",
      "\n",
      "0.22499999999999998 Mayo Clinic \n",
      " ['Department of Clinical Cancer Prevention', 'MD Anderson Cancer Center'] \n",
      "\n",
      "\n",
      "0.0 National Cancer Center Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Profil Institute for Metabolic Research \n",
      " [] \n",
      "\n",
      "\n",
      "0.0 M.D. Anderson Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of California, Irvine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Utah \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Massachusetts General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.4 Brigham and Women's Hospital \n",
      " ['Diabetes Unit', 'Massachusetts General Hospital'] \n",
      "\n",
      "\n",
      "0.16216216216216217 University of California, Los Angeles \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.0 Louisiana State University Health Sciences Center in New Orleans \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Memorial Sloan Kettering Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 H. Lee Moffitt Cancer Center and Research Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Pittsburgh \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Liege \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Johns Hopkins University \n",
      " None \n",
      "\n",
      "\n",
      "0.25 UCSD \n",
      " ['University of California', 'CA', 'National Center for PTSD,'] \n",
      "\n",
      "\n",
      "0.0 University of North Carolina, Chapel Hill \n",
      " None \n",
      "\n",
      "\n",
      "0.6 University of Alabama at Birmingham \n",
      " ['Division of Clinical Immunology and Rheumatology, Department of Medicine', 'University of Alabama', 'AL 35294'] \n",
      "\n",
      "\n",
      "0.0 Baylor Research Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Logan College of Chiropractic \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Universitaetsklinikum Tuebingen \n",
      " None \n",
      "\n",
      "\n",
      "0.13793103448275867 St. Joseph-Krankenhaus Berlin \n",
      " ['Department of Medicine II'] \n",
      "\n",
      "\n",
      "0.0 University of Cincinnati \n",
      " None \n",
      "\n",
      "\n",
      "0.16279069767441856 NEMA Research, Inc. \n",
      " ['Department of Medicine', 'Johns Hopkins University School of Medicine'] \n",
      "\n",
      "\n",
      "0.18518518518518523 Public Health England \n",
      " ['Department of Pediatrics', 'UC Davis School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 Columbia University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Hamamatsu University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Imperial College London \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Washington State University \n",
      " None \n",
      "\n",
      "\n",
      "0.4107142857142857 Department of Neurology; the Cleveland Clinic Foundation \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " ['the Department of Neurology', 'University of California', 'Department of Neurology', 'Neurological Institute', 'University Hospitals Case Medical Center', 'Case Western Reserve University'] \n",
      "\n",
      "\n",
      "0.0 State University of New York - Upstate Medical University \n",
      " None \n",
      "\n",
      "\n",
      "0.5 Baylor College of Medicine \n",
      " ['Department of Pediatrics, Baylor College of Medicine', 'Lille Frank Abercrombie Section of Cardiology', \"Texas Children's Hospital\"] \n",
      "\n",
      "\n",
      "0.0 Innovaderm Research Inc. \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Duke University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Department of Internal Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 CLINICAL TESTING CENTER of BEVERLY HILLS \n",
      " None \n",
      "\n",
      "\n",
      "0.6511627906976745 George Washington University \n",
      " ['Pediatrics', 'Division of Newborn Service', 'George Washington University Medical Center', \"Children's National Medical Center\"] \n",
      "\n",
      "\n",
      "0.0 University of Washington \n",
      " None \n",
      "\n",
      "\n",
      "0.0 St. Jude Children's Research Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.1785714285714286 Hospital Clinic of Barcelona \n",
      " ['Institute of Liver Studies', \"King's College Hospital\", \"King's College\"] \n",
      "\n",
      "\n",
      "0.0 Memorial Sloan Kettering Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Emory University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 State University of New York - Upstate Medical University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Abington Memorial Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Skaraborg Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.972972972972973 St. Jude Children's Research Hospital \n",
      " [\"St Jude Children's Research Hospital\"] \n",
      "\n",
      "\n",
      "0.0 Hospital de Clinicas de Porto Alegre \n",
      " None \n",
      "\n",
      "\n",
      "0.2564102564102564 University of California, San Francisco \n",
      " ['Department of Health Services', 'CA'] \n",
      "\n",
      "\n",
      "0.5106382978723405 University of Louisville \n",
      " ['Department of Surgery, University of Louisville'] \n",
      "\n",
      "\n",
      "0.04166666666666663 NTUH \n",
      " ['Department of Epidemiology and Biostatistics, Xiangya School of Public Health', 'Central South University', 'Changsha 410008'] \n",
      "\n",
      "\n",
      "0.0 Department of Pharmacy, N.T.U.H. \n",
      " None \n",
      "\n",
      "\n",
      "0.19354838709677424 Presidio Ospedaliero di Livorno \n",
      " ['Oncology', 'Pisa University Hospital'] \n",
      "\n",
      "\n",
      "0.0 University of Chicago \n",
      " None \n",
      "\n",
      "\n",
      "0.3191489361702128 Foothills Medical Centre, University of Calgary \n",
      " ['Clinical Trial Service Unit', 'Epidemiological Studies Unit,', 'University of Oxford'] \n",
      "\n",
      "\n",
      "0.0  \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Yale University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital of Goettingen \n",
      " None \n",
      "\n",
      "\n",
      "0.13793103448275867 Northern Orthopaedic Division \n",
      " ['Aalborg Sygehus'] \n",
      "\n",
      "\n",
      "0.23529411764705888 Soul Medicine Institute \n",
      " ['Foundation for Epigenetic Medicine'] \n",
      "\n",
      "\n",
      "0.0 International Centre for Diarrhoeal Disease Research, Bangladesh \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Assistant Professor Of Surgery, Emory University School of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Hospital Universitario Dr. Jose E. Gonzalez \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Paddington Testing Company \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Massachusetts, Worcester \n",
      " None \n",
      "\n",
      "\n",
      "0.0 VA Ann Arbor Healthcare System, Ann Arbor, MI \n",
      " None \n",
      "\n",
      "\n",
      "0.33999999999999997 University of NSW \n",
      "\n",
      " None \n",
      "\n",
      "\n",
      "0.20833333333333337 Rigshospitalet, Denmark \n",
      " ['University of Copenhagen'] \n",
      "\n",
      "\n",
      "0.0 University of Alberta \n",
      " None \n",
      "\n",
      "\n",
      "0.5 Duke University \n",
      " ['Carolinas Cord Blood Bank', 'Translational Therapy Program', 'Duke Translational Research Institute', 'Duke University Medical Center'] \n",
      "\n",
      "\n",
      "0.0 Anesthesiology & Pain Medicine, Severance Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.3142857142857143 Albert Einstein College of Medicine \n",
      " ['Department of Epidemiology and Biostatistics, School of Public Health', 'Imperial College'] \n",
      "\n",
      "\n",
      "0.0 University of Michigan \n",
      " None \n",
      "\n",
      "\n",
      "0.6153846153846154 University of California, San Francisco \n",
      " ['HIV/AIDS Division', 'University of California', 'CA'] \n",
      "\n",
      "\n",
      "0.0 Memorial Sloan Kettering Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Stanford University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 St. Louis University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Seattle Children's Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 New York State Psychiatric Institute \n",
      " None \n",
      "\n",
      "\n",
      "1.0 University of Michigan \n",
      " ['Division of Metabolism, Endocrinology and Diabetes,', 'Department of Internal Medicine', 'University of Michigan Health System', 'University of Michigan'] \n",
      "\n",
      "\n",
      "0.2321428571428571 University of California, San Francisco \n",
      " ['Department of Preventive and Restorative Dental Sciences', 'School of Dentistry, University of California', 'Department of Preventive and Restorative Dental Sciences', 'Dean, School of Dentistry, University of California'] \n",
      "\n",
      "\n",
      "0.0 Shanghai Changzheng Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Erlangen-Nürnberg \n",
      " None \n",
      "\n",
      "\n",
      "0.26315789473684215 Hugo W. Moser Research Institute at Kennedy Krieger, Inc. \n",
      " ['Kennedy Krieger Institute'] \n",
      "\n",
      "\n",
      "0.0 Hopital Beaujon \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Loma Linda University \n",
      " None \n",
      "\n",
      "\n",
      "0.5714285714285714 UT MD Anderson Cancer Center \n",
      " ['Department of Interventional Radiology', 'The University of Texas MD Anderson Cancer Center', 'PO'] \n",
      "\n",
      "\n",
      "0.16666666666666663 Baylor Health Care System \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "1.0 Medical University of South Carolina \n",
      " ['Department of Psychiatry and Behavioral Sciences', 'Medical University of South Carolina'] \n",
      "\n",
      "\n",
      "0.0 Bamrasnaradura Infectious Diseases Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of California, Davis \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Karolinska Institutet \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Health Network-Princess Margaret Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of São Paulo \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Nova Scotia Health Authority \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Skane University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 American University of Beirut Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.10126582278481011 UCSF-Mount Zion \n",
      " ['Department of Neurological Surgery, University of Washington School of Medicine', 'WA, USA'] \n",
      "\n",
      "\n",
      "0.0 Translational Oncology Research International \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Radboud University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Hyogo Prefectural AWAJI Hospital \n",
      " None \n",
      "\n",
      "\n",
      "1.0 University of Mississippi Medical Center \n",
      " ['Department of Orthopedic Surgery', 'University of Mississippi Medical Center'] \n",
      "\n",
      "\n",
      "0.0 University Health Network, Toronto \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Uppsala University \n",
      " ['Department of Medical Sciences', 'Uppsala University', 'Clinical Research Centre', 'Uppsala University'] \n",
      "\n",
      "\n",
      "0.0 United States Naval Medical Center, San Diego \n",
      " None \n",
      "\n",
      "\n",
      "0.9615384615384616 Boston Children’s Hospital \n",
      " ['Department of Surgery, Center for Advanced Intestinal Rehabilitation (CAIR', \"Boston Children's Hospital\", 'Harvard Medical School'] \n",
      "\n",
      "\n",
      "0.0 Union College, New York \n",
      " None \n",
      "\n",
      "\n",
      "0.7755102040816326 US Army Institute of Surgical Research \n",
      " ['United States Army Institute of Surgical Research'] \n",
      "\n",
      "\n",
      "0.0 Columbia University \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Hannover Medical School \n",
      " ['Department of Plastic', 'Reconstructive Surgery', 'Hannover Medical School'] \n",
      "\n",
      "\n",
      "0.5 Boston Children’s Hospital \n",
      " ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] \n",
      "\n",
      "\n",
      "1.0 Jewish General Hospital \n",
      " ['Lady Davis Institute for Medical Research', 'Jewish General Hospital', 'Côte-Ste-Catherine', 'Quebec H3T 1E2'] \n",
      "\n",
      "\n",
      "0.0 Head of dept \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Washington University School of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 The Cleveland Clinic \n",
      " [] \n",
      "\n",
      "\n",
      "0.6 Johns Hopkins University \n",
      " ['Stanford University Medical Center', 'University of California Los Angeles Medical Center', 'CA', 'Indiana University Medical Center', 'Weill Medical College of Cornell University', 'University of Nebraska Medical Center', 'NE', 'Johns Hopkins University Oncology Center', 'British Columbia Cancer Agency Centre for Lymphoid Cancer', 'Toronto-Sunnybrook Regional Cancer Centre', 'Cross Cancer Institute', 'Washington University School of Medicine', 'MO', 'Oregon Health Science University', 'Rush University Medical Center', 'IL', 'University of Iowa Hospitals and Clinics', 'IA', 'Mayo Clinic', 'Dana-Farber Cancer Institute', 'Rocky Mountain Cancer Centers'] \n",
      "\n",
      "\n",
      "0.0 Cetero Research, San Antonio \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Huazhong University of Science and Technology \n",
      " None \n",
      "\n",
      "\n",
      "0.17142857142857137 Center for Neurological Restoration \n",
      " ['Cleveland Clinic'] \n",
      "\n",
      "\n",
      "0.6111111111111112 Augusta University \n",
      " ['Division of Radiation Biology and Toxicology, School of Life Sciences', 'Manipal University', 'Manipal', 'Karnataka'] \n",
      "\n",
      "\n",
      "0.0 Uniformed Services University of the Health Sciences \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Duke University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Oregon Health and Science University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Toronto Rehabilitation Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Rennes University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital, Grenoble \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Kentucky \n",
      " None \n",
      "\n",
      "\n",
      "0.34782608695652173 University Medical Center Hamburg-Eppendorf, Department of Gynecology \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " ['Department of Gynecology', 'Charité - University Medicine Berlin'] \n",
      "\n",
      "\n",
      "0.0 National Bureau of Economic Research \n",
      " None \n",
      "\n",
      "\n",
      "0.21212121212121215 New England School of Acupuncture \n",
      " ['Laboratory of Behavioral Genetics', 'Brain Mind Institute', 'Ecole Polytechnique Federale de Lausanne'] \n",
      "\n",
      "\n",
      "0.31999999999999995 University of Nottingham \n",
      " ['Department of Psychology, University of Pittsburgh', 'PA', 'PA'] \n",
      "\n",
      "\n",
      "0.0 Cork Universtiy Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Crete \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Radboud University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Ophthalmic Consultants of Long Island \n",
      " [] \n",
      "\n",
      "\n",
      "0.0 National Institute of Mental Health (NIMH) \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital Zurich, Ophtalmic Clinic \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Mayo Clinic \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Centre François Baclesse \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Michigan \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Calgary \n",
      " None \n",
      "\n",
      "\n",
      "0.1515151515151515 Hospital Italiano de Buenos Aires \n",
      " ['Department of Health Informatics'] \n",
      "\n",
      "\n",
      "0.0 University of Californa, San Francisco \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Sinai Hospital of Baltimore \n",
      " None \n",
      "\n",
      "\n",
      "0.18367346938775508 Severance Hospital \n",
      " ['The University of Texas MD Anderson Cancer Center'] \n",
      "\n",
      "\n",
      "0.0 Denver Nephrologists, P.C. \n",
      " [] \n",
      "\n",
      "\n",
      "0.0 University Clinical Centre of Kosova \n",
      " None \n",
      "\n",
      "\n",
      "0.0 St. Marianna University School of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Kaplan Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Pittsburgh \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Limerick \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Pharmaceutical Profiles, Ltd \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Kharkov District Clinical Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.4117647058823529 Seoul National University Hospital \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.26190476190476186 Spokane Joint Replacement Center \n",
      " ['Department of Molecular and Human Genetics', 'Baylor College of Medicine', 'TX 77030'] \n",
      "\n",
      "\n",
      "0.0 SCRI Development Innovations, LLC \n",
      " None \n",
      "\n",
      "\n",
      "0.1875 National Marrow Donor Program \n",
      " ['Fakultät für Physik & Astronomie'] \n",
      "\n",
      "\n",
      "0.0 Celerion \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Tokyo Women's Medical University \n",
      " None \n",
      "\n",
      "\n",
      "0.1875 St. Joseph's Healthcare Hamilton \n",
      " ['Department of Medicine'] \n",
      "\n",
      "\n",
      "0.0 Department of Neuroscience, Norwegian University of Science and Technology \n",
      " None \n",
      "\n",
      "\n",
      "0.2325581395348837 Weill Medical College of Cornell University \n",
      " ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] \n",
      "\n",
      "\n",
      "0.0 Laval University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Sunnybrook Health Sciences Centre \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Columbia University \n",
      " None \n",
      "\n",
      "\n",
      "1.0 University of British Columbia \n",
      " ['Centre for Health Evaluation and Outcome Sciences', \"St Paul's Hospital\", 'Department of Medicine and Sleep Disorders Program', 'University of British Columbia'] \n",
      "\n",
      "\n",
      "0.0 University of California, San Diego \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Seoul St. Mary's Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Catholic Home Care \n",
      " None \n",
      "\n",
      "\n",
      "0.4285714285714286 Boston Medical Center \n",
      " ['Department of Medicine', 'Boston University', 'Massachusetts Ave'] \n",
      "\n",
      "\n",
      "0.16666666666666663 Baycrest \n",
      " ['Department of Medicine/Diabetes Unit', 'Massachusetts General Hospital'] \n",
      "\n",
      "\n",
      "0.0 Zentrum für Physikalische und Rehabilitative Medizin des Sophien- und Hufeland-Klinikums Weimar \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Michigan School of Nursing \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Pontificia Universidad Catolica de Chile. Hospital Sotero del Rio. \n",
      " [] \n",
      "\n",
      "\n",
      "0.0 Stony Brook University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 VA Nebraska Western Iowa Health Care System \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Johns Hopkins University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Ohio State University Comprehensive Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Health Network, Princess Margaret Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Given Imaging Ltd. \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Palermo \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Fox Chase Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Diakonhjemmet Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.972972972972973 St. Jude Children's Research Hospital \n",
      " ['Ching-Hon Pui', \"St Jude Children's Research Hospital\", 'University of Tennessee Health Sciences Center', \"Cook Children's Medical Center\"] \n",
      "\n",
      "\n",
      "0.0 Memorial Sloan Kettering Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.37209302325581395 Showa University \n",
      " ['Department of Psychiatry', 'Tokyo Metropolitan Police Hospital', 'Department of Psychiatry', 'Showa University Northern Yokohama Hospital'] \n",
      "\n",
      "\n",
      "0.0 Northwestern University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Shanghai Changzheng Hospital \n",
      " [] \n",
      "\n",
      "\n",
      "0.2542372881355932 Dartmouth-Hitchcock Medical Center \n",
      " ['Division of Hematology', 'The Ohio State University-James Comprehensive Cancer Center'] \n",
      "\n",
      "\n",
      "0.20833333333333337 Region Syddanmark \n",
      " ['Department of Neurology', 'University of California', 'CA'] \n",
      "\n",
      "\n",
      "0.5 Stanford University \n",
      " ['Department of Obstetrics and Gynecology', 'Stanford University School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 Chengdu PLA General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Coordinating/Study PI \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Roma La Sapienza \n",
      " None \n",
      "\n",
      "\n",
      "0.34615384615384615 Beijing Chao Yang Hospital \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.23300970873786409 University Medical Center Groningen \n",
      " ['University of Groningen, Department of Pharmacy, Division of Pharmacoepidemiology and Pharmacoeconomics'] \n",
      "\n",
      "\n",
      "0.1724137931034483 University of Jena \n",
      " ['Department of Nutritional Physiology, Institute of Nutrition', 'Friedrich Schiller University', 'Dornburger Straße'] \n",
      "\n",
      "\n",
      "0.2222222222222222 Valley Retina Institute \n",
      " ['USDA', 'Bee Biology & Systematics Laboratory', 'Utah State University'] \n",
      "\n",
      "\n",
      "0.125 PharmaNet \n",
      " ['Université Laval', 'Association'] \n",
      "\n",
      "\n",
      "0.0 H. Lee Moffitt Cancer Center and Research Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Fraser Health Authority \n",
      " None \n",
      "\n",
      "\n",
      "0.5454545454545454 Universitaire Ziekenhuizen Leuven \n",
      " ['Department of Vascular and Endovascular Surgery', 'Department of Interventional Radiology', 'University Hospital Leuven'] \n",
      "\n",
      "\n",
      "0.6 Laval University \n",
      " ['Department of Physiology and Biophysics', 'Dalhousie University'] \n",
      "\n",
      "\n",
      "0.0 Institut de la Macula y la Retina \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Ann & Robert H Lurie Children's Hospital of Chicago \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Rapid Medical Research of New York \n",
      " None \n",
      "\n",
      "\n",
      "0.0 National Taiwan University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 HaEmek Medical Center, Afula, Israel \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Danish Head and Neck Cancer Group \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Unaffliated \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Mental Health Services in the Capital Region, Denmark \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital, Rouen \n",
      " [] \n",
      "\n",
      "\n",
      "0.0 University Medical Centre Ljubljana \n",
      " None \n",
      "\n",
      "\n",
      "0.4528301886792453 Fred Hutch/University of Washington Cancer Consortium \n",
      " ['Fred Hutchinson Cancer Research Center', 'WA', 'University of Washington', 'WA, USA'] \n",
      "\n",
      "\n",
      "0.0 Duke University \n",
      " None \n",
      "\n",
      "\n",
      "0.6363636363636364 Frederiksberg University Hospital \n",
      " ['The Parker Institute', 'Department of Rheumatology', 'Copenhagen University Hospitals', 'Bispebjerg'] \n",
      "\n",
      "\n",
      "0.0 Medical University of Graz \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Lithuanian University of Health Sciences \n",
      " ['Department of Skin', 'Lithuanian University of Health Sciences', 'Medical Academy'] \n",
      "\n",
      "\n",
      "0.0 University of Maryland \n",
      " None \n",
      "\n",
      "\n",
      "0.0 NorthShore University HealthSystem Research Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Kaplan Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Duke University \n",
      " None \n",
      "\n",
      "\n",
      "0.7857142857142857 National Eye Institute (NEI) \n",
      " ['Neuron–Glia Interactions', 'National Eye Institute', 'National Institutes of Health'] \n",
      "\n",
      "\n",
      "1.0 Showa Inan General Hospital \n",
      " ['Digestive Disease Center', 'Showa Inan General Hospital', 'Shinshu University Graduate School of Medicine'] \n",
      "\n",
      "\n",
      "0.38095238095238093 Department of Veterans Affairs, New Jersey \n",
      " ['Mental Health and Behavioral Sciences Service', 'Veterans Affairs', 'New Jersey Healthcare System'] \n",
      "\n",
      "\n",
      "0.0 Massachusetts General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.75 University of British Columbia \n",
      " ['Emergency Medicine', 'University of British Columbia Vancouver'] \n",
      "\n",
      "\n",
      "0.0 University of California, San Francisco \n",
      " None \n",
      "\n",
      "\n",
      "0.2068965517241379 Sun Yat-sen University \n",
      " ['Division of Gastrointestinal Surgery & Gastric Cancer Center', 'The First Affiliated Hospital'] \n",
      "\n",
      "\n",
      "0.0 KPL Good Food Practice AB \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Fred Hutch/University of Washington Cancer Consortium \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Centre for Tropical Diseases, Negrar (Verona), Italy \n",
      " None \n",
      "\n",
      "\n",
      "0.6515151515151515 Wilmer Eye Institute - Johns Hopkins University School of Medicine \n",
      " ['Wilmer Eye Institute', 'Johns Hopkins University School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 University of Pittsburgh \n",
      " None \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0.0 McGill University Health Center \n",
      " None \n",
      "\n",
      "\n",
      "0.48484848484848486 Ascensia Diabetes Care \n",
      " ['the Wellcome Trust-Medical Research Council Institute of Metabolic Science', 'University of Cambridge', 'H.R.M.', 'Wolfson Diabetes', 'Cambridge University Hospitals NHS Foundation Trust', 'H.R.M.', 'the Elsie Bertram Diabetes Centre', 'R.C.T.', 'H.R.M.', 'the Department of Obstetrics and Gynaecology', 'K.P.S.', 'Norwich University Hospitals NHS Foundation Trust', 'the Norwich Medical School', 'University of East Anglia', 'H.R.M.', 'Ipswich Hospital NHS Trust', 'the Division of Epidemiology and Biostatistics, Leeds Institute of Cardiovascular', 'Metabolic Medicine', 'University of Leeds, Leeds', 'G.R.L.'] \n",
      "\n",
      "\n",
      "0.0 Glostrup University Hospital, Copenhagen \n",
      " None \n",
      "\n",
      "\n",
      "0.19047619047619047 Exempla Saint Joseph Hospital \n",
      " ['Department of Biological Sciences', 'School of Pharmacy and Biochemistry, University of Buenos Aires', 'IQUIFIB-CONICET'] \n",
      "\n",
      "\n",
      "0.0 Imperial College London \n",
      " None \n",
      "\n",
      "\n",
      "0.5 Martin-Luther-Universität Halle-Wittenberg \n",
      " ['Department of Gynaecology and Institute of Clinical Epidemiology', 'Martin Luther University', 'School of Public Health', 'Departments of Pathology and Gynaecology', 'Radiotherapy Center', 'School of Medicine', 'Addis Ababa University', 'Department of Epidemiology, School of Public Health', 'Boston University'] \n",
      "\n",
      "\n",
      "1.0 Tehran University of Medical Sciences \n",
      " ['Endocrinology and Metabolism Research Center', 'Vali-Asr Hospital', 'School of Medicine', 'Tehran University of Medical Sciences'] \n",
      "\n",
      "\n",
      "0.0 Brigham and Women's Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Brigham and Women's Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Université Victor Segalen Bordeaux 2 \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Singapore General Hospital \n",
      " ['Department of Respiratory and Critical Care Medicine', 'Singapore General Hospital'] \n",
      "\n",
      "\n",
      "0.5576923076923077 CleveMed Inc. also dba Great Lakes NeuroTechnologies \n",
      " ['Great Lakes NeuroTechnologies'] \n",
      "\n",
      "\n",
      "0.0 University of Minnesota - Clinical and Translational Science Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Saint Michael's Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Fundação Instituto Mineiro de Estudo Pesquisa Em Nefrologi \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Freiburg \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Utah \n",
      " None \n",
      "\n",
      "\n",
      "0.0 City of Hope Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.18181818181818177 Indiana University \n",
      " ['Department of Medicine', \"Women's Hospital\"] \n",
      "\n",
      "\n",
      "0.0 Oregon Research Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.30434782608695654 Yale University \n",
      " ['Yale School of Medicine', 'Department of Psychiatry', 'CMHC', 'CT 06519'] \n",
      "\n",
      "\n",
      "0.8064516129032258 National Cancer Institute (NCI) \n",
      " ['Molecular Imaging Program', 'National Cancer Institute'] \n",
      "\n",
      "\n",
      "1.0 University of Leicester \n",
      " ['Leicester Diabetes Centre', 'University of Leicester', 'Leicester'] \n",
      "\n",
      "\n",
      "0.5303030303030303 Cancer Institute and Hospital, Chinese Academy of Medical Sciences \n",
      " ['Department of Medical Oncology', 'Cancer Institute Hospital', 'Chinese Academy of Medical Sciences', 'Peking Union Medical College', 'National Center', 'Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs'] \n",
      "\n",
      "\n",
      "0.10810810810810811 SKCCC at JHMI \n",
      " ['Department of Pharmaceutical Sciences', 'Hampton University'] \n",
      "\n",
      "\n",
      "0.627906976744186 Lawson Health Research Institute \n",
      " ['Curtin Health Innovation Research Institute', 'Curtin University'] \n",
      "\n",
      "\n",
      "1.0 Mahidol University \n",
      " ['Department of Anesthesiology, Faculty of Medicine Siriraj Hospital', 'Mahidol University'] \n",
      "\n",
      "\n",
      "0.0 Augusta University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Johns Hopkins University \n",
      " None \n",
      "\n",
      "\n",
      "0.33333333333333337 National Medical Center, Seoul \n",
      " ['Department of Anesthesiology and Pain Medicine', 'Seoul National University Bundang Hospital'] \n",
      "\n",
      "\n",
      "0.0 Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA \n",
      " None \n",
      "\n",
      "\n",
      "0.53125 Peking University Third Hospital \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.0 Policlinico Casilino ASL RMB \n",
      " None \n",
      "\n",
      "\n",
      "1.0 London School of Hygiene and Tropical Medicine \n",
      " ['London School of Hygiene and Tropical Medicine'] \n",
      "\n",
      "\n",
      "0.6190476190476191 Johann Wolfgang Goethe University Hospital \n",
      " ['Division of Vascular Medicine', 'Department of Internal Medicine', 'Goethe University Hospital', 'Frankfurt/Main'] \n",
      "\n",
      "\n",
      "0.326530612244898 Emory University \n",
      " ['Rollins School of Public Health, Emory University'] \n",
      "\n",
      "\n",
      "0.3783783783783784 Poudre Valley Health System \n",
      " ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] \n",
      "\n",
      "\n",
      "0.19444444444444442 Roswell Park Cancer Institute \n",
      " ['Division of Hematology and Oncology, University of Kansas Medical Center'] \n",
      "\n",
      "\n",
      "0.0 Chonnam National University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Emory University \n",
      " ['Department of Neurosurgery, Emory University', 'Winship Cancer Institute', 'Emory University'] \n",
      "\n",
      "\n",
      "0.5283018867924528 Chang Gung Memorial Hospital \n",
      " ['Division of Hematology, Department of Internal Medicine', 'Chang Gung Memorial Hospital-Kaohsiung Medical Center', 'Chang Gung University College of Medicine Kaohsiung'] \n",
      "\n",
      "\n",
      "0.1428571428571429 Taipei Medical University Hospital \n",
      " ['Emory Eye Center', 'Emory University School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 Brooke Army Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Seoul National University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Philadelphia VA Medical Center, Philadelphia, PA \n",
      " None \n",
      "\n",
      "\n",
      "0.7391304347826086 National Center for Tumor Diseases, Heidelberg \n",
      " ['Department of Medical Oncology', 'National Center for Tumor Diseases'] \n",
      "\n",
      "\n",
      "0.0 Universidad Autonoma de San Luis Potosí \n",
      " None \n",
      "\n",
      "\n",
      "0.1428571428571429 Hong Kong Baptist University \n",
      " ['Chinese Academy of Medical Sciences'] \n",
      "\n",
      "\n",
      "0.0 Loma Linda University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Weill Medical College of Cornell University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 All India Institute of Medical Sciences, New Delhi \n",
      " None \n",
      "\n",
      "\n",
      "0.5 Hospital General Universitario Elche \n",
      " ['Department of Surgery', 'Bariatric Surgery Unit', 'General University Hospital Elche'] \n",
      "\n",
      "\n",
      "0.2941176470588235 Parc de Salut Mar \n",
      " ['Rheumatology Service', 'Hospital del Mar'] \n",
      "\n",
      "\n",
      "0.0 Physicians Committee for Responsible Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.2682926829268293 Ludwig-Maximilians - University of Munich \n",
      " ['Department of Trauma Surgery', 'University Hospital', 'LMU'] \n",
      "\n",
      "\n",
      "0.0 School of physical therapy, National Taiwan University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Michigan \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Florida- PHHP, CHP \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital, Lille \n",
      " None \n",
      "\n",
      "\n",
      "0.26 Cardiology department - Pitié Salpêtrière Hospital \n",
      " ['Cardiovascular Research Center', 'Icahn School of Medicine at Mount Sinai'] \n",
      "\n",
      "\n",
      "0.0 Charite University, Berlin, Germany \n",
      " None \n",
      "\n",
      "\n",
      "0.22448979591836737 Roswell Park Cancer Institute \n",
      " ['Norwich University Hospitals NHS Foundation Trust'] \n",
      "\n",
      "\n",
      "0.9565217391304348 University of Sao Paulo \n",
      " ['Department of Preventive Medicine', 'Faculty of Medicine', 'University of São Paulo', 'Center of Research in Mental Health Population, University of São Paulo'] \n",
      "\n",
      "\n",
      "0.25 Imperial College London \n",
      " ['Department of Otolaryngology-Head', 'Neck Surgery', 'University of Washington', 'WA, USA'] \n",
      "\n",
      "\n",
      "0.15384615384615385 Kaleida Health \n",
      " ['Division of Endocrinology', 'State University of New York at Buffalo'] \n",
      "\n",
      "\n",
      "0.3571428571428571 Nationwide Children's Hospital \n",
      " [\"Department of Endocrinology, Metabolism and Diabetes, Nationwide Children's Hospital\", 'Columbus OH'] \n",
      "\n",
      "\n",
      "0.0 Massachusetts General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.35185185185185186 The University of Texas Health Science Center, Houston \n",
      " ['Department of Chemistry', 'University of Illinois'] \n",
      "\n",
      "\n",
      "0.0 Massey Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Miami \n",
      " None \n",
      "\n",
      "\n",
      "0.27586206896551724 Azienda Policlinico Umberto I \n",
      " ['Department of Pediatrics', 'Liver Unit', 'Sapienza University of Rome'] \n",
      "\n",
      "\n",
      "0.0 State University of New York - Upstate Medical University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital Inselspital, Berne \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Section Chief of Neurology, University Hospital Virgen Macarena, Spain \n",
      " [] \n",
      "\n",
      "\n",
      "1.0 National Taiwan University Hospital \n",
      " ['the Department of Anesthesiology', 'National Taiwan University Hospital', 'Y.-C.Y.', 'C.-Y.W.', 'Y.-J.C.', 'C.-M.L.', 'the Graduate Institutes of Physiology, College of Medicine', 'National Taiwan University', 'Department of Medical Imaging', 'Taipei Buddhist Tzu Chi General Hospital', 'Department of Anesthesiology, Far Eastern Memorial Hospital'] \n",
      "\n",
      "\n",
      "0.0 Soonchunhyang University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Mayo Clinic \n",
      " None \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1.0 Massachusetts General Hospital \n",
      " ['Diabetes Unit', 'Department of Medicine', 'Massachusetts General Hospital', 'Harvard Medical School'] \n",
      "\n",
      "\n",
      "0.15254237288135597 Université de Montréal \n",
      " ['Department of Obstetrics and Gynecology , Angers University'] \n",
      "\n",
      "\n",
      "0.0 University of Colorado, Denver \n",
      " None \n",
      "\n",
      "\n",
      "0.15000000000000002 Beijing No.6 Hospital \n",
      " ['Department of Psychiatry, Columbia University', 'The New York State Psychiatric Institute'] \n",
      "\n",
      "\n",
      "0.0 IQ healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel \n",
      " None \n",
      "\n",
      "\n",
      "0.16666666666666663 Massachusetts General Hospital \n",
      " ['Department of Surgery', 'Department of Medicine', 'Department of Radiation Oncology', '4 Department of Radiology, Pancreatic Cancer Program', 'The Medical College of Wisconsin'] \n",
      "\n",
      "\n",
      "0.25 Johns Hopkins University/Sidney Kimmel Cancer Center \n",
      " ['Department of Pharmaceutical Sciences', 'Hampton University'] \n",
      "\n",
      "\n",
      "0.0 University of Kansas Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Bridgeport \n",
      " None \n",
      "\n",
      "\n",
      "0.25 Nova Scotia Health Authority \n",
      " ['Division of Orthopaedics', 'Dalhousie University'] \n",
      "\n",
      "\n",
      "0.0 University of Dublin, Trinity College \n",
      " None \n",
      "\n",
      "\n",
      "0.5454545454545454 Sahlgrenska University Hospital, Sweden \n",
      " ['Department of Surgery', 'Sahlgrenska University Hospital, Institution for Clinical Sciences', 'Sahlgrenska Academy', 'University of Gothenburg'] \n",
      "\n",
      "\n",
      "0.0 Pakistan Association of Cognitive Therapists \n",
      " None \n",
      "\n",
      "\n",
      "0.0 SUNY Upstate Medical University Neurosurgery \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Laval University \n",
      " None \n",
      "\n",
      "\n",
      "0.34285714285714286 Case Comprehensive Cancer Center \n",
      " ['Department of Surgery, Division of Colorectal Surgery', 'Case Western Reserve Medical School'] \n",
      "\n",
      "\n",
      "0.9069767441860466 Icahn School of Medicine at Mount Sinai \n",
      " ['The Icahn School of Medicine at Mount Sinai'] \n",
      "\n",
      "\n",
      "0.0 Isfahan University of Medical Sciences \n",
      " None \n",
      "\n",
      "\n",
      "0.5357142857142857 Abramson Cancer Center of the University of Pennsylvania \n",
      " ['Perelman School of Medicine', 'the University of Pennsylvania'] \n",
      "\n",
      "\n",
      "0.21333333333333337 Medical department, Diagnostic Center, Regional Hospital Silkeborg, Denmark \n",
      " ['Department of Medicine', 'University of Wisconsin', 'WI'] \n",
      "\n",
      "\n",
      "0.0 Washington University School of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Yale University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Colorado, Denver \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of California, San Francisco \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Department of Orthopaedics, University of California at Davis \n",
      " None \n",
      "\n",
      "\n",
      "0.18604651162790697 October 6 University \n",
      " ['Oral Medicine and Periodontology Department', 'Faculty of Dentistry'] \n",
      "\n",
      "\n",
      "0.1964285714285714 Contract Research Organization el AB \n",
      " ['Department of Clinical Pharmacology, University Hospital'] \n",
      "\n",
      "\n",
      "0.0 Montefiore Medical Center, Albert Einstein \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de Néphrologie Bâtiment 3C, 3ème étage, Chemin du grand Revoyet 69495 PIERRE-BENITE \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Shandong Provincial Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Erasme University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Children's Hospital of Eastern Ontario \n",
      " None \n",
      "\n",
      "\n",
      "0.16923076923076918 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) \n",
      " ['Department of Gastroenterology, Academic Medical Center'] \n",
      "\n",
      "\n",
      "0.875 Université de Sherbrooke \n",
      " ['Department of Medicine, Division of Endocrinology', 'University Hospital Center of', 'University of Sherbrooke', 'Clinical Research Center', 'University Hospital Center'] \n",
      "\n",
      "\n",
      "0.26415094339622647 Centre hospitalier de l'Université de Montréal (CHUM) \n",
      " ['Nordita', 'KTH Royal Institute of Technology', 'Stockholm University'] \n",
      "\n",
      "\n",
      "0.1777777777777778 Beijing Anzhen Hospital \n",
      " ['Division of Materials Science and Engineering', 'US-DOE', 'Department of Materials Science and Engineering', 'Iowa State University', 'Ames'] \n",
      "\n",
      "\n",
      "0.23684210526315785 National Cancer Institute (NCI) \n",
      " ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] \n",
      "\n",
      "\n",
      "0.3137254901960784 Universitätsklinik für Innere Medizin III, Salzburg \n",
      " ['IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center', 'Paracelsus Medical University Salzburg'] \n",
      "\n",
      "\n",
      "0.0 Butler Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.20833333333333337 Jilin University \n",
      " ['School of Biomedical Sciences', 'University of Queensland'] \n",
      "\n",
      "\n",
      "0.0 Yonsei University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Shiraz University of Medical Sciences \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Hawaii Pacific Health \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Dana-Farber Cancer Institute \n",
      " [] \n",
      "\n",
      "\n",
      "0.0 Stanford Hospital and Clinics and Lucile Packard Children's Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Federal University of São Paulo \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Fred Hutchinson Cancer Research Center \n",
      " ['Division of Medical Oncology', 'Fred Hutchinson Cancer Research Center', 'University of Washington'] \n",
      "\n",
      "\n",
      "0.19444444444444442 New York State Psychiatric Institute \n",
      " ['Fakultät für Physik & Astronomie'] \n",
      "\n",
      "\n",
      "0.6 University of Arizona \n",
      " ['University of Arizona Cancer Center'] \n",
      "\n",
      "\n",
      "0.0 Associação Fundo de Incentivo à Pesquisa \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Quadram Institute Bioscience \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Beijing Tiantan Hospital \n",
      " ['Beijing Tiantan Stroke Center', 'Beijing Tiantan Hospital', 'Capital Medical University'] \n",
      "\n",
      "\n",
      "0.0 Staff Cardiologist and Clinical Assistant Professor, Division of Cardiology, QE II Health Science Centre, Dalhousie University and Capital District Health Authority \n",
      " None \n",
      "\n",
      "\n",
      "0.9649122807017544 Postgraduate Institute of Medical Education and Research \n",
      " ['Department of Endocrinology', 'Post Graduate Institute of Medical Education and Research', 'Chandigarh'] \n",
      "\n",
      "\n",
      "0.0 Nottingham University Hospital NHS Trust \n",
      " None \n",
      "\n",
      "\n",
      "0.2063492063492064 Seoul National University Bundang Hospital \n",
      " ['the Department of Radiology and Research Institute of Radiology', 'N.J.L.', 'M.S.C.', 'S.C.J.', 'C.-G.C.', 'S.J.K.', 'D.H.L.'] \n",
      "\n",
      "\n",
      "0.0 Henry Ford Health System \n",
      " None \n",
      "\n",
      "\n",
      "0.14814814814814814 West Park Healthcare Centre \n",
      " ['University of Toronto'] \n",
      "\n",
      "\n",
      "0.0 Helsinki University \n",
      " None \n",
      "\n",
      "\n",
      "0.8571428571428572 TC Erciyes University \n",
      " ['Department of Anesthesia', 'Faculty of Medicine', 'Erciyes University'] \n",
      "\n",
      "\n",
      "1.0 University of Florida \n",
      " ['Food Science and Human Nutrition Department', 'University of Florida', 'Institute of Food and Agricultural Sciences', 'Newell'] \n",
      "\n",
      "\n",
      "0.0 Hôpital de la Pitié Salpêtrière - Paris 75013 \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Mayo Clinic \n",
      " None \n",
      "\n",
      "\n",
      "0.6086956521739131 Rigshospitalet, Denmark \n",
      " ['Clinical Microbiology 9301', 'Copenhagen University Hospital', 'Rigshospitalet'] \n",
      "\n",
      "\n",
      "0.0 Oregon Health and Science University \n",
      " None \n",
      "\n",
      "\n",
      "0.17391304347826086 UCSD and CLL Consortium \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.0 Christie Clinc \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Region Örebro County \n",
      " None \n",
      "\n",
      "\n",
      "0.5789473684210527 NYU School of Medicine \n",
      " ['Department of Population Health', 'New York University School of Medicine'] \n",
      "\n",
      "\n",
      "0.17142857142857137 National Taiwan University Hospital \n",
      " ['Neurology', 'Experimental Therapeutics'] \n",
      "\n",
      "\n",
      "0.0 St. Luke's University Hospital and Health Network \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Guangzhou 8th People's Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.39473684210526316 The Ottawa Hospital Research Institute \n",
      " ['Tropical Medicine', 'International Health Clinic', 'Division of Infectious Diseases', 'Ottawa Hospital', 'the University of Ottawa'] \n",
      "\n",
      "\n",
      "0.33333333333333337 Maastro Clinic, The Netherlands \n",
      " ['Department of Radiation Oncology', 'Maastricht University Medical Center'] \n",
      "\n",
      "\n",
      "1.0 Mayo Clinic \n",
      " ['Mayo Clinic'] \n",
      "\n",
      "\n",
      "0.016949152542372836 NKI \n",
      " ['Department for Hematology, Oncology and Clinical Immunology', 'University Hospital', 'Heinrich-Heine-University'] \n",
      "\n",
      "\n",
      "0.0 The Washington University in St. Louis School of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Institut für Pneumologie Hagen Ambrock eV \n",
      " None \n",
      "\n",
      "\n",
      "0.30000000000000004 Bundang CHA Hospital \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.5142857142857142 University of Kansas Medical Center \n",
      " ['University of KwaZulu-Natal', 'Nelson R. Mandela School of Medicine', 'KwaZulu-Natal Department of Health'] \n",
      "\n",
      "\n",
      "0.0 Cairo University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Minnesota - Clinical and Translational Science Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 El Camino Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.6206896551724138 St. Olavs Hospital \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " ['Department of Neuroscience', 'Norwegian University of Science and Technology', 'NTNU', 'Department of Neurosurgery', 'St. Olavs University Hospital', 'National Advisory Unit', 'Spinal Surgery Center', 'St. Olavs University Hospital', 'Norwegian Centre of Competence', 'St. Olavs University Hospital'] \n",
      "\n",
      "\n",
      "0.0 McGill University Health Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Division of Vascular Surgery, UNC at Chapel Hill \n",
      " None \n",
      "\n",
      "\n",
      "0.5 Peking University \n",
      " ['Department of Pharmacy', 'National Taiwan University Hospital', 'Graduate Institute of Clinical Pharmacy', 'National Taiwan University'] \n",
      "\n",
      "\n",
      "0.7692307692307692 Rockefeller Univesrity \n",
      " ['The Rockefeller University'] \n",
      "\n",
      "\n",
      "0.0 Children's Hospital Medical Center, Cincinnati \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Memorial Sloan Kettering Cancer Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Chinese Academy of Medical Sciences \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Medical Research Council \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Taichung Veteran General Hospital, Taiwan \n",
      " None \n",
      "\n",
      "\n",
      "1.0 University of Utah \n",
      " ['Department of Pharmaceutics and Pharmaceutical Chemistry', 'College of Pharmacy', 'University of Utah', 'UT'] \n",
      "\n",
      "\n",
      "1.0 Bispebjerg Hospital \n",
      " ['Institute of Sports Medicine Copenhagen', 'Department of Orthopedic Surgery M', 'Bispebjerg Hospital', 'DK-2400', 'Copenhagen', 'NV'] \n",
      "\n",
      "\n",
      "0.6382978723404256 UT Southwestern Medical Center \n",
      " ['Department of Neurology', 'S.B.', 'A.T.', 'A.A.O.', 'T.J.K., L.M.D.', 'I.K.M.', 'Department of Radiology, Memorial Sloan Kettering Cancer Center', 'R.J.Y.', 'J.T.', 'A.I.H.', 'S.B.T.', 'Department of Pathology, Memorial Sloan Kettering Cancer Center', 'Memorial Sloan Kettering Cancer Center', 'J.R.C.', 'Pathogenesis Program', 'I.K.M.', 'Department of Neurosurgery', 'P.H.G.', 'Department of Medical Physics', 'J.H.O.', 'S.B.T.', 'Agios Pharmaceuticals', 'Department of Neurology', 'Evelyn F. McKnight Brain Institute', 'University of Miami', 'Advanced Imaging Research Center', 'University Of Texas Southwestern Medical Center', 'GE Healthcare', 'Department of Pharmacology, Weill-Cornell Graduate School of Biomedical Sciences', 'I.K.M.'] \n",
      "\n",
      "\n",
      "0.125 Université de Sherbrooke \n",
      " ['Pediatrics'] \n",
      "\n",
      "\n",
      "0.0 Hôpital Larrey, Toulouse, France \n",
      " None \n",
      "\n",
      "\n",
      "0.0 KULeuven, Belgium \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Fundacion Infosalud \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Charite University, Berlin, Germany \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Children's Hospital Medical Center, Cincinnati \n",
      " None \n",
      "\n",
      "\n",
      "0.19999999999999996 Northwestern University \n",
      " ['Department of Medical Oncology and Hematology', 'University of Toronto'] \n",
      "\n",
      "\n",
      "0.618421052631579 Bruyere Research Institute, C. T. Lamont Primary Health Care Research Centre \n",
      " ['Bruyère Research Institute', 'C.T. Lamont Primary Health Care Research Centre', 'University of Ottawa', 'Department of Family Medicine'] \n",
      "\n",
      "\n",
      "0.16000000000000003 Johns Hopkins Bloomberg School of Public Health \n",
      " ['Department of Psychology, University of Pittsburgh', 'PA', 'PA'] \n",
      "\n",
      "\n",
      "0.0 Brody School of Medicine ar East Carolina University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 The University of Texas Health Science Center, Houston \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Seoul National University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.16129032258064513 NTUH Yun-Lin branch \n",
      " ['Department of Internal Medicine', 'National Taiwan University Hospital', 'Chung-Shan South Road'] \n",
      "\n",
      "\n",
      "0.5483870967741935 Chinese University of Hong Kong \n",
      " ['Brain & Mind Research Institute', 'Nerve Research Foundation', 'Level 7', 'Mind Research Institute', 'the University of Sydney', 'NSW'] \n",
      "\n",
      "\n",
      "0.0 AMCR Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 The Methodist Hospital System \n",
      " None \n",
      "\n",
      "\n",
      "0.41860465116279066 Rutgers, The State University of New Jersey \n",
      " ['Post Masters DNP-Practice', 'MSN', 'Rutgers University', 'UMDNJ', 'NJ', 'Saint Peters University Hospital', 'Rutgers University Behavioral Health Care/University Correctional Health Care'] \n",
      "\n",
      "\n",
      "0.0 Department of Internal Medicine I, RWTH Aachen University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.18918918918918914 CSSS de Gatineau \n",
      " ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] \n",
      "\n",
      "\n",
      "0.0 Institut de Radioprotection et de Surete Nucleaire \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Duke University \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Ain Shams University \n",
      " ['Department of Pediatric Hematology', 'Ain Shams University'] \n",
      "\n",
      "\n",
      "0.0 Nanfang Hospital of Southern Medical University \n",
      " None \n",
      "\n",
      "\n",
      "0.4130434782608695 Makerere University \n",
      " ['Makerere University College of Health Sciences', 'School of Public Health Department of Community Health and Behavioural Sciences'] \n",
      "\n",
      "\n",
      "0.23333333333333328 University of Arkansas \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.0 Aalborg University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Umeå University \n",
      " ['Umeå University', 'Department of Clinical Sciences', 'Division of Pediatrics'] \n",
      "\n",
      "\n",
      "0.0 University of Colorado, Denver \n",
      " None \n",
      "\n",
      "\n",
      "0.0 VA Palo Alto Health Care System, Palo Alto, CA \n",
      " None \n",
      "\n",
      "\n",
      "0.6875 University of California, San Diego \n",
      " ['Division of Cardiology', 'Cardiac Electrophysiology Program', 'University of California San Diego Health System', 'Sulpizio Family Cardiovascular Center'] \n",
      "\n",
      "\n",
      "0.30188679245283023 Instituto Mexicano del Seguro Social \n",
      " ['Department of Research Unit', 'Clinical Epidemiology, Medical Unit of High Specialty', 'Specialties Hospital of', 'the Western Medical Center', 'Mexican Institute of Social Security'] \n",
      "\n",
      "\n",
      "0.18867924528301883 Massachusetts General Hospital \n",
      " ['London Centre for Neglected Tropical Disease Research', 'Department of Infectious Disease Epidemiology, School of Public Health', 'St. Marys Campus', 'Imperial College'] \n",
      "\n",
      "\n",
      "0.0 Colorado Neurological Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Copenhagen \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Komfo Anokye Teaching Hospital \n",
      " ['Transfusion Medicine Unit', 'Komfo Anokye Teaching Hospital'] \n",
      "\n",
      "\n",
      "0.2432432432432432 University of Alabama at Birmingham \n",
      " ['Ophthalmology', 'Cellular', 'Indiana University School of Medicine'] \n",
      "\n",
      "\n",
      "1.0 National Taiwan University Hospital \n",
      " ['Department of Pediatrics', 'National Taiwan University Hospital', 'National Taiwan University College of Medicine'] \n",
      "\n",
      "\n",
      "0.0 National Institute of Rehabilitation \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Guangxi Medical University \n",
      " ['Department of Hepatobiliary Surgery', 'Affiliated Tumor Hospital', 'Guangxi Medical University'] \n",
      "\n",
      "\n",
      "0.19148936170212771 Royal Bournemouth Hospital NHS Foundation Trust \n",
      " ['Gene & Stem Cell Therapy Program', 'Centenary Institute', 'Camperdown 2050', 'Australia Sydney Medical School', 'University of Sydney', 'NSW', 'Australia Bioinformatics Laboratory', 'Centenary Institute'] \n",
      "\n",
      "\n",
      "0.0 University of Pittsburgh \n",
      " None \n",
      "\n",
      "\n",
      "0.4130434782608695 University of Miami \n",
      " ['Department of Dermatology, University of Miami', 'Coral Gables'] \n",
      "\n",
      "\n",
      "0.1428571428571429 NRG Oncology \n",
      " ['the Department of Radiology and Research Institute of Radiology', 'N.J.L.', 'M.S.C.', 'S.C.J.', 'C.-G.C.', 'S.J.K.', 'D.H.L.'] \n",
      "\n",
      "\n",
      "0.275 Instituto Dante Pazzanese de Cardiologia \n",
      " ['Department of Neurology', 'Orlando Veteran Affairs Medical Center'] \n",
      "\n",
      "\n",
      "0.0 Southern California Desert Retina Consultants \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital, Basel, Switzerland \n",
      " None \n",
      "\n",
      "\n",
      "0.6052631578947368 University of Rochester \n",
      " ['Department of Neurology', 'University of Rochester Medical Center'] \n",
      "\n",
      "\n",
      "0.625 Lund University Hospital \n",
      " ['Division of Hematology and Transfusion Medicine', 'Department of Laboratory Medicine', 'Lund University'] \n",
      "\n",
      "\n",
      "0.0 Edith cavell clinic, Belgium \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Princess Margaret Cancer Centre \n",
      " None \n",
      "\n",
      "\n",
      "0.0 National Heart, Lung, and Blood Institute (NHLBI) \n",
      " None \n",
      "\n",
      "\n",
      "0.6341463414634146 Wake Forest University Health Sciences \n",
      " ['Pulmonary-Critical Care', 'Wake Forest University School of Medicine', 'NC 27157'] \n",
      "\n",
      "\n",
      "0.6551724137931034 Hunan Province Tumor Hospital \n",
      " ['Lung Cancer', 'Gastroenterology Department', 'Hunan Cancer Hospital', 'Affiliated Tumor Hospital of', 'Xiangya Medical School of Central South University'] \n",
      "\n",
      "\n",
      "0.0 University of Arizona \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Nanfang Hospital of Southern Medical University \n",
      " [] \n",
      "\n",
      "\n",
      "0.0 Savannas Forever Tanzania \n",
      " None \n",
      "\n",
      "\n",
      "0.45833333333333337 University of Konstanz ['University of California, Irvine', 'CA'] \n",
      "\n",
      "\n",
      "1.0 Vanderbilt University Medical Center \n",
      " ['Vanderbilt University Medical Center', 'Department of Medicine', 'TN'] \n",
      "\n",
      "\n",
      "1.0 Richmond Vascular Center \n",
      " ['Richmond Vascular Center'] \n",
      "\n",
      "\n",
      "0.0 Boston Children’s Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.21621621621621623 Vanderbilt University \n",
      " ['Anxiety Treatment and Research Clinic', 'N 3K7'] \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0.19999999999999996 Nationwide Children's Hospital \n",
      " ['Michigan State University', 'Kalamazoo Center for Medical Studies', 'Oakland Drive'] \n",
      "\n",
      "\n",
      "0.2954545454545454 Emergency Medicine Physicians \n",
      " ['University of Nevada School of Medicine', 'Department of Emergency Medicine', 'University Medical Center of Southern Nevada', 'Department of Emergency Medicine'] \n",
      "\n",
      "\n",
      "0.0 University of Cagliari \n",
      " None \n",
      "\n",
      "\n",
      "0.16326530612244894 Associate Professor \n",
      " ['Department of Epidemiology, University of Florida'] \n",
      "\n",
      "\n",
      "0.0 Frederiksberg University Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.3548387096774194 University of Michigan \n",
      " ['Division of Nuclear Medicine', 'Department of Radiology, University of Michigan Medical School'] \n",
      "\n",
      "\n",
      "0.0 -Hôpital Robert Debré, Service de psychiatrie de l'enfant et de l'adolescent \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Illinois Retina and Eye Associates \n",
      " None \n",
      "\n",
      "\n",
      "0.5833333333333333 Loma Linda University \n",
      " ['Department of Biology', 'Johns Hopkins University'] \n",
      "\n",
      "\n",
      "1.0 New York Institute of Technology \n",
      " ['Department of Osteopathic Medicine', 'College of Osteopathic Medicine', 'New York Institute of Technology', 'NYITCOM'] \n",
      "\n",
      "\n",
      "0.0 Shanghai Chest Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.34375 The Netherlands Cancer Institute \n",
      " ['Department of Radiation Oncology', 'Hoed Cancer Center'] \n",
      "\n",
      "\n",
      "0.0 L.V. Prasad Eye Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Yale University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 McMaster University \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Simon Fraser University \n",
      " ['BC Centre for Excellence', 'Faculty of Health Sciences', 'Simon Fraser University'] \n",
      "\n",
      "\n",
      "0.0 Asan Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Colorado, Denver \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Liverpool \n",
      " None \n",
      "\n",
      "\n",
      "0.29166666666666663 Shanghai Jiao Tong University School of Medicine \n",
      " ['Nuclear Physics and Technology', 'Peking University'] \n",
      "\n",
      "\n",
      "0.0 University of Pennsylvania \n",
      " None \n",
      "\n",
      "\n",
      "0.21153846153846156 Sunnybrook Health Sciences Center \n",
      " ['Department of Medical Imaging, University of Toronto'] \n",
      "\n",
      "\n",
      "0.0 NRG Oncology \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital Tuebingen \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Mission Research, New Braunfels, TX \n",
      " None \n",
      "\n",
      "\n",
      "0.22916666666666663 Icahn School of Medicine at Mount Sinai \n",
      " ['Department of Psychiatry and Behavioral Sciences', 'Memorial Sloan Kettering Cancer Center'] \n",
      "\n",
      "\n",
      "0.0 Western Sydney Local Health District \n",
      " None \n",
      "\n",
      "\n",
      "0.2833333333333333 Duke Anesthesiology \n",
      " ['Department of Anesthesiology, Duke University Medical Center'] \n",
      "\n",
      "\n",
      "0.6428571428571428 Kantonsspital Winterthur KSW \n",
      " ['Department of Surgery', 'Cantonal Hospital Winterthur'] \n",
      "\n",
      "\n",
      "0.0 Chulalongkorn University \n",
      " None \n",
      "\n",
      "\n",
      "0.240506329113924 University of California, San Francisco \n",
      " ['Department of Neurological Surgery, University of Washington School of Medicine', 'WA, USA'] \n",
      "\n",
      "\n",
      "0.0 Sheba Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Yale-Griffin Prevention Research Center \n",
      " None \n",
      "\n",
      "\n",
      "0.5087719298245614 University of Wisconsin, Madison \n",
      " ['Department of Pediatrics, University of Wisconsin-Madison', 'WI'] \n",
      "\n",
      "\n",
      "0.0 National Institute of Allergy and Infectious Diseases (NIAID) \n",
      " None \n",
      "\n",
      "\n",
      "0.36363636363636365 Cancer Institute of São Paulo \n",
      " ['Department of Gastroenterology, University of São Paulo'] \n",
      "\n",
      "\n",
      "0.0 University of Dundee \n",
      " [] \n",
      "\n",
      "\n",
      "0.0 Huazhong University of Science and Technology \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Virginia Commonwealth University \n",
      " None \n",
      "\n",
      "\n",
      "0.3285714285714286 University of Minnesota - Clinical and Translational Science Institute \n",
      " ['Marrow Transplant Program', 'University of Minnesota'] \n",
      "\n",
      "\n",
      "0.0 University of California, Irvine \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Albert Einstein College of Medicine \n",
      " ['Department of Radiation Oncology', 'Montefiore Medical Center', 'Albert Einstein College of Medicine'] \n",
      "\n",
      "\n",
      "0.0 Kodama Eye Clinic \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Istituto Auxologico Italiano \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Kyunghee University Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Federal University of São Paulo \n",
      " None \n",
      "\n",
      "\n",
      "0.0 USDA Beltsville Human Nutrition Research Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 CHU Amiens, Service de Dermatologie \n",
      " None \n",
      "\n",
      "\n",
      "0.21153846153846156 General and Teaching Hospital Celje \n",
      " ['Departments of Cardiology and Research and Education'] \n",
      "\n",
      "\n",
      "0.4864864864864865 Indiana University \n",
      " ['Indiana University School of Medicine'] \n",
      "\n",
      "\n",
      "0.19444444444444442 McMaster University \n",
      " [\"Children's Health Research Institute\", 'Molecular Immunology Laboratory', \"Women's\", \"Children's Hospital\"] \n",
      "\n",
      "\n",
      "1.0 Texas Heart Institute \n",
      " ['Texas Heart Institute'] \n",
      "\n",
      "\n",
      "0.1724137931034483 National Institute on Alcohol Abuse and Alcoholism (NIAAA) \n",
      " ['Department of Neurology', 'University of California', 'CA'] \n",
      "\n",
      "\n",
      "0.0 University of Liege \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Zhejiang Cancer Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.2954545454545454 Centre Hospitalier Universitaire de Montreal \n",
      " ['Nordita', 'KTH Royal Institute of Technology', 'Stockholm University'] \n",
      "\n",
      "\n",
      "0.0 Assistance publique hopitaux de Paris - APHP \n",
      " [] \n",
      "\n",
      "\n",
      "0.9166666666666666 Oregon Health and Science University \n",
      " ['Division of Arthritis and Rheumatic Diseases', 'Department of Ophthalmology', 'Oregon Health & Science University'] \n",
      "\n",
      "\n",
      "0.9821428571428571 Tianjin Medical University Cancer Institue and Hospital \n",
      " ['Department of Interventional Therapy', 'Tianjin Medical University Cancer Institute and Hospital', 'National Clinical Research Center of Cancer', 'Cancer Prevention and Therapy'] \n",
      "\n",
      "\n",
      "0.18918918918918914 Henry Ford Hospital - West Bloomfield \n",
      " ['Department of Neurology', 'Wayne State University School of Medicine'] \n",
      "\n",
      "\n",
      "0.21153846153846156 Washington University School of Medicine \n",
      " ['Transcarpathian Regional Clinical Oncologic Hospital', 'Uzhhorod 88000'] \n",
      "\n",
      "\n",
      "0.0 University of Jena \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Arizona State University \n",
      " None \n",
      "\n",
      "\n",
      "0.2542372881355932 Carmel Medical Center \n",
      " ['Department of Medicine, Division of Cardiovascular Diseases', 'Mayo Clinic', 'MN 55905'] \n",
      "\n",
      "\n",
      "0.5365853658536586 University of Maryland \n",
      " ['Department of Medicine', 'University of Maryland School of Medicine'] \n",
      "\n",
      "\n",
      "1.0 Federal University of Bahia \n",
      " ['Health Science Institute', 'Federal University of Bahia', 'BA'] \n",
      "\n",
      "\n",
      "0.0 Laval University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Massachusetts General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of Utah \n",
      " None \n",
      "\n",
      "\n",
      "0.30000000000000004 Mayo General Hospital, Ireland \n",
      " ['Department of Haematology', 'Royal Berkshire Hospital'] \n",
      "\n",
      "\n",
      "0.0 Duke University \n",
      " None \n",
      "\n",
      "\n",
      "0.12765957446808507 Pontifical Catholic University of Argentina \n",
      " ['Raul Carrea Institute for Neurological Research', 'FLENI'] \n",
      "\n",
      "\n",
      "1.0 Université Catholique de Louvain \n",
      " ['Metabolism and Nutrition Research Group', 'Louvain Drug Research Institute', 'Université Catholique de Louvain', 'Walloon Excellence in Life Sciences'] \n",
      "\n",
      "\n",
      "0.0 Medical University of Vienna \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Peking University First Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.75 CORL, Indiana University \n",
      " ['Indiana University', 'School of Optometry'] \n",
      "\n",
      "\n",
      "0.1875 Hospital Universitario 12 de Octubre \n",
      " ['Department of Nephrology, Hospital Universitario'] \n",
      "\n",
      "\n",
      "0.47540983606557374 National Institute of Allergy and Infectious Diseases (NIAID) \n",
      " ['National Institute of Allergy', 'National Institutes of Health'] \n",
      "\n",
      "\n",
      "0.0 Fudan University \n",
      " None \n",
      "\n",
      "\n",
      "1.0 University of Alberta \n",
      " ['Department of Family Medicine', 'University of Alberta'] \n",
      "\n",
      "\n",
      "0.10256410256410253 Catholic University of the Sacred Heart \n",
      " ['Department of Obstetrics and Gynecology'] \n",
      "\n",
      "\n",
      "1.0 University of Glasgow \n",
      " ['Faculty of Medicine', 'University of Glasgow', 'Yorkhill Hospital'] \n",
      "\n",
      "\n",
      "0.6060606060606061 University of Mississippi Medical Center \n",
      " ['Department of Pediatrics, University of Mississippi Medical Center', 'MS'] \n",
      "\n",
      "\n",
      "0.0 New York University Medical School \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Hospital, Lille \n",
      " None \n",
      "\n",
      "\n",
      "0.18333333333333335 Chinese PLA General Hospital \n",
      " ['Institute of Basic Medicine Science, College of Life Science'] \n",
      "\n",
      "\n",
      "0.0 Providence VA Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Universita di Verona \n",
      " None \n",
      "\n",
      "\n",
      "1.0 University of Utah \n",
      " ['University of Utah'] \n",
      "\n",
      "\n",
      "0.0 Cairo University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Olive View-UCLA Education & Research Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.2142857142857143 Peterborough and Stamford Hospitals NHS Foundation Trust \n",
      " ['Department of Molecular and Human Genetics', 'Baylor College of Medicine', 'TX 77030'] \n",
      "\n",
      "\n",
      "0.0 Washington University School of Medicine \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Valduce Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Staff of the department of Oncology \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Yale University \n",
      "  \n",
      "\n",
      "\n",
      "0.0 The University of Hong Kong \n",
      " None \n",
      "\n",
      "\n",
      "0.3913043478260869 University of Iowa \n",
      " ['Department of Epidemiology, University of Iowa'] \n",
      "\n",
      "\n",
      "0.0 Hamilton Health Sciences Corporation \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " None \n",
      "\n",
      "\n",
      "0.6363636363636364 The Royal Wolverhampton NHS Trust \n",
      " ['Deansley Centre', 'Royal Wolverhampton Hospital'] \n",
      "\n",
      "\n",
      "0.0 University of Virginia \n",
      " None \n",
      "\n",
      "\n",
      "0.2093023255813954 Shanghai Chest Hospital \n",
      " ['Department of Medicine', 'Johns Hopkins University School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 OHSU Knight Cancer Institute \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of California, San Diego \n",
      " None \n",
      "\n",
      "\n",
      "0.19999999999999996 Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi \n",
      " ['Division of Neonatology, Department of Pediatrics'] \n",
      "\n",
      "\n",
      "0.0 Hôpital Hôtel-Dieu \n",
      " None \n",
      "\n",
      "\n",
      "0.18181818181818177 Pope Research Corp. \n",
      " ['Division of Rheumatology, Department of Medicine', 'The University of Western Ontario'] \n",
      "\n",
      "\n",
      "0.13793103448275867 Paracelsus Medical University \n",
      " ['Klinik'] \n",
      "\n",
      "\n",
      "0.0 The University of Arizona Cancer Center at Dignity Health St. Joseph's Hospital and Medical Center \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Beijing 302 Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.42000000000000004 Cleveland Clinic, Case Comprehensive Cancer Center \n",
      " ['Cleveland Clinic Foundation'] \n",
      "\n",
      "\n",
      "1.0 National Taiwan University Hospital \n",
      " ['Department of Pharmacy', 'National Taiwan University Hospital', 'Graduate Institute of Clinical Pharmacy', 'National Taiwan University'] \n",
      "\n",
      "\n",
      "0.36363636363636365 Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center \n",
      " ['Thomas Jefferson University Medical College'] \n",
      "\n",
      "\n",
      "0.0 Virginia Commonwealth University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Ruijin Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 CHU Bordeaux \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Pusan National University Hospital \n",
      " ['Department of Nuclear Medicine', 'Department of Internal Medicine Medical Research Institute', 'Pusan National University Hospital', 'Pusan National University'] \n",
      "\n",
      "\n",
      "0.0 Fudan University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Health Network, Toronto \n",
      " None \n",
      "\n",
      "\n",
      "0.08333333333333337 UNC-CH \n",
      " ['Center for Health Services and Society', 'University of California', 'Los Angeles Institute for Neuroscience and Human Behavior'] \n",
      "\n",
      "\n",
      "0.0 MRC Centre for Inflammation Research, Queens Medical Research Institute \n",
      " None \n",
      "\n",
      "\n",
      "1.0 University of Miami \n",
      " ['Department of Kinesiology and Sport Sciences', 'School of Education & Human Development', 'University of Miami', 'Coral Gables', 'Center on Aging, Miller School of Medicine', 'N.W. 9th Avenue', 'Suite 3204'] \n",
      "\n",
      "\n",
      "1.0 Showa Inan General Hospital \n",
      " ['Digestive Disease Center', 'Showa Inan General Hospital', 'Shinshu University Graduate School of Medicine'] \n",
      "\n",
      "\n",
      "0.0 Oxford University Hospitals NHS Trust \n",
      " None \n",
      "\n",
      "\n",
      "0.2222222222222222 Medical University of South Carolina \n",
      " ['Division of Gastroenterology, Department of Internal Medicine', 'University of Michigan Health System', 'Taubman Center', 'MI'] \n",
      "\n",
      "\n",
      "0.0 Anesthesiology Department, NTUH \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Stanford University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Stanford University \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Peking Union Medical College Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Shinshu University \n",
      " None \n",
      "\n",
      "\n",
      "0.18518518518518523 Duke University \n",
      " ['University of KwaZulu-Natal', 'Nelson R. Mandela School of Medicine', 'KwaZulu-Natal Department of Health'] \n",
      "\n",
      "\n",
      "0.0 Ente Ospedaliero Cantonale, Bellinzona \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Chinese Academy of Medical Sciences, Fuwai Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 Massachusetts General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University of California, San Francisco \n",
      " None \n",
      "\n",
      "\n",
      "0.0 University Medical Center Groningen \n",
      " None \n",
      "\n",
      "\n",
      "0.33333333333333337 UMC Utrecht \n",
      " ['Imaging Division', 'University Medical Centre Utrecht'] \n",
      "\n",
      "\n",
      "0.0 University of Virginia \n",
      " None \n",
      "\n",
      "\n",
      "0.9393939393939394 Moscow Clinical Scientific Center \n",
      " ['Moscow Clinical Scientific Centre', 'Central Scientific Research Institute of Gastroenterology'] \n",
      "\n",
      "\n",
      "0.2807017543859649 University Hospital of Poitiers, Department of Cardiology \n",
      " ['Cardiology Department', 'CHU Poitiers', 'Poitiers'] \n",
      "\n",
      "\n",
      "0.18918918918918914 Cairo University \n",
      " ['Department of Obstetrics & Gynecology'] \n",
      "\n",
      "\n",
      "0.24390243902439024 University of Colorado, Denver \n",
      " ['Department of Health and Exercise Science', 'Colorado State University'] \n",
      "\n",
      "\n",
      "0.1428571428571429 Dallas VAMC \n",
      " ['University of Alabama'] \n",
      "\n",
      "\n",
      "0.0 National Institute of Neurological Disorders and Stroke (NINDS) \n",
      " None \n",
      "\n",
      "\n",
      "1.0 Loughborough University \n",
      " ['Health Sciences', 'Loughborough University', 'Loughborough'] \n",
      "\n",
      "\n",
      "0.0 Massachusetts General Hospital \n",
      " None \n",
      "\n",
      "\n",
      "0.972972972972973 St. Jude Children's Research Hospital \n",
      " ['University of Florida', 'Kirsten K. Ness', \"St Jude Children's Research Hospital\"] \n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "lista = df['organization_similarity'].tolist()\n",
    "for i in range(len(lista)):\n",
    "    print(lista[i], df['ct_organization'][i], '\\n',df['ar_organization'][i], '\\n\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  newly diagnosed GBM\n",
      "\n",
      "          -  Diagnosis must be established by open biopsy or tumour resection\n",
      "\n",
      "          -  Tumour must have a supratentorial component\n",
      "\n",
      "          -  Over 18 years\n",
      "\n",
      "          -  pre-treatment evaluations must be met\n",
      "\n",
      "          -  study therapy to begin within 6 weeks of surgery\n",
      "\n",
      "          -  KPS greater or equal to 70\n",
      "\n",
      "          -  patients must sign informed consent\n",
      "\n",
      "          -  If female, patients must not be pregnant or lactating\n",
      "\n",
      "          -  Women of childbearing potential and male participants must practice adequate\n",
      "             contraception\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  prior invasive malignancy )except for non-melanomatous skin cancer) unless disease\n",
      "             free for greater than 3 years\n",
      "\n",
      "          -  recurrent or multifocal malignant gliomas\n",
      "\n",
      "          -  metastatic disease of leptomeningeal spread\n",
      "\n",
      "          -  prior chemo or radiosensitizers for cancers of the head and neck region\n",
      "\n",
      "          -  prior RT to head and neck region except for T1 glottic cancer, resulting in overlap of\n",
      "             radiation fields.\n",
      "\n",
      "          -  Severe active co-morbidity define in protocol\n",
      "\n",
      "          -  Pregnant of lactating women\n",
      "\n",
      "          -  Women of childbearing potential or men who are sexually active who are not willing or\n",
      "             able to use medically acceptable forms of contraception; this exclusion is necessary\n",
      "             due to the treatment involved potentially being teratogenic.\n",
      "\n",
      "          -  prior allergic reaction to temozolomide and/or dichloroacetate\n",
      "\n",
      "          -  History of HIV/AIDS\n",
      "      \n",
      "\n",
      "        Please contact site for information.\n",
      "      \n",
      "\n",
      "        Please contact site for information.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Resident of Alabama\n",
      "\n",
      "          -  Previously employed\n",
      "\n",
      "          -  Currently unemployed due to musculoskeletal disability\n",
      "\n",
      "          -  Feel capable of work\n",
      "\n",
      "          -  Want to work\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Not a resident of Alabama\n",
      "\n",
      "          -  Unable to work\n",
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA\n",
      "\n",
      "        Documentation of plasma glucose below 45 mg/dl is required for enrollment.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must have Stage III-IV (Ann Arbor classification) low-grade Non-Hodgkin's\n",
      "             lymphoma\n",
      "\n",
      "          -  Baseline measurements and evaluations must be obtained within 4 weeks prior to\n",
      "             registration; all areas of disease (evaluable and measurable) should be recorded and\n",
      "             mapped out in order to assess response and uniformity of response to therapy; must\n",
      "             have at least one objective MEASURABLE disease parameter\n",
      "\n",
      "               -  Radiographic findings are acceptable providing that clear-cut measurement can be\n",
      "                  made\n",
      "\n",
      "               -  Abnormalities on scans may be used to document the presence of disease for\n",
      "                  staging purposes; a clearly defined, bidimensionally measurable defect or mass\n",
      "                  measuring at least 2 cm in diameter on a radionuclide or a CT scan will be\n",
      "                  acceptable as measurable disease\n",
      "\n",
      "               -  An enlarged spleen extending at least 2 cm below the costal margin will\n",
      "                  constitute measurable disease providing that no explanation other than\n",
      "                  lymphomatous involvement is likely; for an enlarged liver to constitute the only\n",
      "                  evident measurable disease parameter, liver biopsy proof of lymphoma in the liver\n",
      "                  is required\n",
      "\n",
      "          -  Patients must have a tissue diagnosis of low-grade malignant lymphoma obtained within\n",
      "             12 months prior to registration (according to the International Working Formulation)\n",
      "             as below:\n",
      "\n",
      "               -  ML- small lymphocytic (Category A)\n",
      "\n",
      "               -  ML-follicular-small cleaved (Category B)\n",
      "\n",
      "               -  ML-follicular-mixed small cleaved and large cell (Category C)\n",
      "\n",
      "          -  Patients having both diffuse and follicular architectural elements will be considered\n",
      "             eligible if the histology is predominantly follicular (i.e. >= 50% of the\n",
      "             cross-sectional area); if the interval since tissue diagnosis of low-grade malignant\n",
      "             lymphoma is > 12 months, diagnostic confirmation using either FNA or nodal biopsy is\n",
      "             required to confirm that the histology remains in one of the eligible categories\n",
      "\n",
      "          -  Women of child bearing potential and sexually active males are strongly advised to use\n",
      "             an accepted and effective method of birth control\n",
      "\n",
      "          -  No prior chemotherapy, radiotherapy, or immunotherapy\n",
      "\n",
      "          -  No active, uncontrolled infections (afebrile for > 48 hours off antibiotics)\n",
      "\n",
      "          -  No evidence of a previous or concurrent malignancy, with the exception of 1) treated\n",
      "             carcinoma in situ of the cervix, 2) treated squamous cell or basal cell skin cancer OR\n",
      "             3) any other surgically cured malignancy from which the patient has been disease free\n",
      "             for at least 5 years\n",
      "\n",
      "          -  ECOG performance status 0-1\n",
      "\n",
      "          -  WBC > 3000/mm^3\n",
      "\n",
      "          -  Plts > 100,000/mm^3\n",
      "\n",
      "          -  Creatinine =< 1.5 mg/dl\n",
      "\n",
      "          -  Bilirubin < 2.0 mg/dl\n",
      "\n",
      "          -  LFTs =< 5x ULN (SGOT and Alkaline Phosphate)\n",
      "\n",
      "          -  These lab values must be obtained within 4 weeks prior to protocol entry; patients\n",
      "             with documented marrow involvement at the time of registration are not required to\n",
      "             meet the hematologic parameters above\n",
      "\n",
      "          -  Patient must give signed informed consent\n",
      "      \n",
      "\n",
      "        DISEASE CHARACTERISTICS:\n",
      "\n",
      "          -  Current random fine needle breast aspiration (FNA) evidence of 1 of the following:\n",
      "\n",
      "               -  Hyperplasia with atypia\n",
      "\n",
      "               -  Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4%\n",
      "\n",
      "               -  Hyperplasia without atypia but with a BRCAPRO risk of at least 25%\n",
      "\n",
      "               -  Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2\n",
      "\n",
      "               -  Hyperplasia without atypia but with a history of contralateral ductal carcinoma\n",
      "                  in situ or invasive breast cancer\n",
      "\n",
      "          -  FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal\n",
      "             women\n",
      "\n",
      "          -  Classified as ACR class I-III on mammogram with stepwedge within past 6 months If\n",
      "             intact uterus and/or ovaries, must have color doppler transvaginal pelvic sonogram\n",
      "             within past 6 months showing endometrial thickening no greater than 13 mm\n",
      "             premenopausal or no greater than 8 mm postmenopausal\n",
      "\n",
      "               -  No ovarian cysts felt to be possibly or probably non-physiologic that have not\n",
      "                  resolved to gynecologist's satisfaction on repeat sonogram\n",
      "\n",
      "          -  Must agree to have or have had genetic counseling and genetic testing performed for\n",
      "             BRCA1 and BRCA2\n",
      "\n",
      "          -  No active cancer (e.g., detectable disease)\n",
      "\n",
      "          -  Hormone receptor status:\n",
      "\n",
      "               -  Not specified\n",
      "\n",
      "        PATIENT CHARACTERISTICS:\n",
      "\n",
      "        Age:\n",
      "\n",
      "          -  18 and over\n",
      "\n",
      "        Sex:\n",
      "\n",
      "          -  Female\n",
      "\n",
      "        Menopausal status:\n",
      "\n",
      "          -  Any\n",
      "\n",
      "        Performance status:\n",
      "\n",
      "          -  Not specified\n",
      "\n",
      "        Life expectancy:\n",
      "\n",
      "          -  At least 12 months\n",
      "\n",
      "        Hematopoietic:\n",
      "\n",
      "          -  Hemoglobin greater than 10 g/dL\n",
      "\n",
      "          -  Granulocyte count greater than 1,000/mm^3\n",
      "\n",
      "          -  No deficiencies in protein C, protein S, or antithrombin III\n",
      "\n",
      "          -  No activated protein C resistance\n",
      "\n",
      "        Hepatic:\n",
      "\n",
      "          -  Albumin greater than 3.0 g/dL\n",
      "\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "\n",
      "          -  AST less than 100 U/L\n",
      "\n",
      "          -  Alkaline phosphatase less than 200 U/L\n",
      "\n",
      "        Renal:\n",
      "\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "\n",
      "        Cardiovascular:\n",
      "\n",
      "          -  No history of deep venous thrombosis not related to trauma or pregnancy\n",
      "\n",
      "          -  No severe coronary artery disease\n",
      "\n",
      "          -  No history of prior stroke\n",
      "\n",
      "        Other:\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception during and for 3 months after study\n",
      "\n",
      "          -  No other active cancer\n",
      "\n",
      "          -  No retinal vein thrombosis\n",
      "\n",
      "          -  No concurrent severe poorly controlled migraine\n",
      "\n",
      "          -  No factor V Leiden mutation carrier\n",
      "\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "\n",
      "        Biologic therapy:\n",
      "\n",
      "          -  At least 12 months since prior immunotherapy\n",
      "\n",
      "        Chemotherapy:\n",
      "\n",
      "          -  At least 3 months between completion of prior KUMC phase II difluoromethylornithine\n",
      "             (DFMO) study and baseline aspiration\n",
      "\n",
      "          -  At least 12 months since prior chemotherapy\n",
      "\n",
      "        Endocrine therapy:\n",
      "\n",
      "          -  Must not have started or stopped hormone replacement therapy or oral contraceptives\n",
      "             within 6 months of baseline aspiration\n",
      "\n",
      "          -  Must continue all hormone replacement therapy and/or oral contraceptives that were\n",
      "             being taken at time of baseline aspiration\n",
      "\n",
      "          -  At least 12 months since prior tamoxifen, raloxifene, or other antihormonal therapy\n",
      "\n",
      "        Radiotherapy:\n",
      "\n",
      "          -  At least 3 months since prior radiotherapy\n",
      "\n",
      "        Surgery:\n",
      "\n",
      "          -  At least 6 months between prior oophorectomy and baseline aspiration\n",
      "\n",
      "        Other:\n",
      "\n",
      "          -  At least 2 weeks since the start of other new medication that would be ingested for 1\n",
      "             or more months\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patient must have an ECOG/Zubrod performance status of ≤ 2\n",
      "\n",
      "          -  Patient must have a diagnosis of high-risk primary GIST; NOTE: High risk is defined as\n",
      "             tumor size ≥ 10 cm in maximum dimension, or the presence of tumor rupture before or\n",
      "             during surgery, intraperitoneal hemorrhage or multifocal (< 5) intraperitoneal tumors\n",
      "\n",
      "          -  Patient must have undergone complete gross resection (includes R0 [negative\n",
      "             microscopic margins] and R1 [positive microscopic margins] resections) of a primary\n",
      "             GIST within 70 days prior to registration\n",
      "\n",
      "          -  Patient must have a histologic diagnosis of GIST that is confirmed by central\n",
      "             pathology review\n",
      "\n",
      "          -  Patient's tumor must stain positive for the Kit receptor tyrosine kinase on\n",
      "             immunohistochemistry as determined by the central pathologist using the Dako (Dako\n",
      "             Corp., Carpinteria, CA) anti-CD 117 antibody\n",
      "\n",
      "          -  Patient must have a chest x-ray completed within 28 days prior to registration\n",
      "\n",
      "          -  Patient must have a post-operative CT scan with IV and PO contrast or MRI with\n",
      "             contrast (if allergic to CT contrast) of abdomen and pelvis within 28 days prior to\n",
      "             registration\n",
      "\n",
      "          -  Creatinine ≤ 1.5 times the institution ULN\n",
      "\n",
      "          -  WBC ≥ 2,000/mm^3\n",
      "\n",
      "          -  Platelet ≥ 100,000/mm^3\n",
      "\n",
      "          -  Total bilirubin ≤ 1.5 times the institution ULN\n",
      "\n",
      "          -  AST and ALT ≤ 2.5 times the institution ULN\n",
      "\n",
      "          -  Female of childbearing potential must have negative serum pregnancy test\n",
      "\n",
      "          -  Patient or the patient's legally acceptable representative must provide a signed and\n",
      "             dated written informed consent prior to registration and any study related procedures\n",
      "\n",
      "          -  If patient is a cancer survivor, each of the following criteria must apply:\n",
      "\n",
      "               -  Patient has undergone potentially curative therapy for all prior malignancies,\n",
      "\n",
      "               -  No evidence of any prior malignancies for at least 5 years with no evidence of\n",
      "                  recurrence (except for effectively treated basal cell or squamous carcinoma of\n",
      "                  the skin, carcinoma in-situ of the cervix that has been effectively treated by\n",
      "                  surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral\n",
      "                  breast treated by surgery alone)\n",
      "\n",
      "               -  Patient is deemed by their treating physician to be at low risk for recurrence\n",
      "                  from prior malignancies\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient has received post-operative chemotherapy\n",
      "\n",
      "          -  Patient has received post-operative radiation therapy\n",
      "\n",
      "          -  Patient has received post-operative investigational treatment\n",
      "\n",
      "          -  Patient has received prior therapy with STI571\n",
      "\n",
      "          -  Patient has had an active infection requiring antibiotics within 14 days prior to\n",
      "             registration\n",
      "\n",
      "          -  Patient has objective evidence of residual disease on the post-operative CT scan or\n",
      "             MRI of the abdomen or pelvis\n",
      "\n",
      "          -  Patient, if female and breastfeeding; NOTE: It is not known whether STI571 or its\n",
      "             metabolites are excreted in human milk; however, in lactating female rats administered\n",
      "             100 mg/kg, a dose approximately equal to the maximum clinical dose of 800 mg/day based\n",
      "             on body surface area, STI571 and/or its metabolites were extensively excreted in milk;\n",
      "             it is estimated that approximately 1.5% of a maternal dose is excreted into milk,\n",
      "             which is equivalent to a dose to the infant of 30% the maternal dose per unit body\n",
      "             weight; because many drugs are excreted in human milk and because of the potential for\n",
      "             serious adverse reactions in nursing infants, women should be advised against\n",
      "             breastfeeding while taking STI571\n",
      "\n",
      "          -  Patient has New York Heart Association class 3 or 4 cardiac disease\n",
      "\n",
      "          -  Patient is taking full dose warfarin; NOTE: The use of mini-dose warfarin (1 mg orally\n",
      "             per day) for prevention of central line-associated deep venous thrombosis is permitted\n",
      "      \n",
      "\n",
      "        Adolescents ages 14-19\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of relapsed or refractory multiple myeloma (MM) requiring treatment\n",
      "\n",
      "               -  Durie-Salmon stage I or greater at diagnosis\n",
      "\n",
      "                    -  Patients with non-secretory or oligo-secretory MM (defined as maximum\n",
      "                       urinary M-spike less than 200 mg/24 hours and a maximum serum M-spike less\n",
      "                       than 0.5 g/dL during entire disease course) must have at least 30% bone\n",
      "                       marrow plasma cells\n",
      "\n",
      "                    -  Patients with secretory MM must have measurable disease defined as serum\n",
      "                       monoclonal protein of at least 1 g/dL or urinary M-spike of at least 200\n",
      "                       mg/24 hours\n",
      "\n",
      "          -  Must have received at least 1, but no more than 5 prior therapy regimens\n",
      "\n",
      "               -  Patients who have had 4 or 5 regimens are allowed provided corticosteroids and/or\n",
      "                  thalidomide are part of the regimens\n",
      "\n",
      "               -  No more than 5 prior chemotherapy regimens (as long as 2 contained dexamethasone\n",
      "                  or thalidomide)\n",
      "\n",
      "               -  Prior autologous peripheral blood stem cell transplantation is considered 1 prior\n",
      "                  regimen\n",
      "\n",
      "          -  Performance status - ECOG 0-2\n",
      "\n",
      "          -  Performance status - ECOG 0-3 if secondary to neuropathy or acute bone event (e.g.,\n",
      "             vertebral compression or rib fracture)\n",
      "\n",
      "          -  Absolute neutrophil count at least 750/mm^3\n",
      "\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "\n",
      "          -  Alkaline phosphatase no greater than 2.5 times ULN\n",
      "\n",
      "          -  AST no greater than 2.5 times ULN\n",
      "\n",
      "          -  Creatinine no greater than 3 mg/dL\n",
      "\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "\n",
      "          -  Peripheral neuropathy secondary to prior drug therapy or myeloma-associated neuropathy\n",
      "             allowed\n",
      "\n",
      "          -  No other uncontrolled serious medical condition\n",
      "\n",
      "          -  No uncontrolled infection\n",
      "\n",
      "          -  No other active malignancy\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception\n",
      "\n",
      "          -  See Disease Characteristics\n",
      "\n",
      "          -  No prior allogeneic stem cell transplantation\n",
      "\n",
      "          -  At least 10 days since prior thalidomide\n",
      "\n",
      "          -  No concurrent biologic therapy\n",
      "\n",
      "          -  See Disease Characteristics\n",
      "\n",
      "          -  At least 2 weeks since prior myelosuppressive chemotherapy\n",
      "\n",
      "          -  No other concurrent chemotherapy\n",
      "\n",
      "          -  See Disease Characteristics\n",
      "\n",
      "          -  No concurrent corticosteroids (including as antiemetics) except chronic\n",
      "             corticosteroids for disorders other than myeloma (e.g., rheumatoid arthritis or\n",
      "             adrenal insufficiency)\n",
      "\n",
      "               -  Maximum dose allowed for prednisone is no more than 10 mg/day or hydrocortisone\n",
      "                  no more than 40 mg/day\n",
      "\n",
      "          -  At least 10 days since prior bortezomib or tipifarnib\n",
      "\n",
      "          -  Concurrent bisphosphonates allowed if on stable dose before study entry\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with histologically proven supratentorial malignant primary gliomas will be\n",
      "             eligible for this protocol. These include glioblastoma multiforme (GBM), anaplastic\n",
      "             astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma\n",
      "             (AMO), or malignant astrocytoma NOS (not otherwise specified).\n",
      "\n",
      "          -  Patients must have evaluable or measurable disease and have shown unequivocal evidence\n",
      "             for tumor recurrence or progression by MRI or CT scan. This scan should be performed\n",
      "             within 14 days prior to registration and on a steroid dosage that has been stable for\n",
      "             at least 5 days. If the steroid dose is increased between the date of imaging and the\n",
      "             initiation of treatment, a new 20 baseline MR/CT scan is required. The same type of\n",
      "             scan, i.e., MRI or CT must be used throughout the period of treatment for tumor\n",
      "             measurement.\n",
      "\n",
      "          -  Patients having undergone recent resection of recurrent or progressive tumor will be\n",
      "             eligible as long as the following conditions apply:\n",
      "\n",
      "          -  They have recovered from the effects of surgery\n",
      "\n",
      "          -  Measurable disease following resection of recurrent tumor is not mandated for\n",
      "             eligibility into the study. Patients must have evaluable disease.\n",
      "\n",
      "          -  To best assess the extent of residual disease post-operatively, a CT/MRI should be\n",
      "             done no later than 96 hours in the immediate post-operative period or 4-6 weeks\n",
      "             post-operatively. If the 96 hour scan is more than 2 weeks from registration, the scan\n",
      "             needs to be repeated.\n",
      "\n",
      "          -  The baseline on-study MR/CT is performed within 14 days of registration and on a\n",
      "             steroid dosage that has been stable. If the steroid dose is increased between the date\n",
      "             of imaging and the initiation of Peg-Intron with or without Thalidomide, a new\n",
      "             baseline MR/CT is required on stable steroids for 5 days.\n",
      "\n",
      "          -  Patient must have failed prior radiation therapy and must have an interval of greater\n",
      "             than or equal to 4 weeks from the completion of radiation therapy to study entry.\n",
      "\n",
      "          -  Patients with prior therapy that included interstitial brachytherapy or stereotactic\n",
      "             radiosurgery must have confirmation of true progressive disease rather than radiation\n",
      "             necrosis based upon either PET or Thallium scanning, MR spectroscopy or surgical\n",
      "             documentation of disease.\n",
      "\n",
      "          -  Prior therapy. There are no limitations to number of prior therapies.\n",
      "\n",
      "          -  All patients must sign an informed consent indicating that they are aware of the\n",
      "             investigational nature of this study.\n",
      "\n",
      "          -  Patients must be > 18 years old, and with a life expectancy > 8 weeks.\n",
      "\n",
      "          -  Patients must have a Karnofsky performance status of > 60.\n",
      "\n",
      "          -  Patients must have recovered from the toxic effects of prior therapy (including\n",
      "             resolution of effects on laboratory values): 2 weeks from any investigational agent, 4\n",
      "             weeks from prior cytotoxic therapy, 2 weeks from vincristine, 6 weeks from\n",
      "             nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic\n",
      "             agents e.g. tamoxifen, cis- retinoic acid, etc. (radiosensitizer does not count). Any\n",
      "             questions related to the definition of non-cytotoxic agents should be directed to the\n",
      "             PI.\n",
      "\n",
      "          -  Patients must have adequate bone marrow function (WBC > 3,000/l, ANC > 1,500 mm3,\n",
      "             platelet count of > 100,000/mm3, and hemoglobin > 10 gm%), adequate liver function\n",
      "             (SGOT and bilirubin < 2 times the upper limit of normal), and adequate renal function\n",
      "             (creatinine < 1.5 mg/dL or creatinine clearance > 60 cc/min) before starting therapy.\n",
      "             These tests must be performed within 14 days prior to registration. Eligibility level\n",
      "             for hemoglobin may be reached by transfusion.\n",
      "\n",
      "          -  Patients with a history of any other cancer (except non-melanoma skin cancer or\n",
      "             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy\n",
      "             for that disease for a minimum of 3 years are ineligible.\n",
      "\n",
      "          -  This study was designed to include women and minorities, but was not designed to\n",
      "             measure differences of intervention effects. Males and females will be recruited with\n",
      "             no preference to gender. No exclusion to this study will be based on race. Minorities\n",
      "             will actively be recruited to participate.\n",
      "\n",
      "          -  Patients must not be pregnant or nursing, and all patients (both men and women) must\n",
      "             be willing to practice birth control for 1 month prior, during and for 4 months after\n",
      "             treatment with thalidomide. It has been proposed that thalidomide may interfere with\n",
      "             hormonal-based contraception, therefore, barrier methods of contraception (i.e.\n",
      "             diaphragm, condom) MUST be used rather than, or in addition to birth control pills.\n",
      "\n",
      "          -  No peripheral neuropathy > grade 1.\n",
      "\n",
      "          -  No concurrent use of other investigational agents.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients must not have:\n",
      "\n",
      "          -  Serious active infection\n",
      "\n",
      "          -  Disease that will obscure toxicity or dangerously alter drug metabolism\n",
      "\n",
      "          -  Serious intercurrent medical illness.\n",
      "\n",
      "          -  Significant illness that in the investigator's opinion cannot be adequately controlled\n",
      "             with appropriate therapy or would compromise the patients ability to tolerate this\n",
      "             therapy.\n",
      "\n",
      "          -  Patients must not have received prior therapy with Peg-Intron or Thalidomide.\n",
      "\n",
      "          -  Concurrent chemotherapy, immunotherapy, or radiotherapy is not permitted.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosed with type 1 diabetes mellitus within 3 months prior to study entry\n",
      "\n",
      "          -  Positive for IAA, GAD65, or IA2 antibodies OR positive for GAD65 or IA2 antibodies\n",
      "             after 2 weeks of starting insulin treatment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of treatment with any oral hypoglycemic agent for more than 3 months\n",
      "\n",
      "          -  Ongoing use of medications known to influence glucose tolerance\n",
      "\n",
      "          -  History of immunosuppressive or steroid therapy for more than 3 months within the 2\n",
      "             years prior to study entry\n",
      "\n",
      "          -  Severe active liver, heart, kidney, or immunodeficiency disease that may limit life\n",
      "             expectancy or may require immunosuppression during the study\n",
      "\n",
      "          -  Prior complications related to routine vaccinations\n",
      "\n",
      "          -  Prior participation in a trial for prevention of type 1 diabetes mellitus. Individuals\n",
      "             who are known to have been in the placebo arm of a completed prevention trial are not\n",
      "             excluded.\n",
      "\n",
      "          -  Any condition that may interfere with a participant's ability to comply with the study\n",
      "\n",
      "          -  Pregnancy or planned pregnancy within the time frame of the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed B-cell non-Hodgkin's lymphoma OR acute lymphoblastic leukemia\n",
      "\n",
      "               -  CD20+ (confirmed by flow cytometry of tumor tissue, involved marrow, or CD20\n",
      "                  immunostaining)\n",
      "\n",
      "               -  The following histologies are generally CD20+ and are eligible:\n",
      "\n",
      "                    -  Diffuse large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma,\n",
      "                       or follicular lymphoma, grade III (rare), documented by flow cytometry or\n",
      "                       appropriate immunohistochemistry, any stage\n",
      "\n",
      "                    -  Burkitt's lymphoma or atypical Burkitt's/Burkitt-like lymphoma, any stage\n",
      "\n",
      "                    -  B-cell acute lymphoblastic leukemia, with FABL3 morphology and/or\n",
      "                       demonstration of surface immunoglobin by flow cytometry\n",
      "\n",
      "                    -  Atypical precursor B-cell lymphoblastic lymphoma or other unusual\n",
      "                       histologies that are CD20+\n",
      "\n",
      "          -  Measurable disease by clinical, radiographic, or histologic criteria\n",
      "\n",
      "          -  Must be in first or later recurrence or have disease that is primarily refractory to\n",
      "             conventional therapy\n",
      "\n",
      "          -  No isolated CNS disease\n",
      "\n",
      "          -  Performance status - ECOG 0-2\n",
      "\n",
      "          -  At least 2 months\n",
      "\n",
      "          -  Absolute neutrophil count ≥ 1,000/mm^3*\n",
      "\n",
      "          -  Platelet count ≥ 100,000/mm^3 (transfusion independent)*\n",
      "\n",
      "          -  Hemoglobin ≥ 10.0 g/dL (RBC transfusion allowed)*\n",
      "\n",
      "          -  Bilirubin ≤ 1.5 times normal\n",
      "\n",
      "          -  ALT < 2.5 times normal\n",
      "\n",
      "          -  No chronic renal insufficiency\n",
      "\n",
      "               -  Renal insufficiency allowed provided it is secondary to tumor lysis syndrome\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception during and for 3 months after study\n",
      "             treatment\n",
      "\n",
      "          -  HIV negative\n",
      "\n",
      "          -  No active uncontrolled infection\n",
      "\n",
      "          -  Seizure disorder allowed if well controlled with anticonvulsants\n",
      "\n",
      "          -  No CNS toxicity greater than grade II\n",
      "\n",
      "          -  At least 24 hours since prior growth factor(s)\n",
      "\n",
      "          -  At least 60 days since prior biologic (antineoplastic) therapy\n",
      "\n",
      "          -  Prior stem cell transplantation allowed provided the following criteria are met:\n",
      "\n",
      "               -  More than 60 days since transplantation\n",
      "\n",
      "               -  Hematopoietic lab value requirements are met (See Hematopoietic)\n",
      "\n",
      "               -  No evidence of graft-versus-host disease (if post-allogeneic transplantation)\n",
      "\n",
      "          -  Prior monoclonal antibody therapy allowed (including rituximab)\n",
      "\n",
      "          -  No other concurrent immunomodulating agents\n",
      "\n",
      "          -  More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)\n",
      "\n",
      "          -  No other concurrent chemotherapy\n",
      "\n",
      "          -  No concurrent steroids (except for rituximab infusion-related symptoms)\n",
      "\n",
      "          -  At least 2 weeks since prior local palliative radiotherapy (small port)\n",
      "\n",
      "          -  At least 6 weeks since prior substantial bone marrow radiotherapy\n",
      "\n",
      "          -  At least 6 months since prior craniospinal radiotherapy or radiotherapy to 50% or more\n",
      "             of the pelvis\n",
      "\n",
      "          -  Concurrent radiotherapy to localized painful, airway-compromising, or other acute\n",
      "             organ-threatening lesions allowed provided at least 1 measurable lesion is not\n",
      "             irradiated\n",
      "\n",
      "          -  Recovered from prior therapy\n",
      "\n",
      "          -  No concurrent participation in another phase II study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria\n",
      "\n",
      "        Subjects meeting all of the following inclusion criteria at screening should be considered\n",
      "        for admission to the study:\n",
      "\n",
      "          -  The subject has a diagnosis of diabetes mellitus according to WHO classification for\n",
      "             more than 2 months and less than 5 years before enrollment.\n",
      "\n",
      "          -  The subject's diabetes has been controlled by diet and insulin (plus metformin if\n",
      "             needed) for 2 or more weeks (14 days) prior to the Baseline Visit (Visit 3).\n",
      "\n",
      "          -  The subject is a male or female aged 30 to 65 years. If female and not postmenopausal,\n",
      "             the subject is not pregnant and will use effective contraceptive methods throughout\n",
      "             the study.\n",
      "\n",
      "          -  The subject is positive for GAD autoantibodies, defined as a level greater than the\n",
      "             99th percentile of the GAD antibody index of a normal control population for the\n",
      "             laboratory (e.g., GAD antibody index equal to 0.085).\n",
      "\n",
      "          -  The subject has a fasting C-peptide level 0.30 nmol/L or greater or 0.9 ng/mL at the\n",
      "             time of the Screen Visit (Visit 1 or 2).\n",
      "\n",
      "        Exclusion Criteria\n",
      "\n",
      "        Subjects meeting any of the following exclusion criteria at screening will not be enrolled\n",
      "        in the study:\n",
      "\n",
      "          -  The subject has any significant diseases or conditions, including psychiatric\n",
      "             disorders and substance abuse that, in the opinion of the site investigator, are\n",
      "             likely to affect the subject's response to treatment or their ability to complete the\n",
      "             study.\n",
      "\n",
      "          -  The subject has a history of any kind of malignant tumor.\n",
      "\n",
      "          -  The subject has secondary diabetes mellitus.\n",
      "\n",
      "          -  Within 2 weeks or 14 days of the Baseline Visit or during randomized treatment, the\n",
      "             subject takes an oral anti-diabetic medication other than metformin to treat his/her\n",
      "             diabetes.\n",
      "\n",
      "          -  The subject has clinical evidence of any diabetes-related complication that in the\n",
      "             opinion of the site investigator would interfere with the subject's participation in\n",
      "             and/or completion of the study.\n",
      "\n",
      "          -  The subject has a history of allergy or asthma that in the opinion of the site\n",
      "             investigator would interfere with the subject's participation in and completion of the\n",
      "             study.\n",
      "\n",
      "          -  The subject has a known immune deficiency from any disease, or a condition associated\n",
      "             with an immune deficiency.\n",
      "\n",
      "          -  The subject is receiving immunosuppressive or immunomodulating agents or cytotoxic\n",
      "             therapy, or any medication that, in the opinion of the site investigator, might\n",
      "             interfere with the study.\n",
      "\n",
      "          -  The subject is a pregnant woman or a woman who is planning to become pregnant.\n",
      "\n",
      "          -  The subject has any of the following:\n",
      "\n",
      "               -  chronic hepatitis or liver cirrhosis, or any other chronic liver disease\n",
      "\n",
      "               -  is known to test positive for hepatitis B antigens or hepatitis C antibodies\n",
      "\n",
      "               -  has abnormal liver function, defined as serum AST or ALT 3 times or more the\n",
      "                  upper limit of normal\n",
      "\n",
      "          -  The subject is a known or suspected drug abuser.\n",
      "\n",
      "          -  The subject has influenza-like symptoms on the day of dosing.\n",
      "\n",
      "          -  The subject is known to test positive for HIV antibodies.\n",
      "\n",
      "          -  The subject has chronic hematologic disease.\n",
      "\n",
      "          -  The subject has impaired renal function (serum creatinine greater than 1.4 mg/dL).\n",
      "\n",
      "          -  The subject has severe ketonuria (+++ on urine stix testing; ++ on repeated urine stix\n",
      "             testing).\n",
      "\n",
      "          -  The subject has a BMI greater than 40kg/m2.\n",
      "\n",
      "          -  The subject has hyperlipidemia (fasting serum triglycerides >1000 mg/dL). Suitable\n",
      "             medical therapy for treatment of hyperlipidemia is allowed.\n",
      "\n",
      "          -  The subject has received any investigational drug within 3 months prior to Visit 1.\n",
      "\n",
      "          -  The subject has had a severe blood loss (400 mL or more, e.g., blood donation) within\n",
      "             2 months before the first dosing of the study medication.\n",
      "\n",
      "          -  The subject is a breast-feeding mother or planning to breast-feed.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Eligibility:\n",
      "\n",
      "          -  Aged 75 years or less AND 50% or more blockage of at least one artery in the heart,\n",
      "\n",
      "          -  Heart problems in the last 3 years (including previous heart attack),\n",
      "\n",
      "          -  Previous heart bypass surgery, or previous heart angioplasty with or without a stent,\n",
      "             AND at least 6 natural teeth present in the mouth AND evidence of mild to severe gum\n",
      "             problems.\n",
      "\n",
      "        Exclusion:\n",
      "\n",
      "        Any of the following:\n",
      "\n",
      "          -  A major illness requiring hospitalization,\n",
      "\n",
      "          -  Renal dialysis,\n",
      "\n",
      "          -  Serum creatinine > 3 mg/dl,\n",
      "\n",
      "          -  Organ transplant recipient requiring immunosuppression medication,\n",
      "\n",
      "          -  Surgery needed in the next 3 years,\n",
      "\n",
      "          -  Chemotherapy in the past 3 years,\n",
      "\n",
      "          -  Head and/or neck radiation at any time in the past,\n",
      "\n",
      "          -  Liver dysfunction,\n",
      "\n",
      "          -  Class IV congestive heart failure,\n",
      "\n",
      "          -  Drug or alcohol abuse,\n",
      "\n",
      "          -  Pacemaker or AICD/defibrillator.\n",
      "      \n",
      "\n",
      "        -INCLUSION CRITERIA:\n",
      "\n",
      "          1. There is no age limitation.\n",
      "\n",
      "          2. Patients fulfill at least 2 of the following 3 clinical manifestations:\n",
      "\n",
      "               -  Typical NOMID rash\n",
      "\n",
      "               -  CNS involvement (papilledema, CSF pleocytosis, sensorineural hearing loss)\n",
      "\n",
      "               -  Typical arthropathic changes on radiograph (epiphyseal and/or patellar\n",
      "                  overgrowth.\n",
      "\n",
      "          3. Onset of manifestations of NOMID/CINCA at less than or equal to 6 months of age.\n",
      "\n",
      "          4. Stable dose of steroids, NSAIDs, DMARDs for 4 weeks prior to enrollment visit.\n",
      "\n",
      "          5. Washout period for biologics: 6 half-lives before anakinra administration for all\n",
      "             drugs with anti TNF properties. For etanercept (6 half-lives=24 days) this calculates\n",
      "             to drug discontinuation 3 days before enrollment into the observation period, for\n",
      "             infliximab and adalimumab (6 half-lives=48 days) drug will be discontinued 27 before\n",
      "             the observation period, and for thalidomide (6 half-lives=3 days) drug will be\n",
      "             discontinued for 3 days prior to anakinra administration.\n",
      "\n",
      "          6. Patient's or legal guardian's ability and willingness to give informed consent.\n",
      "\n",
      "          7. Females of childbearing potential (young women who have had at least one menstrual\n",
      "             period regardless of age) must have a negative urine pregnancy test at baseline prior\n",
      "             to performance of any radiologic procedure or administration of study medication.\n",
      "             Women of childbearing age and men able to father a child, who are sexually active,\n",
      "             will be asked to use a form of effective birth control, including abstinence.\n",
      "\n",
      "          8. Negative PPD test using 5 T.U. intradermal testing per CDC guidelines with exception\n",
      "             of inclusion criteria #9 below.\n",
      "\n",
      "          9. Patients with latent TB (positive PPD test) must have adequate therapy for TB\n",
      "             initiated prior to first dose of study medication as recommended in published\n",
      "             guidelines.\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "          1. Having received live virus vaccine during 3 months prior to baseline visit (1st visit\n",
      "             to NIH).\n",
      "\n",
      "          2. Patients with active infections or a history of pulmonary TB infection with or without\n",
      "             documented adequate therapy, Patients with current active TB, or recent close exposure\n",
      "             to an individual with active TB are excluded from the study.\n",
      "\n",
      "          3. Positive testing for HIV, Hepatitis B or C known or documented at screening,\n",
      "             enrollment or baseline visit.\n",
      "\n",
      "          4. Have a history of or concomitant diagnosis of congestive heart failure.\n",
      "\n",
      "          5. History of malignancy.\n",
      "\n",
      "          6. Recent use of IL-1 antagonist within the last three months or prior use of anti CD4\n",
      "             antibody.\n",
      "\n",
      "          7. Known hypersensitivity to E. coli derived products or any components of anakinra.\n",
      "\n",
      "          8. Presence of any other rheumatic disease or major chronic\n",
      "             infectious/inflammatory/immunologic disease (e.g. inflammatory bowel disease,\n",
      "             psoriatic arthritis, spondyloarthropathy, SLE in addition to NOMID/CINCA).\n",
      "\n",
      "          9. Presence of the following at enrollment visit: ALT or AST greater than 2.0 x upper\n",
      "             limit of normal (ULN) of the local laboratories values, creatinine greater than 1.5\n",
      "             xULN, WBC less than 3.6x10(9)/l; platelet count less than 150,000 mm(3).\n",
      "\n",
      "         10. Enrollment in any other investigational clinical study or receiving an investigational\n",
      "             agent, or has not yet completed at least 4 weeks since ending another investigational\n",
      "             device or drug trial.\n",
      "\n",
      "         11. Subjects for whom there is concern about compliance with the protocol procedures by\n",
      "             subject and/or parent/s and legally acceptable representative/s.\n",
      "\n",
      "         12. Lactating females or pregnant females.\n",
      "\n",
      "         13. Patients with asthma will only be included after evaluation by a pulmonary and\n",
      "             infectious disease consultation.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically or cytologically confirmed colorectal cancer\n",
      "\n",
      "               -  Metastatic disease by diagnostic imaging studies\n",
      "\n",
      "          -  Measurable disease\n",
      "\n",
      "               -  At least 1 unidimensionally measurable lesion with minimum lesion size at least\n",
      "                  twice the slice thickness of the imaging study used\n",
      "\n",
      "          -  Refractory to irinotecan, evidenced by clinical documentation\n",
      "\n",
      "               -  Received at least 1 prior irinotecan-containing chemotherapy regimen for\n",
      "                  metastatic disease and progressed during or within 6 weeks after completion of\n",
      "                  therapy\n",
      "\n",
      "          -  Must have received prior irinotecan according to 1 of the following schedules:\n",
      "\n",
      "               -  Weekly administration with a starting dose of 100-125 mg/m^2\n",
      "\n",
      "               -  Biweekly administration (every other week) with a starting dose of approximately\n",
      "                  180 mg/m^2\n",
      "\n",
      "               -  Once every three weekly administration with a starting dose of 300-350 mg/m^2\n",
      "\n",
      "          -  No known brain metastases\n",
      "\n",
      "          -  No prior primary CNS tumors\n",
      "\n",
      "          -  Performance status - ECOG 0-1\n",
      "\n",
      "          -  Performance status - Karnofsky 80-100%\n",
      "\n",
      "          -  More than 3 months\n",
      "\n",
      "          -  WBC >= 3,000/mm^3\n",
      "\n",
      "          -  Absolute neutrophil count >= 1,500/mm^3\n",
      "\n",
      "          -  Platelet count >= 100,000/mm^3\n",
      "\n",
      "          -  Hemoglobin >= 9 g/dL\n",
      "\n",
      "          -  No bleeding diathesis or coagulopathy\n",
      "\n",
      "          -  Bilirubin normal\n",
      "\n",
      "          -  AST and ALT =< 2.5 times upper limit of normal (ULN) (5 times ULN in the presence of\n",
      "             known liver metastases)\n",
      "\n",
      "          -  INR < 1.5 (for patients receiving warfarin)\n",
      "\n",
      "          -  Creatinine =< ULN\n",
      "\n",
      "          -  Creatinine clearance ≥ 60 mL/min\n",
      "\n",
      "          -  No proteinuria\n",
      "\n",
      "          -  No prior stroke\n",
      "\n",
      "          -  No symptomatic congestive heart failure\n",
      "\n",
      "          -  No unstable angina pectoris\n",
      "\n",
      "          -  No uncontrolled hypertension\n",
      "\n",
      "          -  No clinically significant cardiac arrhythmia\n",
      "\n",
      "          -  None of the following arterial thromboembolic events within the past 6 months:\n",
      "\n",
      "               -  Myocardial infarction\n",
      "\n",
      "               -  Cerebrovascular accident\n",
      "\n",
      "               -  Transient ischemic attack\n",
      "\n",
      "               -  Unstable angina\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception during and for at least 3 months\n",
      "             after study participation\n",
      "\n",
      "          -  No significant traumatic injury within the past 28 days\n",
      "\n",
      "          -  No grade 3 or greater neurotoxicity\n",
      "\n",
      "          -  No uncontrolled seizures\n",
      "\n",
      "          -  No prior allergic reactions attributed to compounds of similar chemical or biological\n",
      "             composition to study agents\n",
      "\n",
      "          -  No prior irinotecan intolerance\n",
      "\n",
      "          -  No ongoing or active infection requiring parenteral antibiotics\n",
      "\n",
      "          -  No serious nonhealing active wound, ulcer, or bone fracture\n",
      "\n",
      "          -  No psychiatric illness or social situation that would preclude study compliance\n",
      "\n",
      "          -  No other concurrent uncontrolled illness that would preclude study participation\n",
      "\n",
      "          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant\n",
      "             human antibodies\n",
      "\n",
      "          -  No prior cetuximab\n",
      "\n",
      "          -  No other prior epidermal growth factor receptor-directed therapy\n",
      "\n",
      "          -  No prior anticancer murine or chimeric monoclonal antibody therapy\n",
      "\n",
      "               -  Prior humanized monoclonal antibody therapy allowed\n",
      "\n",
      "          -  No prior bevacizumab\n",
      "\n",
      "          -  No other prior vascular endothelial growth factor-targeted therapy\n",
      "\n",
      "          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
      "\n",
      "          -  More than 4 weeks since prior radiotherapy\n",
      "\n",
      "          -  More than 28 days since prior major surgical procedure or open biopsy\n",
      "\n",
      "          -  Recovered from all prior therapy\n",
      "\n",
      "          -  Any number of prior standard or investigational regimens allowed\n",
      "\n",
      "          -  No other concurrent investigational agents\n",
      "\n",
      "          -  No other concurrent anticancer therapy\n",
      "\n",
      "          -  No recent or concurrent thrombolytic agents\n",
      "\n",
      "          -  No recent or concurrent full-dose warfarin except as required to maintain patency of\n",
      "             preexisting, permanent indwelling IV catheters\n",
      "\n",
      "          -  No concurrent therapeutic heparin\n",
      "\n",
      "               -  Concurrent prophylactic low-molecular weight heparin allowed\n",
      "\n",
      "          -  No concurrent chronic daily aspirin (> 325 mg/day)\n",
      "\n",
      "          -  No concurrent nonsteroidal anti-inflammatory medications known to inhibit platelet\n",
      "             function\n",
      "\n",
      "          -  No concurrent combination antiretroviral therapy for HIV-positive patients\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion criteria\n",
      "\n",
      "          -  HIV infection\n",
      "\n",
      "          -  History of a CD4 cell count less than 200 cells/mm3\n",
      "\n",
      "          -  Stable antiretroviral regimen\n",
      "\n",
      "          -  English-speaking\n",
      "\n",
      "        Exclusion criteria\n",
      "\n",
      "          -  Inability or unwillingness to fill out questionnaires\n",
      "\n",
      "          -  History of non-HIV related life-threatening disease\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must have surgically incurable colon or rectal adenocarcinoma\n",
      "\n",
      "          -  Karnofsky Performance Status of 60% or greater\n",
      "\n",
      "          -  Patients may have symptomatic neuropathy\n",
      "\n",
      "          -  Patients must have a life expectancy of at least 4 months\n",
      "\n",
      "          -  Patients must be alimenting, receiving at least 1500Kcal/day nutrition, by any route\n",
      "\n",
      "          -  Patients must have bidimensional measurable disease for response assessment\n",
      "\n",
      "          -  Patients may have received adjuvant chemotherapy with fluoropyrimidine therapy\n",
      "\n",
      "          -  Patients must have recovered from the toxicities of prior therapy, at least 4 weeks\n",
      "             since prior adjuvant chemotherapy and major surgery\n",
      "\n",
      "          -  Serum creatinine less than 2.4mg%, serum bilirubin less than 3.0mg%, WBC greater than\n",
      "             3,200/mm2, AGC greater than 1,500/mm3, platelet count greater than 90,000/mm3 and SGOT\n",
      "             (AST) and SGPT (ALT) less than 3 times the upper limit of normal\n",
      "\n",
      "          -  Male and non-pregnant, non-lactating female patients must be >18 years old.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Concurrent infection\n",
      "\n",
      "          -  Failure of the patient or the patient's legal representative to sign the Informed\n",
      "             consent\n",
      "\n",
      "          -  Inability to obtain Informed Consent because of psychiatric or complex medical problem\n",
      "\n",
      "          -  Patients with unstable oncologic emergency\n",
      "\n",
      "          -  Patients with unstable medical conditions such as angina, transient ischemic attacks,\n",
      "             rising creatinine, accelerated hypertension, etc.\n",
      "\n",
      "          -  Cerebellar neurologic syndromes such as Parkinson's Disease, multiple sclerosis and\n",
      "             amyotonia\n",
      "\n",
      "          -  Known intolerance to fluoropyrimidine therapy suggestive of dihydropyrimidine\n",
      "             dehydrogenase deficiency.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed or suspected diagnosis of 1 of the following:\n",
      "\n",
      "               -  Intra-abdominal malignancy of 1 of the following types:\n",
      "\n",
      "                    -  Sarcoma\n",
      "\n",
      "                    -  Ovarian cancer\n",
      "\n",
      "                    -  Gastrointestinal malignancies, including, but not limited to, appendiceal\n",
      "                       cancer, colon cancer, or gastric cancer\n",
      "\n",
      "               -  Non-small cell lung cancer\n",
      "\n",
      "          -  Planning to undergo surgical resection of disease\n",
      "\n",
      "          -  Disease has the propensity to spread to the peritoneal cavity (intra-abdominal\n",
      "             malignancy patients)\n",
      "\n",
      "          -  Performance status - ECOG 0-2\n",
      "\n",
      "          -  WBC ≥ 2,000/mm^3\n",
      "\n",
      "          -  Platelet count ≥ 100,000/mm^3\n",
      "\n",
      "          -  Bilirubin < 1.5 mg/dL\n",
      "\n",
      "          -  Creatinine normal\n",
      "\n",
      "          -  Creatinine clearance ≥ 60 mL/min\n",
      "\n",
      "          -  Body weight ≤ 130 kg\n",
      "\n",
      "          -  No G6PD deficiency\n",
      "\n",
      "          -  No porphyria\n",
      "\n",
      "          -  No history of peripheral neuropathy ≥ grade 3\n",
      "\n",
      "          -  Able to tolerate anesthesia and major surgery\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception during and for 1 month after study\n",
      "             participation\n",
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "               1. Males and females between the ages of 18 and 50 years.\n",
      "\n",
      "               2. Healthy by medical history and physical exam.\n",
      "\n",
      "               3. Laboratory values within established guidelines for participation in clinical\n",
      "                  studies: AST less than or equal to 2 times the ULN; SCr less than or equal to\n",
      "                  ULN; hemoglobin equal to or greater than 11 g/dL (for both males and females).\n",
      "\n",
      "               4. Ability to abstain from ingesting fruit juice during pharmacokinetic sampling\n",
      "                  periods (a total of 2 study days), and abstain from eating grapefruit or drinking\n",
      "                  grapefruit juice during the entire study period.\n",
      "\n",
      "               5. Negative serum or urine pregnancy test for females of child-bearing potential.\n",
      "\n",
      "               6. Females of child-bearing potential who are able and willing to practice\n",
      "                  abstinence or use non-hormonal effective methods of birth control during the\n",
      "                  study, such as condoms or diaphragms.\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "          1. Concomitant routine therapy with any prescription, over-the-counter, herbal, or\n",
      "             holistic medications, including oral contraceptives, for 30 days prior to study\n",
      "             participation. Intermittent use of any medication within 30 days prior to screening\n",
      "             will be considered case by case by the principal investigator and the medically\n",
      "             accountable investigator.\n",
      "\n",
      "               -  Concomitant therapy (chronic or intermittent) with any prescription,\n",
      "                  over-the-counter, or herbal drugs (including tinctures, foods, beverages, and\n",
      "                  gum) will not be allowed during the study duration, including any intermittent\n",
      "                  use of allergy medication.\n",
      "\n",
      "               -  Intermittent use of acetaminophen, non-steroidal anti-inflammatory medications\n",
      "                  (i.e. ibuprofen), and loperamide will be allowed during the study, but should not\n",
      "                  be taken on the days of pharmacokinetic blood sampling.\n",
      "\n",
      "               -  A daily multivitamin with minerals will be allowed during the study.\n",
      "\n",
      "          2. Inability to obtain venous access for blood sample collection.\n",
      "\n",
      "          3. The presence or history of any of the following: diabetes mellitus (clinical diagnosis\n",
      "             based on current guidelines, HIV infection, active tuberculosis, cardiac disease (eg.\n",
      "             Hypertension [SBP greater than 140 mmHG or DBP greater than 90 mmHG], heart failure,\n",
      "             arrhythmia, etc.), renal disease, hepatitis or hepatic impairment, pancreatitis,\n",
      "             bleeding disorders, internal bleeding (such as gastrointestinal or intracranial),\n",
      "             respiratory disease (eg. asthma requiring maintenance pharmacologic therapy, chronic\n",
      "             obstructive pulmonary disease, etc.), peptic ulcer disease, osteoporosis,\n",
      "             osteonecrosis, atopy or atopic dermatitis, hormone sensitive cancers or conditions,\n",
      "             organ transplant, seizure disorders, schizophrenia or other psychiatric illnesses that\n",
      "             may interfere with the subject's ability to participate in the study, or any other\n",
      "             condition that may interfere with the interpretation of the study results or not be in\n",
      "             the best interest of the subject in the opinion of the investigators.\n",
      "\n",
      "          4. Plans for elective surgery during the investigation or within 1 month following\n",
      "             completion for subjects in the gingko biloba arm of the study.\n",
      "\n",
      "          5. Positive serum or urine pregnancy test or breastfeeding female.\n",
      "\n",
      "          6. The presence of persistent diarrhea or malabsorption that would interfere with the\n",
      "             subject's ability to absorb drugs.\n",
      "\n",
      "          7. Drug or alcohol abuse that may impair safety or adherence (more than 3 alcoholic\n",
      "             drinks per day, on a daily basis).\n",
      "\n",
      "          8. History of intolerance or allergic reaction to any products containing echinacea,\n",
      "             ginkgo biloba extract, or ginseng (including pills, tinctures, foods, beverages, and\n",
      "             gum).\n",
      "\n",
      "          9. History of intolerance or allergic reaction to lopinavir, ritonavir, midazolam, or\n",
      "             fexofenadine.\n",
      "\n",
      "         10. History of atopy including atopic dermatitis, bronchial asthma, multiple food\n",
      "             allergies, or severe recurring allergic rhinitis.\n",
      "\n",
      "         11. Fasting total cholesterol greater than 240 mg/dL or fasting triglycerides greater than\n",
      "             400 mg/dL.\n",
      "\n",
      "         12. Use of nicotine-containing tobacco products, including cigarettes and chewing tobacco.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  spouse of veteran\n",
      "\n",
      "          -  clinical diagnosis of dementia/Alzheimers\n",
      "\n",
      "          -  verbal approval from primary care provider\n",
      "\n",
      "          -  living with partner\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  not spouse of veteran\n",
      "\n",
      "          -  no clinical diagnosis of dementia\n",
      "\n",
      "          -  no verbal approval from PCP\n",
      "\n",
      "          -  not living with partner\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically proven cancer\n",
      "\n",
      "          -  Confirmed NY-ESO-1 expression\n",
      "\n",
      "          -  No other effective therapy available\n",
      "\n",
      "          -  4 weeks since conventional therapy before start of the current protocol\n",
      "\n",
      "          -  Performance status < 2 (ECOG scale)\n",
      "\n",
      "          -  Age > 18\n",
      "\n",
      "          -  Able and willing to give written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Serious illness\n",
      "\n",
      "          -  Metastatic diseases to central nervous system\n",
      "\n",
      "          -  Concomitant systemic treatment with corticosteroids, anti-histaminic drugs or NSAIDs\n",
      "\n",
      "          -  HIV positive\n",
      "\n",
      "          -  Mental impairment that may compromise the ability to give written informed consent\n",
      "\n",
      "          -  Pregnancy and breastfeeding\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Carry a primary DSM-IV diagnosis of alcohol abuse or dependence\n",
      "\n",
      "          -  Smoke at least one cigarette a day\n",
      "\n",
      "          -  Be willing to sign informed consent and undergo initial assessment and follow-up\n",
      "\n",
      "          -  Be willing to provide at least one collateral contact and collateral contact\n",
      "             information\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically or cytologically confirmed aggressive B-cell non-Hodgkin's lymphoma\n",
      "             (NHL), including any of the following subtypes:\n",
      "\n",
      "               -  Mantle cell lymphoma\n",
      "\n",
      "               -  Diffuse large cell lymphoma\n",
      "\n",
      "               -  Burkitt's lymphoma\n",
      "\n",
      "               -  Transformed NHL* arising from a previously diagnosed low-grade lymphoma,\n",
      "                  including any of the following:\n",
      "\n",
      "                    -  Follicular lymphoma\n",
      "\n",
      "                    -  Small lymphocytic lymphoma\n",
      "\n",
      "                    -  Chronic lymphocytic leukemia\n",
      "\n",
      "          -  Relapsed or refractory disease\n",
      "\n",
      "               -  Relapsed or refractory disease must have occurred during the most recent prior\n",
      "                  therapy\n",
      "\n",
      "          -  Has accessible tissue for biopsy OR evidence of ≥ 50% bone marrow involvement AND\n",
      "             willing to undergo serial biopsy\n",
      "\n",
      "          -  Not eligible for OR refused curative stem cell transplantation\n",
      "\n",
      "          -  No active or untreated CNS lymphoma\n",
      "\n",
      "          -  Performance status - ECOG 0-2\n",
      "\n",
      "          -  Absolute neutrophil count ≥ 1,500/mm^3\n",
      "\n",
      "          -  Platelet count ≥ 75,000/mm^3\n",
      "\n",
      "          -  AST and ALT ≤ 2.5 times upper limit of normal\n",
      "\n",
      "          -  Bilirubin ≤ 1.5 mg/dL\n",
      "\n",
      "          -  Creatinine ≤ 2.0 mg/dL\n",
      "\n",
      "          -  No symptomatic congestive heart failure\n",
      "\n",
      "          -  No unstable angina pectoris\n",
      "\n",
      "          -  No cardiac arrhythmia\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception\n",
      "\n",
      "          -  No known HIV positivity\n",
      "\n",
      "          -  No ongoing or active infection\n",
      "\n",
      "          -  No other uncontrolled illness\n",
      "\n",
      "          -  No psychiatric illness or social situation that would preclude study compliance\n",
      "\n",
      "          -  Prior stem cell transplantation allowed\n",
      "\n",
      "          -  Recovered from all prior biologic therapy-related toxicity\n",
      "\n",
      "          -  Recovered from all prior chemotherapy-related toxicity\n",
      "\n",
      "          -  No other concurrent chemotherapy unless it is used in the chronic daily setting for\n",
      "             other medical conditions, including pulmonary, rheumatologic, or adrenal disorders\n",
      "\n",
      "          -  No concurrent corticosteroids unless they are used in the chronic daily setting for\n",
      "             other medical conditions, including pulmonary, rheumatologic, or adrenal disorders\n",
      "\n",
      "          -  Recovered from all prior radiotherapy-related toxicity\n",
      "\n",
      "          -  No concurrent palliative radiotherapy\n",
      "\n",
      "          -  Recovered from all prior therapy-related toxicity\n",
      "\n",
      "          -  No concurrent anticonvulsants, including valproic acid (except as used in this study)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy volunteers selected by ANRS (French National Agency for Research on AIDS and\n",
      "             Viral Hepatitis)\n",
      "\n",
      "          -  For woman of child-bearing age: use of effective contraception\n",
      "\n",
      "          -  Ability to sign informed consent\n",
      "\n",
      "          -  Beneficiary subjects of social security regimen-- Hepatitis B, hepatitis C, HIV, HTLV1\n",
      "             infection and syphilis negative\n",
      "\n",
      "          -  Hemoglobin over 12.5 g/dl for women and over 13.5 g/dl for men\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Previous participation in an HIV clinical trial\n",
      "\n",
      "          -  Volunteers with risk to contract HIV infection during the trial\n",
      "\n",
      "          -  Previous vaccination in the last month, and volunteers requiring vaccination during\n",
      "             the trial\n",
      "\n",
      "          -  Gift of blood in the last 2 months\n",
      "\n",
      "          -  Eczema, urticaria\n",
      "\n",
      "          -  Medical history of food allergy, Lyell or Stevens Johnson syndrome and aggravated\n",
      "             asthma\n",
      "\n",
      "          -  Previous (last 6 months) or ongoing administration of immunological treatment,\n",
      "             chemotherapy, radiotherapy or corticosteroid\n",
      "\n",
      "          -  Medical history of autoimmune disease\n",
      "\n",
      "          -  Clinical or biological aftermath of previous disease\n",
      "\n",
      "          -  Medical history of uveitis\n",
      "\n",
      "          -  Transfusion in the last 6 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Eligible patients will be at risk for 6-12 month mortality and have one of the\n",
      "             following diagnoses:\n",
      "\n",
      "               -  congestive heart failure, with ejection fraction of <25%;\n",
      "\n",
      "               -  severe chronic obstructive pulmonary disease/emphysema with dependence on oxygen;\n",
      "\n",
      "               -  chronic liver disease with cirrhosis and ascites;\n",
      "\n",
      "               -  colon carcinoma with liver metastases; or\n",
      "\n",
      "               -  non-small cell cancer of the lung, stage III or IV\n",
      "\n",
      "               -  chronic kidney disease on renal replacement therapy, with previous\n",
      "                  hospitalization\n",
      "\n",
      "          -  All participants will be age 55 years or older and will be recruited through the\n",
      "             clinics at the Houston VAMC.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with dementia\n",
      "\n",
      "          -  Patients less than 55 years old\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Males and non pregnant females 18 years of age and older who have confirmed laboratory\n",
      "             diagnosis of HIV infection and documented failure (plasma HIV RNA level over 10,000\n",
      "             copies/ml) to at least two protease inhibitors (ritonavir [RTV] must have been given\n",
      "             at a dose over 400 mg twice a day (bid), in order to qualify for a protease inhibitor\n",
      "             in this study) and one non-nucleoside reverse transcriptase inhibitor (NNRTI)\n",
      "\n",
      "          -  Ongoing antiretroviral therapy at inclusion without change within the last month\n",
      "\n",
      "          -  No threshold of CD4 cell count\n",
      "\n",
      "          -  Patients naive of atazanavir and tenofovir DF\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Cardiomyopathy\n",
      "\n",
      "          -  QTc interval over 450 msec and pause length over 3 seconds on screening EKG\n",
      "\n",
      "          -  Heart rate below 40 bpm\n",
      "\n",
      "          -  Third degree heart block, and clinical symptoms potentially related to heart block\n",
      "\n",
      "          -  Ongoing immunotherapy including IL2, interferon or HIV specific vaccine\n",
      "\n",
      "          -  Ongoing opportunistic infection\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  40 patients aged 25 with insomnia, will be recruited over a 3-6 month interval.\n",
      "\n",
      "          -  All subjects will have a stable sleep/wake schedule with a preferred sleep phase\n",
      "             between 10:00 PM and 8:00 AM.\n",
      "\n",
      "          -  Must live in the Greater Rochester NY area\n",
      "\n",
      "          -  All subjects will meet diagnostic criteria for Psychophysiological Insomnia according\n",
      "             to the International Classification of Sleep Disorders (ICSD). Criteria are: the\n",
      "             complaint of insomnia and impaired daytime function; an indication of learned\n",
      "             sleep-preventing associations and somatized tension; active help seeking. The\n",
      "             complaint of disturbed sleep will have one or more of the following characteristics:\n",
      "             >30 minutes to fall asleep and/or >2 awakenings per night of >15 minutes duration\n",
      "             and/or wake after sleep onset time of > 30 minutes, problem frequency >4 nights/ week,\n",
      "             and problem duration >6 months. In addition, all subjects will complain of fatigue\n",
      "             and/or sleepiness at intake.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  As above\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must have histologically or cytologically confirmed malignant high-grade\n",
      "             (poorly differentiated or undifferentiated) salivary gland carcinoma of the head and\n",
      "             neck (except adenoid cystic carcinoma) that is either metastatic or recurrent and is\n",
      "             not amenable to salvage surgical resection or radiation therapy; eligible histologies\n",
      "             are adenocarcinoma, acinic cell carcinoma, mucoepidermoid carcinoma, salivary duct\n",
      "             carcinoma and undifferentiated carcinoma\n",
      "\n",
      "          -  Patients must have tumors that car HER-2 gene amplification as determined by (i)\n",
      "             fluorescence in situ hybridization (FISH) or (ii) overexpression of HER-2 protein, 2+\n",
      "             to 3+ level assessed by immunohistochemistry\n",
      "\n",
      "          -  Patients must have measurable disease; all measurable disease must be assessed within\n",
      "             28 days prior to registration; all non-measurable disease must be assessed within 42\n",
      "             days prior to registration\n",
      "\n",
      "          -  Patients with known brain metastases are not eligible for this trial because of their\n",
      "             poor prognosis and because they often develop progressive neurologic dysfunction that\n",
      "             would confound the evaluation of neurologic and other adverse events\n",
      "\n",
      "          -  Patients must have and must be willing to submit tumor tissue for pathology review and\n",
      "             translational medicine studies; patients must be offered the opportunity to\n",
      "             participate in specimen banking for future research\n",
      "\n",
      "          -  Patients previously treated with chemotherapy are eligible provided that at least (28\n",
      "             days) has elapsed since the last course of chemotherapy was completed and patient has\n",
      "             recovered from all toxicities\n",
      "\n",
      "          -  Prior radiation must have been completed at least 28 days prior to registration and\n",
      "             all toxicities must have resolved (in the opinion of the treating investigator); prior\n",
      "             surgery must have been completed at least 28 days prior to registration and all\n",
      "             surgical adverse events must have resolved (in the opinion of the treating\n",
      "             investigator)\n",
      "\n",
      "          -  Patients must not be planning on receiving any other investigational agents, other\n",
      "             chemotherapeutic agents, radiation therapy, or hormonal therapy while receiving\n",
      "             treatment on this study except for steroids administered for non-disease-related\n",
      "             conditions (e.g., insulin for diabetes)\n",
      "\n",
      "          -  Patients must have a Zubrod Performance status of 0-2\n",
      "\n",
      "          -  WBC count >= 2,000 ul within 28 days prior to registration\n",
      "\n",
      "          -  ANC count >= 1,000/ul within 28 days prior to registration\n",
      "\n",
      "          -  Platelet count >= 75,000/ul within 28 days prior to registration\n",
      "\n",
      "          -  Bilirubin =< 2.5 x the institutional upper limit of normal within 28 days prior to\n",
      "             registration\n",
      "\n",
      "          -  SGOT or SGPT =< 2.5 x the institutional upper limit of normal within 28 days prior to\n",
      "             registration\n",
      "\n",
      "          -  Patients with liver metastases must have bilirubin and SGOT or SGPT =< 5 x the\n",
      "             institutional upper limit of normal\n",
      "\n",
      "          -  Serum creatinine < 2.5 x the institutional limit of normal within 28 days prior to\n",
      "             registration\n",
      "\n",
      "          -  Patients with a known history of allergic reactions to compounds of similar chemical\n",
      "             or biologic composition to trastuzumab are not eligible\n",
      "\n",
      "          -  No prior malignancy is allowed except for the following: adequately treated basal cell\n",
      "             or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or\n",
      "             II cancer from which the patient is currently in complete remission, or any other\n",
      "             cancer from which the patient has been disease-free for five years\n",
      "\n",
      "          -  Patients must not be pregnant or nursing; women/men of reproductive potential must\n",
      "             have agreed to use an effective contraceptive method\n",
      "\n",
      "          -  If day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next\n",
      "             working day\n",
      "\n",
      "          -  In calculating days of tests and measurements, the day a test or measurement is done\n",
      "             is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks\n",
      "             later would be considered day 28; this allows for efficient patient scheduling without\n",
      "             exceeding the guidelines\n",
      "\n",
      "          -  Patients must be informed of the investigational nature of this study and must sign\n",
      "             and give written informed consent in accordance with institutional and federal\n",
      "             guidelines\n",
      "\n",
      "          -  At the time of patient registration, the treating institution's name and ID number\n",
      "             must be provided to the data operations center in Seattle in order to ensure that the\n",
      "             current (within 365 days) date of institutional review board approval for this study\n",
      "             has been entered into the data base\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Preterm newborns with birth weight equal to or less than 1500 grams and gestational\n",
      "             age equal to or less than 32 weeks.\n",
      "\n",
      "          -  Mother willing to participate in study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Major congenital malformations\n",
      "\n",
      "          -  Congenital infectious diseases\n",
      "\n",
      "          -  Mother not willing to participate in study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Currently not enrolled in methadone-maintenance treatment\n",
      "\n",
      "          -  Demonstration of current opioid dependence as determined by the study physician, a\n",
      "             self-reported history of opioid dependence for one year, and a positive urine test for\n",
      "             opiates\n",
      "\n",
      "          -  Current cocaine abuser with self-reported use of cocaine at least 1 time each week\n",
      "             within the month prior to study entry, positive urine screen for cocaine, and score\n",
      "             greater than 3 on the Severity Dependence Scale\n",
      "\n",
      "          -  Women of childbearing age are eligible under the following conditions: negative\n",
      "             pregnancy test at initial screening, adequate contraceptive use throughout the study,\n",
      "             monthly pregnancy tests, and acknowledgement of fetal toxicity risks due to medication\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Current diagnosis of other drug or alcohol dependence (other than opiates, cocaine, or\n",
      "             tobacco)\n",
      "\n",
      "          -  Serious medical illness (e.g., major heart, kidney, endocrine, or liver disease, or\n",
      "             serious neurological disorders, including history of seizures)\n",
      "\n",
      "          -  Current diagnosis of a serious psychiatric illness or history of psychosis,\n",
      "             schizophrenia, or bipolar type I disorder\n",
      "\n",
      "          -  Suicidal or homicidal thoughts\n",
      "\n",
      "          -  Currently taking psychotropic medications\n",
      "\n",
      "          -  Women who are pregnant, nursing, refuse to use a reliable form of contraception, or\n",
      "             refuse monthly pregnancy testing\n",
      "\n",
      "          -  Greater than 3 times the normal level in liver screening function test (SGOT or SGPT)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Stage II, III or IV Chronic Lymphocytic Leukemia\n",
      "\n",
      "          -  Disease requires chemotherapeutic treatment\n",
      "\n",
      "          -  CT or MRI scan confirming measurable tumor size\n",
      "\n",
      "          -  Documentation of CD markers\n",
      "\n",
      "          -  Up to one prior treatment regimen\n",
      "\n",
      "          -  Expected survival greater than 6 months\n",
      "\n",
      "          -  ECOG performance status of 0-2\n",
      "\n",
      "          -  Adequate renal, bone marrow and liver functions\n",
      "\n",
      "          -  Negative pregnancy test (females of childbearing potential)\n",
      "\n",
      "          -  Must agree to use acceptable birth control, if fertile\n",
      "\n",
      "          -  Must complete Informed Consent\n",
      "\n",
      "          -  No heart disease and must have adequate cardiac function\n",
      "\n",
      "          -  Must test negative for viral Hepatitis B and C\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  More than one prior treatment for Chronic Lymphocytic Leukemia\n",
      "\n",
      "          -  Known sensitivity to Nipent, Rituxan or Cytoxan or any component of these drugs\n",
      "\n",
      "          -  Known HIV or AIDS illness\n",
      "\n",
      "          -  Thyroid disease requiring medication\n",
      "\n",
      "          -  History of any malignancy that could affect the diagnosis or assessment of the study\n",
      "             treatment\n",
      "\n",
      "          -  Pregnancy or breast feeding\n",
      "\n",
      "          -  Evidence of Hepatitis B or C infection\n",
      "\n",
      "          -  Inability to comply with the requirements of the study\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Study subjects must meet all of the following criteria:\n",
      "\n",
      "          -  Subject is less than 17 years of age\n",
      "\n",
      "          -  Neonates must be full-term gestation and have a body weight of at least 2.5 kg\n",
      "\n",
      "          -  Subject requires pharmacologically-induced hypotension for acute blood pressure\n",
      "             management for surgery or other invasive procedure, e.g., cerebral artery embolization\n",
      "\n",
      "          -  Duration of the subject's controlled hypotension is expected to be ≥ 2 hours\n",
      "\n",
      "          -  Subject requires general anesthesia with endotracheal intubation\n",
      "\n",
      "          -  Subject requires placement of intra-arterial line during the surgical or medical\n",
      "             procedure\n",
      "\n",
      "          -  The subject's parent or legal guardian gives permission (informed consent) and subject\n",
      "             gives assent when appropriate.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Subjects will be excluded if any of the following criteria exist:\n",
      "\n",
      "          -  Subject has a known allergy to SNP\n",
      "\n",
      "          -  Subject has a known mitochondrial cytopathy with a disorder of oxidative\n",
      "             phosphorylation or of respiratory chain enzymes\n",
      "\n",
      "          -  Subject has a contraindication to vasodilator therapy for control of blood pressure\n",
      "             during surgery or procedures\n",
      "\n",
      "          -  Subject has participated in other clinical trials for investigational drugs and/or\n",
      "             devices within 30 days prior to enrollment\n",
      "\n",
      "          -  Subject has any serious medical condition which, in the opinion of the investigator,\n",
      "             is likely to interfere with study procedures\n",
      "\n",
      "          -  Subject is moribund (death likely to occur within 48 hours)\n",
      "\n",
      "          -  Subject has a positive result for the urine or serum human chorionic gonadotropin\n",
      "             (HCG) test administered at screening.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients aged between 15 and 55\n",
      "\n",
      "          -  Ethnically Chinese\n",
      "\n",
      "          -  Newly diagnosed epilepsy requiring antiepileptic drug treatment; or patients\n",
      "             previously treated with antiepileptic drugs but have withdrawn from medication for at\n",
      "             least 1 year, and now require resumption of antiepileptic drug therapy due to seizure\n",
      "             relapse.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Post-menopausal women.\n",
      "\n",
      "          -  Pregnant women.\n",
      "\n",
      "          -  Women who have undergone oophorectomy.\n",
      "\n",
      "          -  Women taking or have taken oral contraceptive pills in the previous 3 months.\n",
      "\n",
      "          -  Women diagnosed with or suspected to have polycystic ovarian syndrome.\n",
      "\n",
      "          -  Subjects with diabetes mellitus.\n",
      "\n",
      "          -  Subjects receiving hormone replacement or glucocorticoids.\n",
      "\n",
      "          -  Subjects receiving long-term warfarin.\n",
      "\n",
      "          -  Subjects suffering from significant systemic diseases, or illnesses that interfere\n",
      "             with pituitary-gonadal functions.\n",
      "\n",
      "          -  Subjects with a progressive or degenerative neurological disorder.\n",
      "\n",
      "          -  Subjects who are unable to take their medication reliably.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Primary Diagnosis of Anorexia Nervosa\n",
      "\n",
      "          -  Female, age 12-21\n",
      "\n",
      "          -  Active in a level of care for AN at The Children's Hospital, Denver\n",
      "\n",
      "          -  As long as there is a primary dx of AN, co-morbid diagnoses may be included.\n",
      "\n",
      "          -  If taking an antidepressant, must be on a stable dose for 3 weeks prior to entering\n",
      "             the study, and dose of antidepressant may not be changed during Phase 1 of the study.\n",
      "\n",
      "          -  If choosing to discontinue antidepressant medication, must be off the medication for 3\n",
      "             weeks prior to beginning the study.\n",
      "\n",
      "          -  If sexually active, must use birth control during the study and have a monthly\n",
      "             pregnancy test.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Previous enrollment in this study on a prior admission\n",
      "\n",
      "          -  Previous allergic reaction to risperidone or other atypical neuroleptic\n",
      "\n",
      "          -  Positive pregnancy test\n",
      "\n",
      "          -  Neurologic disorder other than benign essential tremor\n",
      "\n",
      "          -  Taking a psychotropic medication other than antidepressant and discontinuing the\n",
      "             medication is not recommended.\n",
      "\n",
      "          -  Active hepatic or renal disease\n",
      "\n",
      "          -  Wards of the state\n",
      "\n",
      "          -  Males\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age 18 to 35 years\n",
      "\n",
      "          -  male\n",
      "\n",
      "          -  BMI ≥ 27 ≤45 kg/m2\n",
      "\n",
      "          -  willingness to refrain from alcohol and caffeinated beverage consumption for duration\n",
      "             of study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  major medical illness\n",
      "\n",
      "          -  an abnormal screening laboratory test\n",
      "\n",
      "          -  taking any prescription medications that might affect body weight\n",
      "\n",
      "          -  current smoking (1 cigarette during any of the last 7 days)\n",
      "\n",
      "          -  consuming special diets\n",
      "      \n",
      "\n",
      "        Inclusion Criteria\n",
      "\n",
      "          -  Alefacept is indicated for the treatment of adult patients (18 years or older) with\n",
      "             moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or\n",
      "             phototherapy. Patients must have at least one plaque of least 2.5 cm in diameter (for\n",
      "             biopsies).\n",
      "\n",
      "        Exclusion Criteria\n",
      "\n",
      "          -  CD4 < 400/ml\n",
      "\n",
      "          -  WBC less than lower level of normal for the reporting laboratory\n",
      "\n",
      "          -  < 5% Body Surface Area involved with psoriasis\n",
      "\n",
      "          -  Serious infection e.g., latent or active tuberculosis\n",
      "\n",
      "          -  History of AIDS or Hepatitis B,C, all internal cancers, lymphoma, untreated cutaneous\n",
      "             basal or squamous cell carcinoma\n",
      "\n",
      "          -  Systemic anti-psoriasis medications and phototherapy within 28 days of the first dose\n",
      "             of Alefacept\n",
      "\n",
      "          -  Topical anti-psoriasis medications within 14 days of the first dose of Alefacept,\n",
      "             except for moisturizers, tar shampoos (exception, Elidel is permitted to be applied on\n",
      "             the face, groin and axillae areas. These areas are not biopsied.)\n",
      "\n",
      "          -  Inability to understand consent form or comply with study requirements\n",
      "\n",
      "          -  Pregnancy or lactation\n",
      "\n",
      "          -  Concurrent medical illness that would make participation in this clinical trial\n",
      "             ill-advised\n",
      "\n",
      "          -  Any contraindications to using alefacept\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. children presenting with idiopathic clubfoot at BC Children's Hospital and Hospital\n",
      "             for Sick Children\n",
      "\n",
      "          2. children ranging in age from 1 day to 2 months old\n",
      "\n",
      "          3. children who have reached hindfoot stall\n",
      "\n",
      "          4. children with complete pre-study data *From protocol, hindfoot stall is defined:\n",
      "             \"following initial manipulation and casting of clubfoot, when the forefoot can be\n",
      "             abducted beyond 60 degrees but hindfoot equinus persists, requiring need for further\n",
      "             intervention to correct the clubfoot deformity\"\n",
      "\n",
      "        Exclusion Criteria:\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Prostate cancer patients who were recorded at National Taiwan University Hospital from\n",
      "             1977 to 2002.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients or their family who refused our contact or were unable to be contacted\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18+ years of age\n",
      "\n",
      "          -  Diagnosed with HCM defined by the presence of left ventricular hypertrophy with\n",
      "             minimal wall thickness >/= 15mm without the presence of hypertension or systemic\n",
      "             disease that can account for the degree of hypertrophy.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Hypertension present prior to the diagnosis of HCM\n",
      "\n",
      "          -  aortic stenosis with aortic valve area < 1cm2\n",
      "\n",
      "          -  known systemic disease that can cause LVH, such as infiltrative diseases\n",
      "\n",
      "          -  able and willing to provide informed consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Premature babies weighing less than 1500 grams at birth receiving care at Strong\n",
      "             Memorial Hospital Neonatal Intensive Care Unit\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Non-English speaking parents\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. DSM-IV diagnostic criteria for MDD\n",
      "\n",
      "          2. Written informed consent\n",
      "\n",
      "          3. Men or women aged 18-65\n",
      "\n",
      "          4. A baseline Hamilton-D17 score of > 16 at screen visit\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Subjects with suicidal ideation where outpatient treatment is determined unsafe by the\n",
      "             study clinician. These patients will be immediately referred to appropriate clinical\n",
      "             treatment.\n",
      "\n",
      "          2. Pregnant women or women of childbearing potential who are not using a medically\n",
      "             accepted means of contraception (defined as oral contraceptive pill or implant,\n",
      "             condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)\n",
      "\n",
      "          3. Known history of serious or unstable medical illness, including cardiovascular,\n",
      "             hepatic, renal, respiratory, endocrine, neurologic or hematological disease\n",
      "\n",
      "          4. History of seizure disorder, brain injury, any history of known neurological disease\n",
      "             (multiple sclerosis, degenerative disease such as ALS, Parkinson disease and any\n",
      "             movement disorders, etc)\n",
      "\n",
      "          5. History or current diagnosis of the following DSM-IV psychiatric illness: organic\n",
      "             mental disorder, schizophrenia, schizoaffective disorder, delusional disorder,\n",
      "             psychotic disorders not otherwise specified, bipolar disorder, patients with mood\n",
      "             congruent or mood incongruent psychotic features, patients with substance dependence\n",
      "             disorders, including alcohol, active within the last 12 months.\n",
      "\n",
      "          6. History of multiple adverse drug reactions\n",
      "\n",
      "          7. Current use of other psychotropic drugs, including current use of benzodiazepines,\n",
      "             hypnotics, anticonvulsants. Concomitant use of antihistamine drugs will be allowed.\n",
      "\n",
      "          8. Patients who have failed to respond during the course of their current major\n",
      "             depressive episode to at least two adequate antidepressant trials, or have failed more\n",
      "             than one adequate trial with an SSRI antidepressant.\n",
      "\n",
      "          9. Electroconvulsive therapy (ECT) within the past 6 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  patients with primary ovarian cancer\n",
      "\n",
      "          -  ECOG- 0-2\n",
      "\n",
      "          -  Age >= 18\n",
      "\n",
      "          -  no chemotherapy, radiation or immunotherapy in medical history for ovarian cancer\n",
      "\n",
      "          -  adequate bone marrow, liver and kidney reserve: leukocytes ≥ 2.0 x 109/l, platelets ≥\n",
      "             100 x 109/l, bilirubin <= 2,0 mg%, creatinine <= 1,5 mg% or creatinine clearance ≥ 60\n",
      "             ml/ min, hemoglobin ≥ 9 g/ dl SGOT, SGPT an AP within 3 fold of the reference\n",
      "             laboratory's normal range\n",
      "\n",
      "          -  written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  before-existing heart illness, Cardiac infarct within last 6 months\n",
      "\n",
      "          -  Radiotherapy within 4 weeks for study entry\n",
      "\n",
      "          -  Patients in pregnancy or breast feeding (in premenopausal women anticonception has to\n",
      "             be assured: intrauterine devices, surgical methods of sterilization, or, in hormone\n",
      "             insensitive tumors only, oral, subcutaneous or transvaginal hormonal, non-estrogen\n",
      "             containing contraceptives)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Measurable, locally unresectable or metastatic adenocarcinoma of the stomach, GE\n",
      "             junction or esophagus\n",
      "\n",
      "          -  No more than one prior chemotherapy regimen\n",
      "\n",
      "          -  ECOG performance status of < or equal to 2\n",
      "\n",
      "          -  Life expectancy > 12 weeks\n",
      "\n",
      "          -  ANC > 1,500/mm3\n",
      "\n",
      "          -  Hemoglobin > 9.0 gm/dl\n",
      "\n",
      "          -  Platelets > 100,000/mm3\n",
      "\n",
      "          -  SGOT < 3 x ULN\n",
      "\n",
      "          -  Total bilirubin < 2.0 mg/dl\n",
      "\n",
      "          -  Creatinine < 1.5 mg/dl\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior cisplatin or doxorubicin as neoadjuvant or adjuvant therapy with in 1 year of\n",
      "             study entry\n",
      "\n",
      "          -  Clinically apparent central nervous system metastases or carcinomatous meningitis\n",
      "\n",
      "          -  Myocardial infarction in the past 6 months\n",
      "\n",
      "          -  Major surgery in the past 2 weeks\n",
      "\n",
      "          -  Uncontrolled serious medical or psychiatric illness\n",
      "\n",
      "          -  Pregnant or lactating women\n",
      "\n",
      "          -  Concurrent malignancy of any site, except limited basal cell carcinoma or squamous\n",
      "             cell carcinoma of the skin or carcinoma in situ of the cervix\n",
      "\n",
      "          -  History or clinical evidence of congestive heart failure\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Older than 18 years of age.\n",
      "\n",
      "          -  Confirmed diagnosis of active progressive multiple myeloma\n",
      "\n",
      "          -  History of > 2 prior cytotoxic treatment regimens. Bone marrow transplantation will be\n",
      "             considered as one regimen.\n",
      "\n",
      "          -  Current measurable disease based on serum and/or urine M protein and/or measurable\n",
      "             plasmacytoma.\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n",
      "\n",
      "          -  Absolute neutrophil count (ANC) > 1,500 mm3\n",
      "\n",
      "          -  Platelets > 100,000 mm3\n",
      "\n",
      "          -  Serum creatinine < 1.5 upper limit of normal (ULN)\n",
      "\n",
      "          -  Serum bilirubin < 1.5 ULN\n",
      "\n",
      "          -  AST/AGOT and ALT/SGPT < 3.0 ULN\n",
      "\n",
      "          -  Life expectancy > 12 weeks\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Chemotherapy < 3 weeks prior to registration.\n",
      "\n",
      "          -  Biologic or immunotherapy < 2 weeks prior to registration\n",
      "\n",
      "          -  Full field radiotherapy < 4 weeks or limited field radiotherapy < 2 weeks prior to\n",
      "             registration.\n",
      "\n",
      "          -  History or presence of central nervous system (CNS) disease\n",
      "\n",
      "          -  History of leukemia\n",
      "\n",
      "          -  History of another primary malignancy with the exception of inactive basal or squamous\n",
      "             cell carcinoma of the skin\n",
      "\n",
      "          -  Major surgery < 4 weeks prior to registration\n",
      "\n",
      "          -  Prior therapy with anti-vascular endothelial growth factor (VEGF) agents excluding\n",
      "             thalidomide, Revimid, velcade and arsenic trioxide\n",
      "\n",
      "          -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung\n",
      "\n",
      "          -  Pleural effusion or ascites that cause respiratory compromise\n",
      "\n",
      "          -  Female patients that are pregnant or breast feeding\n",
      "\n",
      "          -  Uncontrolled high blood pressure, history of labile hypertension or history of poor\n",
      "             compliance with an antihypertensive regimen\n",
      "\n",
      "          -  Unstable angina pectoris\n",
      "\n",
      "          -  Symptomatic congestive heart failure\n",
      "\n",
      "          -  Myocardial infarction < 6 months prior to registration\n",
      "\n",
      "          -  Serious uncontrolled cardiac arrhythmia\n",
      "\n",
      "          -  Uncontrolled diabetes\n",
      "\n",
      "          -  Active or uncontrolled infection\n",
      "\n",
      "          -  Acute or chronic liver disease\n",
      "\n",
      "          -  Impairment of gastrointestinal (GI) function or GI disease\n",
      "\n",
      "          -  Confirmed HIV infection\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Patients who are male or female age 18-65 years\n",
      "\n",
      "          2. Donor age 18-65 years\n",
      "\n",
      "          3. Patients who are single-organ recipients (kidney only)\n",
      "\n",
      "          4. Women who are of childbearing potential must have a negative serum pregnancy test\n",
      "             before transplantation and agree to use a medically acceptable method of contraception\n",
      "             throughout the treatment period.\n",
      "\n",
      "          5. Subject (recipient) is able to understand the consent form and give written informed\n",
      "             consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Known sensitivity or contraindication to sirolimus, tacrolimus or MMF\n",
      "\n",
      "          2. Patient with significant or active infection\n",
      "\n",
      "          3. Patients with a positive lymphocytotoxic crossmatch using donor lymphocytes and\n",
      "             recipient serum\n",
      "\n",
      "          4. Patients with PRA > 20%\n",
      "\n",
      "          5. Patients who are pregnant or nursing mothers\n",
      "\n",
      "          6. Patients whose life expectancy is severely limited by diseases other than renal\n",
      "             disease\n",
      "\n",
      "          7. Ongoing active substance abuse, drug or alcohol\n",
      "\n",
      "          8. Major ongoing psychiatric illness or recent history of noncompliance\n",
      "\n",
      "          9. Significant cardiovascular disease (e.g.):\n",
      "\n",
      "               -  Significant non-correctable coronary artery disease\n",
      "\n",
      "               -  Ejection fraction below 30%\n",
      "\n",
      "               -  History of recent myocardial infarction\n",
      "\n",
      "         10. Malignancy within 3 years, excluding non-melanoma skin cancers\n",
      "\n",
      "         11. Serologic evidence of infection with HIV or HBVsAg positive\n",
      "\n",
      "         12. Patients with a screening/baseline total white blood cell count < 4,000/mm3; platelet\n",
      "             count < 100,000/mm3; triglycerides > 400 mg/dl; total cholesterol > 300 mg/dl\n",
      "\n",
      "         13. Investigational drug within 30 days prior to transplant surgery\n",
      "\n",
      "         14. Anti-T cell therapy within 30 days prior to transplant surgery\n",
      "\n",
      "         15. Patients using Prednisone\n",
      "\n",
      "         16. Patients who are ABO incompatible\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  1.stroke with clear consciousness 2.Abnormal videofluoroscopic examination 3.Good\n",
      "             cooperation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  1. Lung infection 2. Can not oral feeding\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Type 2 diabetes HbA1c 6.0-8.0% age > 40 years\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        History of alcoholism or alcohol abuse liver disease blood pressure > 150/90\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Healthy adults\n",
      "\n",
      "          -  between 50 and 75 years old\n",
      "\n",
      "          -  having no neuromuscular or musculoskeletal disorders that would jeopardize their\n",
      "             balance control abilities\n",
      "\n",
      "          -  being willing to sign an informed consent approved by the Human Subjects Committee of\n",
      "             the National Taiwan University Hospital\n",
      "\n",
      "        Stroke patients\n",
      "\n",
      "          -  between 50 and 75 years old\n",
      "\n",
      "          -  hemiplegic or hemiparetic as a result of a single cerebral vascular accident\n",
      "\n",
      "          -  medically stable with no ongoing complications\n",
      "\n",
      "          -  independently walking without using any assistive device for at least 10 meters, and\n",
      "             have the exercise endurance for at least 30 minutes\n",
      "\n",
      "          -  having no serious hemianopsia, hemi-inattention or any obvious cognitive problems as\n",
      "             evaluated with the Mini-Mental State examination\n",
      "\n",
      "          -  being willing to sign an informed consent approved by the Human Subjects Committee of\n",
      "             the National Taiwan University Hospital\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  unable to follow the order of the experimenters, and having serious comprehension and\n",
      "             expression impairment\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  severe closed head injury patients or GCS 3-9 patients who receive brain oxygen\n",
      "             monitoring\n",
      "\n",
      "          -  ventriculostomy/ICP monitor\n",
      "\n",
      "          -  at least one reactive pupil\n",
      "\n",
      "          -  no known life threatening disease prior to trauma\n",
      "\n",
      "          -  age 18-70 years old\n",
      "\n",
      "          -  consent for microdialysis/brain 02 monitoring\n",
      "\n",
      "          -  legal family representative present that can give informed consent for perfluorocarbon\n",
      "             administration\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  no motor response\n",
      "\n",
      "          -  both pupils fixed and dilated\n",
      "\n",
      "          -  no consent available\n",
      "\n",
      "          -  allergy to egg proteins\n",
      "\n",
      "          -  coagulopathy\n",
      "\n",
      "          -  major liver injury\n",
      "\n",
      "          -  major pulmonary injury\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  WEIGHT: less than or at 20% over ideal weight, as specified in the 1983 Metropolitan\n",
      "             Height and Weight Tables. Patients who deviate from these ranges may be reviewed on an\n",
      "             individual basis by the Investigator. This criterion is necessary because of\n",
      "             mechanical limitations in fitting overweight individuals into the scanner, and the\n",
      "             risk of excessive claustrophobic responses if tightly constricted.\n",
      "\n",
      "          -  HEALTH: healthy, ambulatory normal or depressed adults\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Presence of aneurysm clips, cardiac pacemakers, cochlear implants, metal in the eyes,\n",
      "             and implanted insulin pumps.\n",
      "\n",
      "          -  Evidence of significant hepatic, gastrointestinal, renal, respiratory, endocrine,\n",
      "             hematologic, neurologic, psychiatric, or cardiovascular system abnormalities.\n",
      "\n",
      "          -  Pregnancy.\n",
      "\n",
      "          -  Patients with a known or suspected history of alcohol or drug misuse and/or a positive\n",
      "             urine drug screen.\n",
      "\n",
      "          -  Patients who are unwilling or unable to abide by the requirements of the study or who\n",
      "             violate the prohibitions and restrictions of the study.\n",
      "\n",
      "          -  Any condition which would make the patient, in the opinion of the Investigator,\n",
      "             unsuitable for the study.\n",
      "\n",
      "          -  Patients on antidepressants may not be taking any other medication, except at the\n",
      "             discretion of the investigator. Untreated depressed or healthy subjects must be free\n",
      "             of all medications except as approved by the investigator.\n",
      "\n",
      "          -  Patients with serious medical illness, history or signs/symptoms of lumbar spine/disc\n",
      "             disease or significant laboratory findings.\n",
      "\n",
      "          -  Patients who present significant suicide risk, e.g. with a history of highly impulsive\n",
      "             suicide attempts.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female 18 years or older\n",
      "\n",
      "          -  DSM-IV diagnosis of major depressive disorder of at least moderate severity, but\n",
      "             without psychotic features\n",
      "\n",
      "          -  Ham-D 17 score of 18 or above\n",
      "\n",
      "          -  Have a documentable history of 2 prior adequate trials of antidepressants including an\n",
      "             SSRI without sufficient response. A clinically adequate trial is defined as having\n",
      "             taken a minimum effective dose of an antidepressant for at least 3 weeks without a\n",
      "             significant change in depressive symptoms.\n",
      "\n",
      "          -  Must be currently on an serotonin uptake inhibitor (to include venlafaxine or\n",
      "             duloxetine) at an adequate dose for at least 3 weeks.\n",
      "\n",
      "          -  Ability and willingness to provide consent for participation in the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any medical condition that would preclude treatment with an SSRI, risperidone, or\n",
      "             bupropion ER\n",
      "\n",
      "          -  Any clinically significant unstable medical condition\n",
      "\n",
      "          -  Diagnosis of bipolar disorder or a primary diagnosis of any psychotic disorder\n",
      "\n",
      "          -  Current psychotic symptoms (hallucination or delusions)\n",
      "\n",
      "          -  Alcohol or drug abuse or dependence in the last 3 months (excluding nicotine and\n",
      "             caffeine dependence/abuse) or abuse within the last month\n",
      "\n",
      "          -  Documented non-response to the combination of a novel antipsychotic or bupropion ER\n",
      "             and a SSRI\n",
      "\n",
      "          -  Concomitant use of any psychotropic other than an SSRI or zolpidem (PRN for sleep)\n",
      "\n",
      "          -  Score of 4 on the suicide item of the Ham-D scale and determination by the\n",
      "             investigator of significant suicide risk\n",
      "\n",
      "          -  Known sensitivity to risperidone or bupropion ER\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Target lesion(s) must be located in a native epicardial vessel with visually estimated\n",
      "             diameter between >= 2.25 mm and <= 4.25 mm and a lesion length <= 32 mm\n",
      "\n",
      "          -  The target lesion(s) must be in a major artery or branch with a visually estimated\n",
      "             stenosis of >= 50% and < 100% with a thrombolysis in myocardial infarction (TIMI) flow\n",
      "             of >= 1\n",
      "\n",
      "          -  Non-study, percutaneous intervention for lesions in a non-target vessel is allowed if\n",
      "             done >= 90 days prior to the index procedure (subjects who received brachytherapy will\n",
      "             be excluded from the trial)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Located within an arterial or saphenous vein graft or distal to a diseased (vessel\n",
      "             irregularity per angiogram and > 20% stenosed lesion by visual estimation) arterial or\n",
      "             saphenous vein graft\n",
      "\n",
      "          -  Lesion involving a bifurcation >= 2 mm in diameter or ostial lesion > 50% stenosed by\n",
      "             visual estimation or side branch requiring predilatation\n",
      "\n",
      "          -  Located in a major epicardial vessel that has been previously treated with\n",
      "             brachytherapy\n",
      "\n",
      "          -  Located in a major epicardial vessel that has been previously treated with\n",
      "             percutaneous intervention < 9 months prior to index procedure\n",
      "\n",
      "          -  Total occlusion (TIMI flow 0), prior to wire passing\n",
      "\n",
      "          -  The target vessel contains thrombus\n",
      "\n",
      "          -  Another significant lesion (> 40% diameter stenosis [DS]) is located in the same\n",
      "             epicardial vessel as the target lesion\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy volunteers age 18 and over\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Significant abnormalities on health history questionnaire or in the results of blood\n",
      "             tests\n",
      "\n",
      "          -  Pregnant or nursing mother\n",
      "\n",
      "          -  Participation in another research study within the past six weeks that is felt by the\n",
      "             Principal Investigator to be incompatible with this study\n",
      "\n",
      "          -  Severe infection in the past two months\n",
      "\n",
      "          -  Immune disorder, or use of any medication that can alter immune system function\n",
      "\n",
      "          -  A medical or mental health finding showing inability to go through the procedure\n",
      "\n",
      "          -  Body mass index (BMI) greater than 29%\n",
      "\n",
      "          -  Chronic back pain, sciatica, or a compression fracture of the spine\n",
      "\n",
      "          -  Positive test results for viral infections: Hepatitis B, Hepatitis C, or HIV (AIDS)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria::- outpatients at least 18 years of age\n",
      "\n",
      "          -  current major depressive episode\n",
      "\n",
      "          -  HDRS greater than or equal to 21\n",
      "\n",
      "          -  good physical health Exclusion Criteria:- history of sensitivity, intolerance, or\n",
      "             non-response to venlafaxine\n",
      "\n",
      "          -  history of sensitivity to hydrocortisone\n",
      "\n",
      "          -  history of bipolar 1 illness\n",
      "\n",
      "          -  meets DSM-IV criteria for a current or past psychotic disorder\n",
      "\n",
      "          -  meets DSM-IV criteria for substance abuse or dependence in previous 6 months\n",
      "\n",
      "          -  significant imminent suicide risk\n",
      "\n",
      "          -  medical condition that would compromise participation in the study\n",
      "\n",
      "          -  woman of child bearing potential not using adequate birth control in the opinion of\n",
      "             the investigator\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  BMI of 25 to 43 kg/m2\n",
      "\n",
      "          -  age > 21 years\n",
      "\n",
      "          -  access to a personal computer (PC)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  BMI above/below 25-43 kg/m2\n",
      "\n",
      "          -  age < 21 years\n",
      "\n",
      "          -  no access to a personal computer (PC)\n",
      "\n",
      "          -  type 2 diabetes\n",
      "\n",
      "          -  participants taking medications known to affect weight, appetite or energy expenditure\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Women without lymphedema must be 1-5 years post breast cancer diagnosis\n",
      "\n",
      "          -  Women with lymphedema must be 1-15 years post breast cancer diagnosis\n",
      "\n",
      "          -  Women with lymphedema must have stable lymphedema. ONE of the following:\n",
      "\n",
      "               -  0-40>10% girth volume difference between the affected and non- affected limb for\n",
      "                  a non-dominant arm\n",
      "\n",
      "               -  6-40% girth volume difference between the affected and non- affected limb for a\n",
      "                  dominant arm inter-limb discrepancy in volume or circumference at the point of\n",
      "                  greatest visible difference OR swelling or obscuration of anatomic architecture\n",
      "                  upon close inspection OR pitting edema.\n",
      "\n",
      "                    -  2 cm circumference difference\n",
      "\n",
      "               -  A prior clinical diagnosis of lymphedema and having had any prior intensive\n",
      "                  lymphedema therapy on the affected arm\n",
      "\n",
      "        As well as ALL of the following four conditions:\n",
      "\n",
      "          -  Women with Lymphedema must have ALL of the following:\n",
      "\n",
      "               -  No recorded arm girth change of 15% or greater within the three months.\n",
      "\n",
      "               -  No more than one lymphedema related infection requiring antibiotics within the\n",
      "                  past 3 months.\n",
      "\n",
      "               -  Participation in all Activities of Daily Living (ADLs) without lymphedema\n",
      "                  exacerbation for the past 3 months.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  For ALL participants (with and without lymphedema)\n",
      "\n",
      "               -  No medical conditions or medications that would prohibit participation in an\n",
      "                  exercise program or would negatively impact our ability to test our primary aims\n",
      "\n",
      "               -  Not morbidly obese (body mass index >50 kg/m2)\n",
      "\n",
      "               -  No plans for additional (e.g. reconstructive) surgery during the study period\n",
      "\n",
      "               -  No bilateral breast cancers (because this prohibits our ability to assess the\n",
      "                  primary outcome of interest)\n",
      "\n",
      "               -  No strength training or other upper body resistive exercise within the past year\n",
      "\n",
      "               -  Not planning to move away from the area over the next year\n",
      "\n",
      "               -  Not pregnant or lactating or planning to become pregnant during the study\n",
      "\n",
      "               -  Among women who have given birth: at least 6 months post pregnancy and at least 3\n",
      "                  months post lactation\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  proteinuria > 1 g/day with ramipril 5 + valsartan 80 mg/day for 2 months\n",
      "\n",
      "          -  proteinuria changes < 50% on 3 separate dosages over 2 months.\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  age < 18 or > 80 years systolic BP < 110 or ≥ 140 mmHg, serum creatinine > 250 mmole/L\n",
      "\n",
      "          -  serum creatinine increase on ramipril + valsartan > 20%\n",
      "\n",
      "          -  intolerance to ACEI or ARB\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Right-handed\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any condition contraindicating an fMRI brain scan\n",
      "\n",
      "          -  Any neurological or psychiatric disorders\n",
      "\n",
      "          -  Any pain syndromes\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Men or women 18 years or older\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Internal spinal hardware\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Subjects must have a diagnosis of PTSD as defined by DSM-IV for at least six months,\n",
      "             supported by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).\n",
      "\n",
      "          2. Subjects must be female between 19 and 64 years of age, inclusive.\n",
      "\n",
      "          3. Subjects must have a minimum past week CAPS score of 50 at Visit 2 (Day 1).\n",
      "\n",
      "          4. Subjects must be in generally good health as confirmed by medical history, baseline\n",
      "             psychiatric history and physical examination, including vital signs.\n",
      "\n",
      "          5. Subjects must have observed the designated washout periods for prohibited medications\n",
      "             outlined under the Concomitant Therapy section of this protocol.\n",
      "\n",
      "          6. Subjects must have a negative urine drug screening (phencyclidine, cocaine,\n",
      "             amphetamines, tetrahydrocannabinol, and opiates) at Visit 1.\n",
      "\n",
      "          7. Subjects must:\n",
      "\n",
      "               1. be postmenopausal for at least one year, or\n",
      "\n",
      "               2. have had a hysterectomy or tubal ligation or otherwise be incapable of pregnancy,\n",
      "                  or\n",
      "\n",
      "               3. have practiced one of the following methods of contraception for at least one\n",
      "                  month prior to study entry: hormonal contraceptives, spermicide and barrier,\n",
      "                  intrauterine device, spousal/partner sterility or\n",
      "\n",
      "               4. be practicing abstinence and agree to continue abstinence or to use an acceptable\n",
      "                  method of contraception (as listed above) should sexual activity commence.\n",
      "\n",
      "             If (c) or (d), subjects must have a negative urine pregnancy test up to one week prior\n",
      "             to Visit 2 (Day 1).\n",
      "\n",
      "          8. Subjects must be able to take oral medication, adhere to medication regimens and be\n",
      "             willing to return for regular visits.\n",
      "\n",
      "          9. Subjects must be able to read and comprehend written instructions and willing to\n",
      "             complete all scales and inventories required by this protocol.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Subjects who have a DSM-IV diagnosis of substance dependence or abuse (with the\n",
      "             exception of nicotine or caffeine dependence) within the past 3 months.\n",
      "\n",
      "          2. Subjects with a current or past history of primary major depressive disorder or major\n",
      "             anxiety disorder (i.e., panic disorder, obsessive-compulsive disorder, social phobia)\n",
      "             as defined by DSM-IV.\n",
      "\n",
      "          3. Subjects with a current or lifetime history of schizophrenia, bipolar disorder, or\n",
      "             other psychotic disorder as defined by DSM-IV.\n",
      "\n",
      "          4. Subjects with a DSM-IV diagnosis of current organic mental disorder, factitious\n",
      "             disorder, or malingering.\n",
      "\n",
      "          5. Subjects who are currently enrolled in a cognitive-behavioral therapy program.\n",
      "\n",
      "             Note: Subjects may be receiving concurrent psychotherapy (other than\n",
      "             cognitive-behavioral therapy), but subjects must not initiate new psychotherapy\n",
      "             treatment during their participation in the trial.\n",
      "\n",
      "          6. Subjects with prior non-response to topiramate for the treatment of PTSD following an\n",
      "             adequate trial.\n",
      "\n",
      "          7. Subjects with a disability or other compensation claim pending for lack of functioning\n",
      "             due to PTSD.\n",
      "\n",
      "          8. Subjects with disability compensation dependent on persisting functional impairment\n",
      "             related to PTSD.\n",
      "\n",
      "          9. Subjects who have previously been treated with topiramate and discontinued treatment\n",
      "             due to an adverse event or subjects with a known hypersensitivity to topiramate.\n",
      "\n",
      "         10. Subjects with clinically unstable disease: cardiovascular, renal, gastrointestinal,\n",
      "             pulmonary, metabolic, endocrine or other systemic disease that could interfere with\n",
      "             their participation in the study.\n",
      "\n",
      "         11. Subjects with a history of nephrolithiasis.\n",
      "\n",
      "         12. Subjects who have SGOT and/or SGPT levels greater than 2 times the upper limit of the\n",
      "             normal range at Screening.\n",
      "\n",
      "         13. Subjects who have active liver disease.\n",
      "\n",
      "         14. Subjects taking antipsychotics within three months of the screening visit.\n",
      "\n",
      "         15. Subjects with progressive or degenerative neurologic disorders (e.g., multiple\n",
      "             sclerosis).\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Patients presenting to a general practitioner / internist with symptoms of GERD defined as:\n",
      "\n",
      "          -  Heartburn - uncomfortable, rising, burning sensation behind the breastbone\n",
      "\n",
      "          -  Regurgitation of gastric acid or sour contents into the mouth\n",
      "\n",
      "          -  Chest pain atypical for cardiac ischemia and more suggestive of GERD\n",
      "\n",
      "          -  Symptoms for more than three weeks with no concurrent use of PPI's or H-2 blockers\n",
      "             during that time period\n",
      "\n",
      "          -  A score greater than or equal to 5 on the AstraZeneca RDQ\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any patients presenting with alarm symptoms (GI bleeding, dysphagia, weight loss,\n",
      "             abdominal mass, lymphadenopathy, or recurrent vomiting)\n",
      "\n",
      "          -  Diabetes (type I or II)\n",
      "\n",
      "          -  Renal insufficiency defined as creatinine >1.6\n",
      "\n",
      "          -  Under 18 years of age\n",
      "\n",
      "          -  Prior surgery on esophagus, stomach or duodenum\n",
      "\n",
      "          -  History of gastric/duodenal ulcers\n",
      "\n",
      "          -  History of H. pylori\n",
      "\n",
      "          -  Known history of Barrett's esophagus (recruited to parallel study)\n",
      "\n",
      "          -  On Coumadin or Heparin therapy\n",
      "\n",
      "          -  Chronic upper abdominal pain more consistent with dyspepsia or other diagnoses\n",
      "\n",
      "          -  Noncompliant patients\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Burn wound size of at least 20% of the body surface area\n",
      "\n",
      "          -  Requires antibiotic therapy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  < 20% total body surface area burn\n",
      "\n",
      "          -  Does not require antibiotic therapy\n",
      "\n",
      "          -  Only requires post-operative antibiotic therapy\n",
      "\n",
      "          -  Bowel obstruction\n",
      "\n",
      "          -  Milk allergy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed PCa\n",
      "\n",
      "          -  Completed radiotherapy to the prostatic area more than 12 months prior to\n",
      "             randomization\n",
      "\n",
      "          -  Rising PSA level (serum PSA > 3 ng/ml (3 μg/L)) and higher than the lowest level\n",
      "             recorded previously since the end of radiotherapy (i.e. higher than the\n",
      "             post-radiotherapy nadir)\n",
      "\n",
      "          -  No definite evidence of distant metastasis (radiological changes compatible with\n",
      "             non-malignant diseases are acceptable)\n",
      "\n",
      "          -  No prior hormonal therapy with the exception of neo-adjuvant cytoreduction prior to\n",
      "             radical radiotherapy or prostatectomy for a maximum duration of 12 months and\n",
      "             completed at least 12 months prior to randomization.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Severe osteoporosis\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  OCD\n",
      "\n",
      "          -  Eligibility to participate in group therapy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  PTSD\n",
      "\n",
      "          -  Suicidal thoughts\n",
      "\n",
      "          -  Psychotic state\n",
      "\n",
      "          -  Severe hostile personality disorder\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patient referred for NM scintigraphy to assess the presence of endocrine or\n",
      "             neuroendocrine tumors.\n",
      "\n",
      "          -  Patient signed informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  The study will not be performed in pregnant or lactating women.\n",
      "\n",
      "          -  Patient will not be able or willing to tolerate the scan until its completion.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Type 2 diabetes mellitus\n",
      "\n",
      "          -  HbA1C > 6.0%\n",
      "\n",
      "          -  Age 18 and above\n",
      "\n",
      "          -  Able to obtain consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Currently taking insulin\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  End-stage renal disease\n",
      "\n",
      "          -  Hemolytic anemia\n",
      "\n",
      "          -  Cinnamon intolerance\n",
      "\n",
      "          -  Inability or unwillingness to adhere to study protocol\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Living in a foster home or receiving kinship care\n",
      "\n",
      "          -  Are about to enter middle school\n",
      "\n",
      "          -  Oregon resident\n",
      "\n",
      "          -  Guardian willing to provide informed consent\n",
      "\n",
      "          -  Female\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  male\n",
      "\n",
      "          -  not in foster care\n",
      "\n",
      "          -  not living in Oregon\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 18 and over\n",
      "\n",
      "          -  Able to speak English\n",
      "\n",
      "          -  Enrolled in the Nova Scotia Health Study (NSHS95)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant\n",
      "\n",
      "          -  Active military personnel\n",
      "\n",
      "          -  Lived in Nova Scotia province for less than 3 months\n",
      "\n",
      "          -  Unable to provide informed consent\n",
      "      \n",
      "\n",
      "        Study selection criteria are not based on gender, ethnicity or race. Nevertheless, we\n",
      "        estimated that 61% of subjects would be females, 73% would be white, and 99% would be\n",
      "        non-hispanic/latino.\n",
      "\n",
      "          -  Inclusion/exclusion criteria are designed to assure the availability of data necessary\n",
      "             for the study and to identify a cohort of patients who, absent adverse medication\n",
      "             effects, are at low risk for sudden death. Thus, inclusion criteria require enrollment\n",
      "             in TennCare, including access to medications. To assure complete identification of all\n",
      "             healthcare encounters and medication use, the study will be restricted to TennCare\n",
      "             enrollees with active enrollment and full pharmacy benefits. We require age 30 years\n",
      "             or older at the beginning of the study. This is the population for which\n",
      "             arrhythmia-related deaths are of greatest concern. Finally, cohort members must have\n",
      "             use of study or control medications, as defined by filling at least one prescription\n",
      "             recorded in the Medicaid pharmacy files.\n",
      "\n",
      "          -  Patients with life-threatening illnesses will be excluded because for such persons it\n",
      "             is not possible to distinguish from deaths related to arrhythmias versus those that\n",
      "             are a consequence of the underlying serious illness.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  confirmed diagnosis of cystic fibrosis based upon 2 of the following: a. sweat\n",
      "             chloride by quantitative pilocarpine electrophoresis ≥60 milliequivalent/Liter\n",
      "             (mEq/L), b. two clinical features consistent with CF, or c. genetic testing\n",
      "             demonstrating two mutations associated with CF\n",
      "\n",
      "          -  confirmation of pancreatic insufficiency based upon fecal elastase of ≤ 100 micrograms\n",
      "             per gram of stool (or an undetectable level)\n",
      "\n",
      "          -  age at enrollment to the trial of 2.0 years to 6.0 years\n",
      "\n",
      "          -  at least 6 months post CF diagnosis\n",
      "\n",
      "          -  consuming an unrestricted fat diet\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  diagnosis of developmental delay (i.e., autism, cerebral palsy, or mental retardation)\n",
      "\n",
      "          -  receiving supplemental enteral nutrition via nasogastric tube, gastrostomy, or total\n",
      "             parenteral nutrition\n",
      "\n",
      "          -  diagnosed with another disease/condition (e.g., insulin dependent diabetes, congenital\n",
      "             heart disease, significant renal disease, history of bowel resection or short bowel\n",
      "             syndrome, colonic strictures) known to affect growth\n",
      "\n",
      "          -  taking a medication (e.g., insulin, growth hormone, chronic use of systemic steroids)\n",
      "             known to affect growth\n",
      "\n",
      "          -  screening assessment shows genetic potential for height as acceptable according to the\n",
      "             2001 Consensus Conference guidelines and diet diary indicates daily Dietary Reference\n",
      "             Intake (DRI) of energy average of 140% or greater (DRI of 100% will be determined as\n",
      "             the estimated energy requirement [EER] based upon the child's age, gender, and an\n",
      "             active physical activity level\n",
      "\n",
      "          -  weight z score (age and gender adjusted) of > 1.0\n",
      "\n",
      "          -  prior participation in the pilot intervention studies conducted by the PI during the\n",
      "             prior period of R01 funding or current participation in an intervention trial\n",
      "             conducted by the Cystic Fibrosis Therapeutics Development Network.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age >18\n",
      "\n",
      "          -  Satisfies the criteria for ischemic stroke: acute focal neurological deficit of likely\n",
      "             ischemic vascular origin.\n",
      "\n",
      "          -  Patient or legally authorized representative has provided written informed consent\n",
      "             prior to study entry.\n",
      "\n",
      "          -  Patient can receive the first treatment dose within 0-24 hours of stroke onset. For\n",
      "             patients found with stroke on awakening, it will be assumed that the stroke occurred\n",
      "             the last time that the patient was known to be normal.\n",
      "\n",
      "          -  Patient has pretreatment brain CT scan compatible with ischemic stroke and excludes\n",
      "             hemorrhagic and non-vascular etiologies of symptoms.\n",
      "\n",
      "          -  Patients taking statins at time of stroke may be included.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Brain imaging study shows a lesion other than ischemic stroke that could explain\n",
      "             patient's symptoms (intracranial or subarachnoid hemorrhage, arteriovenous\n",
      "             malformation, aneurysm, multiple sclerosis, tumor, abscess or other). Asymptomatic\n",
      "             meningiomas are allowed.\n",
      "\n",
      "          -  Patient had a stroke (ischemic or hemorrhagic) with residual deficit within 1 month\n",
      "             prior to treatment.\n",
      "\n",
      "          -  Mild stroke, defined as NIH Stroke Scale <2.\n",
      "\n",
      "          -  Patient has received or is expected to receive intravenous rt-PA within 3 hours or\n",
      "             intra-arterial rt-PA within 6 hours of stroke onset, according to our institutional\n",
      "             standard of care.\n",
      "\n",
      "          -  Receipt of intravenous rt-PA after 3 hours or intra-arterial rt-PA after 6 hours\n",
      "             post-stroke onset.\n",
      "\n",
      "          -  Seizure at presentation or within two weeks prior to stroke.\n",
      "\n",
      "          -  Patient is comatose, regardless of etiology (> 4 points on the first three items of\n",
      "             the NIHSS).\n",
      "\n",
      "          -  History of intolerance or allergic reaction to any statins (myotoxicity, hepatic\n",
      "             dysfunction, rash, etc.)\n",
      "\n",
      "          -  Use of drugs within past 30 days that utilize the cytochrome CYP3A pathway\n",
      "             (cyclosporine, itraconazole, ketoconazole, erythromycin, azithromycin, clarithromycin,\n",
      "             nefazodone).\n",
      "\n",
      "          -  Use of drugs within past 30 days that increase risk of myotoxicity with statins\n",
      "             (gemfibrozil, other fibrates, niacin, amiodarone, verapamil).\n",
      "\n",
      "          -  Baseline major electrolyte disturbances (sodium <125 or >150, potassium <3.0 or >5.5).\n",
      "\n",
      "          -  Recent major trauma (<3 months).\n",
      "\n",
      "          -  Hypothermia (body temperature < 96 degrees Fahrenheit).\n",
      "\n",
      "          -  Baseline hypoxia (defined as oxygen saturation <92% on room air).\n",
      "\n",
      "          -  History of likely or proven systemic viral infection within 30 days.\n",
      "\n",
      "          -  Known HIV infection or use of protease inhibitors.\n",
      "\n",
      "          -  Endocarditis likely as cause of stroke.\n",
      "\n",
      "          -  Mitochondrial disorder likely as cause of stroke.\n",
      "\n",
      "          -  Pregnancy or lactation.\n",
      "\n",
      "          -  History of rhabdomyolysis, myopathy, or other severe muscle disease.\n",
      "\n",
      "          -  History of hepatitis, decompensated liver disease (ascites, bleeding varices or\n",
      "             encephalopathy), or liver failure.\n",
      "\n",
      "          -  Liver function tests (ALT, AST) > 2X upper limit of normal.\n",
      "\n",
      "          -  Unstable cardiovascular (includes uncontrolled hypertension), pulmonary,\n",
      "             gastrointestinal, hepatic or musculoskeletal disease within one month (30 days) prior\n",
      "             to treatment (by reported history).\n",
      "\n",
      "          -  Patient has evidence of congestive heart failure or has history of end-stage\n",
      "             cardiovascular disease (e.g. CHF NYHA Class III or IV or unstable angina).\n",
      "\n",
      "          -  Abnormal ECG showing: Hemodynamically significant arrhythmia or frequent PVCs\n",
      "             (>5/minute) (controlled atrial arrhythmia will not be an exclusion); evidence of acute\n",
      "             myocardial infarction; Mobitz Type II 2nd degree AV block or 3rd degree AV block;\n",
      "             ventricular tachycardia or ventricular fibrillation.\n",
      "\n",
      "          -  Significant renal insufficiency, indicated by serum creatinine >2.0 mg/dl.\n",
      "\n",
      "          -  Hypoglycemia (glucose < 60 mg/dl), significant hyperglycemia (glucose > 400 mg/dl) or\n",
      "             diabetic ketoacidosis.\n",
      "\n",
      "          -  Any of these hematologic abnormalities: Hb <10 g/dl; WBC <3.0 x 103/mm3; Platelet\n",
      "             count <50,000/mm3\n",
      "\n",
      "          -  Received an investigational drug within 30 days.\n",
      "\n",
      "          -  Severe behavioral or social problems that may interfere with the conduct of clinical\n",
      "             study procedures.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Arthritis according to the American Rheumatism Association or osteoarthritis of the\n",
      "             knee\n",
      "\n",
      "          -  age older than 18 years\n",
      "\n",
      "          -  active gonarthritis in the setting of a rheumatic inflammatory disease such as\n",
      "             rheumatoid arthritis, spondyloarthropathies, undifferentiated oligoarthritis or\n",
      "             monarthritis since at least 4 weeks with proof of joint or ostearthritis of the knee\n",
      "             effusion in ultrasound\n",
      "\n",
      "          -  visual analogue scale (pain) >30 mm\n",
      "\n",
      "          -  weight between 50 and 90 kg\n",
      "\n",
      "          -  signed informed consent\n",
      "\n",
      "          -  negative urine pregnancy test in women of child-bearing potential\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pregnancy / lactation\n",
      "\n",
      "          -  severe infection, suspicion for opportunistic infection within the last 2 months\n",
      "             (herpes zoster, cytomegaly-, pneumocystis carinii-infection), HIV- infection\n",
      "\n",
      "          -  malignant disease\n",
      "\n",
      "          -  severe cardiac, renal, hematologic, pulmonary, neurologic, gastrointestinal (amongst\n",
      "             others gastric or duodenal ulcer) or hepatic (viral hepatitis, toxic liver disease\n",
      "             etc) disease, uncontrolled high blood pressure, recurrent thrombosis/ embolism\n",
      "\n",
      "          -  psychiatric disease\n",
      "\n",
      "          -  significant bone marrow dysfunction with impaired hematopoiesis\n",
      "\n",
      "          -  one of the following laboratory findings: thrombocytopenia < 100 /nl, Quick < 50%\n",
      "\n",
      "          -  significant pathological findings in physical examination, especially findings\n",
      "             indicating an infectious cause for arthritis (septic arthritis) or Lyme arthritis\n",
      "\n",
      "          -  participation in clinical trials within the last 30 days\n",
      "\n",
      "          -  intake of illegal drugs (such as cocaine, heroin...), substance abuse (alcohol,\n",
      "             excessive intake of analgetic drugs, benzodiazepines)\n",
      "\n",
      "          -  intake of anticoagulating drugs\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diabetes Mellitus, type 2, as defined by at least one of the following:\n",
      "\n",
      "               -  Previous diagnosis of diabetes\n",
      "\n",
      "               -  two glucose levels consistent with diabetes (fasting glucose >7.0 mmol/L or\n",
      "                  random glucose >11.0 mmol/L )\n",
      "\n",
      "               -  HbA1C > 6.5% using DCCT standardized methods And\n",
      "\n",
      "        Coronary Disease, as defined by at least one of the following:\n",
      "\n",
      "          -  Admitting diagnosis of acute coronary syndrome defined by 2/3 of typical history,\n",
      "             enzyme changes, dynamic ECG changes\n",
      "\n",
      "          -  Prior history of acute coronary syndrome defined as above\n",
      "\n",
      "          -  Previously documented myocardial infarction\n",
      "\n",
      "          -  Previous coronary revascularization procedure\n",
      "\n",
      "          -  Coronary artery disease defined by coronary angiography\n",
      "\n",
      "          -  Exercise or persantine nuclear perfusion imaging positive for ischemia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Refusal to enter the study\n",
      "\n",
      "          -  Inability to understand consent forms and provide informed consent\n",
      "\n",
      "          -  Anticipated length of non-ICU hospital stay less than 48 hours\n",
      "\n",
      "          -  Diabetes Mellitus, type 1\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age > 55 years\n",
      "\n",
      "          -  meet DSM-IV criteria for primary degenerative dementia\n",
      "\n",
      "          -  meet NINCDS-ARDA criteria for probable Alzheimer's Disease of at least one year's\n",
      "             duration\n",
      "\n",
      "          -  mild to moderate cognitive impairment (Global Deterioration Scale GDS <6, Mini-Mental\n",
      "             State Examination >10\n",
      "\n",
      "          -  on a stable dose of a cholinesterase inhibitor for at least 3 months\n",
      "\n",
      "          -  apathetic group only: Neuropsychiatric Inventory (NPI) Apathy subscale score >=2\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  abnormal biochemical screening: blood cell count, vitamin B12, thyroid function tests,\n",
      "             and syphilis screening tests\n",
      "\n",
      "          -  significant medical illness or other medical/neurological conditions which diminish\n",
      "             cognitive function\n",
      "\n",
      "          -  evidence of seizure disorder\n",
      "\n",
      "          -  an Hachinski ischemic score >3 indicating vascular dementia\n",
      "\n",
      "          -  a brain computed tomographic (CT) scan revealing focal lesions, or inconsistent with\n",
      "             AD\n",
      "\n",
      "          -  electrocardiographic, laboratory or physical evidence of significant cardiovascular\n",
      "             disease\n",
      "\n",
      "          -  presence of premorbid or current psychiatric diagnosis including: major depression,\n",
      "             schizophrenia, psychotic symptoms of a severity likely to provoke violent or dangerous\n",
      "             behaviour (i.e., command hallucinations to harm people or persecutory delusions that\n",
      "             provoke violent reactions)\n",
      "\n",
      "          -  current or past psychoactive substance abuse or dependence (including alcohol,\n",
      "             excluding nicotine)\n",
      "\n",
      "          -  contraindications to receiving dextroamphetamine or methylphenidate\n",
      "\n",
      "          -  have had administration of a depot neuroleptic injection within one treatment cycle of\n",
      "             the first visit\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18 years of age or older\n",
      "\n",
      "          -  Diagnosis of pulmonary fibrosis confirmed by physical examination, pulmonary function\n",
      "             testing, chest X-ray, and computed tomography (CT) scans.\n",
      "\n",
      "          -  Adult patients who are seeking treatment at the Dorothy P. and Richard P. Simmons\n",
      "             Center for Interstitial Lung Disease.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Under 18 years of age\n",
      "\n",
      "          -  Non-fibrotic ILD\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  diagnosis of frozen shoulder of at least one month duration\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  shoulder arthritis\n",
      "\n",
      "          -  rotator cuff tears\n",
      "\n",
      "          -  any chronic, serious, uncontrolled medical condition\n",
      "\n",
      "          -  inability to conform to study visits (20-30 per year)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Subject must be 35-85 years of age and able to give informed consent.\n",
      "\n",
      "          2. Coronary artery disease requiring bypass grafting using at least two saphenous vein\n",
      "             bypass grafts carried out through median sternotomy and utilizing cardiopulmonary\n",
      "             bypass.\n",
      "\n",
      "          3. Use of an approved statin anticipated for at least 24 months after surgery.\n",
      "\n",
      "          4. Subject must not be a candidate for concurrent ventricular surgical restoration, AICD\n",
      "             placement, or valvular surgery.\n",
      "\n",
      "          5. Agreeable to CTA at 6 weeks and IVUS intervention at 12-months post-CABG. Subjects\n",
      "             agreeable to additional CTA at 6, 12 and 24 months preferred.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Acute traumatic injury or vasculitis.\n",
      "\n",
      "          2. Insulin-dependent diabetes.\n",
      "\n",
      "          3. Procedure is for revision for an existing bypass graft.\n",
      "\n",
      "          4. Procedure is to be minimally invasive (except for harvesting of the graft segment).\n",
      "\n",
      "          5. Concurrent cardiac valvular surgery.\n",
      "\n",
      "          6. Patients with any medical condition that, in the investigator's judgment, makes the\n",
      "             patient ineligible or places the patient at undue risk (e.g. conditions that preclude\n",
      "             standard invasive follow-up procedures such as IVUS and angiography, i.e. renal\n",
      "             failure, bleeding diathesis, or peripheral vascular disease preventing catheterization\n",
      "             via the groin).\n",
      "\n",
      "          7. Subject has clinical evidence of infection that the Investigator deems significant to\n",
      "             the completion of the procedure, or that could compromise the subject's safety.\n",
      "\n",
      "          8. Subject has recent history (within past 6 months) of alcohol or drug abuse.\n",
      "\n",
      "          9. If female, subject is pregnant or trying to become pregnant.\n",
      "\n",
      "         10. Calculated creatinine clearance < 30 mls/min for non-diabetics or < 50 mls/min for\n",
      "             non-insulin dependent diabetics.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age between 18 and 75 years\n",
      "\n",
      "          -  liver biopsy performed (less 18 month before inclusion), fibrosis score F2,F3 or F3+\n",
      "             in Metavir classification,\n",
      "\n",
      "          -  patients without antiviral therapy\n",
      "\n",
      "          -  contraindication to anti viral treatment\n",
      "\n",
      "          -  non responders or relapsers patients to past antiviral treatment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  hepatocellular carcinoma\n",
      "\n",
      "          -  HIV\n",
      "\n",
      "          -  alcool abuser\n",
      "\n",
      "          -  cirrhosis\n",
      "\n",
      "          -  anti-fibrotic treatment\n",
      "\n",
      "          -  pregnancy or breast feeding\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Pregnant women with uncomplicated singleton pregnancy\n",
      "\n",
      "          -  No metabolic disorders and prepregnancy BMI < 30 kg/m2\n",
      "\n",
      "          -  Intention to exclusively breast-feed for 4 mo\n",
      "\n",
      "          -  Fish intake below the Danish mean or above 80th percentile (reference group)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pre- or post term delivery (< 37 or > 43 wks of gestation)\n",
      "\n",
      "          -  Abnormal weight for gestation (outside 10th-90th percentile range)\n",
      "\n",
      "          -  Apgar score 5 min after delivery < 8\n",
      "\n",
      "          -  Infant admission to a neonatal department\n",
      "\n",
      "          -  If supplementation did not begin within 2 wks after delivery\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with locally advanced or metastatic breast cancer receiving weekly Docetaxel\n",
      "             chemotherapy with rest weeks in between at regular time intervals. The timing of rest\n",
      "             weeks between cycles is not restricted. Examples of allowed regimens are Docetaxel 36\n",
      "             mg/m2 day 1 and 8 every 3 weeks; day 1, 8, 15 every 4 weeks; day 1, 8, 15, 21, 28, 35,\n",
      "             42, 49 every 10 weeks. Dosing and rest weeks can be further modified depending on the\n",
      "             clinical situation, but dose intensity should be at least 60 mg/m2 every 3 weeks\n",
      "             during the 9 week treatments for eligibility. Combination with other chemotherapy\n",
      "             (such as capecitabine) is allowed.\n",
      "\n",
      "          -  Capability to administer eye drops (either by patient or companion).\n",
      "\n",
      "          -  Written informed consent.\n",
      "\n",
      "          -  Age > 18 y\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Systemic criteria:\n",
      "\n",
      "               -  Previous administration of Docetaxel.\n",
      "\n",
      "               -  Pregnancy.\n",
      "\n",
      "          -  Eye criteria:\n",
      "\n",
      "               -  Ocular surface, corneal, conjunctival or eyelid disease.\n",
      "\n",
      "               -  Soft contact lens wearing\n",
      "\n",
      "               -  Glaucoma\n",
      "\n",
      "          -  Lacrimal criteria:\n",
      "\n",
      "               -  Hypersecretion of tears: ocular surface, corneal, conjunctival or eyelid disease.\n",
      "\n",
      "               -  Functional blockage of lacrimal drainage without anatomical obstruction (facial\n",
      "                  nerve palsy, displacement of the lower lacrimal punctum from the lacrimal lake,\n",
      "                  involutional lower eyelid laxity).\n",
      "\n",
      "               -  Anatomical obstruction of lacrimal drainage system:\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of one of the following:\n",
      "\n",
      "               -  Relapsed or refractory acute leukemia (acute myeloid leukemia [AML], acute\n",
      "                  lymphoblastic leukemia [ALL], or acute leukemia unclassifiable) following at\n",
      "                  least one prior systemic treatment\n",
      "\n",
      "               -  Acute leukemia in a patient 60 years or older (no requirement for prior\n",
      "                  treatment)\n",
      "\n",
      "               -  Acute leukemia that has evolved from a prior myelodysplastic syndrome\n",
      "\n",
      "               -  Chronic myelogenous leukemia (CML) in blast crisis following prior imatinib\n",
      "                  mesylate therapy\n",
      "\n",
      "               -  Refractory anemia with excess blasts-2 (RAEB-2)\n",
      "\n",
      "               -  No known CNS leukemia\n",
      "\n",
      "          -  ECOG performance status 0-2\n",
      "\n",
      "          -  WBC < 50,000µL\n",
      "\n",
      "          -  Hydroxyurea and/or leukaphereses may be used to lower WBC\n",
      "\n",
      "          -  Creatinine =< 1.5 times upper limit of normal (ULN) OR creatinine clearance >= 50\n",
      "             mL/min\n",
      "\n",
      "          -  Total bilirubin =< 2 times ULN\n",
      "\n",
      "          -  AST/ALT =< 2.5 times ULN\n",
      "\n",
      "          -  QTc interval =< 0.470 seconds\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception during and for 3 months after study\n",
      "             participation\n",
      "\n",
      "          -  No other condition that would preclude study participation\n",
      "\n",
      "          -  At least 3 weeks since prior treatment (expect leukaphereses)\n",
      "\n",
      "          -  No valproic acid therapy within the past 2 weeks\n",
      "\n",
      "          -  No prior autologous or allogeneic bone marrow or stem cell transplantation\n",
      "\n",
      "          -  No hydroxyurea use within the past 24 hours\n",
      "\n",
      "          -  No concurrent treatment with other anti-cancer agents or investigational agents\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically proven in operable advanced gastric adenocarcinoma (including\n",
      "             adenocarcinoma of the gastrooesophageal junction) or relapse gastric adenocarcinoma\n",
      "\n",
      "          -  Subjects must be able to take orally\n",
      "\n",
      "          -  Measurable lesion and/or non-measurable lesion defined by RECIST\n",
      "\n",
      "          -  ECOG performance status ≦ 1\n",
      "\n",
      "          -  Hgb ≧ 8g/dL, WBC 4000-12000/mm3, platelets ≧ 100,000/mm3\n",
      "\n",
      "          -  Creatine ≦ upper normal limit (UNL)\n",
      "\n",
      "          -  Total bilirubin ≦ 1.5 X UNL\n",
      "\n",
      "          -  AST, ALT and ALP ≦ 2.5 x UNL\n",
      "\n",
      "          -  No prior chemotherapy\n",
      "\n",
      "          -  Life expectancy estimated than 3 months\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Active double cancer\n",
      "\n",
      "          -  Gastrointestinal bleeding\n",
      "\n",
      "          -  Excessive amounts of ascites require drainage\n",
      "\n",
      "          -  Known brain metastases\n",
      "\n",
      "          -  Symptomatic peripheral neuropathy ≧ garde 2. by NCI-CTCAE ver.3.0\n",
      "\n",
      "          -  Pulmonary fibrosis, Intestinal pneumonitis\n",
      "\n",
      "          -  History of hypersensitivity to fluoropyrimidines, docetaxel or medications formulated\n",
      "             with polysorbate 80\n",
      "\n",
      "          -  Any previous chemotherapy or radiotherapy for AGC\n",
      "\n",
      "          -  Pregnancy or lactation women, or women with suspected pregnancy or men with willing to\n",
      "             get pregnant\n",
      "\n",
      "          -  Treatment with any investigational product during the last 4 weeks prior to study\n",
      "             entry\n",
      "\n",
      "          -  Definite contraindications for the use of corticosteroids\n",
      "\n",
      "          -  Any subject judged by the investigator to be unfit for any reason to participate in\n",
      "             the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Veterans who are scheduled for one of the four elective surgical procedures;\n",
      "\n",
      "          -  who give informed consent to participate in the study;\n",
      "\n",
      "          -  and who are also part of the NSQIP.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Inability to give informed consent;\n",
      "\n",
      "          -  requirement for surrogate consent;\n",
      "\n",
      "          -  non-elective surgery;\n",
      "\n",
      "          -  requirement for more than one elective surgery;\n",
      "\n",
      "          -  refusal to participate;\n",
      "\n",
      "          -  inability to communicate in English;\n",
      "\n",
      "          -  severe visual problems;\n",
      "\n",
      "          -  severe psychiatric illness;\n",
      "\n",
      "          -  ongoing substance abuse.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Phase 1 (dose escalation)\n",
      "\n",
      "          -  patients with histological proven gastrointestinal neoplasms, without standard therapy\n",
      "             option\n",
      "\n",
      "          -  measurable or evaluable disease\n",
      "\n",
      "          -  >= second-line therapy (metastasized stage) Phase 2 (efficacy)\n",
      "\n",
      "          -  patients with proven colorectal neoplasms\n",
      "\n",
      "          -  measurable disease, metastasized\n",
      "\n",
      "          -  previous chemotherapy with 5-FU/FA (\"AIO-regimen\")\n",
      "\n",
      "          -  age between 18 and 75 years, both male and female\n",
      "\n",
      "          -  life expectancy > 3 months\n",
      "\n",
      "          -  WHO-performance status <= 2\n",
      "\n",
      "          -  adequate bone marrow function: hemoglobin >= 10 mg/dl, neutrophils >= 2.0 *\n",
      "             1000000000/l, thrombocytes >= 150 * 1000000000/l\n",
      "\n",
      "          -  adequate renal and liver function: bilirubin <= 1.25 * ULN(<= 1.5 ULN * by liver\n",
      "             metastases), creatinine <= 1.25 * ULN, ASAT and ALAT <= 3 * ULN (<= 5* ULN by liver\n",
      "             metastases; AP <= 3* ULN\n",
      "\n",
      "          -  written informed consent prior to inclusion into the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pretreated with mitomycin c\n",
      "\n",
      "          -  contraindication concerning 5-FU (e.g. anxiety, myocardial infarction within last 6\n",
      "             months, significant toxicities during previous therapy with 5-FU\n",
      "\n",
      "          -  florid infections\n",
      "\n",
      "          -  ileus or subileus, morbus crohn or colitis, ulcerative\n",
      "\n",
      "          -  actual chronic diarrhea\n",
      "\n",
      "          -  other uncontrolled severe concurrent disease excluding cytotoxic intervention\n",
      "\n",
      "          -  second malignancy except basal cell carcinoma or cervical carcinoma in situ\n",
      "\n",
      "          -  known cns metastases or carcinomatous leptomeningitis\n",
      "\n",
      "          -  pregnancy or lactation period\n",
      "\n",
      "          -  no effective contraception\n",
      "\n",
      "          -  concomitant treatment with another antineoplastic agents\n",
      "\n",
      "          -  participation in another clinical trial within the last 4 weeks\n",
      "\n",
      "          -  patients being unwilling or unable to undergo trial specific procedures\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Hypertensive patients with diabetes mellitus\n",
      "\n",
      "          -  Hypertensive patients\n",
      "\n",
      "          -  Hypertensive patients with renal disease\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Cardiac, hematologic or hepatic disease\n",
      "\n",
      "          -  Renal insufficiency (serum creatinine values> 2 mg/L)\n",
      "\n",
      "          -  Hormone-induced hypertension\n",
      "\n",
      "          -  Cerebral infarction or hemorrhage\n",
      "\n",
      "          -  Other major diseases\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Adult male or female over the age of 18\n",
      "\n",
      "          2. Having been diagnosed with chronic periodontitis\n",
      "\n",
      "          3. >18 fully erupted teeth\n",
      "\n",
      "          4. Has had no periodontal instrumentation in the four months prior to initiation of study\n",
      "             treatment\n",
      "\n",
      "          5. Subject has at least 4 sites with pocket depth of 6-9 mm in at least two quadrants of\n",
      "             the mouth.\n",
      "\n",
      "          6. Subject is willing and able to return for treatment and evaluation procedures\n",
      "             scheduled throughout the course of this clinical study\n",
      "\n",
      "          7. The subject is capable of giving informed consent\n",
      "\n",
      "          8. Subject is willing to sign a consent form\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Is pregnant or nursing or who plans to become pregnant in the next 4 months\n",
      "\n",
      "          2. Having significant liver disease by subject report\n",
      "\n",
      "          3. Having an active malignancy of any type by subject report\n",
      "\n",
      "          4. Having chronic disease or diminished mental capacity that would mitigate the ability\n",
      "             to comply with the protocol\n",
      "\n",
      "          5. Having any significant disease (either acute or chronic) or who is taking medication\n",
      "             with concomitant oral manifestations that in the opinion of the investigator would\n",
      "             interfere with evaluation of safety or efficacy of PerioWave®\n",
      "\n",
      "          6. Having an active periapical abscess or periodontal abscess or a history of acute\n",
      "             necrotizing ulcerative gingivitis\n",
      "\n",
      "          7. Treatment with antibiotics within the 1-month period prior to beginning the study or\n",
      "             any systemic condition which requires antibiotic coverage for routine periodontal\n",
      "             procedures (e.g. heart conditions, joint replacements, etc) by report of the subject\n",
      "\n",
      "          8. Known allergy to methylene blue\n",
      "\n",
      "          9. Has glucose-6-phosphate dehydrogenase (G6PD) deficiency by subject report\n",
      "\n",
      "         10. Currently uses anti-coagulant therapy at therapeutic doses\n",
      "\n",
      "         11. Currently uses photosensitizing medications\n",
      "\n",
      "         12. Participated in investigational treatment in the last 30 days or expectation for using\n",
      "             a separate investigational treatment during the time of the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. DSM-IV criteria for chronic schizophrenia or schizoaffective disorder\n",
      "\n",
      "          2. Sub-optimal treatment-response\n",
      "\n",
      "          3. Total score > 60 on the Positive and Negative Syndrome Scale (PANSS) at baseline of\n",
      "             run-in phase and again at baseline of double blind phase\n",
      "\n",
      "          4. Age 18-64 years old\n",
      "\n",
      "          5. Signed informed consent\n",
      "\n",
      "          6. Patient is in good general medical health\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          1. History of failure to respond to 400 mg/day or more of clozapine for 8 contiguous\n",
      "             weeks\n",
      "\n",
      "          2. History of failure to respond to quetiapine treatment at dosages > 1200 mg daily for 6\n",
      "             contiguous weeks\n",
      "\n",
      "          3. History of quetiapine intolerance (e.g., clinically significant leukopenia or\n",
      "             agranulocytosis, or severe dystonic reactions)\n",
      "\n",
      "          4. Significant recent history of violence or suicidal activity, which required > 4\n",
      "             episodes of PRN anti-agitation medication per week\n",
      "\n",
      "          5. Mental retardation\n",
      "\n",
      "          6. Depot antipsychotic within 30 days before randomization\n",
      "\n",
      "          7. Significant medical illness requiring frequent dose adjustment or medication changes\n",
      "\n",
      "        Clozapine non-responders are explicitly excluded, as they would be unlikely to show a\n",
      "        response in this study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 65 or older\n",
      "\n",
      "          -  Mini-Mental State Examination (MMSE) score 23 or greater\n",
      "\n",
      "          -  Vision scored greater than 20/50\n",
      "\n",
      "          -  Minimal dependence in hygiene, bathing, and dressing\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Significant decline in cognitive skills, physical abilities, or functional\n",
      "             independence\n",
      "\n",
      "          -  Inability to complete study activities as evidenced by MMSE and vision scores lower\n",
      "             than Inclusion Criteria requirement\n",
      "\n",
      "          -  Diagnosis of Alzheimer's disease\n",
      "\n",
      "          -  Stroke in previous 12 months\n",
      "\n",
      "          -  Cancer with limited life expectance\n",
      "\n",
      "          -  Current chemotherapy or radiation treatment\n",
      "\n",
      "          -  Communication problems\n",
      "\n",
      "          -  Planned move from study area\n",
      "\n",
      "          -  Scheduling conflicts that would preclude participation in study activities\n",
      "\n",
      "          -  Prior involvement in similar cognitive training studies\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Eighteen years of age or older (male or female).\n",
      "\n",
      "          2. If female, agreed to use suitable contraception to prevent pregnancy.\n",
      "\n",
      "          3. HIV positive as confirmed by viral load using nucleic acid sequence based\n",
      "             amplification (NASBA), or enzyme-linked immunosorbent assay (ELISA) and Western Blot,\n",
      "             for cohort A, B, C, and D. HIV negative by ELISA and Western blot for cohort E.\n",
      "\n",
      "          4. Karnofsky Performance Status score of at least 60.\n",
      "\n",
      "          5. No active opportunistic infection. Prophylaxis for MAl, CMV, Pneumocystis Pneumonia\n",
      "             except Bactrim), or herpes was permitted.\n",
      "\n",
      "          6. Current CD4 count >200.\n",
      "\n",
      "          7. Stable triple therapy antiretroviral regimen (cohorts A, B, C, and D) for the\n",
      "             preceding 8 weeks and willing to make no changes in regimen during the study.\n",
      "\n",
      "          8. Not taking any unapproved or experimental treatment for HIV, including antiretrovirals\n",
      "             and immune modulators (such as interferons or interleukins).\n",
      "\n",
      "          9. Capable and willing to provide informed consent.\n",
      "\n",
      "         10. Agreed not to take Epoetin during the trial.\n",
      "\n",
      "         11. Baseline laboratory values:\n",
      "\n",
      "        Neutrophils > 1000 cells/mm3; Platelets > 75,000 cells/mL; SGOT <3 times upper limit of\n",
      "        normal; SGPT <3 times upper limit of normal; Creatinine <2.0 mg/dL.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Known or suspected allergy to procaine hydrochloride.\n",
      "\n",
      "          2. Patients taking DHEA supplementation or oral ketoconazole (which have anticortisol\n",
      "             properties).\n",
      "\n",
      "          3. Patients using sulfonamides (including Septra/Bactrim).\n",
      "\n",
      "          4. Required use of sulfonamides, eg, Septra/Bactrim. (Procaine hydrochloride may\n",
      "             inactivate sulfonamides).\n",
      "\n",
      "          5. Patients with glaucoma using anti-cholinesterase inhibitors (Humorsol [demecarium\n",
      "             bromide] echothiophate iodide, Floropryl [isoflurophate], Isopto-Eserine\n",
      "             [physostigmine salicylate]). Anti-cholinesterase Inhibitors should not be used while\n",
      "             on procaine hydrochloride, since procaine itself has some anti-cholinesterase\n",
      "             activity.\n",
      "\n",
      "          6. Patients with less than 6 months life expectancy.\n",
      "\n",
      "          7. Patients with adrenal insufficiency (determined by screening ACTH stimulation test).\n",
      "\n",
      "          8. Patients with lymphoma.\n",
      "\n",
      "          9. Patients with active hepatitis (viral or drug induced).\n",
      "\n",
      "         10. Patients with cancer, except peripheral Kaposi's sarcoma.\n",
      "\n",
      "         11. Patients on dialysis.\n",
      "\n",
      "         12. Patients who are pregnant.\n",
      "\n",
      "         13. Female patients of childbearing age who can not use two forms of birth control or\n",
      "             abstain from sexual intercourse during the trial.\n",
      "\n",
      "         14. Any medical, psychological, psychiatric, or substance use problem that, in the opinion\n",
      "             of the Principal Investigator, interferes with the patient's ability to complete the\n",
      "             study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        HEALTHY SUBJECTS:\n",
      "\n",
      "          -  Men 21-65 years of age;\n",
      "\n",
      "          -  Premenopausal women over 21 years of age taking oral contraceptives;\n",
      "\n",
      "          -  Postmenopausal women less than 65 years of age;\n",
      "\n",
      "        CHRONIC KIDNEY DISEASE SUBJECTS:\n",
      "\n",
      "          -  Men 21-65 years of age;\n",
      "\n",
      "          -  Premenopausal women over 21 years of age taking oral contraceptives;\n",
      "\n",
      "          -  Postmenopausal women less than 65 years of age;\n",
      "\n",
      "          -  Creatinine clearance between 30 and 59 ml/min/1.73 m2 as calculated using the equation\n",
      "             derived from the Modification of Diet in Renal Disease (MDRD) study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Medications affecting bone metabolism;\n",
      "\n",
      "          -  Abnormal liver or GI function;\n",
      "\n",
      "          -  Extreme electrolyte abnormalities;\n",
      "\n",
      "          -  BMI >30 kg/m2.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        HEALTHY SUBJECTS:\n",
      "\n",
      "          -  Men 21-65 years of age;\n",
      "\n",
      "          -  Premenopausal women over 21 years of age taking oral contraceptives;\n",
      "\n",
      "          -  Postmenopausal women less than 65 years of age;\n",
      "\n",
      "        CHRONIC KIDNEY DISEASE SUBJECTS:\n",
      "\n",
      "          -  Men 21-65 years of age;\n",
      "\n",
      "          -  Premenopausal women over 21 years of age taking oral contraceptives;\n",
      "\n",
      "          -  Postmenopausal women less than 65 years of age;\n",
      "\n",
      "          -  Creatinine clearance between 30 and 59 ml/min/1.73 m2 as calculated using the equation\n",
      "             derived from the Modification of Diet in Renal Disease (MDRD) study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Medications affecting bone metabolism;\n",
      "\n",
      "          -  Abnormal liver or GI function;\n",
      "\n",
      "          -  Extreme electrolyte abnormalities;\n",
      "\n",
      "          -  BMI >30 kg/m2.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Age 18 - 75 Ejection fraction <35% Heart failure limited by fatigue and shortness of breath\n",
      "        -\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Inability to exercise. Patients with shortness of breath while resting. Patient requiring\n",
      "        intravenous medication. Patients taking the following medications: nitroglycerine\n",
      "        pill/patch/paste, isordil and Imdur\n",
      "\n",
      "        -\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients from 1 to 13 years of age that have diagnosis of bacterial conjunctivitis in\n",
      "             either or both eyes (for < 3 days duration) based on clinical observation; matched\n",
      "             healthy controls\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Cannot have had bacterial conjunctivitis symptoms as reported by parent for > 2 days\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed diagnosis of 1 of the following:\n",
      "\n",
      "               -  Malignant extracranial solid tumor\n",
      "\n",
      "                    -  Recurrent or refractory disease\n",
      "\n",
      "                    -  Known bone marrow metastases* allowed\n",
      "\n",
      "               -  Imatinib mesylate-resistant Philadelphia chromosome-positive (Ph+) acute\n",
      "                  lymphoblastic leukemia (ALL), defined as M3 bone marrow in a patient who\n",
      "                  previously received imatinib mesylate-containing treatment regimen\n",
      "\n",
      "               -  Imatinib mesylate-resistant Ph+ chronic myelogenous leukemia (CML), as defined by\n",
      "                  any of the following:\n",
      "\n",
      "                    -  Increasing WBC or platelet count while on imatinib mesylate therapy\n",
      "\n",
      "                    -  Lack of any cytogenetic response after an adequate duration of imatinib\n",
      "                       mesylate therapy, as defined by 1 of the following:\n",
      "\n",
      "                         -  Failed to achieve a complete hematologic response after completion of 3\n",
      "                            months of imatinib mesylate treatment\n",
      "\n",
      "                         -  Failed to achieve a partial or complete cytogenetic response (i.e., ≤\n",
      "                            35% Ph+ cells) after 6 months of imatinib mesylate treatment\n",
      "\n",
      "                    -  Appearance of accelerated or blastic feature while on imatinib mesylate\n",
      "                       therapy\n",
      "\n",
      "                    -  Reappearance of Ph+ clones after an initial complete cytogenetic response to\n",
      "                       imatinib mesylate\n",
      "\n",
      "                    -  More than 30% increase in Ph+ cells in peripheral blood or bone marrow\n",
      "                       cytogenetics while on imatinib mesylate therapy\n",
      "\n",
      "                    -  Imatinib mesylate intolerance, as defined by development of adverse effects\n",
      "                       requiring discontinuation of imatinib mesylate therapy\n",
      "\n",
      "          -  Measurable disease (for patients with CML or ALL)\n",
      "\n",
      "               -  Determined by hematologic, cytogenetic, and molecular studies for CML\n",
      "\n",
      "               -  Determined by bone marrow blast percentage for ALL\n",
      "\n",
      "          -  Measurable or evaluable disease (for patients with solid tumors)\n",
      "\n",
      "          -  No known curative therapy or survival-prolonging therapy with an acceptable quality of\n",
      "             life\n",
      "\n",
      "          -  No CNS solid tumors\n",
      "\n",
      "               -  CNS-positive leukemia allowed\n",
      "\n",
      "          -  Karnofsky performance status (PS) ≥ 50% (for patients > 10 years of age)\n",
      "\n",
      "          -  Lansky PS ≥ 50% (for patients ≤ 10 years of age)\n",
      "\n",
      "          -  No evidence of graft-vs-host disease\n",
      "\n",
      "          -  Solid tumors:\n",
      "\n",
      "               -  Absolute neutrophil count ≥ 1,000/mm^3 (750/mm^3 if bone marrow infiltration)\n",
      "\n",
      "               -  Platelet count ≥ 100,000/mm^3 (transfusion independent) (50,000/mm^3 if bone\n",
      "                  marrow infiltration)\n",
      "\n",
      "               -  Hemoglobin ≥ 8.0 g/dL (red blood cell [RBC] transfusions allowed)\n",
      "\n",
      "          -  ALL/CML:\n",
      "\n",
      "               -  Platelet count ≥ 20,000/mm^3 (platelet transfusions allowed)\n",
      "\n",
      "               -  Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)\n",
      "\n",
      "          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR\n",
      "             creatinine based on age, as follows:\n",
      "\n",
      "               -  No greater than 0.6 mg/dL (1-23 months of age)\n",
      "\n",
      "               -  No greater than 0.8 mg/dL (2- 5 years of age)\n",
      "\n",
      "               -  No greater than 1.0 mg/dL (6-9 years of age)\n",
      "\n",
      "               -  No greater than 1.2 mg/dL (10-12 years of age)\n",
      "\n",
      "               -  No greater than 1.4 mg/dL (13 years of age and over [female])\n",
      "\n",
      "               -  No greater than 1.5 mg/dL (13-15 years of age [male])\n",
      "\n",
      "               -  No greater than 1.7 mg/dL (16 years of age and over [male])\n",
      "\n",
      "          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n",
      "\n",
      "          -  ALT ≤ 110 U/L\n",
      "\n",
      "          -  Albumin ≥ 2 g/dL\n",
      "\n",
      "          -  Normal 12-lead EKG with corrected QTc < 450 msec AND meets 1 of the following\n",
      "             criteria:\n",
      "\n",
      "               -  Shortening fraction normal\n",
      "\n",
      "               -  Ejection fraction normal\n",
      "\n",
      "          -  No evidence of dyspnea at rest\n",
      "\n",
      "          -  No exercise intolerance\n",
      "\n",
      "          -  Pulse oximetry > 94% if there is a clinical indication for determination\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception\n",
      "\n",
      "          -  No uncontrolled infection\n",
      "\n",
      "          -  No swallowing dysfunction that would prevent taking an oral or liquid medication\n",
      "\n",
      "          -  See Disease Characteristics\n",
      "\n",
      "          -  Recovered from prior chemotherapy, immunotherapy, or radiotherapy\n",
      "\n",
      "          -  No myelosuppressive chemotherapy within the past 3 weeks (6 weeks for nitrosoureas)\n",
      "\n",
      "          -  At least 7 days since prior growth factors\n",
      "\n",
      "          -  At least 14 days since prior pegfilgrastim\n",
      "\n",
      "          -  At least 7 days since prior biologic agents\n",
      "\n",
      "          -  At least 2 weeks since prior local small-port palliative radiotherapy\n",
      "\n",
      "          -  At least 3 months since prior total-body irradiation, craniospinal radiation, or\n",
      "             radiation to ≥ 50% of the pelvis\n",
      "\n",
      "          -  At least 6 weeks since other prior substantial bone marrow radiation\n",
      "\n",
      "          -  At least 3 months since prior stem cell transplantation\n",
      "\n",
      "          -  Hydroxyurea cytoreduction for Ph+ leukemia allowed provided it is discontinued 24\n",
      "             hours before first dose of dasatinib\n",
      "\n",
      "          -  Prior intrathecal (IT) therapy allowed (for patients with CNS-positive leukemia)\n",
      "\n",
      "          -  Concurrent IT therapy comprising hydrocortisone, cytarabine, methotrexate, or\n",
      "             cytarabine (liposomal) allowed (for patients with CNS-positive leukemia)\n",
      "\n",
      "          -  No other concurrent investigational drugs\n",
      "\n",
      "          -  No other concurrent anticancer agents, including chemotherapy, radiotherapy,\n",
      "             immunotherapy, or biologic therapy\n",
      "\n",
      "          -  No concurrent enzyme-inducing anticonvulsants, including any of the following:\n",
      "\n",
      "               -  Phenytoin\n",
      "\n",
      "               -  Phenobarbital\n",
      "\n",
      "               -  Carbamazepine\n",
      "\n",
      "               -  Felbamate\n",
      "\n",
      "               -  Primdone\n",
      "\n",
      "               -  Oxcarbazepine\n",
      "\n",
      "          -  No concurrent antithrombotic or antiplatelet agents, including any of the following:\n",
      "\n",
      "               -  Warfarin\n",
      "\n",
      "               -  Heparin\n",
      "\n",
      "               -  Low-molecular weight heparin\n",
      "\n",
      "               -  Aspirin\n",
      "\n",
      "               -  Ibuprofen\n",
      "\n",
      "               -  Other nonsteroidal anti-inflammatory drugs\n",
      "\n",
      "          -  No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, and\n",
      "             voriconazole\n",
      "\n",
      "          -  No concurrent highly active antiretroviral treatment for HIV-positive patients\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patient is undergoing in-vitro fertilization protocol (both IVF and intracytoplasmic\n",
      "             sperm injection - ICSI)\n",
      "\n",
      "          -  Patient is acupuncture naïve.\n",
      "\n",
      "          -  Patient has basal serum follicle-stimulating hormone (FSH) < 10\n",
      "\n",
      "          -  Patient has given informed consent to participate in study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient has had acupuncture performed previously or currently\n",
      "\n",
      "          -  Patient has basal serum FSH of 10 or more\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Survival for Malignant Germ Cell Tumors in Males and Females.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        VA Pittsburgh Healthcare System, Philadelphia VA Medical Center, Louis Stokes Cleveland\n",
      "        VAMC, AA primary care patients > age 50 who meet clinical criteria for knee OA (i.e.,\n",
      "        chronic, frequent knee pain based on the NHANES questions, WOMAC score = 39, and\n",
      "        radiographic evidence of knee OA with K-L grade =2) are eligible for enrollment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have prior history of any:\n",
      "\n",
      "               -  major joint replacement\n",
      "\n",
      "               -  terminal illness (e.g., end-stage cancer)\n",
      "\n",
      "               -  physician-diagnosed inflammatory arthritis (i.e., rheumatoid arthritis,\n",
      "                  connective tissue disease, ankylosing spondylitis or other seronegative\n",
      "                  spondyloarthropathy)\n",
      "\n",
      "               -  contra-indications to replacement surgery (e.g., lower extremity paralysis as\n",
      "                  result of stroke)\n",
      "\n",
      "          -  Patients who are not willing to be randomized\n",
      "\n",
      "          -  Do not have the presence of knee OA\n",
      "\n",
      "          -  Do not have telephone service\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Males or females, 18 years of age or older.\n",
      "\n",
      "          -  Acute ischemic cerebral stroke (IS) with uncontrollable hypertension that may need to\n",
      "             be controlled for the purpose of considering thrombolytic therapy or anticoagulation\n",
      "             therapy.\n",
      "\n",
      "          -  Intracerebral hemorrhagic (ICH) stroke patients, including subarachnoid hemorrhage\n",
      "             (SAH) (surgically treated or not), any territory with an appropriate study (head CT\n",
      "             scan or MRI scan) providing results consistent with this diagnosis, who may require\n",
      "             the control of hypertension or control of blood pressure.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Allergy to Nicardipine or known hypersensitivity to Nicardipine.\n",
      "\n",
      "          -  Chronic renal failure or Creatinine blood sample levels> 2.0.\n",
      "\n",
      "          -  Impaired hepatic function defined as a two times value of liver enzymes.\n",
      "\n",
      "          -  Severe left ventricular dysfunction defined as ventricular ejection fraction < 30%.\n",
      "\n",
      "          -  Patients or authorized representative who refused be enrolled into this study.\n",
      "\n",
      "          -  Advanced aortic stenosis.\n",
      "\n",
      "          -  Pregnant or nursing women will not be enrolled in this study.\n",
      "\n",
      "          -  No patient will be allowed to be enrolled in this study more than once.\n",
      "\n",
      "          -  Patients may not be enrolled into other clinical studies during their involvement with\n",
      "             this study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age ≥ 18 years\n",
      "\n",
      "          2. Histologic diagnosis of adenocarcinoma of the prostate.\n",
      "\n",
      "          3. Metastatic disease on chest X-ray, bone scan, or computed tomography (CT) scan.\n",
      "\n",
      "          4. Failed after receiving a minimum of two cycles of a docetaxel based first line therapy\n",
      "             regimen. Failure is defined as disease progression within 6 months of discontinuing\n",
      "             first line docetaxel therapy. Disease progression is defined as one or more of the\n",
      "             following:\n",
      "\n",
      "               -  Progressive measurable (target) disease (by Response Evaluation Criteria in Solid\n",
      "                  Tumors [RECIST] criteria): at least a 20% increase in the sum of the longest\n",
      "                  diameters of measurable lesions (organ masses or lymph nodes) over the smallest\n",
      "                  sum observed (baseline or nadir) or the appearance of one or more new lesions as\n",
      "                  assessed by CT scan or chest X-ray.\n",
      "\n",
      "               -  Bone scan progression: one or more new lesions on bone scan while on or following\n",
      "                  docetaxel treatment.\n",
      "\n",
      "               -  Increasing serum PSA level: rise in PSA on three consecutive measurements\n",
      "                  obtained at least one week apart. If the third PSA value is less than the second,\n",
      "                  an additional fourth test to confirm a rising PSA will be acceptable.\n",
      "\n",
      "          5. Baseline laboratory values as stated below:\n",
      "\n",
      "               -  Creatinine ≤ 1.5 x upper limit of normal (ULN)\n",
      "\n",
      "               -  Bilirubin ≤ 1.1 x ULN (unless elevated secondary to conditions such as Gilbert's\n",
      "                  disease)\n",
      "\n",
      "               -  SGOT (AST) ≤ 1.5 x ULN\n",
      "\n",
      "               -  Castrate serum testosterone level (< 50 ng/mL-or-< 1.7 mmol/L).\n",
      "\n",
      "          6. If not treated with bilateral orchiectomy, patients must be willing to continue\n",
      "             luteinizing hormone releasing hormone analogues throughout the study.\n",
      "\n",
      "          7. Adequate bone marrow function defined as absolute neutrophil count (ANC) ≥ 1.5 x 10^9\n",
      "             cells/L and platelet count ≥ 100 x 10^9/L.\n",
      "\n",
      "          8. Karnofsky score ≥ 60\n",
      "\n",
      "          9. Received no other chemotherapy, radioisotope therapy, strontium 89, or samarium 153.\n",
      "             (Prior radiotherapy and steroids following first line docetaxel therapy are allowed.)\n",
      "\n",
      "         10. Received no more than one prior biological response modifier therapy following first\n",
      "             line docetaxel therapy.\n",
      "\n",
      "         11. At least 21 days since completing the last dose of docetaxel, biological response\n",
      "             modifier, and/or radiotherapy. (Exception for radiotherapy: at least 7 days since\n",
      "             completing a single fraction of ≤ 800 cGy to a restricted field.)\n",
      "\n",
      "         12. Has recovered from all therapy related toxicity to ≤ grade 2, (except alopecia and\n",
      "             anemia.)\n",
      "\n",
      "         13. Willing and able to give informed consent and follow protocol requirements.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Life expectancy less than 12 weeks.\n",
      "\n",
      "          2. Patient is beyond 6 months following the last dose of docetaxel.\n",
      "\n",
      "          3. Patient could not tolerate a dose of docetaxel of at least 45 mg/m² at the end of\n",
      "             first line therapy due to toxicity.\n",
      "\n",
      "          4. History of or current documented brain metastasis or carcinomatous meningitis, treated\n",
      "             or untreated. (Brain imaging in asymptomatic patients is not required.)\n",
      "\n",
      "          5. Current symptomatic cord compression requiring surgery or radiation therapy. (Once\n",
      "             treated, patients are eligible for the study.)\n",
      "\n",
      "          6. Active second malignancy (except non melanomatous skin or superficial bladder cancer).\n",
      "\n",
      "          7. Prior radiotherapy to > 25% of the bone marrow.\n",
      "\n",
      "          8. Uncontrolled medical conditions such as a major active infection, myocardial\n",
      "             infarction or stroke within 3 months, uncontrolled hypertension, and/or significant\n",
      "             concurrent medical illness, that, in the opinion of the Investigator, would preclude\n",
      "             protocol therapy.\n",
      "\n",
      "          9. History of or active congestive heart failure.\n",
      "\n",
      "         10. Known allergy or hypersensitivity to docetaxel or polysorbate 80 (diluent).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Fulfill the criteria of schizophrenia according to the Diagnostic and Statistic\n",
      "             Manual, fourth edition (DSM-IV).\n",
      "\n",
      "          -  Free from antipsychotics for at least 7 days before enrollment.\n",
      "\n",
      "          -  Agree to participate in the study and provide informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Meet DSM-IV criteria of major mood disorder, current substance dependence or mental\n",
      "             retardation\n",
      "\n",
      "          -  History of epilepsy, head trauma or CNS diseases\n",
      "\n",
      "          -  Major, untreated medical diseases\n",
      "\n",
      "          -  Pregnancy or lactation\n",
      "\n",
      "          -  Receiving psychotropic agents or depot within three months prior to study entry\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Primipara\n",
      "\n",
      "          -  Healthy mother and child\n",
      "\n",
      "          -  Danish speaking\n",
      "\n",
      "          -  Perineal laceration or episiotomy that can be sutured by a midwife.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Large perineal lacerations\n",
      "\n",
      "          -  Heavy bleeding after childbirth\n",
      "\n",
      "          -  No need for pain relief\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Signed written informed consent,\n",
      "\n",
      "          -  20 to 75 years old,\n",
      "\n",
      "          -  Plan to undergo coronary angiography (CAG) or Percutaneous coronary intervention (PCI)\n",
      "             and LDL-C ≥ 140 mg/dL (untreated patients) or LDL-C ≥ 100 mg/dL (treated patients)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Acute myocardial infarction within 72 hours after the onset,\n",
      "\n",
      "          -  Heart failure of New York Heart Association (NYHA) Class III or above,\n",
      "\n",
      "          -  Serious arrhythmia,\n",
      "\n",
      "          -  Being treated with LDL-apheresis\n",
      "\n",
      "          -  History of serious reaction or hypersensitivity to other HMG-CoA reductase inhibitors.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed adenocarcinoma of the prostate\n",
      "\n",
      "          -  Progressive metastatic disease (i.e., positive bone scan or measurable disease)\n",
      "             despite castrate levels of testosterone (either from orchiectomy or luteinizing\n",
      "             hormone-releasing hormone [LHRH] agonist therapy)\n",
      "\n",
      "               -  Progressive disease after discontinuing hormonal therapy\n",
      "\n",
      "               -  Progressive disease is based on any of the following*:\n",
      "\n",
      "                    -  Transaxial imaging\n",
      "\n",
      "                    -  Rise in prostate-specific antigen (PSA)\n",
      "\n",
      "                    -  Radionuclide bone scan (must show new metastatic lesions)\n",
      "\n",
      "          -  Nonmeasurable or measurable disease\n",
      "\n",
      "               -  For measurable disease, progression is defined by RECIST criteria\n",
      "\n",
      "               -  Positive bone scan and elevated PSA required for nonmeasurable disease\n",
      "\n",
      "                    -  PSA evidence of progressive prostate cancer during or after first-line\n",
      "                       chemotherapy consists of a PSA level ≥ 2 ng/mL that has risen on ≥ 2\n",
      "                       successive occasions ≥ 1 week apart\n",
      "\n",
      "          -  Received ≥ 3 prior courses of paclitaxel- or docetaxel-based therapy, with disease\n",
      "             progression documented during therapy or after cessation of therapy\n",
      "\n",
      "               -  No more than 1 prior chemotherapy regimen\n",
      "\n",
      "               -  Re-treatment with the same taxane-based regimen allowed\n",
      "\n",
      "               -  Changes in prior chemotherapy regimen (addition of other agents) for disease\n",
      "                  progression are considered 2 chemotherapy regimens, and are not allowed\n",
      "\n",
      "          -  PSA ≥ 2 ng/mL\n",
      "\n",
      "          -  Testosterone < 50 ng/dL\n",
      "\n",
      "               -  Patients must continue primary androgen deprivation with LHRH analogue if they\n",
      "                  have not undergone orchiectomy\n",
      "\n",
      "          -  No known active brain metastases\n",
      "\n",
      "          -  ECOG performance status 0-2\n",
      "\n",
      "          -  Life expectancy ≥ 12 weeks\n",
      "\n",
      "          -  Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance > 40 mL/min\n",
      "\n",
      "          -  ALT and AST < 2.5 times ULN\n",
      "\n",
      "          -  Granulocyte count ≥ 2,000/mm³\n",
      "\n",
      "          -  Platelet count ≥ 100,000/mm³\n",
      "\n",
      "          -  Bilirubin < 1.5 times ULN\n",
      "\n",
      "          -  Ejection fraction normal by MUGA scan or echocardiogram\n",
      "\n",
      "          -  No significant cardiovascular disease, including any of the following:\n",
      "\n",
      "               -  Congestive heart failure (New York Heart Association class III-IV heart disease)\n",
      "\n",
      "               -  Active angina pectoris\n",
      "\n",
      "               -  Myocardial infarction within the past 6 months\n",
      "\n",
      "          -  No serious infections or nonmalignant medical illnesses that are uncontrolled or whose\n",
      "             control may be jeopardized by study therapy\n",
      "\n",
      "          -  No psychiatric illness or social situation that would preclude study compliance\n",
      "\n",
      "          -  No pre-existing motor or sensory peripheral neuropathy > grade 1\n",
      "\n",
      "          -  No known prior severe hypersensitivity reactions to agents containing Cremophor® EL\n",
      "\n",
      "          -  No \"currently active\" second malignancy other than nonmelanoma skin cancer\n",
      "\n",
      "               -  Patients are not considered to have a \"currently active\" malignancy if they have\n",
      "                  completed therapy and are considered to be at < 30% risk of relapse\n",
      "\n",
      "          -  Fertile patients must use effective contraception prior to, during, and for 3 months\n",
      "             after completion of study treatment\n",
      "\n",
      "          -  See Disease Characteristics\n",
      "\n",
      "          -  No prior mitoxantrone hydrochloride, ixabepilone, or other epothilones\n",
      "\n",
      "          -  At least 4 weeks since prior hormonal therapy (i.e., any dose of megestrol,\n",
      "             finasteride, or any herbal product known to decrease PSA levels [e.g., saw palmetto or\n",
      "             PC-SPES]) other than LHRH agonist or a stable dose of corticosteroids from a prior\n",
      "             chemotherapy regimen\n",
      "\n",
      "          -  More than 4 weeks since other prior systemic therapies for prostate cancer\n",
      "\n",
      "          -  At least 4 weeks since prior radiation therapy\n",
      "\n",
      "          -  More than 8 weeks since prior radiopharmaceuticals (e.g., strontium chloride Sr 89 or\n",
      "             samarium Sm 153 lexidronam pentasodium)\n",
      "\n",
      "          -  No concurrent moderate to strong CYP3A4 inhibitors\n",
      "\n",
      "          -  No concurrent prophylactic colony-stimulating factors\n",
      "\n",
      "          -  No concurrent radiotherapy\n",
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "        Consecutive patients admitted with the diagnosis of preterm labor/contractions or PROM.\n",
      "\n",
      "        \"Preterm labor/contractions\" will be defined as:\n",
      "\n",
      "          1. gestational age: 20-36 weeks;\n",
      "\n",
      "          2. intact membranes; and\n",
      "\n",
      "          3. regular uterine contractions greater than or equal to 8 in 60 minutes.\n",
      "\n",
      "        Preterm PROM will be defined as:\n",
      "\n",
      "          1. gestational age 20-36 weeks; and\n",
      "\n",
      "          2. spontaneous rupture of membranes as diagnosed by sterile speculum examination\n",
      "             confirming pooling of amniotic fluid in the vagina, a positive Nitrazine test result,\n",
      "             and a positive ferning test result. In cases of suspected but unconfirmed preterm\n",
      "             PROM, indigo carmin instillation will be performed. The vaginal leakage of indigo\n",
      "             carmin will confirm the diagnosis in these cases.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy young adult males with myopia <-8D\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Best corrected visual acuity <6/9\n",
      "\n",
      "          -  Previous intraocular surgery\n",
      "\n",
      "          -  Intraocular pressure >21mmHg\n",
      "\n",
      "          -  Gonioscopic findings of angle closure\n",
      "\n",
      "          -  Clinical evidence of pseudo-exfoliation, uveitis or pigment dispersion syndrome,\n",
      "             corneal or media opacities, retinal pathology or neurological diseases\n",
      "\n",
      "          -  Family history in a first degree relative of glaucoma or other optic neuropathy.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Women at any age with early stage breast cancer (stage I-II) and American Society of\n",
      "             Anesthesiologists (ASA) score of I-II.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Ductal carcinoma in situ (DCIS; stage 0 cancer),\n",
      "\n",
      "          -  Advanced or distant metastatic stage,\n",
      "\n",
      "          -  Receiving any neoadjuvant therapy,\n",
      "\n",
      "          -  History of receiving any antibiotics within prior 3 months,\n",
      "\n",
      "          -  History of immunodeficiency,\n",
      "\n",
      "          -  Having a remote infection,\n",
      "\n",
      "          -  History of reaction to study antibiotics,\n",
      "\n",
      "          -  Denial of signing the consent form.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically or cytologically confirmed diagnosis of 1 of the following:\n",
      "\n",
      "               -  Relapsed or refractory acute myeloid leukemia (AML)\n",
      "\n",
      "                    -  Patients with acute promyelocytic leukemia t(15;17) must have failed prior\n",
      "                       tretinoin and arsenic trioxide-containing regimen\n",
      "\n",
      "                         -  Must be refractory to both agents with absence of durable hematologic\n",
      "                            response OR relapsed after a complete response duration of < 6 months\n",
      "\n",
      "               -  Relapsed or refractory acute lymphoblastic leukemia\n",
      "\n",
      "               -  Chronic myelogenous leukemia in accelerated or blastic phase\n",
      "\n",
      "                    -  Must be refractory to treatment with imatinib mesylate or dasatinib\n",
      "\n",
      "                         -  Disease progression despite continued treatment with imatinib mesylate\n",
      "                            or dasatinib\n",
      "\n",
      "                    -  Patients in accelerated or blastic phase are eligible if unable to tolerate\n",
      "                       imatinib mesylate provided their disease has progressed on dasatinib or if\n",
      "                       unable to tolerate dasatinib\n",
      "\n",
      "               -  AML arising in the setting of underlying myelodysplastic syndromes (MDS) and/or\n",
      "                  myeloproliferative disorders (MPD)\n",
      "\n",
      "               -  Secondary or therapy-related AML\n",
      "\n",
      "          -  No active CNS leukemia\n",
      "\n",
      "          -  Leukostasis OR leukemic blast count > 50,000/mm³ allowed provided patient is treated\n",
      "             with emergency leukapheresis or hydroxyurea to reduce leukemic blast count to <\n",
      "             30,000/mm³\n",
      "\n",
      "          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%\n",
      "\n",
      "          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n",
      "\n",
      "          -  AST and ALT ≤ 2.5 times ULN\n",
      "\n",
      "          -  Creatinine ≤ 2.0 mg/dL\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception\n",
      "\n",
      "          -  No history of cytarabine-related neurotoxicity\n",
      "\n",
      "          -  No history of allergic reactions attributed to compounds of similar chemical or\n",
      "             biologic composition to vorinostat (SAHA) or other agents used in the study\n",
      "\n",
      "          -  No other uncontrolled illness, including, but not limited to, any of the following:\n",
      "\n",
      "               -  Symptomatic congestive heart failure\n",
      "\n",
      "               -  Unstable angina pectoris\n",
      "\n",
      "               -  Cardiac arrhythmia\n",
      "\n",
      "               -  Psychiatric illness or social situation that would preclude compliance with study\n",
      "                  requirements\n",
      "\n",
      "          -  Infection allowed provided patient is receiving active treatment\n",
      "\n",
      "          -  No HIV positivity\n",
      "\n",
      "          -  See Disease Characteristics\n",
      "\n",
      "          -  Recovered from prior therapy\n",
      "\n",
      "               -  Persistent alopecia, fingernail discoloration, or hematologic abnormalities\n",
      "                  (primarily related to underlying disease) > 4 weeks after last course of\n",
      "                  chemotherapy or radiotherapy does not exclude patient\n",
      "\n",
      "          -  At least 2 weeks since prior valproic acid or any other histone deacetylase inhibitor\n",
      "\n",
      "          -  No more than 3 prior courses of induction/reinduction chemotherapy, including\n",
      "             induction and consolidation therapy or induction therapy after any bone marrow\n",
      "             transplantation or similar procedure\n",
      "\n",
      "               -  Prior low-dose azacitidine, growth factors, cytokines, thalidomide, interferon,\n",
      "                  or imatinib mesylate for treatment of preceding MDS/MPD do not count as prior\n",
      "                  induction/reinduction therapy\n",
      "\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas [e.g., carmustine]\n",
      "             or mitomycin C) or radiotherapy\n",
      "\n",
      "          -  At least 24 hours since prior hydroxyurea\n",
      "\n",
      "          -  At least 2 weeks since prior imatinib mesylate, hematopoietic growth factors, and\n",
      "             biological agents\n",
      "\n",
      "          -  At least 4 weeks since prior autologous stem cell transplantation\n",
      "\n",
      "          -  Prior allogeneic stem cell transplantation allowed if all of the following criteria\n",
      "             are met:\n",
      "\n",
      "               -  At least 90 days since prior transplant\n",
      "\n",
      "               -  No evidence of graft-vs-host disease\n",
      "\n",
      "               -  At least 2 weeks since prior immunosuppressive therapy\n",
      "\n",
      "          -  No other concurrent anticancer agents or therapies\n",
      "\n",
      "          -  No other concurrent investigational agents\n",
      "\n",
      "          -  Concurrent hydroxyurea or leukapheresis allowed on days 1-10 of study treatment to\n",
      "             control rising leukemic blasts (blasts > 30,000/mm³) or leukostasis\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  > 6 years of age.\n",
      "\n",
      "          -  Documented sweat chloride greater than 60 mEq/mL by quantitative pilocarpine\n",
      "             iontophoresis test or homozygous for deltaF508 genetic mutation (or heterozygous for\n",
      "             two well-characterized mutations) and one or more clinical features consistent with\n",
      "             CF.\n",
      "\n",
      "          -  Most recent FEV1 between 25% and 75% predicted when clinically stable; must be\n",
      "             obtained at or within 3 months prior to study visit.\n",
      "\n",
      "          -  P. aeruginosa present in the most recent sputum or throat culture obtained within 6\n",
      "             months prior to study visit.\n",
      "\n",
      "          -  Able to expectorate sputum on a routine basis.\n",
      "\n",
      "          -  Written informed consent provided.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Administration of any anti-pseudomonal antibiotics by any route within 14 days prior\n",
      "             to study visit.\n",
      "\n",
      "          -  Participation in a research protocol that potentially involves antibiotic treatment\n",
      "             within 14 days prior to study visit.\n",
      "\n",
      "          -  Requiring treatment with intravenous or inhaled anti-pseudomonal antibiotics at study\n",
      "             visit.\n",
      "\n",
      "          -  B. cepacia complex present in the most recent sputum or throat culture obtained within\n",
      "             6 months prior to study visit.\n",
      "\n",
      "          -  Post lung transplantation.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Part 1: Preterm newborns (>1 week postnatal age, gestational age> 23 weeks, birth weight\n",
      "        <1000g), intubated and mechanically ventilated, and breathing spontaneously. Infants should\n",
      "        be breathing on a triggered mode of ventilation (SIMV, assist control, or pressure support)\n",
      "        with the following ventilator parameters: assist control/pressure support < 20 cm H2O,\n",
      "        PEEP4-7 cm H2O, SIMV rate< 30, FIO2<40%/.\n",
      "\n",
      "        Part 2:Newborns recovering from respiratory illness and deemed to be ready for elective\n",
      "        extubation by their attending physician, intubated and mechanically ventilated, and\n",
      "        breathing spontaneously.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Protocols 1 and 2: Pneumothorax, degenerative neuromuscular disease, bleeding disorders,\n",
      "        cardiovascular instability (defined as hypotension or need for treatment with volume\n",
      "        expansion or inotropes in the previous 24 hours), cyanotic congenital cardiovascular\n",
      "        disease, treatment with narcotics, phrenic nerve damage/diaphragm paralysis, esophageal\n",
      "        perforation, use of high frequency oscillatory ventilation\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Exacerbation of COPD\n",
      "\n",
      "          -  Age >= 75 years\n",
      "\n",
      "          -  Living in hospital catchment area\n",
      "\n",
      "          -  Informed consent\n",
      "\n",
      "          -  Adequate social or familial support\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients requiring assisted ventilation or intensive monitoring\n",
      "\n",
      "          -  History of dementia\n",
      "\n",
      "          -  Severe renal or hepatic failure\n",
      "\n",
      "          -  Cancer\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        All trauma patients with ongoing significant haemorrhage (systolic blood pressure less than\n",
      "        90 mmHg and/or heart rate more than 110 beats per minute), or who are considered to be at\n",
      "        risk of significant haemorrhage, and are within 8 hours of the injury, are eligible for\n",
      "        trial entry if they appear to be at least 16 years old. Although entry is allowed up to 8\n",
      "        hours from injury, the earlier that patients can be treated the better.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        The fundamental eligibility criterion is the responsible doctor's 'uncertainty' as to\n",
      "        whether or not to use an antifibrinolytic agent in a particular adult with traumatic\n",
      "        haemorrhage. Patients for whom the responsible doctor considers there is a clear indication\n",
      "        for antifibrinolytic therapy should not be randomised. Likewise, patients for whom there is\n",
      "        considered to be a clear contraindication to antifibrinolytic therapy (such as, perhaps,\n",
      "        those who have clinical evidence of a thrombotic disseminated intravascular coagulation)\n",
      "        should not be randomised. Where the responsible doctor is substantially uncertain as to\n",
      "        whether or not to use an antifibrinolytic, all these patients are eligible for\n",
      "        randomisation and should be considered for the trial. There are no other pre-specified\n",
      "        exclusion criteria\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  preoperative PSA>20ng/ml\n",
      "\n",
      "          -  postoperative PSA >0.2 ng/ml\n",
      "\n",
      "          -  Gleason > 7\n",
      "\n",
      "          -  pT3b\n",
      "\n",
      "          -  signated infomed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  neoadjuvant hormonaltherapy before RP\n",
      "\n",
      "          -  R1 RP\n",
      "\n",
      "          -  N+ RP\n",
      "\n",
      "          -  unstable cncomitant conditions\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Good general health\n",
      "\n",
      "          -  Available for the duration of the study\n",
      "\n",
      "          -  Willing to use acceptable forms of contraception for the duration of the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney\n",
      "             disease\n",
      "\n",
      "          -  Behavioral, cognitive, or psychiatric disease that, in the opinion of the\n",
      "             investigator, may interfere with the study\n",
      "\n",
      "          -  Significant laboratory abnormalities\n",
      "\n",
      "          -  Medical, work, or family problems as a result of alcohol or illegal drug use within 12\n",
      "             months prior to study entry\n",
      "\n",
      "          -  History of severe allergic reaction or anaphylaxis\n",
      "\n",
      "          -  Emergency room visit or hospitalization for severe asthma within 6 months prior to\n",
      "             study entry\n",
      "\n",
      "          -  HIV-1 infected\n",
      "\n",
      "          -  Hepatitis C virus (HCV) infected\n",
      "\n",
      "          -  Hepatitis B surface antigen positive\n",
      "\n",
      "          -  Immunodeficiency syndrome\n",
      "\n",
      "          -  Use of corticosteroids or immunosuppressive medications within 30 days prior to study\n",
      "             entry. Participants using topical or nasal corticosteroids are not excluded.\n",
      "\n",
      "          -  Live vaccine within 4 weeks prior to study entry\n",
      "\n",
      "          -  Killed vaccine within 2 weeks prior to study entry\n",
      "\n",
      "          -  Absence of spleen\n",
      "\n",
      "          -  Blood products within 6 months prior to study entry\n",
      "\n",
      "          -  Previous dengue virus or other flavivirus (e.g., yellow fever virus, St. Louis\n",
      "             encephalitis, West Nile virus) infection\n",
      "\n",
      "          -  Previously received yellow fever or dengue vaccine\n",
      "\n",
      "          -  Plans to travel to an area where dengue infection is common\n",
      "\n",
      "          -  Received an investigational agent within 30 days prior to study entry\n",
      "\n",
      "          -  Other condition that, in the opinion of the investigator, would interfere with the\n",
      "             study\n",
      "\n",
      "          -  Pregnancy or breastfeeding\n",
      "      \n",
      "\n",
      "        This study will only enroll the Surgeons of the Vanderbilt Hand and Upper Extremity Center.\n",
      "        There will be no inclusion/exclusion criteria for the type of surgery that will be\n",
      "        monitored, nor the patients that are having surgery. If a mini c-arm fluoroscopy is used\n",
      "        the amount of radiation received by the Surgeon's hand for that surgery will be monitored\n",
      "        by a gas-sterilized radiation ring dosimeter. The amount of scatter radiation the Surgeon\n",
      "        will be exposed to will be recorded by a badge dosimeter located on the Surgeon's scrub\n",
      "        collar, and one badge dosimeter that will be located under the required lead gown worn by\n",
      "        the Surgeon.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients age 18 years or older at time of consent\n",
      "\n",
      "          -  Patients with clinical symptoms suggesting ischemic heart disease or having evidence\n",
      "             of myocardial ischemia and scheduled for clinically indicated percutaneous\n",
      "             revascularization\n",
      "\n",
      "          -  Eligibility and consent to undergo PCI procedure\n",
      "\n",
      "          -  Patient is an acceptable candidate for percutaneous transluminal coronary\n",
      "             angioplasty,stenting,and emergency coronary artery bypass grafting\n",
      "\n",
      "          -  Willing and able to sign informed consent form approved by local IRB/Ethics Committee\n",
      "             and to follow protocol, including 6-month follow-up angiography\n",
      "\n",
      "          -  At least 1 target segment meeting definition of non-acute total coronary occlusion\n",
      "\n",
      "          -  High-grade native coronary stenosis\n",
      "\n",
      "          -  Thrombolysis in Myocardial Infarction 0 or 1 antegrade flow\n",
      "\n",
      "          -  Target occlusion successfully crossed with commercially available coronary guidewire\n",
      "\n",
      "          -  Occluded segment suitable for placement of coronary stents\n",
      "\n",
      "          -  Treated segment can accommodate 3.0mm or greater diameter balloon\n",
      "\n",
      "          -  Segment not beyond severe tortuosity (45° or more) or excessively distal location\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients undergoing treatment of a non-target vessel that is also a total coronary\n",
      "             occlusion\n",
      "\n",
      "          -  Patients with any history of allergy to iodinated contrast that cannot be effectively\n",
      "             managed medically, or any known allergy to clopidogrel bisulfate (Plavix®), aspirin,\n",
      "             heparin, ticlopidine, stainless steel, or sirolimus\n",
      "\n",
      "          -  Evidence of acute myocardial infarction within 72 hours of intended treatment (Q-wave\n",
      "             or non-Q-wave myocardial infarction having creatine kinase enzymes 2X the upper limit\n",
      "             of normal with presence of a creatine kinase myocardial-band isoenzyme above\n",
      "             Institution's ULN, or troponin above the Institution's ULN)\n",
      "\n",
      "          -  Previous coronary interventional procedure of any kind within 3 months prior to the\n",
      "             procedure in target vessel\n",
      "\n",
      "          -  Planned interventional treatment of either target or any non-target vessel within 30\n",
      "             days post-procedure with a bare metal or Cypher® sirolimus eluting coronary stent\n",
      "\n",
      "          -  Planned interventional treatment of either the target or any non-target vessel within\n",
      "             6 months post-procedure with a paclitaxel-eluting TAXUSTM stent\n",
      "\n",
      "          -  Any contraindication to cardiac catheterization or to any standard concomitant\n",
      "             therapies used during routine cardiac catheterization and PCI\n",
      "\n",
      "          -  Target lesion requires planned treatment with a device after successful crossing other\n",
      "             than PTCA prior to stent\n",
      "\n",
      "          -  Patients with history of clinically significant abnormal laboratory findings including\n",
      "\n",
      "          -  Current (within previous two weeks) neutropenia (<1000 neutrophils/mm3)\n",
      "\n",
      "          -  Thrombocytopenia (<100,000 platelets/mm3)\n",
      "\n",
      "          -  AST, ALT, alkaline phosphatase, or bilirubin > 1.5XULN\n",
      "\n",
      "          -  Serum creatinine > 1.5 mg/dL\n",
      "\n",
      "          -  Patients with evidence of ongoing or active clinical instability including the\n",
      "             following\n",
      "\n",
      "          -  Sustained systolic blood pressure < 100mmHg or cardiogenic shock\n",
      "\n",
      "          -  Acute pulmonary edema or severe congestive heart failure\n",
      "\n",
      "          -  Suspected acute myocarditis, pericarditis, endocarditis, or cardiac tamponade\n",
      "\n",
      "          -  Suspected dissecting aortic aneurysm\n",
      "\n",
      "          -  Hemodynamically significant valvular heart disease, hypertrophic cardiomyopathy,\n",
      "             restrictive cardiomyopathy, or congenital heart disease\n",
      "\n",
      "          -  Target lesion involves a bifurcation including a diseased side branch 2.25mm or more\n",
      "             in diameter requiring treatment\n",
      "\n",
      "          -  Prior coronary bypass surgery of target lesion with patent bypass graft (balloon\n",
      "             angioplasty alone, without coronary stenting, is permitted)\n",
      "\n",
      "          -  History of stroke or transient ischemic attack within prior 6 months\n",
      "\n",
      "          -  Female patients of childbearing potential\n",
      "\n",
      "          -  Active peptic ulcer or upper gastrointestinal bleeding within prior 6 months\n",
      "\n",
      "          -  History of bleeding diathesis or coagulopathy or refusal of blood transfusions\n",
      "\n",
      "          -  Patients with any other pathology such as cancer, mental illness, which in the opinion\n",
      "             of the investigator, might put the patient at risk, preclude follow-up, or in any way\n",
      "             confound the results of the study\n",
      "\n",
      "          -  Known previous medical condition yielding expected survival less than 1 year\n",
      "\n",
      "          -  Patients who are unable or unwilling to comply with the protocol or not expected to\n",
      "             complete the study period, including its follow-up requirements\n",
      "\n",
      "          -  Currently participating in an investigational drug or another device study that has\n",
      "             not completed the primary endpoint or that clinically interferes with the current\n",
      "             study endpoints; or requires coronary angiography, intravascular ultrasound, or other\n",
      "             coronary artery imaging procedures\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically proven high grade B-NHL (CD 20 >= 20 % positive)\n",
      "\n",
      "          -  Age >= 18 years\n",
      "\n",
      "          -  At least one pretreatment with anthracycline polychemotherapy +/- radiatio:\n",
      "\n",
      "          -  first relapse nad contraindication for aggressive salvage therapy e.g. high dose\n",
      "             therapy with autologous stem cell transplantation\n",
      "\n",
      "          -  second relapse (after aggressive salvage therapy)\n",
      "\n",
      "          -  patient's refusal of aggressive salvage therapy in first relapse\n",
      "\n",
      "          -  informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  untreated patients\n",
      "\n",
      "          -  pretreatment with bendamustine\n",
      "\n",
      "          -  primary CNS- lymphoma\n",
      "\n",
      "          -  Karnofsky index < 50 (except caused by lymphoma)\n",
      "\n",
      "          -  HIV positive, hepatitis B or C\n",
      "\n",
      "          -  serious concurrent disease\n",
      "\n",
      "          -  non-compensated heart failure (>=NYHA 3)\n",
      "\n",
      "          -  non-compensated hypertension\n",
      "\n",
      "          -  renal insufficiency (creatinine > 2.0 mg/dl), not related to lymphoma\n",
      "\n",
      "          -  hepatic insufficiency with transaminase values greater than 3-fold of normal values\n",
      "             and/or bilirubin levels > 200 µmol/l, not related to lymphoma\n",
      "\n",
      "          -  missing compliance respective incapability to comply (e.g.cerebral dysfunction\n",
      "\n",
      "          -  pregnancy\n",
      "\n",
      "          -  hematopoetic insufficiency not lymphoma related (leucocyte count <= 2500/µl,\n",
      "             granulocyte count <= 1000/µl, platelet count <= 80000/µl)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female aged 18-60 years\n",
      "\n",
      "          -  Moderate asthma with baseline FEV1 40-75% predicted\n",
      "\n",
      "          -  Previous use of albuterol (salbutamol)\n",
      "\n",
      "          -  At least 20% improvement in FEV1 following 2.5 mg albuterol (salbutamol) delivered by\n",
      "             nebulizer\n",
      "\n",
      "          -  O2 saturation > 90%\n",
      "\n",
      "          -  Non-smoker for > 6 months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Upper respiratory tract infection or asthma exacerbation within 14 days of screening\n",
      "\n",
      "          -  Clinically significant abnormal chest radiograph\n",
      "\n",
      "          -  History of cardiovascular disorder including coronary insufficiency, cardiac\n",
      "             arrhythmias or hypertension\n",
      "\n",
      "          -  Unable to tolerate bronchodilator withdrawal\n",
      "\n",
      "          -  Known hypersensitivity to albuterol (salbutamol)\n",
      "\n",
      "          -  Change in asthma treatment regimen in past 30 days\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Planned implantation of drug eluting stent\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Planned intervention with other stents than study stents\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically/cytologically confirmed soft tissue sarcoma of gynecologic tract\n",
      "             including 1 of the following subtypes: uterine leiomyosarcoma, malignant mixed\n",
      "             mullerian tumor/carcinosarcoma, disease originating in ovary/fallopian tube allowed\n",
      "\n",
      "          -  Locally advanced/unresectable/metastatic disease\n",
      "\n",
      "          -  Previously treated disease must have radiographic/clinical evidence of PD\n",
      "\n",
      "          -  Measurable disease-at least 1 lesion in at least 1 dimension (longest diameter) as\n",
      "             >=20mm with conventional techniques or as >=10mm with spiral CT scan\n",
      "\n",
      "          -  Indicator lesions may not have been previously treated with\n",
      "             surgery/radiotherapy/radiofrequency ablation unless PD has been confirmed\n",
      "\n",
      "          -  ECOG PS 0-2 OR Karnofsky PS 60-100%\n",
      "\n",
      "          -  Life expectancy>=3 months\n",
      "\n",
      "          -  WBC>=3,000/mm^3\n",
      "\n",
      "          -  Absolute neutrophil count>=1,500/mm^3\n",
      "\n",
      "          -  Platelet count>=75,000/mm^3\n",
      "\n",
      "          -  Bilirubin=<1.5xULN\n",
      "\n",
      "          -  AST and ALT=<3xULN\n",
      "\n",
      "          -  INR=<1.5 (unless on warfarin)\n",
      "\n",
      "          -  Creatinine=<1.5xULN OR creatinine clearance>=60 mL/min\n",
      "\n",
      "          -  Urine protein<1+ by dipstick OR 24-hour urine protein<500 mg OR urine\n",
      "             protein:creatinine ratio<1\n",
      "\n",
      "          -  Not pregnant/nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception during and for ≥6 months after\n",
      "             treatment - No other active malignancy within past 5 years except adequately treated\n",
      "             cervical carcinoma in situ/nonmelanoma skin cancer\n",
      "\n",
      "          -  No known hypersensitivity to Chinese hamster ovary cell products/other recombinant\n",
      "             human antibodies\n",
      "\n",
      "          -  No history of allergic reactions attributed to compounds of similar\n",
      "             chemical/biological composition to study agents\n",
      "\n",
      "          -  No serious/nonhealing wound/ulcer/bone fracture\n",
      "\n",
      "          -  No abdominal fistula/gastrointestinal perforation/bowel obstruction/intraabdominal\n",
      "             abscess within past 28 days\n",
      "\n",
      "          -  No significant traumatic injuries within past 28 days\n",
      "\n",
      "          -  No evidence of bleeding diathesis/coagulopathy\n",
      "\n",
      "          -  No uncontrolled intercurrent illness including but not limited to: Ongoing/active\n",
      "             infection, psychiatric illness or social situations that would preclude study\n",
      "             compliance\n",
      "\n",
      "          -  <=2 prior cytotoxic chemotherapy regimen for recurrent, locally advanced or metastatic\n",
      "             disease\n",
      "\n",
      "          -  Recovered from prior therapy\n",
      "\n",
      "          -  No prior antiangiogenic agent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  < 4weeks since prior chemotherapy (<6 weeks for nitrosoureas/carmustine/mitomycin C),\n",
      "             prior investigational treatment, radiotherapy and major surgery/open biopsy\n",
      "\n",
      "          -  1 week since prior core biopsy\n",
      "\n",
      "          -  1 month since prior thrombolytic agents\n",
      "\n",
      "          -  Concurrent full-dose anticoagulants with INR>1.5 allowed if: In-range INR (usually\n",
      "             between 2-3) on stable dose of oral anticoagulant or low molecular weight heparin,\n",
      "\n",
      "          -  OR; For patients on warfarin, the upper target for INR is ≤3 No active\n",
      "             bleeding/pathological condition that carries a high risk of bleeding (e.g. tumor\n",
      "             invading major vessels/known varices)\n",
      "\n",
      "          -  No evidence of CNS disease including primary brain tumor/brain metastasis\n",
      "\n",
      "          -  No other concurrent investigational agents - No concurrent major surgery\n",
      "\n",
      "          -  No concurrent combination antiretroviral therapy for HIV-positive patients\n",
      "\n",
      "          -  Clinically significant cardiovascular disease including:\n",
      "\n",
      "               -  Cerebrovascular accident within past 6 months,\n",
      "\n",
      "               -  Uncontrolled hypertension defined as BP>150/100mmHg OR systolic BP>180mmHg if\n",
      "                  diastolic BP<90 mmHg, on ≥2 repeated determinations on separate days within past\n",
      "                  3 months,\n",
      "\n",
      "          -  OR; Antihypertensive medications allowed as long as dose and number of\n",
      "             antihypertensive medications have not increased within past 2 weeks, Myocardial\n",
      "             infarction, coronary artery bypass graft, or unstable angina within past 6 months, OR;\n",
      "\n",
      "          -  OR; NYHA class III-IV congestive heart failure, serious cardiac arrhythmia requiring\n",
      "             medication, or unstable angina pectoris within past 6 months, Clinically significant\n",
      "             peripheral vascular disease within past 6 months\n",
      "\n",
      "          -  OR; pulmonary embolism, deep vein thrombosis, or other thromboembolic event within\n",
      "             past 6 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Men and women over age 18 with alcohol dependence\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Currently meets Diagnostic and Statistical Manual 4 Text Revision (DSM-IV-TR) criteria\n",
      "             for dependence on illicit substances\n",
      "\n",
      "          -  Significant medical disorders that will increase potential risk or interfere with\n",
      "             study participation\n",
      "\n",
      "          -  Women with childbearing potential who are pregnant, nursing, or refuse to use a\n",
      "             reliable method of birth control\n",
      "\n",
      "          -  Treatment with an investigational drug in the last month.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All women > 18 years of age presenting to the Division of Urogynecology at the\n",
      "             University of Rochester Medical Center/Strong Memorial Hospital and undergoing\n",
      "             gynecologic surgery which requires postoperative placement of a transurethral\n",
      "             catheter.\n",
      "\n",
      "          -  Subjects must be competent to give informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any patient less than 18 years of age.\n",
      "\n",
      "          -  Patients with suprapubic catheters postoperatively.\n",
      "\n",
      "          -  Patients undergoing surgery that does not require transurethral catheterization\n",
      "             postoperatively.\n",
      "\n",
      "          -  Patients not competent to give informed consent.\n",
      "\n",
      "          -  Patients who are pregnant.\n",
      "\n",
      "          -  Patients undergoing procedures requiring prolonged bladder decompression (i.e. fistula\n",
      "             repair).\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Enrolled in University of Michigan's Nephrology Anemia Clinic\n",
      "\n",
      "          -  18 years old or older\n",
      "\n",
      "          -  Have kidney disease but are not on dialysis\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Not enrolled in University of Michigan's Nephrology Anemia Clinic\n",
      "\n",
      "          -  Less than 18 years of age\n",
      "\n",
      "          -  Hematocrit that is less than 28.5%\n",
      "\n",
      "          -  Currently participating in a clinical trial with an intervention\n",
      "\n",
      "          -  Planning to change their tobacco use habits during the study period\n",
      "\n",
      "          -  Have had dose changes of certain medications for cholesterol or diabetes within one\n",
      "             month of study enrollment\n",
      "\n",
      "          -  Are currently receiving:\n",
      "\n",
      "               -  darbepoetin\n",
      "\n",
      "               -  erythopoietin\n",
      "\n",
      "               -  medications to lower your immune system\n",
      "\n",
      "          -  Have had problems within the last 3 months with:\n",
      "\n",
      "               -  Bleeding\n",
      "\n",
      "               -  Heart attack or stroke\n",
      "\n",
      "               -  Heart or blood vessel procedures\n",
      "\n",
      "          -  Are pregnant or lactating\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma, any cellular classification,\n",
      "             any stage, any grade.\n",
      "\n",
      "          -  Adult or pediatric patients receiving lymph node excision for purposes other than\n",
      "             cancer therapy (i.e. tonsillectomy, sleep apnea).\n",
      "\n",
      "          -  A routine procedure for tissue collection is planned.\n",
      "\n",
      "          -  Ability to understand and the willingness to sign a written informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients without NHL or Hodgkin's disease\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the\n",
      "             breast; this is defined as HER-2+ by IHC 3+ staining or FISH+. Prior adjuvant\n",
      "             Trastuzumab therapy is permitted. Patients must not be eligible for therapy of known\n",
      "             curative potential for metastatic breast cancer if it is identified during the course\n",
      "             of the study.\n",
      "\n",
      "          2. Patients may have measurable or evaluable disease.\n",
      "\n",
      "          3. Stable CNS disease that has been adequately treated and is not under active treatment\n",
      "             allowed.\n",
      "\n",
      "          4. Age 18 years or older.\n",
      "\n",
      "          5. Able to give informed consent.\n",
      "\n",
      "          6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or\n",
      "             1.\n",
      "\n",
      "          7. No systemic oral steroids administered within 28 days prior to initiating treatment on\n",
      "             protocol. Topical, ocular, and nasal steroids are allowed, as are those applied to\n",
      "             mucus membranes.\n",
      "\n",
      "          8. No prior or currently active autoimmune disease requiring management with systemic\n",
      "             immunosuppression. This includes inflammatory bowel disease, systemic vasculitis,\n",
      "             scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated\n",
      "             thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's\n",
      "             syndrome, sarcoidosis, or other rheumatologic disease. Asthma or chronic obstructive\n",
      "             pulmonary disease that does not require daily systemic corticosteroids is acceptable.\n",
      "\n",
      "          9. Not pregnant, and on appropriate birth control if of child-bearing potential.\n",
      "\n",
      "         10. No history of other malignancies within the prior five years (excluding a history of\n",
      "             carcinoma in situ of the cervix, superficial non-melanoma skin cancer, and superficial\n",
      "             bladder cancer).\n",
      "\n",
      "         11. Adequate bone marrow reserve with ANC > 1000 and platelets > 100,000.\n",
      "\n",
      "         12. Adequate renal function with serum creatinine < 2.0.\n",
      "\n",
      "         13. Adequate hepatic reserve with serum bilirubin < 2.0, AST/ALT < 2X the upper limit of\n",
      "             normal, and alkaline phosphatase < 5X the upper limit of normal. Serum bilirubin > 2.0\n",
      "             is acceptable in the setting of known Gilbert's syndrome.\n",
      "\n",
      "         14. Adequate cardiac reserve with a cardiac ejection fraction within the lower limit of\n",
      "             facility normal by MUGA, or 45% by echocardiogram.\n",
      "\n",
      "         15. No active major medical or psychosocial problems that could be complicated by study\n",
      "             participation.\n",
      "\n",
      "         16. HIV negative.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. No histologic documentation of breast adenocarcinoma.\n",
      "\n",
      "          2. Breast adenocarcinoma that is not amplified for HER-2/neu gene expression by at least\n",
      "             2-fold by FISH analysis, or that is less than IHC 3+ when FISH negative.\n",
      "\n",
      "          3. Cardiac dysfunction documented by an ejection fraction less than the lower limit of\n",
      "             the facility normal by multi-gated acquisition (MUGA) scan, or 45% by echocardiogram.\n",
      "\n",
      "          4. Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs\n",
      "             resulting in dyspnea at rest.\n",
      "\n",
      "          5. History of autoimmune disease as detailed above.\n",
      "\n",
      "          6. Systemic oral corticosteroid treatment within 28 days prior to initiating treatment on\n",
      "             study.\n",
      "\n",
      "          7. Uncontrolled medical problems.\n",
      "\n",
      "          8. Evidence of active acute or chronic infection.\n",
      "\n",
      "          9. Chemotherapy, radiation therapy, or biologic therapy (except Trastuzumab) within 28\n",
      "             days prior to initiating treatment on study. Hormonal therapy and supportive therapy\n",
      "             with bisphosphonates will be allowed.\n",
      "\n",
      "         10. Participation in an investigational new drug trial within 28 days prior to initiating\n",
      "             treatment on study.\n",
      "\n",
      "         11. Pregnant or breast feeding.\n",
      "\n",
      "         12. Hepatic, renal, or bone marrow dysfunction as detailed above.\n",
      "\n",
      "         13. Concurrent malignancy or history of other malignancy within the last five years except\n",
      "             as noted above.\n",
      "\n",
      "         14. Corn allergy.\n",
      "\n",
      "         15. Known severe hypersensitivity to Trastuzumab (excluding mild to moderate infusion\n",
      "             reactions that are easily managed and do not recur).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Asthmatic and control children, aged 5 to 16 years\n",
      "\n",
      "          -  Children with doctor-diagnosed asthma, known at the department of Paediatric\n",
      "             Pulmonology, University Hospital Maastricht\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Presence of a disease that might interfere with the results of this study (e.g. recent\n",
      "             upper airway infection, heart disease, anatomic abnormalities of the airways and other\n",
      "             chronic inflammatory diseases such as Crohns disease and rheumatoid arthritis)\n",
      "\n",
      "          -  Mental retardation\n",
      "\n",
      "          -  Inability to perform the EBC procedure properly\n",
      "\n",
      "          -  Active smoking\n",
      "\n",
      "          -  The use of one of the following medication: Papaverin, Sodium nitroprusside, ACE\n",
      "             inhibitors, Oxymetazoline, L-arginine, or NOS inhibitors\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18 years of age or older with 1-4 brain metastases, each with a maximum diameter of no\n",
      "             more than 3 cm on contrast-enhanced MRI scans, and were derived from a histologically\n",
      "             confirmed systemic cancer, Karnofsky Performance Status (KPS) score of 70 or more\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with metastases from small cell carcinoma, lymphoma, germinoma, and multiple\n",
      "             myeloma were excluded.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Patient inclusion criteria will be:\n",
      "\n",
      "          -  18 years of age or greater\n",
      "\n",
      "          -  Admission to the internal medical or cardiology services at LAC/USC Medical Center\n",
      "\n",
      "          -  Discharge directly from the medical service to home\n",
      "\n",
      "          -  During admission, being evaluated or treated for congestive heart failure or coronary\n",
      "             artery disease.\n",
      "\n",
      "        Patient Exclusion criteria :\n",
      "\n",
      "          -  Moderate or severe cognitive dysfunction\n",
      "\n",
      "          -  Severe psychiatric disability such that the patient has, or there is an application\n",
      "             for, a conservator, or any psychiatric illness with current psychotic features\n",
      "\n",
      "          -  Not having speaking proficiency in either English or Spanish language.\n",
      "\n",
      "          -  If the patient was previously enrolled in the study on a prior hospitalization, he or\n",
      "             she will also be excluded.\n",
      "\n",
      "        Nurse Inclusion Criteria:\n",
      "\n",
      "          -  Performing the patient education at hospital discharge for a patient enrolled in the\n",
      "             study\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of Cystic Fibrosis based on genotype and/or positive sweat-test\n",
      "\n",
      "          -  Written informed consent based on written and spoken information\n",
      "\n",
      "          -  No chronic airway-infections with Gram-negative bacteria\n",
      "\n",
      "          -  Fertile, sexually active women must use contraception (p-pills, IUD or other methods\n",
      "             with a similar Pearl-index) when participating in the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  P. aeruginosa in airway secretions obtained less than 3 months prior to inclusion\n",
      "\n",
      "          -  Chronic infection of the airways caused by Gram-negative bacteria (Burkholderia\n",
      "             species, Achromobacter xylosoxidans, Pandorea apista or Stenotrophomonas maltophilia)\n",
      "\n",
      "          -  Chronic infection of the airways caused by P. aeruginosa (chronic infection is defined\n",
      "             by continuing growth of the microorganism for 6 months and/or an increase in specific,\n",
      "             precipitating antibodies to a level of at least 2)\n",
      "\n",
      "          -  Previous infection with a strain of P. aeruginosa resistant to ciprofloxacin or\n",
      "             colistin\n",
      "\n",
      "          -  Previous participation in a pseudomonas-vaccination-study\n",
      "\n",
      "          -  Patients younger than 1 year\n",
      "\n",
      "          -  Pregnant or lactating women, or sexually active women unwilling to use safe\n",
      "             contraception (p-pills, IUD or method with similar Pearl-index) when participating in\n",
      "             the study\n",
      "\n",
      "          -  Severe insufficiency of the liver or kidneys as judged by the local investigator\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with acute myocardial infarction with electrocardiographic criterion and/or\n",
      "             typical history of angina pectoris and planned revascularisation according to the\n",
      "             acute myocardial infarction disease management guidelines of the University Hospital\n",
      "             Bern. Including both, patients undergoing primary PCI and patients referred for rescue\n",
      "             PCI after failed thrombolytic therapy\n",
      "\n",
      "          -  Patients > 18 years old of either sex\n",
      "\n",
      "          -  Patients who have given informed consent to the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients unable to give informed consent e.g. because of mechanical ventilation\n",
      "\n",
      "          -  Patients with cardiogenic shock\n",
      "\n",
      "          -  Patients with myocardial infarction secondary to occlusion of a recently\n",
      "             revascularized vessel (subacute stent thrombosis)\n",
      "\n",
      "          -  Patients with severe arrhythmias\n",
      "\n",
      "          -  Patients whose door-to-balloon time exceeds 120 minutes\n",
      "\n",
      "          -  Pregnancy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Female\n",
      "\n",
      "          -  African American or Black\n",
      "\n",
      "          -  5% to 10% prior probability of having a BRCA1 or BRCA2 mutation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Men\n",
      "\n",
      "          -  Individuals who are not African American or Black\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Nonsmoking men and premenopausal women, ages 18-45\n",
      "\n",
      "          -  Body mass index ≥ 27 kg/m2\n",
      "\n",
      "          -  Body weight < 200 kg\n",
      "\n",
      "          -  Evidence of insulin resistance, as suggested by any one of the following:\n",
      "\n",
      "          -  Fasting glucose ≥ 100 mg/dL\n",
      "\n",
      "          -  Impaired glucose tolerance, with a glucose concentration of ≥ 140 mg/dL 2 hours after\n",
      "             a 75-gram oral glucose challenge\n",
      "\n",
      "          -  A fasting insulin concentration ≥ 9 mIU/L\n",
      "\n",
      "          -  At least two of the following:\n",
      "\n",
      "          -  Waist circumference > 35\" in women or > 40\" in men\n",
      "\n",
      "          -  Prehypertension or hypertension, with BP > 120/80 mmHg but < 145/90 mmHg on 2\n",
      "             antihypertensive agents or less\n",
      "\n",
      "          -  TG > 150 but < 500 mg/dL\n",
      "\n",
      "          -  HDL < 40 mg/dL in men or < 50 mg/dL in women\n",
      "\n",
      "          -  Willingness to consume only study food and drink for the duration of the study and to\n",
      "             be randomized to one of the three diets\n",
      "\n",
      "          -  Willingness to maintain consistent intake of coffee and/or tea during the inpatient\n",
      "             periods\n",
      "\n",
      "          -  Willingness to avoid the use of all over-the-counter or prescription vitamins, dietary\n",
      "             supplements, and herbal products during the study, with the exception of the\n",
      "             multivitamin supplement (Flintstones® Plus Iron.)\n",
      "\n",
      "          -  Willingness to continue current antihypertensive medications at the same dose and\n",
      "             schedule throughout the study, unless a change is advised.\n",
      "\n",
      "          -  Willingness to avoid the use of non-steroidal anti-inflammatory drugs including\n",
      "             low-dose daily aspirin, for at least ten days prior to the first admission and during\n",
      "             each admission.\n",
      "\n",
      "          -  Willingness to avoid the use of acetaminophen (Tylenol) and furosemide (Lasix) for at\n",
      "             least 48 hours prior to and during the 24-hour urine collection.\n",
      "\n",
      "          -  Willingness to avoid the use of sulfonamide antibiotics for at least 1 week prior to\n",
      "             and during the 24-hour urine collection.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Current tobacco smoking\n",
      "\n",
      "          -  History of a bleeding disorder\n",
      "\n",
      "          -  Findings suggestive of cardiovascular disease.\n",
      "\n",
      "          -  Blood pressure ≥ 145/90 mmHg after 10 minutes of rest on two or more screening visits,\n",
      "             or treatment with three or more antihypertensive agents at any blood pressure.\n",
      "\n",
      "          -  Fasting glucose ≥ 165 mg/dL, glycosylated hemoglobin > 8%, or any treatment with oral\n",
      "             hypoglycemic agents, insulin sensitizing agents , insulin, incretin mimetics, amylin\n",
      "             analogues, or endocannabinoid receptor antagonists.\n",
      "\n",
      "          -  History of chronic glucocorticoid use, oral glucocorticoid use for more than 5 days in\n",
      "             the previous year, or anticipated treatment with oral or intravenous glucocorticoids\n",
      "             during the study period.\n",
      "\n",
      "          -  Current treatment with weight loss medications.\n",
      "\n",
      "          -  History of bariatric surgery\n",
      "\n",
      "          -  Current treatment with any cholesterol-lowering medications.\n",
      "\n",
      "          -  Hyperthyroidism or untreated hypothyroidism.\n",
      "\n",
      "          -  Pregnancy, desired pregnancy, or lactation within the study period.\n",
      "\n",
      "          -  Peri- or postmenopausal status.\n",
      "\n",
      "          -  Obstructive sleep apnea.\n",
      "\n",
      "          -  Active gallstone disease\n",
      "\n",
      "          -  Known history of chronic hepatitis, or liver enzymes more than 2.5 times the upper\n",
      "             limit of normal\n",
      "\n",
      "          -  Known infection with HIV or confirmed positive test for HIV antibody\n",
      "\n",
      "          -  Inflammatory bowel disease, active cancer, or any other medical condition that may\n",
      "             cause significant acute weight loss or gain\n",
      "\n",
      "          -  Sustained weight loss > 5% of body weight in the previous two months, or sustained\n",
      "             weight loss > 10% of body weight in the previous six months\n",
      "\n",
      "          -  History of kidney stones\n",
      "\n",
      "          -  Renal disease, as evidenced by a serum creatinine above the normal limit on more than\n",
      "             one screening visit\n",
      "\n",
      "          -  Serum calcium, potassium, or magnesium above the normal limit, confirmed on two\n",
      "             screening tests\n",
      "\n",
      "          -  Seizure disorder\n",
      "\n",
      "          -  History of any inpatient psychiatric admission within the past two years\n",
      "\n",
      "          -  History of schizophrenia, psychosis, or bipolar disorder\n",
      "\n",
      "          -  History of anorexia nervosa or bulimia nervosa or a history of medical or\n",
      "             psychological treatment for an eating disorder\n",
      "\n",
      "          -  Severe binge eating disorder\n",
      "\n",
      "          -  Active moderate to severe depression.\n",
      "\n",
      "          -  History of alcohol or drug abuse within the previous two years\n",
      "\n",
      "          -  History, physical, or laboratory findings suggestive of any other medical or\n",
      "             psychological condition that would, in the opinion of the principal investigator, make\n",
      "             the candidate ineligible for the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must be > 18 years of age, with no upper age limit.\n",
      "\n",
      "          -  Patients must have an ECOG performance status of 0 or 1.\n",
      "\n",
      "          -  Any patient with a hematologic malignancy which is unlikely to be cured by\n",
      "             conventional treatment is eligible for this study.\n",
      "\n",
      "          -  Patients for whom a disease specific protocol exists will be transplanted on those\n",
      "             protocols as discussed in the introduction.\n",
      "\n",
      "          -  Patients who have had prior autografts may be treated on this protocol.\n",
      "\n",
      "          -  Patients must have adequate physical function as measured by the following criteria:\n",
      "\n",
      "          -  Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection fraction at\n",
      "             rest must be >40%.\n",
      "\n",
      "          -  Hepatic: Aspartate transaminase (AST) micro 3x the upper limits of normal and total\n",
      "             serum bilirubin < 2.5 mg/dL. Patients with a higher bilirubin from \"benign conditions\"\n",
      "             such as Gilbert's disease may still be eligible for the study.\n",
      "\n",
      "          -  Renal: Serum creatinine within the normal range or if creatinine outside normal range\n",
      "             then creatinine clearance > 60 ml/min/1.73m2. Serum creatinine must be less than or\n",
      "             equal to 2.0 mg/dl.\n",
      "\n",
      "          -  Pulmonary: Asymptomatic or, if symptomatic, DLCO (diffusion capacity) > 45% of\n",
      "             predicted (corrected for hemoglobin)\n",
      "\n",
      "          -  The patient or guardian(s) must be able to give informed consent to the study.\n",
      "\n",
      "          -  Patient must have a suitable donor who is identical for HLA (human leukocyte antigens)\n",
      "             -A, -B, -C, -DR. Single antigen mismatches for HLA-A, -B, -C, -DR are also permitted.\n",
      "             Donors obtained through the National Marrow Donor Program (NMDP) will follow NMDP\n",
      "             guidelines.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who are eligible for a standard myeloablative transplant and for whom a\n",
      "             standard myeloablative transplant is preferable will not be treated on this protocol.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  The primary selection criteria include women and men between the ages of 18 and 65\n",
      "             who:\n",
      "\n",
      "               1. Meet DSM-IV criteria for opiate dependence,\n",
      "\n",
      "               2. Maintain a stable dose of methadone for two weeks prior to recruitment and,\n",
      "\n",
      "               3. a) fail to achieve \"take-home\" status for methadone dosing during at least the\n",
      "                  first four months of methadone treatment, b) test positive on at least two\n",
      "                  toxicology screens for illicit drugs during the month prior to recruitment c)\n",
      "                  have never achieved two consecutive toxicology screens free of illicit substances\n",
      "                  since entering the current treatment episode.\n",
      "\n",
      "               4. Meet study criteria for chronic stress\n",
      "\n",
      "                    1. unemployment criteria, and\n",
      "\n",
      "                    2. affective disorder criteria.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  (1) Patients with significantly unstable or uncontrolled medical illness which may\n",
      "             interfere with participation in treatment (e.g., patients likely to require\n",
      "             hospitalization during the study period).\n",
      "\n",
      "             (2) Patients with a psychotic or organic mental disorder according to DSM-IV criteria.\n",
      "\n",
      "             (3) Patients receiving medication affecting methadone metabolism (e.g. rifampin).\n",
      "\n",
      "             (4) Patients with uncontrolled bipolar disorder as evidenced by meeting current\n",
      "             criteria for mania or hypomania or meeting criteria for rapid cycling in the last year\n",
      "             (as indicated by structured questioning of all patients meeting criteria for bipolar\n",
      "             disorder).\n",
      "\n",
      "             (5) Patients unable to complete the informed consent or unable to understand study\n",
      "             procedures in the informed consent process.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Female patients between 18 and 65 years of age undergoing bilateral reduction\n",
      "             mammaplasty with anchor shaped incisions, who have given written informed consent.\n",
      "\n",
      "          -  Patients with a Body Mass Index of 15-32 kg/m2 inclusive.\n",
      "\n",
      "          -  Patients of child bearing potential who are using method(s) of contraception\n",
      "             acceptable to the Investigator and agree to do so from at least the screening visit\n",
      "             until 1 month after administration of the trial investigational products.\n",
      "\n",
      "          -  Patients with, in the opinion of the Investigator, clinically acceptable results for\n",
      "             the laboratory tests specified in the trial protocol.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with significant breast asymmetry that may result in asymmetrical operative\n",
      "             incisions being made on the left and rights breasts.\n",
      "\n",
      "          -  Patients with breast asymmetry that may result in different post-operative tensions on\n",
      "             the wounds of the left and right breasts.\n",
      "\n",
      "          -  Patients who have had surgery in the area to be incised within one year of trial\n",
      "             surgery.\n",
      "\n",
      "          -  Patients with a history of a bleeding disorder.\n",
      "\n",
      "          -  Patients with a history of breast malignancy.\n",
      "\n",
      "          -  Patients with a skin disorder that is chronic or currently active and which the\n",
      "             Investigator considers will adversely affect the healing of the wounds or involves the\n",
      "             areas to be examined in this trial.\n",
      "\n",
      "          -  Patients who on direct questioning and/or physical examination, have evidence of any\n",
      "             past or present clinically significant medical condition that would impair wound\n",
      "             healing.\n",
      "\n",
      "          -  Patients with a history of clinically significant hypersensitivity to any of the drugs\n",
      "             or surgical dressings to be used in this trial.\n",
      "\n",
      "          -  Patients who are taking, or have taken, any investigational drugs in the 3 months\n",
      "             prior to the screening visit.\n",
      "\n",
      "          -  Patients who are taking regular, continuous, oral corticosteroid therapy.\n",
      "\n",
      "          -  Patients undergoing investigations or changes in management for an existing medical\n",
      "             condition.\n",
      "\n",
      "          -  Patients who are or who become pregnant up to and including the day of surgery or who\n",
      "             are lactating.\n",
      "\n",
      "          -  Patients with diseases or conditions that could, in the opinion of the Investigator,\n",
      "             interfere with the assessment of safety or efficacy of the investigational product.\n",
      "\n",
      "          -  Patients who, in the opinion of the Investigator, are not likely to complete the\n",
      "             trial.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  At least 6 months post injury\n",
      "\n",
      "          -  Difficulties in social and emotional functioning\n",
      "\n",
      "          -  Entering Grades 10 and 11 in 2007\n",
      "\n",
      "          -  English fluency\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Extreme behaviour, mood and cognitive disturbance\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Presence of Critical Limb ischemia according to the guidelines of the Transatlantic\n",
      "             Consensus Group (TASC) Rutherford grade II or III. Perfusion is measured with absolute\n",
      "             perfusion pressure and ankle-brachial index (ABI) and transcutaneous oxygen tension\n",
      "             (TcpO2); for inclusion, ABI has to be less than or equal to 0.6 or absolute ankle\n",
      "             pressure must be less than 60 mmHg. If ABI is technically not feasible, e.g. in\n",
      "             patients with media calcification, inclusion criteria are a tcpO2 value (supine,\n",
      "             forefoot, 44°C) of less than 20 mmHg if there is no tissue loss, or a tcpO2 of less\n",
      "             than 40 mmHg if there is tissue loss.\n",
      "\n",
      "          -  No sufficient response to best standard care delivered for six weeks.\n",
      "\n",
      "          -  No surgical or radiological interventional option for revascularisation as confirmed\n",
      "             by a vascular surgeon and an interventional radiologist\n",
      "\n",
      "          -  Age older than 18 years\n",
      "\n",
      "          -  Signed informed consent\n",
      "\n",
      "          -  Absence of life-threatening complications from the ischemic limb\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Expected life span less than six months\n",
      "\n",
      "          -  Bone marrow diseases which preclude transplantation (eg lymphoma, leukaemia,\n",
      "             myelodysplastic syndrome and others)\n",
      "\n",
      "          -  Renal failure on hemodialysis\n",
      "\n",
      "          -  Life threatening complications of limb ischemia with the need for immediate limb\n",
      "             amputation to avoid death or clinical deterioration\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female subjects older than 30 years of age.\n",
      "\n",
      "          -  Subjects with a photodamage grade of at least 4 on the Griffiths photonumeric scale\n",
      "             (symmetrical photodamage on the two target areas)\n",
      "\n",
      "          -  Subjects with mottled hyper-pigmentation on the face\n",
      "\n",
      "          -  Subjects willing and capable of cooperating to the extent and degree required by the\n",
      "             protocol\n",
      "\n",
      "          -  Subjects must read the Patient Information Sheet and read and sign the Informed\n",
      "             Consent form prior to any study related procedures.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects who are at risk in terms of precautions, warnings, and contra-indication in\n",
      "             the package insert for Metvix®\n",
      "\n",
      "          -  Subjects with suspected porphyria\n",
      "\n",
      "          -  Subjects with specific wash-out period for interfering treatments\n",
      "\n",
      "          -  Subjects requiring concurrent treatment that would interfere with study objectives\n",
      "             and/or evaluations\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Advanced HF (Stage D or advanced Stage C HF) with:\n",
      "\n",
      "             symptoms of dyspnea at rest or with minimal exertion systolic dysfunction or preserved\n",
      "             systolic function (\"diastolic heart failure\") Outpatient care setting (office, clinic\n",
      "             or home hospice).\n",
      "\n",
      "          2. Patient already receiving optimal medical therapy per ACC/AHA guidelines (ACEI or ARB\n",
      "             + β-blocker +aldosterone antagonist) for at least 1 month or explanation of\n",
      "             intolerance of specific medication. We will exclude those not on optimized medications\n",
      "             with no notation of intolerance; however, we will keep a tally to quantify patients\n",
      "             who are considered \"advanced Heart Failure\" but are not on recommended medications.\n",
      "\n",
      "          3. Can be awaiting LVAD, transplantation or other procedure\n",
      "\n",
      "          4. Age > 18 years and able to sign informed consent to participate\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Cognitive or other impairment which prevents accurate assessment of symptoms or\n",
      "             ability to provide informed consent.\n",
      "\n",
      "          2. Heart failure due to recent onset of acute viral myocarditis, peripartum myocarditis.\n",
      "\n",
      "          3. Patient on hemodialysis or receiving mechanical ventilation\n",
      "\n",
      "          4. Patients receiving investigational agents or devices.\n",
      "\n",
      "          5. Patients who have received heart transplant or a destination Left Ventricular Assist\n",
      "             Device\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients 65 years or older who have been prescribed one or more of the targeted\n",
      "             medications and who have a creatinine from within the previous year on record will be\n",
      "             included.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients on dialysis\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Currently between 4 and 11 months of age;\n",
      "\n",
      "          2. Between 37 and 42 weeks' completed gestation at birth;\n",
      "\n",
      "          3. Birth weight greater than 2.5 kg; and\n",
      "\n",
      "          4. No evidence of acute or chronic disease\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Fed 30 minutes prior to immunization;\n",
      "\n",
      "          2. Received analgesic/sedative the day of the immunizations;\n",
      "\n",
      "          3. Parent wishes to feed the infant during the immunizations;\n",
      "\n",
      "          4. Infant is diagnosed with a major congenital disorder where the behavioral responses to\n",
      "             painful stimuli may be altered; or\n",
      "\n",
      "          5. Language barriers preclude the process of obtaining parental consent.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Lung transplant recipients between the ages of 18 and 65 years old\n",
      "\n",
      "          -  All patients must be able to give written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Lung transplant recipients who are unable to undergo bronchoscopy\n",
      "\n",
      "          -  Lung transplant recipients who are unable to give informed consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Ages 3 to <9 years\n",
      "\n",
      "          -  Short stature with height >2.25 Standard Deviation below the mean\n",
      "\n",
      "          -  Prepubertal (Tanner stage I) at commencement of trial\n",
      "\n",
      "          -  Peak Growth Hormone above 10ng/ml in at least one provocative test for Growth Hormone\n",
      "             secretion\n",
      "\n",
      "          -  Signing informed consent forms\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Intra Uterine Growth Retardation\n",
      "\n",
      "          -  Growth retardation associated with malignancy, severe chronic disease, genetic\n",
      "             syndromes and endocrine disorders\n",
      "\n",
      "          -  Diabetes\n",
      "\n",
      "          -  Treatment with any medical product which may interfere with Growth Hormone\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  cytological or histologically proven NSCLC\n",
      "\n",
      "          -  unresectable stage III NSCLC\n",
      "\n",
      "          -  presence of at least one measurable lesion (RECIST criteria)\n",
      "\n",
      "          -  adequate haematological, renal and hepatic function\n",
      "\n",
      "          -  adequate lung function reserve\n",
      "\n",
      "          -  good condition, weight loss <10% over previous 6 months, life expectancy > 3 months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  previous chemotherapy for NSCLC\n",
      "\n",
      "          -  distant metastasis or a pleural or pericardial effusion\n",
      "\n",
      "          -  treatment for malignant disease in the past or serious concomitant medical or\n",
      "             psychiatric disease\n",
      "\n",
      "          -  active uncontrolled infection at time of inclusion\n",
      "\n",
      "          -  interstitial lung disease\n",
      "\n",
      "          -  auto-immune systemic disease with potential involvement of the lungs\n",
      "\n",
      "          -  concomitant use of amiodarone\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Cases:\n",
      "\n",
      "          -  clinical diagnosis of hypoplastic left heart syndrome, status post Norwood procedure,\n",
      "             bidirectional Glenn, and completion Fontan, ages 4-5 years old, English-speaking\n",
      "             patient and parent, informed consent\n",
      "\n",
      "        Controls:\n",
      "\n",
      "        Healthy children 4-5 years old, English-speaking patient and parent, informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Congenital or acquired abnormality associated with neurologic morbidity independent of\n",
      "             cardiac lesion\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Eligibility for this protocol is as follows:\n",
      "\n",
      "          -  All subjects must be within 2 months of their primary breast cancer diagnosis,\n",
      "\n",
      "          -  All subjects must be at least 18 years of age,\n",
      "\n",
      "          -  All subjects must be able to read and write English at the 6th-grade level\n",
      "\n",
      "          -  Not homeless\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Men and women 18 and over\n",
      "\n",
      "          -  Patients undergoing refractive surgery\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Concurrent ocular conditions or pathology that could affect patient's ability to\n",
      "             complete study\n",
      "\n",
      "          -  Concurrent use of topical medications other than study medications\n",
      "\n",
      "          -  Use of systemic medications with ocular drying sequelae:\n",
      "\n",
      "               -  Antihistamines\n",
      "\n",
      "               -  Decongestants\n",
      "\n",
      "               -  Antispasmotics\n",
      "\n",
      "               -  Antidepressants\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Able and willing to read, understand, and provide written Informed Consent;\n",
      "\n",
      "          -  Male or Female in the age range of 18-85 years;\n",
      "\n",
      "          -  Subject is suspected to have pleural effusion;\n",
      "\n",
      "          -  Body mass index (BMI) > 21.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Chest wall deformation;\n",
      "\n",
      "          -  Spine deformation (including severe scoliosis);\n",
      "\n",
      "          -  Hirsutism;\n",
      "\n",
      "          -  Potentially contagious skin lesion on the back;\n",
      "\n",
      "          -  Skin lesion that would interfere with sensor placement;\n",
      "\n",
      "          -  Cardiac pacemaker or implantable defibrillator;\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 13-22 years, at least two years post-menarche\n",
      "\n",
      "          -  Body mass index (BMI, kg/m2) between 18 -30 kg/m2\n",
      "\n",
      "          -  Surgical diagnosis of endometriosis\n",
      "\n",
      "          -  Clinical decision to treat with a GnRH agonist, leuprolide depot (Lupron Depot®; TAP\n",
      "             Pharmaceuticals, Inc.) 11.25 mg intra-muscular every 3 months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Concomitant chronic diseases which affect bone health, such as cystic fibrosis,\n",
      "             inflammatory bowel disease, renal disease, or diabetes mellitus\n",
      "\n",
      "          -  Markedly impaired liver function or liver failure\n",
      "\n",
      "          -  Personal history of thromboembolic event (such as deep venous thrombosis)\n",
      "\n",
      "          -  Medication use known to affect bone metabolism:\n",
      "\n",
      "               -  Glucocorticoid therapy (including inhaled steroids) or anticonvulsants used in\n",
      "                  the last 6 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Requires aortic valve replacement (heart surgery such as bypass is allowed at the same\n",
      "             time).\n",
      "\n",
      "          -  Legal age.\n",
      "\n",
      "          -  Signed informed consent prior to surgery.\n",
      "\n",
      "          -  Willing to complete all follow-up requirements.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant or nursing women.\n",
      "\n",
      "          -  Have already had a valve replaced other than the aortic valve.\n",
      "\n",
      "          -  Needs another valve replaced.\n",
      "\n",
      "          -  Cannot return for required follow-up visits.\n",
      "\n",
      "          -  Have active endocarditis.\n",
      "\n",
      "          -  Acute preoperative neurological event (such as a stroke).\n",
      "\n",
      "          -  Renal dialysis.\n",
      "\n",
      "          -  History of substance abuse within one year, or a prison inmate.\n",
      "\n",
      "          -  Participating in another study.\n",
      "\n",
      "          -  Life expectancy less than two years.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  case report of a patient with trisomy 21 and primum atrial septum defect with\n",
      "             associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days\n",
      "             of life\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  those who do not fit into inclusion criteria\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18 years of age or older\n",
      "\n",
      "          -  Must have received prior therapy for their myeloma and have relapsed and/or\n",
      "             relapsed/refractory multiple myeloma\n",
      "\n",
      "          -  Monoclonal protein in the serum of greater than or equal to 1 gm/dL or monoclonal\n",
      "             light chain in the urine protein electrophoresis of greater than or equal to 200mg/24\n",
      "             hours, or measurable light chains by free light chain assay of greater than or equal\n",
      "             to 10mg/dl, or measurable plasmacytoma\n",
      "\n",
      "          -  ECOG Performance Status 0, 1 or 2\n",
      "\n",
      "          -  Laboratory values as outlined in the protocol\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Uncontrolled infection\n",
      "\n",
      "          -  Cytotoxic chemotherapy less than 2 weeks, or biologic therapy less than 2 weeks, or\n",
      "             corticosteroids less than 2 weeks prior to registration. Patients may be receiving\n",
      "             chronic corticosteroids if they are being given for disorders other than myeloma.\n",
      "\n",
      "          -  Pregnant or nursing women\n",
      "\n",
      "          -  Men or women of childbearing potential who are unwilling to employ adequate\n",
      "             contraception\n",
      "\n",
      "          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy\n",
      "             considered investigational within 14 days before enrollment\n",
      "\n",
      "          -  Known to be HIV positive\n",
      "\n",
      "          -  Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV\n",
      "             hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or\n",
      "             electrocardiographic evidence of acute ischemia or active conduction system\n",
      "             abnormalities\n",
      "\n",
      "          -  Hypersensitivity to bortezomib, boron or mannitol\n",
      "\n",
      "          -  Serious medical or psychiatric illness likely to interfere with participation in this\n",
      "             clinical trial\n",
      "\n",
      "          -  Patients who may need or are receiving live vaccines for immunization\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  1. Male and non-pregnant, non breast-feeding female outpatients at least 18 years of\n",
      "             age (no upper age limit).\n",
      "\n",
      "          -  2. History of constipation; the subject reports, on average, two or fewer spontaneous\n",
      "             bowel movements per week that result in a feeling of complete evacuation and or one or\n",
      "             more of the following for at least 6 months before the selection visit:\n",
      "\n",
      "               1. very hard (little balls) and/or hard stools at least a quarter of the stools\n",
      "\n",
      "               2. sensation of incomplete evacuation following at least a quarter of the stools\n",
      "\n",
      "               3. straining at defecation at least a quarter of the time. The above criteria are\n",
      "                  only applicable for spontaneous bowel movements, i.e., not preceded within a\n",
      "                  period of 24 hours by the intake of a laxative agent or by the use of an enema.\n",
      "\n",
      "        Subjects who never have spontaneous bowel movements are considered to be constipated and\n",
      "        are eligible for the trial.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  1. Subjects in whom constipation is thought to be drug-induced, or subjects using any\n",
      "             disallowed medication.\n",
      "\n",
      "          -  2. Subjects suffering from endocrine disorders, metabolic disorders or neurologic\n",
      "             disorders.\n",
      "\n",
      "          -  3. Subjects with a megacolon/megarectum or a diagnosis of pseudo-obstruction.\n",
      "\n",
      "          -  4. Constipation as a result of surgery.\n",
      "\n",
      "          -  5. Known or suspected organic disorders of the large bowel, i.e. obstruction,\n",
      "             carcinoma, or inflammatory bowel disease.\n",
      "\n",
      "          -  6. Subjects with severe and clinically uncontrolled cardiovascular, liver, or lung\n",
      "             disease, neurologic or psychiatric disorders (including active alcohol or drug abuse),\n",
      "             cancer or AIDS, and other gastrointestinal or endocrine disorders.\n",
      "\n",
      "          -  7. Subjects with impaired renal function.\n",
      "\n",
      "          -  8. Subjects with clinically significant abnormalities of haematology, urinalysis, or\n",
      "             blood chemistry.\n",
      "\n",
      "          -  9. Females of child-bearing potential without adequate contraceptive protection during\n",
      "             the trial.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  are 18 years of age or older on admission;\n",
      "\n",
      "          -  Pregnant as determined by sonogram results\n",
      "\n",
      "          -  have a current sexual partner who they have seen recently at least 3 times a week\n",
      "\n",
      "          -  male partner has regular alcohol or illicit drug use (at least 4 of 7 days typical\n",
      "             use) and is not incarcerated.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  woman or partner report current suicidal ideation\n",
      "\n",
      "          -  woman or partner meet diagnostic criteria for a current DSM-IV Axis I thought disorder\n",
      "             (i.e. schizophrenia)\n",
      "\n",
      "          -  woman or partner demonstrate significant cognitive impairment that precludes them from\n",
      "             completing the initial assessment battery\n",
      "\n",
      "          -  woman has evidence of physical violence or abuse\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  children in good health who were dentate and 6-27 months\n",
      "\n",
      "          -  a signed informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  antibiotic usage within the previous 14 days\n",
      "\n",
      "          -  oral topical fluoride administration within the previous 7 days\n",
      "\n",
      "          -  previous routine professional dental care\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  CAP enrolled\n",
      "\n",
      "          -  Age 18 or older\n",
      "\n",
      "          -  Evidence of use of opiate and/or cocaine use in the past 30 days\n",
      "\n",
      "          -  Assigned to pharmacotherapy free modality\n",
      "\n",
      "          -  CAP admission at an estimated gestational age (EGA) <34 weeks\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  Endorses current suicidal ideation\n",
      "\n",
      "          -  Any medical disorders requiring extended or future hospitalization\n",
      "\n",
      "          -  Meet diagnostic criteria for current DSM-IV alcohol dependence\n",
      "\n",
      "          -  Meet diagnostic criteria for a current DSM-IV Axis I thought disorder (i.e.\n",
      "             schizophrenia)\n",
      "\n",
      "          -  Demonstrate significant cognitive impairment that precludes them from completing the\n",
      "             initial assessment battery\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age > 21 year\n",
      "\n",
      "          -  Glomerular Filtration Rate (GFR) 15-60ml/min calculated by MDRD formula\n",
      "\n",
      "          -  Scheduled to undergo elective PCI\n",
      "\n",
      "          -  Able to receive 12 hours of pre-hydration\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  GFR less than 15ml/min or patients diagnosed with end stage renal failure\n",
      "\n",
      "          -  Increase in serum creatinine levels of > 0.5mg/dl or 44umol/l in the previous 24 hours\n",
      "\n",
      "          -  Preexisting dialysis\n",
      "\n",
      "          -  Pulmonary edema or moderate to severe congestive heart failure (New York Heart\n",
      "\n",
      "          -  Association [NYHA] III-IV)\n",
      "\n",
      "          -  Patient unable to withstand the fluid load and hemodynamics compromise\n",
      "\n",
      "          -  Uncontrolled hypertension (untreated systolic blood pressure > 160 mmHg, or diastolic\n",
      "             blood pressure > 100mmHg.)\n",
      "\n",
      "          -  Emergency cardiac catheterization (i.e. patient presenting with ST segment elevation\n",
      "             myocardial infarction undergoing primary angioplasty)\n",
      "\n",
      "          -  Recent exposure to radiographic contrast (within two days of the study).\n",
      "\n",
      "          -  Allergic to radio-contrast\n",
      "\n",
      "          -  Administration of sodium bicarbonate solution or NAC within 48 hours before the PCI.\n",
      "\n",
      "          -  Patient unable to give consent\n",
      "\n",
      "          -  Clinically vulnerable condition requiring continuous fluid therapy e.g. severe sepsis\n",
      "\n",
      "          -  Use of NSAID, aminoglycocide, cyclosporin, cysplatin within 48 hours prior to PCI and\n",
      "             throughout the study duration\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of STEMI\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  On site resuscitated patients\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Stratum 1:\n",
      "\n",
      "               -  Currently not receiving an enzyme-inducing anticonvulsant\n",
      "\n",
      "                    -  Patients receiving non-enzyme inducing anticonvulsants are eligible for this\n",
      "                       stratum\n",
      "\n",
      "               -  Histologically confirmed WHO grade IV astrocytoma (glioblastoma multiforme [GBM])\n",
      "                  including gliosarcoma\n",
      "\n",
      "          -  Stratum 2 (USA patients only):\n",
      "\n",
      "               -  Currently on stable dose of an enzyme-inducing anticonvulsant (with confirmed\n",
      "                  therapeutic serum levels) for at least 2 weeks prior to study registration\n",
      "                  including any of the following:\n",
      "\n",
      "                    -  Phenytoin\n",
      "\n",
      "                    -  Carbamazepine\n",
      "\n",
      "                    -  Phenobarbital\n",
      "\n",
      "               -  Histologically confirmed grade IV astrocytoma (GBM), gliosarcoma, grade III\n",
      "                  astrocytoma, oligodendroglioma, or mixed oligoastrocytoma\n",
      "\n",
      "          -  All patients must have unequivocal evidence of tumor progression by MRI or CT scan\n",
      "             performed no longer than 14 days prior to study registration\n",
      "\n",
      "               -  Patients undergoing surgery for progressive disease with nonmeasurable disease on\n",
      "                  post-operative MRI, ideally obtained within 48 hours of surgery, (i.e.,\n",
      "                  macroscopic gross total resection) are eligible\n",
      "\n",
      "          -  ECOG performance status 0-2 (Karnofsky ≥ 60%)\n",
      "\n",
      "          -  Life expectancy > 3 months\n",
      "\n",
      "          -  Leukocytes ≥ 3,000/μL\n",
      "\n",
      "          -  Absolute neutrophil count ≥ 1,500/μL\n",
      "\n",
      "          -  Platelet count ≥ 100,000/μL\n",
      "\n",
      "          -  Hemoglobin ≥ 9 g/dL\n",
      "\n",
      "          -  Serum calcium ≤ 12.0 mg/dL\n",
      "\n",
      "          -  Total bilirubin within normal institutional limits (ULN)\n",
      "\n",
      "          -  AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN\n",
      "\n",
      "          -  Creatinine < 1.5 X institutional ULN\n",
      "\n",
      "          -  Patients must have QTc < 500 msec\n",
      "\n",
      "          -  The following groups of patients are eligible provided they have New York Heart\n",
      "             Association class II cardiac function on baseline ECHO or MUGA:\n",
      "\n",
      "               -  Those with a history of class II heart failure who are asymptomatic on treatment\n",
      "\n",
      "               -  Those with prior anthracycline exposure\n",
      "\n",
      "               -  Those who have received central thoracic radiation that included the heart in the\n",
      "                  radiotherapy port\n",
      "\n",
      "          -  Women of childbearing potential and men must agree to use adequate contraception\n",
      "             (hormonal or barrier method of birth control or abstinence) prior to study entry and\n",
      "             for the duration of study participation\n",
      "\n",
      "               -  All women of childbearing potential must have a negative pregnancy test prior to\n",
      "                  receiving sunitinib malate\n",
      "\n",
      "          -  Patients with a history of QTc prolongation (defined as a QTc interval >= 500 msec),\n",
      "             serious ventricular arrhythmia (VT or VF > 3 beats in a row) or other significant ECG\n",
      "             abnormalities are excluded\n",
      "\n",
      "          -  Patients with poorly controlled hypertension (systolic BP ≥ 140 mm Hg or diastolic BP\n",
      "             ≥ 90 mm Hg) are ineligible\n",
      "\n",
      "          -  Patients with any condition (e.g., gastrointestinal tract disease resulting in an\n",
      "             inability to take oral medication or a requirement for IV alimentation, prior surgical\n",
      "             procedures affecting absorption, or active peptic ulcer disease) that impairs their\n",
      "             ability to swallow and retain sunitinib malate tablets are excluded\n",
      "\n",
      "          -  Patients with any of the following conditions are excluded:\n",
      "\n",
      "               -  Serious or non-healing wound, ulcer, or bone fracture\n",
      "\n",
      "               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal\n",
      "                  abscess within 28 days of treatment\n",
      "\n",
      "               -  History of myocardial infarction, cardiac arrhythmia, stable or unstable angina,\n",
      "                  symptomatic congestive heart failure, or coronary or peripheral artery bypass\n",
      "                  graft or stenting within 12 months prior to study entry\n",
      "\n",
      "               -  Class III or IV heart failure as defined by the NYHA functional classification\n",
      "                  system\n",
      "\n",
      "          -  Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid\n",
      "             function in the normal range with medication are ineligible\n",
      "\n",
      "          -  Patients with uncontrolled intercurrent illness including, but not limited to, ongoing\n",
      "             or active infections requiring antibiotics or psychiatric illness/social situations\n",
      "             that would limit compliance with study requirements are ineligible\n",
      "\n",
      "          -  Pregnant women are excluded from this study\n",
      "\n",
      "          -  Breastfeeding should be discontinued if the mother is treated with sunitinib malate\n",
      "\n",
      "          -  Patients are eligible if they received up to 1 previous chemotherapy regimen\n",
      "\n",
      "          -  ≥ 12 weeks must have elapsed from the completion of radiation therapy\n",
      "\n",
      "          -  ≥ 4 weeks from previous non-nitrosoureas-based cytotoxic chemotherapy\n",
      "\n",
      "          -  ≥ 6 weeks from any nitrosoureas\n",
      "\n",
      "          -  ≥ 2 weeks from last cytostatic chemotherapy such as erlotinib hydrochloride or\n",
      "             tamoxifen\n",
      "\n",
      "          -  Patients who have undergone previous stereotactic radiosurgery, intratumoral\n",
      "             chemotherapy, or brachytherapy are eligible if functional imaging (PET or SPECT scan,\n",
      "             MR spectroscopy, or dynamic MRI) supports the diagnosis of recurrent tumor or\n",
      "             recurrent disease is confirmed histologically\n",
      "\n",
      "          -  Concurrent steroids allowed provided the patients is on a stable or decreasing dose\n",
      "             for at least 7 days prior to baseline tumor assessment (MRI and/or CT scan)\n",
      "\n",
      "          -  Patients who have received prior treatment with any other antiangiogenic agent (e.g.,\n",
      "             bevacizumab, sorafenib, pazopanib, AZD2171, PTK787, or VEGF Trap) are ineligible\n",
      "\n",
      "          -  Patients who require use of therapeutic doses of coumarin-derivative anticoagulants\n",
      "             such as warfarin or enoxaparin are excluded, although warfarin doses of up to 2 mg\n",
      "             daily are permitted for prophylaxis of thrombosis\n",
      "\n",
      "               -  Low molecular weight heparin is permitted provided the patient's PT INR is < 1.5\n",
      "\n",
      "          -  Use of agents with proarrhythmic potential (e.g., terfenadine, quinidine,\n",
      "             procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone,\n",
      "             indapamide, or flecainide) is not permitted during the study\n",
      "\n",
      "          -  No other investigational or commercial agents or non-investigational therapy designed\n",
      "             to treat the brain malignancy (i.e., radiation therapy, systemic or intratumoral\n",
      "             chemotherapy, biological agents, immunotherapy, or hormonal therapy) is allowed during\n",
      "             the study period\n",
      "\n",
      "          -  HIV-positive patients on combination antiretroviral therapy are ineligible\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of allergic reactions attributed to compounds of similar chemical or\n",
      "             biological composition to sunitinib malate\n",
      "\n",
      "          -  Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or\n",
      "             mitomycin C) or radiation therapy within 12 weeks prior to entering the study or those\n",
      "             who have not recovered from adverse events due to agents administered more than 4\n",
      "             weeks earlier\n",
      "\n",
      "               -  At least 4 weeks must have elapsed since any major surgery\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        1) Men or woman older than 18 years with stage I-IV renal cell carcinoma 2) Zubrod\n",
      "        performance status of less than or equal to 2 3) have no serious intercurrent medical\n",
      "        illness 4) read and speak English\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        1) Score of 23 or below on the Mini-mental 2) History of primary or secondary\n",
      "        immunodeficiency 3) Taking immunosuppressive drugs such as systemic corticosteroid 4)\n",
      "        Patients who are undergoing a surgical procedure and do not sign the general tissue consent\n",
      "        form 5) Patients with major psychiatric diagnoses or currently seeking psychological\n",
      "        counseling.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  patients with total thyroidectomy plus central neck dissection\n",
      "\n",
      "          -  if primary tumor size was more than 1 cm in papillary thyroid cancer\n",
      "\n",
      "          -  there was any evidence of lymph node enlargement in paratracheal lymph node group\n",
      "             preoperatively or intraoperatively\n",
      "\n",
      "          -  patients who underwent minimal resection of the surrounding soft tissues, including\n",
      "             the sternothyroid or sternohyoid muscle, for extracapsular extension of thyroid cancer\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  patients who required lateral compartment neck dissection or mediastinal dissection\n",
      "             for preexisting lymph node metastasis\n",
      "\n",
      "          -  patients had clinical or laboratory indicators of coagulation disorders\n",
      "\n",
      "          -  patients with preexisiting vocal cord palsy, fixation of the tumor to the recurrent\n",
      "             laryngeal nerve requiring trnasection of the nerve\n",
      "\n",
      "          -  patients with massive extracapsular extension to the surrounding soft tissues.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age greater than or equal to 2 years\n",
      "\n",
      "          2. Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD\n",
      "             prophylaxis allowed\n",
      "\n",
      "          3. If a prevalent case (defined as enrollment three or more months after chronic GVHD\n",
      "             diagnosis), then subject must be within 2 years of stem cell infusion\n",
      "\n",
      "          4. Diagnosis of chronic GVHD meeting the diagnostic criteria of the diagnosis and staging\n",
      "             group of the NIH consensus conference\n",
      "\n",
      "          5. Need for systemic treatment, defined as any medication or intervention delivered\n",
      "             systemically, including extracorporeal photopheresis. If a patient only received\n",
      "             topical or local therapy at diagnosis, but subsequently requires systemic treatment,\n",
      "             they may be enrolled upon initiation of systemic therapy. (Note, these patients will\n",
      "             be classified as incident or prevalent cases depending on time from chronic GVHD\n",
      "             diagnosis, not start of systemic therapy)\n",
      "\n",
      "          6. Progression-free for their malignancy at enrollment (no evidence of primary disease\n",
      "             progression since transplant, although residual disease may still be present)\n",
      "\n",
      "          7. Evaluation at the transplant center at the time of study enrollment, and agreement to\n",
      "             be re-evaluated at the transplant center at 3 and 6 months\n",
      "\n",
      "          8. Signed, informed consent and if applicable, child assent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Inability to verbally communicate in English\n",
      "\n",
      "          2. Inability to comply with study procedures\n",
      "\n",
      "          3. Anticipated survival less than 6 months due to co-morbid disease or persistent\n",
      "             malignancy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  5 mg/day of amlodipine is administered for more than 3 months\n",
      "\n",
      "          -  Systolic or diastolic blood pressure >= 140/90 mmHg (more than 2 times measurements at\n",
      "             outpatient clinic before start of the study)\n",
      "\n",
      "          -  Outpatients\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Secondary hypertension including renovascular hypertension with single kidney or\n",
      "             bilateral stenosis\n",
      "\n",
      "          -  Administration of antihypertensives other than amlodipine\n",
      "\n",
      "          -  Cardiovascular disease (cerebral hemorrhage, cerebral infarction, TIA, angina,\n",
      "             myocardial infarction, acute renal failure) occurs less than 6 months before start of\n",
      "             the study\n",
      "\n",
      "          -  Serum creatinine >= 2.0 mg/dl\n",
      "\n",
      "          -  Severe hypertension (systolic or diastolic blood pressure >= 180/110 mmHg) or\n",
      "             malignant hypertension (hypertensive organ damage is rapidly developing)\n",
      "\n",
      "          -  Chronic heart failure (NYHA class>=III to VI)\n",
      "\n",
      "          -  Contraindication of telmisartan or hydrochlorothiazide\n",
      "\n",
      "          -  Hyper- (>= 5.5 mEq/L) or hypo- (<=3.5 mEq/l) potassemia\n",
      "\n",
      "          -  Untreated hyperuricemia or uncontrolled hyperuricemia (serum uric acid >= 8.0 mg/dl)\n",
      "\n",
      "          -  Diabetic patients who require insulin therapy, uncontrolled diabetic patients\n",
      "             (hemoglobin A1c >=9.0%), or patients who possess the risk of hypoglycemic attack\n",
      "\n",
      "          -  Patients inadequate for the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Patients with histological confirmation solid malignancy refractory to conventional\n",
      "             standard therapies for their condition.\n",
      "\n",
      "          2. Eligible subjects MUST have at least one measurable lesion as defined by RECIST\n",
      "             guidelines. If the measurable disease is restricted to a solitary lesion, its\n",
      "             neoplastic nature should be confirmed by cytology/histology. Measurable lesions MUST\n",
      "             not have been in a previously irradiated field or injected with biological agents.\n",
      "\n",
      "          3. Pediatric patients will be eligible at the discretion of the primary investigator.\n",
      "\n",
      "          4. ECOG performance status score </= 2.\n",
      "\n",
      "          5. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically\n",
      "             sterile) must use acceptable contraceptive methods (abstinence, intrauterine device\n",
      "             [IUD], oral contraceptive or double barrier device), and must have a negative blood or\n",
      "             urine pregnancy test within 1 week before beginning treatment. Sexually active men\n",
      "             must also use acceptable contraceptive methods.\n",
      "\n",
      "          6. Patients must provide written informed consent prior to treatment.\n",
      "\n",
      "          7. At least four weeks from completion of prior therapy to day 1 of study drug.\n",
      "\n",
      "          8. Baseline toxicity assessment less than or equal to grade 1 except treatment induced\n",
      "             alopecia (NCI Common Terminology Criteria for Adverse Events [CTCAE] version 3.0).\n",
      "\n",
      "          9. Evidence of adequate multi-organ functional status as reflected by the following\n",
      "             clinical laboratory values: - Serum creatinine </= 2 times the upper normal limit OR a\n",
      "             calculated creatinine clearance </= 50 cc/min. - Total bilirubin </= 2 times the upper\n",
      "             normal limit. - Alanine aminotransferase (ALT), OR aspartate aminotransferase (AST)\n",
      "             </= 3 times the upper limit of normal.\n",
      "\n",
      "         10. Granulocytes in peripheral blood greater than or equal to 1 x 10(9) per liter,\n",
      "             hemoglobin greater than or equal to 8.5 g/dL, and platelets greater than or equal to\n",
      "             50,000 cells/microL.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Uncontrolled systemic infection (documented with microbiological studies).\n",
      "\n",
      "          2. Active heart disease as defined by an acute myocardial infarction within the previous\n",
      "             6 months before starting therapy, stable or unstable angina, clinically significant\n",
      "             arrhythmia requiring medical management, OR New York Heart Association Classification\n",
      "             of Functional Activities. Class 3: Patient has marked limitation in activities due to\n",
      "             symptoms, even during less-than-ordinary activity and is comfortable only at rest OR\n",
      "             Class 4: Severe limitations. Patient experiences symptoms even while at rest.\n",
      "\n",
      "          3. Concomitant therapy for solid cancer.\n",
      "\n",
      "          4. Pregnant subjects and those who are breast-feeding.\n",
      "\n",
      "          5. History of an invasive second primary malignancy diagnosed within the previous 3 years\n",
      "             except for Stage I Endometrial/Cervical Carcinoma or Prostate Carcinoma treated\n",
      "             surgically, and non-melanoma skin cancer.\n",
      "\n",
      "          6. Documented personal or family history of prolonged QT syndrome.\n",
      "\n",
      "          7. 12 lead electrocardiogram with a corrected QT interval >/= 460 milliseconds.\n",
      "\n",
      "          8. History of confusion or dementia.\n",
      "\n",
      "          9. History of seizure disorder.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Newly diagnosed cervical cancer: clinical Stage IB -IIIB\n",
      "\n",
      "          2. Invasive pure squamous cell carcinoma\n",
      "\n",
      "          3. Planned treatment with concurrent cisplatinum/5-fluorouracil chemotherapy and pelvic\n",
      "             radiation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        1. Previous cervical cancer treatment including but not limited to transvaginal cone\n",
      "        irradiation\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  After written informed consent patients undergoing elective open colon surgery, or\n",
      "             open hysterectomy or myomectomy, or spine surgery or hip replacement will be included\n",
      "             in the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients having severe cardiac or renal insufficiency\n",
      "\n",
      "          -  Patients with severe coronary artery disease\n",
      "\n",
      "          -  Patients with insulin-dependent diabetes mellitus\n",
      "\n",
      "          -  Patients with severe COPD\n",
      "\n",
      "          -  Patients with symptoms of infections or sepsis\n",
      "\n",
      "          -  Patients with allergy to hydroxyethylstarch.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  penetrating extremity injury with tourniquet use\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  non penetrating extremity injury\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  diagnosis of Mycobacterium tuberculosis infection\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  all other granulomatous or neoplastic diseases\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  36-84 month old children\n",
      "\n",
      "          -  Child must meet the DSM-IV criteria for AD or PDD NOS as determined via a parent\n",
      "             interview on the ADI-R and on child observation via the ADOS, or DD.\n",
      "\n",
      "          -  Child must have categorical and dimensional evidence of clinically significant ADHD\n",
      "             symptoms in multiple settings that have been present for at least six months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Child with prior failed treatment with an adequate trial of methylphenidate;\n",
      "\n",
      "          -  Concurrent treatment with other medications that have CNS effects or that affect\n",
      "             performance (e.g., antidepressants, antipsychotics, alpha-agonists, adrenergic\n",
      "             blockers, lithium carbonate, sedating antihistamines, decongestant or\n",
      "             sympathomimetics);\n",
      "\n",
      "          -  Child with a current history of chronic tic disorder (e.g., Tourette syndrome with\n",
      "             current severity of moderate or more), or a family history of Tourette's Disorder.\n",
      "             Children with chronic mild tics will be eligible for the study;\n",
      "\n",
      "          -  Child who has a major medical condition that would interfere with involvement in the\n",
      "             study or would be affected negatively by methylphenidate (i.e., heart disease, high\n",
      "             blood pressure, glaucoma, untreated or unstable hyperthyroidism, uncontrolled seizure\n",
      "             disorder, or illnesses that would require hospitalization). Children with seizures\n",
      "             will be eligible for the study if the seizure medication is stable for 3 months and\n",
      "             the child is seizure-free for at least 6 months;\n",
      "\n",
      "          -  Child with co-morbid psychiatric diagnoses of Major Depression, Bipolar Disorder, a\n",
      "             psychotic disorder, Rett's Disorder, Childhood Disintegrative Disorder, or other\n",
      "             psychiatric disorders in addition to PDD and ADHD that may require treatment with\n",
      "             additional/alternative medication;\n",
      "\n",
      "          -  Current history of physical, sexual, or emotional abuse;\n",
      "\n",
      "          -  The patient has taken an investigational drug within the last 30 days.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with end-stage renal disease who have received hemodialysis thrice weekly for\n",
      "             at least 90 days\n",
      "\n",
      "          -  Serum albumin > 30 g/L.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who refuse to sign a letter of informed consent\n",
      "\n",
      "          -  Women who are or are trying to become pregnant or are breast-feeding.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  10-18 years old\n",
      "\n",
      "          -  BMI > or = 95th percentile\n",
      "\n",
      "          -  > 1 year postburn and out of pressure garments\n",
      "\n",
      "          -  Live within 100 minle radius of SHC\n",
      "\n",
      "          -  Informed consent and HIPPA form signed\n",
      "\n",
      "          -  Parent/guardia willing to make time commitment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Undergone major surgery in the 4 months prior to start of program or have any major\n",
      "             surgery planned in 2 year time frame\n",
      "\n",
      "          -  Physical/health condition that precludes regular exercise\n",
      "\n",
      "          -  Significant mental health diagnosis\n",
      "\n",
      "          -  Advised by MD not to exercise\n",
      "\n",
      "          -  Thyroid disease, routine steroid use,pregnancy\n",
      "\n",
      "          -  Unable to understand the instructions/content of program\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with GERD grade A and B (mild to moderate severe disease) diagnosed by\n",
      "             routine endoscopy will be recruited in different clinical and ambulant centres of\n",
      "             gastroenterology; written informed consent is obligatory\n",
      "\n",
      "          -  Range of Age: 20-70\n",
      "\n",
      "          -  BMI: 20-30\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who are allergic to proton-pump inhibitors or show incompatibility\n",
      "\n",
      "          -  Patients who have lactase deficiency\n",
      "\n",
      "          -  Patients who have severe chronic disease\n",
      "\n",
      "          -  Patients who participated in another study during the last three months\n",
      "\n",
      "          -  Patients who are pregnant\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:children\n",
      "\n",
      "          -  Age 2-17 with a diagnosis of perforated appendicitis\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Age <2 and >18\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Immunocompromise\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy males\n",
      "\n",
      "          -  body mass index between 20-25\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  use of any medication\n",
      "\n",
      "          -  smoking\n",
      "\n",
      "          -  consumption of 3 or more glasses of alcohol per day\n",
      "\n",
      "          -  involved in top sport\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Voluntary written informed consent before performance of any study-specific procedure\n",
      "             not part of routine medical care, with the understanding that consent may be withdrawn\n",
      "             by the subject at any time without prejudice to future medical care.\n",
      "\n",
      "          -  Female subject is either post-menopausal or surgically sterilized or willing to use\n",
      "             acceptable method of birth control for duration of study.\n",
      "\n",
      "          -  Male subject agrees to use acceptable method for contraception for duration of study.\n",
      "\n",
      "          -  Histologically-confirmed indolent or mantle cell lymphoma, utilizing the World Health\n",
      "             Organization (WHO) classification. The biopsy must fulfill one of the following\n",
      "             criteria:\n",
      "\n",
      "               -  Follicular lymphoma, grades 1-3\n",
      "\n",
      "               -  Marginal zone lymphoma\n",
      "\n",
      "               -  Small lymphocytic lymphoma (circulating lymphocyte count must be < 5,000)\n",
      "\n",
      "               -  Lymphoplasmacytic lymphoma\n",
      "\n",
      "               -  Mantle cell lymphoma [confirmed by cyclin D1+ or FISH for t(11;14)]\n",
      "\n",
      "          -  Age ≥ 18 years\n",
      "\n",
      "          -  Must have received at least one prior chemotherapy regimen for lymphoma. Patients\n",
      "             treated only with antibody therapy or only with radiation therapy are not eligible.\n",
      "\n",
      "          -  Zubrod performance status ≤ 3\n",
      "\n",
      "          -  Patients must have measurable disease or an indication to receive additional therapy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient has platelet count of ≤75,000/mm^3 within 14 days before enrollment.\n",
      "\n",
      "          -  Patient has absolute neutrophil count of < 1,000/mm^3 within 14 days before\n",
      "             enrollment.\n",
      "\n",
      "          -  Patient has calculated or measured creatinine clearance of <30 mL/minute within 14\n",
      "             days before enrollment.\n",
      "\n",
      "          -  Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment.\n",
      "\n",
      "          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart\n",
      "             Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled\n",
      "             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active\n",
      "             conduction system abnormalities. Prior to study entry, any ECG abnormality at\n",
      "             Screening has to be documented by the investigator as not medically relevant.\n",
      "\n",
      "          -  Patient has hypersensitivity to boron or mannitol\n",
      "\n",
      "          -  Female subject is pregnant or breast-feeding. Confirmation subject is not pregnant\n",
      "             must be established by negative serum ß-human chorionic gonadotropin (ß-hCG) pregnancy\n",
      "             test result obtained during screening. Pregnancy testing is not required for\n",
      "             post-menopausal or surgically sterilized women.\n",
      "\n",
      "          -  Patient has received chemotherapy or antibody therapy within 28 days before enrollment\n",
      "\n",
      "          -  Serious medical or psychiatric illness likely to interfere with participation in this\n",
      "             clinical study.\n",
      "\n",
      "          -  Patient has received other investigational drugs with 14 days before enrollment\n",
      "\n",
      "          -  Diagnosed or treated for another malignancy within 3 years of enrollment, with the\n",
      "             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of\n",
      "             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.\n",
      "\n",
      "          -  Prior exposure to bendamustine\n",
      "\n",
      "          -  Prior exposure to bortezomib if Time to Progression (TTP) after bortezomib containing\n",
      "             regimen was < 6 months. If TTP after bortezomib containing regimen was > 6 months,\n",
      "             then patient is allowed to enroll on the study.\n",
      "\n",
      "          -  Patient has concomitant active malignancy requiring therapy\n",
      "\n",
      "          -  Patient is known to be HIV positive (test result not required for enrollment).\n",
      "\n",
      "          -  History of solid organ transplantation, or post transplant lymphoproliferative\n",
      "             disorder\n",
      "\n",
      "          -  Patient has history of allogeneic stem cell transplantation.\n",
      "\n",
      "          -  Patient has history of autologous stem cell transplantation or radioimmunotherapy\n",
      "             within the previous 4 months.\n",
      "\n",
      "          -  Patient has received any other investigational drugs within 14 days prior to\n",
      "             enrollment\n",
      "\n",
      "          -  History of, or clinically apparent CNS lymphoma\n",
      "\n",
      "          -  Any clinically significant abnormality in screening blood chemistry, hematology, or\n",
      "             urinalysis results that, in the judgment of the investigator, would impede adequate\n",
      "             evaluation of adverse events and/or response to treatment, or that requires aggressive\n",
      "             intervention\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Patients with hematologic malignancies, who are at high risk of complications after\n",
      "             conventional myeloablative transplantation\n",
      "\n",
      "          2. Patients must have a 6/6 matched, related donor. Matching at HLA Class II will be\n",
      "             based on PCR of sequence specific primers (SSP). Among family member transplants,\n",
      "             serologic matching at Class I is sufficient\n",
      "\n",
      "          3. Patient age greater than 18\n",
      "\n",
      "          4. Performance status 0-2\n",
      "\n",
      "          5. Life expectancy of > 100 days without transplantation\n",
      "\n",
      "          6. Written informed consent must be obtained in all cases from the patient\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Pregnancy\n",
      "\n",
      "          2. Prior Allogeneic Stem Cell Transplantation from any donor\n",
      "\n",
      "          3. Evidence of HIV infection or active Hepatitis B or C infection\n",
      "\n",
      "          4. Heart failure uncontrolled by medications\n",
      "\n",
      "          5. Total bilirubin > 2.0 mg/dl that is due to hepatocellular dysfunction\n",
      "\n",
      "          6. AST > 90\n",
      "\n",
      "          7. Cholesterol > 300 mg/dl or Triglycerides > 400 mg/dl while adequately treated\n",
      "\n",
      "          8. Uncontrolled bacterial, viral or fungal infection\n",
      "\n",
      "          9. Requirement for voriconazole at the time of hospital admission\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  cerebral palsy (diplegia and hemiplegia)\n",
      "\n",
      "          -  indication for anti-spastic treatment with Botulinum toxin\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  fixed contractures\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  females\n",
      "\n",
      "          -  at least 2 seizures per month\n",
      "\n",
      "          -  more than 50% of the seizures occur 7 days before or 7 days after the onset of menses\n",
      "\n",
      "          -  patient of the Toronto Western Hospital Epilepsy Clinic\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  cardiovascular history\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  DSM-IV diagnostic criteria for MDD (diagnosed with the use of SCID)\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "          -  Men or women aged 18-65\n",
      "\n",
      "          -  A baseline Hamilton-D17 score of > 16.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects with suicidal ideation where outpatient treatment is determined unsafe by the\n",
      "             study clinician. These patients will be immediately referred to appropriate clinical\n",
      "             treatment.\n",
      "\n",
      "          -  Pregnant women or women of childbearing potential who are not using a medically\n",
      "             accepted means of contraception (defined as oral contraceptive pill or implant,\n",
      "             condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)\n",
      "\n",
      "          -  Serious or unstable medical illness, including cardiovascular, hepatic, renal,\n",
      "             respiratory, endocrine, neurologic or hematologic disease\n",
      "\n",
      "          -  History of seizure disorder,\n",
      "\n",
      "          -  History or current diagnosis of the following DSM-IV psychiatric illness: organic\n",
      "             mental disorder, schizophrenia, schizoaffective disorder, delusional disorder,\n",
      "             psychotic disorders not otherwise specified, bipolar disorder, patients with mood\n",
      "             congruent or mood incongruent psychotic features, patients with substance dependence\n",
      "             disorders, including alcohol, active within the last 12 months.\n",
      "\n",
      "          -  History or current diagnosis of dementia, or a score of < 26 on the Mini Mental Status\n",
      "             Examination (Folstein, 1975) at the screening visit.\n",
      "\n",
      "          -  History of multiple adverse drug reactions or allergy to the study drugs.\n",
      "\n",
      "          -  Patients with mood congruent or mood incongruent psychotic features.\n",
      "\n",
      "          -  Patients having shown minimal or no response to a standard course of antidepressant\n",
      "             treatment with an SSRI. A standard course will be defined as the following medications\n",
      "             taken for > 4 weeks: fluoxetine > 20 mg/day, sertraline > 50 mg/day, paroxetine > 20\n",
      "             mg/day, fluvoxamine > 50 mg/day, citalopram > 20 mg/day, venlafaxine > 150 mg/day.\n",
      "\n",
      "          -  Clinical or laboratory evidence of hypothyroidism.\n",
      "\n",
      "          -  Patients who have had electroconvulsive therapy (ECT) within the 6 months preceding\n",
      "             baseline.\n",
      "\n",
      "          -  History of intolerance to Cytomel\n",
      "\n",
      "          -  History of cardiac pathology or diabetes\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects with schizophrenia or another psychotic disorder according to DSM IV criteria\n",
      "             who requires long term antipsychotic therapy\n",
      "\n",
      "          -  Currently treated with either an atypical antipsychotic, other than risperidone, a\n",
      "             conventional depot antipsychotic or oral conventional antipsychotic\n",
      "\n",
      "          -  Subject has been symptomatically stable on a stable dose of an antipsychotic the last\n",
      "             month\n",
      "\n",
      "          -  Subject and/or patient's relative, guardian or legal representative has signed the\n",
      "             informed consent form\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  First antipsychotic treatment ever\n",
      "\n",
      "          -  On clozapine during the last 3 month\n",
      "\n",
      "          -  Serious unstable medical condition\n",
      "\n",
      "          -  History or current symptoms of tardive dyskinesia\n",
      "\n",
      "          -  History of neuroleptic malignant syndrome\n",
      "\n",
      "          -  Pregnant or breast-feeding female\n",
      "\n",
      "          -  Female patient of childbearing potential without adequate contraception.\n",
      "\n",
      "          -  Participation in an investigational drug trial in the 30 days prior to selection\n",
      "\n",
      "          -  Known intolerance/non-responder to risperidone\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologic or cytologic diagnosis of adenocarcinoma of the pancreas that is locally\n",
      "             advanced & not amenable to resection with curative intent.\n",
      "\n",
      "          -  Must not have received prior systemic therapy for locally advanced disease.\n",
      "\n",
      "          -  ECOG performance status must be 0-2.\n",
      "\n",
      "          -  Adequate hepatic, renal & bone marrow function.\n",
      "\n",
      "          -  Radiographic evidence of disease is required.\n",
      "\n",
      "          -  Life expectancy > 12 weeks.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior treatment with Capecitabine & other EGFR inhibitor.\n",
      "\n",
      "          -  Patients with GI tract disease resulting in an inability to take oral medications.\n",
      "\n",
      "          -  Significant GI disorders with diarrhea as a major symptom.\n",
      "\n",
      "          -  Uncontrolled intercurrent illness including active infection,symptomatic congestive\n",
      "             heart failure, unstable angina pectoris, cardiac arrhythmias now well controlled with\n",
      "             medication, myocardial infarction within the previous 6 months, psychiatric\n",
      "             illness/social situations that would limit compliance with study requirements.\n",
      "\n",
      "          -  Patients with metastases.\n",
      "\n",
      "          -  Patients who have had chemotherapy.\n",
      "\n",
      "          -  Patients may not be receiving any other investigational agents, or have participated\n",
      "             in any investigational drug study.\n",
      "\n",
      "          -  Extensive symptomatic fibrosis of the lungs.\n",
      "\n",
      "          -  Females who are pregnant or lactating.\n",
      "\n",
      "          -  History of any other malignancy in the last 2 years, except prior history of in situ\n",
      "             cancer, basal or squamous cell skin cancer are eligible.\n",
      "\n",
      "          -  Known DPD deficiency.\n",
      "\n",
      "          -  Receiving therapeutic doses of Coumarin-derivative anticoagulant therapy. Patients\n",
      "             requiring anticoagulation who may be safely switched to LMWH are eligible.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Male or Female subject between 18 to 80 years of age\n",
      "\n",
      "          2. Subject is scheduled to undergo elective cardiac surgical procedure(s) to be performed\n",
      "             on cardiopulmonary bypass including:\n",
      "\n",
      "               -  coronary artery bypass and/or\n",
      "\n",
      "               -  mitral valve surgery (repair or replacement)\n",
      "\n",
      "               -  aortic valve surgery (repair or replacement)\n",
      "\n",
      "               -  tricuspid valve surgery (repair or replacement)\n",
      "\n",
      "          3. Left Ventricular Ejection Fraction ≥ 30%\n",
      "\n",
      "          4. Subject is willing and able to provide written informed consent\n",
      "\n",
      "          5. Subject has a life expectancy of at least 2 years\n",
      "\n",
      "          6. Subject is willing and able to return for scheduled follow-up visits\n",
      "\n",
      "          7. TREATMENT SUBJECTS ONLY: Subject has a 3 month documented history of continuous atrial\n",
      "             fibrillation\n",
      "\n",
      "          8. CONTROL SUBJECTS ONLY: Subject is not in atrial fibrillation at time of surgery\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Lone AF without indication(s) for concomitant CABG and/or mitral valve surgery, aortic\n",
      "             valve surgery, tricuspid valve surgery or double valve surgery\n",
      "\n",
      "          2. Prior cardiac surgery (Redo -including previous ablation)\n",
      "\n",
      "          3. Patient requires atrial septal defect repair or any other concomitant open-heart\n",
      "             procedure, other than CABG and/or mitral valve surgery; aortic valve surgery,\n",
      "             tricuspid valve surgery or double valve surgery\n",
      "\n",
      "          4. Serum creatinine concentration greater than 2.0 mg/dl\n",
      "\n",
      "          5. Class IV NYHA heart failure symptoms and/or Class IV CCS anginal symptoms\n",
      "\n",
      "          6. Prior history of cerebrovascular accident within 6 months or at any time if there is\n",
      "             residual neurologic deficit\n",
      "\n",
      "          7. Active infection\n",
      "\n",
      "          8. Known carotid artery stenosis greater than 80%\n",
      "\n",
      "          9. Severe peripheral arterial occlusive disease defined as claudication with minimal\n",
      "             exertion\n",
      "\n",
      "         10. A known drug and/or alcohol addiction\n",
      "\n",
      "         11. Mental impairment or other conditions which may not allow the the subject to\n",
      "             understand the nature, significance and scope of the study\n",
      "\n",
      "         12. Pregnancy or desire to get pregnant within 12 months of study enrollment\n",
      "\n",
      "         13. Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        DISEASE CHARACTERISTICS:\n",
      "\n",
      "          -  Histologically or cytologically confirmed diagnosis of a solid tumor malignancy within\n",
      "             the past 5 years\n",
      "\n",
      "               -  If the original histologic proof of malignancy is > 5 years, then pathological\n",
      "                  (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or\n",
      "                  brain metastasis)\n",
      "\n",
      "          -  Brain metastases must be visible on contrast-enhanced MRI or a contrast enhanced CT\n",
      "             scan (for patients unable to undergo MRI within the past 28 days)\n",
      "\n",
      "               -  Patients unable to undergo MRI imaging because of non-compatible devices are\n",
      "                  eligible, provided the contrast-enhanced CT scans are obtained and are of\n",
      "                  sufficient quality\n",
      "\n",
      "               -  Patients who had undergone radiosurgery or surgical resection and are planning\n",
      "                  adjuvant whole-brain radiotherapy do not have to have visible disease but do need\n",
      "                  a baseline MRI\n",
      "\n",
      "          -  Must have stable systemic disease (i.e. no evidence of systemic disease progression\n",
      "             within the past 3 months)\n",
      "\n",
      "          -  Patients with brain metastases at initial presentation are eligible and do not need to\n",
      "             demonstrate 3 months of stable scans\n",
      "\n",
      "        PATIENT CHARACTERISTICS:\n",
      "\n",
      "        Inclusion\n",
      "\n",
      "          -  Karnofsky performance status 70-100%\n",
      "\n",
      "          -  Serum creatinine ≤ 3 mg/dL and creatinine clearance ≥ 30 mL/min\n",
      "\n",
      "          -  Total bilirubin ≤ 2.5 mg/dL\n",
      "\n",
      "          -  Blood urea nitrogen (BUN) < 20 mg/dL\n",
      "\n",
      "          -  Mini-mental status exam score ≥ 18\n",
      "\n",
      "          -  Negative serum pregnancy test\n",
      "\n",
      "          -  Fertile patients must practice adequate contraception\n",
      "\n",
      "        Exclusion\n",
      "\n",
      "          -  Severe, active co-morbidity, defined as follows:\n",
      "\n",
      "               -  Unstable angina and/or congestive heart failure requiring hospitalization within\n",
      "                  the last 6 months\n",
      "\n",
      "               -  Transmural myocardial infarction within the last 6 months\n",
      "\n",
      "               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time\n",
      "                  of registration\n",
      "\n",
      "               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness\n",
      "                  requiring hospitalization or precluding study therapy at the time of registration\n",
      "\n",
      "               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects\n",
      "\n",
      "          -  Pregnant or lactating women\n",
      "\n",
      "          -  Prior allergic reaction to memantine hydrochloride\n",
      "\n",
      "          -  Current alcohol or drug abuse\n",
      "\n",
      "          -  Intractable seizures while on adequate anticonvulsant therapy (i.e., more than one\n",
      "             seizure per month for the past 2 months)\n",
      "\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "\n",
      "        Inclusion\n",
      "\n",
      "          -  At least 14 days but no more than 56 days since prior therapy for brain metastasis,\n",
      "             including radiosurgery and surgical resection\n",
      "\n",
      "          -  No systemic chemotherapy for 14 days prior, during, or for 14 days after completion of\n",
      "             whole-brain radiotherapy (WBRT)\n",
      "\n",
      "        Exclusion\n",
      "\n",
      "          -  Prior cranial radiotherapy\n",
      "\n",
      "               -  Patients may have received up to 3 prior WBRT treatments and still be registered\n",
      "                  and randomized on the protocol provided WBRT parameters meet protocol\n",
      "                  requirements\n",
      "\n",
      "          -  Chronic short-acting benzodiazepine use\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Histologically confirmed colorectal carcinoma with inoperable, locally advanced, or\n",
      "             metastatic disease, not amenable to curative therapy\n",
      "\n",
      "          2. Measurable disease or non-measurable but assessable disease according to the Response\n",
      "             Evaluation Criteria in Solid Tumors (RECIST)\n",
      "\n",
      "          3. Patients with no previous treatment (radiotherapy or chemotherapy). Patients who have\n",
      "             received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more\n",
      "             than 180 days after the end of such treatment.\n",
      "\n",
      "             Preoperative or postoperative irradiation (<30 Gy) for rectal cancer is possible\n",
      "\n",
      "          4. Age >20 years\n",
      "\n",
      "          5. Life expectancy of at least 3 months\n",
      "\n",
      "          6. ECOG PS of 0 or 1\n",
      "\n",
      "          7. Adequate function of major organs as defined below:\n",
      "\n",
      "               1. Hemoglobin >9.0 g/dL\n",
      "\n",
      "               2. White blood cell count >3,000/mm3\n",
      "\n",
      "               3. Neutrophil count >1,500/mm3\n",
      "\n",
      "               4. Platelet count >100,000/mm3\n",
      "\n",
      "               5. Total bilirubin <1.5 mg/dL\n",
      "\n",
      "               6. AST and ALT <100 U/L (<200 U/L in patients with liver metastasis)\n",
      "\n",
      "               7. Serum creatinine <1.2 mg/dL\n",
      "\n",
      "               8. Creatinine clearance estimate by the Cockcroft-Gault method >50 mL/min (reduce\n",
      "                  initial dosage by one step if ≥50 but <80 mL/min)\n",
      "\n",
      "          8. Able to take capsules orally.\n",
      "\n",
      "          9. No electrocardiographic abnormalities within 28 days before enrollment that would\n",
      "             clinically preclude the execution of the study, as judged by the investigator.\n",
      "\n",
      "         10. Voluntary written informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Serious drug hypersensitivity or a history of drug allergy\n",
      "\n",
      "          2. Active double cancer\n",
      "\n",
      "          3. Active infections (e.g., patients with pyrexia of 38℃ or higher)\n",
      "\n",
      "          4. History of gastrointestinal perforation, intestinal tract paralysis, or ileus within 1\n",
      "             year.\n",
      "\n",
      "          5. Uncontrolled hypertension\n",
      "\n",
      "          6. Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart\n",
      "             failure, renal failure, hepatic failure, or poorly controlled diabetes)\n",
      "\n",
      "          7. Moderate or severe ascites or pleural effusion requiring treatment\n",
      "\n",
      "          8. Watery diarrhea\n",
      "\n",
      "          9. Treatment with flucytosine or atazanavir sulfate\n",
      "\n",
      "         10. Metastasis to the CNS\n",
      "\n",
      "         11. Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing\n",
      "             mothers. Men who are currently attempting to conceive children.\n",
      "\n",
      "         12. Severe mental disorder\n",
      "\n",
      "         13. Continuous treatment with steroids\n",
      "\n",
      "         14. Urine dipstick for proteinuria should be <2+\n",
      "\n",
      "         15. Patient with a past history of thrombosis, cerebral infarction, myocardial infarction,\n",
      "             or pulmonary embolism\n",
      "\n",
      "         16. Major surgical procedure, open biopsy, or clinically significant traumatic injury\n",
      "             within 4 weeks\n",
      "\n",
      "         17. Long-term daily treatment with aspirin (>325 mg/day)\n",
      "\n",
      "         18. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of\n",
      "             bleeding\n",
      "\n",
      "         19. Judged ineligible for participation in the study by the investigator for safety\n",
      "             reasons.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Receiving diabetes treatment with insulin for a minimum of 3 months\n",
      "\n",
      "          -  Body Mass Index (BMI) of ≤ 34 kg/m2 and ≥ 25 kg/m2\n",
      "\n",
      "          -  HbA1c ≤ 8.5% based upon results from a central laboratory\n",
      "\n",
      "          -  Non-smoking Males and females ≥ 18 and ≤ 70 years of age\n",
      "\n",
      "          -  A clinical diagnosis of type 2 diabetes mellitus for ≥ 12 months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Total daily insulin requirement of ≥ 1.2 U/kg body weight\n",
      "\n",
      "          -  Use of Symlin® (pramlintide acetate) and/or Byetta® (exenatide) within the preceding 8\n",
      "             weeks\n",
      "\n",
      "          -  Two or more severe hypoglycemic episodes within 6 months of screening\n",
      "\n",
      "          -  Any hospitalization or emergency room visit due to poor diabetic control within 6\n",
      "             months of Screening\n",
      "\n",
      "          -  Severe complications of diabetes\n",
      "\n",
      "          -  Previous exposure to any inhaled insulin product\n",
      "\n",
      "          -  Currently using an insulin delivery pump\n",
      "\n",
      "          -  Allergy or known hypersensitivity to insulin or to any of the drugs to be used in the\n",
      "             trial\n",
      "\n",
      "          -  Any clinically important pulmonary disease, confirmed by documented history, pulmonary\n",
      "             function testing, or radiologic findings\n",
      "\n",
      "          -  Chronic use of systemic steroids\n",
      "\n",
      "          -  Inability to perform PFT maneuvers to meet the recommended American Thoracic Society\n",
      "             (ATS) standards of acceptability and repeatability\n",
      "\n",
      "          -  Significant improvement in spirometry following bronchodilation\n",
      "\n",
      "          -  Active respiratory infection\n",
      "\n",
      "          -  Seizure disorder\n",
      "\n",
      "          -  Significant cardiovascular dysfunction and/or history within 3 months of Screening\n",
      "\n",
      "          -  Uncontrolled hypertension with a systolic blood pressure of >160 mm Hg and/or\n",
      "             diastolic blood pressure > 95 mm Hg at screening, despite pharmacologic treatment\n",
      "\n",
      "          -  Clinical nephrotic syndrome or renal dysfunction or disease\n",
      "\n",
      "          -  Cancer (other than an excised cutaneous basal cell carcinoma) within the past 5 years\n",
      "             or any history of lung neoplasms\n",
      "\n",
      "          -  History of active viral and/or cirrhotic hepatic disease and/or abnormal liver enzymes\n",
      "\n",
      "          -  Active infection eg, Human Immunodeficiency Virus (HIV), Hepatitis, or history of\n",
      "             severe infection within 30 days of Screening\n",
      "\n",
      "          -  Anemia\n",
      "\n",
      "          -  A previous diagnosis of systemic autoimmune or collagen vascular disease requiring\n",
      "             prior or current treatment with systemic corticosteroids, cytotoxic drugs or\n",
      "             penicillamine\n",
      "\n",
      "          -  Any concurrent illness, other than diabetes mellitus not controlled by a stable\n",
      "             therapeutic regime\n",
      "\n",
      "          -  Current or previous chemotherapy or radiation therapy that may result in pulmonary\n",
      "             toxicity\n",
      "\n",
      "          -  Clinically significant abnormalities on screening laboratory evaluation\n",
      "\n",
      "          -  Female subjects who are pregnant, lactating or planning to become pregnant during the\n",
      "             clinical trial period\n",
      "\n",
      "          -  Female subjects of childbearing potential (defined as pre-menopausal and not\n",
      "             surgically sterilized or post-menopausal for less than 2 years) not practicing\n",
      "             adequate birth control.\n",
      "\n",
      "          -  Current drug or alcohol abuse, or a history of drug or alcohol abuse, that, in the\n",
      "             opinion of the PI, would not make the subject a suitable candidate for participation\n",
      "             in the clinical trial\n",
      "\n",
      "          -  Exposure to any investigational medications or devices within the previous 30 days\n",
      "             prior to trial entry or participation in another clinical trial during this trial\n",
      "\n",
      "          -  Unable and/or unlikely to comprehend and/or follow the trial protocol\n",
      "\n",
      "          -  Concurrent medical or major psychiatric condition which, in the opinion of the PI,\n",
      "             makes the subject unsuitable for the clinical trial, or could limit the validity of\n",
      "             the informed consent and/or impair the subject's ability to participate in the trial\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Previously untreated stage IV indolent B-cell lymphoma [Amendment May 2001:\n",
      "             eligibility restricted to follicular lymphoma]\n",
      "\n",
      "          2. Age <76\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        N/A\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Those scheduled to undergo radical prostatectomy for the treatment of prostate cancer.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  minors\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Renal transplant recipients greater than 18 years of age, who have given written\n",
      "             consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Taking medications that may alter the metabolism of tacrolimus or mycophenolate sodium\n",
      "\n",
      "          -  Experienced an acute rejection episode prior to the pharmacokinetic profile collection\n",
      "\n",
      "          -  Serum creatinine >2 mg/dL\n",
      "\n",
      "          -  Neutropenia (Absolute Neutrophil Count < 1.3x10^3/mL)\n",
      "\n",
      "          -  Received a previous transplant other than a kidney\n",
      "\n",
      "          -  Receiving chronic steroids at time of transplant\n",
      "\n",
      "          -  Known hypersensitivity to tacrolimus, mycophenolate mofetil, mycophenolate sodium,\n",
      "             mycophenolic acid or any of its excipients\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Subjects aged 18 years or greater\n",
      "\n",
      "          2. Operative treatment of one of the following injuries\n",
      "\n",
      "               -  An elbow dislocation with or without associated fractures\n",
      "\n",
      "               -  An olecranon fracture-dislocation, but not simple olecranon fractures\n",
      "\n",
      "               -  A distal humerus fracture\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. An existing diagnosis of one of the following conditions\n",
      "\n",
      "               -  Injury to the central nervous system, thorax, or abdomen precluding the immediate\n",
      "                  use of non-steroidal anti-inflammatory medications\n",
      "\n",
      "               -  Fracture of any long bone since non-steroidal anti-inflammatory medications may\n",
      "                  increase the risk of nonunion\n",
      "\n",
      "               -  History of gastritis, peptic ulcer disease, or upper gastrointestinal bleeding\n",
      "\n",
      "               -  Impaired renal function (creatinine > 2.0), hypovolemia, heart failure, high\n",
      "                  blood pressure ( > 160/90), fluid retention, asthma, liver dysfunction (bilirubin\n",
      "                  > 2.0), or a coagulation disorder\n",
      "\n",
      "               -  Allergy to non-steroidal anti-inflammatory medications\n",
      "\n",
      "               -  Asthma, nasal polyps, urticaria, and hypotension associated with the use of\n",
      "                  NSAIDs\n",
      "\n",
      "               -  Considerable dehydration\n",
      "\n",
      "          2. Pregnant or breast-feeding women\n",
      "\n",
      "          3. Concomitant use of one of the following drugs:\n",
      "\n",
      "               -  Aspirin\n",
      "\n",
      "               -  Other naproxen products (ec-naprosyn, anaprox, anaprox ds, naprosyn suspension,\n",
      "                  aleve)\n",
      "\n",
      "               -  Methotrexate\n",
      "\n",
      "               -  Diuretics (thiazides / furosemide)\n",
      "\n",
      "               -  ACE-inhibitors (captopril, enalapril, ramipril etc.)\n",
      "\n",
      "               -  Beta-blockers (propanolol etc.)\n",
      "\n",
      "               -  Probenecid (for gout or hyperuricemia)\n",
      "\n",
      "               -  H2-blockers, sucralfate and intensive antacid therapy\n",
      "\n",
      "               -  Lithium\n",
      "\n",
      "               -  Anticoagulants / Warfarin (coumadin, waran, jantoven etc.)\n",
      "\n",
      "               -  Sulfonamides\n",
      "\n",
      "               -  Anticonvulsant medication (peganone, mesantoin, cerebyx, dilantin, etc.)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Healthy male, African-American volunteers\n",
      "\n",
      "          2. 18-35 years of age,\n",
      "\n",
      "          3. No personal or first degree relative with hypertension or diabetes,\n",
      "\n",
      "          4. Blood pressure <130/85 mmHg and > 90/60 at the screening visit,\n",
      "\n",
      "          5. Body mass index <30 kg/m2,\n",
      "\n",
      "          6. No clinically significant abnormalities on screening tests (complete blood count,\n",
      "             serum electrolytes, liver enzymes, thyroid stimulating hormone, urinalysis and\n",
      "             electrocardiogram).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Alcohol intake >2 beverage/night,\n",
      "\n",
      "          2. Smoking,\n",
      "\n",
      "          3. Recreational drug use,\n",
      "\n",
      "          4. Personal history of coronary disease, diabetes, hypertension, stroke, kidney disease,\n",
      "             or illness requiring overnight hospitalization in the past 6 months,\n",
      "\n",
      "          5. Prescription or herbal medication use,\n",
      "\n",
      "          6. Ischemic changes on resting electrocardiogram,\n",
      "\n",
      "          7. Known hypersensitivity to any of the study drugs,\n",
      "\n",
      "          8. Other active medical problems detected by examination or laboratory testing.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  The child met DSM-IV criteria for a diagnosis of a principal anxiety disorder based on\n",
      "             a semi-structured interview\n",
      "\n",
      "          -  The child was not taking any psychiatric medication at the initial assessment, or was\n",
      "             taking a stable dose of psychiatric medication (i.e., at least one month at a stable\n",
      "             dose prior to the baseline assessment), and\n",
      "\n",
      "          -  If medication was being used, families stated an intention to maintain that dose\n",
      "             throughout the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  The child was currently in child-focused psychotherapy\n",
      "\n",
      "          -  The family was currently in family therapy or a parenting class\n",
      "\n",
      "          -  Either the child or the parents evidenced psychotic symptoms\n",
      "\n",
      "          -  The child began taking psychiatric medication or increased his/her dose of medication\n",
      "             during the intervention, or\n",
      "\n",
      "          -  For any reason the child or parents appeared unable to participate in the intervention\n",
      "             program.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adults and children with non-acute carbon monoxide poisoning who underwent SPECT brain\n",
      "             imaging as part of their evaluation and treatment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  None.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients ≥18 with AJCC stage III or IV melanoma two weeks to one year after becoming\n",
      "             clinically free of disease will be eligible.\n",
      "\n",
      "          -  For all patients' pathology slides must be reviewed by the Memorial Hospital\n",
      "             Department of Pathology to confirm diagnosis of cutaneous melanoma.\n",
      "\n",
      "          -  All patients must have a Karnofsky performance status of ≥80.\n",
      "\n",
      "          -  Patients may have received previous radiation, chemotherapy or systemic immunotherapy\n",
      "             (completed at least 4 weeks prior to vaccination).\n",
      "\n",
      "          -  A CBC must be performed within 2 weeks prior to vaccination with the WBC > or equal to\n",
      "             3.0 cells/mm3, Platelets >100,000/mm3,\n",
      "\n",
      "          -  A screening profile must be performed within 2 weeks prior to vaccination with the\n",
      "             total bilirubin ≤ 2.0, and other LFTs within normal limits for patient's age.\n",
      "\n",
      "          -  Chest, abdomen and pelvic CT or MRI must be performed within 4 weeks of the initiation\n",
      "             of treatment showing no evidence of disease.\n",
      "\n",
      "          -  Women of child bearing potential and sexually active males must be counseled to use an\n",
      "             accepted and effective method of contraception (including abstinence) while on\n",
      "             treatment.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients previously treated with KLH or ganglioside containing vaccines, or monoclonal\n",
      "             antibodies against gangliosides are not eligible.\n",
      "\n",
      "          -  Women must not be pregnant (negative βHCG within 2 weeks of vaccination if of\n",
      "             childbearing potential).\n",
      "\n",
      "          -  Patients with other active cancers within the past 2 years, (excluding basal cell,\n",
      "             squamous carcinomas of the skin or cervical carcinoma-in-situ) are not eligible.\n",
      "\n",
      "          -  Any medical condition which might make it difficult for the patient to complete the\n",
      "             full course of treatments or to respond immunologically to them is grounds for\n",
      "             exclusion, at the discretion of the Principal Investigator.\n",
      "\n",
      "          -  Patients requiring anti-inflammatory medications such a steroids, NSAIDS or full dose\n",
      "             aspirin are not eligible.\n",
      "\n",
      "          -  There must be no evidence of metastatic disease at the time of the first vaccine.\n",
      "             However, patients who develop new metastases during treatment may continue on\n",
      "             treatment as long as no systemic treatment is indicated and any local treatment such\n",
      "             as surgical resection or radiation would not cause a delay in vaccination or two weeks\n",
      "             or more.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed metastatic adenocarcinoma of the lung\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1\n",
      "\n",
      "          -  No radiation therapy within 2 weeks of first vaccine administration\n",
      "\n",
      "          -  No chemotherapy within 4 weeks of first vaccine administration\n",
      "\n",
      "          -  No steroid therapy within 4 weeks of first vaccine administration\n",
      "\n",
      "          -  Patient's written informed consent\n",
      "\n",
      "          -  Adequate organ function (measured within a week of beginning treatment)\n",
      "\n",
      "          -  Patients will be tested for human leukocyte antigen A0201 (HLA-A0201) as determined by\n",
      "             flow cytometry followed by molecular analysis of a peripheral blood specimen, however\n",
      "             this result will not be an inclusion criterion.\n",
      "\n",
      "          -  Measurable metastatic tumor as defined by standard Response Evaluation Criteria In\n",
      "             Solid Tumors (RECIST) criteria. Lesions must be accurately measured in at least one\n",
      "             dimension with the longest diameter greater than or equal 20mm. With spiral computer\n",
      "             tomography (CT) scan, lesion must be greater than or equal to 10 mm at least one\n",
      "             dimension.\n",
      "\n",
      "          -  Patient's must have received, and completed first line chemotherapy.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Symptomatic brain metastasis\n",
      "\n",
      "          -  Any acute medical problems requiring active intervention\n",
      "\n",
      "          -  Current corticosteroid (other than replacement doses in patients who are hypoadrenal)\n",
      "             or other immunosuppressive therapy\n",
      "\n",
      "          -  Any other pre-existing immunodeficiency condition (including known HIV infection)\n",
      "\n",
      "          -  Pregnant or lactating women -- Patients in reproductive age must agree to use\n",
      "             contraceptive methods for the duration of the study (*A pregnancy test will be\n",
      "             obtained before treatment).\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3 or 4\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Recovered from Anorexia Nervosa\n",
      "\n",
      "          -  Not taking medication for emotional problems\n",
      "\n",
      "          -  Regular menstrual cycle\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Women who are pregnant or nursing\n",
      "\n",
      "          -  Psychoactive medications in the past 30 days\n",
      "\n",
      "          -  Neurological disorders.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        PATIENT\n",
      "\n",
      "          1. Diseases\n",
      "\n",
      "             Hematological malignancies confirmed histologically and not rapidly progressing:\n",
      "\n",
      "               -  AML in CR (defined as ≤ 5% marrow blasts and absence of blasts in the peripheral\n",
      "                  blood);\n",
      "\n",
      "               -  MDS with ≤ 5% marrow blasts and absence of blasts in the peripheral blood;\n",
      "\n",
      "               -  CML in CP;\n",
      "\n",
      "               -  MPS not in blast crisis and not with extensive marrow fibrosis,\n",
      "\n",
      "               -  ALL in CR;\n",
      "\n",
      "               -  Multiple myeloma not rapidly progressing;\n",
      "\n",
      "               -  CLL;\n",
      "\n",
      "               -  Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);\n",
      "\n",
      "               -  Hodgkin's disease with chemosensitive disease.\n",
      "\n",
      "          2. Clinical situations\n",
      "\n",
      "               -  Theoretical indication for a standard allo-transplant, but not feasible because:\n",
      "\n",
      "                    -  Age > 50 yrs;\n",
      "\n",
      "                    -  Unacceptable end organ performance;\n",
      "\n",
      "                    -  Patient's refusal.\n",
      "\n",
      "               -  Indication for a standard auto-transplant: perform mini-allotransplantation 2-6\n",
      "                  months after standard autotransplant.\n",
      "\n",
      "          3. Other inclusion criteria\n",
      "\n",
      "               -  Male or female; fertile patients must use a reliable contraception method;\n",
      "\n",
      "               -  Age < 75 yrs;\n",
      "\n",
      "               -  Informed consent given by patient or his/her guardian if of minor age.\n",
      "\n",
      "        DONOR\n",
      "\n",
      "          -  Related to the recipient (sibling, parent or child) or unrelated;\n",
      "\n",
      "          -  Male or female;\n",
      "\n",
      "          -  Any age;\n",
      "\n",
      "          -  10 of 10 (HLA-A, -B, -C, -DRB1, and -DQB1) HLA allele matched;\n",
      "\n",
      "          -  Weight > 15 Kg (because of leukapheresis);\n",
      "\n",
      "          -  Fulfills criteria for allogeneic PBSC donation according to standard procedures;\n",
      "\n",
      "          -  Informed consent given by donor or his/her guardian if of minor age, as per donor\n",
      "             center standard procedures.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        PATIENT\n",
      "\n",
      "          -  Any condition not fulfilling inclusion criteria;\n",
      "\n",
      "          -  HIV positive;\n",
      "\n",
      "          -  Non-hematological malignancy(ies) (except non-melanoma skin cancer) < 3 years before\n",
      "             nonmyeloablative HCT.\n",
      "\n",
      "          -  Life expectancy severely limited by disease other than malignancy;\n",
      "\n",
      "          -  Administration of cytotoxic agent(s) for \"cytoreduction\" within three weeks prior to\n",
      "             initiating the nonmyeloablative transplant conditioning (Exceptions are hydroxyurea\n",
      "             and imatinib mesylate);\n",
      "\n",
      "          -  CNS involvement with disease refractory to intrathecal chemotherapy.\n",
      "\n",
      "          -  Terminal organ failure, except for renal failure (dialysis acceptable)\n",
      "\n",
      "          -  Uncontrolled infection;\n",
      "\n",
      "          -  Karnofsky Performance Score <70%;\n",
      "\n",
      "          -  Patient is a fertile man or woman who is unwilling to use contraceptive techniques\n",
      "             during and for 12 months following treatment;\n",
      "\n",
      "          -  Patient is a female who is pregnant or breastfeeding;\n",
      "\n",
      "          -  Previous radiation therapy precluding the use of 2 Gy TBI or 8 Gy TLI;\n",
      "\n",
      "        DONOR\n",
      "\n",
      "          -  Any condition not fulfilling inclusion criteria;\n",
      "\n",
      "          -  Unable to undergo leukapheresis because of poor vein access or other reasons.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Ability to understand and provide informed consent\n",
      "\n",
      "          -  Male or Female (non-pregnant), age 18-50\n",
      "\n",
      "          -  Females must be: Surgically sterile (hysterectomy, bilateral oophorectomy, bilateral\n",
      "             tubal ligation), OR postmenopausal (at least 1 year since last menses), OR using a\n",
      "             medically acceptable form of birth control throughout the duration of the study.\n",
      "\n",
      "          -  Clinical history of seasonal or perennial allergic rhinitis for at least two years,\n",
      "             with or without mild persistent asthma\n",
      "\n",
      "          -  Positive puncture skin test greater than or equal to 5 mm diluent control\n",
      "\n",
      "          -  Positive Immunocap to Fel d 1 > 0.35 kallikrein unit/L\n",
      "\n",
      "          -  Positive intranasal cat allergen challenge as defined by > 5 sneezes or a tripling of\n",
      "             measured nasal lavage mediators\n",
      "\n",
      "          -  In vitro assay of basophil responsiveness to cat allergen with greater than 20%\n",
      "             histamine release\n",
      "\n",
      "          -  The use of antihistamines, cromolyn, leukotriene modifiers and other non-steroid\n",
      "             (astelin and topical decongestants), nasal medications will be allowed, but they will\n",
      "             be withheld for 5 days prior to each nasal allergen provocation session. Inhaled\n",
      "             corticosteroids for mild asthma will be permissible.\n",
      "\n",
      "          -  No known contraindications to therapy with omalizumab\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Asthma with forced expiratory volume at one second (FEV1) < 80%, moderate to severe\n",
      "             asthma classification per National Asthma Education and Prevention Program Expert\n",
      "             Panel (NAEP) Standards (1997 National Asthma Education and Prevention Program Expert\n",
      "             Panel Report II guidelines)\n",
      "\n",
      "          -  Serum IgE levels less than 30 IU/mL or greater than 700 IU/mL at the time of\n",
      "             enrollment will be excluded\n",
      "\n",
      "          -  Unexplained elevation of erythrocyte sedimentation rate (ESR), hematocrit < 32%, white\n",
      "             blood cell (WBC) count 2400/microliter lower limit of normal, platelet <\n",
      "             75000/microliter, creatinine > 141.4 micromolar/L, or aspartate aminotransferase (AST)\n",
      "             > 100 IU/L\n",
      "\n",
      "          -  Body weight less than 30 kg or greater than 150 kg will be excluded.\n",
      "\n",
      "          -  Plans to become pregnant or breastfeed will be excluded from the study\n",
      "\n",
      "          -  A perforated nasal septum, structural nasal defect, large nasal polyps causing\n",
      "             obstruction, evidence of acute or chronic sinusitis\n",
      "\n",
      "          -  A life expectancy less than 6 months\n",
      "\n",
      "          -  A terminal illness as determined by the investigator\n",
      "\n",
      "          -  A history of malignancy, anaphylaxis or bleeding disorder are also exclusion\n",
      "             illnesses.\n",
      "\n",
      "          -  Mental illness or history of drug or alcohol abuse that, in the opinion of the\n",
      "             investigator, would interfere with the participant's ability to comply with study\n",
      "             requirements.\n",
      "\n",
      "          -  Inability or unwillingness of a participant to give written informed consent or comply\n",
      "             with study protocol\n",
      "\n",
      "          -  Use of any investigational drugs within 8 weeks of participation\n",
      "\n",
      "          -  Contraindications to omalizumab include patients with a previous hypersensitivity to\n",
      "             omalizumab\n",
      "\n",
      "          -  Recent recipient of any licensed or investigational live attenuated vaccine(s) within\n",
      "             two months of study initiation such as flu mist.\n",
      "\n",
      "          -  Prior use of omalizumab\n",
      "\n",
      "          -  Frequent sinusitis (>2/ documented episodes per year) or active sinusitis within 2\n",
      "             weeks of enrollment\n",
      "\n",
      "          -  Use of immunotherapy within the last 5 years\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  female victims of partner violence\n",
      "\n",
      "          -  at least one month out of the abusive relationship\n",
      "\n",
      "          -  meet DSM-IV (American Psychiatric Association, 1994) criteria for PTSD and an alcohol\n",
      "             use disorder\n",
      "\n",
      "          -  literate in English\n",
      "\n",
      "          -  have not changed psychotropic medications or dosages within the past two months and\n",
      "             agree not to during the active phase (first 12 weeks) of the intervention\n",
      "\n",
      "          -  have an identified primary care physician\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  moderate or severe cognitive impairment as measured by a Mini-Mental State Examination\n",
      "             score less than or equal to 18\n",
      "\n",
      "          -  Histories of psychosis or mania may be excluded because the presence of these\n",
      "             disorders is thought to impede progress in psychotherapy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Signed informed consent.\n",
      "\n",
      "          -  Man or woman between 18 and 70 years of age.\n",
      "\n",
      "          -  Diagnosis of Crohn's disease confirmed during index surgery.\n",
      "\n",
      "          -  Detailed assessment of disease localization by colonoscopy, small bowel radiography,\n",
      "             and/or other appropriate methods (e.g., MRI, CT) within 6 months prior inclusion into\n",
      "             the study.\n",
      "\n",
      "          -  Resection for ileal or ileo-colonic Crohn's disease with ileo-colonic anastomosis\n",
      "             (i.e., without grossly visible disease at the resection margins); neoterminal ileum\n",
      "             should be assessable by endoscopy.\n",
      "\n",
      "          -  Ability to start oral nutrition and medication intake within 14 days after index\n",
      "             surgery.\n",
      "\n",
      "          -  Negative pregnancy test at screening visit in females of childbearing potential.\n",
      "\n",
      "          -  Use of appropriate contraceptive methods for females of childbearing potential and\n",
      "             males with procreative capacity during treatment.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Short bowel syndrome.\n",
      "\n",
      "          -  Previous long term therapy with ciprofloxacin (> 6 weeks prior before surgery)\n",
      "\n",
      "          -  Patients in whom any visible lesions at the anastomosis were left after index surgery.\n",
      "\n",
      "          -  Serious secondary illnesses of an acute or chronic nature, which in the opinion of the\n",
      "             Investigator renders the patient unsuitable for inclusion into the study.\n",
      "\n",
      "          -  Dementia\n",
      "\n",
      "          -  Uncontrolled Diabetes Type I type II\n",
      "\n",
      "          -  Known drug abuse\n",
      "\n",
      "          -  Known parasitic disease of the digestive system\n",
      "\n",
      "          -  Active replicating Hepatitis B or Hepatitis C\n",
      "\n",
      "          -  HIV-infection\n",
      "\n",
      "          -  Seizure disorder\n",
      "\n",
      "          -  Serum creatinine levels exceeding 1.5 mg/dL or 130 μmol/L.\n",
      "\n",
      "          -  Presence of an ileal or colonic stoma.\n",
      "\n",
      "          -  Known previous or concurrent malignancy (other than that considered surgically cured,\n",
      "             with no evidence for recurrence for 5 years).\n",
      "\n",
      "          -  Application of non-steroidal anti-inflammatory drugs as long term treatment.\n",
      "\n",
      "          -  Known intolerance/hypersensitivity to ciprofloxacin or other quinolones or drugs of\n",
      "             similar chemical structure or pharmacological profile.\n",
      "\n",
      "          -  Chronic use of CYP1A2 substrates (aminophylline, fluvoxamine, mexiletine, mirtazapine,\n",
      "             ropinirole, tizanidine, trifluoperazine)\n",
      "\n",
      "          -  Well-founded doubt about the patient's cooperation.\n",
      "\n",
      "          -  Existing pregnancy, lactation, or intended pregnancy or impregnation within the next 3\n",
      "             months.\n",
      "\n",
      "          -  Non-use of appropriate contraceptives in females of childbearing potential (e.g.\n",
      "             condoms, intrauterine device [IUD], hormonal contraception for females, or a means of\n",
      "             contraception for a particular patient considered adequate by the responsible\n",
      "             investigator) during treatment.\n",
      "\n",
      "          -  Participation in another clinical trial within the last 30 days, simultaneous\n",
      "             participation in another clinical trial, or previous participation in this trial.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  ACR lupus criteria\n",
      "\n",
      "          -  18<age<65\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  chronic infection or cancer\n",
      "\n",
      "          -  pregnancy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Greater than 18 years of age\n",
      "\n",
      "          -  ASA classification of I, II, or III\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Anesthesiologist plans to use a combination of medications other than propofol for\n",
      "             sedation.\n",
      "\n",
      "          -  ASA classification IV or higher\n",
      "\n",
      "          -  Lesions on forehead or earlobes\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Ages between 20 and 40\n",
      "\n",
      "          -  Ability to maintain normal balance\n",
      "\n",
      "          -  Willingness to undergo HVLA manipulation to the SI Joints\n",
      "\n",
      "          -  Normal blood pressure\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any visual or vestibular condition or systemic illness that would affect balance\n",
      "\n",
      "          -  Any recent surgery, unstable joints of the lower extremity, recent hip and knee joint\n",
      "             replacements or fitted hip or knee pins, bolts and/or plates\n",
      "\n",
      "          -  Currently have any infection, acute inflammation, recent wounds, injury, tumors or\n",
      "             other malignancy\n",
      "\n",
      "          -  Currently taking any medications; prescription or herbal muscle stimulants, relaxants,\n",
      "             etc.\n",
      "\n",
      "          -  A history of acute disc herniation, discopathy or spondylolysis\n",
      "\n",
      "          -  A history of acute thrombosis, serious cardiovascular disease, diabetes, have\n",
      "             irregular heartbeats(arrhythmia) or wear a pacemaker\n",
      "\n",
      "          -  Any implanted device or prosthesis type of device\n",
      "\n",
      "          -  Any Spinal manipulation within 48 hours\n",
      "\n",
      "          -  Ages under 20 and over 40\n",
      "\n",
      "          -  Estimated BMI greater than 30\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  central venous catheter placement\n",
      "\n",
      "          -  Need for extracorporeal renal replacement therapy (acute and chronic renal failure)\n",
      "\n",
      "          -  Anticipated duration of dialysis therapy less than or equal to 30 days\n",
      "\n",
      "          -  Age between 18 and 85 years\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Known Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV)/Human Immunodeficiency Virus\n",
      "             (HIV) infection\n",
      "\n",
      "          -  Known pregnancy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  central venous catheter placement\n",
      "\n",
      "          -  Need for extracorporeal renal replacement therapy (acute and chronic renal failure)\n",
      "\n",
      "          -  Age over 18 years\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "          -  Needed catheter length 15 cm or 20 cm\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Known infectivity with Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV)/Human\n",
      "             Immunodeficiency Virus (HIV)\n",
      "\n",
      "          -  Any infection associated with one or more positive blood cultures within 10 days prior\n",
      "             to catheter implantation\n",
      "\n",
      "          -  Bacteremia with a former catheter within 10 days prior to catheter implantation\n",
      "\n",
      "          -  Known pregnancy\n",
      "\n",
      "          -  Lactation\n",
      "\n",
      "          -  Participation in another clinical study during the preceding 30 days\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  BMI of 27-40 kg/m2\n",
      "\n",
      "          -  30-75 years of age\n",
      "\n",
      "          -  Stable body weight for the preceding 6 months\n",
      "\n",
      "          -  Diagnosis of type 2 diabetes for at least 6 months prior to enrollment\n",
      "\n",
      "          -  HbA1c of 6.5 to 9.0\n",
      "\n",
      "          -  Treatment by diet or oral agents only\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnancy or lactation\n",
      "\n",
      "          -  Active cardiac, pulmonary, renal, liver, or gastrointestinal disease\n",
      "\n",
      "          -  Untreated thyroid disease or hypertension\n",
      "\n",
      "          -  Hypertriglyceridemia with levels of TG > 500 mg/dl\n",
      "\n",
      "          -  Use of insulin\n",
      "\n",
      "          -  Use of specific medications that may alter lipid or glucose metabolism (other than the\n",
      "             statins)\n",
      "\n",
      "          -  Use of medications that commonly cause significant alterations in body weight (e.g.,\n",
      "             corticosteroids).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Females and Males age 18-75 without significant health problems as determined by the\n",
      "             Principal Investigator.\n",
      "\n",
      "          2. Nonsmoker\n",
      "\n",
      "          3. Ability to understand informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Pregnancy\n",
      "\n",
      "          2. Any serious or unstable disease within 6 months; seizure risk; diabetes mellitus\n",
      "             requiring insulin or oral hypoglycemic medication; diagnosis of eating disorder, use\n",
      "             of MAOI in the prior 14 days; hepatic or renal impairment; clinically significant\n",
      "             cardiovascular disease within 6 months; uncontrolled hypertension; severe chronic\n",
      "             obstructive pulmonary disease; baseline systolic blood pressure higher than150mm Hg or\n",
      "             diastolic blood pressure higher than 95 mm Hg; history of cancer (except treated basal\n",
      "             cell or squamous cell carcinoma of the skin); history of clinically significant\n",
      "             allergic reactions or laboratory abnormalities,and patients taking AREDS Eye Vitamins.\n",
      "\n",
      "          3. Major depressive disorder within the past year requiring treatment; history of panic\n",
      "             disorder, psychosis, bipolar disorder, or eating disorder\n",
      "\n",
      "          4. Intention to donate blood or blood products during treatment phase of the study;\n",
      "\n",
      "          5. Alcohol or drug abuse/dependency within the past year\n",
      "\n",
      "          6. Use of tobacco products other than cigarettes or use of marijuana\n",
      "\n",
      "          7. Body mass index (calculated as weight in kilograms divided by the square height in\n",
      "             meters) less than 15 or greater than 38 or weight less than 45.5 kg\n",
      "\n",
      "          8. NRT, antidepressants, antipsychotics, mood stabilizers/anticonvulsants, naltrexone,\n",
      "             steroids or insulin.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Child in receipt of the preschool booster vaccination or Menitorix under the Hib\n",
      "             catchup campaign\n",
      "\n",
      "          -  Written informed consent from a parent/ guardian\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  None\n",
      "      \n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          1. Adult male or female > 18 years of age\n",
      "\n",
      "          2. Scheduled to undergo bariatric surgery\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          1. Vitamin D deficiency\n",
      "\n",
      "          2. Primary hyperparathyroidism\n",
      "\n",
      "          3. Treatment with lithium or thiazide diuretics which may alter PTH levels\n",
      "\n",
      "          4. Osteomalacia\n",
      "\n",
      "          5. Untreated hyperthyroidism, liver disease, Cushing's syndrome, rheumatoid arthritis,\n",
      "             myeloma or Paget's disease\n",
      "\n",
      "          6. Impaired renal function (serum creatinine >2.0mg/dl) or history of renal\n",
      "             osteodystrophy\n",
      "\n",
      "          7. Use of any anti-obesity medications for over 2 weeks 90 days prior to study\n",
      "\n",
      "          8. Participation in any research study 90 days prior to study\n",
      "\n",
      "          9. Any malabsorption syndromes such as celiac sprue\n",
      "\n",
      "         10. Previous bariatric surgery\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Asthma patients, who need hospitalized treatment, who do not respond with initial\n",
      "             treatment including bronchodilator and IV methylprednisolone therapy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Need for incubation\n",
      "\n",
      "          -  With severe complications\n",
      "\n",
      "          -  Received systemic glucocorticosteroid therapy in the previous 4 weeks\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Confirmed closed tibial fracture on one limb only\n",
      "\n",
      "          -  Normal blood count\n",
      "\n",
      "          -  Normal coagulation screen\n",
      "\n",
      "          -  Life expectancy of at least 12 months\n",
      "\n",
      "          -  Ability to give written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with additional lower limb injuries\n",
      "\n",
      "          -  Patients with abnormal lower limb vasculature\n",
      "\n",
      "          -  Pregnant or lactating women\n",
      "\n",
      "          -  Unexplained abnormal baseline laboratory results\n",
      "\n",
      "          -  Males and females who are capable of reproduction and will not take acceptable\n",
      "             measures to prevent reproduction during the study\n",
      "\n",
      "          -  Subjects who test positive for HTLV, HIV, hepatitis B or hepatitis C, have a chronic\n",
      "             inflammatory disease, autoimmune disease or are on chronic immunosuppressive\n",
      "             medications\n",
      "\n",
      "          -  History of alcohol or drug abuse within 3 months of screening\n",
      "\n",
      "          -  Subjects with evidence (clinical, laboratory, or imaging) of cancer or cancer\n",
      "             recurrence within the past 5 years (other than non-melanoma skin cancer or in situ\n",
      "             cervical carcinoma)\n",
      "\n",
      "          -  Currently enrolled in another investigational device or drug trial that has not\n",
      "             completed the required follow-up period\n",
      "\n",
      "          -  Patients unable to give written informed consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  type 2 diabetes mellitus\n",
      "\n",
      "          -  diabetic peripheral neuropathy\n",
      "\n",
      "          -  A1C of 6.0-10.0%\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Terminal diagnosis\n",
      "\n",
      "          -  Dementia\n",
      "\n",
      "          -  Anemia\n",
      "\n",
      "          -  Significant renal dysfunction\n",
      "\n",
      "          -  History of B-12 deficiency\n",
      "\n",
      "          -  Peripheral vascular disease\n",
      "\n",
      "          -  Current smoker\n",
      "\n",
      "          -  History of kidney stones\n",
      "\n",
      "          -  Current ascorbic acid use\n",
      "\n",
      "          -  Presence or foot infection and/or ulcer\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  scoring 4 to 20 on the National Institute of Health Stroke Scale (NIHSS)\n",
      "\n",
      "          -  showing a perfusion-diffusion mismatch on MRI of 20 %\n",
      "\n",
      "          -  enrolment within a 3 h to 9 h time window after symptom onset.\n",
      "\n",
      "          -  18-85 years of age\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Participation in any interventional trial in the previous 30 days.\n",
      "\n",
      "          -  Women in the childbearing age.\n",
      "\n",
      "          -  Any history of intracranial hemorrhage, subarachnoid hemorrhage, neoplasm,\n",
      "             arteriovenous malformation or aneurysm.\n",
      "\n",
      "          -  Conditions that, according to the judgment of the investigator, might impose an\n",
      "             additional risk to any individual stroke patient when receiving study medication (this\n",
      "             applied to patients on platelet-function inhibitors as well).\n",
      "\n",
      "          -  MRI exclusion criteria: Evidence of ICH, Evidence of SAH, Signs of extensive early\n",
      "             infarction on DWI assessed by evidence of involvement of >1/3 of the middle cerebral\n",
      "             artery (MCA) territory. No perfusion deficit, Internal carotid artery (ICA) occlusion\n",
      "             ipsilateral to stroke lesion without additional ipsilateral MCA, anterior cerebral\n",
      "             artery (ACA) or posterior cerebral artery (PCA) occlusion. Any intracranial pathology\n",
      "             that would interfere with the MRI assessment of acute ischemic stroke.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Over the age of 18 years\n",
      "\n",
      "          -  Able to understand and sign consent without surrogate signature\n",
      "\n",
      "          -  Subject weight is within the 300lb limit of the MR scanning table\n",
      "\n",
      "          -  Subject's bodily habitus allows the subject to fit within the MR bore\n",
      "\n",
      "          -  Subject being able to lie quiescent for a period of up to 60 minutes in a supine\n",
      "             position\n",
      "\n",
      "          -  Subject would be able to hold breath at times for periods of 15-30 seconds\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects with pacemakers, TENS units, metallic prostheses, metal foreign bodies such\n",
      "             as bullets, shrapnel, metallic slivers, shavings or foreign bodies\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Pediatric resident at Baylor College of Medicine\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Not a pediatric resident at Baylor College of Medicine\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 18 or older;\n",
      "\n",
      "          -  Patient with moderate to severe plaque psoriasis for whom a decision to use etanercept\n",
      "             has been made;\n",
      "\n",
      "          -  At the investigator discretion, patient who would benefit from systemic therapy;\n",
      "\n",
      "          -  PASI (psoriasis area and severity index) ≥ 10 and BSA (body surface area affected by\n",
      "             psoriasis) ≥ 10 at day 0;\n",
      "\n",
      "          -  Unless surgically sterile (or at least 1 year post-menopausal for women), abstinent or\n",
      "             homosexual, patient (men and women) willing to use adequate contraceptive method for\n",
      "             at least 30 days before Day 0 and until one month after the last drug administration;\n",
      "\n",
      "          -  Patient capable of giving informed consent;\n",
      "\n",
      "          -  Patient with normal or non clinically significant chest X ray within six months of\n",
      "             screening;\n",
      "\n",
      "          -  Patient with negative purified protein derivative (PPD) within 3 months of Day 0;\n",
      "\n",
      "          -  Negative urine pregnancy test for women of childbearing potential\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient used topical steroid, topical tar preparations, or other anti-psoriatic\n",
      "             preparations except tar or salicylic acid shampoo or hydrocortisone for the face,\n",
      "             scalp, genital and inframammary areas within two weeks of Day 0;\n",
      "\n",
      "          -  Patient with presence of erythrodermic, pustular or a predominantly guttate psoriasis;\n",
      "\n",
      "          -  At the investigator's discretion, patient with any significant infection within 30\n",
      "             days of screening or a patient at risk of septicemia;\n",
      "\n",
      "          -  Patient with evidence of any skin condition that would interfere with the evaluation\n",
      "             of psoriasis;\n",
      "\n",
      "          -  Patient used investigational drugs within 12 weeks or three half-life of Day 0\n",
      "             whichever is longer;\n",
      "\n",
      "          -  Patient used systemic anti-psoriatic drugs such as steroids, retinoids, methotrexate,\n",
      "             cyclosporine within four weeks of Day 0;\n",
      "\n",
      "          -  Patient used any biologic such as alefacept, etanercept, efalizumab, infliximab and\n",
      "             adalimumab within 12 weeks of Day 0;\n",
      "\n",
      "          -  Patient used ultraviolet light therapy (UVB or nbUVB) within four weeks of Day 0 or\n",
      "             PUVA (psoralen ultra violet A) within eight weeks of Day 0;\n",
      "\n",
      "          -  Patient with prior or concurrent use of cyclophosphamide;\n",
      "\n",
      "          -  Patient with concurrent sulfasalazine therapy or concurrent use of anakinra;\n",
      "\n",
      "          -  Patient with an unstable or serious medical condition as defined by the investigator\n",
      "             or presence of any significant medical condition that might cause this study to be\n",
      "             detrimental to the patient.\n",
      "\n",
      "          -  Uncontrolled or severe comorbidities such as diabetes mellitus requiring insulin;\n",
      "             congestive heart failure (NYHA (New York Heart Association) class III or IV) or\n",
      "             history of myocardial infarction or cerebrovascular accident or transient ischemic\n",
      "             attack within three months of screening visit; unstable angina pectoris; uncontrolled\n",
      "             hypertension, oxygen-dependent severe pulmonary disease;\n",
      "\n",
      "          -  Patient with a known sero-positivity for HIV (human immunodeficiency virus) or history\n",
      "             of any other immunosuppressing disease;\n",
      "\n",
      "          -  Patient with active or chronic hepatitis B or C;\n",
      "\n",
      "          -  Patient with any active or chronic infection within four weeks before screening or\n",
      "             between the screening and baseline visits;\n",
      "\n",
      "          -  Patient with any mycobacterial disease, patient with a positive PPD, a chest X-Ray\n",
      "             suggestive of tuberculosis or patient taking anti-tuberculosis medication;\n",
      "\n",
      "          -  Patient with a known hypersensitivity to etanercept or one of its components or known\n",
      "             to have antibodies to etanercept;\n",
      "\n",
      "          -  Patient who received a live attenuated vaccines within 12 weeks of Day 0 or plan to\n",
      "             receive one during the study;\n",
      "\n",
      "          -  Current pregnancy or lactation;\n",
      "\n",
      "          -  At the investigator's discretion, patient with current or history of alcohol or drug\n",
      "             abuse that would interfere with the ability of the patient to comply with the study\n",
      "             protocol;\n",
      "\n",
      "          -  Patient with systemic lupus erythematosus or demyelinating disorder (optic neuritis,\n",
      "             multiple sclerosis or other);\n",
      "\n",
      "          -  Patient with a history of cancer within five years of Day 0 or presence of cancer\n",
      "             except for treated basal or squamous cell carcinoma and in situ cervix carcinoma;\n",
      "\n",
      "          -  Patient who failed to respond to nbUVB in the past;\n",
      "\n",
      "          -  Patient who have a contra-indication to nbUVB;\n",
      "\n",
      "          -  Patient with latex sensitivity (applicable only if they are using prefilled syringe or\n",
      "             prefilled SureClickTM autoinjector presentations);\n",
      "\n",
      "          -  Patient with a history of non-compliance with other therapies.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed newly diagnosed glioblastoma multiforme\n",
      "\n",
      "          -  Has undergone prior gross total resection (GTR) followed by conformal radiotherapy*\n",
      "             with or without concurrent chemotherapy\n",
      "\n",
      "               -  GTR is defined as ≥ 95% volumetric resection of the contrast-enhancing component\n",
      "                  on the preoperative MRI\n",
      "\n",
      "               -  Residual radiographic contrast enhancement on post-resection CT scan or MRI must\n",
      "                  be ≤ 1 cm in maximal diameter in any two perpendicular axial planes\n",
      "\n",
      "               -  No evidence of disease progression after completion of radiotherapy* NOTE:\n",
      "                  *Patients may enroll in part 2 of the study within 2 weeks after surgery; these\n",
      "                  patients will receive radiotherapy with concurrent chemotherapy during the study\n",
      "\n",
      "          -  EGFRvIII-positive tumor by immunohistochemistry, polymerase chain reaction, or related\n",
      "             molecular techniques\n",
      "\n",
      "          -  Karnofsky performance status 80-100%\n",
      "\n",
      "          -  Curran group status I-IV\n",
      "\n",
      "          -  Signed informed consent form\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Absolute Neutrophil Count (ANC) < 1,000/mm³\n",
      "\n",
      "          -  Platelet count < 50,000/mm³\n",
      "\n",
      "          -  Prothrombin Time/Partial Thromboplastin Time (PT/PTT) > 1.5 times normal\n",
      "\n",
      "          -  Positive hepatitis B (HB) surface antigen (HbsAg), antibody to hepatitis B surface\n",
      "             antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc)\n",
      "\n",
      "          -  Pregnant or nursing\n",
      "\n",
      "          -  Positive pregnancy test\n",
      "\n",
      "          -  Active infection requiring treatment\n",
      "\n",
      "          -  Unexplained febrile illness (T max > 101.5 F)\n",
      "\n",
      "          -  Inflammatory bowel disease, lupus erythematosus, rheumatoid arthritis, or other\n",
      "             autoimmune disease\n",
      "\n",
      "          -  Known immunosuppressive disease\n",
      "\n",
      "          -  Known HIV infection\n",
      "\n",
      "          -  Diffuse leptomeningeal disease\n",
      "\n",
      "          -  Unstable or severe concurrent medical condition, such as severe heart and lung disease\n",
      "             or active hepatitis\n",
      "\n",
      "          -  Demonstrated allergy to temozolomide or inability to tolerate temozolomide for reasons\n",
      "             other than lymphopenia\n",
      "\n",
      "          -  Concurrent corticosteroids (except for nasal or inhaled steroids) at a dose above\n",
      "             physiologic levels (> 2 mg of dexamethasone/day).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients scheduled for elective CABG over age 18\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Under age 18\n",
      "\n",
      "          -  Emergent CABG\n",
      "\n",
      "          -  Prior exposure to nephrotoxic drug\n",
      "\n",
      "          -  Dialysis patients\n",
      "\n",
      "          -  Uncontrolled hypertension\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Subjects meeting all of the following criteria will be considered for admission to the\n",
      "        study:\n",
      "\n",
      "          -  Patients giving informed consent for retro-auricular laser ablation between 25 and 55\n",
      "             years old.\n",
      "\n",
      "          -  Retro-auricular area is free of any irritation, scars or dermatologic conditions which\n",
      "             might interfere with the study.\n",
      "\n",
      "          -  Willing and able to participate in the study and follow all study directions.\n",
      "\n",
      "          -  Able to read, understand and sign the consent form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant, nursing, or planning a pregnancy during the course of the study, as\n",
      "             determined by the interview and a urine pregnancy test.\n",
      "\n",
      "          -  Systemic or cutaneous disease that may interfere with the study results.\n",
      "\n",
      "          -  Presence of irritation or dermatologic skin conditions in the retro-auricular area.\n",
      "\n",
      "          -  Known allergies to materials within the test formulations.\n",
      "\n",
      "          -  Systemic or cutaneous therapy with medication that impacts wound healing (steroids,\n",
      "             immune modulators, immune suppressants).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  low birth weight, less than 1500 grams\n",
      "\n",
      "          -  weight of at least 1000 grams at time of entry into study\n",
      "\n",
      "          -  must be at least one week of age\n",
      "\n",
      "          -  must have relative medical stability\n",
      "\n",
      "          -  gestational age between 28-32 weeks\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  infants with major congenital anomaly\n",
      "\n",
      "          -  those that require mechanical ventilatory support\n",
      "\n",
      "          -  those that are restricted in their movement or ability to undergo the intervention\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  males between 18 to 50 years of age in good general health based on normal screening\n",
      "             evaluation\n",
      "\n",
      "          -  must agree not to participate in another research drug study during participation\n",
      "\n",
      "          -  must agree to not donate blood during the study\n",
      "\n",
      "          -  must be willing to comply with the study protocol and procedures\n",
      "\n",
      "          -  must agree to use an acceptable form of contraception\n",
      "\n",
      "          -  agrees to not take medications other than the study drugs for the duration of the\n",
      "             study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subject in poor health, determined by medical history physical and lab results\n",
      "\n",
      "          -  a known history or current use of alcohol, drug or steroid abuse and/or use of more\n",
      "             than 3 alcohol beverages per day\n",
      "\n",
      "          -  Participation in a long-term contraceptive study within the past two months\n",
      "\n",
      "          -  History of bleeding disorders or current use of anti-coagulants\n",
      "\n",
      "          -  History of sleep apnea and/or major psychiatric disorders\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients between the ages of 4 and 21 years who are enrolled on SJMB03 and to be\n",
      "             admitted for either Course 2 or Course 3 of high dose chemotherapy and stem cell\n",
      "             rescue.\n",
      "\n",
      "          -  English - speaking and able to understand English items on the study instruments as\n",
      "             these are only available in English.\n",
      "\n",
      "          -  Patients willing to give assent to participate in the study and whose parents are\n",
      "             willing to give permission according to institutional guidelines for their child to\n",
      "             participate.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Inability or unwillingness of research participant or legal guardian/representative to\n",
      "             give written informed consent.\n",
      "\n",
      "          -  Patients experiencing serious neurological effects such as posterior fossa syndrome\n",
      "             that interfere with their ability to self-report on fatigue and mood.\n",
      "\n",
      "          -  Patient is bedridden and unable to participate in an activity.\n",
      "\n",
      "          -  Patients or parents who would find participating in the consent process too\n",
      "             emotionally demanding as determined by the treatment team.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Liver transplantation for HCV-related liver disease performed at least 3 years before\n",
      "             weaning;\n",
      "\n",
      "          -  Peripheral blood Vgd1+/Vgd2+ T cell ratio >2.33 and/or increased expression of KLRF1\n",
      "             and SLAMF7 genes in peripheral blood (measured by qPCR).\n",
      "\n",
      "          -  No indication for treatment with pegylated a-interferon plus ribavirin during the\n",
      "             weaning procedure;\n",
      "\n",
      "          -  Stability of liver function tests for at least 6 months;\n",
      "\n",
      "          -  No evidences of autoimmune liver disease;\n",
      "\n",
      "          -  Absence of acute and/or chronic rejection episodes during the 12 months before\n",
      "             weaning;\n",
      "\n",
      "          -  Basal liver biopsy without signs of acute and/or chronic rejection.\n",
      "\n",
      "          -  Absence of decompensated chronic liver disease.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  HIV infection\n",
      "\n",
      "          -  Double liver-kidney transplantation\n",
      "\n",
      "          -  HCV cholestatic fibrosing hepatitis\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Any adult patient who is planned or scheduled for surgical excision or biopsy of a\n",
      "             solid or complex cystic renal mass would be eligible for the study\n",
      "\n",
      "          -  Histology of the renal mass must be unknown at the time of enrollment\n",
      "\n",
      "          -  Patients who have renal masses that are evident on conventional US imaging\n",
      "\n",
      "          -  Patients will have a correlative abdominal CT and/or MRI\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with any history of cardiac shunts.\n",
      "\n",
      "          -  Patients with history of pulmonary hypertension or unstable cardiopulmonary\n",
      "             conditions, including patients on mechanical ventilation.\n",
      "\n",
      "          -  Patients without peripheral IV access\n",
      "\n",
      "          -  Pregnant patients and children\n",
      "\n",
      "          -  Patients with any known contrast allergies, allergy to perflutren, or any components\n",
      "             of Definity or microbubble contrast\n",
      "\n",
      "          -  Patients who have renal masses that are not evident on conventional US imaging\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male and female patients meeting Diagnostic and Statistical Manual of Mental\n",
      "             Disorders, 4th edition (DSM IV) criteria for PTSD assessed by the Structured Clinical\n",
      "             Interview for DSM IV (SCID).\n",
      "\n",
      "          -  All patients with PTSD will be greater than 18 years of age, and will be required to\n",
      "             give informed consent.\n",
      "\n",
      "          -  Patients will be recruited from newspaper advertisements and fliers.\n",
      "\n",
      "          -  All patients must be free of major medical illness on the basis of history and\n",
      "             physical examination, lab testing, and electrocardiogram, and must not be actively\n",
      "             abusing substances or alcohol.\n",
      "\n",
      "          -  Patients should be free of psychotropic medications for four weeks before the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant and breast-feeding women will not be studied. Female subjects will be\n",
      "             required to have a negative pregnancy test before the study. Female subjects of\n",
      "             childbearing age will be advised to use barrier contraception for the duration of the\n",
      "             study, in addition to other forms of contraception that they may be using.\n",
      "\n",
      "          -  Serious medical or neurological illness or a hypersensitivity to paroxetine.\n",
      "\n",
      "          -  Past or present steroid use.\n",
      "\n",
      "          -  Electroconvulsive therapy (ECT) within the 6 months prior to study entry.\n",
      "\n",
      "          -  Organic mental disorders or epilepsy\n",
      "\n",
      "          -  History of head trauma\n",
      "\n",
      "          -  Cerebral infectious disease or dyslexia.\n",
      "\n",
      "          -  History of psychosis, schizophrenia, or eating disorders.\n",
      "\n",
      "          -  Active suicidality or homicidality\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Newborn infants up to 15 days of age\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Non English speaking family and infants with significant medical problems at birth\n",
      "             needing NICU stay\n",
      "\n",
      "          -  foster children and wards of state\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Pregnant women after 24 weeks' gestation.\n",
      "\n",
      "          2. First cesarean delivery.\n",
      "\n",
      "          3. Age > 18 years.\n",
      "\n",
      "          4. Cesarean to be performed by a participating surgeon.\n",
      "\n",
      "          5. Non-closure of the visceral or parietal peritoneum.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Any prior abdominal surgery including prior cesarean, laparoscopy, appendectomy,\n",
      "             cholecystectomy or any uterine adnexal or bowel surgery.\n",
      "\n",
      "          2. Clinical diagnosis of chorioamnionitis.\n",
      "\n",
      "          3. Women having tubal ligation at the time of primary cesarean.\n",
      "\n",
      "          4. Inability to obtain informed consent.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Body Mass Index <35 kg/m2\n",
      "\n",
      "          -  Systolic Blood Pressure >=140 mmHg and/or Diastolic Blood Pressure >=95 mmHg\n",
      "\n",
      "          -  No known clinical disease except hypertension\n",
      "\n",
      "          -  No cardiovascular medication\n",
      "\n",
      "          -  Apnea-Hypopnea Index < 5/h (no OSA), or Apnea Hypopnea Index >=15/h (OSA)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Manifest diabetes, liver- or kidney disease Signs of atrial fibrillation or former\n",
      "             myocardial infarction at electrocardiogram\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age less than or equal to 21 years at time of study entry.\n",
      "\n",
      "          -  No prior therapy for this malignancy except for one dose of intrathecal therapy and\n",
      "             the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or\n",
      "             less ) for hyperleukocytosis.\n",
      "\n",
      "          -  Written informed consent according to institutional guidelines\n",
      "\n",
      "          -  Female patients of childbearing potential must have a negative serum pregnancy test\n",
      "             within 2 weeks prior to enrollment\n",
      "\n",
      "          -  Male and female participants must use an effective contraceptive method during the\n",
      "             study and for a minimum of 6 months after study treatment.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Down syndrome\n",
      "\n",
      "          -  Acute Promyelocytic Leukemia (APL)\n",
      "\n",
      "          -  Juvenile Myelomonocytic Leukemia (JMML)\n",
      "\n",
      "          -  Fanconi anemia (FA)\n",
      "\n",
      "          -  Kostmann syndrome\n",
      "\n",
      "          -  Shwachman syndrome\n",
      "\n",
      "          -  Other bone marrow failure syndromes\n",
      "\n",
      "          -  Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as\n",
      "             specified in the protocol.\n",
      "\n",
      "          -  Use of investigational agents within 30 days or any anticancer therapy within 2 weeks\n",
      "             before study entry with the exception of IT therapy, hydroxyurea, or low-dose\n",
      "             cytarabine as stated above. The patient must have recovered from all acute toxicities\n",
      "             from any previous therapy.\n",
      "\n",
      "          -  Systemic fungal, bacterial, viral, or other infection not controlled (defined as\n",
      "             exhibiting ongoing signs/symptoms related to the infection and without improvement,\n",
      "             despite appropriate antibiotics or other treatment).\n",
      "\n",
      "          -  Pregnant or lactating patients.\n",
      "\n",
      "          -  Any significant concurrent disease, illness, or psychiatric disorder that would\n",
      "             compromise patient safety or compliance, interfere with consent, study participation,\n",
      "             follow up, or interpretation of study results.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Hypertensive patients with controlled or uncontrolled blood pressure\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Secondary causes of hypertension;\n",
      "\n",
      "          -  Systolic Blood pressure >= 180 mmHg and/or diastolic blood pressure >= 110 mmHg\n",
      "\n",
      "          -  Complain of side effects related to Statins\n",
      "\n",
      "          -  Diabetes\n",
      "\n",
      "          -  Established target-organ damage (myocardial infarction, stroke, angina, heart failure,\n",
      "             peripheral vascular disease)\n",
      "\n",
      "          -  Renal disease (creatinine > 1,5 mgdl).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Average-risk subjects (no family history of CRC, no personal history of polyps or\n",
      "             CRC).\n",
      "\n",
      "          -  50 years of age or greater, but less than 80 years old.\n",
      "\n",
      "          -  Due for CRC screening.\n",
      "\n",
      "          -  Upcoming appointment scheduled with primary care provider.\n",
      "\n",
      "          -  Primary care provider has agreed to refer patients for consideration of enrollment in\n",
      "             the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Family history of CRC in a first-degree relative.\n",
      "\n",
      "          -  Personal history of colonic adenomatous polyps, CRC or inflammatory bowel disease.\n",
      "\n",
      "          -  Symptoms for which colonoscopy or sigmoidoscopy would otherwise be performed\n",
      "             (hematochezia, new onset diarrhea or constipation, abdominal pain).\n",
      "\n",
      "          -  CRC screening current (FOBT within preceding 12 months, flexible sigmoidoscopy or\n",
      "             double contrast barium enema within 5 years, or colonoscopy within 10 years).\n",
      "\n",
      "          -  Comorbid illness precluding endoscopic evaluation (coronary artery disease with\n",
      "             myocardial infarction within 6 months, unstable angina or congestive heart failure,\n",
      "             chronic obstructive pulmonary disease requiring home oxygen, other diseases that limit\n",
      "             life expectancy to less than 10 years).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Subject is undergoing a major surgical oncology procedure and has potential for\n",
      "             extensive blood loss.\n",
      "\n",
      "          2. Subject is ≥ 18 years of age.\n",
      "\n",
      "          3. Subject or Subject's Legally Authorized Representative (LAR) has signed an\n",
      "             IRB-approved informed consent form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Subject has medical, social, or psychological factors that, in the opinion of the\n",
      "             Investigator, could impact safety or compliance with study procedures.\n",
      "\n",
      "          2. Subject is < 18 years of age.\n",
      "\n",
      "          3. Subject or Subject's LAR did not sign IRB-approved informed consent form.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Participants of health check program at our hospital who will receive a scheduled\n",
      "             X-ray computed tomography examination for either lung (20 cases) or heart (20 cases).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Those whose age are under 50 or above 70 year-olds will be excluded.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  NTUH pharmacists\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  NTUH pharmacists who have never recorded drug related problems\n",
      "      \n",
      "\n",
      "        DISEASE CHARACTERISTICS:\n",
      "\n",
      "          -  Histologically confirmed colorectal cancer\n",
      "\n",
      "               -  Unresectable metastatic disease\n",
      "\n",
      "          -  Measurable disease, defined as ≥ 1 measurable lesion according to RECIST criteria\n",
      "\n",
      "          -  No prior chemotherapy for metastatic disease\n",
      "\n",
      "          -  No untreated brain metastases, spinal cord compression, or primary brain tumors\n",
      "\n",
      "          -  No history or evidence of CNS disease by physical examination unless adequately\n",
      "             treated (e.g., uncontrolled seizure despite standard medical therapy or history of\n",
      "             stroke)\n",
      "\n",
      "        PATIENT CHARACTERISTICS:\n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          -  ECOG performance status (PS) 0-2 (≤ 70 years of age) OR ECOG PS 0 (71-75 years of age)\n",
      "\n",
      "          -  Life expectancy ≥ 12 weeks\n",
      "\n",
      "          -  Neutrophils ≥ 1.5 x 10^9/L\n",
      "\n",
      "          -  Platelet count ≥ 100 x 10^9/L\n",
      "\n",
      "          -  Hemoglobin > 9 g/dL\n",
      "\n",
      "          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)\n",
      "\n",
      "          -  AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN if f liver metastases present)\n",
      "\n",
      "          -  Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN if liver metastases present)\n",
      "\n",
      "          -  Creatinine clearance > 50 mL/min OR serum creatinine ≤ 1.5 times ULN\n",
      "\n",
      "          -  Proteinuria < 2+ by dipstick OR urine protein ≤ 1 g by 24-hr urine collection\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use effective contraception\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  Serious, nonhealing wound, ulcer, or bone fracture\n",
      "\n",
      "          -  Evidence of bleeding diathesis or coagulopathy\n",
      "\n",
      "          -  Uncontrolled hypertension\n",
      "\n",
      "          -  Clinically significant (i.e., active) cardiovascular disease, including any of the\n",
      "             following:\n",
      "\n",
      "               -  Cerebrovascular accidents within the past 6 months\n",
      "\n",
      "               -  Myocardial infarction within the past 6 months\n",
      "\n",
      "               -  Unstable angina\n",
      "\n",
      "               -  New York Heart Association class II-IV congestive heart failure\n",
      "\n",
      "               -  Serious cardiac arrhythmia requiring medication\n",
      "\n",
      "          -  Known allergy to Chinese hamster ovary cell proteins or any of the components of the\n",
      "             study medications\n",
      "\n",
      "          -  Other co-existing malignancy or malignancy diagnosed within the past 5 years, except\n",
      "             for basal cell or squamous cell carcinoma, or carcinoma in situ of the cervix\n",
      "\n",
      "          -  Symptomatic peripheral neuropathy ≥ grade 1 according to the NCI Common Toxicity\n",
      "             Criteria\n",
      "\n",
      "          -  Lack of physical integrity of the upper gastrointestinal tract\n",
      "\n",
      "          -  Malabsorption syndrome\n",
      "\n",
      "          -  Inability to take oral medication\n",
      "\n",
      "          -  Significant traumatic injury within the past 28 days\n",
      "\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "\n",
      "          -  See Disease Characteristics\n",
      "\n",
      "          -  More than 4 weeks since prior radiotherapy\n",
      "\n",
      "          -  More than 10 days since prior and no concurrent ongoing treatment with anticoagulants\n",
      "             for therapeutic purposes\n",
      "\n",
      "          -  More than 28 days since prior and no concurrent major surgical procedure\n",
      "\n",
      "          -  More than 28 days since prior open biopsy\n",
      "\n",
      "          -  More than 30 days since prior investigational agents\n",
      "\n",
      "          -  No concurrent chronic daily high-dose acetylsalicylic acid (> 325 mg/day)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  regular sleep habits\n",
      "\n",
      "          -  BMI 20 to 27 kg/m2\n",
      "\n",
      "          -  at least one parent, sibling or grandparent with type 2 diabetes\n",
      "\n",
      "          -  no regular exercise habits\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  active smoker\n",
      "\n",
      "          -  night or shift work\n",
      "\n",
      "          -  have highly variable sleep habits\n",
      "\n",
      "          -  have a hormonal disorder\n",
      "\n",
      "          -  have a sleep disorder\n",
      "\n",
      "          -  have an active medical problem\n",
      "\n",
      "          -  for women: use of birth control pills\n",
      "\n",
      "          -  for women: irregular menstrual periods or pregnancy\n",
      "\n",
      "          -  use of medications/compounds that can disrupt sleep\n",
      "      \n",
      "\n",
      "        Inclusion Criteria\n",
      "\n",
      "          -  A diagnosis of a ruptured or unruptured brain aneurysm deemed suitable for repair by\n",
      "             neuroendovascular techniques involving intraluminal occlusion by detachable platinum\n",
      "             coils, stent-assisted coiling, pipeline stent, balloon-assisted coiling, covered stent\n",
      "             only, neck-bridge device, re-coiling, or re-treatment of a previously coiled/treated\n",
      "             aneurysm. There are no restrictions on adjunctive devices. For patients with a\n",
      "             ruptured aneurysm, endovascular repair must take place within 72 hours of the ictal\n",
      "             haemorrhage.\n",
      "\n",
      "          -  If the aneurysm has ruptured, patient should be Grade I-III on the World Federation of\n",
      "             Neurological Surgeons (WFNS) grading scale for subarachnoid hemorrhage. If the patient\n",
      "             is intubated but alert and able to follow commands (at least a 2-step command), and is\n",
      "             not kept intubated for neurological status (i.e., WFNS Grade IV or V), the patient is\n",
      "             considered WFNS Grade III and is eligible for the trial.\n",
      "\n",
      "          -  Absence of ongoing ischemic symptoms such as transient ischemic attacks, minor\n",
      "             strokes, stroke-in-evolution, or clinical evidence of cerebral vasospasm within 2\n",
      "             weeks prior to randomization. (If a CT scan, cerebral angiogram, or other imaging\n",
      "             performed during the 2 weeks prior to randomization shows radiological vasospasm\n",
      "             deemed by the treating physician to be potentially clinically significant, the subject\n",
      "             is excluded.)\n",
      "\n",
      "          -  Brain MRI imaging (DWI and FLAIR sequences) within 2 weeks prior to the endovascular\n",
      "             aneurysm repair procedure as detailed in Section 8.2. Imaging must not demonstrate any\n",
      "             focal ischemic stroke defined as a new region of restricted diffusion and/or a focal\n",
      "             area of reduced perfusion on a relative mean transit time (rMTT) or relative time to\n",
      "             peak (rTTP) map\n",
      "\n",
      "          -  Male or female with a minimum age of 18 years on the day of enrolment.\n",
      "\n",
      "          -  Female subjects of childbearing potential: Negative pregnancy test. After enrolment,\n",
      "             blood will be drawn from women of childbearing potential for a confirmatory test of\n",
      "             pregnancy as evaluated by a serum B-hCG test. The definition of non-childbearing\n",
      "             potential includes the following:\n",
      "\n",
      "               -  Surgically sterile (e.g., hysterectomy with or without oophorectomy; fallopian\n",
      "                  tube ligation; endometrial ablation), at least 30 days prior to signature of the\n",
      "                  Informed Consent form\n",
      "\n",
      "               -  At least 5 years post-menopause (i.e., 6 years post last menstrual period), or\n",
      "                  menopause confirmed by follicle-stimulating hormone (FSH) testing. Non-surgically\n",
      "                  sterile females or females with undocumented post-menopausal status must be\n",
      "                  willing to use a medically approved method of birth control for 3 months after\n",
      "                  completion of dosing.\n",
      "\n",
      "          -  Non-surgically sterile males or males with partners of childbearing potential must be\n",
      "             willing to use condoms with spermicide for 3 months after completion of dosing.\n",
      "\n",
      "          -  Body weight less than or equal to 180 kg.\n",
      "\n",
      "          -  Normal or abnormal but not clinically significant findings in the\n",
      "\n",
      "               -  non-neurological physical examination\n",
      "\n",
      "               -  12-lead ECG\n",
      "\n",
      "               -  PQ or PR interval less than or equal to 210 msec;\n",
      "\n",
      "               -  In unruptured aneurysm cases, QTc interval less than 450 msec for males or 470\n",
      "                  msec for females. For ruptured aneurysm cases, QTc interval is not restricted.\n",
      "\n",
      "               -  vital signs\n",
      "\n",
      "               -  blood pressure between 80-180/50-100 mm Hg,\n",
      "\n",
      "               -  body temperature less than or equal to 38.5oC\n",
      "\n",
      "          -  Informed consent and availability of the subject for the entire study period and\n",
      "             willingness of the subject to adhere to protocol requirements, as evidenced by a\n",
      "             signed Informed Consent Form.\n",
      "\n",
      "        Exclusion Criteria\n",
      "\n",
      "          -  Dissecting or mycotic brain aneurysm. Fusiform or atherosclerotic intracerebral\n",
      "             aneurysms may be eligible for the trial if endovascular treatment is planned with a\n",
      "             goal of exclusion of the aneurysm from the circulation.\n",
      "\n",
      "          -  Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment.\n",
      "\n",
      "          -  Known history of life-threatening allergic reaction to any medication.\n",
      "\n",
      "          -  Chronic renal disease defined as a baseline serum creatinine > 150 umol/L.\n",
      "\n",
      "          -  Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.\n",
      "\n",
      "          -  Women who are breastfeeding.\n",
      "\n",
      "          -  Any clinically significant psychiatric or psychological disease, which would preclude\n",
      "             the patient from completing the protocol.\n",
      "\n",
      "          -  Pre-morbid (estimated) modified Rankin scale score of greater than 2.\n",
      "\n",
      "          -  Previous serious traumatic brain injury that would preclude the patient from\n",
      "             completing the protocol or preclude MRI analysis of small strokes.\n",
      "\n",
      "          -  Patients with known HIV infection.\n",
      "\n",
      "          -  Patients who are unable to have an MRI scan for any reason.\n",
      "\n",
      "          -  Participation in a clinical trial with an investigational drug within 30 days\n",
      "             preceding this study. Previous participation in the ENACT trial (e.g,, to treat a\n",
      "             prior aneurysm), participation in another trial involving NA-1 or prior receipt of\n",
      "             NA-1.\n",
      "\n",
      "          -  Any other medical condition that the site investigator deems would put the patient at\n",
      "             excessive risk of participation in the study or an expected life expectancy less than\n",
      "             1 year or that would result in inability to collect clinical outcomes at 30 days.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  A low endogenous PTH production as verified by low plasma levels of intact PTH,\n",
      "             necessitating treatment with 1alpha-hydroxylated vitamin D analogs.\n",
      "\n",
      "          -  At least one years of continuous alphacalcidol, calcitriol, or dihydrotachysterol\n",
      "             treatment prior to study entry.\n",
      "\n",
      "          -  Prior to start of study, participants are required to have received a daily supplement\n",
      "             of at least 400 IU (10 microgram) of vitamin D (ergocalciferol or cholecalciferol) for\n",
      "             at least 3 months or 25hydroxyvitamin D levels above 50 nmol/l. Subjects may be\n",
      "             treated with ergocalciferol or cholecalciferol during a run-in period of three months\n",
      "             before entering the study.\n",
      "\n",
      "          -  Normal plasma magnesium level (If not, magnesium supplements may be provided during a\n",
      "             3 months run in period).\n",
      "\n",
      "          -  Plasma calcium levels within the normal reference range or slightly below (P-Ca\n",
      "             ionized 1.00 to 1.30).\n",
      "\n",
      "          -  Use of safe contraceptive methods (fertile women).\n",
      "\n",
      "          -  Speak and read Danish.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Known allergic reactions to any of the compounds in the trial medication.\n",
      "\n",
      "          -  Severely impaired renal function (plasma creatinine > 200 micromol/l).\n",
      "\n",
      "          -  Severely impaired hepatic function (Plasma alanine aminotransferase (ALAT) > 100 U/l\n",
      "             and/or alkaline phosphatase > 400 U/l).\n",
      "\n",
      "          -  Previous or present malignancies (except a treated skin cancer that is not melanoma or\n",
      "             treated carcinoma in situ, 2 years since last therapy).\n",
      "\n",
      "          -  Prior radiation therapy involving the skeleton.\n",
      "\n",
      "          -  Current treatment with raloxifene, calcitonin, systemic corticosteroids above 5 mg a\n",
      "             day, fluoride, lithium, PTH, or digoxin.\n",
      "\n",
      "          -  Treatment with anticonvulsant's (within the last 2 years).\n",
      "\n",
      "          -  Immobilization (more than two week within the last 6 months).\n",
      "\n",
      "          -  Granulomatous disease.\n",
      "\n",
      "          -  Paget's disease of bone.\n",
      "\n",
      "          -  Pregnancy / planned within the next year. Hospitalized due to chronic drug or alcohol\n",
      "             abuse. Severe malabsorption syndrome.\n",
      "\n",
      "          -  Major medical or social problems that will be likely to preclude participation for one\n",
      "             year.\n",
      "\n",
      "          -  Unwillingness to participate.\n",
      "      \n",
      "\n",
      "        DISEASE CHARACTERISTICS:\n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          -  Diagnosis of hepatic neuroendocrine metastases not suitable for radical therapies\n",
      "             (e.g., resection or liver transplantation)\n",
      "\n",
      "               -  Histologically proven neuroendocrine tumor\n",
      "\n",
      "               -  Tumors are hypervascular based on visual estimation by investigator\n",
      "\n",
      "          -  Predominant to the liver disease, but extrahepatic disease is not an exclusion\n",
      "\n",
      "               -  No predominant extrahepatic liver disease\n",
      "\n",
      "               -  No significant life-threatening extrahepatic disease, in the judgment of the\n",
      "                  physician\n",
      "\n",
      "          -  Recent-interval progression of hepatic liver metastases\n",
      "\n",
      "          -  No diffuse hepatic neuroendocrine metastases defined as massive ill-defined tumor\n",
      "             involvement measuring > 90% tumor burden\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  Clinically evident ascites (a radiographic finding of trace ascites on imaging is\n",
      "             acceptable)\n",
      "\n",
      "          -  Complete occlusion of the entire portal venous system\n",
      "\n",
      "          -  Evidence of cirrhosis or portal hypertension\n",
      "\n",
      "          -  Vascular resistance peripheral to the feeding arteries precluding passage of PVA\n",
      "             microporous hydrospheres/doxorubicin hydrochloride\n",
      "\n",
      "        PATIENT CHARACTERISTICS:\n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n",
      "\n",
      "          -  Must have preserved liver function (Child-Pugh class A-B) without significant liver\n",
      "             decompensation\n",
      "\n",
      "               -  No advanced liver disease (e.g., Child-Pugh C class or active gastrointestinal\n",
      "                  bleeding, encephalopathy, or ascites [trace ascites is acceptable]), meeting the\n",
      "                  following criteria:\n",
      "\n",
      "                    -  Bilirubin > 3 mg/dL\n",
      "\n",
      "                    -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and\n",
      "                       alkaline phosphatase > 5 times upper limit of normal\n",
      "\n",
      "                    -  Serum creatinine > 2.0 mg/dL\n",
      "\n",
      "                    -  Albumin ≤ 2.0 g/dL\n",
      "\n",
      "          -  No vascular anatomy or blood that precludes catheter placement or emboli injection\n",
      "\n",
      "          -  No presence of arteries supplying the lesion not large enough to accept PVA\n",
      "             microporous hydrospheres/doxorubicin hydrochloride\n",
      "\n",
      "          -  No collateral vessel pathways potentially endangering normal territories during\n",
      "             embolization\n",
      "\n",
      "          -  No feeding arteries smaller than distal branches from which they emerge\n",
      "\n",
      "          -  Not pregnant\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  See Disease Characteristics\n",
      "\n",
      "          -  Another active primary tumor\n",
      "\n",
      "          -  Any contraindication for hepatic embolization procedures, including any of the\n",
      "             following:\n",
      "\n",
      "               -  Porto-systemic shunt\n",
      "\n",
      "               -  Hepatofugal blood flow\n",
      "\n",
      "               -  Impaired clotting tests (i.e., platelet count < 50,000/mm³, international\n",
      "                  normalized ratio (INR) ≥ 1.8, or partial thromboplastin time (PTT) ≥ 39 seconds)\n",
      "\n",
      "               -  Renal failure\n",
      "\n",
      "               -  Severe peripheral vascular disease precluding catheterization\n",
      "\n",
      "          -  Any contraindication for doxorubicin hydrochloride administration (i.e., serum\n",
      "             bilirubin > 5 mg/dL or leukocyte count < 1,500 cells/mm³)\n",
      "\n",
      "          -  Allergy to contrast media\n",
      "\n",
      "          -  Intolerant to occlusion procedures\n",
      "\n",
      "          -  Presence of end arteries leading directly to cranial nerves\n",
      "\n",
      "          -  Presence or likely onset of hemorrhage\n",
      "\n",
      "          -  Presence of severe atheromatous disease\n",
      "\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  Prior anticancer therapy for hepatic neuroendocrine metastases, except previous\n",
      "             surgical therapy\n",
      "\n",
      "          -  Any continuing complication or prior cancer therapy that has not improved or resolved\n",
      "             prior to 21 days before start of treatment, if the investigator determines that the\n",
      "             continuing complication will compromise the safety of the patient after treatment with\n",
      "             PVA microporous hydrospheres/doxorubicin hydrochloride\n",
      "\n",
      "          -  Presence of patent extra-to-intracranial anastomoses or shunts\n",
      "\n",
      "          -  Use of PVA microporous hydrospheres/doxorubicin hydrochloride in the following\n",
      "             applications:\n",
      "\n",
      "               -  Embolization of large-diameter arteriovenous shunts\n",
      "\n",
      "               -  Pulmonary arterial vasculature\n",
      "\n",
      "               -  Any vasculature where the use of PVA microporous hydrospheres/doxorubicin\n",
      "                  hydrochloride could pass directly into the internal carotid artery or the\n",
      "                  above-listed vessels\n",
      "\n",
      "          -  Concurrent enrollment in another clinical study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Implantation of a market-approved Medtronic Connexus CRT-D- or DR-ICD-device\n",
      "\n",
      "          -  Patient consents to study\n",
      "\n",
      "          -  Ability to replace follow-ups with CareLink follow-ups\n",
      "\n",
      "          -  Ability to attend all follow-ups at study center\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Permanent AF\n",
      "\n",
      "          -  Less than 18 years of age\n",
      "\n",
      "          -  Life expectancy less than 15 months\n",
      "\n",
      "          -  Participation in another clinical study\n",
      "\n",
      "          -  Pregnancy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        -\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        -\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of cholangiocarcinoma\n",
      "\n",
      "          -  Ability to complete forms and attend phone coaching sessions\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  None\n",
      "      \n",
      "\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Men and Women 21 years old and older with metabolic syndrome\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Smokers\n",
      "\n",
      "          2. Female subjects who are pregnant or lactating\n",
      "\n",
      "          3. Subjects taking any medications that would interfere with outcomes of the study i.e.\n",
      "             lipid lowering medications, anti-inflammatory drugs (i.e. ibuprofen), dietary\n",
      "             supplements\n",
      "\n",
      "          4. Subjects with any known allergy or intolerance to foods involved in the\n",
      "             study(cantaloupe, egg, dairy, wheat, beans, couscous, grape seed extract)\n",
      "\n",
      "          5. Subjects who are actively trying to lose weight\n",
      "\n",
      "          6. Subjects with unusual dietary habits (i.e. pica, anorexia nervosa, extreme food\n",
      "             restriction, binging and/or purging disorders)\n",
      "\n",
      "          7. Subjects who are addicted to drugs or alcohol or who are <1 year recovery program\n",
      "\n",
      "          8. Subjects who present with significant psychiatric or neurological disturbances as\n",
      "             determined by the primary investigator (i.e. uncontrolled bipolar disorder) These\n",
      "             subjects will be referred to their primary care doctor for further care.\n",
      "\n",
      "          9. Subjects with documented atherosclerotic disease, inflammatory disease, diabetes\n",
      "             mellitus (fasting blood sugar ≥126 mg/dl), uncontrolled hypertension (≥ 140/90mmHg),\n",
      "             liver and kidney disease as identified by routine blood tests (chemistry panels).\n",
      "             These subjects will be referred to their primary care doctor for further care.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age ≥18\n",
      "\n",
      "          -  Fulfilling American College of Rheumatology (ACR) criteria for RA.\n",
      "\n",
      "          -  Disease duration ≤ 5 years.\n",
      "\n",
      "          -  Either under treatment with methotrexate (in a maximum tolerable up to 20 mg/week\n",
      "             orally or subcutaneously), or previous treatment with methotrexate withdrawn due to\n",
      "             documented side effects.\n",
      "\n",
      "          -  Patients should be bio-naïve.\n",
      "\n",
      "          -  Disease activity: Disease Activity Score (DAS28)>3.2 and Swollen joint count (SJC)>1\n",
      "             and Tender Joint Count (TJC)>1.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        For fMRI - left handedness and all forms of metallic implants.\n",
      "\n",
      "          -  Fulfilling ACR criteria for fibromyalgia.\n",
      "\n",
      "          -  Severe ischemic heart disease.\n",
      "\n",
      "          -  Concurrent treatment for depression/anxiety with antidepressant drugs.\n",
      "\n",
      "          -  Contraindication to adalimumab.\n",
      "\n",
      "          -  Active or latent tuberculosis.\n",
      "\n",
      "          -  Chronic infections including hepatitis B or C.\n",
      "\n",
      "          -  Malignancy, multiple sclerosis, Systemic lupus erythematosus.\n",
      "\n",
      "          -  Other reason as evaluated by the PI.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Meets one of the following sets of criteria:\n",
      "\n",
      "               -  Dose-escalation group:\n",
      "\n",
      "                    -  Histologically and/or cytologically confirmed solid malignancy\n",
      "\n",
      "                    -  Metastatic or unresectable disease\n",
      "\n",
      "                    -  Disease for which standard curative or palliative measures do not exist or\n",
      "                       are no longer effective\n",
      "\n",
      "               -  Expansion group:\n",
      "\n",
      "                    -  Histologically and/or cytologically confirmed endometrial (endometrioid,\n",
      "                       uterine papillary serious carcinoma, or carcinosarcoma) or renal cell cancer\n",
      "\n",
      "                    -  Metastatic or unresectable disease\n",
      "\n",
      "                    -  Disease for which standard curative or palliative measures do not exist or\n",
      "                       are no longer effective\n",
      "\n",
      "          -  Measurable or non-measurable disease\n",
      "\n",
      "               -  Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥\n",
      "                  1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional\n",
      "                  techniques or as ≥ 10 mm with spiral CT scan\n",
      "\n",
      "          -  No known brain metastases\n",
      "\n",
      "          -  ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%)\n",
      "\n",
      "          -  Life expectancy > 12 weeks\n",
      "\n",
      "          -  Leukocytes ≥ 3,000/mm^3\n",
      "\n",
      "          -  ANC ≥ 1,500/mm^3\n",
      "\n",
      "          -  Platelet count ≥ 100,000/mm^3\n",
      "\n",
      "          -  Hemoglobin ≥ 90 g/L (or ≥ 9 g/dL)\n",
      "\n",
      "          -  Total bilirubin normal\n",
      "\n",
      "          -  AST/ALT ≤ 2.5 times upper limit of normal\n",
      "\n",
      "          -  Serum creatinine normal OR creatine clearance ≥ 60 mL/min\n",
      "\n",
      "          -  Fasting cholesterol ≤ 350 mg/dL (9.0 mmol/L)\n",
      "\n",
      "          -  Fasting triglycerides ≤ 400 mg/dL (4.56 mmol/L)\n",
      "\n",
      "          -  No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or\n",
      "             hypokalemia defined as less than the lower limit of normal for the institution,\n",
      "             despite adequate electrolyte supplementation\n",
      "\n",
      "               -  Note: it is acceptable to use corrected calcium when interpreting calcium levels\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Negative pregnancy test\n",
      "\n",
      "          -  Fertile patients must use two effective forms of contraception (i.e., barrier\n",
      "             contraception and one other method of contraception) for ≥ 4 weeks before, during, and\n",
      "             for ≥ 12 months after completion of study therapy\n",
      "\n",
      "          -  Able to swallow medication\n",
      "\n",
      "          -  No malabsorption syndrome or other condition that would interfere with intestinal\n",
      "             absorption\n",
      "\n",
      "          -  No diarrhea ≥ grade 2 that is not under control with standard anti-diarrhea\n",
      "             medications\n",
      "\n",
      "          -  No uncontrolled concurrent illness including, but not limited to, any of the\n",
      "             following:\n",
      "\n",
      "               -  Ongoing or active infection\n",
      "\n",
      "               -  Symptomatic congestive heart failure\n",
      "\n",
      "               -  Unstable anginal pectoris\n",
      "\n",
      "               -  Cardiac arrhythmia other than chronic, stable atrial fibrillation\n",
      "\n",
      "               -  Psychiatric illness or social situations that would limit compliance with study\n",
      "                  medications\n",
      "\n",
      "          -  QTc ≤ 450 msec in males and a QTc ≤ 470 msec in females, as measured by ECG using\n",
      "             Bazett formula\n",
      "\n",
      "          -  No history of risk factors for QT interval prolongation including, but not limited to,\n",
      "             a family or personal history of any of the following:\n",
      "\n",
      "               -  Long QT syndrome\n",
      "\n",
      "               -  Torsades de pointes\n",
      "\n",
      "               -  Recurrent syncope without known etiology\n",
      "\n",
      "               -  Sudden unexpected death\n",
      "\n",
      "          -  No pre-existing significant pulmonary infiltrates of unknown origin\n",
      "\n",
      "          -  No serologic positivity for hepatitis A, B, or C or history of liver disease or other\n",
      "             forms of hepatitis or cirrhosis\n",
      "\n",
      "          -  No HIV-positive patients on combination antiretroviral therapy\n",
      "\n",
      "          -  No history of allergic reactions attributed to compounds of similar chemical or\n",
      "             biologic composition to gamma-secretase inhibitor RO4929097 or temsirolimus\n",
      "\n",
      "          -  Female patients may not donate ova during or after study treatment\n",
      "\n",
      "          -  Male patients may not donate sperm during and for ≥ 12 months after completion of\n",
      "             study treatment\n",
      "\n",
      "          -  Patients may not donate blood during and for ≥ 12 months after completion of study\n",
      "             treatment\n",
      "\n",
      "          -  Any number of prior therapies allowed\n",
      "\n",
      "          -  Recovered from side effects of previous systemic anticancer therapy to < CTCAE grade 2\n",
      "             toxicity (except alopecia)\n",
      "\n",
      "          -  Concurrent leuteinizing hormone-releasing hormone agonist allowed in patients with\n",
      "             castration-resistant prostate cancer\n",
      "\n",
      "          -  No prior gamma-secretase inhibitor or any inhibitor of the PI3K/Akt/mTOR pathway\n",
      "\n",
      "          -  At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for carmustine,\n",
      "             nitrosoureas, or mitomycin C)\n",
      "\n",
      "               -  Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for\n",
      "                  symptomatic palliation\n",
      "\n",
      "          -  No other concurrent investigational agents\n",
      "\n",
      "          -  No concurrent medications with narrow therapeutic indices that are metabolized by\n",
      "             cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)\n",
      "\n",
      "          -  No concurrent medications that are strong inducers, inhibitors, or substrates of\n",
      "             CYP3A4\n",
      "\n",
      "          -  No antiarrhythmics or other concurrent medications with known potential to prolong QT\n",
      "             interval\n",
      "\n",
      "          -  No concurrent food that may interfere with the metabolism of gamma-secretase inhibitor\n",
      "             RO4929097, including grapefruit or grapefruit juice\n",
      "\n",
      "          -  No other concurrent anticancer agents or therapies\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Macular traction retinal detachment lasting three months or less secondary to diabetic\n",
      "             retinopathy.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Massive vitreous hemorrhage preventing from detailed posterior pole examination;\n",
      "\n",
      "          -  Previous intra-ocular surgery other than cataract surgery\n",
      "\n",
      "          -  Hemodialysis, known bleeding disorders or use of anticoagulants drugs other than\n",
      "             aspirin\n",
      "\n",
      "          -  Prothrombin time, partial thromboplastin time or platelet count without normal limits\n",
      "\n",
      "          -  History of previous thromboembolic events\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age greater than18 years\n",
      "\n",
      "          -  Chronic neuropathic pain of central or peripheral origin for 3 months or longer as\n",
      "             determined by the study physician and a score of 4/10 or greater on the DN4\n",
      "\n",
      "          -  Moderate to severe pain as defined by average 7-day pain score of greater than 4 on an\n",
      "             11-point numerical rating scale for pain intensity (NRS-PI).\n",
      "\n",
      "          -  Physician has identified that an opioid is a valid adjunctive treatment for the\n",
      "             chronic neuropathic pain.\n",
      "\n",
      "          -  Concomitant non-opioid analgesic medications must have been stable for 14 days.\n",
      "\n",
      "          -  Co-interventions such as TENS, acupuncture and massage must have been stable for 14\n",
      "             days prior to the trial\n",
      "\n",
      "          -  If taking an opioid, maximum dose of opioid in oral morphine equivalents (OME) is 90\n",
      "             mg/24 hours.\n",
      "\n",
      "          -  Ability to follow the protocol with reference to cognitive and situational conditions;\n",
      "             e.g., stable housing, able to attend follow-up visits.\n",
      "\n",
      "          -  Willing and able to give written informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients on a dose of opioid that exceeds 90 mg/24 hours in OME\n",
      "\n",
      "          -  Pregnant or lactating women (women of childbearing potential must have negative\n",
      "             pregnancy test)\n",
      "\n",
      "          -  History of psychosis\n",
      "\n",
      "          -  History of (within the past 2 years) , or current, substance dependency disorder\n",
      "\n",
      "          -  Excluded medications are listed in Appendix 1.\n",
      "\n",
      "          -  Presence of clinically significant cardiac or pulmonary disorder on physical exam that\n",
      "             would compromise participants' safety in the trial as judged by the study physician.\n",
      "\n",
      "          -  Presence of significant conduction delay, ischemia or arrhythmia on screening ECG\n",
      "\n",
      "          -  Presence of severe pain disorder other than the chronic neuropathic pain under study\n",
      "             that would interfere with patient's ability to determine effect of study treatment on\n",
      "             the chronic neuropathic pain\n",
      "\n",
      "          -  Abnormalities above 1.5 times upper range of normal on screening CBC, blood chemistry\n",
      "             including BUN, Cr, LDH, AST, ALT\n",
      "\n",
      "          -  Patients with a history of allergy to any opioid.\n",
      "\n",
      "          -  Participation in another clinical trial in the 30 days prior to enrolment.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Healthy elderly subjects\n",
      "\n",
      "          -  No cognitive symptoms reported by patient and/or informant\n",
      "\n",
      "          -  Normal performance on cognitive tests\n",
      "\n",
      "          -  General cognition and functional performance preserved such that a diagnosis of MCI or\n",
      "             dementia cannot be made by physician at the time of the baseline visit\n",
      "\n",
      "          -  Between 60 and 90 years of age\n",
      "\n",
      "          -  Fluent in Swedish\n",
      "\n",
      "          -  Agrees to at least one lumbar puncture, and neuropsychological testing.\n",
      "\n",
      "        Mild cognitive impairment\n",
      "\n",
      "          -  Cognitive symptoms reported by patient and/or informant\n",
      "\n",
      "          -  Between 60 and 80 years of age\n",
      "\n",
      "          -  Mini-Mental State Exam score between 24 and 30\n",
      "\n",
      "          -  General cognition and functional performance sufficiently preserved such that a\n",
      "             diagnosis of dementia cannot be made by physician at the time of the baseline visit\n",
      "\n",
      "          -  Fluent in Swedish\n",
      "\n",
      "          -  Agrees to at least one lumbar puncture, and neuropsychological testing.\n",
      "\n",
      "        Exclusion Criteria (for both MCI and healthy elderly):\n",
      "\n",
      "          -  Any significant neurologic disease other than dementia disorders, such as Huntington's\n",
      "             disease, normal pressure hydrocephalus, brain tumor, seizure disorder, subdural\n",
      "             hematoma, multiple sclerosis, or history of significant head trauma followed by\n",
      "             persistent neurologic defaults or known structural brain abnormalities.\n",
      "\n",
      "          -  Major depression as described in DSM-IV.\n",
      "\n",
      "          -  History of schizophrenia or other recurrent psychotic disorder\n",
      "\n",
      "          -  History of alcohol or substance abuse or dependence within the past 5 years\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  documented H.pylori infection by a CLO test or a Urea Breath Test\n",
      "\n",
      "          -  sign the informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Age under 18 or older than 80 years\n",
      "\n",
      "          -  Allergies to any of the drugs used\n",
      "\n",
      "          -  Recent antibiotic therapy (within 2 weeks of enrolment)\n",
      "\n",
      "          -  Severe ulcers or bleeding\n",
      "\n",
      "          -  Gastric perforation or obstruction\n",
      "\n",
      "          -  Previous gastrectomy\n",
      "\n",
      "          -  Gastric cancer\n",
      "\n",
      "          -  Pregnancy or lactation\n",
      "\n",
      "          -  Prior eradication therapy for H. pylori\n",
      "\n",
      "          -  Severe concomitant disease or condition making the treatment unlikely to be effective\n",
      "             i.e. alcoholism, drug addiction, and history of poor compliance.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically or cytologically proven adenocarcinoma of the pancreas\n",
      "\n",
      "          -  Patients must have locally advanced unresectable disease not amenable to curative\n",
      "             resection or extrapancreatic metastases; patients must have EITHER radiographically\n",
      "             measurable disease (defined as at least one lesion that can be accurately measured in\n",
      "             at least one dimension [longest diameter to be recorded] as >= 20 mm with conventional\n",
      "             techniques or as >= 10 mm with spiral computed tomography [CT] scan) AND/OR a serum\n",
      "             CA19-9 measurement > 2 x ULN\n",
      "\n",
      "          -  One prior line of systemic therapy for advanced disease (locally advanced or\n",
      "             metastatic)\n",
      "\n",
      "               -  The following represent acceptable examples meeting the definition of one prior\n",
      "                  line of therapy:\n",
      "\n",
      "                    -  Gemcitabine as a single agent or in combination with other agents; patients\n",
      "                       receiving (a) gemcitabine initially alone, with the eventual addition of a\n",
      "                       second agent; or (b) gemcitabine as part of a combination regimen, followed\n",
      "                       by gemcitabine alone; are eligible\n",
      "\n",
      "                    -  A non-gemcitabine-based regimen, including (but not limited to) leucovorin\n",
      "                       calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin\n",
      "                       (FOLFIRINOX) or any combination of components therein\n",
      "\n",
      "                    -  Treatment as part of a clinical trial involving cytotoxic agents, small\n",
      "                       molecule inhibitors, monoclonal antibodies, and/or immunomodulatory agents\n",
      "\n",
      "               -  For patients with locally advanced disease, prior radiation to the primary tumor\n",
      "                  is allowable as long as there is clear evidence of disease progression (either\n",
      "                  radiographic locoregional disease progression and/or a rising CA19-9 level);\n",
      "                  patients may have received chemotherapy both concurrently and/or sequentially\n",
      "                  with (either before or after) the radiation and still be eligible for the study,\n",
      "                  as this would be considered all part of the same course of treatment\n",
      "\n",
      "               -  Treatment given in the adjuvant setting (radiation and/or chemotherapy, given\n",
      "                  either concurrently or sequentially) does not count as prior therapy as long as\n",
      "                  progressive disease occurs > 6 months following completion of treatment\n",
      "\n",
      "          -  Life expectancy of greater than 8 weeks\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n",
      "\n",
      "          -  Absolute neutrophil count (ANC) >= 1500/uL\n",
      "\n",
      "          -  Platelet count >= 100,000/uL\n",
      "\n",
      "          -  International normalized ratio (INR) =< 1.5 (except those subjects who are receiving\n",
      "             full-dose warfarin)\n",
      "\n",
      "          -  Total bilirubin =< 2.0 mg/dL\n",
      "\n",
      "          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 times the\n",
      "             upper limit of normal for subjects\n",
      "\n",
      "          -  Serum creatinine of =< 2.0 mg/dL\n",
      "\n",
      "          -  Pregnancy test for women of childbearing potential (serum or urine beta-human\n",
      "             chorionic gonadotropin [HCG])\n",
      "\n",
      "          -  All patients must be informed of the investigational nature of this study and must\n",
      "             sign and give written informed consent in accordance with institutional and federal\n",
      "             guidelines\n",
      "\n",
      "          -  Women of child-bearing potential and men must agree to use adequate contraception\n",
      "             (hormonal or barrier method of birth control; abstinence) prior to study entry, for\n",
      "             the duration of study participation, and for four weeks after dosing with AZD6244\n",
      "             ceases; women of child-bearing potential must have a negative pregnancy test prior to\n",
      "             entry; should a woman become pregnant or suspect she is pregnant while participating\n",
      "             in this study, she should inform her treating physician immediately; please note that\n",
      "             the AZD6244 manufacturer recommends that adequate contraception for male patients\n",
      "             should be used for 16 weeks post-last dose due to sperm life cycle\n",
      "\n",
      "          -  Ability to understand and the willingness to sign a written informed consent document\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n",
      "             nitrosoureas or mitomycin C) prior to entering the study or those who have not\n",
      "             recovered from adverse events due to agents administered more than 4 weeks earlier\n",
      "\n",
      "          -  Patients may not be receiving any other investigational agents\n",
      "\n",
      "          -  Patients with known brain metastases should be excluded from this clinical trial\n",
      "\n",
      "          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n",
      "             composition to AZD6244 (or its excipient Captisol) or erlotinib\n",
      "\n",
      "          -  Previous mitogen-activated protein kinase kinase (MEK) or epidermal growth factor\n",
      "             receptor (EGFR) inhibitor use\n",
      "\n",
      "          -  Patients with corrected QT (QTc) interval > 480 msecs or other factors that increase\n",
      "             the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia,\n",
      "             family history of long QT interval syndrome) including heart failure that (i) meets\n",
      "             New York Heart Association (NYHA) class III and IV definitions or (ii) is demonstrated\n",
      "             by an left ventricular (LV) ejection fraction < 55% on baseline echocardiogram, are\n",
      "             excluded\n",
      "\n",
      "          -  Required use of a concomitant medication that can prolong the QT interval\n",
      "\n",
      "          -  There are potential interactions between erlotinib and cytochrome P450, family 3,\n",
      "             subfamily A, polypeptide 4 (CYP3A4) inhibitors and CYP3A4 promoters; although caution\n",
      "             and careful monitoring are recommended when use of these compounds is necessary, use\n",
      "             of these compounds does not exclude patients from participating in this trial\n",
      "\n",
      "          -  Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g. inflammatory\n",
      "             bowel disease), or significant bowel resection that would preclude adequate absorption\n",
      "\n",
      "          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n",
      "             infection or psychiatric illness/social situations that would limit compliance with\n",
      "             study requirements\n",
      "\n",
      "          -  Pregnant women are excluded from this study; therefore, a negative pregnancy test is\n",
      "             required for women of childbearing potential; breastfeeding should be discontinued if\n",
      "             the mother is treated with AZD6244\n",
      "\n",
      "          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n",
      "             therapy are ineligible\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Written informed consent before beginning any protocol specified procedures\n",
      "\n",
      "          -  Histologically proven pancreatic adenocarcinoma\n",
      "\n",
      "          -  Any T, any N, M0 disease that has had all gross disease resected (R0 or R1 resection)\n",
      "\n",
      "          -  ECOG Performance status index 0 or 1\n",
      "\n",
      "          -  Absolute Neutrophils >= 1.5 x 10^9/L\n",
      "\n",
      "          -  Platelets >= 100 x 10^9/L\n",
      "\n",
      "          -  Hemoglobin >= 10 g/dL\n",
      "\n",
      "          -  Total bilirubin =< 2.0 x UNL; subjects with Gilbert's syndrome, confirmed by\n",
      "             genotyping or invader UGTIA1 molecular assay before study entry must have total\n",
      "             bilirubin < 3 x UNL\n",
      "\n",
      "          -  ASAT (SGOT) and ALAT (SGPT) =< 2.5 x UNL\n",
      "\n",
      "          -  Alkaline Phosphatase =< 5 x UNL\n",
      "\n",
      "          -  Creatinine < 1.5 x UNL\n",
      "\n",
      "          -  Serum Na, K+, Magnesium, Phosphate and Calcium >= LNL\n",
      "\n",
      "          -  First study treatment must be given within 60 days after surgery and within 7 days\n",
      "             after randomization\n",
      "\n",
      "          -  Patients must be accessible for treatment and follow-up and compliant with study\n",
      "             procedures\n",
      "\n",
      "          -  Negative pregnancy test (urine or serum) within 7 days before first study treatment\n",
      "             for all women of childbearing potential, whom also must implement adequate\n",
      "             non-hormonal contraceptive measures during study treatment and for at least 3 months\n",
      "             after the last dose of study therapy\n",
      "\n",
      "          -  Ability to take oral medication (dasatinib must be swallowed whole)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior or concurrent systemic anticancer therapy (immunotherapy, hormonal therapy,\n",
      "             biological therapy, or chemotherapy) for pancreatic cancer\n",
      "\n",
      "          -  Prior or concurrent radiation therapy for pancreatic cancer\n",
      "\n",
      "          -  Pregnant or lactating patients\n",
      "\n",
      "          -  M1 pancreatic cancer\n",
      "\n",
      "          -  Concurrent congestive heart failure, unstable angina pectoris, or M1 within the 6\n",
      "             months before first study treatment\n",
      "\n",
      "          -  Uncontrolled hypertension or high-risk uncontrolled arrhythmias\n",
      "\n",
      "          -  Any history of clinically significant ventricular arrhythmias (such as ventricular\n",
      "             tachycardia, ventricular fibrillation, or torsades de pointes)\n",
      "\n",
      "          -  Diagnosed or suspected congenital long QT syndrome\n",
      "\n",
      "          -  Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)\n",
      "\n",
      "          -  History of significant neurologic or psychiatric disorders including psychotic\n",
      "             disorders, dementia or seizures that would prohibit the understanding and giving of\n",
      "             informed consent\n",
      "\n",
      "          -  Past or current history of neoplasm other than pancreatic adenocarcinoma, except for:\n",
      "             curatively treated non-melanoma skin cancer; in situ carcinoma of the cervix; other\n",
      "             cancer curatively treated and with no evidences of disease for at least 1 year\n",
      "\n",
      "          -  Concurrent treatment with other experimental drugs or treatment with investigational\n",
      "             drugs within 30 days of first study treatment\n",
      "\n",
      "          -  Currently receiving drugs with known significant CYP 3A4 inhibitory effects (such as\n",
      "             ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem, verapamil,\n",
      "             ritonavir, indinavir)\n",
      "\n",
      "          -  Concurrent administration with inducers of CYP 3A4 may result in a lower exposure to\n",
      "             dasatinib and are therefore not allowed (e.g., phenytoin, carbamazepine, rifampicin,\n",
      "             phenobarbital, pentobarbital, or St John's Wort)\n",
      "\n",
      "          -  Known allergy reactions to dasatinib or gemcitabine or excipients used in the study\n",
      "\n",
      "          -  History of significant bleeding disorders unrelated to cancer, including: diagnosed\n",
      "             congenital bleeding disorders (e.g., Von Willebrand's disease); diagnosed acquired\n",
      "             bleeding disorder within 1 year (e.g., acquired anti-factor VIII antibodies); ongoing\n",
      "             or recent (=< 3 months) significant gastrointestinal bleeding\n",
      "\n",
      "          -  Patients currently taking drugs that are generally accepted to have a risk of causing\n",
      "             Torsades De Pointes including: quinidine, procainamide, disopyramide; amiodarone,\n",
      "             sotalol, ibutilide, dofetilide; erythromycins, clarithromycin; chlorpromazine,\n",
      "             haloperidol, mesoridazine, thioridazine, pimozide; cisapride, bepridil, droperidol,\n",
      "             methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine,\n",
      "             sparfloxacin, lidoflazine\n",
      "\n",
      "          -  Concurrent treatment with intravenous bisphosphonates; prior treatment should be\n",
      "             stopped at least 2 weeks before first dose of study treatment\n",
      "\n",
      "          -  Concurrent medical condition which may increase the risk of toxicity, including\n",
      "             pleural or pericardial effusion or any grade\n",
      "\n",
      "          -  Active uncontrolled infection requiring parenteral antimicrobials\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Cardiac surgery with extracorporal circulation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Use of oral antiarrhythmics\n",
      "\n",
      "          -  theophylline use\n",
      "\n",
      "          -  Use of sulfonylureas\n",
      "\n",
      "          -  Atrial arrythmias\n",
      "\n",
      "          -  Right ventricular failure\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy female aged between 20 to 35 years\n",
      "\n",
      "          -  BMI:18.0-26.0\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Females who are pregnant\n",
      "\n",
      "          -  Drug use affecting sex hormone secretion\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Anyone admitted to the University of Mississippi Medical Center with a pelvic ring or\n",
      "             acetabular injury\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Those not fitting the inclusion criteria\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with colorectal liver metastases already treated by chemotherapy and\n",
      "             scheduled for surgical resection\n",
      "\n",
      "          -  Patients with colorectal liver metastases scheduled to receive chemotherapy with\n",
      "             possibility of future liver resection.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Acute or Chronic Renal Disease with Estimated GFR (eGFR) <30 mL/min.\n",
      "\n",
      "          -  Hypersensitivity to MRI contrast or CT contrast or to any ingredient in the\n",
      "             formulation or component of the container.\n",
      "\n",
      "          -  Patients with: acute or chronic severe renal impairment (glomerular filtration rate\n",
      "             <30 mL/min/1.73 m2), or acute renal insufficiency of any severity due to the\n",
      "             hepato-renal syndrome or in the perioperative liver transplantation period.\n",
      "\n",
      "          -  General contraindications to MRI such as pacemaker or ferromagnetic implants.\n",
      "\n",
      "          -  Severe cardiovascular problems\n",
      "\n",
      "          -  Pregnant or nursing women\n",
      "\n",
      "          -  Age <18 years\n",
      "\n",
      "          -  Liver Surgery is not a possibility.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  symptoms of stable angina pectoris according to the treating physician\n",
      "\n",
      "          -  scheduled for coronary angiography\n",
      "\n",
      "          -  written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pathological Q-wave in the 12-lead resting ECG\n",
      "\n",
      "          -  known previous myocardial infarction\n",
      "\n",
      "          -  previous PCI (percutaneous coronary intervention) or CABG (coronary artery bypass\n",
      "             graft)\n",
      "\n",
      "          -  history of congestive heart failure\n",
      "\n",
      "          -  anything that contraindicates a MRI investigation (e.g. pacemaker, claustrophobia,\n",
      "             intracranial clips)\n",
      "\n",
      "          -  lack of suitability for participation in the trial, for any reason, as judged by the\n",
      "             Investigator.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age ≥ 18 years\n",
      "\n",
      "          -  Patients choosing to undergo surgical treatment for prostate cancer\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior treatment of prostate cancer by any means\n",
      "\n",
      "          -  History of glaucoma, macular degeneration, or diabetic retinopathy\n",
      "\n",
      "          -  History of eye trauma/injury\n",
      "\n",
      "          -  History of non-refractive eye surgery\n",
      "\n",
      "          -  Allergy to topical anesthetic (this will be used during the eye exam)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age >3 months\n",
      "\n",
      "          -  Intestinal failure patients\n",
      "\n",
      "          -  Silicone catheter for the administration of parenteral nutrition\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Age < 3 months\n",
      "\n",
      "          -  Weight < 5 kg\n",
      "\n",
      "          -  Documented allergy to ethanol\n",
      "\n",
      "          -  Evidence of tunnel site infection\n",
      "\n",
      "          -  Patients receiving continuous renal replacement therapy\n",
      "\n",
      "          -  Concomitant use of metronidazole\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult Day Program Participants with early dementia able to consent or assent with\n",
      "             surrogate permission\n",
      "\n",
      "          -  Control participants (55-100+ yo) able to participate at location with doctor\n",
      "             permission\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  history of significant TBI, psychiatric condition, substance abuse, physical\n",
      "             conditions that preclude participation in cognitive testing or strengthening exercises\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subject must be at least 18 years of age; of either gender and in good general health.\n",
      "\n",
      "          -  Subject has sustained burn wounds of less than 30 percent of the total body surface\n",
      "             area\n",
      "\n",
      "          -  Burn wounds do not involve the harvesting area\n",
      "\n",
      "          -  Subject has sustained burn wounds that, in the judgment of the attending surgeon,\n",
      "             require excision and grafting of sufficient extent to justify two donor sites of equal\n",
      "             and symmetrical size on non-dependent body surfaces areas\n",
      "\n",
      "          -  The scheduled excision and grafting procedure is the first such operation for the\n",
      "             subject during this hospitalization\n",
      "\n",
      "          -  Subject agrees to participate in follow-up evaluations\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Critical illnesses such as those requiring ventilator support, or having a systemic\n",
      "             infection or hemodynamic instability, defined as a mean arterial pressure less than 60\n",
      "             or requiring vasoactive medications to support blood pressure\n",
      "\n",
      "          -  Major acute or chronic medical illnesses that could affect wound healing (e.g.\n",
      "             peripheral vascular disease, insulin dependent diabetes, blood clotting disorder)\n",
      "\n",
      "          -  Subjects receiving treatment with medications that inhibit or compromise wound\n",
      "             healing. Examples include therapeutic anticoagulants, antiplatelet drugs, and systemic\n",
      "             steroids such as warfarin, clopidogrel or prednisone. The use of anticoagulants does\n",
      "             not include DVT (Deep Vein Thrombosis) prophylaxis. Subjects may use aspirin or\n",
      "             lovenox\n",
      "\n",
      "          -  Cellulitis or other infection of the potential donor sites\n",
      "\n",
      "          -  Donor site has been previously harvested for grafting\n",
      "\n",
      "          -  Subjects with greater than 30% total body surface area burns\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Prisoners\n",
      "      \n",
      "\n",
      "        Inclusion Criteria\n",
      "\n",
      "          -  Subject is at least 18 years of age\n",
      "\n",
      "          -  Subject is scheduled for an elective coronary catheterization\n",
      "\n",
      "          -  Subject is willing and able to provide informed written consent prior to the index\n",
      "             catheterization\n",
      "\n",
      "          -  LipiScan IVUS CIS use is not contra-indicated\n",
      "\n",
      "          -  At least one submitted Chemogram is obtained entirely within a native coronary artery\n",
      "\n",
      "          -  Patient has been diagnosed with: stable angina (CCS I or CCS II);a positive functional\n",
      "             test for ischemia (within the preceding 30 days); OR Stabilized acute coronary\n",
      "             syndrome (unstable angina (CCS III, or CCS IV), non STEMI, or STEMI with no chest pain\n",
      "             or other cardiac symptoms for >24 hours\n",
      "\n",
      "          -  Blood cardiac biomarker (i.e. troponin I, CK-MB) levels less than the local laboratory\n",
      "             ULN within 12 hours of the time of PCI guidewire placement.\n",
      "\n",
      "          -  Subject is to undergo PCI of a single lesion in a single native coronary artery during\n",
      "             the enrollment procedure.\n",
      "\n",
      "          -  There is prior intent to treat the target lesion as part of the patient's clinical\n",
      "             care.\n",
      "\n",
      "          -  The target lesion angiographic stenosis visually estimated as >=50% and <100%\n",
      "\n",
      "          -  The target lesion reference vessel diameter must be >=2.5mm (visually estimated)\n",
      "\n",
      "          -  Total target lesion length must be ≤60 mm (visually estimated)\n",
      "\n",
      "          -  The minimum landing zone requirements for the FilterWire device can be met.\n",
      "\n",
      "          -  There must be no major side branches (>2.0 mm in diameter) within the target lesion.\n",
      "\n",
      "          -  There must be no major side branches (>2.0mm in diameter) between the target lesion\n",
      "             and the filter nitinol loop landing zone.\n",
      "\n",
      "        Exclusion Criteria\n",
      "\n",
      "          -  Subject is currently, or within the preceding 30 days, participating in a device or\n",
      "             pharmaceutical treatment protocol.\n",
      "\n",
      "          -  Subject life expectancy at time of enrollment is less than 2 years;\n",
      "\n",
      "          -  Subject is pregnant or suspected to be pregnant at time of enrollment\n",
      "\n",
      "          -  Prior coronary bypass graft surgery (CABG)\n",
      "\n",
      "          -  PCI performed within the 24hours prior to the start of the study procedure\n",
      "\n",
      "          -  A PCI is planned within the 30 days following the enrollment procedure.\n",
      "\n",
      "          -  Unable to take aspirin and a thienopyridine for at least 30 days\n",
      "\n",
      "          -  Patient experienced a STEMI or non STEMI within the past 24 hours\n",
      "\n",
      "          -  Documented LVEF <25%\n",
      "\n",
      "          -  the patient has multi-lesion or multi-vessel disease requiring revascularization of\n",
      "             multiple lesions during the enrollment catheterization\n",
      "\n",
      "          -  Any angiographic evidence of thrombus in any coronary artery\n",
      "\n",
      "          -  There is evidence of dissection or procedural complication prior to randomization\n",
      "\n",
      "          -  Patient has unprotected left main (≥50% stenosis) or left main equivalent disease\n",
      "\n",
      "          -  Target Lesion is located in the distal segment of the target native coronary artery\n",
      "\n",
      "          -  Proximal bound of the target lesion is located within 3mm of the ostium of the target\n",
      "             vessel or major side branch (>2mm diameter by visual estimate)\n",
      "\n",
      "          -  Target lesion is excessively calcified\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  lateral elbow tendinopathy\n",
      "\n",
      "          -  informed consent\n",
      "\n",
      "          -  ability to run at least 40-60min per week with a XCO-Trainer device\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  other sources of lateral elbow pain (joint instabilities, fractures)\n",
      "\n",
      "          -  no consent\n",
      "\n",
      "          -  no ability to run at least 40-60min per week using a XCO-Trainer device\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  12-21 years of age\n",
      "\n",
      "          -  arriving for routine care to dental office\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  dentally, medically, or psychologically unstable at the time of the visit\n",
      "\n",
      "          -  cannot read or understand English at a 6th grade level\n",
      "\n",
      "          -  unavailable for 1-month post-visit assessment\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Neoadjuvant setting\n",
      "\n",
      "          1. Histologically confirmed diagnosis of adenocarcinoma of the breast\n",
      "\n",
      "          2. Patient candidate for neoadjuvant chemotherapy (taxane-based)\n",
      "\n",
      "          3. Triple negative (ERnegative, PRnegative and Her2negative as defined by local\n",
      "             standards)\n",
      "\n",
      "          4. Normal coagulation profile; including INR/ PTT ≤ 1.5 x ULN.\n",
      "\n",
      "          5. ECOG 0,1 or 2\n",
      "\n",
      "          6. Provide written consent after the investigational nature, study design, risks and\n",
      "             benefits of the study have been explained.\n",
      "\n",
      "          7. Able to adhere to the study visit schedule and other protocol requirements.\n",
      "\n",
      "        Metastatic setting\n",
      "\n",
      "          1. Patients with histologically confirmed primary adenocarcinoma of the breast\n",
      "\n",
      "          2. Metastatic (stage IV) disease at initial diagnosis or following previous diagnosis of\n",
      "             primary breast cancer\n",
      "\n",
      "          3. At least one metastatic site accessible for biopsy.\n",
      "\n",
      "          4. ER-negative, PgR negative and HER2 negative as per local standards\n",
      "\n",
      "          5. Scheduled to receive chemotherapy for triple negative metastatic breast cancer.\n",
      "\n",
      "          6. Measurable disease (at least one unidimensionally measurable lesion)\n",
      "\n",
      "          7. Normal coagulation profile; including INR/ PTT ≤ 1.5 x ULN.\n",
      "\n",
      "          8. ECOG 0,1 or 2\n",
      "\n",
      "          9. Life expectancy of 12 or more weeks.\n",
      "\n",
      "         10. Provide written consent after the investigational nature, study design, risks and\n",
      "             benefits of the study have been explained.\n",
      "\n",
      "         11. Able to adhere to the study visit schedule and other protocol requirements\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Neoadjuvant setting\n",
      "\n",
      "          1. Positive for ER, PR or Her2 as defined by local standards\n",
      "\n",
      "          2. Clinical or radiological evidence of metastatic disease\n",
      "\n",
      "          3. Inadequate or unusable tissue as the only tissue available for biopsy\n",
      "\n",
      "          4. Other non-malignant systemic disease to preclude treatment with chemotherapy regimen\n",
      "             or prevent follow-up\n",
      "\n",
      "          5. Diagnosis of inflammatory breast cancer\n",
      "\n",
      "          6. Known infection with HIV or hepatitis\n",
      "\n",
      "        Metastatic setting\n",
      "\n",
      "          1. Patients with ER+, PR+ or HER2+ tumors demonstrated by local standards\n",
      "\n",
      "          2. Inadequate or unusable tissue as the only tissue available for biopsy\n",
      "\n",
      "          3. Other non-malignant systemic disease to preclude treatment with standard chemotherapy\n",
      "             regimen or prevent follow-up\n",
      "\n",
      "          4. Abnormal coagulation profile\n",
      "\n",
      "          5. The planned concurrent administration of therapies (e.g. palliative radiotherapy) that\n",
      "             target metastatic sites accessible for biopsy\n",
      "\n",
      "          6. Known infection with HIV or hepatitis\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Irritable bowel syndrome (Rome II)\n",
      "\n",
      "          -  Presence of complaints < 12 months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Gastrointestinal disorders, other than IBS\n",
      "\n",
      "          -  Previous psychotherapeutic treatment for IBS\n",
      "\n",
      "          -  Severe psychological comorbidity\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All patients age 18 and above, hospitalized in GHWs at Barnes Jewish Hospital.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Minors, patients younger than 18 years old.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18 to 80 years of age\n",
      "\n",
      "          -  male and female\n",
      "\n",
      "          -  hypothalamic pituitary disorders (study subjects)\n",
      "\n",
      "          -  history of regular, age appropriate menses (control subjects)\n",
      "\n",
      "          -  male subjects with normal serum testosterone and follicle stimulating hormone (FSH)\n",
      "             (control subjects)\n",
      "\n",
      "          -  normal FSH in post-menopausal subjects (control subjects)\n",
      "\n",
      "          -  normal thyroid stimulating hormone (TSH), free thyroxine (T4), prolactin (control\n",
      "             subjects)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  unable to give consent\n",
      "\n",
      "          -  pregnancy\n",
      "\n",
      "          -  active acromegaly\n",
      "\n",
      "          -  pheochromocytoma\n",
      "\n",
      "          -  active Cushing's disease\n",
      "\n",
      "          -  pituitary insult within past 6 weeks\n",
      "\n",
      "          -  elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\n",
      "\n",
      "          -  renal failure\n",
      "\n",
      "          -  history of malignancy\n",
      "\n",
      "          -  severe acute illness\n",
      "\n",
      "          -  uncontrolled hypertension\n",
      "\n",
      "          -  Diabetes mellitus (DM) type 1\n",
      "\n",
      "          -  Hemoglobin (Hgb) A1c >9% in last 3 months in Type 2 DM\n",
      "\n",
      "          -  severe coronary artery disease\n",
      "\n",
      "          -  women <50 years of age with untreated hypogonadism\n",
      "\n",
      "          -  men with untreated hypogonadism\n",
      "\n",
      "          -  growth hormone treatment in the past 3 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Patients inclusion for study:\n",
      "\n",
      "          1. Patient age > 18 years.\n",
      "\n",
      "          2. Plan to undergo one of the following types of transplant, using bone marrow from a\n",
      "             related donor:\n",
      "\n",
      "               -  Myeloablative, HLA matched or partially HLA-mismatched (haploidentical),\n",
      "                  related-donor bone marrow transplantation that includes high-dose\n",
      "                  posttransplantation Cy\n",
      "\n",
      "               -  Nonmyeloablative, HLA matched or partially HLA-mismatched, related-donor bone\n",
      "                  marrow transplantation that includes high-dose posttransplantation Cy Note:\n",
      "                  Patients who receive posttransplantation rituximab are eligible.\n",
      "\n",
      "        Patients inclusion for vaccine:\n",
      "\n",
      "          1. Receipt of the type of myeloablative or nonmyeloablative BMT\n",
      "\n",
      "          2. The bone marrow donor has received the pre-bone marrow harvest vaccine (either Prevnar\n",
      "             or hepatitis A vaccine) on this study.\n",
      "\n",
      "        Donors inclusion:\n",
      "\n",
      "        1. Donor age > 18 years.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Patients exclusion for study entry:\n",
      "\n",
      "          1. Hypersensitivity to either the components of hepatitis A vaccine (including neomycin)\n",
      "             or the components of the PCV7 and PCV13 vaccines (including diphtheria toxin).\n",
      "\n",
      "          2. Severe latex allergy.\n",
      "\n",
      "        Patients exclusion for vaccine:\n",
      "\n",
      "          1. Graft failure.\n",
      "\n",
      "          2. Disease progression or relapse, or disease persistence requiring treatment.Note:\n",
      "             Patients with asymptomatic or low-volume disease progression or relapse may be\n",
      "             eligible, determined on a case-by-case basis by the PI.\n",
      "\n",
      "          3. Systemic immunosuppression for GVHD treatment or prophylaxis within 4 weeks (+/- 5\n",
      "             days) prior to vaccination.\n",
      "\n",
      "          4. Pregnant or breastfeeding\n",
      "\n",
      "        Donors exclusion:\n",
      "\n",
      "          1. Hypersensitivity to both the components of hepatitis A vaccine (including neomycin)\n",
      "             and the components of the PCV7 and PCV13 vaccines (including diphtheria toxin).\n",
      "\n",
      "          2. Severe latex allergy.\n",
      "\n",
      "          3. Expected to be on systemic immunosuppressants between the time of vaccination and the\n",
      "             bone marrow donation.\n",
      "\n",
      "          4. Pregnant or breastfeeding\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy adult male and female subjects, 18-65 years of age inclusive\n",
      "\n",
      "          -  BMI 18 to 32 kg/m2 inclusive\n",
      "\n",
      "          -  Female subjects must be surgically sterile or postmenopausal for the past year and\n",
      "             have a negative urine pregnancy test. Male subjects and their partners of childbearing\n",
      "             potential must be willing to use two methods of contraception, one of which must be a\n",
      "             barrier method (e.g. condom) for up to 90 days after the last study drug\n",
      "             administration.\n",
      "\n",
      "          -  Willing and able to remain in the clinical research unit as required by the protocol\n",
      "\n",
      "          -  Willing and able to provide written informed consent prior to any study related\n",
      "             procedures and to comply with all study requirements\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,\n",
      "             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or\n",
      "             psychiatric disease\n",
      "\n",
      "          -  History or presence of any disease, medical condition, or surgery, which may have an\n",
      "             effect on drug absorption, metabolism, distribution, or excretion of the\n",
      "             investigational product\n",
      "\n",
      "          -  Laboratory test results (including hepatic and renal panels, complete blood count,\n",
      "             chemistry panel, and urinalysis) that the investigator believes show clinically\n",
      "             relevant significant abnormalities for the normal reference range\n",
      "\n",
      "          -  Any abnormality in the ECG (including QTc ≥450 msec) that in the opinion of the\n",
      "             investigator increases the risk of participating in the study\n",
      "\n",
      "          -  History or presence of alcoholism or drug abuse within the year prior to dosing\n",
      "\n",
      "          -  Tobacco use, either current or within 3 months prior to dosing\n",
      "\n",
      "          -  Use of any prescription medications or herbal remedies within 14 days prior to dosing,\n",
      "             or use of over-the-counter medications or vitamins within 7 days prior to dosing,\n",
      "             unless approved by the Sponsor\n",
      "\n",
      "          -  Donation of whole blood within 56 days prior to the study\n",
      "\n",
      "          -  Plasma donation within 7 days prior to the study\n",
      "\n",
      "          -  Participation in an investigational device study or receipt of an investigational drug\n",
      "             within 4 weeks prior to dosing\n",
      "\n",
      "          -  Positive urine test for drugs of abuse\n",
      "\n",
      "          -  Confirmed HIV, hepatitis B, or hepatitis C infection\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  ASA physical status class I-III\n",
      "\n",
      "          -  Aged 60 years or above\n",
      "\n",
      "          -  Elective major surgery under general anesthesia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  ASA-PS>=IV\n",
      "\n",
      "          -  Aged under 60 yr old\n",
      "\n",
      "          -  Body mass index (BMI) >30\n",
      "\n",
      "          -  Neurologic disease\n",
      "\n",
      "          -  Cardiac surgery and neurologic surgery\n",
      "\n",
      "          -  Anticonvulsant drugs\n",
      "\n",
      "          -  Chronic analgesics intake\n",
      "\n",
      "          -  Participating in the investigation of another study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects 18 years of age or older.\n",
      "\n",
      "          -  The physician must have chosen to treat the patient with Xeomin® (incobotulinumtoxinA)\n",
      "             prior to and independent of enrollment in this study.\n",
      "\n",
      "          -  Subjects who are eligible to be treated with a botulinum toxin for cervical dystonia\n",
      "             or blepharospasm based upon the physicians' clinical experience. There are no\n",
      "             restrictive subject entry criteria.\n",
      "\n",
      "          -  Subjects who are able to read, speak and understand English.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects who are enrolled in any clinical trial (currently or within the past 3\n",
      "             months) in which treatments are imposed by a protocol are not eligible for this trial.\n",
      "\n",
      "          -  Any subject for whom botulinum toxin treatment would be contraindicated; see Xeomin®\n",
      "             Prescribing Information for further details.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Constipation as defined by Rome III criteria (3,4). Also, patients should have\n",
      "             insufficient criteria for IBS, and only rarely experience loose stools without the use\n",
      "             of laxatives.\n",
      "\n",
      "          -  Adults between the ages of 18-75 years\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients taking drugs that are known to be constipating will be excluded or asked to\n",
      "             discontinue medications for at least 2 weeks and reassessed. Patients who remain\n",
      "             constipated will be eligible for enrollment.\n",
      "\n",
      "          -  Co-morbid illnesses such as severe cardiovascular disease, chronic renal failure\n",
      "\n",
      "          -  Previous gastrointestinal surgery except cholecystectomy and appendectomy.\n",
      "\n",
      "          -  Neurologic diseases such as multiple sclerosis, strokes, spinal cord injuries, and\n",
      "             those who have problems with cognizance, i.e. a mini-mental score of <15 and/or are\n",
      "             legally blind\n",
      "\n",
      "          -  Hirschsprung' s disease, or active local anorectal problems such as anal fissures,\n",
      "             bleeding hemorrhoids,\n",
      "\n",
      "          -  Alternating constipation and diarrhea and those who fulfill the Rome-III criteria for\n",
      "             irritable bowel syndrome.\n",
      "\n",
      "          -  Subjects with a known allergy to psyllium or plums.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 18-50\n",
      "\n",
      "          -  Plans to remain in DC area for at least one year\n",
      "\n",
      "          -  willingness to participate in all study procedures\n",
      "\n",
      "          -  general good health\n",
      "\n",
      "          -  military health care beneficiary\n",
      "\n",
      "          -  able to provide informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior travel to geographic areas where leishmania transmitting sand flies are common\n",
      "\n",
      "          -  positive antibody to sand fly saliva on screening blood test\n",
      "\n",
      "          -  pregnancy\n",
      "\n",
      "          -  elevated serum IgE\n",
      "\n",
      "          -  history of chronic medical illness\n",
      "\n",
      "          -  adult history of treatment requiring anemia\n",
      "\n",
      "          -  large reactions to insect bites\n",
      "\n",
      "          -  history of multiple vasovagal reactions to phlebotomy\n",
      "\n",
      "          -  difficult venous access for phlebotomy\n",
      "\n",
      "          -  Taking medications that could interfere with immune responses\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects must give written informed consent to participate in the study prior to\n",
      "             screening. Consent will be documented by the subject's dated signature that will be\n",
      "             counter-signed and dated by a witness.\n",
      "\n",
      "          -  Healthy non-smoking, by history, adult male and/or female volunteers between the ages\n",
      "             of 18 and 45 years old and with a Body Mass Index (BMI) of ≥18-≤32 kg/m2.\n",
      "\n",
      "          -  Subjects must be in good health as determined by screening medical history, physical\n",
      "             examination, vital signs, electrocardiogram, blood chemistry, hematology, and\n",
      "             urinalysis (U/A) performed at screening.\n",
      "\n",
      "          -  Normal Hematology Clinical Laboratory, Results, including: Normal White Blood Cell\n",
      "             (WBC) and differential, Hematocrit, Hemoglobin, Platelet Counts\n",
      "\n",
      "          -  Normal Electrocardiogram (ECG) and a measure between Q wave and T wave in the heart's\n",
      "             electrical cycle at baseline (QTcB) ≤ 430 msec (males) or ≤ 430 msec (females)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Male and/or female subjects who consume more than 28 units of alcohol per week (one\n",
      "             unit of alcohol equals ½ pint of beer, 4 ounces of wine, or 1 ounce of spirits) or\n",
      "             those subjects who have a significant history of alcoholism or drug/chemical abuse\n",
      "             within the last 2 years. Subjects must agree to abstain from alcohol, cola, tea,\n",
      "             coffee, chocolate and other caffeinated drink and food from 2 days before Period 1,\n",
      "             Day 1 and throughout confinement.\n",
      "\n",
      "          -  Subjects who have used tobacco products or nicotine-containing products (including\n",
      "             smoking cessation aids, such as gums or patches) within 3 months prior to Day -1.\n",
      "\n",
      "          -  Subjects with positive results on tests for drugs of abuse, or alcohol at screening\n",
      "             and check-in.\n",
      "\n",
      "          -  Concomitant Medications: Any drugs, vitamins, over the counter (OTC) medicines and\n",
      "             nutraceuticals if used within the previous 7 days of check-in as deemed clinically\n",
      "             significant by the Principal Investigator (PI).\n",
      "\n",
      "          -  Subjects who have used any drugs or substances known to be strong inhibitors or strong\n",
      "             inducers of CYP 3A4/5 enzymes (also known as cytochrome P-450 enzymes) or\n",
      "             P-Glycoprotein (Pgp) within 30 days prior to Period 1, Day -1. Subjects must agree to\n",
      "             abstain from grapefruit/grapefruit juice and seville oranges for 2 days before period\n",
      "             Ia, Day -1 and throughout the study.\n",
      "\n",
      "          -  Use of other investigational drugs at the time of enrollment (consenting), or 5\n",
      "             half-lives of enrollment whichever is longer; or longer if required by local\n",
      "             regulations, and for any other limitation of participation in an investigational trial\n",
      "             based on local regulations.\n",
      "\n",
      "          -  History of unstable psychiatric illness requiring medications or hospitalization\n",
      "             within the previous 12 months.\n",
      "\n",
      "          -  History of concurrent illness that required hospitalization within 14 days prior to\n",
      "             Day 1 of the study.\n",
      "\n",
      "          -  Any condition that in the clinical judgment of the Investigator would make the subject\n",
      "             unsuitable for participation.\n",
      "\n",
      "          -  Allergies or allergic reactions to any of the products used in this study.\n",
      "\n",
      "          -  Subjects who have had a clinically significant illness within 4 weeks prior to Day -1.\n",
      "\n",
      "          -  Subjects with QTcB interval duration >430 msec (males) or >450 (females) obtained from\n",
      "             the ECG recorder's measurements on the screening ECG taken after at least 5 minutes of\n",
      "             quiet rest in supine position.\n",
      "\n",
      "          -  History or current evidence of clinically significant hepatic, renal, cardiovascular\n",
      "             (i.e., deep venous thrombosis, pulmonary embolism), psychological, pulmonary,\n",
      "             metabolic, endocrine, neurologic (i.e., transient ischemic attack or stroke within the\n",
      "             past 6 months) infectious, gastrointestinal (i.e., any condition which may affect drug\n",
      "             absorption) hematologic, oncologic disease, retinopathy, or other medical disorders,\n",
      "             as determined by screening history, physical examination, laboratory test results, or\n",
      "             12-lead ECG.\n",
      "\n",
      "          -  History of unexplained syncope.\n",
      "\n",
      "          -  Subjects with creatinine clearance < 80 mL/min (based on Cockcroft-Gault equation).\n",
      "\n",
      "          -  Subjects who, in the opinion of the Investigator, should not participate in the study.\n",
      "\n",
      "          -  Any employee of the Duke Clinical Research Unit (DCRU).\n",
      "\n",
      "          -  Subjects who have blood relatives of another study participant.\n",
      "\n",
      "          -  Subjects must be compliant and meet all inclusion and exclusion criteria unless,\n",
      "             following discussions between the Principal Investigator or his designate, it is\n",
      "             determined that a minor exception is not indicative of clinically significant safety\n",
      "             risk and unlikely to confound the results of the study.\n",
      "      \n",
      "\n",
      "        1. Pediatric study\n",
      "\n",
      "               -  Inclusion Criteria\n",
      "\n",
      "                    -  Enrollment in the BEEP emollient intervention study (IRB #6083)\n",
      "\n",
      "                    -  Overall good health\n",
      "\n",
      "               -  Exclusion Criteria\n",
      "\n",
      "                    -  Have a history of or are being evaluated for a skin barrier disease\n",
      "\n",
      "                    -  Have an active skin infection\n",
      "\n",
      "                    -  Are receiving phototherapy\n",
      "\n",
      "                    -  Any immunodeficiency disorder or severe genetic skin disorder\n",
      "\n",
      "                    -  Any other serious condition that would make the use of emollients\n",
      "                       inadvisable\n",
      "\n",
      "                    -  Any other major medical problems that the investigator deems may increase\n",
      "                       the risk of adverse events with the intervention\n",
      "\n",
      "          2. Adult Study\n",
      "\n",
      "               -  Inclusion Criteria\n",
      "\n",
      "                    -  Have a history of atopic dermatitis\n",
      "\n",
      "                    -  12 years or older\n",
      "\n",
      "                    -  4 x 4 cm of non-lesional skin on both inner forearms\n",
      "\n",
      "                    -  No other conditions that would make the use of the four emollients harmful\n",
      "                       to the subject, such as known allergy to an emollient or a component o the\n",
      "                       emollient\n",
      "\n",
      "               -  Exclusion Criteria\n",
      "\n",
      "                    -  Use of topical steroids on the inner forearms or oral immunosuppressive\n",
      "                       medications for 4 weeks prior to participation in the study.\n",
      "\n",
      "                    -  Receiving phototherapy or systemic immunosuppressive therapy three months\n",
      "                       prior to participation in the study.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Sustained a traumatic incomplete SCI between C4 and C7 levels\n",
      "\n",
      "          -  18 years of age or older\n",
      "\n",
      "          -  Less than 6 months post injury\n",
      "\n",
      "          -  Unable to grasp objects\n",
      "\n",
      "          -  Participants must have functional biceps and deltoid muscle strength which allows them\n",
      "             to place their hand in the working space in front of themselves, i.e., at least a\n",
      "             grade 3 on manual muscle testing\n",
      "\n",
      "          -  Participants should have a clear understanding of the goal of the study, which is to\n",
      "             compare the FES technology to conventional occupational therapy (which may or may not\n",
      "             enhance recovery)\n",
      "\n",
      "          -  Participants should be able to read and understand and provide informed consent, and\n",
      "             in a situation where there is a difficulty in understanding ( e.g. language barrier),\n",
      "             have a relative or friend willing and able to accompany you to all treatment and\n",
      "             assessment sessions, for your own safety\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        •Contraindications for FES:\n",
      "\n",
      "          -  cardiac pacemakers\n",
      "\n",
      "          -  skin lesions, allergy, wound or rash at potential electrode sites\n",
      "\n",
      "          -  denervation of targeted muscles\n",
      "\n",
      "          -  pressure ulcers\n",
      "\n",
      "          -  patient suffers from the cardiovascular conditions such as hypertension that is\n",
      "             uncontrolled or autonomic dysreflexia requiring medication\n",
      "\n",
      "          -  Patients on Botox therapy for their upper limb or have received Botox for the upper\n",
      "             extremity in the last six months\n",
      "\n",
      "          -  Participation in any other interventional study that may affect upper extremity\n",
      "             function\n",
      "\n",
      "          -  Participants with co existing Traumatic brain injury\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Any adult patient known or clinically suspected to present a peripheral arterial\n",
      "             disease, the assessment of which requires an MRA of the peripheral arteries.\n",
      "\n",
      "          -  MRA will be prescribed by the vascular surgery or cardiology departments. The patient\n",
      "             should be conscious and cooperative. Clear and intelligible oral and written\n",
      "             information will be given to the patient. The patients giving written informed consent\n",
      "             will be included in the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  A contraindication to MRI, in particular pacemakers or implantable defibrillators,\n",
      "             cochlear implants, neurosurgical clips, intra-orbital or brain metallic foreign\n",
      "             bodies, endo prothesis since less than 4 weeks or osteosynthesis material since less\n",
      "             than 6 weeks\n",
      "\n",
      "          -  Contraindication to the injection of contrast agent: pregnancy, lactation, history of\n",
      "             allergic reaction to contrast agent injection.\n",
      "\n",
      "          -  Hemodynamically unstability, acute respiratory failure, a precarious condition or a\n",
      "             need for continuous monitoring incompatible with the constraints of MR imaging.\n",
      "\n",
      "          -  Age under 18 or under legal protection measure or without social coverage.\n",
      "\n",
      "          -  A refusal or inability of obtaining informed consent from the patient.\n",
      "\n",
      "        Patients withdrawing their informed consent will be excluded.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  preliminary treatment of cardiac arrest by fire fighters (Basic Life support)\n",
      "\n",
      "          -  more than 18 years\n",
      "\n",
      "          -  patient affiliated to the social security system or equivalent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  certain death\n",
      "\n",
      "          -  patient deprived of freedom by judicial or administrative decision\n",
      "\n",
      "          -  patient under legal protection\n",
      "\n",
      "          -  Pregnancy, parturient or breast feeding\n",
      "\n",
      "          -  facial trauma\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients who are scheduled for hernia repair.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant females.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Patients with primary squamous cell vulvar cancer except stage Ia disease regardless\n",
      "             of the received treatment\n",
      "\n",
      "          2. Patients with recurrent squamous cell vulvar cancer, if the relapse was not only\n",
      "             treated with a surgical excision.\n",
      "\n",
      "          3. Or alternatively, dependent on the decision of the participating center:\n",
      "\n",
      "             -Patients with primary or relapsed squamous cell vulvar cancer receiving radio- and/or\n",
      "             chemotherapy for treatment regardless of nodal involvement.\n",
      "\n",
      "          4. Patients who were diagnosed with and treated for primary or relapsed vulvar cancer\n",
      "             between 1998 and 2008\n",
      "\n",
      "          5. Women aged ≥ 18 years\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Patients with benign or precursor lesions (VIN - vulvar intraepithelial neoplasia) of\n",
      "             the vulva\n",
      "\n",
      "          2. Patients with non-squamous neoplasia of the vulva (e.g. melanoma)\n",
      "\n",
      "          3. Patients with verrucous vulvar cancer\n",
      "\n",
      "          4. Patients with relapsed squamous cell vulvar cancer only receiving surgical excision\n",
      "             for treatment.\n",
      "\n",
      "          5. Patients with secondary cancers if those interfered with the treatment of vulvar\n",
      "             disease\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Employee of Express Scripts\n",
      "\n",
      "          -  Employee at a targeted Express Scripts location\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Non-employees of Express Scripts\n",
      "      \n",
      "\n",
      "        Inclusion\n",
      "\n",
      "          1. deployed to the \"Gulf Theater of operations, as defined by 38 CFR 3.317, includes\n",
      "             Iraq, Kuwait, Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf\n",
      "             of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the\n",
      "             airspace above all of these locations\" between August 1990 and the present date,\n",
      "\n",
      "          2. they have at least 2 of the following symptoms from the 3 CDC clusters of symptom that\n",
      "             have lasted for more than 6 months. Each symptom cluster must be characterized as\n",
      "             \"mild-moderate\" or \"severe\" with at least one symptom in each cluster required to be\n",
      "             severe. The clusters are:\n",
      "\n",
      "        A-Fatigability\n",
      "\n",
      "          -  fatigue 24 hours or more after exertion B-Mood and Cognition\n",
      "\n",
      "          -  feeling depressed or\n",
      "\n",
      "          -  feeling irritable or\n",
      "\n",
      "          -  difficulty thinking or concentrating or\n",
      "\n",
      "          -  feeling worried, tense, anxious or\n",
      "\n",
      "          -  problems finding words or\n",
      "\n",
      "          -  problems getting to sleep C-Musculoskeletal\n",
      "\n",
      "          -  joint pain or muscle pain\n",
      "\n",
      "        Exclusion:\n",
      "\n",
      "          -  Currently enrolled in another clinical trial\n",
      "\n",
      "          -  Have another disease that likely could account for the symptoms, as determined by our\n",
      "             Medical Monitor\n",
      "\n",
      "          -  Severe psychiatric illness (in the last 2 years psychiatric hospitalization, suicidal\n",
      "             attempt, alcohol or substance abuse, use of antipsychotic medication) as measured by\n",
      "             the Primary Care Evaluation of Mental Disorder (Prime MD).\n",
      "\n",
      "          -  Unable to complete the protocol on based on the evaluation of the Medical Monitor\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult patients (18-75 years of age)\n",
      "\n",
      "          -  diagnosis of asthma\n",
      "\n",
      "          -  step 2, 3 or 4 on the BTS asthma guidelines.\n",
      "\n",
      "          -  Well controlled asthma and good lung function, as defined as a Juniper asthma control\n",
      "             score of < 1.5.\n",
      "\n",
      "          -  Not oral steroids in the last 3 months.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Incapable of giving informed consent.\n",
      "\n",
      "          -  Poor treatment concordance.\n",
      "\n",
      "          -  Pregnant women.\n",
      "\n",
      "          -  Extensive co-morbidity.\n",
      "\n",
      "          -  Previous admission to ITU with asthma.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients undergoing axillary clearance surgery\n",
      "\n",
      "          -  ASA physical status I - III\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient refusal\n",
      "\n",
      "          -  Pre-existing pain conditions\n",
      "\n",
      "          -  Regular use of opioid analgesia\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Severe cardiac, renal or hepatic disease\n",
      "\n",
      "          -  Psychiatric illness precluding ability to give informed consent\n",
      "\n",
      "          -  Intercurrent neurological disease\n",
      "\n",
      "          -  Contraindications to bupivacaine or morphine use\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with primary open or pseudoexfoliation glaucoma that are undergoing cataract\n",
      "             surgery\n",
      "\n",
      "          -  Patients undergoing cataract surgery without evidence of other ocular disease.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Evidence of any ocular disease, other than specified in the inclusion criteria\n",
      "\n",
      "          -  Previous ophthalmic surgery or trauma\n",
      "\n",
      "          -  Significant visual field defect (MD<-12dB) or an increased cup to disc ratio (>0.9).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Males or non-pregnant, non-lactating females who are 18 years or older\n",
      "\n",
      "          -  Laboratory-proven acute Q fever since the year 2007 and/or positive serology fitting a\n",
      "             past infection with Coxiella burnetii;\n",
      "\n",
      "          -  AND being severely fatigued, defined by scoring 35 or higher on the subscale fatigue\n",
      "             severity of the CIS;\n",
      "\n",
      "          -  AND being fatigued for at least 6 months;\n",
      "\n",
      "          -  AND disabled because of the fatigue, defined by scoring 450 or higher on the SIP\n",
      "\n",
      "          -  Subjects must sign a written informed consent form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Fulfilling criteria for chronic Q fever, namely:\n",
      "\n",
      "               -  IFA IgG fase I ≥ 1024, ≥ 3 months after acute Q fever and/or\n",
      "\n",
      "               -  Positive Coxiella burnetii PCR on serum or tissue, 1 month after acute Q fever\n",
      "\n",
      "          -  Acute Q fever in the setting of a prosthetic cardiac valve or aneurysm surgery or\n",
      "             stenting necessitating prophylactic use of doxycycline;\n",
      "\n",
      "          -  Pregnancy or unwillingness to use effective contraceptives during the entire study\n",
      "             period;\n",
      "\n",
      "          -  Imminent death;\n",
      "\n",
      "          -  Inability to give informed consent;\n",
      "\n",
      "          -  Allergy or intolerance to doxycycline;\n",
      "\n",
      "          -  Somatic or psychiatric illness that could explain the chronic fatigue;\n",
      "\n",
      "          -  Subjects who are currently enrolled on other investigational drug trials or receiving\n",
      "             investigational agents;\n",
      "\n",
      "          -  Receiving antibiotics for more than 4 weeks, potentially active against Coxiella\n",
      "             burnetii, for any other reason since Q-fever diagnosis;\n",
      "\n",
      "          -  Subjects who are receiving and cannot discontinue barbiturates, phenytoin, or\n",
      "             carbamazepine (these drugs may increase the metabolism of doxycycline and therefore\n",
      "             reducing half-life of doxycycline);\n",
      "\n",
      "          -  Moderate or severe liver disease (AF, ALAT, ASAT > 3 times the upper limit of normal).\n",
      "\n",
      "          -  Current engagement in a legal procedure concerning financial benefits (only current\n",
      "             involvement interferes with the effectivity of cognitive behavioral therapy. Once the\n",
      "             appeal procedure ends, subjects can be included)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Healthy males and females ≥ 18 years old\n",
      "\n",
      "          2. Negative urine pregnancy results for females of childbearing potential\n",
      "\n",
      "          3. Able to read and sign an informed consent form and show willingness to comply with the\n",
      "             study protocol visits and procedures\n",
      "\n",
      "          4. Has 20/40 BCVA or better in at least one eye\n",
      "\n",
      "          5. Does not currently wear contact lenses\n",
      "\n",
      "          6. For Aqueous-Deficiency Group:\n",
      "\n",
      "               -  Has symptoms of Dry Eye\n",
      "\n",
      "               -  Schirmer testing ≤ 10 mm\n",
      "\n",
      "               -  Tear Break Up Time ≤ 8 seconds\n",
      "\n",
      "               -  Conjunctival staining ≥ 1+\n",
      "\n",
      "               -  Meibomian gland inspissations ≤ 1+\n",
      "\n",
      "               -  No lid thickening, lid erythema, or thickened, turbid meibomian gland secretions\n",
      "\n",
      "          7. For Meibomian Gland Disease Group:\n",
      "\n",
      "               -  Has symptoms of Dry Eye\n",
      "\n",
      "               -  Schirmer testing ≥ 10 mm\n",
      "\n",
      "               -  Tear Break Up Time ≤ 8 seconds\n",
      "\n",
      "               -  Conjunctival staining ≥ 1+\n",
      "\n",
      "               -  Meibomian gland inspissations ≥ 2+\n",
      "\n",
      "          8. For Normal Group:\n",
      "\n",
      "               -  Has no symptoms of Dry Eye\n",
      "\n",
      "               -  Schirmer testing > 10 mm\n",
      "\n",
      "               -  Tear Break Up Time > 8 seconds\n",
      "\n",
      "               -  No or trace Conjunctival staining\n",
      "\n",
      "               -  No Meibomian gland inspissations\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Any topical medication within the last three months, except for artificial tears\n",
      "\n",
      "          2. Unable to discontinue use of artificial tears during the course of the day for Visit 2\n",
      "\n",
      "          3. Any Systemic disease, which in the opinion of the Investigator, may affect ocular\n",
      "             health or confound study results\n",
      "\n",
      "          4. Any active ocular disease other than Dry Eye Disease, Meibomian Gland Disease or\n",
      "             Sjogren's Syndrome, which in the opinion of the Investigator, may affect ocular health\n",
      "             or confound study results\n",
      "\n",
      "          5. Clinically significant lid or conjunctival abnormalities, neovascularization, corneal\n",
      "             scars or corneal opacities\n",
      "\n",
      "          6. Clinically significant limbal or bulbar injection, or corneal staining not due to DES\n",
      "\n",
      "          7. Has worn hard or rigid gas permeable contact lenses within 1 year\n",
      "\n",
      "          8. Has worn soft contact lenses within 1 week\n",
      "\n",
      "          9. Has had eye surgery or an eye injury within 6 months\n",
      "\n",
      "         10. Positive urine pregnancy results for females of childbearing potential\n",
      "\n",
      "         11. Any changes in current medication within 30 days of Visit 2 or anticipated change\n",
      "             during course of study, which in the opinion of the Investigator may confound study\n",
      "             results\n",
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "        PATIENTS WITH AUTISM OR ASD (INCLUSION CRITERIA):\n",
      "\n",
      "          1. Subjects must have a diagnosis of autistic disorder (299.0) or Asperger s disorder\n",
      "             (299.80), as determined using the Diagnostic and Statistical Manual-IV (DSM-IV) and\n",
      "             confirmation with the Autism Diagnostic Interview-Revised (Lord 1997) and/or Autism\n",
      "             Diagnostic Observation Scale (ADOS). (A diagnosis of Pervasive Developmental Disorder,\n",
      "             or PDD, will not suffice for this protocol).\n",
      "\n",
      "          2. Subjects must be adults between 18-45 years old.\n",
      "\n",
      "          3. Subjects must be healthy based on history and physical examination.\n",
      "\n",
      "          4. Subjects must be \"binders\" to [11C]PBR28 as determined via one of two ways: by prior\n",
      "             participation in a PET scan with [11C]PBR28 or by in vitro testing of their\n",
      "             leukocytes. We found that non-binders have markedly reduced affinity of [3H]PBR28 to\n",
      "             leukocyte membranes. The in vitro binding has shown no overlapping values between\n",
      "             binders (~90%) and non-binders.\n",
      "\n",
      "          5. Subjects must either provide informed consent, or they must assent in combination with\n",
      "             informed consent by a legal guardian or durable power of attorney (DPA).\n",
      "\n",
      "        HEALTHY VOLUNTEERS (INCLUSION CRITERIA):\n",
      "\n",
      "          1. Subjects must be adults between 18-45 years old.\n",
      "\n",
      "          2. Subjects must be healthy based on history and physical examination\n",
      "\n",
      "          3. Subjects must be binders to [11 C]PBR28 (see point 4 above for details)\n",
      "\n",
      "          4. Prior to the PET scan, all healthy subjects must have had within the prior year an MRI\n",
      "             scan of the brain to rule out significant structural abnormalities.\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "        PATIENTS WITH AUTISM OR ASD (EXCLUSION CRITERIA):\n",
      "\n",
      "          1. Any history of alcohol or substance dependence, as these conditions may alter uptake\n",
      "             of [11C]PBR28.\n",
      "\n",
      "          2. Any history of alcohol or substance abuse within the past 6 months, as these\n",
      "             conditions may alter uptake of [11C]PBR28.\n",
      "\n",
      "          3. Schizophrenia.\n",
      "\n",
      "          4. In addition to the diagnosis of autistic disorder, ASD or Asperger, any other Axis I\n",
      "             disorder that requires inpatient hospitalization during this study, or is at the time\n",
      "             of enrollment worsening relative to baseline. We will not completely exclude all Axis\n",
      "             I disorders, because it is typical for patients with autism /ASD to carry comorbid\n",
      "             Axis I disorders, including Generalized Anxiety Disorder (GAD), social phobia,\n",
      "             obsessive compulsive disorder (OCD), dysthymia, Major Depressive Disorder.\n",
      "\n",
      "          5. Intellectual quotient (IQ) less than 30, as including the lowest functioning patients\n",
      "             would make the experiment logistically challenging and would broaden heterogeneity too\n",
      "             much.\n",
      "\n",
      "          6. Clinically significant laboratory abnormalities as assessed by the PI, medically\n",
      "             responsible investigator or consultant.\n",
      "\n",
      "          7. Serious medical problems including but not limited to chronic neurological disease\n",
      "             such as multiple sclerosis, autoimmune diseases, poorly controlled seizure disorder,\n",
      "             or serious cardiopulmonary disease.\n",
      "\n",
      "          8. Active seizure disorder, as defined as having had a seizure in the past year or being\n",
      "             on antiepileptic medications for seizures.\n",
      "\n",
      "          9. Positive HIV status.\n",
      "\n",
      "         10. Head trauma resulting in a period of unconsciousness lasting longer than 5 minutes.\n",
      "\n",
      "         11. Exposure to radiation in the past year (i.e., PET from other research), which when\n",
      "             combined with this study would be above the allowable limits.\n",
      "\n",
      "         12. Positive urine drug screen at time of enrollment.\n",
      "\n",
      "         13. Pregnancy at time of scan (beta HCG will be measured in all female patients within 24\n",
      "             hours before start of scan and must be negative).\n",
      "\n",
      "         14. In patients who will get an MRI scan at NIH, metallic foreign bodies that would be\n",
      "             affected by the MRI magnet, or a fear of enclosed spaces that would prohibit MRI\n",
      "             scanning.\n",
      "\n",
      "         15. Allergy to propofol or eggs (since egg products are used to formulate propofol),.\n",
      "\n",
      "         16. Snoring, as this increases the likelihood of complications from propofol sedation.\n",
      "\n",
      "         17. Currently taking antibacterial drugs (such as Amoxicillin-Clavulanate/ Augmentin ,\n",
      "             Metronidazole/Flagyl Minocycline/Minocin ). We will not discontinue any medications in\n",
      "             any subjects.\n",
      "\n",
      "         18. Currently taking antiviral drugs (such as Acyclovir/Zovirax , Interferon beta 1/Avonex\n",
      "             , Valacyclovir/Valtrex ). We will not discontinue any medications in any subjects.\n",
      "\n",
      "         19. Taking corticosteroids within the 6 months prior to study enrollment (such as\n",
      "             Dexamethasone/Decadron , Hydrocortisone/Hydrocortone , Methylprednisone/Medrol ). We\n",
      "             will not discontinue any medications in any subjects.\n",
      "\n",
      "         20. Taking immunosuppressants in the past 6 months prior to study enrollment (such as\n",
      "             Azathioprine/Imuran , Infliximab/Remicade , Sulfasalazine/ Azulfidine ,\n",
      "             Olsalazine/Dipentum ). We will not discontinue any medications in any subjects.\n",
      "\n",
      "         21. Any history of taking immunosuppressants in the context of chemotherapy or organ\n",
      "             transplant. Medications in this class might include Tacrolimus/Prograf ,\n",
      "             6-mercaptopurine/Purinethol , and Methotrexate/Trexall . We will not discontinue any\n",
      "             medications in any subjects.\n",
      "\n",
      "         22. Currently taking Clozapine/Clozaril , as high doses in rats increases TSPO. With the\n",
      "             exception of clozapine, patients may be on centrally-acting medications, including\n",
      "             medications for mood and behavioral disturbances. These medications may be\n",
      "             antiepileptic medications, so long as the antiepileptics are being used for symptoms\n",
      "             of mood and behavior as opposed to seizure disorder.\n",
      "\n",
      "        Healthy Volunteers (Exclusion criteria):\n",
      "\n",
      "          1. Any past or present Axis I disorder. The exception is substance abuse which ended over\n",
      "             6 months prior to enrollment.\n",
      "\n",
      "          2. Intellectual disability or significant learning problems, as determined by IQ testing\n",
      "             lower than 70, inability to read or write, or history of being unable to take regular\n",
      "             classes while in school.\n",
      "\n",
      "          3. Clinically significant laboratory abnormalities, as defined as laboratory values that\n",
      "             are out of normal range or require clinical workup and/or treatment.\n",
      "\n",
      "          4. With the exception of isolated doses of benzodiazepine which may be administered once\n",
      "             or twice by the investigators of this study, psychotropic medication use (including\n",
      "             benzodiazepines and illicit drugs) during the 28 days (42 days if fluoxetine) prior to\n",
      "             the PET scan. Investigators of this study may administer lorazepam for anxiety (see\n",
      "             procedures).\n",
      "\n",
      "          5. Serious medical problems including but not limited to chronic neurological disease\n",
      "             such as multiple sclerosis, autoimmune diseases or cardiopulmonary disease that would\n",
      "             significantly increase risk with propofol sedation.\n",
      "\n",
      "          6. Positive HIV status.\n",
      "\n",
      "          7. Metallic foreign bodies that would be affected by the MRI magnet or fear of enclosed\n",
      "             spaces likely to make the subject unable to undergo an MRI scan.\n",
      "\n",
      "          8. Head trauma resulting in a period of unconsciousness lasting longer than 5 minutes.\n",
      "\n",
      "          9. Exposure to radiation in the past year (i.e., PET from other research), which when\n",
      "             combined with this study would be above the allowable limits.\n",
      "\n",
      "         10. Positive urine drug screen at time of enrollment\n",
      "\n",
      "         11. Inability to lie flat on a camera bed for about 2.5 hours per PET scan and 1 hour for\n",
      "             MRI.\n",
      "\n",
      "         12. Allergy to propofol or eggs, since egg products are used to formulate propofol\n",
      "\n",
      "         13. Pregnancy at time of scan (beta HCG will be measured in all female patients within 24\n",
      "             hours prior to start of scan and must be negative).\n",
      "\n",
      "         14. Snoring, as this condition increases the likelihood of complications from propofol\n",
      "             sedation.\n",
      "\n",
      "         15. Currently taking antibacterial drugs (such as Amoxicillin-Clavulanate/ Augmentin ,\n",
      "             Metronidazole/Flagyl Minocycline/Minocin ). We will not discontinue any medications in\n",
      "             any subjects.\n",
      "\n",
      "         16. Currently taking antiviral drugs (such as Acyclovir/Zovirax , Interferon 1/Avonex ,\n",
      "             Valacyclovir/Valtrex ). We will not discontinue any medications in any subjects.\n",
      "\n",
      "         17. Taking corticosteroids within the 6 months prior to study enrollment (such as\n",
      "             Dexamethasone/Decadron , Hydrocortisone/Hydrocortone , Methylprednisone/Medrol ). We\n",
      "             will not discontinue any medications in any subjects.\n",
      "\n",
      "         18. Taking immunosuppressants in the past 6 months prior to study enrollment (such as\n",
      "             Azathioprine/Imuran , Infliximab/Remicade , Sulfasalazine/ Azulfidine ,\n",
      "             Olsalazine/Dipentum ). We will not discontinue any medications in any subjects.\n",
      "\n",
      "         19. Any history of taking immunosuppressants in the context of chemotherapy or organ\n",
      "             transplant. Medications in this class might include Tacrolimus/Prograf ,\n",
      "             6-mercaptopurine/Purinethol , and Methotrexate/Trexall . We will not discontinue any\n",
      "             medications in any subjects.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          -  healthy patients of at least 18 years of age or above\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  diagnosis of glaucoma or other optic neuropathies\n",
      "\n",
      "          -  corneal disorder that make IOP measurement impossible\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  The support person must\n",
      "\n",
      "               1. reside in Minnesota\n",
      "\n",
      "               2. be 18 years of age or older\n",
      "\n",
      "               3. provide written informed consent\n",
      "\n",
      "               4. be a never or former cigarette smoker (no cigarette smoking in the past 6 months)\n",
      "\n",
      "               5. want to support a current cigarette smoker (has smoked a total of >1 cigarettes\n",
      "                  during the past 7 days) who is 18 years of age or older, resides in Minnesota,\n",
      "                  and has not been enrolled in a helpline or any other cessation program in the\n",
      "                  last 3 months\n",
      "\n",
      "               6. be able and willing to participate in all aspects of the study\n",
      "\n",
      "               7. have access to a working telephone\n",
      "\n",
      "               8. have current and anticipated contact (any combination of face-to-face, telephone,\n",
      "                  text messaging, or electronic mail) with the smoker on at least 3 days a week for\n",
      "                  the 30 week study duration.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Support persons will be excluded if another support person from the same household has\n",
      "             enrolled.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18 < age < 70 man or woman\n",
      "\n",
      "          -  Patient with a cytologically or histologically proven primary solid tumor\n",
      "\n",
      "          -  With measurable and inoperable brain metastasis,\n",
      "\n",
      "          -  Without meningeal carcinomatosis ,\n",
      "\n",
      "          -  ECOG performance status ≤ 2,\n",
      "\n",
      "          -  No previous treatment with angiogenesis inhibitors less than 3 months before\n",
      "             inclusion,\n",
      "\n",
      "          -  No chemotherapy and/or immunotherapy less than 3 weeks before treatment,\n",
      "\n",
      "          -  No contra-indication to bevacizumab,\n",
      "\n",
      "          -  No proteinuria with urine dipstick for proteinuria > 2+\n",
      "\n",
      "          -  Blood sample ≤ 7 days before inclusion:\n",
      "\n",
      "          -  Hemoglobin ≥ 10 G/100 ml\n",
      "\n",
      "          -  Neutrophils count ≥ 1500 /mm3\n",
      "\n",
      "          -  Platelets ≥ 100 000 /mm3\n",
      "\n",
      "          -  Normal coagulation test: INR ≤ 1,5 ET TCA ≤ 1,5 x LSN 7 days before inclusion\n",
      "\n",
      "          -  A written informed consent must be obtained.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Haemorrhagic brain metastasis,\n",
      "\n",
      "          -  Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg).\n",
      "             Patients with high initial blood pressure are eligible if entry criteria are met after\n",
      "             initiation or adjustment of antihypertensive medication,\n",
      "\n",
      "          -  Prior brain radiation therapy\n",
      "\n",
      "          -  Concomitant anticoagulant treatment\n",
      "\n",
      "          -  Significant surgical procedure less than 28 days before inclusion (1 day if minor\n",
      "             surgical act)\n",
      "\n",
      "          -  Significant cardio-vascular disease, eg:\n",
      "\n",
      "          -  Cerebral vascular thrombosis/haemorrhage or myocardial infarction <6 months\n",
      "\n",
      "          -  Congestive heart failure > 2 NYHA\n",
      "\n",
      "          -  Uncontrolled coronary disease\n",
      "\n",
      "          -  Prior venous and/or arterial thrombosis < 6 months before inclusion\n",
      "\n",
      "          -  Severe concurrent uncontrolled medical disease,\n",
      "\n",
      "          -  Any psychiatric disorder that might prevent the subject from completing the treatment\n",
      "             or interfere with the interpretation of the study results,\n",
      "\n",
      "          -  Pregnancy or breast feeding\n",
      "\n",
      "          -  Individual deprived of liberty or placed under the authority of a tutor.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  85th - 97th percentile BMI\n",
      "\n",
      "          -  parent/care giver ability to converse in English\n",
      "\n",
      "          -  working telephone\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  child under current subspecialty care for overweight/obesity\n",
      "\n",
      "          -  child currently taking weight-altering medication (at enrollment)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  English speaking\n",
      "\n",
      "          -  Non metastatic cancer\n",
      "\n",
      "          -  1 month post chemotherapy/radiation treatment (hormone treatment okay)\n",
      "\n",
      "          -  Diagnosis of Primary or Secondary Insomnia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Presence of another sleep disorder\n",
      "\n",
      "          -  Presence of another Axis I diagnosis (not in remission)\n",
      "\n",
      "          -  Inability to attend at least 5 out of the 8 treatment sessions\n",
      "\n",
      "          -  Randomization Refusal\n",
      "\n",
      "          -  Previous participation in CBT-I or MBSR\n",
      "\n",
      "          -  Shift work\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Women between 50 and 69 years old\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Breast Neoplasms\n",
      "\n",
      "          -  Bilateral mastectomy\n",
      "\n",
      "          -  Disabled Persons\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  HIV-1 antibody negative with similar characteristics to HIV-1 positive cohort\n",
      "\n",
      "          -  HIV-positive subjects naive to antiretroviral therapy\n",
      "\n",
      "          -  HIV-positive subjects stable on or off antiretroviral therapy for a minimum of 6\n",
      "             months\n",
      "\n",
      "          -  Good venous access\n",
      "\n",
      "          -  Able to provide informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Hemoglobin < 9g/dl\n",
      "\n",
      "          -  Hematocrit < 27%\n",
      "\n",
      "          -  Active treatment for cancer\n",
      "\n",
      "          -  Hospitalization or IV antibiotic use within the last 4 months\n",
      "\n",
      "          -  Immunosuppressive therapy within the last 4 months\n",
      "      \n",
      "\n",
      "        The following are the main inclusion criteria for all subjects:\n",
      "\n",
      "          1. Males or females age > 18 years\n",
      "\n",
      "          2. Informed consent\n",
      "\n",
      "          3. Subjects with chronic medical conditions such as hypertension and diabetes should be\n",
      "             considered stable by the principal investigator\n",
      "\n",
      "          4. Women should be postmenopausal or surgically sterile\n",
      "\n",
      "          5. Able to return for all study assessments\n",
      "\n",
      "        In addition, the following main inclusion criteria apply for subjects with suspected\n",
      "        prosthetic joint infection:\n",
      "\n",
      "          1. Operative intervention planned in the 30 days following study enrollment\n",
      "\n",
      "          2. Prosthetic joint implant in site for more than 3 months prior to enrollment\n",
      "\n",
      "        The following are the main exclusion criteria for all subjects:\n",
      "\n",
      "          1. Unable to comply with study requirements\n",
      "\n",
      "          2. Indication in the opinion of the principal investigator for surgery within 48 hours of\n",
      "             presentation.\n",
      "\n",
      "          3. Receipt of any antibiotic therapy in the 2 weeks preceding imaging\n",
      "\n",
      "          4. Immunosuppression, e.g., human immunodeficiency virus (HIV) infection, s/p organ\n",
      "             transplantation, receipt of steroids for > 10 days at > 10 mg of prednisone equivalent\n",
      "             daily within the 90 days prior to enrollment\n",
      "\n",
      "          5. Requirement for any medication that predisposes to lactic acidosis (e.g., metformin,\n",
      "             iron, isoniazid and salicylates; see Appendix A)\n",
      "\n",
      "          6. Requirement for any medication that has potential mitochondrial toxicity, e.g.,\n",
      "             nucleoside analogues (zidovudine, didanosine, stavudine)\n",
      "\n",
      "          7. History of an inherited mitochondrial disorder (e.g., Leber's hereditary neuropathy,\n",
      "             neuropathy, ataxia, retinitis pigmentosa and ptosis [NARP], myoneurogenic\n",
      "             gastrointestinal encephalopathy [MNGIE], myoclonic epilepsy with ragged red fibers\n",
      "             [MERFF] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and stroke-like\n",
      "             syndrome [MELAS]\n",
      "\n",
      "          8. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n",
      "\n",
      "          9. Pre-existing myopathy or neuropathy\n",
      "\n",
      "         10. Abnormal liver function tests defined as alanine aminotransferase (ALT) > the upper\n",
      "             limit of normal (ULN), aspartate aminotransferase (AST) > ULN, gamma glutamyl\n",
      "             transferase (GGT) > ULN\n",
      "\n",
      "         11. Alcohol use > 3 units per day in men or 2 units per day in women or active intravenous\n",
      "             drug use\n",
      "\n",
      "         12. Creatinine clearance < 30 mL/min\n",
      "\n",
      "         13. Body mass index > 40\n",
      "\n",
      "         14. Life expectancy < 6 months\n",
      "\n",
      "         15. Hypersensitivity to iodine\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Between 20 aged and 45 years old in healthy males\n",
      "\n",
      "          -  Body weight ≥ 55kg and 18.5 ≤ IBW < 25\n",
      "\n",
      "          -  Agreement with written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subject has a history affects the ADME of drug\n",
      "\n",
      "          -  Hypersensitivity reactions to drugs or clinically significant hypersensitivity\n",
      "             reactions in the history of party\n",
      "\n",
      "          -  Inadequate subject by medical examination(medical history, physical examination, ECG,\n",
      "             laboratory test)\n",
      "\n",
      "          -  AST,ALT > UNL * 1.25 or Total bilirubin > UNL * 1.5\n",
      "\n",
      "          -  Estimated GFR(MDRD) < 80\n",
      "\n",
      "          -  SBP >150 mmHg, SBP < 100 mmHg or DBP > 100 mmHg, DBP < 60 mmHg or Pulse > 100 per/min,\n",
      "             Pulse < 50 per/min\n",
      "\n",
      "          -  Substance abuse, or a history of drug abuse showed a positive for the party\n",
      "\n",
      "          -  Continued to be taking caffeine (caffeine > 5 cup/day), drinking (alcohol > 210\n",
      "             g/week) or cannot stop drinking or severe heavy smoker(cigarette > 10 cigarettes per\n",
      "             day)during clinical trials\n",
      "\n",
      "          -  Medication with drug-mediated induction/inhibition metabolic enzyme within 30 days or\n",
      "             with may affect the clinical trial\n",
      "\n",
      "          -  Medication within 2 weeks in the first professional medical, medicine, OTC, vitamins\n",
      "             taking\n",
      "\n",
      "          -  Subject takes grapefruit within 1 month\n",
      "\n",
      "          -  Previously participated in other trial within 60 days\n",
      "\n",
      "          -  Previously donate whole blood within 60 days or component blood within 30 days\n",
      "\n",
      "          -  An impossible one who participates in clinical trial by investigator's decision\n",
      "             including laboratory test result\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Men or women greater than or equal to 18 years of age\n",
      "\n",
      "          -  The subject has voluntarily signed and dated the most recent informed consent form\n",
      "             approved by an Institutional Review Board\n",
      "\n",
      "          -  Screening estimated glomerular filtration rate (eGRF) greater than or equal to 30 and\n",
      "             less than or equal to 45 mL/min/1.72m2 plus or minus 10% for subjects with CKD and\n",
      "             greater than 60mL/min for subjects acting as normal healthy controls\n",
      "\n",
      "          -  Willing and able to cooperate with all aspects of the study protocol\n",
      "\n",
      "          -  No evidence of significant gastrointestinal (GI) disorder that would impair GI\n",
      "             motility or function\n",
      "\n",
      "          -  No recent active illness or hospitalization within 12 weeks prior to the Day\n",
      "             1/Baseline visit\n",
      "\n",
      "          -  No recent or voluntary change in diet within 4 weeks prior to Day 1/ Baseline visit\n",
      "\n",
      "          -  No history of intolerance or adverse effects to lanthanum carbonate\n",
      "\n",
      "          -  No use of calcium supplements for at least 2 weeks prior to Day 1\n",
      "\n",
      "          -  Must have no dietary restrictions or significant allergies and be willing to eat a\n",
      "             non-vegan standardized meal\n",
      "\n",
      "          -  Subjects taking nutritional vitamin D or any active vitamin D must be on stable doses\n",
      "             with no change during the 4 week period prior to Day 1\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Current history of drug or alcohol abuse as assessed by the Principal Investigator\n",
      "\n",
      "          -  Receiving active chemotherapy treatment for a malignancy\n",
      "\n",
      "          -  Has received dialysis or has acute kidney injury within 12 weeks prior to screening or\n",
      "             during screening\n",
      "\n",
      "          -  Subject has a clinical condition that in the judgement of the Principal Investigator\n",
      "             could potentially pose a health risk to the patient while involved int he study\n",
      "\n",
      "          -  Received or has received an investigational product (or is currently using an\n",
      "             investigational device) within 30 days prior to screening\n",
      "\n",
      "          -  Evidence of active (clinically significant) infections within 14 days prior to Day1/\n",
      "             Baseline visit (in the opinion of the investigator)\n",
      "\n",
      "          -  Use of phosphate binding medications (calcium carbonate or acetate with meals,\n",
      "             lanthanum carbonate, or sevelamer carbonate)within 7 days prior to the Day 1/ Baseline\n",
      "             visit\n",
      "\n",
      "          -  Significant GI co-morbidity that would preclude use of lanthanum carbonate phosphate\n",
      "             binder (e.g. colostomy with unformed stool, uncontrolled diarrhea)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patient is 3- 6 years old\n",
      "\n",
      "          -  Patient is scheduled for hernia repair surgery at University Clinical center of Kosovo\n",
      "             Patients is ASA I/II Patient meets criteria to receive either propofol or sevoflurane\n",
      "             anesthesia Patient's parent/guardian provides written consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  allergy to any of the drugs\n",
      "\n",
      "          -  preoperative anxiety\n",
      "\n",
      "          -  postoperative agitation\n",
      "\n",
      "          -  ASA physical status >II\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients who have been diagnosed as HAM according to the WHO criteria\n",
      "\n",
      "          -  Patients who are positive for HTLV-I antibody in the spinal fluid\n",
      "\n",
      "          -  Patients, if female, who are not pregnant or breastfeeding, either agreed to take\n",
      "             contraceptive measures during and two years after the treatment, or sterile\n",
      "\n",
      "          -  Patients, if male, who agreed to take contraceptive measures during and six months\n",
      "             after the treatment\n",
      "\n",
      "          -  Patients who have been informed and understood the contents of the study and consented\n",
      "             to participate in the signed form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who has a rapid progress in the symptoms defined as an increase of two or\n",
      "             more in Osame's Motor Disability Score for HAM patients in the past one year.\n",
      "\n",
      "          -  Patients of hyperlipidemia (serum triglyceride higher than 400 mg/dL)\n",
      "\n",
      "          -  Patients who were administered new or increased dose of corticosteroid in the past 8\n",
      "             weeks before the intervention\n",
      "\n",
      "          -  Patients who received steroid pulse therapy in the past 8 weeks before the\n",
      "             intervention\n",
      "\n",
      "          -  Patients who were administered new or increased dose of immunosuppressant in the past\n",
      "             8 weeks before the intervention\n",
      "\n",
      "          -  Patients with a history of serious drug allergy\n",
      "\n",
      "          -  Patients with significant complication such as malignancy, severe heart failure, and\n",
      "             other serious diseases.\n",
      "\n",
      "          -  Patients who were in the past administered etretinate.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Female subjects 18 years or over.\n",
      "\n",
      "          -  Subjects suspected of breast cancer. The clinical suspicion will include one of the\n",
      "             following: positive mammography, ultrasound (US), magnetic resonance imaging (MRI),\n",
      "             suspected physical exam. Final analysis will be done in relation to pathology only.\n",
      "\n",
      "          -  Subjects scheduled biopsy/surgery\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Female Subjects less than 18 years of age\n",
      "\n",
      "          -  Previous or concurrent malignancies\n",
      "\n",
      "          -  Autoimmune disorders diagnosed subjects\n",
      "\n",
      "          -  Hematological malignancies\n",
      "\n",
      "          -  Subjects under active chemotherapy treatment or chemotherapy in the past 6 months\n",
      "\n",
      "          -  Steroid treatment in the past 3 months\n",
      "\n",
      "          -  Subject undergoing immunosuppressive treatments\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        3.1 Conditions for Patient Eligibility\n",
      "\n",
      "        3.1.1 Pathologically (histologically or cytologically) proven diagnosis of solid malignancy\n",
      "        3.1.2 Eligible disease sites include the following\n",
      "\n",
      "          -  Breast\n",
      "\n",
      "          -  Prostate\n",
      "\n",
      "          -  GI (including colorectal, anal, esophagus, pancreas, gastric with the exception of\n",
      "             patients with colon cancer and liver-only metastatic disease )\n",
      "\n",
      "          -  Head and neck\n",
      "\n",
      "          -  Skin (melanoma and squamous cell carcinoma)\n",
      "\n",
      "          -  Lung (both small cell and non-small cell)\n",
      "\n",
      "          -  Sarcoma (both soft tissue and bone)\n",
      "\n",
      "          -  Gynecologic (endometrial, cervical, ovarian, vaginal, vulvar)\n",
      "\n",
      "        3.1.3 Patients are stage IV (M1) or recurrent with any combination of T and N with\n",
      "        oligometastatic disease as defined by 5 or fewer total sites of metastatic disease 3.1.4\n",
      "        Can have recurrent disease from the primary disease (this is definition of oligorecurrent\n",
      "        disease) but cannot have any other primary cancer diagnosed or treated within the last 3\n",
      "        years other than cutaneous skin cancer.\n",
      "\n",
      "        3.1.5 Prior systemic chemotherapy is allowable 3.1.4 Zubrod Performance Status 0-1 3.1.5\n",
      "        Age ≥ 18 3.1.6 CBC/differential obtained within 4 weeks prior to registration on study,\n",
      "        with adequate bone marrow function defined as follows: 3.1.6.1 Absolute neutrophil count\n",
      "        (ANC) ≥ 1,800 cells/mm3; 3.1.6.2 Platelets ≥ 100,000 cells/mm3; 3.1.6.3 Hemoglobin ≥ 8.0\n",
      "        g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is\n",
      "        acceptable.); 3.1.7 Women of childbearing potential and male participants must practice\n",
      "        adequate contraception 3.1.8 Patient must provide study specific informed consent prior to\n",
      "        study entry\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        3.2.1 Ineligible disease sites include the following\n",
      "\n",
      "          -  Lymphoma\n",
      "\n",
      "          -  Leukemia\n",
      "\n",
      "          -  Multiple myeloma\n",
      "\n",
      "          -  Primary CNS\n",
      "\n",
      "          -  Peritoneal carcinomatosis\n",
      "\n",
      "          -  Colon cancer with liver-only metastatic disease that is treatable with surgical\n",
      "             resection 3.2.2 Other\n",
      "\n",
      "          -  Diffuse metastatic spread confined to one organ system is ineligible; examples of this\n",
      "             include leptomeningeal spread in the CNS and peritoneal carcinomatosis.\n",
      "\n",
      "          -  Metastatic disease sites must be treatable with stereotactic radiosurgery (at\n",
      "             discretion of treating physician). Patients with oligometastatic sites not amenable to\n",
      "             SRS treatment, either through size or locations, are ineligible for this trial.\n",
      "\n",
      "        3.2.4 Severe, active co-morbidity, defined as follows: 3.2.4.1 Unstable angina and/or\n",
      "        congestive heart failure requiring hospitalization within the last 6 months; 3.2.4.2\n",
      "        Transmural myocardial infarction within the last 6 months; 3.2.4.3 Acute bacterial or\n",
      "        fungal infection requiring intravenous antibiotics at the time of registration; 3.2.4.4\n",
      "        Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note,\n",
      "        however, that laboratory tests for liver function and coagulation parameters are not\n",
      "        required for entry into this protocol.\n",
      "\n",
      "        3.2.5 Pregnancy or women of childbearing potential and men who are sexually active and not\n",
      "        willing/able to use medically acceptable forms of contraception; this exclusion is\n",
      "        necessary because the treatment involved in this study may be significantly teratogenic.\n",
      "\n",
      "        3.2.6 Patients unable to have an FDG-PET scan, either through insurance coverage, patient\n",
      "        decision or other reason are not eligible for this study.\n",
      "\n",
      "        3.2.7 Oligometastatic disease sites not eligible based on concern for toxicity:\n",
      "\n",
      "          -  trachea involvement (direct invasion, tumors close to or abutting trachea are\n",
      "             eligible)\n",
      "\n",
      "          -  heart (direct invasion or involvement, pericardial lymph nodes can be treated) 3.2.8\n",
      "             Patients unable to have SRS through insurance coverage or ability to pay for SRS\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy adults aged 18-40 years\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of gastrointestinal-related conditions, diabetes mellitus or cardiovascular\n",
      "             disease\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy males or non-pregnant, non-lactating, surgically sterile or post-menopausal\n",
      "             females (post-menopausal was defined as > 2 years post-last period and more than 50\n",
      "             years of age), or using an acceptable form of contraception as defined in section\n",
      "             9.3.2 (g)\n",
      "\n",
      "          -  Aged 18-65 years\n",
      "\n",
      "          -  Body Mass Index of between 18 and 30 kg/m2\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Participation in a clinical research study involving investigational drugs or dosage\n",
      "             forms within the previous 4 months\n",
      "\n",
      "          -  Subjects who had sought advice from their GP or consulted a counsellor for abuse or\n",
      "             misuse of alcohol, non-medical, medicinal drugs, or other substance-abuse such as\n",
      "             solvents. Any current or past use of Class A drugs such as opiates, ecstasy, LSD, and\n",
      "             amphetamines (Class B). Volunteers that admitted to past use of cannabis were not\n",
      "             excluded as long as they had a negative drugs of abuse test and had been abstinent for\n",
      "             at least 12 months\n",
      "\n",
      "          -  Positive drugs of abuse test result\n",
      "\n",
      "          -  Regular alcohol consumption in males >21 units per week and females >14 units per\n",
      "             week. (one unit of alcohol was defined as 0.5 pint (280 ml) of beer or cider, 1 glass\n",
      "             (125 ml) wine, 1 glass (70 ml) of sherry or port, 1 measure (25 ml) of whisky, brandy\n",
      "             or rum. For low alcohol drinks, one unit of alcohol was defined as 2 glasses (250 ml)\n",
      "             of low alcohol wine and 5 half pints (840 ml) of low alcohol beer)\n",
      "\n",
      "          -  Current smokers, i.e. those who had smoked within the last 12 months\n",
      "\n",
      "          -  A breath carbon monoxide reading of greater than 10 ppm either at the pre-study\n",
      "             medical examination or on a study day prior to dosing\n",
      "\n",
      "          -  Females of child bearing potential who were sexually active and either not surgically\n",
      "             sterile, post-menopausal or not using a form of acceptable contraceptive\n",
      "             (contraceptive pills/injection, condoms with spermicide, IUCDs (coils) and diaphragms\n",
      "             with spermicide (only if the woman was 35 or more) or abstinence\n",
      "\n",
      "          -  Radiation exposure from clinical trials, including that from the present study and\n",
      "             from diagnostic X-rays but excluding background radiation, exceeding 5 mSv in the last\n",
      "             twelve months or 10 mSv in the last five years. No subject whose occupational exposure\n",
      "             is monitored will participate in the study\n",
      "\n",
      "          -  Clinically significant abnormal biochemistry, haematology or urinalysis\n",
      "\n",
      "          -  Screening FEV1 < 80% of the predicted value for their age, sex, height and race\n",
      "\n",
      "          -  History of chronic respiratory disorders or bronchospasm\n",
      "\n",
      "          -  History of adverse reaction or allergy to ketorolac or di-sodium EDTA\n",
      "\n",
      "          -  History of severe or multiple allergies, including hayfever and perennial rhinitis\n",
      "\n",
      "          -  History of adverse reaction or allergy to aspirin or any other non-steroidal anti\n",
      "             inflammatory drug (e.g., ibuprofen, flurbiprofen, ketoprofen or diclofenac)\n",
      "\n",
      "          -  History of infantile bronchiolitis, or a history or the presence of asthma, or wheezy\n",
      "             respiration, hayfever and perennial rhinitis\n",
      "\n",
      "          -  History of nasal fracture, nasal deformity or nasal polyps\n",
      "\n",
      "          -  History of disease, surgery, or abnormality of the upper respiratory tract, especially\n",
      "             the nasal cavity\n",
      "\n",
      "          -  History of significant nose bleeds\n",
      "\n",
      "          -  Sinusitis within four weeks of the first study period\n",
      "\n",
      "          -  Nasal jewelry or nasal piercings\n",
      "\n",
      "          -  Subjects using topical nasal medication e.g. decongestants, within 14 days prior to\n",
      "             the first dosing day\n",
      "\n",
      "          -  Upper respiratory tract infection (excluding otitis media) within 14 days of the first\n",
      "             study day, or lower respiratory tract infection within the previous 3 months\n",
      "\n",
      "          -  Subjects taking any medication that might affect the respiratory tract within 14 days\n",
      "             of the first study day\n",
      "\n",
      "          -  Non-prescription and prescription medication (including vitamins and natural or herbal\n",
      "             remedies eg. St Johns Wort) within 14 days of the first study day (oral\n",
      "             contraceptives, contraceptive implants or depot injections, intra-uterine devices with\n",
      "             hormonal implants, Hormone Replacement Therapy (HRT) and occasional paracetamol (up to\n",
      "             4 g daily) were permitted)\n",
      "\n",
      "          -  History of peptic ulceration or gastrointestinal bleeding\n",
      "\n",
      "          -  History of kidney disease\n",
      "\n",
      "          -  History of clotting disorders\n",
      "\n",
      "          -  Failure to satisfy the Principal Medical Investigator of fitness to participate for\n",
      "             any other reason\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  written informed consent\n",
      "\n",
      "          -  ambulatory male and female patients 18 years of age or older\n",
      "\n",
      "          -  summarised score of signs and symptoms of blepharitis of 15 or more at baseline\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  different ocular conditions\n",
      "\n",
      "          -  different system conditions\n",
      "\n",
      "          -  several concomitant medications\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Aged 17-70 years\n",
      "\n",
      "          -  Migraine\n",
      "\n",
      "               -  With or without aura\n",
      "\n",
      "               -  The first attack of migraine was earlier than 50 years of age\n",
      "\n",
      "               -  One to 8 moderate to severe migraine attacks per month in the 2 months preceding\n",
      "                  the screening\n",
      "\n",
      "          -  Willing and able to give written informed consent\n",
      "\n",
      "          -  Able to read, comprehend and complete the diary form\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Not able to distinguish between migraine and non-migraine headache\n",
      "\n",
      "          -  Combined headache, including the tension type headache and medication overuse headache\n",
      "\n",
      "          -  Pregnant, actively trying to become pregnant or breast-feeding women\n",
      "\n",
      "          -  Uncontrolled and significant medical illness\n",
      "\n",
      "          -  Vertebrobasilar or hemiplegic migraine according to the International Headache Society\n",
      "             diagnostic criteria\n",
      "\n",
      "          -  Having intracranial metal implants or a cardiac pacemaker\n",
      "\n",
      "          -  A history of epilepsy or other organic brain disorders\n",
      "\n",
      "          -  A history of psychological diseases\n",
      "\n",
      "          -  Having changed medications for migraine within 1 month before giving us informed\n",
      "             consent\n",
      "\n",
      "          -  Drug abuser or alcoholics\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Minimum age 20 years, maximum age 80 years\n",
      "\n",
      "          -  Osteoarthritis of the hip\n",
      "\n",
      "          -  Elective THA\n",
      "\n",
      "          -  Signed Informed Consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Osteoporosis\n",
      "\n",
      "          -  Revisions\n",
      "\n",
      "          -  Clinically obese (>40 body mass index [BMI])\n",
      "\n",
      "          -  Femoral dysplasia\n",
      "\n",
      "          -  Trochanteric osteotomy\n",
      "\n",
      "          -  Inflammatory arthritis\n",
      "\n",
      "          -  Breast-feeding, pregnancy, or women of childbearing potential without documentation of\n",
      "             a negative pregnancy test and not utilizing contraception\n",
      "\n",
      "          -  Patients with a history of having taken or currently taking bisphosphonates, PTH,\n",
      "             fluoride therapy or strontium ranelate or patients taking other chronic medications\n",
      "             that in the investigator's opinion are known to affect bone mineral density in a\n",
      "             substantial way\n",
      "\n",
      "          -  Patients with severe medical condition(s) that in the view of the investigator\n",
      "             prohibits participation in the study\n",
      "\n",
      "          -  Use of other investigational agent in the last 30 days\n",
      "\n",
      "          -  Unable to sign Informed Consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subject is male or female, aged at least 18 years.\n",
      "\n",
      "          -  Subject has a histologically or cytologically confirmed diagnosis of an advanced,\n",
      "             malignant, incurable solid tumor(s) or lymphoma that is metastatic and/or unresectable\n",
      "             and/or for which standard curative measures either are not applicable, or do not\n",
      "             exist, or are no longer effective. Subjects with curative treatment options are not\n",
      "             eligible for the protocol.\n",
      "\n",
      "          -  Subject is not receiving any active treatment for his/her malignancy (except for\n",
      "             prostate cancer subjects receiving luteinizing hormone-releasing hormone (LHRH)\n",
      "             agonists and antiandrogens such as: Flutamide, Dutasteride, and Finasteride).\n",
      "\n",
      "          -  Subject's Eastern Cooperative Group (ECOG) performance status is 0, 1 or 2 at\n",
      "             Screening.\n",
      "\n",
      "          -  Subject has acceptable liver function at Screening\n",
      "\n",
      "          -  Subject has a normal serum creatinine.\n",
      "\n",
      "          -  Subject has acceptable hematologic status at Screening\n",
      "\n",
      "          -  Female subjects of childbearing potential (i.e., women who have not been surgically\n",
      "             sterilized or have not been post-menopausal for at least one year), and male subjects\n",
      "             with partners of childbearing potential, must agree to use medically acceptable\n",
      "             methods of contraception beginning on Study Day 1 and continuing until at least four\n",
      "             weeks after administration of the subject's final dose of RRx-001.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Impaired cardiac function that in the opinion of the Investigator could interfere with\n",
      "             the conduct of the study or could put the subject at unacceptable risk.\n",
      "\n",
      "          -  Right-to-left, bidirectional, or transient right-to-left cardiac shunts.\n",
      "\n",
      "          -  Subjects with a history of acute cerebral infarction or transient ischemic attack\n",
      "             within 90 days prior to Study Day 1.\n",
      "\n",
      "          -  Acute myocardial infarction or acute coronary syndromes less than one year prior to\n",
      "             enrollment.\n",
      "\n",
      "          -  Serious ventricular arrythmias or high risk for arrhythmias due to prolongation of the\n",
      "             QT interval.\n",
      "\n",
      "          -  Subjects who experienced a major surgery, radiotherapy, or immunotherapy within the\n",
      "             last 21 days prior to Study Day 1 (limited palliative radiation is allowed within 14\n",
      "             days prior to Study Day 1).\n",
      "\n",
      "          -  Chemotherapy regimens with delayed toxicity within the 28 days prior to Study Day 1\n",
      "             (except for nitrosourea or mitomycin C treatments within 42 days prior to Study Day\n",
      "             1).\n",
      "\n",
      "          -  Chemotherapy regimens given continuously or on a weekly basis that Investigator\n",
      "             believes to have a limited potential for delayed toxicity within 14 days prior to\n",
      "             Study Day 1.\n",
      "\n",
      "          -  Use of an investigational anti-cancer drug within 42 days prior to Study Day 1.\n",
      "\n",
      "          -  Subject has symptomatic and/or untreated central nervous system metastases and/or\n",
      "             intracranial hypertension.\n",
      "\n",
      "          -  Subject has a known history of an active and/or an uncontrolled infection with\n",
      "             hepatitis A or hepatitis B.\n",
      "\n",
      "          -  Subject with a known history of a positive HIV status.\n",
      "\n",
      "          -  Subjects with pulmonary edema.\n",
      "\n",
      "          -  Subjects with respiratory failure\n",
      "\n",
      "          -  Subjects with severe emphysema, pulmonary emboli, pulmonary fibrosis or other\n",
      "             conditions that cause pulmonary hypertension due to compromised pulmonary arterial\n",
      "             vasculature.\n",
      "\n",
      "          -  Subjects with Raynaud's syndrome.\n",
      "\n",
      "          -  Subjects with a serious co-morbid medical condition.\n",
      "\n",
      "          -  If female, subject is pregnant and/or breastfeeding.\n",
      "\n",
      "          -  Any subject with congenital or acquired methemoglobinemia.\n",
      "\n",
      "          -  Any subject with a history of inherited anemia or hemoglobinopathy including but not\n",
      "             limited to hereditary spherocytosis, hereditary elliptocytosis, hereditary\n",
      "             ovalocytosis,\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Unrelated donor who donated either unstimulated BM or filgrastim-mobilized PBSC\n",
      "             between July 1, 1999 and approximately five years post study activation.\n",
      "\n",
      "          2. Unrelated donor who received at least one injection of filgrastim or more, but did not\n",
      "             donate filgrastim-mobilized PBSC between July 1, 1999 and approximately five years\n",
      "             post study activation.\n",
      "\n",
      "          3. Donation was managed by a U.S. NMDP donor center.\n",
      "\n",
      "          4. Signed informed consent for participation in this long-term donor follow-up study.\n",
      "             Concurrent enrollment on other studies is permitted.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Unrelated donor who donated filgrastim-mobilized bone marrow.\n",
      "\n",
      "          2. Donation was managed by a non-U.S. donor center.\n",
      "\n",
      "          3. Donor is unable to verbally communicate in any of the following languages: English,\n",
      "             Spanish, Mandarin Chinese, Cantonese Chinese, Vietnamese, Korean, or Portuguese.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Non-smoking (within the last 6 months) men and women aged 18 to 45 years who are\n",
      "             considered healthy\n",
      "\n",
      "          -  Body mass index (BMI) < 32 kg/m2\n",
      "\n",
      "          -  FEV1 ≥ 80% of the Third National Health and Nutrition Examination Survey (NHANES III)\n",
      "             predicted\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pre-existing asthma or chronic obstructive pulmonary disease (COPD)\n",
      "\n",
      "          -  History of coronary artery disease, peripheral vascular disease, or congestive heart\n",
      "             failure\n",
      "\n",
      "          -  Blood donation within the previous 3 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Infants with birth weight less than 1500g\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Sever bacteremia\n",
      "\n",
      "          -  Congenital anomaly\n",
      "\n",
      "          -  Not suitable for the trial defined by an attending neonatologist\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  adult patients\n",
      "\n",
      "          -  high clinical suspicion for infection\n",
      "\n",
      "          -  require positive pressure ventilation\n",
      "\n",
      "          -  supraclavicular central line for central venous pressure measurement\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Substitute decision maker unable to consent\n",
      "\n",
      "          -  amputation\n",
      "\n",
      "          -  pacemaker\n",
      "\n",
      "          -  pregnant\n",
      "\n",
      "          -  require longterm hemodialysis\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Home dwelling prior to fracture\n",
      "\n",
      "          -  age>70yr\n",
      "\n",
      "          -  able to walk 10m\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  expected life expectancies <3 months\n",
      "\n",
      "          -  exercises contraindicated due to medical conditions\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed adenocarcinoma or poorly differentiated carcinoma of the\n",
      "             intrathoracic esophagus or gastroesophageal junction (GEJ) and deemed resectable by\n",
      "             the thoracic surgeon.\n",
      "\n",
      "          -  No prior chemotherapy for esophageal or GEJ cancer.\n",
      "\n",
      "          -  ECOG Performance status 0-2.\n",
      "\n",
      "          -  Adequate bone marrow, kidney and liver function.\n",
      "\n",
      "          -  Ability to understand and the willingness to sign a written informed consent document.\n",
      "\n",
      "          -  Subjects of child-bearing potential must agree to use effective means of contraception\n",
      "             (men and women).\n",
      "\n",
      "          -  Prior malignancy is acceptable if the subject is considered to be cured. In most cases\n",
      "             this will mean a 5-year disease-free period.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with cervical esophageal cancer or esophageal cancer with squamous cell\n",
      "             carcinoma morphology.\n",
      "\n",
      "          -  Subjects receiving any other investigational agent or received prior chemotherapy for\n",
      "             esophageal or GEJ cancer.\n",
      "\n",
      "          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n",
      "             composition to azacitidine, epirubicin, oxaliplatin, capecitabine and mannitol.\n",
      "\n",
      "          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure.\n",
      "\n",
      "          -  History of myocardial infarction or unstable angina within 6 months prior to study\n",
      "             enrollment.\n",
      "\n",
      "          -  Pregnant (positive pregnancy test) or lactating women.\n",
      "\n",
      "          -  Patients with active infection, serious inter-current medical conditions.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  newly diagnosed adult patients with lung cancer, with a prognosis of at least 3 months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  cognitive impairment\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  A woman with imaging signs suggesting a diagnosis of DCIS who is scheduled for\n",
      "             ultrasound and a biopsy is eligible for the study.\n",
      "\n",
      "          -  At least 18 years of age\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant or possibly pregnant or breast feeding\n",
      "\n",
      "          -  Unable to provide informed consent\n",
      "\n",
      "          -  Drug or multiple allergies\n",
      "\n",
      "          -  Known cardiac shunts\n",
      "\n",
      "          -  Known cardiac or chronic pulmonary disease\n",
      "\n",
      "          -  Hypersensitivity to perflutren\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age 50-79 years at time of enrollment\n",
      "\n",
      "          -  ever smokers (10 or more pack-years)\n",
      "\n",
      "          -  participation in MESA or EMCAP studies\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  clinical cardiovascular disease (left congestive heart failure (CHF), valve disease,\n",
      "             coronary artery disease (CAD), stroke, or congenital heart disease),\n",
      "\n",
      "          -  asthma, pulmonary embolism or lung disease other than COPD,\n",
      "\n",
      "          -  weight > 300 lbs,\n",
      "\n",
      "          -  chronic renal insufficiency ([estimated glomerular filtration rate (eGFR)] < 45\n",
      "             mL/min/1.73 m2),\n",
      "\n",
      "          -  cancer,\n",
      "\n",
      "          -  atrial fibrillation, and\n",
      "\n",
      "          -  contraindications to magnetic resonance imagine (MRI), gadolinium, albuterol or\n",
      "             spirometry testing.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Residents completing Intensive Care Unit rotations\n",
      "\n",
      "          -  For focus groups and interviews, patients and families members admitted during the\n",
      "             study period and nurses and attending physicians working during the study period\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  None\n",
      "      \n",
      "\n",
      "        Inclusion:\n",
      "\n",
      "          1. Diagnosis of morbid obesity BMI > 40\n",
      "\n",
      "          2. Female, age 18-75\n",
      "\n",
      "          3. Mentally competent to give informed consent\n",
      "\n",
      "          4. Scheduled to undergo a transvaginal NOTES sleeve gastrectomy\n",
      "\n",
      "        Exclusion:\n",
      "\n",
      "          1. Pregnant women\n",
      "\n",
      "          2. BMI < 40\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  the patients with pathologically proved NASH (non-alcoholic steato-hepatitis)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  alcohol consumption > 20g/day\n",
      "\n",
      "          -  viral hepatitis B and C\n",
      "\n",
      "          -  autoimmune hepatitis\n",
      "\n",
      "          -  Wilson's disease\n",
      "\n",
      "          -  hemochromatosis\n",
      "\n",
      "          -  alpha-1 antitrypsin deficiency\n",
      "\n",
      "          -  breast-feeding or pregnant females\n",
      "\n",
      "          -  subjects planning to become pregnant\n",
      "\n",
      "          -  severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or\n",
      "             psychological problems)\n",
      "\n",
      "          -  those not consenting for the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        On program at Catholic Home Care (CHC) Have a diagnosis of CHF NYHA II or III Medically\n",
      "        stable 60 - 85 years of age at completion of study Able to follow commands Normal vision\n",
      "        (with corrective lenses, if necessary) Willing to participate in a program for 1 year Have\n",
      "        a reliable caregiver that is willing to assist as necessary -\n",
      "\n",
      "        Exclusion Criteria:Latex allergy, Unstable CHF NYHA IV Pain that interferes with activity\n",
      "        Active neurological and or orthopedic problems, Cancer, End stage renal disease Decreased\n",
      "        balance as indicated on Tinetti balance assessment < 10/16.\n",
      "\n",
      "        -\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Currently enrolled undergraduate student at UMass Boston,\n",
      "\n",
      "          -  Have completed high school,\n",
      "\n",
      "          -  24yrs old or older AND/OR part time students,\n",
      "\n",
      "          -  Noncompliant in at least 1 of 4 behaviors: fruit & vegetable intake, sugar sweetened\n",
      "             beverage intake, fast food intake, or physical activity),\n",
      "\n",
      "          -  Willing to randomized into either study group,\n",
      "\n",
      "          -  Be able to give informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Have any contraindications to physical activity\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  fluent in written and spoken English,\n",
      "\n",
      "          -  have sustained (1) a moderate to severe TBI as defined by a 6-hour GCS of 12 or less\n",
      "             OR (2) complicated mild TBI with GCS 13-15 and associated abnormal findings on CT or\n",
      "             MRI scan OR (3) other form of acquired brain injury (ABI) that is not related to a\n",
      "             congenital, developmental or degenerative disorder but which occurred through a\n",
      "             medical problem or disease process including stroke,\n",
      "\n",
      "        Exclusion Criteria: other significant neurological or psychiatric history such as multiple\n",
      "        sclerosis or psychiatric illness requiring hospitalization, concurrent moderate to severe\n",
      "        depression.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Ambulatory postmenopausal women, who had their last menstrual period at least 2 years\n",
      "             before beginning the study\n",
      "\n",
      "          -  Free of severe acute or chronically disabling conditions with a life expectancy of at\n",
      "             least 5 years\n",
      "\n",
      "          -  Expected to remain ambulatory throughout the entire study and expected to return for\n",
      "             all study visits\n",
      "\n",
      "          -  Expected to be compliant with study procedures, including procedures for WBV usage\n",
      "\n",
      "          -  Women who have no language barrier, are cooperative, and who give informed consent\n",
      "             before entering the study\n",
      "\n",
      "          -  Women must be on standard therapy with alendronate or raloxifene for at least 3 months\n",
      "             before the commencement of WBV, and their treatment must be expected to remain stable\n",
      "             throughout the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Participation in another clinical study within the last 30 days and/or during the\n",
      "             study\n",
      "\n",
      "          -  Subjects who are inmates of psychiatric wards, prisons, or any other state\n",
      "             institutions\n",
      "\n",
      "          -  Investigators or any other team member involved directly or indirectly in the conduct\n",
      "             of the clinical study\n",
      "\n",
      "          -  Thrombophlebitis, deep venous thrombosis, any thromboembolic disorders (including\n",
      "             pulmonary or retinal embolism) within the last year\n",
      "\n",
      "          -  Any vascular disorders of the lower extremities with the exception of asymptomatic\n",
      "             varicosis\n",
      "\n",
      "          -  Current bone disorders other than primary osteoporosis, such as hyperparathyroidism,\n",
      "             Paget's disease, renal osteodystrophy, osteomalacia, osteonecrosis, spondylolisthesis\n",
      "\n",
      "          -  Vertebral fracture or fractures of the lower extremities within the last 6 months\n",
      "             before start of WBV\n",
      "\n",
      "          -  Frequent occurrence of muscle spasms limiting the use of WBV\n",
      "\n",
      "          -  Spastic disorders\n",
      "\n",
      "          -  Morbus Sudeck (CRPS I)\n",
      "\n",
      "          -  Malignancy within the past 2 years with the exception of in situ removal of basal cell\n",
      "             carcinoma\n",
      "\n",
      "          -  Severe cardiovascular disorder, such as but not limited to: not controllable\n",
      "             hypertension, clinically relevant cardiac arrhythmia and cardiac valve disorder, heart\n",
      "             failure (NYHA III-IV)\n",
      "\n",
      "          -  Cerebral vascular accident within the past 1 year\n",
      "\n",
      "          -  Any neurologic/psychiatric disorder which might interfere with the conduct of the\n",
      "             trial or the study results such as, but not limited to, the following: Depression,\n",
      "             schizophrenia, dementia, Parkinson's disease, epilepsy\n",
      "\n",
      "          -  Benign Paroxysmal Positional Vertigo\n",
      "\n",
      "          -  Frequent occurrence of migraine attacks (more than once per month), limiting the use\n",
      "             of WBV\n",
      "\n",
      "          -  Active renal lithiasis or gall stones as defined by any colic within 6 months prior to\n",
      "             start of WBV\n",
      "\n",
      "          -  Acute inflammation, infection and/or fever\n",
      "\n",
      "          -  Immune compromised conditions such as, but not limited to, rheumatoid arthritis, HIV\n",
      "\n",
      "          -  severe diabetes, e.g. defined by the coexistence of an arterial occlusive disease\n",
      "\n",
      "          -  Major surgical interventions within 3 months prior to WBV\n",
      "\n",
      "          -  Metallic or plastic implants like joint implants, pace makers, cardiac valves, stents,\n",
      "             eye lenses that limit the use of WBV\n",
      "\n",
      "          -  Any acute joint inflammation of the lower extremities or other parts of the body which\n",
      "             might interfere with the use of WBV within the last 6 months before start of WBV\n",
      "\n",
      "          -  Start or change in regimen of physical therapy, or extreme sportive activity within 1\n",
      "             month prior to study and during the study\n",
      "\n",
      "          -  Treatment with doses of any of the following medications more recently than 6 months\n",
      "             before beginning the study: Androgen, Calcitonin, Estrogen, Progestin, strontium\n",
      "             ranelate, parathormone, proton pump inhibitors\n",
      "\n",
      "          -  Long term treatment (more than 6 months) with Heparin within the last 2 years\n",
      "\n",
      "          -  Patients in the alendronate group must be naïve to other bisphosphonates and raloxifen\n",
      "\n",
      "          -  Patients in the raloxifen group must be naïve to all bisphosphonates\n",
      "\n",
      "          -  Treatment with WBV within the last 6 months\n",
      "\n",
      "          -  Treatment with therapeutic doses of systemic corticosteroids for more than 1 month\n",
      "             during the 12 months before beginning the study\n",
      "\n",
      "          -  Treatment with 50,000 IU or more of vitamin D once weekly more recently than 3 months\n",
      "             before beginning the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  cancer patients with confirmed diagnosis of breast, colorectal, lung or prostate\n",
      "             cancer\n",
      "\n",
      "          -  early stage (I or II, diagnosed within past 2 to 12 months) OR advanced stage (III or\n",
      "             IV, diagnosed or progressed within past 2 to 12 months)\n",
      "\n",
      "          -  age 18 or older\n",
      "\n",
      "          -  physically/mentally able to participate\n",
      "\n",
      "          -  speak/read/write English\n",
      "\n",
      "          -  have access to internet at home\n",
      "\n",
      "          -  have a family caregiver willing to participate\n",
      "\n",
      "          -  family caregivers must be age 18 or older, physically/mentally able to participate,\n",
      "             able to speak/read/write English, identified by the patient as his or her primarily\n",
      "             family caregiver, and have access to and willing to use the internet. \"Family\n",
      "             caregiver\" is defined as the family member or significant other identified by the\n",
      "             patient as his or her primary source of emotional or physical support during the\n",
      "             current cancer experience and confirmed by the designated individual.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Family caregivers will be excluded from the study if they themselves have been\n",
      "             diagnosed with cancer in the previous year or are receiving active treatment for\n",
      "             cancer. This criteria was established so all dyads are managing effects of cancer in\n",
      "             patients, not the family caregivers.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Glaucoma or glaucoma suspect\n",
      "\n",
      "          -  Use of topical glaucoma medication in both eyes for at least 1 year prior to\n",
      "             enrollment\n",
      "\n",
      "          -  VA of 20/60 or better with habitual correction in at least one eye\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Previous history of allergy to fluorescein\n",
      "\n",
      "          -  Received topical anesthesia for IOP measurement or other reason within the last 2\n",
      "             hours.\n",
      "\n",
      "          -  Rejects participation\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with either definite MS according to the revised McDonald criteria (Polman\n",
      "             2005) or patients with CIS (defined as an initial MS relapse with objective\n",
      "             documentation and 2 or more lesions within the CNS of which at least one must involve\n",
      "             the brain)\n",
      "\n",
      "          -  Patients on GA therapy for at least 6 months\n",
      "\n",
      "          -  Age 18 - 70\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Unwilling to comply with study procedures\n",
      "\n",
      "          -  Use of other DMT in conjunction with GA\n",
      "\n",
      "          -  Unable to provide informed consent.\n",
      "\n",
      "          -  Current (past 30 days) substance abuse\n",
      "\n",
      "          -  Newly initiated (past 30 days) psychiatry treatment\n",
      "\n",
      "          -  Enrolled in another program of meditation in the past six months.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with diagnosis of Schizophrenia or Schizoaffective Disorder as per by their\n",
      "             medical record diagnosis.\n",
      "\n",
      "          -  Patients currently on olanzapine therapy and BMI >29.9.\n",
      "\n",
      "          -  Patients treated with olanzapine for greater than or equal to 3 months prior to\n",
      "             enrollment.\n",
      "\n",
      "          -  Patient would be required to have either attempted dietary, lifestyles modifications\n",
      "             and/or participated in weight loss programs.\n",
      "\n",
      "          -  Patients with no history of psychiatric hospitalizations in past six months and judged\n",
      "             by treating clinician to be suitable for antipsychotic medication switch.\n",
      "\n",
      "          -  Patients with adequate decisional capacity to make a choice about participating in\n",
      "             this research study.\n",
      "\n",
      "          -  Patients, who are able to comprehend and satisfactorily comply with protocol\n",
      "             requirements and have an ability to read and write English.\n",
      "\n",
      "          -  Patients, who signed the written consent given prior to entering any study procedure.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with a history of treatment resistant schizophrenia or past trials with\n",
      "             clozapine.\n",
      "\n",
      "          -  Patients with a concurrent DSM-IV diagnosis of PTSD as per their medical record.\n",
      "\n",
      "          -  Substance Dependence or Abuse (excluding nicotine) within one month prior to the\n",
      "             screening visit.\n",
      "\n",
      "          -  Patients with a history of non-response, intolerance or hypersensitivity ot\n",
      "             perphenazine.\n",
      "\n",
      "          -  Subjects with history of treatment of clozapine.\n",
      "\n",
      "          -  Patients who based on history of mental status examination have a significant risk of\n",
      "             committing suicide.\n",
      "\n",
      "          -  Patients who are homicidal or violent and who are in the Investigator's opinion in\n",
      "             significant imminent risk of hurting others.\n",
      "\n",
      "          -  Female patients who are pregnant, planning to become pregnant, or if of childbearing\n",
      "             potential, not using an acceptable method of birth control.\n",
      "\n",
      "          -  Patient currently receiving depot neuroleptics.\n",
      "\n",
      "          -  Patients with visual impairments.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        -Age > 18 years old and undergoing liver transplantation.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Clinical instability as judged by the attending physicians whereby autoregulation\n",
      "             monitoring may interfere with clinical care.\n",
      "\n",
      "          -  Women of child bearing potential require a negative urine human chorionic gonadotropin\n",
      "             (HCG) test to be enrolled.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must have histologically confirmed biliary tract carcinoma that is surgically\n",
      "             unresectable\n",
      "\n",
      "               -  Cytological confirmation is not allowed on this study, as tissue is needed for\n",
      "                  correlative science analysis\n",
      "\n",
      "               -  Either fresh-frozen tissue (FFT) or paraffin-embedded tissue blocks (PETB) will\n",
      "                  be required from patients before enrolling on this study\n",
      "\n",
      "               -  No biopsies will be required unless there is insufficient tissue or if the PETB\n",
      "                  available is more than 12 months old\n",
      "\n",
      "          -  Patients must have measurable disease, defined as at least one lesion that can be\n",
      "             accurately measured in at least one dimension (longest diameter to be recorded) as ≥\n",
      "             10 mm with spiral CT scan (CT scan slice thickness no greater than 5 mm)\n",
      "\n",
      "               -  Malignant lymph nodes will be considered measurable if they are ≥ 15 mm in short\n",
      "                  axis\n",
      "\n",
      "          -  Patients must have received one prior therapy for metastatic disease\n",
      "\n",
      "               -  No prior Akt inhibitors allowed\n",
      "\n",
      "          -  Patients with known brain metastases should be excluded from this clinical trial\n",
      "\n",
      "          -  Life expectancy greater than 12 weeks\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) =<2 (Karnofsky >=\n",
      "             60%)\n",
      "\n",
      "          -  Leukocytes >= 3,000/mcL\n",
      "\n",
      "          -  Absolute neutrophil count (ANC) >= 1,500/mcL\n",
      "\n",
      "          -  Platelet count >= 100,000/mcL\n",
      "\n",
      "          -  Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)\n",
      "\n",
      "          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n",
      "             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT] =<\n",
      "             2.5 x IULN\n",
      "\n",
      "          -  Creatinine within normal institutional limits OR creatinine clearance >= 60\n",
      "             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\n",
      "             (measured or calculated using the Cockroft-Gualt formula)\n",
      "\n",
      "          -  Women of childbearing potential and men must use two forms of contraception (hormonal\n",
      "             or barrier method of birth control; abstinence) prior to study entry and for the\n",
      "             duration of study participation\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Able to swallow oral tablets\n",
      "\n",
      "          -  No history of allergic reactions attributed to compounds of similar chemical or\n",
      "             biologic composition to Akt Inhibitor MK2206 (MK2206) or other agents used in the\n",
      "             study\n",
      "\n",
      "          -  Patients with diabetes or in risk for hyperglycemia should not be excluded from trials\n",
      "             with MK2206, but the hyperglycemia should be well controlled on oral agents before the\n",
      "             patient enters the trial\n",
      "\n",
      "          -  Cardiovascular: baseline QTcF > 450 msec (male) or QTcF > 470 msec (female) will\n",
      "             exclude patients from entry on study\n",
      "\n",
      "          -  Patients with clinically significant bundle branch block or pre-existing clinically\n",
      "             significant bradycardia will be excluded from the study\n",
      "\n",
      "          -  No uncontrolled intercurrent illness including, but not limited to, ongoing or active\n",
      "             infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac\n",
      "             arrhythmia; or psychiatric illness/social situations that would limit compliance with\n",
      "             study requirements\n",
      "\n",
      "          -  No concurrent grapefruit or grapefruit juice\n",
      "\n",
      "          -  For patients having prior cryotherapy, radiofrequency ablation, ethanol injection,\n",
      "             transarterial chemoembolization (TACE), or photodynamic therapy, the following\n",
      "             criteria must be met:\n",
      "\n",
      "               -  6 weeks has elapsed since that therapy\n",
      "\n",
      "               -  Indicator lesion(s) is/are outside the area of prior treatment or, if the only\n",
      "                  indicator lesion is inside the prior treatment area, there must be clear evidence\n",
      "                  of disease progression associated with that lesion\n",
      "\n",
      "               -  Edges of the indicator lesion are clearly distinct on CT scanning\n",
      "\n",
      "               -  Prior radiation therapy with or without the use of a fluoropyrimidine as a\n",
      "                  radiosensitizer in the adjuvant setting will be allowed on study if > 12 weeks\n",
      "                  have elapsed since therapy\n",
      "\n",
      "               -  Prior palliative radiation therapy will allowed as long as > 4 weeks have elapsed\n",
      "                  since therapy\n",
      "\n",
      "          -  No patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or\n",
      "             mitomycin C) prior to entering the study or those who have not recovered from adverse\n",
      "             events due to agents administered more than 4 weeks earlier\n",
      "\n",
      "          -  Patients may not be receiving any other investigational agents\n",
      "\n",
      "          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n",
      "             therapy are ineligible\n",
      "\n",
      "          -  Patients receiving any medications or substances that are inhibitors or inducers of\n",
      "             CYP 450 3A4 are ineligible\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed diagnosis of malignancy other than lymphoma\n",
      "\n",
      "          -  Presence of femoral metastases at high risk of pathologic fracture (Mirels' score 8 or\n",
      "             more)\n",
      "\n",
      "          -  At least 18 years of age\n",
      "\n",
      "          -  Able to provide written informed consent\n",
      "\n",
      "          -  Able to participate in follow-up\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Surgical consultation for the purpose of obtaining a tissue/histological diagnosis\n",
      "             only, not for treatment\n",
      "\n",
      "          -  Histological diagnosis of lymphoma\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          1. Patient age is ≥ 18 years old,\n",
      "\n",
      "          2. Patients with history suggestive and /OR symptoms suggestive of small bowel disease\n",
      "             and whom are eligible and indicated for SB capsule endoscopy,\n",
      "\n",
      "          3. Patient and/or legal guardian is able and agrees to sign the Informed Consent Form\n",
      "\n",
      "        Exclusion criteria\n",
      "\n",
      "          1. Patient has dysphagia,\n",
      "\n",
      "          2. Patient is known or is suspected to suffer from intestinal obstruction,\n",
      "\n",
      "          3. Patient has known previous stricture/obstruction of the SB or colon,\n",
      "\n",
      "          4. Patient has a cardiac pacemakers or other implanted electro medical devices, 5. Women\n",
      "             who are either pregnant or nursing at the time of screening, who intend to be during\n",
      "             the study period, or are of child-bearing potential and do not practice medically\n",
      "             acceptable methods of contraception,\n",
      "\n",
      "        6. Patient is expected to undergo MRI examination within 7 days after ingestion of the\n",
      "        capsule, 7. Patient has had prior abdominal surgery of the gastrointestinal tract other\n",
      "        than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on\n",
      "        the clinical judgment of the investigator, 8. Patient has any condition, which precludes\n",
      "        compliance with study and/or device instructions, 9. Patient suffers from life threatening\n",
      "        conditions, 10. Patient is currently participating in another clinical study, 11. Patient\n",
      "        has known slow gastric emptying time\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Must have participated in RV144, received the active product, and completed all 4\n",
      "             vaccination visits per protocol.\n",
      "\n",
      "          -  Must be able to understand and complete the informed consent process.\n",
      "\n",
      "          -  Must successfully complete a Test of Understanding prior to enrollment\n",
      "\n",
      "               -  The volunteer must answer 80% or 8 out of 10 of the questions correctly including\n",
      "                  two compulsory questions answered correctly.\n",
      "\n",
      "               -  If the volunteer is unable to do so, he or she will be given two more\n",
      "                  opportunities to repeat the TOU.\n",
      "\n",
      "               -  If after three attempts to pass the TOU the volunteer is still unable to do so,\n",
      "                  the volunteer will become ineligible for study participation.\n",
      "\n",
      "          -  Must be in good general health without clinically significant medical history.\n",
      "\n",
      "          -  HIV-uninfected per predefined algorithm within 45 days of enrollment.\n",
      "\n",
      "          -  Laboratory screening analysis\n",
      "\n",
      "               -  Hemoglobin: Women ≥12.0 g/dL. Men ≥12.5 g/dL\n",
      "\n",
      "               -  White cell count: 4,000 to 11,000 cells/mm3\n",
      "\n",
      "               -  Platelets: 150,000 to 450,000/mm3\n",
      "\n",
      "               -  Normal liver function: ALT/AST ≤1.25 institutional upper limit of reference range\n",
      "\n",
      "               -  Creatinine: ≤1.25 institutional upper limit of reference range\n",
      "\n",
      "          -  Urinalysis (dipstick) for blood and protein no greater than 1+, glucose negative\n",
      "\n",
      "          -  Female-Specific Criteria:\n",
      "\n",
      "               -  Negative human choriogonadotropin (β-HCG) pregnancy test (urine) for women prior\n",
      "                  to each vaccination (same day).\n",
      "\n",
      "               -  Be using adequate birth control methods for 45 days prior to the first\n",
      "                  vaccine/placebo vaccination and will continue to be followed for at least 3\n",
      "                  months after the final vaccine/placebo vaccination. Adequate birth control is\n",
      "                  defined as follows: Contraceptive medications delivered orally, intramuscularly,\n",
      "                  vaginally, or implanted underneath the skin, surgical methods (hysterectomy or\n",
      "                  bilateral tubal ligation), condoms, diaphragms, intrauterine device (IUD),\n",
      "                  abstinence.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        1. Women breast-feeding or pregnant (positive pregnancy test) or planning to become\n",
      "        pregnant during the window between study enrollment and 3 months after the last vaccination\n",
      "        visit.\n",
      "\n",
      "          -  History of anaphylaxis or other serious adverse reaction to vaccines including to RV\n",
      "             144 vaccines, or allergies or reactions likely to be exacerbated by any component of\n",
      "             the vaccine or placebo, including eggs, egg products, streptomycin, or neomycin.\n",
      "\n",
      "          -  Subject has received any of the following substances:\n",
      "\n",
      "               -  Chronic use of therapies which may modify immune response, such as IV immune\n",
      "                  globulin and systemic corticosteroids (in doses of > 20 mg/day prednisone\n",
      "                  equivalent for periods exceeding 10 days).\n",
      "\n",
      "                  -The following exceptions are permitted and will not exclude study participation:\n",
      "                  use of corticosteroid nasal spray for rhinitis, topical corticosteroids for an\n",
      "                  acute uncomplicated dermatitis; or a short course (duration of 10 days or less,\n",
      "                  or a single injection) of corticosteroid for a nonchronic condition (based on\n",
      "                  investigator clinical judgment) at least 2 weeks prior to enrollment in this\n",
      "                  study.\n",
      "\n",
      "               -  Blood products within 120 days prior to HIV screening.\n",
      "\n",
      "               -  Immunoglobulins within 14 days prior to HIV screening.\n",
      "\n",
      "               -  Any vaccine within 14 days prior to initial study vaccine administration in the\n",
      "                  present study.\n",
      "\n",
      "               -  Receipt of investigational HIV vaccine product other than the RV 144 regimen.\n",
      "\n",
      "               -  Investigational research agents within 30 days prior to initial study vaccine\n",
      "                  administration in the present study.\n",
      "\n",
      "               -  Use of anti-tuberculosis prophylaxis or therapy during the past 90 days.\n",
      "\n",
      "          -  Any medical, psychiatric, social condition, occupational reason, or other\n",
      "             responsibility that, in the judgment of the investigator, is a contraindication to\n",
      "             protocol compliance or impairs a subject's ability to give informed consent.\n",
      "\n",
      "          -  Psychiatric condition that precludes compliance with the protocol; past or present\n",
      "             psychoses; past or present bipolar disorder; disorder requiring lithium; or within 5\n",
      "             years prior to enrollment, a history of suicide plan or attempt.\n",
      "\n",
      "          -  Study site employees who are involved in the protocol and/or may have direct access to\n",
      "             study related area.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients that will be submitted to \"standard\" protocols for CT of the: head, chest,\n",
      "             abdomen, lumbar spine and cardiac\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Non standard MDCT examination\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  current age at or above 18 years;\n",
      "\n",
      "          -  breast, colorectal, prostate, and/or thoracic cancer diagnosis,stage I, II, IIIa;\n",
      "\n",
      "          -  approaching or attending the last treatment appointment of chemotherapy and or\n",
      "             radiation therapy for the cancer diagnosis\n",
      "\n",
      "          -  English speaking (able to read English at an 8th grade level);\n",
      "\n",
      "          -  have a mailing address;\n",
      "\n",
      "          -  have residential phone service;\n",
      "\n",
      "          -  able to give informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  patients who have received surgery only with no adjuvant therapy;\n",
      "\n",
      "          -  second primary cancer or recurrent disease;\n",
      "\n",
      "          -  patients receiving brachytherapy only\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  ASA 1 - 2.\n",
      "\n",
      "          -  Anatomic volunteers or patients scheduled for hand surgery\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Nerulogic disease or sequela\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Diagnosis of newly diagnosed lymphoblastic lymphoma (patients must have <25% tumor\n",
      "             cells in bone marrow by morphology)\n",
      "\n",
      "          2. Age ≤ 21 years\n",
      "\n",
      "          3. Limited prior therapy, including systemic glucocorticoids for 1 week or less, 1 dose\n",
      "             of vincristine, emergency radiation therapy to the mediastinum, and 1 dose of IT\n",
      "             chemotherapy. Other circumstances must be cleared by PI or co-PI.\n",
      "\n",
      "          4. Written, informed consent and assent following guidelines of the Institutional Review\n",
      "             Board, National Cancer Institute (NCI), Food and Drug Administration (FDA), and Office\n",
      "             of Human Research Protections (OHRP).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Participants with prior therapy, other than therapy specified in 3 above.\n",
      "\n",
      "          2. Participants who are pregnant or lactating.\n",
      "\n",
      "          3. Inability or unwillingness of research participant or legal guardian/representative to\n",
      "             give written informed consent.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Advanced renal cell carcinoma. Advanced disease is defined as unresectable, locally\n",
      "             recurrent disease or metastatic disease. This must by confirmed by MSKCC pathology\n",
      "             review with the following requirements:\n",
      "\n",
      "          -  Phase 1b: Any histologic subtype of RCC.\n",
      "\n",
      "          -  Phase 2: clear cell type RCC or predominant clear cell component.\n",
      "\n",
      "        Patients will be screened for prior systemic therapies:\n",
      "\n",
      "          -  Phase 1b: Any prior therapy.\n",
      "\n",
      "          -  Phase 2: Progression of disease on at least one prior treatment with an mTOR inhibitor\n",
      "             (such as everolimus, temsirolimus, ridaforolimus). Other prior systemic therapies\n",
      "             including VEGF directed therapy (e.g. sunitinib, sorafenib, bevacizumab) and\n",
      "             immunotherapy (e.g. IL-2, interferon-α) are also permitted. Evidence of\n",
      "             unidimensionally measurable disease per RECIST 1.1 (Eisenhauer, Therasse et al. 2009).\n",
      "\n",
      "          -  Resolution of all acute toxic effects of prior systemic treatments, radiotherapy or\n",
      "             surgical procedures to NCI CTCAE Version 4.0 grade ≤1.\n",
      "\n",
      "          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, which\n",
      "             is not declining during the last 2 weeks.\n",
      "\n",
      "          -  18 years of age or older.\n",
      "\n",
      "        Adequate organ function as defined by the following criteria:\n",
      "\n",
      "          -  Absolute neutrophil count (ANC) ≥1,000/μL\n",
      "\n",
      "          -  Platelets ≥100,000/μL\n",
      "\n",
      "          -  Hemoglobin ≥9.0 g/dL\n",
      "\n",
      "          -  Serum calcium ≤12.0 mg/dL\n",
      "\n",
      "          -  Serum creatinine ≤1.5 x upper limit of normal (ULN); if this is exceeded, estimated\n",
      "             creatinine clearance must be ≥ 30 ml/min\n",
      "\n",
      "          -  Total serum bilirubin ≤ 1.5 x ULN (in patients with known Gilbert Syndrome, a total\n",
      "             bilirubin of ≤ 3 x ULN, with direct bilirubin ≤ 1.5 x ULN)\n",
      "\n",
      "          -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT)\n",
      "\n",
      "             ≤3 x ULN (≤5 x ULN in the setting of hepatic metastases)\n",
      "\n",
      "          -  INR ≤ 2. (Anticoagulation with warfarin is contraindicated)\n",
      "\n",
      "          -  Fasting plasma glucose (FPG) ≤ 140mg/dL\n",
      "\n",
      "          -  HgbA1c ≤ 8%\n",
      "\n",
      "          -  Fasting serum cholesterol ≤300 mg/dL, fasting triglycerides ≤ 2.5 x ULN. NOTE: In case\n",
      "             one or both of these thresholds are exceeded, the patient can only be included after\n",
      "             initiation of appropriate lipid lowering medication. Signed and dated informed consent\n",
      "             document indicating that the subject (or legally acceptable representative) has been\n",
      "             informed of all pertinent aspects of the trial prior to undergoing study screening\n",
      "             procedures.\n",
      "\n",
      "          -  Subject's willingness and ability to comply with scheduled visits, treatment plans,\n",
      "             laboratory tests, and other study procedures.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have received prior treatment with a P13K inhibitor (Phase 2 portion\n",
      "             only).\n",
      "\n",
      "          -  Patients within 28 days post major surgery (e.g., intra-thoracic, intra-abdominal or\n",
      "             intra-pelvic) or significant traumatic injury.\n",
      "\n",
      "          -  Patients who had radiation therapy within 28 days prior to start of study treatment\n",
      "             (palliative radiotherapy to bone lesions allowed if completed 2 weeks prior to study\n",
      "             treatment start).\n",
      "\n",
      "          -  Patients who have received chemotherapy, immunotherapy or other investigational agents\n",
      "             ≤ 2 weeks prior to study treatment start.\n",
      "\n",
      "        Patients currently receiving medications known to be inducers or moderate / strong\n",
      "        inhibitors of CYP3A4 (see table 9.2 for a list) Patients must discontinue such medications\n",
      "        ≥ 7 days prior to initiation of study treatment.\n",
      "\n",
      "          -  Patients currently receiving medications with a significant risk to induce Torsades de\n",
      "             Pointes\n",
      "\n",
      "          -  Patients who are currently receiving treatment with warfarin sodium (Coumadin®). If\n",
      "             treatment is discontinued or switched to an alternate anticoagulant prior to\n",
      "             enrollment, INR within ≤48h prior to study initiation has to return to ≤ 2 x ULN.\n",
      "\n",
      "          -  Patients receiving chronic treatment with systemic corticosteroids or other\n",
      "             immunosuppressive agents (inhaled or topical steroids are allowed)\n",
      "\n",
      "          -  Patients with evidence or history of central nervous system (CNS) metastases or spinal\n",
      "             cord compression, unless prior treatment with surgery or radiotherapy AND no\n",
      "             progression of CNS disease within 6 months prior to enrollment. Patients must not be\n",
      "             receiving chronic corticosteroid therapy for CNS metastases.\n",
      "\n",
      "          -  Patients who have a history of severe medical conditions or other conditions that\n",
      "             could affect their participation in the study such as:\n",
      "\n",
      "          -  symptomatic intrinsic lung disease requiring oxygen supplementation at baseline\n",
      "\n",
      "          -  uncontrolled hypertension (i.e., SBP>180 mmHg or DBP >100mmHg)\n",
      "\n",
      "          -  any active (acute or chronic) or uncontrolled infection/disorders that impair the\n",
      "             ability to evaluate the patient or for the patient to complete the study\n",
      "\n",
      "          -  liver disease such as cirrhosis or decompensated liver disease.\n",
      "\n",
      "          -  Impairment of gastrointestinal function that may impair absorption of BEZ235 (e.g.\n",
      "             ulcerative diseases, uncontrolled nausea/vomiting; diarrhea ≥ grade 2; malabsorption\n",
      "             syndromes after prior small-bowel resection)\n",
      "\n",
      "          -  Immunocompromised patients and/or history of HIV seropositivity\n",
      "\n",
      "        Patients with prior or current cardiac problems including:\n",
      "\n",
      "          -  History of unstable angina pectoris (at any time), symptomatic congestive heart\n",
      "             failure (NYHA III, IV) (at any time), serious uncontrolled cardiac arrhythmia (at any\n",
      "             time), myocardial infarction or cerebrovascular accidents ≤ 6 months prior to first\n",
      "             study treatment or history of left ventricular dysfunction\n",
      "\n",
      "          -  reduced left ventricular ejection fraction (LVEF) of <50% on screening with\n",
      "             echocardiogram or multiple gates acquisition (MUGA) scan\n",
      "\n",
      "          -  severe valvulopathies with documented compromise in cardiac function\n",
      "\n",
      "          -  Any of the following on screening ECG:\n",
      "\n",
      "          -  QTc interval > 480 msec (or family history of congenital QTc prolongation)\n",
      "\n",
      "          -  Right bundle branch block + left anterior hemiblock (bifascicular block)\n",
      "\n",
      "          -  Complete left bundle branch block\n",
      "\n",
      "          -  Any conduction abnormality requiring pacemaker\n",
      "\n",
      "          -  Symptomatic sinus bradycardia\n",
      "\n",
      "          -  Any ventricular arrhythmia except for benign premature ventricular contractions\n",
      "\n",
      "          -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with\n",
      "             medication\n",
      "\n",
      "          -  Symptomatic pericarditis\n",
      "\n",
      "          -  Documented cardiomyopathy of any cause\n",
      "\n",
      "          -  Female patients who are pregnant or breast feeding; pregnancy is defined as the state\n",
      "             of a female after conception and until the termination of gestation, confirmed by a\n",
      "             positive serum βhCG laboratory test (> 5 mIU/mL).\n",
      "\n",
      "          -  Patients unwilling or unable to comply with adequate double barrier contraception\n",
      "             throughout the trial and for 12 weeks after the last dose of study drug (by both male\n",
      "             and female patients). This includes the following considerations:\n",
      "\n",
      "          -  Hormonal contraceptives may be affected by cytochrome P450 interactions, and are\n",
      "             therefore considered neither indicated nor effective.\n",
      "\n",
      "          -  Adequate barrier methods of contraception include: diaphragm, condom (by the partner),\n",
      "             intrauterine device (copper), sponge or spermicide.\n",
      "\n",
      "          -  Women are considered post-menopausal and not of child bearing potential if they have\n",
      "             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile\n",
      "             (e.g., age appropriate, history of vasomotor symptoms) or six months of spontaneous\n",
      "             amenorrhea with serum FSH levels > 40 mIU/mL [for US only: and estradiol < 20 pg/mL]\n",
      "             or have had surgical bilateral oophorectomy (with or without hysterectomy) at least\n",
      "             six weeks ago. In the case of oophorectomy alone, only when the reproductive status of\n",
      "             the woman has been confirmed by follow up hormone level assessment is she considered\n",
      "             not of child bearing potential\n",
      "\n",
      "          -  Patients who have a history of another primary malignancy and are off treatment for ≤\n",
      "             3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the\n",
      "             uterine cervix.\n",
      "\n",
      "          -  Patients who have received attenuated live vaccines within one week of study entry.\n",
      "             Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral\n",
      "             polio, BCG, yellow fever, varicella and TY21a typhoid vaccines.\n",
      "\n",
      "          -  Known intolerance to the study drug (or any of the excipients), and/or known\n",
      "             hypersensitivity to PI3K inhibitor (eg. GDC-0980), and/or known hypersensitivity to\n",
      "             rapamycins (eg. Sirolimus, everolimus, temsirolimus) or any of the excipients.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  clinical diagnosis of Major Depressive Disorder\n",
      "\n",
      "          -  Must be able to swallow tablets\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pregnant\n",
      "\n",
      "          -  breastfeeding\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects must be healthy and willing to complete the study procedures.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects must not have any chronic pain conditions or take any pain medications on a\n",
      "             regular basis. Must not have any chronic wounds. Must not have any medical conditions\n",
      "             that interfere with pain sensation. Must not have an allergy to skin adhesives.\n",
      "             Patients must not be taking any immunosuppressive medications. Patients must not have\n",
      "             any chronic infections.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Who had fever (>38.0ºC)\n",
      "\n",
      "          -  At least two of the following symptoms: chills, headache, myalgia, fatigue, nasal\n",
      "             symptoms, sore throat, cough\n",
      "\n",
      "          -  Started therapy within 48 hours of onset of influenza-like illness\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Respiratory diseases, such as asthma or COPD\n",
      "\n",
      "          -  Woman with a positive urine pregnancy test\n",
      "\n",
      "          -  Woman without contraception during the study\n",
      "\n",
      "          -  Allergic to zanamivir, Paracetamol or lactose\n",
      "\n",
      "          -  WBC ≥ 10.5×109/L; neutrophil percentage ≥ 80%\n",
      "\n",
      "          -  Hepatic function impairment: AST ≥ 2×ULN, ALT ≥ 2×ULN\n",
      "\n",
      "          -  Renal function impairment: Cr > 221μmol/L\n",
      "\n",
      "          -  Influenza vaccination in the 12 months prior the beginning of the study\n",
      "\n",
      "          -  History of tumor, psychiatric disorders, epilepsy or drug abuse\n",
      "\n",
      "          -  Patients receiving corticosteroids, immunosuppressants\n",
      "\n",
      "          -  HIV positive\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of CLL as per National Cancer Institute Working Group Guidelines\n",
      "\n",
      "          -  Patients undergoing routine blood draws as part of their ongoing follow up for CLL\n",
      "\n",
      "          -  18 years or older\n",
      "\n",
      "          -  Ability to provide consent in English\n",
      "\n",
      "          -  Patient must have measurable disease as defined by an absolute lymphocyte count\n",
      "             greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL\n",
      "             involvement.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have received cytotoxic drug, oral or intravenous steroid or targeted\n",
      "             antibody therapy for their CLL,\n",
      "\n",
      "          -  other hematologic malignancy or other disease process within the past 6 months are\n",
      "             excluded.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Health service staff and employee in the Region of Southern Denmark.\n",
      "\n",
      "          -  Tendency to depressive symptoms in the winter season SPAQ>7.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  clinical diagnosis sarcoidoses\n",
      "\n",
      "          -  tuberculosis\n",
      "\n",
      "          -  bipolar affective disorder\n",
      "\n",
      "          -  schizophrenia\n",
      "\n",
      "          -  hypercalcemia\n",
      "\n",
      "          -  hyperphosphatemia\n",
      "\n",
      "          -  pregnancy\n",
      "\n",
      "          -  hyperparathyroidism\n",
      "\n",
      "          -  reduced kidney function\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 18 years or older\n",
      "\n",
      "          -  Pregnant\n",
      "\n",
      "          -  Less than 16 weeks gestation\n",
      "\n",
      "          -  Body mass index 25 or greater at first prenatal visit\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of spontaneous preterm delivery between 20-32 weeks gestation\n",
      "\n",
      "          -  Medical contraindication to exercise or walking during pregnancy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  either gender and 18-65 years old;\n",
      "\n",
      "          -  acute or subacute traumatic spinal cord injury (defined as SCI resulting from an\n",
      "             exteneral non-penetrating cause that occurred within 4 weeks);\n",
      "\n",
      "          -  neurological status of ASIA A;\n",
      "\n",
      "          -  neurological level between C5-T11;\n",
      "\n",
      "          -  MRI shows injury site is within 3 vertebral level and necrotic focus, if exist, is\n",
      "             less than 1/3 of the spinal cord diameter;\n",
      "\n",
      "          -  professional judgment determinate that subjects need a spinal decompression surgery;\n",
      "\n",
      "          -  subjects able to complete neurological examination;\n",
      "\n",
      "          -  subjects have voluntarily signed and dated an informed consent form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  penetration SCI such as gun-shoot, knife-cutting or SCI caused by non-traumatic\n",
      "             conditions;\n",
      "\n",
      "          -  spinal cord lesion exceeds three segments or necrotic focus with diameter larger than\n",
      "             1/3 of the spinal cord;\n",
      "\n",
      "          -  severe complications;\n",
      "\n",
      "          -  significant medical diseases or infection;\n",
      "\n",
      "          -  pregnant or lactating woman, or female of childbearing potential and who is unwilling\n",
      "             to use an effective contraceptive method while enrolled in the study;\n",
      "\n",
      "          -  unavailability of suitable umbilical cord blood cells;\n",
      "\n",
      "          -  contraindication of lithium carbonate and/or spinal decompression surgery\n",
      "\n",
      "          -  subject is currently participating in another study or has been taking any\n",
      "             investigational drug within the last 4 weeks prior to screening;\n",
      "\n",
      "          -  investigator suggests that the subject would not be suitable to participate this study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Written Informed Consent Form signed voluntarily before the first study-related\n",
      "             activity.\n",
      "\n",
      "          2. Aged between 18 and 70 years, inclusive.\n",
      "\n",
      "          3. Subjects with a history of the cardinal symptoms of GERD (both heartburn and\n",
      "             regurgitation) prior to PPI therapy.\n",
      "\n",
      "          4. Subjects with symptoms of GERD for at least 6 months prior to the Screening Visit.\n",
      "\n",
      "          5. Subjects who have persistent symptoms of regurgitation for 3 or more days over the\n",
      "             past week with or without heartburn while on PPI.\n",
      "\n",
      "          6. Subjects have at least some improvement to the symptom of heartburn while on PPI\n",
      "             therapy.\n",
      "\n",
      "          7. Subjects on PPI therapy for at least 8 weeks prior to the Screening Visit of which the\n",
      "             last 4 weeks are on a stable labeled dose for any GERD indication according to the\n",
      "             country label, where a change of PPI therapy would not impact the symptoms\n",
      "             (twice-daily dosing of PPI is not allowed in the last 4 weeks)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Subjects who show no response to heartburn while on PPI therapy.\n",
      "\n",
      "          2. Subjects with dyspepsia symptoms that are more predominant than their GERD symptoms\n",
      "             (heartburn and/or regurgitation).\n",
      "\n",
      "          3. Subjects with prior endoscopic anti-reflux procedure or major GI surgery or subjects\n",
      "             with major GI disorders.\n",
      "\n",
      "          4. Presence of severe and clinically uncontrolled cardiovascular, liver, lung or\n",
      "             neurologic disease, cancer or AIDS.\n",
      "\n",
      "          5. Alarm symptoms suggestive of malignancies or organic disease.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  clinical diagnosis of inflammatory rheumatic diseases\n",
      "\n",
      "          -  patients candidates to anti-TNF treatment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female subjects over eighteen years old or less than 65 years old.\n",
      "\n",
      "          -  Able to understand and provide informed consent or have a legally authorized\n",
      "             representative capable of providing consent.\n",
      "\n",
      "          -  Clinical diagnosis of primary anal fistula categorized as trans-sphincteric fistula\n",
      "             tract determined to be of cryptoglandular origin (primary or recurrent).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Presence of horseshoe fistula.\n",
      "\n",
      "          -  History of immunosuppression therapy/treatment within previous six months.\n",
      "\n",
      "          -  Fistulas with active abscess, infection, or acute inflammation\n",
      "\n",
      "          -  History of Choron's Disease\n",
      "\n",
      "          -  History of Ulcerative Colitis\n",
      "\n",
      "          -  History of HIV or other immune system disease\n",
      "\n",
      "          -  History of collagen disease\n",
      "\n",
      "          -  History of radiation to the anorectal region\n",
      "\n",
      "          -  Allergies to pig tissue or pig products\n",
      "\n",
      "          -  Religious or cultural objection to the use of pig tissue\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria for clusters:\n",
      "\n",
      "          -  University Medical Hospital in the Netherlands\n",
      "\n",
      "        Exclusion Criteria for clusters:\n",
      "\n",
      "          -  Absence of consent to be randomized\n",
      "\n",
      "        Inclusion Criteria for participants:\n",
      "\n",
      "          -  Health care staff at University Medical Hospitals\n",
      "\n",
      "          -  Patients cared for during the study influenza epidemics of selected divisions\n",
      "\n",
      "        Exclusion Criteria for participants:\n",
      "\n",
      "          -  None\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Nonsmoker\n",
      "\n",
      "          -  Body mass index: 20-26 kg/m²\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Intake of pharmaceuticals\n",
      "\n",
      "          -  Allergy against canola protein or soy protein\n",
      "\n",
      "          -  Kidney disease\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Eligible eyes will have active PDR with high risk characteristics (HRC) as defined by\n",
      "             the DRS. All eyes must meet at least one or both of the following criteria:\n",
      "\n",
      "               -  Mild neovascularization of the disc (NVD) of at least 1/4 to 1/3 disc area as\n",
      "                  shown in standard photograph 10A of the DRS.\n",
      "\n",
      "               -  Moderate neovascularization of the retina elsewhere (NVE) of at least 1/2 disc\n",
      "                  area as shown in standard photograph 7 of the DRS.\n",
      "\n",
      "          2. ETDRS visual acuity score greater than or equal to 24 letters (approximately 20/320)\n",
      "             and less than or equal to 85 letters (approximately 20/20) by the ETDRS visual acuity\n",
      "             protocol at the screening visit.\n",
      "\n",
      "          3. Eyes with mild pre-retinal hemorrhage (PRH) or mild vitreous hemorrhage (VH) that does\n",
      "             not interfere with clear visualization of the macula and optic disc are eligible for\n",
      "             this study.\n",
      "\n",
      "          4. Evaluating physician believes that PRP can be safely withheld for 3 weeks.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Presence of moderate or dense PRH or VH that prevents clear visualization of the\n",
      "             macula and/or optic disc.\n",
      "\n",
      "          2. Presence of either:\n",
      "\n",
      "               -  significant epiretinal membranes involving the macula, OR\n",
      "\n",
      "               -  proliferative diabetic membranes along the major retinal arcades that are\n",
      "                  extensive enough to cause either:\n",
      "\n",
      "                    -  significant vitreomacular traction, OR\n",
      "\n",
      "                    -  significant impairment in visual acuity.\n",
      "\n",
      "          3. Presence of any tractional retinal detachment.\n",
      "\n",
      "          4. Severe ischemia involving the foveal avascular zone as determined by fluorescein\n",
      "             angiography performed at the initial screening visit.\n",
      "\n",
      "          5. Significant media opacity (due to cornea, anterior chamber, or lens) precluding clear\n",
      "             visualization of the macula or optic disc.\n",
      "\n",
      "          6. Presence of neovascular glaucoma with or without hyphema.\n",
      "\n",
      "          7. Previous treatment with intravitreal steroid injections in the study eye within 6\n",
      "             months of baseline.\n",
      "\n",
      "          8. Previous treatment with peribulbar steroid injections in the study eye within 90 days\n",
      "             of baseline\n",
      "\n",
      "          9. Previous PRP laser treatment in the study eye within 90 days of baseline visit.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria: Healthy adults\n",
      "\n",
      "          -  Male or female\n",
      "\n",
      "          -  Non-smoker\n",
      "\n",
      "          -  18-55 years old\n",
      "\n",
      "          -  BMI > 18.5 and < 30.0\n",
      "\n",
      "          -  With medically acceptable form of contraception (female only).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any clinically significant abnormality or vital sign abnormalities\n",
      "\n",
      "          -  Any abnormal laboratory test\n",
      "\n",
      "          -  History of alcohol or drug abuse or dependence within 1 year and/or positive drug,\n",
      "             cotinine, or alcohol tests\n",
      "\n",
      "          -  Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce\n",
      "             or inhibit hepatic drug metabolism prior to study medication\n",
      "\n",
      "          -  Positive pregnancy test, breastfeeding or lactating\n",
      "\n",
      "          -  Use of medication other than hormonal contraceptives or topical products, including\n",
      "             OTC, natural health products, MAO inhibitors\n",
      "\n",
      "          -  Participation in an investigational study within 30 days prior to dosing\n",
      "\n",
      "          -  Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within\n",
      "             30 days), or of > 499 mL (within 56 days) prior to dosing.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Understand and voluntarily sign an informed consent form\n",
      "\n",
      "          -  Able to adhere to the study visit schedule and other protocol requirements\n",
      "\n",
      "          -  Patients must have histologically or cytologically confirmed CD5+/CD20+ B-Cell chronic\n",
      "             lymphocytic leukemia or small lymphocytic lymphoma. The diagnosis of CLL is based upon\n",
      "             the National Comprehensive Cancer Network (NCCN) guidelines. Any outside pathology\n",
      "             slides used as inclusion criteria for the patient will be reviewed at this institution\n",
      "             to confirm the diagnosis. The patient must meet all of the following CLL criteria to\n",
      "             participate in this study: absolute lymphocyte count > 5000/μL; CD20+ and CD5+; Bone\n",
      "             marrow (BM) lymphocytes ≥ 30%; Or previous confirmed diagnosis of CLL/SLL with less\n",
      "             than 5000/μl or less than 30% lymphocytes in BM.\n",
      "\n",
      "          -  Patients are eligible if they have relapsed or refractory CLL/SLL.\n",
      "\n",
      "          -  All previous cancer therapy, including radiation, hormonal therapy and surgery, must\n",
      "             have been discontinued at least 4 weeks prior to treatment in this study.\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 at study entry\n",
      "\n",
      "          -  Laboratory test results within these ranges: Absolute neutrophil count ≥ 1000/mm³,\n",
      "             Platelet count ≥50,000 /mm³, Renal function assessed by calculated creatinine\n",
      "             clearance ≥ 30ml/min by Cockcroft-Gault formula, Total bilirubin ≤ 1.5 x upper limit\n",
      "             of normal (ULN), aspartic transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT)\n",
      "             ≤ 2.5 x ULN, Alkaline phosphatase <2.5 x ULN\n",
      "\n",
      "          -  Disease free of prior malignancies for ≥ 5 years with exception of currently treated\n",
      "             basal cell, squamous cell carcinoma of the skin, or carcinoma \"in situ\" of the cervix\n",
      "             or breast\n",
      "\n",
      "          -  All study participants must be registered into the mandatory RevAssist® program, and\n",
      "             be willing and able to comply with the requirements of RevAssist®.\n",
      "\n",
      "          -  Females of childbearing potential (FCBP)† must have a negative serum or urine\n",
      "             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again\n",
      "             within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be\n",
      "             filled within 7 days) and must either commit to continued abstinence from heterosexual\n",
      "             intercourse or begin TWO acceptable methods of birth control, one highly effective\n",
      "             method and one additional effective method AT THE SAME TIME, at least 28 days before\n",
      "             she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men\n",
      "             must agree to use a latex condom during sexual contact with a FCBP even if they have\n",
      "             had a successful vasectomy.\n",
      "\n",
      "          -  Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients\n",
      "             intolerant to acetylsalicylic acid (ASA) may use warfarin or low molecular weight\n",
      "             heparin)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that\n",
      "             would prevent the patient from signing the informed consent form\n",
      "\n",
      "          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed\n",
      "             while taking lenalidomide)\n",
      "\n",
      "          -  Any condition, including the presence of laboratory abnormalities, which places the\n",
      "             patient at unacceptable risk if he/she were to participate in the study or confounds\n",
      "             the ability to interpret data from the study\n",
      "\n",
      "          -  Evidence of laboratory Tumor Lysis Syndrome (TLS) by Cairo-Bishop Definition. Patients\n",
      "             may be enrolled upon correction of electrolyte abnormalities.\n",
      "\n",
      "          -  Use of any other experimental drug or therapy within 28 days of baseline\n",
      "\n",
      "          -  Known hypersensitivity to thalidomide\n",
      "\n",
      "          -  The development of erythema nodosum if characterized by a desquamating rash while\n",
      "             taking thalidomide or similar drugs\n",
      "\n",
      "          -  Any prior use of lenalidomide\n",
      "\n",
      "          -  Concurrent use of other anti-cancer agents or treatments\n",
      "\n",
      "          -  Known seropositive for or active viral infection with human immunodeficiency virus\n",
      "             (HIV)\n",
      "\n",
      "          -  Positive serology for hepatitis B (HB) defined as a positive test for HBsAg. In\n",
      "             addition, if negative for HBsAg but HBcAb positive and HBsAb negative, a HB DNA test\n",
      "             will be performed and if positive the patient will be excluded. Note: If HBcAb\n",
      "             positive and HBsAb positive, which is indicative of a past infection, the patient can\n",
      "             be included. Patients who are seropositive because of hepatitis B virus vaccine are\n",
      "             eligible.\n",
      "\n",
      "          -  Positive serology for hepatitis C (HC) defined as a positive test for hepatitis C\n",
      "             antibodies (HCAb), in which case reflexively perform a HC recombinant immunoblot assay\n",
      "             (RIBA) on the same sample to confirm the result\n",
      "\n",
      "          -  Patients who have current active hepatic or biliary disease (with exception of\n",
      "             patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable\n",
      "             chronic liver disease per investigator assessment) are ineligible.\n",
      "\n",
      "          -  Chronic or current infectious disease requiring systemic antibiotics, antifungal, or\n",
      "             antiviral treatment such as, but not limited to, chronic renal infection, chronic\n",
      "             chest infection with bronchiectasis, tuberculosis and active Hepatitis C\n",
      "\n",
      "          -  History of significant cerebrovascular disease in the past 6 months or ongoing event\n",
      "             with active symptoms or sequelae\n",
      "\n",
      "          -  Clinically significant cardiac disease including unstable angina, acute myocardial\n",
      "             infarction within 6 months prior to randomization, congestive heart failure [New York\n",
      "             Heart Association (NYHA) III-IV], and arrhythmia unless controlled by therapy, with\n",
      "             the exception of extra systoles or minor conduction abnormalities\n",
      "\n",
      "          -  Significant concurrent, uncontrolled medical condition including, but not limited to,\n",
      "             renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or\n",
      "             psychiatric disease which in the opinion of the investigator may represent a risk for\n",
      "             the patient\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult (> 19 years)\n",
      "\n",
      "          -  Admitted to RCH neuroscience unit\n",
      "\n",
      "          -  Primary diagnosis is neurological (brain injury/insult)\n",
      "\n",
      "          -  Non-intubated\n",
      "\n",
      "          -  Dependent for oral care and unable to direct their own oral care\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  < 19 years\n",
      "\n",
      "          -  Off service patients\n",
      "\n",
      "          -  Intubated, on bilevel positive airway pressure or continuous positive airway pressure\n",
      "             devices, (respiratory assistive devices)\n",
      "\n",
      "          -  Palliative\n",
      "\n",
      "          -  Capable of directing their own oral care\n",
      "\n",
      "          -  Unable to receive oral care due to: oral tubes, nasal/oral airways, wired jaws, or\n",
      "             behaviours such as resistiveness, combativeness, non-compliance, etc.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Signed informed consent\n",
      "\n",
      "          -  Stenosis (> 75%) or occlusion of the superficial femoral artery (lesion up to 3 cm\n",
      "             distal to Hunter's canal and 4 cm proximal to the patella)\n",
      "\n",
      "          -  TASC II (2007)type A, B or C lesions\n",
      "\n",
      "          -  Target vessel diameter between 4.5 and 7 mm\n",
      "\n",
      "          -  Debilitating claudication or critical limb ischemia (Rutherford 2 to 5)\n",
      "\n",
      "          -  At least 1 outflow vessel down to the ankle\n",
      "\n",
      "          -  Patient is at least 18 years old\n",
      "\n",
      "          -  Life expectancy > 2 years\n",
      "\n",
      "          -  Patient is compliant with the requested follow-up visits\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  No informed consent\n",
      "\n",
      "          -  Rutherford 6\n",
      "\n",
      "          -  TASC II type D lesions\n",
      "\n",
      "          -  Patient is not 18 years old\n",
      "\n",
      "          -  Patient is pregnant\n",
      "\n",
      "          -  Acute ischemia\n",
      "\n",
      "          -  Patient is not compliant with the requested follow-up visits\n",
      "\n",
      "          -  Unable to cross target lesion with guidewire\n",
      "\n",
      "          -  Patient is allergic to nickel-titanium\n",
      "\n",
      "          -  Presence of an aneurysm in the SFA\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  pain, paresthesia or numbness in the upper-limb with cervical or periscapular pain for\n",
      "             less than 3 months\n",
      "\n",
      "          -  at least one neurological sign (dermatomes, myotomes or reflexes) of an inferior\n",
      "             motoneuron lesion to the upper-limb\n",
      "\n",
      "          -  positive responses to at least 3 of the 4 following clinical tests: Spurling Test,\n",
      "             Upper Limb Tension Test, Cervical Distraction Test, and less than 60o of cervical\n",
      "             rotation on the impaired side\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  prior surgery to the cervicothoracic spine\n",
      "\n",
      "          -  bilateral upper-limb symptoms\n",
      "\n",
      "          -  signs of superior motoneuron impairments (bilateral paresthesia, hyperreflexia,\n",
      "             spasticity)\n",
      "\n",
      "          -  cervical spine infiltration in the previous four weeks\n",
      "\n",
      "          -  current use of steroidal anti-inflammatory drugs\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  subfoveal or juxtafoveal CNV owing to AMD, defined by fluorescein angiography (FA)\n",
      "\n",
      "          -  presence on SD-OCT of subretinal or intraretinal fluid associated or not with macular\n",
      "             edema\n",
      "\n",
      "          -  Best corrected visual acuity (BCVA) in the study eye between 20/20 and 20/125,\n",
      "             inclusive\n",
      "\n",
      "          -  total area of the lesion (including blood, neovascularization and scar/atrophy) of ≤8\n",
      "             disc areas, of which at least 50% must be active choroidal neovascularization (CNV)\n",
      "             (defined as the neovascular component of the lesion as defined by FA\n",
      "\n",
      "          -  all angiographic subtypes [predominantly classic, minimally classic and occult] were\n",
      "             eligible)\n",
      "\n",
      "          -  clear ocular media and adequate pupillary dilatation to allow collection of fundus\n",
      "             photographs and FA of a sufficient quality to be analyzed\n",
      "\n",
      "          -  intraocular pressure of 21 mmHg or less\n",
      "\n",
      "          -  and no previous treatment for AMD\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  presence of scarring or atrophy >75% of the total lesion size (patients with subfoveal\n",
      "             scar or atrophy were excluded)\n",
      "\n",
      "          -  subretinal haemorrhage >75% of the total lesion size; presence of serous retinal\n",
      "             pigment epithelial detachments >5 disc areas\n",
      "\n",
      "          -  presence of intraocular inflammation (≥ trace cell or flare), epiretinal membrane,\n",
      "             macular hole or vitreous haemorrhage\n",
      "\n",
      "          -  history of idiopathic or autoimmune-associated uveitis in either eye\n",
      "\n",
      "          -  significant media opacities, including cataract, which might interfere with VA,\n",
      "             assessment of toxicity or fundus photography in the study eye\n",
      "\n",
      "          -  presence of other causes of CNV, including pathological myopia (spherical equivalent\n",
      "             of -3 diopters or more, or axial length of 25 mm or more, or fundus findings\n",
      "             suggestive of pathologic myopia), ocular histoplasmosis syndrome, angioid streaks,\n",
      "             choroidal rupture and multifocal choroiditis\n",
      "\n",
      "          -  any retinal treatment (aside from antioxidants), including (but not limited to)\n",
      "             intravitreal injections, photodynamic therapy with verteporfin, laser photocoagulation\n",
      "             or surgery\n",
      "\n",
      "          -  history of rhegmatogenous retinal detachment, pars plana vitrectomy or corneal\n",
      "             transplant\n",
      "\n",
      "          -  and previous radiation in the region of the study eye.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Children between 1 month and 17 years of age who undergo gastrostomy tube placement by\n",
      "             a member of the pediatric surgery faculty at Children's Memorial Hospital will be\n",
      "             eligible for inclusion in this study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Children undergoing gastrostomy tube placement by gastroenterology or interventional\n",
      "             radiology at Children's Memorial Hospital.\n",
      "\n",
      "          -  Mother or caregiver of the patient is currently pregnant, breastfeeding and/or\n",
      "             planning on getting pregnant within the next 60 days (silver HD has not been studied\n",
      "             in pregnant or breastfeeding women)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Healthy post menopausal women between the ages of 40-85+yrs who complain of vaginal dryness\n",
      "        with at least three urogenital symptoms from the following: vaginal dryness, vaginal\n",
      "        irritation, vaginal soreness, dysuria, dyspareunia, bleeding with coitus & one of these\n",
      "        symptoms must be moderate to severe as determined by patient, Moderate: discomforting and\n",
      "        aware of it with activities. Severe: discomforting enough to interfere with activities\n",
      "        Activities include sitting, walking, running, urinating, as well as sexual activity\n",
      "\n",
      "          -  BMI 18-34 (inclusive).\n",
      "\n",
      "          -  Patients having a LMP at least one year ago, either natural or surgical.\n",
      "\n",
      "          -  Patients with a normal mammogram within 9 months prior to enrollment.\n",
      "\n",
      "          -  Patients able to adhere to the visit schedule and protocol requirements and be\n",
      "             available to complete the study.\n",
      "\n",
      "          -  Patients who provide written informed consent to participate in the study.\n",
      "\n",
      "          -  FSH > 40 mIU/m.\n",
      "\n",
      "          -  Estradiol < 20 pg/ml.\n",
      "\n",
      "          -  Vaginal PH > 5.\n",
      "\n",
      "          -  < 5% superficial cells as assessed by vaginal cytology.\n",
      "\n",
      "          -  Normal pelvic and breast exams by investigator.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Patients using HRT (cannot have used for past 3 months).\n",
      "\n",
      "          -  Patients consuming over the last three months high soy diet or any foods or other\n",
      "             compounds that are sold as remedies for the post menopausal symptoms.\n",
      "\n",
      "          -  Any history of significant cancer or pre-cancer, neurological, renal, cardiovascular,\n",
      "             respiratory (e.g. asthma, COPD), hypercoagulability, hematopoietic disease, immune\n",
      "             deficiency or any other clinically significant medical disorder, which in the\n",
      "             investigator's judgment contraindicate administration of the study medications.\n",
      "\n",
      "          -  Patients with any clinically significant abnormality upon examination at screening\n",
      "             visit.\n",
      "\n",
      "          -  Patients with a known history of drug or alcohol abuse.\n",
      "\n",
      "          -  Known hypersensitivity and/or allergy to soy or flax.\n",
      "\n",
      "          -  Participation in another clinical trial within the past 30 days.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. can stand for 5 minutes without support\n",
      "\n",
      "          2. with normal or corrected to normal vision\n",
      "\n",
      "          3. age between 20-35 years old for young adults group, and 65-80 years old for older\n",
      "             adults group\n",
      "\n",
      "          4. had fall history in the past 3 years for the older adults group.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. pregnant women\n",
      "\n",
      "          2. with cancer diagnosis\n",
      "\n",
      "          3. with sensory-motor deficits\n",
      "\n",
      "          4. with osteoporosis for older adults group (T-score below -2.5)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  women with vaginal wall prolapse grade 2 and more\n",
      "\n",
      "          -  no contraindication to vaginal wall repair or tvt-o\n",
      "\n",
      "          -  No stress incontinence\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  urinary tract malformations\n",
      "\n",
      "          -  past urinary stress incontinence surgical procedure\n",
      "\n",
      "          -  UDI - question 17 or 18 - positive answer\n",
      "\n",
      "          -  Occult urinary stress incontinence\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically diagnosed with squamous cell carcinomas of the larynx (no glottis stage\n",
      "             I+II), pharynx, oral cavity or in lymph nodes from an unknown primary tumour (stage\n",
      "             I-IV and tumour node metastasis (TNM) classification, UICC, Geneva, 1987)\n",
      "\n",
      "          -  Terminated curative radiotherapy treatment with/without chemotherapy;\n",
      "\n",
      "          -  No metastases\n",
      "\n",
      "          -  Complete tumour remission\n",
      "\n",
      "          -  No current or previous malignancies that could prevent participation and training\n",
      "\n",
      "          -  No excessive alcohol intake (men > 21 and women > 14 units/wk)\n",
      "\n",
      "          -  No recent systematic resistance training or creatine ingestion (within 2 months)\n",
      "\n",
      "          -  If woman, not pregnant\n",
      "\n",
      "          -  WHO performance status of 0-1\n",
      "\n",
      "          -  No psychological, social or geographical conditions that could disturb participation\n",
      "\n",
      "          -  Written consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  liver metastasis\n",
      "\n",
      "          -  solid tumor\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  poor performance\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18-65 years of age.\n",
      "\n",
      "          -  Newly suicide attempt within one month of the inclusion date.\n",
      "\n",
      "          -  A minimum of two characteristics in the DSM-IV Borderline Personality Disorder (BPD)\n",
      "\n",
      "          -  Informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Severe depression.\n",
      "\n",
      "          -  Bipolar disorder.\n",
      "\n",
      "          -  Psychosis within the schizophrenic spectrum.\n",
      "\n",
      "          -  Anorexia Nervosa.\n",
      "\n",
      "          -  Substance abuse.\n",
      "\n",
      "          -  Mental retardation.\n",
      "\n",
      "          -  Dementia.\n",
      "\n",
      "          -  Lack of informed consent\n",
      "      \n",
      "\n",
      "        -  Inclusion Criteria:\n",
      "\n",
      "               -  Patient with a spontaneous flutter or with a flutter recurrence when it was not\n",
      "                  considered appropriate to use a preventive treatment so far. The flutter may have\n",
      "                  been paroxysmal or may still be present.\n",
      "\n",
      "               -  Patient with at least one documented episode of typical flutter defined as\n",
      "                  follows: negative F waves in the inferior territory, positive in V1 and negative\n",
      "                  in V6 lead, F wave pattern with characteristic \"saw tooth\" appearance and finally\n",
      "                  a heart rate comprised between 240 and 320 beats per minute.\n",
      "\n",
      "               -  Patient with effective anticoagulant therapy for at least 3 weeks.\n",
      "\n",
      "               -  Patient with at least one episode of AF (lasting more than 1 minute) documented\n",
      "                  on an ECG or a 24 hour Holter recording\n",
      "\n",
      "               -  Patient who signed an informed consent.\n",
      "\n",
      "               -  Patient with age ≥ 18 yo and ≤ 75 yo\n",
      "\n",
      "          -  Exclusion Criteria:\n",
      "\n",
      "               -  Patients with the following characteristics will be excluded:\n",
      "\n",
      "                    -  Contraindication to right-heart catheterization\n",
      "\n",
      "                    -  Contraindication to an anticoagulant treatment\n",
      "\n",
      "                    -  Patient for which AF is predominant (more recordings of AF than Flutter)\n",
      "\n",
      "                    -  Persistent AF at the time of inclusion visit\n",
      "\n",
      "                    -  History of mitral valve surgery\n",
      "\n",
      "                    -  Known disorders of blood clotting\n",
      "\n",
      "                    -  Cardiothyreosis\n",
      "\n",
      "               -  Life expectancy < 24 months\n",
      "\n",
      "               -  Less than 18 years old and pregnant ladies. As before any ablation, a pregnancy\n",
      "                  test will be done the day before or the day of the procedure\n",
      "\n",
      "               -  Patient less than 18 years old\n",
      "\n",
      "               -  Patient under guardianship\n",
      "\n",
      "               -  Patient deprived of their liberty by a court decision\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with singleton pregnancies at gestational ages 25+0 to 33+6 weeks after an\n",
      "             episode of preterm labor, with cervical length ≤25mm:\n",
      "\n",
      "          -  Patients presenting with signs and symptoms of preterm labor will be admitted and\n",
      "             given the standard treatment for preterm labor, i.e. tocolysis for 48 hours, and\n",
      "             antenatal steroids.\n",
      "\n",
      "          -  Those who will remain undelivered for 48 hours and will be found to have a cervical\n",
      "             length of 25mm or less will be offered entrance into the study.\n",
      "\n",
      "          -  Preterm labor will be defined as at least 4 contractions in 30 minutes with cervical\n",
      "             change assessed by digital cervical examination.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with preterm premature rupture of membranes (PPROM) will be excluded from the\n",
      "             study, due to the possibility of ascending infection, as will those with suspected\n",
      "             chorioamnionitis.\n",
      "\n",
      "          -  We will not include multiple pregnancies.\n",
      "\n",
      "          -  Patients with medical conditions that contraindicate tocolysis, such as non-reassuring\n",
      "             fetal heart tracings, will also be excluded.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        IF PROTOCOL 2546 SERVES AS AN ADJUNCT PROTOCOL, THE PATIENTS ONLY NEEDS TO MEET INCLUSION\n",
      "        CRITERIA 1 THROUGH 5A\n",
      "\n",
      "          -  Availability of human leukocyte antigen (HLA)-identical sibling donor\n",
      "\n",
      "          -  Transplantation with PBSC\n",
      "\n",
      "          -  CSP-based postgrafting immunosuppression\n",
      "\n",
      "          -  Willingness to give informed consent\n",
      "\n",
      "          -  Patient is enrolled on an investigational nonmyeloablative HCT protocol or a\n",
      "             nonmyeloablative treatment plan with postgrafting CSP that does not use acute GVHD as\n",
      "             its primary endpoint (protocol 2546 serves as adjunct protocol); OR\n",
      "\n",
      "          -  Patient is not enrolled on an investigational nonmyeloablative HCT protocol, in which\n",
      "             case protocol 2546 serves as an independent primary treatment protocol and the patient\n",
      "             must meet the following inclusion and exclusion criteria:\n",
      "\n",
      "          -  Patients must have a hematologic malignancy treatable by nonmyeloablative HCT; the\n",
      "             following diseases will be permitted although other diagnoses can be considered if\n",
      "             approved by Patient Care Conference (PCC) and the principal investigator:\n",
      "\n",
      "          -  Aggressive non-Hodgkin lymphomas (NHL) and other histologies such as diffuse large\n",
      "             B-cell NHL - not eligible for autologous HCT, not eligible for high-dose allogeneic\n",
      "             HCT, or after failed autologous HCT\n",
      "\n",
      "          -  Mantle-cell NHL - may be treated in first complete remission (CR); (diagnostic lumbar\n",
      "             puncture [LP] required pre-transplant)\n",
      "\n",
      "          -  Low grade NHL - with < 6 month duration of CR between courses of conventional therapy\n",
      "\n",
      "          -  Chronic lymphocytic leukemia (CLL) - must have either:\n",
      "\n",
      "               -  Failed to meet National Cancer Institute (NCI) Working Group criteria for\n",
      "                  complete or partial response after therapy with a regimen containing fludarabine\n",
      "                  phosphate (FLU) (or another nucleoside analog) or experience disease relapse\n",
      "                  within 12 months after completing therapy with a regimen containing FLU (or\n",
      "                  another nucleoside analog)\n",
      "\n",
      "               -  Failed FLU-cyclophosphamide (CY)-Rituximab (FCR) combination chemotherapy at any\n",
      "                  time point; or\n",
      "\n",
      "               -  Have \"17p deletion\" cytogenetic abnormality; patients should have received\n",
      "                  induction chemotherapy but could be transplanted in 1st CR\n",
      "\n",
      "               -  Patients with a diagnosis of CLL (or small lymphocytic lymphoma) that progresses\n",
      "                  to prolymphocytic leukemia (PLL); or\n",
      "\n",
      "               -  Patients with T-cell CLL or PLL\n",
      "\n",
      "          -  Hodgkin lymphoma - must have received and failed frontline therapy\n",
      "\n",
      "          -  Multiple myeloma - must have received prior chemotherapy; consolidation of\n",
      "             chemotherapy by autografting prior to nonmyeloablative HCT is permitted\n",
      "\n",
      "          -  Acute myeloid leukemia (AML) - must have < 5% marrow blasts at the time of transplant\n",
      "\n",
      "          -  Acute lymphocytic leukemia (ALL) - must have < 5% marrow blasts at the time of\n",
      "             transplant\n",
      "\n",
      "          -  Chronic myeloid leukemia (CML) - Patients will be accepted if they have shown\n",
      "             intolerance to tyrosine kinase inhibitors or are beyond first chronic phase (CP1) and\n",
      "             if they have received previous myelosuppressive chemotherapy or HCT, and have < 5%\n",
      "             marrow blasts at time of transplant\n",
      "\n",
      "          -  Myelodysplasia (MDS)/myeloproliferative syndrome (MPS) - Patients must have < 5%\n",
      "             marrow blasts at time of transplant\n",
      "\n",
      "          -  Waldenstrom's macroglobulinemia - must have failed 2 courses of therapy\n",
      "\n",
      "          -  Patients < 12 years of age must be approved by the principal investigator and by a\n",
      "             relevant patient review committee, such as the Fred Hutchinson Cancer Research Center\n",
      "             (FHCRC) Patient Care Conference (PCC)\n",
      "\n",
      "          -  Patients must have either relapsed after previous high-dose chemotherapy and\n",
      "             autologous or allogeneic HCT, or else be ineligible for such an approach due to age,\n",
      "             failure to mobilize sufficient hematopoietic stem cells, medical comorbidities, or\n",
      "             patient refusal\n",
      "\n",
      "          -  Patients who refuse to be treated on a conventional autologous or allogeneic HCT\n",
      "             protocol\n",
      "\n",
      "          -  DONOR: Age >= 18 years\n",
      "\n",
      "          -  DONOR: HLA genotypically identical sibling\n",
      "\n",
      "          -  DONOR: Willingness to give informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        IF PROTOCOL 2546 SERVES AS AN ADJUNCT PROTOCOL, THE PATIENT ONLY NEEDS TO MEET EXCLUSION\n",
      "        CRITERIA 1 THROUGH 3\n",
      "\n",
      "          -  Myeloablative preparative regimen\n",
      "\n",
      "          -  Participation in an investigational study that has acute GVHD as the primary endpoint\n",
      "\n",
      "          -  The allogeneic PBSC donor has a contraindication to statin treatment\n",
      "\n",
      "          -  Patients eligible for and willing to receive potentially curative high-dose\n",
      "             chemotherapy and autologous HCT\n",
      "\n",
      "          -  Cardiac ejection fraction < 30% on multi gated acquisition scan (MUGA) scan or cardiac\n",
      "             echocardiogram (echo) or active symptomatic coronary artery disease; patients with\n",
      "             cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology\n",
      "             consultation as clinically indicated\n",
      "\n",
      "          -  Corrected diffusion capacity of the lung for carbon monoxide (DLCO) < 40% of\n",
      "             predicted, total lung capacity (TLC) < 30% of predicted, forced expiratory volume in\n",
      "             one second (FEV1) < 30% of predicted, or receiving continuous supplementary oxygen\n",
      "\n",
      "          -  Patients with clinical or laboratory evidence of liver disease should be evaluated in\n",
      "             conjunction with the gastrointestinal (GI) consult service for the cause of the liver\n",
      "             disease, its clinical severity, and the degree of portal hypertension; patients will\n",
      "             be excluded if they are found to have fulminant liver failure, cirrhosis of the liver\n",
      "             with evidence of portal hypertension, bridging fibrosis, alcoholic hepatitis,\n",
      "             esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy,\n",
      "             refractory ascites related to portal hypertension, bacterial or fungal liver abscess,\n",
      "             chronic viral hepatitis with total serum bilirubin > 3mg/dl, or actively symptomatic\n",
      "             biliary disease\n",
      "\n",
      "          -  Patients with renal failure are eligible; however, patients with pre-existing renal\n",
      "             insufficiency will likely have further compromise in renal function and may require\n",
      "             dialysis\n",
      "\n",
      "          -  Patients who are seropositive for human immunodeficiency virus (HIV)\n",
      "\n",
      "          -  Women who are pregnant or breast-feeding\n",
      "\n",
      "          -  Fertile men or women unwilling to use contraception during HCT and for 12 months\n",
      "             afterward\n",
      "\n",
      "          -  Patients with active non-hematological malignancies (except non-melanoma skin cancers)\n",
      "             or those with non-hematological malignancies (except non-melanoma skin cancers) who\n",
      "             have been rendered with no evidence of disease, but have a greater than 20% chance of\n",
      "             having disease recurrence within 5 years; this exclusion does not apply to patients\n",
      "             with non-hematologic malignancies that do not require therapy\n",
      "\n",
      "          -  Karnofsky score < 60 for adult patients\n",
      "\n",
      "          -  Lansky-play performance score < 50 for pediatric patients\n",
      "\n",
      "          -  Patients with fungal pneumonia with radiological progression after receipt of\n",
      "             amphotericin formulation or mold-active azoles for greater than 1 month\n",
      "\n",
      "          -  DONOR: Age < 18 years\n",
      "\n",
      "          -  DONOR: History of liver disease; a donor with a history of liver disease would be\n",
      "             eligible if the serum alanine aminotransferase (ALT) or aspartate aminotransferase\n",
      "             (AST) are < 2 times upper limit of normal (ULN)\n",
      "\n",
      "          -  DONOR: History of myopathy\n",
      "\n",
      "          -  DONOR: Hypersensitivity to atorvastatin\n",
      "\n",
      "          -  DONOR: Pregnancy\n",
      "\n",
      "          -  DONOR: Nursing mother\n",
      "\n",
      "          -  DONOR: Current serious systemic illness\n",
      "\n",
      "          -  DONOR: Concurrent treatment with strong inhibitors of hepatic CYP 3A4 (i.e.\n",
      "             clarithromycin, erythromycin, protease inhibitors, azole antifungals)\n",
      "\n",
      "          -  DONOR: Failure to meet local criteria for stem cell donation\n",
      "\n",
      "          -  DONOR: Total creatinine kinase > 2 times the ULN\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects must give written informed consent to participation in the study prior to\n",
      "             screening. Consent will be documented by the subject's dated signature that will be\n",
      "             counter-signed and dated by a witness. The appropriate HIPAA authorization forms must\n",
      "             be signed and dated by the subject.\n",
      "\n",
      "          -  Subjects must be healthy non-smoking adult male and female volunteers between the ages\n",
      "             of 18 and 40 years, with a BMI of 18-30 kg/m2 and weighing at least 150 lbs. Subjects\n",
      "             health status will be determined by the medical history, physical examination, vital\n",
      "             signs, electrocardiogram, blood chemistry, hematology, and urinalysis performed at\n",
      "             screening.\n",
      "\n",
      "          -  Subjects must be willing to fast a minimum of 8 hours prior to screening.\n",
      "\n",
      "          -  Subjects must be willing to abstain from alcohol and xanthine-containing food and\n",
      "             beverages from the time of admission to the clinical research inpatient unit through\n",
      "             at least 48 hours following discharge.\n",
      "\n",
      "          -  Subjects must be willing to remain in the clinical research unit continuously for the\n",
      "             inpatient portion of the study from admission to discharge.\n",
      "\n",
      "          -  Women who are of non-childbearing potential, must be either surgically sterile\n",
      "             (removal of both ovaries and/ or uterus at least 12 months prior to dosing), or\n",
      "             naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive\n",
      "             months prior to dosing on Day -1, with an FSH level at screening of ≥ 40 mIU/mL.\n",
      "\n",
      "          -  Women of child-bearing potential must have a negative serum pregnancy test within 48\n",
      "             hours of receiving study drug and must agree to avoid pregnancy during study and for\n",
      "             one month after the last dose of study drug\n",
      "\n",
      "          -  Male subjects of child-fathering potential must agree to avoid causing pregnancy\n",
      "             during study and for three months after the last dose of study drug.\n",
      "\n",
      "          -  Subjects must agree not to donate blood, plasma, platelets, or any other blood\n",
      "             components during the study and for 4 weeks after the last dose.\n",
      "\n",
      "          -  Male subjects must agree not to donate sperm during the study and for 12 weeks after\n",
      "             the last dose.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects with laboratory results outside the normal range, if considered clinically\n",
      "             significant by the Investigator. In addition, subjects must have a normal hematocrit\n",
      "             and hemoglobin concentration and be ≥ 36% and ≥ 12.0 g/dL, respectively.\n",
      "\n",
      "          -  A mental capacity that is limited to the extent that the subject cannot provide legal\n",
      "             consent or understand information regarding the side effects of the study drug.\n",
      "\n",
      "          -  Currently abusing drugs or alcohol or with a history of drug or alcohol abuse within\n",
      "             the past two years.\n",
      "\n",
      "          -  Unwillingness or lack of ability to comply with the protocol, or to reside in the\n",
      "             inpatient unit during the required time period, or to cooperate fully with the\n",
      "             Principle Investigator and site personnel.\n",
      "\n",
      "          -  Use of any of the following: Any concomitant medication including oral contraceptive\n",
      "             hormones. Subjects who have received any prescribed or non-prescribed\n",
      "             (over-the-counter [OTC]) systemic medication, topical medications, or herbal\n",
      "             supplements within 14 days from Day 1. St. John's Wort (hypericin) must not have been\n",
      "             taken for at least 30 days prior to Period 1, Day 1. Any drugs, foods or substances\n",
      "             known to be strong inhibitors or strong inducers of CYP enzymes (also known as\n",
      "             cytochrome P450 enzymes); especially CYP 1A2, or Pgp within 30 days prior to Period 1,\n",
      "             Day 1\n",
      "\n",
      "          -  Clinically significant ECG abnormality in the opinion of the Investigator. Vital signs\n",
      "             or clinically significant laboratory values at the screening visit that in the opinion\n",
      "             of the Investigator would make the subject an inappropriate candidate for the study.\n",
      "\n",
      "          -  Has taken any other investigational drug during the 30 days prior to the screening\n",
      "             visit or is currently participating in another investigational clinical trial.\n",
      "\n",
      "          -  Made any significant donation (including plasma) or have had a significant loss of\n",
      "             blood within 30 or 90 days prior to Period 1, Day 1.\n",
      "\n",
      "          -  History or manifestation of clinically significant neurological, gastrointestinal,\n",
      "             renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine,\n",
      "             hematologic or other medical disorders.\n",
      "\n",
      "          -  Subjects who are carriers of the Hepatitis B surface antigen (HbsAg), Hepatitis C\n",
      "             antibody, or HIV antibody\n",
      "\n",
      "          -  Serious mental or physical illness within the past year.\n",
      "\n",
      "          -  Male subjects who consume more than 28 units of alcohol per week and female subjects\n",
      "             who consume more than 21 units of alcohol per week (one unit of alcohol equals 250 mL\n",
      "             of beer, 100 mL or a medium glass of wine, or 25 mL of spirits) or those subjects who\n",
      "             have a significant history of alcoholism or drug/ chemical abuse within the last 2\n",
      "             years\n",
      "\n",
      "          -  Failure to agree to abstain from alcohol, cola, tea, coffee, chocolate and other\n",
      "             caffeinated drink/ food from 2 days before dosing and throughout confinement\n",
      "\n",
      "          -  Positive results on screening tests for drugs of abuse, cotinine or alcohol at\n",
      "             screening or the pre-dose assessment at check-in\n",
      "\n",
      "          -  Subjects who have used tobacco products or nicotine-containing products (including\n",
      "             smoking cessation aids, such as gums or patches) within 12 months prior to Period 1,\n",
      "             Day 1\n",
      "\n",
      "          -  Women of childbearing potential who are pregnant (as based on test results) or are\n",
      "             breast feeding\n",
      "\n",
      "          -  Subjects who have a history of hypersensitivity or idiosyncratic reaction to any of\n",
      "             the products administered during the study.\n",
      "\n",
      "          -  Subjects who, in the opinion of the Investigator, should not participate in the study.\n",
      "\n",
      "          -  Subjects who are employed by the DCRU\n",
      "\n",
      "          -  Subjects who have a history of unexplained syncope; i.e., autonomic dysfunction.\n",
      "\n",
      "          -  Subjects who have a history of hypotension, including orthostatic hypotension\n",
      "\n",
      "          -  A positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody\n",
      "             at screening.\n",
      "\n",
      "          -  Lack of ability to understand verbal and/ or written English\n",
      "\n",
      "          -  History of severe hypersensitivity or allergic reaction to study medication\n",
      "\n",
      "          -  Failure to agree to abstain from grapefruit and grapefruit juice as well as oranges\n",
      "             and orange juice from 10 days before the first dose and throughout the study\n",
      "\n",
      "          -  History of clinically significant illness within 4 weeks prior to Day 1\n",
      "\n",
      "          -  Receipt of a transfusion or any blood products within 90 days prior to Period 1, Day 1\n",
      "\n",
      "          -  History of participation in another investigational study or who have participated in\n",
      "             an investigational study within the past 30 days prior to Period 1, Day 1\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        A medical doctor will perform the screening of potential participants. Subjects must meet\n",
      "        the following inclusion criteria to be eligible for study entry:\n",
      "\n",
      "          -  Knee OA diagnosed according to the American College of Rheumatology criteria (26),\n",
      "             with clinical symptoms and radiographically verified tibio-femoral osteoarthritis in\n",
      "             one or both knees.\n",
      "\n",
      "          -  Aged between 40 and 65 yrs.\n",
      "\n",
      "          -  Untrained (i.e. less than 2 hours of exercise per week)\n",
      "\n",
      "          -  Subject must not be using assistive walking device\n",
      "\n",
      "          -  Willing and able to complete study visits and procedures\n",
      "\n",
      "          -  Willing to hold activity and exercise level generally consistent during the study\n",
      "             except that encompassed in the study.\n",
      "\n",
      "          -  In general good health, in the opinion of the investigator, based on medical history\n",
      "             and physical examination and, if necessary, laboratory values. Laboratory tests are\n",
      "             prescribed by the medical doctor at the screening visit.\n",
      "\n",
      "          -  A body mass index (BMI) of 19<BMI≤32kg/m2\n",
      "\n",
      "          -  Speaks, reads and writes Danish and/or English language\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Subjects who meet any of the following exclusion criteria will be ineligible for study\n",
      "        entry:\n",
      "\n",
      "          -  Subjects depending on walking device\n",
      "\n",
      "          -  Pregnant or breastfeeding\n",
      "\n",
      "          -  Radiographic evidence of Patello-femoral knee OA only (and no tibio-femoral OA).\n",
      "\n",
      "          -  History of symptoms of autoimmune disorders (e.g., inflammatory bowel disease,\n",
      "             multiple sclerosis, lupus, rheumatoid arthritis)\n",
      "\n",
      "          -  Planned surgical procedure during the duration of the study\n",
      "\n",
      "          -  History or diagnosis of musculoskeletal injuries or pathologies, including but not\n",
      "             limited to:\n",
      "\n",
      "               -  Anterior cruciate ligament injuries\n",
      "\n",
      "               -  Meniscal injuries related to trauma (degenerative changes allowed)\n",
      "\n",
      "               -  Patellofemoral Pain Syndrome\n",
      "\n",
      "               -  Low back pain\n",
      "\n",
      "          -  History, diagnosis, or signs and symptoms of clinically significant cardiovascular\n",
      "             disease, including but not limited to:\n",
      "\n",
      "               -  Ischemic heart disease\n",
      "\n",
      "               -  Arthrosclerosis\n",
      "\n",
      "               -  Peripheral artery disease\n",
      "\n",
      "          -  History, diagnosis, or signs and symptoms of diabetes\n",
      "\n",
      "          -  History, diagnosis, or signs and symptoms of neurological disorders including but not\n",
      "             limited to\n",
      "\n",
      "               -  Stroke\n",
      "\n",
      "               -  Parkinson's disease\n",
      "\n",
      "               -  Multiple sclerosis\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18-40 years\n",
      "\n",
      "          -  non smoker\n",
      "\n",
      "          -  BMI: 20-30 kg/m²\n",
      "\n",
      "          -  Healthy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  hypercalcemia > 2,65 mmol/L\n",
      "\n",
      "          -  pregnancy\n",
      "\n",
      "          -  chronic diseases\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Male or female subject older than 50 years.\n",
      "\n",
      "          2. Subject has to read Patient Information Sheet and read and sign the Informed Consent\n",
      "             form prior to any study related procedure.\n",
      "\n",
      "          3. AK with the largest diameter ≤3 cm (measuring the longest axis).\n",
      "\n",
      "          4. 2 or more AK with symmetrical distribution on the face or scalp.\n",
      "\n",
      "          5. Clinically and histologically confirmed AK of grade I or II.\n",
      "\n",
      "          6. Subject must be willing and capable of cooperating to the extent and degree required\n",
      "             by the protocol.\n",
      "\n",
      "          7. Patient is not the subject of the administrative or legal judicial proceeding.\n",
      "\n",
      "          8. Subject has social health security required by laws of health care institutions.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Patients with more than 5 AK in the planned treatment area.\n",
      "\n",
      "          2. A recurrent AK: AK that has been previously treated in the study area.\n",
      "\n",
      "          3. Very hyperkeratotic, grade 3 (on a 0-3 scale) AK lesions among the target lesions.\n",
      "\n",
      "          4. AK located on the nose.\n",
      "\n",
      "          5. Other skin lesions (diseases) in the tumor study area.\n",
      "\n",
      "          6. Subject with known hereditary basal cell carcinoma syndromes (Gorlin-Goltz,\n",
      "             Basex-Dupre-Christol et al.).\n",
      "\n",
      "          7. Subject with a history of cutaneous photosensitization or porphyria or Xeroderma\n",
      "             pigmentosum, hypersensitivity to porphyrins, or photodermatosis.\n",
      "\n",
      "          8. Subject who had received photosensitizing drugs 30 days before study start.\n",
      "\n",
      "          9. Subjects who had received immunomodulatory or immunosuppressive therapies, including\n",
      "             systemic and topical steroids, imiquimod or solaraze, interferon and acitretin 6\n",
      "             months prior to study treatment initiation.\n",
      "\n",
      "         10. Subject who had participated in another investigational drug or device research study\n",
      "             within 30 days of enrolment.\n",
      "\n",
      "         11. Subject had received in the study area laser resurfacing, chemical peels, topical\n",
      "             application fluorouracil or other drugs for the treatment of AKs within 2 months\n",
      "             before study entry.\n",
      "\n",
      "         12. Subject with known hypersensitivity to 5-aminolevulinc acid, a similar compound or\n",
      "             excipients of the cream.\n",
      "\n",
      "         13. Subject with known status after organ transplantation.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Documented diagnosis of multiple myeloma.\n",
      "\n",
      "          -  Greater than or equal to grade 2 BIPN as defined by the National Cancer Institute -\n",
      "             -Common Toxicity Criteria (NCI-CTC) 4.0.\n",
      "\n",
      "          -  BIPN symptoms persist after bortezomib has been discontinued.\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3.\n",
      "\n",
      "          -  Men and women who are ≥ 18 years old\n",
      "\n",
      "          -  The patient is aware of the nature of his or her diagnosis, understands the study\n",
      "             regimen, its requirements, risks, and discomforts, and is able and willing to sign an\n",
      "             informed consent form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior acupuncture within the past month.\n",
      "\n",
      "          -  Life expectancy is < 3 months.\n",
      "\n",
      "          -  Plan to go on experimental drug for multiple myeloma that is known to cause peripheral\n",
      "             neuropathy in the next 14 weeks.\n",
      "\n",
      "          -  Concomitant treatment with chemotherapy, unless approval is given by the Principal\n",
      "             Investigator.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All patients presenting for elective cardiac surgery with CPB will be eligible for\n",
      "             enrollment.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Preoperative renal failure requiring dialysis\n",
      "\n",
      "          2. Significant hepatic dysfunction (liver function tests > 2 times upper normal limit)\n",
      "\n",
      "          3. Preoperative ejection fraction < 30%\n",
      "\n",
      "          4. Pulmonary disease necessitating home oxygen therapy\n",
      "\n",
      "          5. Preoperative requirement for inotropic agents or intraaortic balloon pump to maintain\n",
      "             hemodynamic stability\n",
      "\n",
      "          6. Allergy to methadone or fentanyl\n",
      "\n",
      "          7. Preoperative pain, use of preoperative opioids, or recent history of opioid abuse\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Aged greater than 18 years\n",
      "\n",
      "          2. Mechanically ventilated for more than 6 hours\n",
      "\n",
      "          3. Endotracheal intubation anticipated to be routine (not difficult) based upon\n",
      "             preoperative airway assessment\n",
      "\n",
      "          4. Signed informed consent\n",
      "\n",
      "          5. Sexually active female subjects of childbearing potential must be practicing adequate\n",
      "             contraception during the treatment period -\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Gross / massive hemoptysis\n",
      "\n",
      "          2. Received lung transplantation in the past\n",
      "\n",
      "          3. Admitted from other hospital already mechanically ventilated\n",
      "\n",
      "          4. Previously received mechanical ventilation\n",
      "\n",
      "          5. Active bronchial bleeding\n",
      "\n",
      "          6. Pregnant women, women who plan to become pregnant and breastfeeding women.\n",
      "\n",
      "          7. Substance or alcohol abuse\n",
      "\n",
      "          8. Participation in concurrent trials\n",
      "\n",
      "          9. Any reasons making the patient a poor candidate in the opinion of the investigator -\n",
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "          -  Subjects will be eligible for this study if they have ISCU myopathy or carry a\n",
      "             mutation in ISCU.\n",
      "\n",
      "        No exclusions will be made based on gender or, ethnicity and adults\n",
      "\n",
      "        will be the only patients included.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female individuals,\n",
      "\n",
      "          -  18-65 years of age,\n",
      "\n",
      "          -  who meet DSM-IV diagnostic criteria for schizophrenia or schizoaffective disorder,\n",
      "\n",
      "          -  who are newly admitted to Central Regional Hospital for treatment of an acute\n",
      "             psychotic exacerbation,\n",
      "\n",
      "          -  who provide signed informed consent to participate, will be included.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Females who are lactating or pregnant,\n",
      "\n",
      "          -  individuals with a prior history of poor therapeutic response or sensitivity to\n",
      "             asenapine, will be excluded\n",
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "        Participants will be eligible if they were enrolled in the AREDS2 protocol and willing to\n",
      "        have their blood drawn and saliva collected.\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "        Participants will not be eligible if they were not enrolled in AREDS2 and are not willing\n",
      "        to have their blood drawn and saliva collected.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with colorectal polyps up to 10 mm in diameter. The patients continue to take\n",
      "             antithrombotic agents.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  patients are less than 20 years old,\n",
      "\n",
      "          -  pregnant,\n",
      "\n",
      "          -  American Society of Anesthesiologists class III and IV,\n",
      "\n",
      "          -  overweight (body weight > 100 kg), or\n",
      "\n",
      "          -  allergic to propofol used or its components (soybeans or eggs),\n",
      "\n",
      "          -  with previous colorectal surgical resection.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female Operation Iraqi Freedom/ Operation Enduring Freedom (OIF/OEF) veteran\n",
      "\n",
      "          -  Positive for PTSD, based on PTSD Checklist (PCL) score greater than or equal to 50\n",
      "\n",
      "          -  Availability of a family member who is both willing to participate in the study AND\n",
      "             has contact with the veteran 3 or more times per week\n",
      "\n",
      "          -  Ability to access a computer with internet access to take educational training and\n",
      "             surveys\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Not and OIF/OEF veteran\n",
      "\n",
      "          -  Negative for PTSD, based on PCL score less than 50\n",
      "\n",
      "          -  Unavailability of a family member who is both willing to participate in the study or\n",
      "             has contact with the veteran 3 or more times per week\n",
      "\n",
      "          -  Inability to access a computer with internet access to take the educational training\n",
      "             and surveys\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  American Society of Anesthesiologists (ASA) class I\n",
      "\n",
      "          -  Age between 18 and 45\n",
      "\n",
      "          -  BMI 18-28 kg/m^2\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Concurrent significant medical illness (heart disease including untreated\n",
      "             hypertension, Clinically significant kidney disease, liver disease, or lung disease,\n",
      "             History of myasthenia gravis or other muscle and nerve disease)\n",
      "\n",
      "          -  Anxiety disorder requiring treatment\n",
      "\n",
      "          -  Concurrent medications known to affect anesthesia, upper airway muscles or respiratory\n",
      "             function (e.g., gabaergic anxiolytics, antipsychotics)\n",
      "\n",
      "          -  Individuals with a history of allergy or adverse reaction to lidocaine, propofol, or\n",
      "             sevoflurane\n",
      "\n",
      "          -  For women: pregnancy\n",
      "\n",
      "          -  Suggestion of obstructive sleep apnea (OSA) or any other sleep disorder (e.g.\n",
      "             witnessed apneas, gasping or choking during sleep, unexplained excessive daytime\n",
      "             sleepiness)\n",
      "\n",
      "          -  History of drug or alcohol abuse\n",
      "\n",
      "          -  Acute intermittent porphyria\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  > 19 years old\n",
      "\n",
      "          -  Able to provide voluntary and informed consent\n",
      "\n",
      "          -  Distal radius fracture is the main traumatic injury\n",
      "\n",
      "          -  Planned reduction to be performed by the EP\n",
      "\n",
      "          -  Treating EP trained to perform EU for fractures OR one of the study authors available\n",
      "             to perform EU\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  < 19 years old\n",
      "\n",
      "          -  Patient unable to provide voluntary and informed consent\n",
      "\n",
      "          -  Distal radius fracture is only one of several significant injuries\n",
      "\n",
      "          -  No reduction to be performed by the EP\n",
      "\n",
      "          -  EP not trained to perform EU for fractures AND no study author available to perform EU\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Males and females of child-bearing age, age 18-40 years\n",
      "\n",
      "          2. Weight between 45 and 90 kg and a body mass index (BMI) from 18 to 29 kg/m2\n",
      "             (calculated using the following formula: weight in kilograms/(height in meters)2)\n",
      "\n",
      "          3. Both males and females must be documented (via genetic testing) to carry an EDA\n",
      "             mutation associated with XLHED; or have the clinical signs and symptoms associated\n",
      "             with HED and/or a family history of HED and provide a blood sample to be sent for\n",
      "             genetic testing that confirms an EDA mutation associated with XLHED\n",
      "\n",
      "          4. No major medical issues that the investigator considers to be a contraindication of\n",
      "             participation\n",
      "\n",
      "          5. No scalp shaving in the month prior to first dose (males only)\n",
      "\n",
      "          6. Women must use a \"highly effective\" method of contraception throughout the trial.\n",
      "             Highly effective methods of birth control are defined as those, alone or in\n",
      "             combination, which result in a low failure rate (i.e. less than 1% per year) when used\n",
      "             consistently and correctly. These methods include implants, injectables, oral\n",
      "             contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal\n",
      "             ligation or a vasectomized partner.\n",
      "\n",
      "          7. No treatment with an investigational drug within the last three months\n",
      "\n",
      "          8. Signed written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Women who are pregnant (confirmed via urine pregnancy test) or breastfeeding at\n",
      "             screening or planning to become pregnant at any time during the study period\n",
      "\n",
      "          2. Known history of hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody\n",
      "\n",
      "          3. Known history of HIV infection\n",
      "\n",
      "          4. Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists\n",
      "\n",
      "          5. Known hypersensitivity to lidocaine or lidocaine-like agents\n",
      "\n",
      "          6. Presence of pacemakers\n",
      "\n",
      "          7. Subjects who are not able or are not willing to comply with the procedures of this\n",
      "             protocol\n",
      "\n",
      "          8. Subject has a condition which in the opinion of the investigator would not allow for\n",
      "             safe conduct of the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  histologically confirmed adenocarcinoma in colorectal cancer\n",
      "\n",
      "          -  clinical stage Ⅲ or Ⅳa(with potential radical resective metastatic lesions),≥ 12 lymph\n",
      "             nodes examined\n",
      "\n",
      "          -  no cancer cells were found in ascites\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group(ECOG) performance status of 0-2\n",
      "\n",
      "          -  male or female, between 18 and 75 years old\n",
      "\n",
      "          -  adequate hematologic, hepatic and renal functions\n",
      "\n",
      "          -  without severe heart disease in the last 6 months before enrolled. If with\n",
      "             hypertension or coronary artery disease, it can be controlled\n",
      "\n",
      "          -  not enrolled into others clinical trial during this study\n",
      "\n",
      "          -  all patients should sign the informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  can not be tolerated operation\n",
      "\n",
      "          -  receiving others therapy(including Traditional Chinese herbs)for this disease, can not\n",
      "             obey the investigator during the study\n",
      "\n",
      "          -  can not be tolerated the adverse effect of drugs in these regimens\n",
      "\n",
      "          -  major surgery within 4 weeks prior to study treatment start, or lack of complete\n",
      "             recovery from major surgery\n",
      "\n",
      "          -  metastatic disease more than one organ\n",
      "\n",
      "          -  pregnant or lactating women\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Males and females\n",
      "\n",
      "          -  Age 18-65 years at visit 1\n",
      "\n",
      "          -  BMI 19-29\n",
      "\n",
      "          -  Hb ≥ 120 g/l for women and ≥ 130 g/l for men\n",
      "\n",
      "          -  Healthy as assessed by the screening laboratory tests and blood pressure determined by\n",
      "             the MD\n",
      "\n",
      "          -  Signed informed consent and biobank consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Participation in a clinical study with blood sampling within 30 days prior to\n",
      "             screening visit and throughout the study\n",
      "\n",
      "          -  Use of oral antibiotics or probiotics during 2 weeks prior to visit 1. Other\n",
      "             probiotics other than the study products are not allowed during the study period.\n",
      "\n",
      "          -  Pregnant or lactating or wish to become pregnant during the period of the study.\n",
      "\n",
      "          -  Lack of suitability for participation in the trial, for any reason, as judged by the\n",
      "             personnel at Good Food Practice AB.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  A diagnosis of CD established by referring physician(s) and confirmed by our review of\n",
      "             the clinical presentation, clinical course, endoscopic and imaging findings, and\n",
      "             histology of mucosal tissue specimens\n",
      "\n",
      "          -  An adverse prognosis, documented by persistent signs and symptoms of CD that have\n",
      "             failed to respond satisfactorily to medical and surgical therapies in the past,\n",
      "             including but not limited to systemic immune suppressive drugs and biopharmaceuticals;\n",
      "             to be considered as refractory to medical and surgical therapy, there must be\n",
      "             clinical, endoscopic, and histologic evidence of active inflammatory Crohn's Disease\n",
      "             that has either persisted or recurred despite exhaustive treatment with available\n",
      "             pharmaceutical and surgical therapies; exhaustive treatment is defined as prior\n",
      "             exposure to the following, without durable improvement:\n",
      "\n",
      "               -  Systemic glucocorticoids at or above a prednisone equivalent of 40 mg/day for at\n",
      "                  least 2 weeks, or until drug toxicity or intolerance develops\n",
      "\n",
      "               -  Methotrexate (25 mg per week for at least 3 months, or until drug toxicity or\n",
      "                  intolerance develops) and/or a thiopurine antimetabolite (either 2.5 mg/kg\n",
      "                  azathioprine or 1.5 mg/kg 6-mercaptopurine in patients homozygous wild-type for\n",
      "                  the thiopurine-S-methyltransferase [TPMT] gene, or either 1.5 mg/kg azathioprine\n",
      "                  or 1 mg/kg 6-mercaptopurine in patients heterozygous for TPMT, or doses of these\n",
      "                  drugs capable of producing a 6-thioguanine nucleotide level of 230-400 without\n",
      "                  producing a 6-methylmercaptopurine nucleotide level above 5700 for at least 3\n",
      "                  months, or until drug allergy, intolerance or toxicity develops); if a patient is\n",
      "                  homozygous mutant for the TPMT gene, thiopurines would be contraindicated and\n",
      "                  their use would not be a requirement for enrollment in this protocol\n",
      "\n",
      "               -  Use of at least two anti-tumor necrosis factor (TNF)-alpha therapies, that is,\n",
      "                  infliximab (at least 5 mg/kg every 8 weeks for at least 3 months, or until drug\n",
      "                  allergy, toxicity or intolerance or anti-infliximab antibodies develop) and/or\n",
      "                  adalimumab (at least 40 mg subcutaneously [SQ] every 2 weeks for at least 3\n",
      "                  months, or until drug allergy, toxicity or intolerance develops) and/or\n",
      "                  certolizumab pegol (at least 400 mg SQ every 4 weeks for at least 3 months, or\n",
      "                  until drug allergy, toxicity or intolerance develops)\n",
      "\n",
      "               -  Due to the serious risk of progressive multifocal leukoencephalopathy (PML) and\n",
      "                  the reluctance of some patients to agree to therapy that carries such risk, prior\n",
      "                  exposure to natalizumab is not required to meet the definition of exhaustive\n",
      "                  pharmaceutical treatment; neither will use of natalizumab among patients who are\n",
      "                  John Cunningham (JC) virus antibody seronegative be an exclusionary criterion\n",
      "\n",
      "               -  Exhaustive surgical treatment will be defined as indicated operations for\n",
      "                  complications of Crohn's Disease up to the point where the risks of surgery (for\n",
      "                  example, mortality or post-operative morbidity such as short bowel syndrome or\n",
      "                  extensive adhesions with high risk for inadvertent enterotomy) are deemed by\n",
      "                  patients and their physicians to be unacceptably high; indicated operations for\n",
      "                  complications of Crohn's Disease include, but are not limited to, surgical\n",
      "                  resection of involved intestine, stricturoplasty, drainage, curettage, or\n",
      "                  adhesiolysis of tissues affected by Crohn's disease\n",
      "\n",
      "               -  Exposure of patients to investigational drug therapies for Crohn's Disease, that\n",
      "                  is, to drugs that are not Food and Drug Administration (FDA) approved for this\n",
      "                  indication, will not be a criterion for either inclusion or exclusion\n",
      "\n",
      "          -  Endoscopic and histologic evidence of active intestinal inflammation consistent with\n",
      "             CD; in the event that the involved mucosa cannot be readily reached by endoscopic\n",
      "             biopsy, an imaging test that shows typical changes of CD in the intestinal tract will\n",
      "             suffice as evidence of active intestinal inflammation; the presence of intestinal\n",
      "             stomas does not exclude the patient from study\n",
      "\n",
      "          -  Severe CD as defined by one of the following:\n",
      "\n",
      "               -  CDAI >= 250\n",
      "\n",
      "               -  Need for total parenteral nutrition to maintain weight\n",
      "\n",
      "               -  Recurrent intestinal inflammation caused by CD following surgical resection\n",
      "\n",
      "          -  Identification of a HLA-matched hematopoietic cell donor without a history of a\n",
      "             disorder that can be transmitted by hematopoietic cells, including but not limited to\n",
      "             inflammatory bowel disease, and without nucleotide-binding oligomerization domain\n",
      "             containing 2 (NOD2) mutations in the case of a HLA matched sibling\n",
      "\n",
      "          -  DONORS will be a HLA-identical sibling or HLA-matched unrelated donor; unrelated\n",
      "             donors are required to be matched by high resolution allele level typing for HLA-A, B,\n",
      "             C and DRB1 and intermediate resolution Sequence Specific Oligonucleotide Probes\n",
      "             (SSOP), identifying alleles in groups of related families historically defined as\n",
      "             antigens for DQB1; an unrelated donor is considered matched if patient and donor share\n",
      "             HLA-A, B, C alleles with identical sequences at exons 2 and 3, DRB1 alleles with\n",
      "             identical sequences at exon 2, and DQB1 results that include the same allele groups\n",
      "\n",
      "          -  DONORS will have the ability to understand and the willingness to sign a written\n",
      "             informed consent document for bone marrow harvest.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  A current complication of CD that would jeopardize survival after hematopoietic cell\n",
      "             transplantation, including but not limited to the following:\n",
      "\n",
      "               -  Abscess, phlegmon, necrotizing skin lesion, or inflammatory fistula\n",
      "\n",
      "               -  Intestinal fibrotic stricture and intestinal obstruction\n",
      "\n",
      "               -  Uncontrolled mucosal, organ, or systemic infection with a bacterial, viral,\n",
      "                  fungal, or parasitic organism\n",
      "\n",
      "               -  Sclerosing cholangitis\n",
      "\n",
      "          -  History of progressive multifocal leukoencephalopathy\n",
      "\n",
      "          -  Organ dysfunction or disease that would jeopardize survival after hematopoietic cell\n",
      "             transplantation, including but not limited to the following:\n",
      "\n",
      "               -  Renal insufficiency as defined by an estimated glomerular filtration rate (GFR) <\n",
      "                  60 mL/minute\n",
      "\n",
      "               -  Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive\n",
      "                  heart failure, valvular heart disease, cardiomyopathy, uncontrolled\n",
      "                  arrhythmia(s), or left ventricular ejection fraction < 50%\n",
      "\n",
      "               -  Pulmonary dysfunction that poses a risk of mortality after transplant, defined as\n",
      "                  pulmonary disease-moderate, using pre-transplant pulmonary function testing per\n",
      "                  the Fred Hutchinson Cancer Research Center (FHCRC) Standard Practice Manual\n",
      "\n",
      "               -  Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction,\n",
      "                  including but not limited to jaundice, hepatic encephalopathy, or portal\n",
      "                  hypertension\n",
      "\n",
      "               -  Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an\n",
      "                  absolute neutrophil count or lymphocyte count below the lower limit of normal, or\n",
      "                  a platelet count below 50,000/mm^3\n",
      "\n",
      "               -  Poorly controlled hypertension despite appropriate therapy, defined as a\n",
      "                  diastolic blood pressure greater than 90 mm Hg while on therapy\n",
      "\n",
      "               -  Neurologic dysfunction that affects activities of daily living and medical care\n",
      "\n",
      "               -  Poorly controlled diabetes mellitus, defined as persistent hyperglycemia despite\n",
      "                  therapy or recurrent hypoglycemia while on therapy\n",
      "\n",
      "               -  Extreme protein-calorie malnutrition defined by body mass index < 18 kg/m^2 and\n",
      "                  unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months)\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Fertile men or women unwilling to use contraceptive techniques during and for 12\n",
      "             months following transplant\n",
      "\n",
      "          -  History of smoking either tobacco or other herbal products in the last 3 months\n",
      "\n",
      "          -  Human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus\n",
      "             (HCV) seropositivity\n",
      "\n",
      "          -  Patients whose life expectancy is severely limited by illness other than CD\n",
      "\n",
      "          -  Untreated psychiatric illness, including drug/alcohol abuse, that would compromise\n",
      "             compliance\n",
      "\n",
      "          -  Inability to give voluntary informed consent or obtain a parent or guardian's informed\n",
      "             consent\n",
      "\n",
      "          -  Demonstrated lack of compliance with prior medical care\n",
      "\n",
      "          -  History of a malignancy, excluding adequately treated squamous cell skin cancer, basal\n",
      "             cell carcinoma, and carcinoma in situ\n",
      "\n",
      "          -  Hematopoietic cell transplant-co-morbidity Index greater than 2\n",
      "\n",
      "          -  DONOR: Identical twin\n",
      "\n",
      "          -  DONOR: Pregnant or lactating females\n",
      "\n",
      "          -  DONOR: HIV seropositivity or presence of HBV deoxyribonucleic acid (DNA) or HCV\n",
      "             ribonucleic acid (RNA) in the serum\n",
      "\n",
      "          -  DONOR: Current serious systemic illness including uncontrolled infections\n",
      "\n",
      "          -  DONOR: Malignancy within 10 years prior to donation of marrow, excluding adequately\n",
      "             treated squamous cell skin cancer and basal cell carcinoma; treatment must have been\n",
      "             completed (with the exception of hormonal therapy for breast cancer) with\n",
      "             cure/remission status verified for at least 10 years at time of marrow harvest\n",
      "\n",
      "          -  DONOR: History of or symptoms consistent with inflammatory bowel disease or a serious\n",
      "             autoimmune disorder\n",
      "\n",
      "          -  DONOR: Homozygous NOD2 mutation\n",
      "\n",
      "          -  DONOR: History of a serious disease or disorder that could be adoptively transferred\n",
      "             by infusion of donor hematopoietic cells\n",
      "\n",
      "          -  DONOR: Failure to meet institutional criteria for donation as described in the\n",
      "             Standard Practice Guidelines\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male and female patients older than 5 years and weighting > 15 kg\n",
      "\n",
      "          -  Current residence in non-endemic areas\n",
      "\n",
      "          -  Either direct diagnosis of S. stercoralis infection AND positive serology at any titer\n",
      "             OR positive serology at \"high\" titer, irrespective of results of direct tests\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant or lactating women\n",
      "\n",
      "          -  Subjects suffering from CNS diseases\n",
      "\n",
      "          -  Disseminated strongyloidiasis\n",
      "\n",
      "          -  Immunocompromised patients.\n",
      "\n",
      "          -  Lack of informed consent\n",
      "\n",
      "          -  Previous treatment with ivermectin (in the last year)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age 50 years or older;\n",
      "\n",
      "          2. 12-lead electrocardiogram (ECG) performed at least 2 weeks but less than 4 weeks prior\n",
      "             to entry into the study showing a QTc <440 with no evidence of current or prior\n",
      "             myocardial ischemia, infarction or significant arrhythmia as determined by review and\n",
      "             signature of the cardiologist.\n",
      "\n",
      "          3. Adequate bone marrow function:\n",
      "\n",
      "             Absolute granulocyte count ≥1500 cells/mm3; Platelet count ≥100,000 cells/mm3;\n",
      "             Hemoglobin ≥9.0gm/ dL;\n",
      "\n",
      "          4. PT/PTT within the institution upper limit of normal (ULN) or INR <1.1 ;\n",
      "\n",
      "          5. Adequate hepatic function:\n",
      "\n",
      "             Total bilirubin within the institution ULN; Alanine and aspartate aminotransferase\n",
      "             (ALT/AST) <3 times the institutional ULN;\n",
      "\n",
      "          6. Adequate renal function: serum creatinine ≤2.0 mg/dL;\n",
      "\n",
      "          7. Ophthalmic criteria:\n",
      "\n",
      "               1. Best corrected visual acuity in the study eye of ≤20/40 and ≥20/800 in the fellow\n",
      "                  eye.\n",
      "\n",
      "               2. Subfoveal choroidal neovascularization (as illustrated by fluorescein\n",
      "                  angiography) secondary to age-related macular degeneration, with a total lesion\n",
      "                  size of ≤12 total disc areas, of which at least 50% must be active CNV.\n",
      "\n",
      "               3. Subretinal hemorrhage ≤50% of total lesion size;\n",
      "\n",
      "               4. For patients with minimally classic and purely occult CNV, there must be\n",
      "                  documented evidence of ≥2 lines of vision loss (ETDRS) during the previous 12\n",
      "                  weeks;\n",
      "\n",
      "               5. Clear ocular media and adequate papillary dilatation to permit good quality\n",
      "                  stereoscopic fundus photography;\n",
      "\n",
      "          8. Male fertile patients must abstain from sexual intercourse or use effective birth\n",
      "             control;\n",
      "\n",
      "          9. Women must be post-menopausal for at least 12 months prior to study entry, or\n",
      "             surgically sterile, or must be using two forms of effective contraception.\n",
      "\n",
      "         10. Able to return for all study visits within required visit windows;\n",
      "\n",
      "         11. Be able to give written informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Previous subfoveal thermal laser therapy;\n",
      "\n",
      "          2. Any subfoveal scarring or atrophy, or >25% of the total lesion size is made up of\n",
      "             scarring or atrophy;\n",
      "\n",
      "          3. Significant media opacities, including cataract, which can interfere with visual\n",
      "             acuity, assessment of toxicity, or fundus photography;\n",
      "\n",
      "          4. Presence of other causes of choroidal neovascularization, including pathologic myopia\n",
      "             (spherical equivalent of ≥-8.0 diopters, or axial length of ≥25mm), ocular\n",
      "             histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal\n",
      "             choroiditis and other uveitic entities;\n",
      "\n",
      "          5. Any condition that might interfere with assessment of the progression of CNV;\n",
      "\n",
      "          6. Any intraocular surgery in the study eye within 12 weeks of screening for the study;\n",
      "\n",
      "          7. Other treatment for AMD of the study eye within 12 weeks prior to screening;\n",
      "\n",
      "          8. Known allergy to fluorescein;\n",
      "\n",
      "          9. Any current or history of significant gastrointestinal, oral, or nasal bleeding;\n",
      "\n",
      "         10. Serious intercurrent infections or other nonmalignant medical illnesses that are\n",
      "             uncontrolled or whose control may be jeopardized by the complications of this therapy;\n",
      "\n",
      "         11. Grade 2 (CTC v.3.0) or greater pre-existing peripheral neuropathy;\n",
      "\n",
      "         12. Psychiatric disorders or other conditions rendering patients incapable of complying\n",
      "             with the requirements of the protocol;\n",
      "\n",
      "         13. Pregnant or breast-feeding women;\n",
      "\n",
      "         14. History of angina, myocardial infarction, CHF, non-controlled atrial arrhythmias or\n",
      "             clinically significant arrhythmias including conduction abnormality, nodal junctional\n",
      "             arrhythmias and dysrhythmias, sinus bradycardia or tachycardia, supraventricular\n",
      "             arrhythmias, atrial fibrillation or flutter, syncope or vasovagal episodes;\n",
      "\n",
      "         15. Abnormal cardiac stress test;\n",
      "\n",
      "         16. Uncontrolled hypertension (consistently >150/100mmHg irrespective of medication);\n",
      "\n",
      "         17. Uncontrolled hypokalemia and/or hypomagnesemia;\n",
      "\n",
      "         18. ECG with evidence of prior myocardial infarction, QTc > 450 msec or other clinically\n",
      "             significant abnormalities;\n",
      "\n",
      "         19. Drug(s) known to prolong the QTc interval;\n",
      "\n",
      "         20. Patients with conditions associated with QTc prolongation;\n",
      "\n",
      "         21. Any investigational drug or device within 4 weeks prior to screening;\n",
      "\n",
      "         22. Decreased ejection fraction ≤50% or prior myocardial infarction.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age between 18-75 years\n",
      "\n",
      "          -  No contraindications to placement of a lumbar plexus posterior block or paravertebral\n",
      "             block.\n",
      "\n",
      "          -  ASA status I-III\n",
      "\n",
      "          -  Scheduled for open total hip arthroplasty with the same surgeon.\n",
      "\n",
      "          -  Patients without painful conditions or chronic use of opioid or antineuropathic\n",
      "             medications.\n",
      "\n",
      "          -  Patient who are not expected to receive therapeutic anticoagulation in the\n",
      "             postoperative period.\n",
      "\n",
      "          -  No Known allergies to the medications used in the study.\n",
      "\n",
      "          -  Patients willing to receive spinal anesthesia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Age under 18 years or older than 75 years.\n",
      "\n",
      "          -  Any contraindication to a placement of continuous lumbar plexus Block.\n",
      "\n",
      "          -  American Society of Anesthesiologist physical status IV or greater.\n",
      "\n",
      "          -  Chronic painful conditions.\n",
      "\n",
      "          -  Preoperative opioid tolerant use.\n",
      "\n",
      "          -  Coagulation Abnormalities or patients who are expected to be on therapeutic\n",
      "             anticoagulants postoperatively.\n",
      "\n",
      "          -  Allergy to any of the drugs/agents used study protocol.\n",
      "\n",
      "          -  Personal or family history of malignant hyperthermia.\n",
      "\n",
      "          -  Serum creatinine greater than 1.4 mg/dl.\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Having an altered mental status (not oriented to place, person, or time)\n",
      "\n",
      "          -  Any comorbid condition that, in the judgment of the consulting orthopedic surgeon, or\n",
      "             intraoperative anesthesiologist, would proscribe the patient from any aspect of the\n",
      "             study.\n",
      "\n",
      "          -  Patient refusal.\n",
      "\n",
      "          -  Lumbar plexus block performed with loss of resistance technique\n",
      "\n",
      "          -  Patient requiring postoperative management in the ICU\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients will be eligible for inclusion if they have a diagnosis of idiopathic PD.\n",
      "\n",
      "          -  The subjects must speak either English or French sufficiently to fill out\n",
      "             questionnaires and understand the instructions for dance classes (classes will be\n",
      "             bilingual).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Patients who cannot stand for at least 30 min and walk for ≥3 m without an assistive\n",
      "             device.\n",
      "\n",
      "          2. Individuals with Hoehn and Yahr stage IV- V (severe and nonambulatory)\n",
      "\n",
      "          3. Dementia, defined according to PD dementia criteria as MMSE< 26/30 and ADL impairment\n",
      "             secondary to cognitive loss, or inability to understand consent process60\n",
      "\n",
      "          4. Serious hearing and vision problems that could affect the participation in dance\n",
      "             classes.\n",
      "\n",
      "          5. Change to dopaminergic therapy over the preceding three months, or changes to\n",
      "             antiparkinsonian medication are anticipated during the study protocol\n",
      "\n",
      "          6. Serious medical conditions, including cardiac disease or evidence of musculoskeletal\n",
      "             problem which precludes dancing or can be worsened by exercise\n",
      "\n",
      "          7. History of frequent falls, with more than 3 falls in the last 12 months\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Have a diagnosis of diabetes\n",
      "\n",
      "          -  Be 18 years of age or older\n",
      "\n",
      "          -  Be able to speak, read and understand English and understand the Informed Consent\n",
      "             document.\n",
      "\n",
      "          -  Be willing to complete study procedures\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Infections or skin disorders at the puncture site (at the discretion of the site\n",
      "             professional staff).\n",
      "\n",
      "          -  Hemophilia, bleeding disorder, or clotting problems. Persons taking aspirin (81 mg or\n",
      "             325 mg) daily or Plavix® are not reason for exclusion.\n",
      "\n",
      "          -  Physical (dexterity), visual, or neurological impairments that would make the person\n",
      "             unable to perform testing with the BGM (at the discretion of the site professional\n",
      "             staff).\n",
      "\n",
      "          -  A condition, in the opinion of the Investigator, would put the subject at risk or\n",
      "             influence the conduct of the study or interpretation of the results. The reason for\n",
      "             exclusion will be documented by the professional staff.\n",
      "\n",
      "          -  Previously participated in a blood glucose monitoring study using Contour TS system or\n",
      "             use the Contour TS for personal use when monitoring blood glucose.\n",
      "\n",
      "          -  Working for a competitive medical device company or having an immediate family member\n",
      "             or someone who is not a family member but is living within the household of someone\n",
      "             who works for such a company\n",
      "\n",
      "          -  Working for a medical laboratory, hospital or other clinical setting that involves\n",
      "             training on and clinical use of blood glucose monitors\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age between 18 and 30 years\n",
      "\n",
      "          -  written consent\n",
      "\n",
      "          -  ASA 1\n",
      "\n",
      "          -  BMI between 18 and 25\n",
      "\n",
      "          -  males\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  unable to communicate in Danish\n",
      "\n",
      "          -  relevant drug allergy\n",
      "\n",
      "          -  alcohol or/and drug abuse\n",
      "\n",
      "          -  daily intake of prescription pain medication the last 4 weeks\n",
      "\n",
      "          -  pain medication in the last 48 hours\n",
      "\n",
      "          -  previously operated abdominal\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  over 18 years old,\n",
      "\n",
      "          -  diabetes as defined by HgA1C over 6.5%,\n",
      "\n",
      "          -  uncontrolled blood pressure (SBP > 130 and or DBP > 80)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pregnancy,\n",
      "\n",
      "          -  transplanted organ,\n",
      "\n",
      "          -  MI/CHF/CVA within 3 months,\n",
      "\n",
      "          -  dialysis,\n",
      "\n",
      "          -  arrhythmia,\n",
      "\n",
      "          -  metastatic cancer,\n",
      "\n",
      "          -  dementia,\n",
      "\n",
      "          -  visual or hearing difficulties\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        HHT\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Unable to provide informed consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  newly diagnosed breast cancer\n",
      "\n",
      "          -  no metastasis detected\n",
      "\n",
      "          -  operation for breast cancer\n",
      "\n",
      "          -  female patient\n",
      "\n",
      "          -  unilateral breast cancer\n",
      "\n",
      "          -  informed consent given\n",
      "\n",
      "          -  age min. 18 yrs.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  metastasis of breast cancer\n",
      "\n",
      "          -  bilateral breast cancer\n",
      "\n",
      "          -  other cancer within the last 5yrs\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Newly diagnosed type 2 diabetes patients based on American Diabetes Association\n",
      "             criteria (2011) for diagnosis of diabetes\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  previous intake of oral hypoglycemic agents for treatment of diabetes or other\n",
      "             hyperglycemia associated conditions\n",
      "\n",
      "          -  intake of glucocorticoids in the past one year\n",
      "\n",
      "          -  major illnesses of heart, lung, kidney, and liver.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age ≥ 18 years at screening\n",
      "\n",
      "          -  Documented past history of myocardial infarction OR past evidence of multivessel\n",
      "             coronary artery disease by angiography.\n",
      "\n",
      "               -  To qualify on the basis of past history of myocardial infarction, the event must\n",
      "                  be documented either by hospital records or by evidence on current ECG of Q waves\n",
      "                  in two contiguous leads and/or an imaging test demonstrating wall motion\n",
      "                  abnormality or scar. The patient must also have completed any planned coronary\n",
      "                  revascularization procedures associated with the qualifying event, and be\n",
      "                  clinically stable for at least 60 days prior to screening.\n",
      "\n",
      "               -  To qualify on the basis of multivessel coronary disease, there must be past\n",
      "                  angiographic evidence of atherosclerosis in at least 2 major epicardial vessels\n",
      "                  defined either as the presence of a stent, a coronary bypass graft, or an\n",
      "                  angiographic lesion of 60% or greater. Left main coronary artery disease that has\n",
      "                  been revascularized with a stent or bypass graft will qualify as multivessel\n",
      "                  disease, as will the presence of a 50% or greater isolated left main stenosis.\n",
      "                  The patient must also have completed any planned coronary revascularization\n",
      "                  procedures associated with the qualifying event, and be clinically stable for at\n",
      "                  least 60 days prior to screening.\n",
      "\n",
      "          -  History of type 2 diabetes or metabolic syndrome at time of study enrollment\n",
      "\n",
      "          -  Willingness to participate as evidenced by signing the study informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior history of chronic infectious disease, tuberculosis, or severe fungal disease;\n",
      "             chronic hepatitis B or C infection; renal insufficiency; interstitial pneumonitis,\n",
      "             bronchiectasis, or pulmonary fibrosis; known chronic pericardial effusion, pleural\n",
      "             effusion, or ascites; chronic liver disease; myeloproliferative disorders in the past\n",
      "             5 years; non-basal cell malignancy or treated lymphoproliferative disease within the\n",
      "             past 5 years; known HIV positive; life expectancy of < 3 years;\n",
      "\n",
      "          -  Chronic inflammatory condition such as lupus or rheumatoid arthritis, ulcerative\n",
      "             colitis or Crohn's disease\n",
      "\n",
      "          -  White blood cell count < 3,500/ul, hematocrit < 32 percent, or platelet count <\n",
      "             75,000/ul\n",
      "\n",
      "          -  Liver transaminase levels (AST or ALT) >upper limit of normal (ULN) or albumin < the\n",
      "             lower limit of normal (LLN);\n",
      "\n",
      "          -  Creatinine clearance < 40 ml/min as estimated with the Cockroft-Gault equation;\n",
      "\n",
      "          -  History of alcohol abuse or unwillingness to limit alcohol consumption to less than 4\n",
      "             drinks per week\n",
      "\n",
      "          -  Women of child bearing potential, even if they are currently using contraception, and\n",
      "             women intending to breastfeed.\n",
      "\n",
      "          -  Men who plan to father children during the study period or who are unwilling to use\n",
      "             effective forms of contraception.\n",
      "\n",
      "          -  Requirement for use of drugs that alter folate metabolism\n",
      "             (trimethoprim/sulfamethoxazol) or reduce tubular excretion (probenecid) or known\n",
      "             allergies to antibiotics making avoidance of trimethoprim impossible;\n",
      "\n",
      "          -  Current indication for methotrexate therapy;\n",
      "\n",
      "          -  Chronic use of oral steroid therapy or other immunosuppressive or biologic response\n",
      "             modifiers. Eligible study participants will be encouraged to have up to date\n",
      "             pneumococcal and influenza vaccinations as recommended based on their age and\n",
      "             underlying medical conditions.\n",
      "\n",
      "          -  Chest X-ray evidence in the past 12 months of interstitial pneumonitis,\n",
      "             bronchiectasis, or pulmonary fibrosis. For participants who do not have a chest X-ray\n",
      "             in the prior 12 months, a chest X-ray will be obtained at baseline as part of the\n",
      "             study protocol.\n",
      "\n",
      "          -  New York Heart Association Class IV congestive heart failure.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria for Participants with AERD:\n",
      "\n",
      "          -  History of physician-diagnosed asthma\n",
      "\n",
      "          -  History of nasal polyposis\n",
      "\n",
      "          -  History of at least one clinical reaction to oral aspirin or other nonselective COX\n",
      "             inhibitor with features of both lower (cough, chest tightness, wheezing, dyspnea) and\n",
      "             upper (rhinorrhea, sneezing, nasal obstruction, conjunctival itching and discharge)\n",
      "             airway involvement.\n",
      "\n",
      "          -  Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in baseline dose\n",
      "             of oral glucocorticoids for at least 3 months, and no history of hospitalization or\n",
      "             emergency room visits for asthma for at least the prior 6 months).\n",
      "\n",
      "          -  No current smoking, defined as no daily tobacco smoking for at least 6 months and not\n",
      "             more than one instance of tobacco smoking in the last 3 months.\n",
      "\n",
      "          -  Non-pregnant\n",
      "\n",
      "          -  Only those individuals who would otherwise meet clinical qualifications for aspirin\n",
      "             desensitization and treatment with high-dose aspirin will be considered for enrollment\n",
      "             in the study.\n",
      "\n",
      "        Inclusion Criteria for Participants who are Aspirin Tolerant Asthmatics:\n",
      "\n",
      "          -  History of physician-diagnosed asthma.\n",
      "\n",
      "          -  No current nasal polyposis confirmed by nasal examination.\n",
      "\n",
      "          -  No history of any adverse reaction to aspirin or a COX inhibitor.\n",
      "\n",
      "          -  Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in baseline dose\n",
      "             of oral glucocorticoids for at least 3 months, and no history of hospitalization or\n",
      "             emergency room visits for asthma for at least the prior 6 months).\n",
      "\n",
      "          -  No current smoking\n",
      "\n",
      "          -  Non-pregnant\n",
      "\n",
      "        Inclusion Criteria for Non Asthmatics with Allergic Rhinitis:\n",
      "\n",
      "          -  No history of physician-diagnosed asthma.\n",
      "\n",
      "          -  No current nasal polyposis confirmed by nasal examination.\n",
      "\n",
      "          -  No history of any adverse reaction to aspirin or a COX inhibitor.\n",
      "\n",
      "          -  No current smoking\n",
      "\n",
      "          -  Non-pregnant\n",
      "\n",
      "          -  Clinical history of symptoms consistent with allergic rhinitis and previously\n",
      "             documented allergy to at least one environmental,immunoglobulin E (IgE) testing).\n",
      "\n",
      "          -  Normal lung function (baseline FEV1 of 80% of predicted or better).\n",
      "\n",
      "          -  A score of 4 or below on the Asthma Screening Questionnaire (33) and negative\n",
      "             responses to asthma history questions\n",
      "\n",
      "        Exclusion Criteria for participants with AERD:\n",
      "\n",
      "          -  Current breastfeeding\n",
      "\n",
      "          -  History of bleeding diathesis or current use of anticoagulant or antiplatelet drugs\n",
      "\n",
      "          -  Hypersensitivity to montelukast or thienopyridines\n",
      "\n",
      "          -  History of peptic ulcer disease or gastrointestinal bleed\n",
      "\n",
      "          -  Current severe gastro-esophageal reflux disease (GERD), defined as patient currently\n",
      "             requiring more than 2 total doses of medication per day to treat persistent symptoms:\n",
      "             either more than 2 doses of any single medication type (antacid, proton pump\n",
      "             inhibitor, or H2 receptor antagonist), or more than 2 types of medication per day to\n",
      "             treat symptoms\n",
      "\n",
      "          -  History of systemic or life-threatening respiratory reaction to aspirin requiring\n",
      "             intubation or administration of adrenalin\n",
      "\n",
      "          -  Current use of any oral beta blocker (due to the risk of bronchospasm associated with\n",
      "             beta blockers).\n",
      "\n",
      "          -  History of transient ischemic attack or stroke, or diabetes.\n",
      "\n",
      "          -  Current presence of uncontrolled hypertension.\n",
      "\n",
      "          -  History of hepatic impairment or alcoholism, or evidence of abnormal liver function at\n",
      "             Screening Visit. Aspartate transaminase (AST) and alanine transaminase (ALT) levels\n",
      "             may not exceed 1.5x the upper limit of normal at Screening Visit (AST may not exceed\n",
      "             52 IU/L, ALT may not exceed 78 IU/L).\n",
      "\n",
      "        Exclusion Criteria for Participants with Aspirin Tolerant Asthma and Non Asthmatics with\n",
      "        Allergic Rhinitis:\n",
      "\n",
      "          -  Current breastfeeding\n",
      "\n",
      "          -  History of bleeding diathesis or current use of anticoagulant or antiplatelet drugs\n",
      "\n",
      "          -  Hypersensitivity to montelukast or thienopyridines\n",
      "\n",
      "          -  History of peptic ulcer disease or gastrointestinal bleed\n",
      "\n",
      "          -  Current severe GERD\n",
      "\n",
      "          -  Current use of any oral beta blocker.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  males and females outpatients aged 30-65 years old\n",
      "\n",
      "          -  practicing professionals in contact with patients, students,...\n",
      "\n",
      "          -  symptoms suggestive of burnout syndrome\n",
      "\n",
      "          -  minimum score to the BMS-10 = 4\n",
      "\n",
      "          -  able to understand the sdudy documents\n",
      "\n",
      "          -  agreeing to go to dates of controls\n",
      "\n",
      "          -  able to give informed consent\n",
      "\n",
      "          -  affiliated to a French national insurance program\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  current anxiolytic or antidepressant treatment\n",
      "\n",
      "          -  allergy known about one of the components of the food complement in the study\n",
      "\n",
      "          -  intolerance in the lactose and in the proteins of milk\n",
      "\n",
      "          -  pregnancy or feeding\n",
      "\n",
      "          -  progressive pathology involving life-threatening during study\n",
      "\n",
      "          -  professional on sick leave\n",
      "\n",
      "          -  cancer not stabilized for at least five years or considered as not recovered\n",
      "\n",
      "          -  subjects deprived of liberty court decision\n",
      "\n",
      "          -  subjects in the psychic incapacity to understand the constraints of the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All patients 21 years old and older diagnosed with suspected diffuse parenchymal lung\n",
      "             disease (multi-lobar pulmonary infiltrates)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  None\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Aged 18 years or older\n",
      "\n",
      "          -  Clinical diagnosis of essential tremor\n",
      "\n",
      "          -  Able to provide informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Significant medical or psychiatric illness\n",
      "\n",
      "          -  Not capable of following the required clinical instructions\n",
      "\n",
      "          -  Serious medical conditions that compromise safety\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  A child and his or her parent(s) will be eligible for the study if:\n",
      "\n",
      "               -  the two to four year old child is scheduled to receive or eligible for (based on\n",
      "                  an upcoming birthday) a recommended well child visit conducted by a pediatric or\n",
      "                  family practice care provider;\n",
      "\n",
      "               -  the child has no medical problems that would preclude study participation as\n",
      "                  determined by the physician conducting the well child visit (e.g. serious disease\n",
      "                  that would make following guidelines for parent encouragement of healthy diet and\n",
      "                  physical activity infeasible);\n",
      "\n",
      "               -  the child's BMI is greater than or equal to the 50th percentile according to CDC\n",
      "                  age and sex reference standards\n",
      "                  http://www.cdc.gov/nchs/data/nhanes/growthcharts/bmiage.txt;\n",
      "\n",
      "               -  the child's parent/guardian agrees to participation in the study and is not\n",
      "                  planning to move out of the state in the next three years\n",
      "\n",
      "               -  the primary caregiver is willing and able to complete the evaluation measures and\n",
      "                  participate in intervention activities if assigned to the active intervention\n",
      "                  group.\n",
      "\n",
      "               -  the parent speaks either English or Spanish.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  A child will be excluded if she or he does not meet the above eligibility criteria\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  patients older than 18 years old.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  no consent.\n",
      "\n",
      "          -  suspicion of sepsis.\n",
      "\n",
      "          -  Patients with elevated troponin or procalcitonin before enrollment.\n",
      "\n",
      "          -  patients who had non-elective angioplasty (e.g. rescue angioplasty, primary\n",
      "             angioplasty, salvage angioplasty, or emergency angioplasty)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Renal transplant patients\n",
      "\n",
      "          -  Age between 18 and 85 years\n",
      "\n",
      "          -  Recipients of living or deceased donors\n",
      "\n",
      "          -  Donor under the age of 85 years\n",
      "\n",
      "          -  Panel Reactivity Antibodies (PRA) over or equal to 30%\n",
      "\n",
      "          -  4-5 months post-transplant\n",
      "\n",
      "          -  CNI-based immunosuppressive regimen\n",
      "\n",
      "          -  Stable graft function (creatinine lower than 2.0 mg/dl)\n",
      "\n",
      "          -  No currently acute rejection\n",
      "\n",
      "          -  Proteinuria lower than 800mg/d\n",
      "\n",
      "          -  No laboratory or physical clinically significant signs presented for the last 2 months\n",
      "             before screening.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Recipient of multiple organs\n",
      "\n",
      "          -  Recipient with a history of focal segmental glomerulosclerosis or membranous\n",
      "             glomerulonephritis\n",
      "\n",
      "          -  Presence of uncontrolled hypercholesterolemia (≥350 mg/dL)hypertriglyceridemia (over\n",
      "             or equal to 500 mg/dL)\n",
      "\n",
      "          -  Patients with eGFR lower than 40 ml/min/1.73m2\n",
      "\n",
      "          -  Evidence of acute rejection within 2 months before screening\n",
      "\n",
      "          -  Thrombocytopenia (lower than 75,000/mm3)\n",
      "\n",
      "          -  Neutropenia (lower than 1,500/mm3)\n",
      "\n",
      "          -  Leukocytopenia (lower than 2500/mm3)\n",
      "\n",
      "          -  Anemia (hemoglobin lower than 6.0g/dL)\n",
      "\n",
      "          -  Severe liver disease (including transaminases or bilirubin equal or over 3 times\n",
      "             normal)\n",
      "\n",
      "          -  Proteinuria over 800mg/dL\n",
      "\n",
      "          -  Systemic infection or pneumonia (active infection)\n",
      "\n",
      "          -  Positive for Hepatitis B, Hepatitis C or HIV.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All except patients with exclusion criteria\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  dialysis-dependent chronic kidney disease\n",
      "\n",
      "          -  lack of written consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with distal femur fracture (AO/OTA Type 33A and 33C).\n",
      "\n",
      "          -  Patients 17 years of age and older.\n",
      "\n",
      "          -  Patients able to be operated on by selected surgeons at the participating centers.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Patients who are enrolled in an investigational treatment trial.\n",
      "\n",
      "          -  Patients who are not expected to survive the follow-up period.\n",
      "\n",
      "          -  Considered an inappropriate participant by the study physician.\n",
      "\n",
      "          -  Revision surgery.\n",
      "\n",
      "          -  Patients currently incarcerated or awaiting incarceration.\n",
      "\n",
      "          -  Severe spinal injury with neurological deficit resulting in paralysis.\n",
      "\n",
      "          -  Fracture fixed more than 28 days after injury.\n",
      "\n",
      "          -  Acute or chronic of systematic infections\n",
      "\n",
      "          -  Patients with periprosthetic fractures.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients diagnosed with solid tumors who are being assessed for participation in phase\n",
      "             I clinical trials of investigational cancer therapies\n",
      "\n",
      "          -  Able to read or understand English\n",
      "\n",
      "          -  Ability to read and/or understand the study protocol requirements, and provide written\n",
      "             informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient diagnosed with hematologic or brain cancers\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients admitted with acute coronary syndrome (unstable angina, non-ST elevation\n",
      "             myocardial infarction) and referred for coronary angiography.\n",
      "\n",
      "          -  Current therapy with clopidogrel (at least 300mg loading dose, or 75mg po daily for >5\n",
      "             days)\n",
      "\n",
      "          -  Age range 21-75 years.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Unable to give consent\n",
      "\n",
      "          -  Age younger than 21 years, greater than 75 years\n",
      "\n",
      "          -  History of stroke\n",
      "\n",
      "          -  Body weight <60 kg\n",
      "\n",
      "          -  Acute STEMI,\n",
      "\n",
      "          -  Thrombocytopenia<100'000,\n",
      "\n",
      "          -  requirement for chronic warfarin therapy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. 13 - 17 years of age\n",
      "\n",
      "          2. Referral for a 1st or 2nd Minor in Possession (Alcohol) or Less Than an Ounce\n",
      "             (Marijuana) offense\n",
      "\n",
      "          3. Adolescents living at home with at least one parent willing to participate in the\n",
      "             study\n",
      "\n",
      "          4. Adolescents with sufficient English-language ability to permit participation in the\n",
      "             interventions\n",
      "\n",
      "          5. Parent(s) with sufficient English- or Spanish-language ability to complete the\n",
      "             English- or Spanish-language versions of PW and the assessment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Evidence of psychotic or organic state of sufficient severity to interfere with\n",
      "             understanding study procedures\n",
      "\n",
      "          2. Danger to self and/or services other than outpatient treatment are required\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Between ages 13-18 years\n",
      "\n",
      "          -  Able to read and write in English.\n",
      "\n",
      "          -  Smokers: Smoking 5 or more cigarettes daily for at least 6 months; Baseline urine\n",
      "             cotinine levels > 500 ng/ml\n",
      "\n",
      "          -  Nonsmokers: Never smokers; Baseline urine cotinine levels < 50 ng/ml\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Current criteria for dependence on another psychoactive substance\n",
      "\n",
      "          -  Current diagnosis of psychosis, major depression or panic disorder\n",
      "\n",
      "          -  Regular use of any psychoactive drugs including anxiolytics and antidepressants unless\n",
      "             the medication has been taken consistently for 2 months, is currently being monitored\n",
      "             by a physician, and the condition for which the medication is taken is considered to\n",
      "             be stable\n",
      "\n",
      "          -  Pregnant or lactating girls, based on self report.\n",
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "          -  Adult subjects (greater than or equal to18 years old), with documented renal\n",
      "             malignancy or metastatic renal cancer, with at least one tumor greater than or equal\n",
      "             to1 cm in diameter (not within the liver), who are scheduled for treatment using an\n",
      "             anti-angiogenic therapy agent\n",
      "\n",
      "          -  Platelet count of >100,000 times 10(6)/L, hemoglobin value of >9 g/dL, PT and an aPTT\n",
      "             < 2 times normal limits.\n",
      "\n",
      "          -  Clinically acceptable medical history, physical examination and vital signs findings\n",
      "             during the screening period (from <4 weeks before administration of [18F]\n",
      "             Fluciclatide); i.e. Eastern Cooperative Oncology Group (ECOG) performance score of 0\n",
      "             to 2.\n",
      "\n",
      "          -  The subject has had no open surgical wounds in close proximity to the target lesion(s)\n",
      "             within 10 days prior to study entry.\n",
      "\n",
      "          -  The subject has not had a needle/core biopsy of the target lesion within 10 days of\n",
      "             PET/CT imaging.\n",
      "\n",
      "          -  The subject has not had radiation therapy to the region of the target lesion.\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "          -  The subject is pregnant or nursing.\n",
      "\n",
      "          -  The subject is being treated with doses of heparin or warfarin resulting in elevation\n",
      "             of PT or aPTT >2 times normal.\n",
      "\n",
      "          -  The subject has received any anti-angiogenic agent (e.g. bevacizumab, sorafenib,\n",
      "             sunitinib) within 60 days prior to pre-treatment (baseline) [18F] Fluciclatide PE\n",
      "             imaging. This stipulation does not apply after the baseline [18F] Fluciclatide PET\n",
      "             imaging.\n",
      "\n",
      "          -  The subject has any contraindication to any of the study procedures, products used or\n",
      "             its constituents (e.g. severe claustrophobia unrelieved by oral anxiolytics).\n",
      "\n",
      "          -  The subject is unable to lie still for 75 minutes.\n",
      "\n",
      "        2.1.2.6 The subject is known to have a history of hyper- or hypo-coagulation syndromes\n",
      "        resulting in prolongation of bleeding parameters. Such coagulopathies include but are not\n",
      "        limited to Von Willebrand disease, Protein C deficiency, Protein S deficiency, Hemophilia\n",
      "        A/B/C, Factor-V Leiden, and Bernard-Soulier syndrome.\n",
      "\n",
      "          -  The subject has undergone a surgical procedure to the target lesion within 28 days\n",
      "             prior to baseline [18F] Fluciclatide administration OR is scheduled to undergo a\n",
      "             surgical procedure between the baseline and post 1-cycle [18F] Fluciclatide PET/CT.\n",
      "\n",
      "          -  The subject has only bone metastasis\n",
      "\n",
      "        ADDITIONAL EXCLUSION CRITERIA FOR SUBJECTS UNDERGOING OPTIONAL MR:\n",
      "\n",
      "          -  Serum creatinine within 2 weeks prior to MRI greater than or equal to1.8mg/dl OR\n",
      "             estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m(2).\n",
      "\n",
      "          -  The subject has known allergy to gadolinium\n",
      "\n",
      "        2.1.3.3 The subject has contraindications to MRI\n",
      "\n",
      "          -  Subjects must weigh <136 kg (weight limit for scanner table).\n",
      "\n",
      "          -  Subjects cannot have pacemakers, cerebral aneurysm clips, shrapnel injury, or other\n",
      "             implanted electronic devices or metal not compatible with MRI.\n",
      "      \n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          1. Royal Free Hospital - patients >50 years old referred to the vascular clinic for\n",
      "             suspected peripheral arterial disease\n",
      "\n",
      "          2. Leicester\n",
      "\n",
      "               -  age 70 years or older\n",
      "\n",
      "               -  age 50-69 years with a history of smoking, diabetes or peripheral arterial\n",
      "                  disease\n",
      "\n",
      "               -  50-69 years with at least two peripheral arterial disease risk factors\n",
      "                  (hyperlipidaemia, hypertension, family history of cardiovascular disease,\n",
      "                  previous ischaemic event: myocardial infarction, stroke and TIA)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. bilateral amputation that precludes placement of the Padd sensors on the feet\n",
      "\n",
      "          2. acute deep venous thrombosis, within the previous six months (application of ABPI\n",
      "             pressure cuff on legs is not advisable for these patients)\n",
      "\n",
      "          3. skin damage or infection that precludes placement of sensors\n",
      "\n",
      "          4. active psychotic illness or severe cognitive impairment\n",
      "\n",
      "          5. inability to lie supine\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age: 18～70 years\n",
      "\n",
      "          -  Confirmed malignant tumor patients by histopathological or cytological diagnosis, not\n",
      "             previously treated with chemotherapy or radiotherapy,suitable for chemotherapy with\n",
      "             carboplatin combined with taxol or cyclophosphamide combined with pharmorubicin\n",
      "\n",
      "          -  Karnofsky score ≥ 70\n",
      "\n",
      "          -  Normal coagulation function, no evidences of hemorrhage,WBC ≥ 3,500 per cubic\n",
      "             milliliter, ANC ≥ 1,500 per cubic milliliter, PLT ≥ 100,000 per cubic milliliter\n",
      "\n",
      "          -  Normal liver, heart, kidney function\n",
      "\n",
      "          -  Life expectancy > 3 months\n",
      "\n",
      "          -  Signed informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Not adequately controlled infections(e.g. ANC ≥ 12,000 per cubic\n",
      "             milliliter,temperature > 38.2℃)\n",
      "\n",
      "          -  Evidence of metastatic disease in bone marrow,or with other malignant tumors\n",
      "\n",
      "          -  Subjects with symptomatic brain metastases\n",
      "\n",
      "          -  Pregnant or breast-feeding or in menstrual period females\n",
      "\n",
      "          -  Participated more than 3 clinical trials in nearly a year(as subjects)\n",
      "\n",
      "          -  Currently participated in any other clinical trials,or Used any prescription\n",
      "             medication could impact on the metabolism of investigational drug, or participated in\n",
      "             any other clinical trial within one month from the date of the screening visit\n",
      "\n",
      "          -  Donation of whole blood or a unit of blood within three months prior to the start of\n",
      "             study\n",
      "\n",
      "          -  Known hypersensitivity to filgrastim or any of the products to be administered during\n",
      "             dosing\n",
      "\n",
      "          -  Evidence of, or treatment for, drug or alcohol abuse within one year from date of\n",
      "             screening visit\n",
      "\n",
      "          -  Other conditions which in the opinion of the investigator preclude enrollment into the\n",
      "             study\n",
      "      \n",
      "\n",
      "        Inclusion:\n",
      "\n",
      "          -  Patients must have histologically or cytologically confirmed metastatic or\n",
      "             unresectable adenocarcinoma of the colon or rectum.\n",
      "\n",
      "          -  Patients must have measurable disease, defined as at least one lesion that can be\n",
      "             accurately measured in at least one dimension (longest diameter to be recorded for\n",
      "             non-nodal lesions and short axis for nodal lesions) as >20 mm with conventional\n",
      "             techniques or as >10 mm with spiral CT scan, MRI, or calipers by clinical exam. See\n",
      "             Section 11 for the evaluation of measurable disease.\n",
      "\n",
      "          -  Patients must be either intolerant or refractory to one or more standard line(s) of\n",
      "             chemotherapy treatment prior to enrollment. Toxicity from prior regimens must be\n",
      "             resolved to less than or equal to grade 1 prior to enrollment. Patients with grade 2\n",
      "             neurotoxicity may be enrolled on a case by case basis at the discretion of the\n",
      "             principle investigator. Patients should be off all treatment for at least 4 weeks\n",
      "             prior to trial enrollment.\n",
      "\n",
      "          -  Age >18 years. Because no dosing or adverse event data are currently available on the\n",
      "             use of gemcitabine in combination with docetaxel in patients <18 years of age with\n",
      "             colorectal adenocarcinoma, children are excluded from this study, but will be eligible\n",
      "             for future pediatric trials.\n",
      "\n",
      "          -  ECOG performance status 0 or 1 (Karnofsky >70%, see Appendix A).\n",
      "\n",
      "          -  Life expectancy of greater than 12 weeks.\n",
      "\n",
      "          -  Patients must have normal organ and marrow function.\n",
      "\n",
      "        Additional eligibility criteria:\n",
      "\n",
      "          -  Microsatellite instability phenotype of archival tissue biopsy determined by treating\n",
      "             institution by PCR and IHC assay\n",
      "\n",
      "          -  Methylation CHFR gene promoter in archival tissue biopsy\n",
      "\n",
      "          -  As gemcitabine and docetaxel are known to be teratogenic, women of child-bearing\n",
      "             potential and men must agree to use adequate contraception (hormonal or barrier method\n",
      "             of birth control; abstinence) prior to study entry and for the duration of study\n",
      "             participation. Should a woman become pregnant or suspect she is pregnant while she or\n",
      "             her partner is participating in this study, she should inform her treating physician\n",
      "             immediately. Men treated or enrolled on this protocol must also agree to use adequate\n",
      "             contraception prior to the study, for the duration of study participation, and 4\n",
      "             months after completion of treatment.\n",
      "\n",
      "          -  Ability to understand and the willingness to sign a written informed consent document.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering\n",
      "             the study or those who have not recovered from adverse events due to agents\n",
      "             administered more than 4 weeks earlier.\n",
      "\n",
      "          -  Patients who are receiving any other investigational agents.\n",
      "\n",
      "          -  Patients with known brain metastases should be excluded from this clinical trial\n",
      "             because of their poor prognosis and because they often develop progressive neurologic\n",
      "             dysfunction that would confound the evaluation of neurologic and other adverse events.\n",
      "\n",
      "          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n",
      "             composition to gemcitabine or docetaxel.\n",
      "\n",
      "          -  Patients receiving any medications or substances that are inhibitors or inducers of\n",
      "             CYP 3A4 are ineligible. Lists including medications and substances known or with the\n",
      "             potential to interact with the cytochrome 450 3A4 isoenzyme are provided in appendix\n",
      "             C.\n",
      "\n",
      "          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n",
      "             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n",
      "             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n",
      "             study requirements.\n",
      "\n",
      "          -  Pregnant women are excluded from this study because of the potential for teratogenic\n",
      "             or abortifacient effects of study medications. Because there is an unknown but\n",
      "             potential risk for adverse events in nursing infants secondary to treatment of the\n",
      "             mother with gemcitabine and docetaxel breastfeeding should be discontinued if the\n",
      "             mother is treated. These potential risks may also apply to other agents used in this\n",
      "             study including supportive medications.\n",
      "\n",
      "          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of\n",
      "             the potential for pharmacokinetic interactions with gemcitabine and docetaxel. In\n",
      "             addition, these patients are at increased risk of lethal infections when treated with\n",
      "             marrow-suppressive therapy. Appropriate studies will be undertaken in patients\n",
      "             receiving combination antiretroviral therapy when indicated.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age ≥ 18 years.\n",
      "\n",
      "          2. Ejection fraction ≤ 35 %.\n",
      "\n",
      "          3. QRS duration ≥ 120 msec.\n",
      "\n",
      "          4. NYHA class II-IV.\n",
      "\n",
      "          5. On maximum tolerated heart failure medication therapy ≥ 6 weeks.\n",
      "\n",
      "          6. Clinically accepted for CRT device implantation.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Failure to provide consent.\n",
      "\n",
      "          2. CCS class III-IV angina.\n",
      "\n",
      "          3. Recent Q-wave myocardial infarction or revascularization procedure ( ≤ 3 months).\n",
      "\n",
      "          4. Standard contra-indications to MRI.\n",
      "\n",
      "          5. Documented severe allergy to intravenous contrast dye ( iodinated CT contrast or\n",
      "             Gadolinium MRI contrast).\n",
      "\n",
      "          6. Estimated Glomerular Filtration Rate (eGFR) ≤ 45 ml/min/m2.\n",
      "\n",
      "          7. Patient is pregnant.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  has laminectomy with instrumentation or equal or more than 3 levels laminectomy\n",
      "\n",
      "          -  age 18-65 years\n",
      "\n",
      "          -  ASA 1-3\n",
      "\n",
      "          -  elective operation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  allergy to tranexamic acid\n",
      "\n",
      "          -  anemia (Hb<12 g/dl in female or Hb<13 g/dl in male)\n",
      "\n",
      "          -  history of CVT, IHD, PE, strokes\n",
      "\n",
      "          -  liver disease\n",
      "\n",
      "          -  chronic kidney disease with creatinie>2.0 mg/dl\n",
      "\n",
      "          -  receive anticoagulant or coagulopathy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. A complaint of dry mouth as assessed by a response of 30mm or greater on a Dry Mouth\n",
      "             Visual Analog Scale (VAS)\n",
      "\n",
      "          2. Clinical Diagnosis of primary or secondary Sjogren's syndrome.\n",
      "\n",
      "          3. Over the age of 18.\n",
      "\n",
      "          4. Taking less than three drugs associated with causing xerostomia or salivary gland\n",
      "             hypofunction.\n",
      "\n",
      "          5. Willing to use natural novel topical dry mouth products.\n",
      "\n",
      "          6. Prior minor salivary gland biopsy and serology from Sjogren's Syndrome/Xerostomia\n",
      "             work‐up.\n",
      "\n",
      "          7. Willing to return for all study‐associated visits.\n",
      "\n",
      "          8. Able to read, understand, and sign the informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Have received radiation to the head and neck region.\n",
      "\n",
      "          2. Unable to read and understand the consent form.\n",
      "\n",
      "          3. On greater than three drugs associated with xerostomia or salivary gland hypofunction.\n",
      "\n",
      "          4. Require dento‐alveolar surgery or extensive dental treatment during the course of the\n",
      "             study.\n",
      "\n",
      "          5. Require hospitalization for any medical problem during the course of the study.\n",
      "\n",
      "          6. Unable to take green tea leaf extract and/or pilocarpus jaborandi leaf extract and/or\n",
      "             xylitol because of allergy\n",
      "\n",
      "          7. Uncontrolled medical conditions that require changes in medication during the course\n",
      "             of the study.\n",
      "\n",
      "          8. Regularly consume green tea and/or components of pilocarpus jaborandi.\n",
      "\n",
      "          9. Are pregnant\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Undergoing Colonoscopy at Johns Hopkins\n",
      "\n",
      "          -  Ages 18 to 90\n",
      "\n",
      "          -  Access to email (themselves or designee)\n",
      "\n",
      "          -  Access to internet outside of physician visit\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Unable to consent\n",
      "\n",
      "          -  Unwilling to participate\n",
      "\n",
      "          -  Unable to care for themselves\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  have experiences of more than 100 cases of endotracheal intubation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  have acute or chronic musculoskeletal disease or pain\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All participants must have a diagnosis of Type 2 diabetics.\n",
      "\n",
      "          -  Diabetes began after age 30\n",
      "\n",
      "          -  Mentees: Have an HbA1c > 8% on 2 different occasions in the course of 24 months, with\n",
      "             at least one measure within 3 months of enrollment\n",
      "\n",
      "          -  Mentors for Phase 1: Had an HbA1c of > 8% in the past 3 years and an HbA1c < (or equal\n",
      "             to) 7.5% within 3 months of enrollment\n",
      "\n",
      "          -  Mentors for Phase 2: Former mentee\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Does not speak English\n",
      "\n",
      "          -  Unable to understand consents\n",
      "\n",
      "          -  Severe speech impediment\n",
      "\n",
      "          -  over the age of 75\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Healthy Chinese subjects, male, 20 to 45 years of age included, and in good health as\n",
      "             determined by past medical history, physical examination, vital signs,\n",
      "             electrocardiogram, and laboratory tests at screening.\n",
      "\n",
      "          2. At Screening, vital signs (systolic and diastolic blood pressure and pulse rate) will\n",
      "             be assessed in the sitting position after the subject has rested for 5 minutes. All of\n",
      "             vital signs should be within normal ranges:\n",
      "\n",
      "               -  Body temperature (Body) between 35.0-37.0°C\n",
      "\n",
      "               -  90 ≤ systolic blood pressure <140 mm Hg\n",
      "\n",
      "               -  60≤ diastolic blood pressure < 90 mm Hg\n",
      "\n",
      "               -  50≤ pulse rate ≤ 100\n",
      "\n",
      "          3. Body weight need to be at least 50kg or above, 19kg/m2≤ Body Mass Index(BMI) ≤25kg/m2\n",
      "\n",
      "          4. Be able to communicate well with the investigator, to understand and comply with the\n",
      "             requirements of the study. Understand and sign the written informed consent prior to\n",
      "             any screening procedures.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. History or clinical manifestations of significant metabolic, hepatic, renal,\n",
      "             hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological,\n",
      "             genetic or psychiatric disorders.\n",
      "\n",
      "          2. A past medical history of clinically significant ECG abnormalities or a family history\n",
      "             (grandparents, parents and siblings) of long QT syndrome, or QTc interval > 440 ms for\n",
      "             male or any abnormal ECG findings at screening.\n",
      "\n",
      "          3. Medical histories of syncope, electrophysiological changes, heart failure, reduced\n",
      "             exercise tolerance, cardiomyopathy, pericarditis, myocarditis or other cardiac\n",
      "             disorders as determined by the investigator.\n",
      "\n",
      "          4. Current electrolyte abnormalities (specifically hypokalemia) in laboratory examination\n",
      "             during the screening that are clinical significant as determined by investigator.\n",
      "\n",
      "          5. Current or recent history (< 30 days prior to Screening) of a clinically significant\n",
      "             illness.\n",
      "\n",
      "          6. Use of any prescription drugs, herbal supplements, within 4 weeks prior to initial\n",
      "             dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins\n",
      "             included) within 4 week prior to initial dosing.\n",
      "\n",
      "          7. Positive results of human immunodeficiency virus, Hepatitis B surface antigen or\n",
      "             Hepatitis C antibody testing.\n",
      "\n",
      "          8. History of any hypersensitivity or allergic reaction of moxifloxacin or other types\n",
      "             fluoroquinolones.\n",
      "\n",
      "          9. Use of tobacco or history of use of tobacco ( > 5 tobacco/week) or nicotine-containing\n",
      "             products in the 3 months prior to screening.\n",
      "\n",
      "         10. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of\n",
      "             such abuse as indicated by the laboratory assays conducted during the screening and/or\n",
      "             at baseline.\n",
      "\n",
      "         11. Dosing of study drug in any clinical investigation within 3 months prior to initial\n",
      "             dosing.\n",
      "\n",
      "         12. Donation or loss of 200 ml or more of blood within 3 months prior to participation, or\n",
      "             donation of component blood within 3 months prior to participation.\n",
      "\n",
      "         13. Consumption of alcohol-, caffeine --containing foods or beverages within 48 hours\n",
      "             preceding study drug administration.\n",
      "\n",
      "         14. Other conditions which investigator deems potential harm to subjects if participate\n",
      "             the study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Inappropriate sinus tachycardia (HR >100 bpm at rest ECG and/or medium Holter ECG HR\n",
      "             >90 bpm)\n",
      "\n",
      "          -  Age > 18 years;\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Secondary causes of sinus tachycardia;\n",
      "\n",
      "          -  Structural heart diseases,\n",
      "\n",
      "          -  Postural orthostatic tachycardia syndrome;\n",
      "\n",
      "          -  Sinus nodal reentrant tachycardia;\n",
      "\n",
      "          -  Contraindications to beta-blockers;\n",
      "\n",
      "          -  Administration of beta-blockers, non-di-hydropiridinic calcium channels antagonists,\n",
      "             class I and III anti-arrhythmic drugs or digitalis at the time of enrollment;\n",
      "\n",
      "          -  Age < 18 years;\n",
      "\n",
      "          -  Inability of giving informed consent;\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Pupils enrolled at participating schools in classes 1-7.\n",
      "\n",
      "          -  Provision of informed consent from parent or legal guardian.\n",
      "\n",
      "          -  Provision of assent by student.\n",
      "\n",
      "          -  Detectable infection with A.lumbricoides, T. trichiura and/or hookworm species.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pupils unwilling to participate in the study.\n",
      "\n",
      "          -  Pupils who are infected with S. haematobium or S. mansoni. These children will be\n",
      "             treated with praziquantel.\n",
      "\n",
      "          -  Known or suspected sickle-cell trait.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age 18-90 years\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  none\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18-35 years old\n",
      "\n",
      "          -  Currently married\n",
      "\n",
      "          -  Intends to live in the study area for the next 24 months\n",
      "\n",
      "          -  Plans to have children in the next year\n",
      "\n",
      "          -  Agrees to participate with informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Currently pregnant\n",
      "\n",
      "          -  Delivered in the previous six months\n",
      "\n",
      "          -  Regularly consumed IFA or MM supplements in the past 2 months\n",
      "\n",
      "          -  Severe anemia (Hb < 7 g/L)\n",
      "\n",
      "          -  History of high risk pregnancy including abruptio placenta, placenta previa,\n",
      "             gestational diabetes, pregnancy induced hypertension, coagulation disorders,\n",
      "             thrombocytopenia or chronic vascular, renal or systemic disease and drug use\n",
      "\n",
      "          -  Chronic hematological diseases, hereditary defects of red cells or hemoglobin\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Patients with a minor injury or injuries, defined as:\n",
      "\n",
      "          1. no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and\n",
      "             admission;\n",
      "\n",
      "          2. no blood transfusion requirement;\n",
      "\n",
      "          3. base deficit < 5 mEq/L;\n",
      "\n",
      "          4. no requirement for mechanical ventilation other than transiently during orthopedic\n",
      "             surgery.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Pregnancy\n",
      "\n",
      "          2. corticosteroid use,\n",
      "\n",
      "          3. prisoners, and/or\n",
      "\n",
      "          4. head trauma as determined by computed tomography (head trauma may itself induce\n",
      "             diabetes insipidus, a marker of pituitary damage and vasopressin deficiency), and/or\n",
      "\n",
      "          5. evidence of spinal cord injury (another cause of vasodilatory shock).\n",
      "\n",
      "        Patients will also be excluded if pre-hospital provider information cannot be obtained, or\n",
      "        indicates that the trauma occurred more than one 1 hour prior to emergency department\n",
      "        admission.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Biopsy-proven locally-advanced HNSCC, including those with cancers of the oral cavity,\n",
      "             oropharynx, hypopharynx, larynx, nasopharynx or paranasal sinuses\n",
      "\n",
      "          -  Stage III, IVa or IVb disease\n",
      "\n",
      "          -  No prior definitive surgery for present diagnosis\n",
      "\n",
      "          -  Appropriate candidate for concurrent cisplatin and radiation as definitive treatment;\n",
      "             patients who receive induction chemotherapy as part of a definitive treatment program\n",
      "             that will include concurrent CRT are eligible for this study\n",
      "\n",
      "          -  Hemoglobin >= 10 g/dL (100 g/l)\n",
      "\n",
      "          -  Absolute neutrophil count >= 2,000 cells/mm^3 (2 x 10^9/l)\n",
      "\n",
      "          -  Platelets >= 100,000 cells/mm^3 (100 x 10^9/l)\n",
      "\n",
      "          -  Serum creatinine =< 1.5 mg/dL (133 umol/l) or calculated creatinine clearance >= 50\n",
      "             ml/min using the Cockcroft-Gault formula\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n",
      "\n",
      "          -  Able to give written informed consent\n",
      "\n",
      "          -  Be willing and able to comply with study procedures\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Non-regional metastatic disease (stage IVc)\n",
      "\n",
      "          -  Previous malignancy within the last 5 years except for adequately treated basal or\n",
      "             squamous cell carcinoma of the skin or cervical intra-epithelial neoplasia\n",
      "\n",
      "          -  Prior chemotherapy or radiotherapy for HNSCC, or any prior radiotherapy that would\n",
      "             compromise delivery of a radical dose to the HNSCC\n",
      "\n",
      "          -  Known to be positive for hepatitis C or human immunodeficiency virus (HIV)\n",
      "\n",
      "          -  Unable to tolerate oral medication (unless a feeding tube is in place)\n",
      "\n",
      "          -  History of hypersensitivity to platinum drugs\n",
      "\n",
      "          -  Symptomatic peripheral neuropathy >= National Cancer Institute (NCI)-Common\n",
      "             Terminology Criteria for Adverse Events (CTCAE) grade II\n",
      "\n",
      "          -  Pregnant, lactating or unwilling to use adequate contraception\n",
      "\n",
      "          -  Women of child-bearing potential and men must agree to use adequate contraception\n",
      "             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\n",
      "             the duration of study participation\n",
      "\n",
      "          -  Planned use of amifostine for prophylaxis against radiation-induced xerostomia\n",
      "\n",
      "          -  Patients taking selenium supplements in excess of 100 ug/day\n",
      "\n",
      "          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n",
      "             infection, symptomatic congestive heart failure, unstable angina pectoris, clinically\n",
      "             significant cardiac arrhythmia, or psychiatric illness/social situations that would\n",
      "             limit compliance with study requirements\n",
      "\n",
      "          -  Evidence of any other significant medical disorder or laboratory finding that in the\n",
      "             opinion of the Investigator compromises the subject's safety during the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  ASA physical status II, with chronic, clinically complete cord injuries scheduled for\n",
      "             a surgery for pressure sore below the level of the neurologic lesion under general\n",
      "             anesthesia.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Cardiovascular, pulmonary, or metabolic diseases. Patients who took medications that\n",
      "             would influence autonomic or cardiovascular responses to the surgery\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must meet the following eligibility requirements to be enrolled in the study:\n",
      "\n",
      "               1. Patient must be 18 years of age or older.\n",
      "\n",
      "               2. Patient must have known or strongly suspected recurrent or metastatic cancer from\n",
      "                  a solid tumor with at least one identifiable lesion > 1.5 cm as diagnosed by\n",
      "                  conventional imaging.\n",
      "\n",
      "               3. Patient must have adequate kidney function defined as serum creatinine of < 1.5 X\n",
      "                  ULN.\n",
      "\n",
      "               4. Patient must have adequate liver function defined as transaminases (SGOT and/or\n",
      "                  SGPT) may be up to 2.5 X ULN if alkaline phosphatase is <ULN or alkaline\n",
      "                  phosphatase may be up to 2.5 X ULN if Transaminases are < ULN. If alkaline\n",
      "                  phosphatase is outside of these parameters and is due to bone metastases verified\n",
      "                  by assessment of isoenzymes, then the subject is eligible.\n",
      "\n",
      "               5. Patient must provide written informed consent prior to enrollment.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients must be excluded in any of the following conditions are present:\n",
      "\n",
      "               1. Patient is pregnant or breastfeeding.\n",
      "\n",
      "               2. Patient is simultaneously participating in another investigational drug study,\n",
      "                  excluding the follow-up phase.\n",
      "\n",
      "               3. Patient has received an investigational agent within 7 days prior to enrollment.\n",
      "\n",
      "               4. Patient is unable to tolerate conditions for radionuclide imaging.\n",
      "\n",
      "               5. Patient has been administered another radiopharmaceutical that would interfere\n",
      "                  with the assessment of Technetium Tc 99m EC20.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with new diagnosed hematological diseases (acute and chronic myeloid and\n",
      "             lymphoid leukemia, multiple myeloma, non-Hodgkin's and Hodgkin's lymphoma,\n",
      "             myelodysplastic syndromes)\n",
      "\n",
      "          -  Patients who are receiving chemotherapy and have ongoing febrile episodes\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  None\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Morbid obesity,BMIs> 40 kg/m2\n",
      "\n",
      "          -  Subjects who underwent bariatric surgery\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Obese subjects with complicated metabolic disorders\n",
      "\n",
      "          -  Thyroid disease\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  gynecologic abdominal laparotomy patients\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  non gynecologic abdominal laparotomy patients\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Signed the informed consent form prior to study participation.\n",
      "\n",
      "          -  A healthy male volunteer between 20 and 55 years old.\n",
      "\n",
      "          -  Body weight between 55kg and 90kg, BMI between 18 and 27.\n",
      "\n",
      "          -  Appropriate subject for the study judging from investigator(physical examination,\n",
      "             laboratory test, interview, etc.)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Have the medical history of allergic diseases including hypersensitivity against drug\n",
      "             or clinically significant allergic diseases\n",
      "\n",
      "          -  Clinically significant hepatic, renal, respiratory system, endocrine system, nervous\n",
      "             system, immune system, hematologic, psychiatric, circulatory system, tumor or have\n",
      "             history of tumor\n",
      "\n",
      "          -  Have abnormal laboratory result.\n",
      "\n",
      "               -  Hemoglobin < 12g/dL or > 17g/dL\n",
      "\n",
      "               -  Vitamin B12 < 200pg/mL\n",
      "\n",
      "               -  Ferritin < 21.8ng/mL\n",
      "\n",
      "               -  Transferrin < 190mg/dL\n",
      "\n",
      "               -  Reticulocyte over the normal limit\n",
      "\n",
      "               -  Positive for the Triage TOX drug on urine (cocaine, amphetamines, barbiturates,\n",
      "                  opiates, benzodiazepine, cannabinoids)\n",
      "\n",
      "               -  Positive for HIV antibody, HBsAg, HCV antibody test\n",
      "\n",
      "          -  A heavy smoker (cigarette > 10 cigarettes per day)\n",
      "\n",
      "          -  Administer EPO, darbepoetin, immunoglobulin or IV iron within 3 months prior to the\n",
      "             first IP administration\n",
      "\n",
      "          -  Have hypersensitivity reactions history for EPO, darbepoetin, excipient of IP or iron\n",
      "             tablets\n",
      "\n",
      "          -  sit SBP < 90mmHg or sit SBP > 140mmHg or sit DBP < 55mmHg or sit DBP > 90mmHg or Pulse\n",
      "             rate > 100 per/min\n",
      "\n",
      "          -  History of hemoglobinopathy or inflammatory disease or drug abuse within 6 months\n",
      "             before screening\n",
      "\n",
      "          -  Subject takes ethical drug or herbal medicine within 14 days, OTC or vitamin\n",
      "             supplements within 7 days before the first IP administration\n",
      "\n",
      "          -  Participated in the other clinical trials and administrated IP within 8 weeks prior to\n",
      "             the first IP administration\n",
      "\n",
      "          -  A heavy alcohol consumer (alcohol > 21 units/week) or cannot stop drinking\n",
      "\n",
      "          -  Bleed or donate blood (> 400mL) within 8 weeks before the first IP administration\n",
      "\n",
      "          -  Participated in this clinical trials and administrated IP\n",
      "\n",
      "          -  Have a diet within 2 days before the first IP administration or cannot stop having\n",
      "\n",
      "               -  food containing grapefruit\n",
      "\n",
      "               -  food containing caffeine\n",
      "\n",
      "          -  Disagree to avoid getting pregnant during clinical trial\n",
      "\n",
      "          -  An impossible one who participates in clinical trial by investigator's decision\n",
      "             including laboratory test result, other reason\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Veterans will have to meet the following inclusion criteria in order to be enrolled in this\n",
      "        RCT:\n",
      "\n",
      "          -  Men and women at least 18 years of age.\n",
      "\n",
      "          -  Meet current DSM-IV-TR criteria for PTSD as determined by the Clinician Administered\n",
      "             PTSD Scale (CAPS)\n",
      "\n",
      "          -  Insomnia Severity Index score > 14, the commonly used threshold for clinical insomnia,\n",
      "             with self-reported duration of insomnia >6 months.\n",
      "\n",
      "          -  Ability to read and speak English (assessment instruments and therapy will be\n",
      "             available only in English)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Veterans will be excluded from participation if they meet any of the following exclusion\n",
      "        criteria:\n",
      "\n",
      "          -  Unable or unwilling to provide informed consent.\n",
      "\n",
      "          -  Unwilling to participate in supervised group sessions at the community based\n",
      "             outpatient clinic\n",
      "\n",
      "          -  No telephone access or inability to return for follow-up testing.\n",
      "\n",
      "          -  Individuals with an untreated sleep disorder [e.g., obstructive sleep apnea\n",
      "             (apnea-hypopnea index 15 events/hr), periodic limb movement disorder (10 leg\n",
      "             movements/hr of sleep with arousals), central sleep apnea ( 50% of apneas are\n",
      "             central), Cheyne-Stokes respiration, obesity hypoventilation syndrome, and\n",
      "             narcolepsy].\n",
      "\n",
      "          -  A clinically unstable medical condition as defined by a new diagnosis or change in\n",
      "             medical management in the previous 2 months.\n",
      "\n",
      "          -  Evidence of substance dependence during the preceding twelve months. Evidence of \"at\n",
      "             risk\" drinking behavior over the past month. Namely for men: more than 4 drinks on a\n",
      "             given night, drinking on more than 3 nights a week, or more than 14 total drinks in a\n",
      "             week; for women: more than 3 drinks in a given night, drinking on more than 3 nights a\n",
      "             week, or more than 7 total drinks in a week.\n",
      "\n",
      "          -  Individuals with bipolar disorder, delirium, dementia, amnestic disorder,\n",
      "             schizophrenia and other psychotic disorders as determined by the SCID questionnaire. A\n",
      "             concurrent anxiety disorder or depressive disorder diagnosis will be allowed.\n",
      "\n",
      "          -  Individuals with prominent current suicidal or homicidal ideation. This will be\n",
      "             assessed by the clinical psychologist administering the SCID and CAPS. In cases of\n",
      "             prominent current suicidal or homicidal ideation appropriate safety measures will be\n",
      "             taken. Following stabilization, Veterans who continue to be interested in\n",
      "             participating in the study may be re-assessed.\n",
      "\n",
      "          -  Unable to perform tests due to inability to communicate verbally, inability to read\n",
      "             and write; less than a 5th grade reading level; visual, hearing or cognitive\n",
      "             impairment (e.g., previous head injury).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Locally advanced squamous cell carcinoma of the head and neck and participation in the\n",
      "             HICARE-phase-IV-trial\n",
      "\n",
      "          -  Cetuximab-induced painful rhagades, i.e. SUPO Score 2-3 (see Figure 2)\n",
      "\n",
      "          -  Compliance to the photo documentation\n",
      "\n",
      "          -  Ability of subject to understand character and individual consequences of the clinical\n",
      "             trial\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Cetuximab-induced rhagades without any pain, i.e. SUPO Score 1\n",
      "\n",
      "          -  Cetuximab-induced rhagades, SUPO Score 4, i.e. superinfection of the rhagades\n",
      "\n",
      "          -  Patients not being enrolled in the HICARE trial\n",
      "\n",
      "          -  Substance misuse, psychoactive substance abuse or psychological/social conditions\n",
      "             leading to a decreased patients' compliance with possible bad influence to the results\n",
      "             of the study\n",
      "\n",
      "          -  Known allergic reaction to ethyl-2-cyanoacrylate (ECA)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Signed informed consent\n",
      "\n",
      "          -  Women over 25 years of age\n",
      "\n",
      "          -  Dermatologic diagnostic of melasma\n",
      "\n",
      "          -  Phototype III or more\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant or breastfeeding\n",
      "\n",
      "          -  Postbirth, abortion in the past 6 months\n",
      "\n",
      "          -  Having an endocrine or autoimmune disease\n",
      "\n",
      "          -  Under hormonal therapy of any kind including contraceptives or it´s use in the past 6\n",
      "             months\n",
      "\n",
      "          -  Currently under treatment for melasma including sunscreens\n",
      "\n",
      "          -  Currently under radiation therapy, chemotherapy, immunosuppressants of any kind or\n",
      "             phototherapy or it´s use in the past 6 months\n",
      "\n",
      "          -  Having used or are consuming photosensitizing substances, oral or topical\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  either gender aged 18 to 65 years\n",
      "\n",
      "          -  have FC diagnosed as Rome III criterial\n",
      "\n",
      "          -  have diagnosis of Excessive Constipation according to the TCM theory\n",
      "\n",
      "          -  complete spontaneous bowel movement (CSBM) ≦2times/w\n",
      "\n",
      "          -  severity of constipation≧3pts (7 pts scale from 0 to 6pts) and the overall scoring of\n",
      "             constipation-related symptoms≧6pts (6items in 7pts scale) for self symptom assessment\n",
      "             in the run-in period\n",
      "\n",
      "          -  normal colonic evaluation (colonoscopy or barium enema) within 12 months\n",
      "\n",
      "          -  normal liver and renal function in blood test within 3 months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  drug-induced constipation\n",
      "\n",
      "          -  secondary causes of constipation (i.e. medical history of diabetes mellitus and\n",
      "             thyroid disease)\n",
      "\n",
      "          -  abdominal surgery (i.e. Caesarean operation)\n",
      "\n",
      "          -  severe diseases (i.e. cancer and acute present asthma)\n",
      "\n",
      "          -  allergy to CHM (i.e. G6PD deficiency), senna and tartrazine\n",
      "\n",
      "          -  pregnancy or breast-feeding\n",
      "\n",
      "          -  psychiatric or addictive disorders\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Pathologically confirmed non-lymphoma liver metastases or\n",
      "\n",
      "        New radiographic liver lesions consistent with metastases in patients with known\n",
      "        pathologically confirmed non-lymphoma cancer\n",
      "\n",
      "        1-3 liver lesions measurable on CT/MRI or PET/CT performed within 6 weeks prior to study\n",
      "        entry\n",
      "\n",
      "        Liver metastases measuring <5cm\n",
      "\n",
      "        Life expectancy >6 months\n",
      "\n",
      "        Disease outside the liver is allowed\n",
      "\n",
      "        Age ≥ 18\n",
      "\n",
      "        ECOG Performance Scale = 0-1\n",
      "\n",
      "        Adequate bone marrow function, defined as follows:\n",
      "\n",
      "          -  Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 based upon CBC/differential obtained\n",
      "             within 4 weeks prior to registration on study\n",
      "\n",
      "          -  Platelets ≥ 60,000 cell/mm3 based upon CBC/differential obtained within 4 weeks prior\n",
      "             to registration on study\n",
      "\n",
      "          -  Hemoglobin ≥ 8.0 g/dl based upon CBC/differential obtained within 4 weeks prior to\n",
      "             registration on study (Note: the use of transfusion or other intervention to achieve\n",
      "             Hgb ≥ 8.0 is acceptable.)\n",
      "\n",
      "        Adequate kidney function (serum creatinine <2mg/dL) based on chemistry panel obtained\n",
      "        within 4 weeks prior to registration on study\n",
      "\n",
      "        Adequate liver function, defined as total bilirubin <5 mg/dL, serum albumin >2.0g/dL, serum\n",
      "        levels of liver enzymes < 5 times the upper limit of normal, and INR < 1.5\n",
      "\n",
      "        Previous liver resection or ablative therapy is permitted\n",
      "\n",
      "        Chemotherapy and/or targeted agent therapy must be completed at least 2 weeks prior to\n",
      "        radiation and started at least 14 days after completion of SBPT Women of childbearing\n",
      "        potential and male participants must practice adequate contraception\n",
      "\n",
      "        Patient must sign study specific informed consent prior to study entry\n",
      "\n",
      "        Pretreatment evaluations required for eligibility include:\n",
      "\n",
      "          -  A complete history and general physical examination\n",
      "\n",
      "          -  For women of childbearing potential, a serum or urine pregnancy test must be performed\n",
      "             within 72 hours prior to registration\n",
      "\n",
      "          -  INR, total bilirubin, albumin, alkaline phosphatase, ALT, AST within 4 weeks prior to\n",
      "             study entry\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Prior invasive malignancy other than liver met primary (except non-melanomatous skin\n",
      "        cancer) unless disease free for > 3years\n",
      "\n",
      "        Prior radiotherapy that would results in overlap of radiation fields\n",
      "\n",
      "        Prior radiotherapy to the liver\n",
      "\n",
      "        Severe, active co-morbidity that may impact survival\n",
      "\n",
      "        CNS metastases\n",
      "\n",
      "        Tense ascites requiring frequent paracentesis\n",
      "\n",
      "        Active liver infection\n",
      "\n",
      "        Pregnancy, nursing women, or women of child bearing potential, and men who are sexually\n",
      "        active and not willing/able to use medically acceptable forms of contraception\n",
      "\n",
      "        Metastases location within 2cm of GI tract\n",
      "\n",
      "        -\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Males and females, ages 2 yrs to 8 yrs\n",
      "\n",
      "          -  Children already undergoing a lumbar puncture procedure for clinical or diagnostic\n",
      "             purposes\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Presence of any significant neurological diseases, as judged by the co-investigators\n",
      "\n",
      "          -  Presence of any significant medical conditions including cancer\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All ACLF due to HEV\n",
      "\n",
      "          -  Consent to participate in trial and collection of blood.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant and nursing mothers.\n",
      "\n",
      "          -  Severe anemia\n",
      "\n",
      "          -  Other etiologies of ACLF (eg. Alcohol, drugs, reactivation of hepatitis B and\n",
      "             hepatitis C, variceal bleeding, surgical intervention and sepsis)\n",
      "\n",
      "          -  Hepatocellular carcinoma (HCC)\n",
      "\n",
      "          -  Hepatorenal syndrome (HRS) at admission\n",
      "\n",
      "          -  Presence of life threatening cardiovascular, respiratory and neurological disease\n",
      "\n",
      "          -  Acquired Immunodeficiency Syndrome\n",
      "\n",
      "          -  Patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)\n",
      "\n",
      "          -  Refusal to provide consent to participate in the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  diagnosis of mammary neoplasms and plans to undergo an elective ALND of Berg´s levels\n",
      "             I and II due to axillary metastasis determined preoperatively by core biopsy or\n",
      "             evidence of metastasis in the SLNB in the intraoperative or in the differed analysis.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  chronic renal failure due to possible toxicity of gentamicin\n",
      "\n",
      "          -  patients undergoing a modified radical mastectomy.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients:\n",
      "\n",
      "               1. A diagnosis of knee OA and suitable for the study as determined by a responsible\n",
      "                  physician, based on a medical evaluation including medical history, physical\n",
      "                  examination, laboratory tests and cardiac monitoring.\n",
      "\n",
      "               2. Have a radiological and clinical diagnosis of knee OA based upon American College\n",
      "                  of Rheumatology (ACR) criteria (1986) affecting at least one knee of a minimum of\n",
      "                  3 months in symptom duration prior to screening.\n",
      "\n",
      "               3. Subject is either male or female and at least 45 years of age.\n",
      "\n",
      "               4. A minimum of 4 out of 10 on the numerical rating scale (Brief Pain Inventory- BPI\n",
      "                  item 5) at screening and/ or a requirement for the use of an analgesic for the\n",
      "                  pain in the OA knee. In addition, baseline pain must be stable for at least 72\n",
      "                  hours prior to fMRI assessment or fMRI assessment may be delayed.\n",
      "\n",
      "               5. A maximum of 8 out of 10 on the NRS at screening. Enrolment may be delayed if, in\n",
      "                  the opinion of the investigator, the severity of pain represents an isolated\n",
      "                  incident.\n",
      "\n",
      "               6. A female subject is eligible to participate if she is of non-childbearing\n",
      "                  potential.\n",
      "\n",
      "               7. Body weight <120kg.\n",
      "\n",
      "               8. Capable of giving written informed consent, which includes compliance with the\n",
      "                  requirements and restrictions listed in the consent form.\n",
      "\n",
      "               9. Subject demonstrates an understanding of the study and a willingness to\n",
      "                  participate as evidenced by voluntary written informed consent.\n",
      "\n",
      "          -  Controls:\n",
      "\n",
      "               1. Subject is either male or female and at least 45 years of age.\n",
      "\n",
      "               2. Absence of clinically relevant neurologic and psychiatric disease and history of\n",
      "                  head trauma with loss of consciousness.\n",
      "\n",
      "               3. Absence of non-compensated medical diseases and pain disorders that may\n",
      "                  relevantly affect brain function and pain perception.\n",
      "\n",
      "               4. No clinical evidence of knee OA.\n",
      "\n",
      "               5. A female subject is eligible to participate if she is of non-childbearing\n",
      "                  potential.\n",
      "\n",
      "               6. Body weight <120kg.\n",
      "\n",
      "               7. Capable of giving written informed consent, which includes compliance with the\n",
      "                  requirements and restrictions listed in the consent form.\n",
      "\n",
      "               8. Subject demonstrates an understanding of the study and a willingness to\n",
      "                  participate as evidenced by voluntary written informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. - Subjects will not be permitted to heavily exercise for 12 hours prior to fMRI\n",
      "             assessment\n",
      "\n",
      "          2. - Subjects will be required to refrain from the following treatments: I.- Analgesic\n",
      "             and anti-inflammatory drugs for 3 days prior to fMRI assessment except for rescue\n",
      "             medication. Rescue medication will be based on paracetamol (dosed 1g/8h), which in any\n",
      "             case must be withdrawn for a minimum of 24 h prior to fMRI assessment or the fMRI\n",
      "             assessment may be delayed.\n",
      "\n",
      "        II.- Steroid injections into the joint or muscle for three months prior to fMRI assessment\n",
      "        III.- Hyaluronan injections into index knee within the previous 6 months prior fMRI\n",
      "        assessment IV.- Non-pharmacological treatments, such as heat wraps or massage for 24 hours\n",
      "        prior to fMRI assessment.\n",
      "\n",
      "        V.- Antidepressants not allowed: MAOIs, Tricyclic antidepressants, mixed 5HT & NE reuptake\n",
      "        inhibitors (eg. Duloxetine). SISR are not allowed as a recent prescription, moreover they\n",
      "        are allowed in case of chronic use (more than 6 weeks). If those drugs are used for less\n",
      "        than 6 weeks, patients could participate in the study after a washout period.\n",
      "\n",
      "        VI.- Anticonvulsant indicated as a pain killer are not allowed, but patients could\n",
      "        participate in the study after a washout period.\n",
      "\n",
      "        VII.- Patients can take low doses of hypnotic drugs (eg. Lorazepam 1mg/OD or Diazepam\n",
      "        5mg/OD) if they are used as a chronic prescription (more than 6 weeks). If they are used\n",
      "        for less than 6 weeks, patients could participate in the study after a washout period.\n",
      "\n",
      "        Subjects will be allowed to take their chronic (non-analgesic and non-anti-inflammatory)\n",
      "        medications if the treatments have been used continuously for at least six weeks prior to\n",
      "        assessment.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        A diagnosis of rheumatoid arthritis based on 2010 ACR / EULAR Rheumatoid Arthritis\n",
      "        Classification Criteria. Classification as \"definite RA\" is based on:\n",
      "\n",
      "          -  the confirmed presence of synovitis in at least 1 joint\n",
      "\n",
      "          -  absence of an alternative diagnosis that better explains the synovitis\n",
      "\n",
      "          -  and achievement of a total score of 6 or greater (of a possible 10): 24 Joint\n",
      "             involvement, designating the metacarpophalangeal joints, proximal interphalangeal\n",
      "             joints, the interphalangeal joint of the thumb, second through third\n",
      "             metatarsophalangeal joint and wrist as small joints, and elbows, hip joints and knees\n",
      "             as large joints:\n",
      "\n",
      "               1. Involvement of 1 large joint gives 0 points\n",
      "\n",
      "               2. Involvement of 2-10 large joints gives 1 point\n",
      "\n",
      "               3. Involvement of 1-3 small joints (with or without involvement of large joints)\n",
      "                  gives 2 points\n",
      "\n",
      "               4. Involvement of 4-10 small joints (with or without involvement of large joints)\n",
      "                  gives 3 points\n",
      "\n",
      "               5. Involvement of more than 10 joints (with involvement of at least 1 small joint)\n",
      "                  gives 5 points\n",
      "\n",
      "          -  Serological parameters - including the rheumatoid factor as well as anti-citrullinated\n",
      "             protein antibody (ACPA):\n",
      "\n",
      "               1. Negative RF and negative ACPA gives 0 points\n",
      "\n",
      "               2. Low-positive RF or low-positive ACPA gives 2 points\n",
      "\n",
      "               3. High-positive RF or high-positive ACPA gives 3 points Acute phase reactants: 1\n",
      "                  point for elevated erythrocyte sedimentation rate (ESR) or elevated C-reactive\n",
      "                  protein (CRP) value Duration of arthritis: 1 point for symptoms lasting six weeks\n",
      "                  or longer\n",
      "\n",
      "          -  Continuing or recurring pain (i.e., joint pain daily, unless on pain medication).\n",
      "\n",
      "          -  Age at least 18 years\n",
      "\n",
      "          -  Ability and willingness to participate in all components of the study\n",
      "\n",
      "          -  Willingness to be assigned to either the diet group or supplement group\n",
      "\n",
      "          -  Pain medications unchanged within last 6 weeks.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  < 18 years of age\n",
      "\n",
      "          -  Rheumatoid arthritis for more than 6 years\n",
      "\n",
      "          -  Alcohol consumption of more than 2 drinks per day or the equivalent, episodic\n",
      "             increased drinking (e.g., more than 2 drinks per day on weekends), or a history of\n",
      "             alcohol abuse or dependency followed by any current use\n",
      "\n",
      "          -  Use of recreational drugs in the past 6 months (past drug use, if fully recovered, is\n",
      "             not a criteria for exclusion)\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Unstable medical or psychiatric illness\n",
      "\n",
      "          -  Likely to be disruptive in group sessions (as determined by research staff)\n",
      "\n",
      "          -  Already following a low-fat, vegan diet\n",
      "\n",
      "          -  Lack of English fluency\n",
      "\n",
      "          -  Inability to maintain current medication regimen\n",
      "\n",
      "          -  Inability or unwillingness to participate in all components of the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Acute, unilateral, unstable, inversion ankle sprain (Grade II, III)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Conditions affecting the neuromuscular- or musculoskeletal System\n",
      "\n",
      "          -  Previous surgical interventions to the foot, ankle, knee or hip; known FAI, CAI\n",
      "\n",
      "          -  Conditions possibly affecting balance\n",
      "\n",
      "          -  Cardiovascular disease including thrombosis\n",
      "\n",
      "          -  Respiratory diseases\n",
      "\n",
      "          -  Abdominal diseases (including gallstones)\n",
      "\n",
      "          -  Urological diseases (including kidney- and bladder stones)\n",
      "\n",
      "          -  Gynaecological diseases and + intrauterine devices\n",
      "\n",
      "          -  Neurological diseases including epilepsia within the last 2 years\n",
      "\n",
      "          -  Acute injuries to the head\n",
      "\n",
      "          -  Patient is not available for follow up visits\n",
      "\n",
      "          -  Patient unable to give informed consent\n",
      "\n",
      "          -  Patient suspected to be non-compliant\n",
      "      \n",
      "\n",
      "        Experimental group:\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  patients with the diagnosis including lumbar spondylosis, low back pain, osteoporosis,\n",
      "             compression fracture, back pain treated at National Taiwan University Hospital\n",
      "\n",
      "          -  received rehabilitation at the Physical Therapy Center in recent ten years.\n",
      "\n",
      "        Control group:\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  patients with the diagnosis including lumbar spondylosis, low back pain, osteoporosis,\n",
      "             compression fracture, back pain treated at National Taiwan University Hospital\n",
      "\n",
      "          -  not received rehabilitation at the Physical Therapy Center in recent ten years.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Adults\n",
      "\n",
      "          -  If Primary Caregiver is the Parent/Legal guardian: The parent/legal guardian must\n",
      "             provide written informed consent for the child and her/himself (if s/he is the primary\n",
      "             caregiver) prior to participation.\n",
      "\n",
      "          -  If Primary Caregiver is not the Parent/Legal Guardian: If another individual is the\n",
      "             primary caregiver, then this individual must provide written informed consent for\n",
      "             her/himself prior to participation.\n",
      "\n",
      "          -  The parent/legal guardian and the participating primary caregiver must each be at\n",
      "             least 18 years old or an emancipated minor\n",
      "\n",
      "          -  The parent/legal guardian must consent and allow examination of the oral cavity of\n",
      "             her/his child. The primary caregiver must complete the caries risk assessment\n",
      "             questionnaire.\n",
      "\n",
      "          -  The primary caregiver must be willing to participate, anticipate being the child's\n",
      "             primary caregiver during the study period, and anticipate being available for all\n",
      "             examinations (baseline, 18 month follow up, and 36 month follow up), in addition to\n",
      "             intermediate contacts in between examinations.\n",
      "\n",
      "        Children\n",
      "\n",
      "          -  Child must be 9-15 months of age at the time of the baseline study visit.\n",
      "\n",
      "          -  Child must be generally healthy (i.e., no current medical condition that makes it\n",
      "             difficult for her/him to receive a dental examination).\n",
      "\n",
      "          -  Child must allow examination of the oral cavity.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Adults\n",
      "\n",
      "          -  A participant pair (adult-child) who demonstrates an inability to comply with study\n",
      "             protocol requirements will be excluded - this determination will be at the Site\n",
      "             Primary Investigator's discretion.\n",
      "\n",
      "          -  Non-English, non-Spanish reading/speaking individuals will be excluded, as they will\n",
      "             not be able to comprehend the consent document or complete the risk questionnaire.\n",
      "\n",
      "        Children\n",
      "\n",
      "          -  Children who are in foster care at study initiation will be excluded, due to the\n",
      "             likelihood that their primary caregiver will change multiple times during the length\n",
      "             of the study.\n",
      "\n",
      "          -  Need for antibiotic and/or sedative premedication prior to dental exam.\n",
      "\n",
      "          -  Uncontrolled epilepsy.\n",
      "\n",
      "          -  Active cancer treatment.\n",
      "\n",
      "          -  Unrepaired congenital heart defects that would require premedication prior to dental\n",
      "             exam.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 60+\n",
      "\n",
      "          -  Generally Healthy\n",
      "\n",
      "          -  On stable does of medications\n",
      "\n",
      "          -  Absence of significant behavioral or cognitive dysfunction\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Significant cognitive or behavioral problems or symptoms\n",
      "\n",
      "          -  History of falls >2 in the past month\n",
      "\n",
      "          -  Unstable medical conditions such as uncontrolled diabetes, uncontrolled cardiac\n",
      "             disease, uncontrolled hypertension, or other that would increase risk of side effects\n",
      "             performing physical activity\n",
      "\n",
      "          -  History of substance abuse in last 6 months\n",
      "\n",
      "          -  Known structural brain abnormality, previous major debilitating strokes or seizures,\n",
      "             traumatic brain injury\n",
      "\n",
      "          -  Had complete neuropsychological testing in the last 6 months\n",
      "\n",
      "          -  Previous participation in cognitive or exercise training study within last 3 months\n",
      "\n",
      "          -  Currently engaging in moderate to heavy exercise >125 mins. week at 75% Target Heart\n",
      "             Rate\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  dated and signed informed consent\n",
      "\n",
      "          -  virale serology negative or negative result less than 6 months\n",
      "\n",
      "          -  virale serology negative for HBV or vaccinated patient\n",
      "\n",
      "          -  insured\n",
      "\n",
      "          -  virale serology negative or negative result less than 6 months\n",
      "\n",
      "          -  negative pregnancy test or female menopause for at least 1 year\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  subject enable adult, under guardianship or under protective measures of justice\n",
      "\n",
      "          -  Refusal or inability to give informed consent\n",
      "\n",
      "          -  The hypereosinophilic syndrome explained origin other than than atopy, bullous\n",
      "             pemphigoid, the Churg-Strauss syndrome and DRESS\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients hospitalized for coronary angiography\n",
      "\n",
      "          -  Sinus Rhythm\n",
      "\n",
      "          -  Left ventricular Ejection Fraction > 50%\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Age < 18years\n",
      "\n",
      "          -  Hypertrophic Cardiomyopathy\n",
      "\n",
      "          -  Cardiac transplantation\n",
      "\n",
      "          -  Mitral stenosis\n",
      "\n",
      "          -  Mitral insufficiency >2/4\n",
      "\n",
      "          -  Severe calcification of mitral annulus\n",
      "\n",
      "          -  Mitral prothesis or mitral repair\n",
      "\n",
      "          -  aortic prothesis\n",
      "\n",
      "          -  Severe aortic stenosis\n",
      "\n",
      "          -  Atrial fibrillation\n",
      "\n",
      "          -  Acute coronary syndrom < 3 months\n",
      "\n",
      "          -  Left ventricular thrombus\n",
      "\n",
      "          -  Severe renal Failure\n",
      "\n",
      "          -  failure of radial way for coronary angiography\n",
      "\n",
      "          -  coronary lesion indicating an angioplasty\n",
      "\n",
      "          -  impossibility to perform an exercise\n",
      "\n",
      "          -  refusal or inability to sign informed consent\n",
      "\n",
      "          -  no French medical insurance\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy men and women between 18 and 65 years\n",
      "\n",
      "          -  Increased level of stress (visual analog scale >40 mm (0-100))\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Regular walking training in the last 6 weeks\n",
      "\n",
      "          -  Medical therapy with psychopharmacological drugs\n",
      "\n",
      "          -  Regular mindfulness based meditations/exercises in the last 6 weeks\n",
      "\n",
      "          -  CAM therapies against stress in the last 6 weeks\n",
      "\n",
      "          -  medium or severe chronic diseases\n",
      "\n",
      "          -  Stress due to chronic diseases\n",
      "\n",
      "          -  Acute disease at inclusion\n",
      "\n",
      "          -  Not being able to walk\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 2\n",
      "\n",
      "          -  Histologically confirmed recurrent or T2/T3/T4 squamous cell carcinoma of the\n",
      "             oropharynx or oral cavity that are amenable to surgery\n",
      "\n",
      "          -  Tumor accessible for unrestricted illumination for interstitial photodynamic therapy\n",
      "             (PDT) (accessibility as determined by the physician)\n",
      "\n",
      "          -  Life expectancy of at least 6 months in the judgment of the physician\n",
      "\n",
      "          -  Blood urea nitrogen (BUN) =< upper limit of normal (ULN)\n",
      "\n",
      "          -  White blood count > 3,000 per microliter or\n",
      "\n",
      "          -  Absolute neutrophil count (ANC) > 1500 per microliter\n",
      "\n",
      "          -  Serum calcium within normal limits; note: serum calcium will be corrected for low\n",
      "             albumin, if necessary\n",
      "\n",
      "          -  Subjects of child-bearing potential must agree to use adequate contraceptive methods\n",
      "             (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry\n",
      "             and for the duration of study participation; should a woman become pregnant or suspect\n",
      "             she is pregnant while she or her partner is participating in this study, she should\n",
      "             inform her treating physician immediately\n",
      "\n",
      "          -  Subject or legal representative must understand the investigational nature of this\n",
      "             study and sign an Institutional Review Board approved written informed consent form\n",
      "             prior to receiving any study related procedure\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects who have had radiotherapy within the last 3 months\n",
      "\n",
      "          -  Subjects with known brain metastases should be excluded from this clinical trial\n",
      "\n",
      "          -  Tumor invading a major blood vessel (such as the carotid artery)\n",
      "\n",
      "          -  Tumor invading the skull base\n",
      "\n",
      "          -  Subjects with ophthalmic disease\n",
      "\n",
      "          -  Tumor is not clearly shown on an imaging scan/location and extension of tumor that\n",
      "             precludes effective PDT, in the judgment of the primary investigator (PI)\n",
      "\n",
      "          -  Location and extension of the tumor precludes an effective interstitial photodynamic\n",
      "             therapy (iPDT)\n",
      "\n",
      "          -  Patients with known hypersensitivity to porphyrins or with porphyria\n",
      "\n",
      "          -  Has distant metastasis that decreases life expectancy to less than 6 months\n",
      "\n",
      "          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n",
      "             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n",
      "             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n",
      "             study requirements\n",
      "\n",
      "          -  Pregnant or nursing female subjects\n",
      "\n",
      "          -  Unwilling or unable to follow protocol requirements and the light exposure precautions\n",
      "\n",
      "          -  Any condition which in the investigator's opinion deems the subject an unsuitable\n",
      "             candidate to receive study drug\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Pregnant women attending antenatal care in selected primary care clinics with Family Health\n",
      "        Programs, who score a PHQ-9>=5 just after the first antenatal consultation or around the\n",
      "        20th week of pregnancy.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Moderate to high suicidal risk (assessed with a standardised protocol),\n",
      "\n",
      "          -  Ongoing psychiatric treatment,\n",
      "\n",
      "          -  Not able to understand Portuguese.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Dialysis dependant for over 90 days\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Haemodialysis for less than 90 days\n",
      "\n",
      "          2. Patients with anticipated life expectancy less than 6 months secondary to significant\n",
      "             morbidity e.g. metastatic malignancy, advanced human immunodeficiency virus\n",
      "\n",
      "          3. Patients with acute liver disease; History of underlying haematological condition;\n",
      "\n",
      "          4. Elective planned change of renal replacement modality within the 12 months.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  INCLUSION CRITERIA:\n",
      "\n",
      "               1. Females and males with Type 1 diabetes as ascertained by islet autoantibodies\n",
      "                  (GAD-65 and/or islet cell antibodies)\n",
      "\n",
      "               2. Age 15-30 years - This age group is being chosen as most will have completed\n",
      "                  puberty with the accompanying physiologic phase of increased insulin resistance.\n",
      "                  In addition, this age group shows increased self-management capabilities.\n",
      "                  Extending the age up to 30 years will allow us to include young adults, since\n",
      "                  type 1 diabetes is frequently diagnosed in the late teen and early adult years.\n",
      "                  This study is not powered to detect differences in liraglutide efficacy in\n",
      "                  different age group but it may provide insight into the effectiveness in the\n",
      "                  teenage population, in whom optimal glycemic control is often a challenge.\n",
      "\n",
      "               3. Type 1 diabetes duration greater than 1 year to ensure that a majority of\n",
      "                  subjects are beyond the partial remission period.\n",
      "\n",
      "               4. Fasting C-peptide level ≤ 0.3 ng/ml.\n",
      "\n",
      "               5. HbA1c level equal or less than 9%\n",
      "\n",
      "               6. Insulin delivery by CSII - the choice is made to facilitate adherence to study\n",
      "                  drug and also to enable us have a homogeneous group to analyze without having to\n",
      "                  analyze the data for the covariants of CSII vs. multiple daily injection therapy.\n",
      "\n",
      "               7. Subjects willing to wear a CGM sensor and perform home blood glucose monitoring\n",
      "                  four times daily and with symptoms of hypoglycemia.\n",
      "\n",
      "               8. Subjects well-versed in carbohydrate counting.\n",
      "\n",
      "               9. BMI < 95th% for age and gender.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  EXCLUSION CRITERIA:\n",
      "\n",
      "               1. Previous exposure to liraglutide\n",
      "\n",
      "               2. History of abdominal surgery\n",
      "\n",
      "               3. History of gastroparesis or gastrointestinal reflux disease;\n",
      "\n",
      "               4. History of acute or chronic pancreatitis\n",
      "\n",
      "               5. Cirrhosis or hepatic disease defined as transaminases levels > 3 times normal\n",
      "\n",
      "               6. Impaired renal function defined as serum creatinine >1.5.\n",
      "\n",
      "               7. HIV or Hepatitis C positive status\n",
      "\n",
      "               8. Pregnant/breastfeeding females\n",
      "\n",
      "               9. Individuals with steroid-induced or cystic fibrosis related diabetes\n",
      "\n",
      "              10. Diabetic Ketoacidosis within 6 months of the study\n",
      "\n",
      "              11. History of severe hypoglycemia (seizure, loss of consciousness) within 6 months\n",
      "                  of the study\n",
      "\n",
      "              12. History of medullary thyroid cancer or MEN2 syndrome\n",
      "\n",
      "              13. Any other life-threatening cardiac or non-cardiac disease\n",
      "\n",
      "              14. Participation in a concurrent clinical trial or participation in a trial within\n",
      "                  30 days preceding the study period.\n",
      "\n",
      "              15. Unable to give informed consent/assent.\n",
      "\n",
      "              16. Adolescents and adults who are considered underweight based on body mass index\n",
      "                  (BMI):\n",
      "\n",
      "                    1. For adolescents: BMI less than the 5th percentile\n",
      "\n",
      "                    2. For adults: BMI below 18.5\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  children and adolescents ages 4-18 years old with newly diagnosed type 1 diabetes.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  age less than 4 years\n",
      "\n",
      "          -  pregnant females\n",
      "\n",
      "          -  previous or known history of Vitamin D deficiency or insufficiency\n",
      "\n",
      "          -  current use of Vitamin D supplementation or multi-vitamin containing >800 IU daily\n",
      "\n",
      "          -  or concurrent development and/or history of other significant systemic illness or\n",
      "             non-endocrine autoimmune disorder.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 18-90\n",
      "\n",
      "          -  Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin\n",
      "             analog monotherapy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be\n",
      "             stable for at least 3 months prior to entry into the study\n",
      "\n",
      "          -  Initiation or discontinuation of testosterone or estrogen within 3 months of entry\n",
      "\n",
      "          -  Pregnant and nursing women\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Approved to participate by PCP (Patients with diabetes, hypertension, or dyslipidemia\n",
      "             will be eligible if approved by their PCP)\n",
      "\n",
      "          -  Age ≥ 21 years\n",
      "\n",
      "          -  Body mass index (BMI) 25 to 45 kg/m2 and weight ≤ 400 pounds\n",
      "\n",
      "          -  Goal of losing weight (not just maintain weight)\n",
      "\n",
      "          -  Willing to change diet, physical activity in order to lose weight.\n",
      "\n",
      "          -  Currently uses text messaging in English on mobile phone\n",
      "\n",
      "          -  Willing to use send and receive text messages for this study without direct\n",
      "             compensation for cost of messages (general compensation for study participation will\n",
      "             be provided)\n",
      "\n",
      "          -  Have a scale at home for self-monitoring weight\n",
      "\n",
      "          -  Fluent in English (speak, read, write)\n",
      "\n",
      "          -  Commit to return for follow-up weight at 6 months regardless of amount of weight lost\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Involuntary or voluntary weight loss of ≥ 5% body weight in previous 6 months\n",
      "\n",
      "          -  Participating in research project involving weight loss, exercise, or dietary\n",
      "             modification in the previous 6 months\n",
      "\n",
      "          -  Any of the following medical conditions which could affect weight or for which weight\n",
      "             loss is contraindicated\n",
      "\n",
      "               -  End-stage liver disease\n",
      "\n",
      "               -  End-stage kidney disease\n",
      "\n",
      "               -  Cancer within previous 2 years (except non-melanoma skin cancer)\n",
      "\n",
      "          -  Myocardial infarction, stroke, or transient ischemic attack within previous 6 months\n",
      "\n",
      "          -  Unstable angina\n",
      "\n",
      "          -  Severe arthritis or other medical conditions which would prevent brisk walking\n",
      "\n",
      "          -  Schizophrenia\n",
      "\n",
      "          -  Hospitalization for psychiatric problems during the prior 12 months.\n",
      "\n",
      "          -  Current use or anticipated future use (during 6 month study) of medications that could\n",
      "             cause weight loss:\n",
      "\n",
      "               -  phentermine\n",
      "\n",
      "               -  orlistat (prescription Xenical or OTC Alli)\n",
      "\n",
      "               -  topiramate\n",
      "\n",
      "               -  buprioprion\n",
      "\n",
      "               -  exenatide (Byetta)\n",
      "\n",
      "               -  liraglutide (Victoza)\n",
      "\n",
      "          -  Prior bariatric surgery or plans for bariatric surgery in next 6 months\n",
      "\n",
      "          -  Pregnant or breast feeding within the previous 6 months\n",
      "\n",
      "          -  Planning to become pregnant in next 6 months\n",
      "\n",
      "          -  Consumes > 14 alcoholic drinks per week\n",
      "\n",
      "          -  Current use of illicit drugs\n",
      "\n",
      "          -  Planning to move out of the area in the next 6 months\n",
      "\n",
      "          -  Another member of household or a close contact is participating in the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must have low or intermediate risk adenocarcinoma of the prostate as defined\n",
      "             by:\n",
      "\n",
      "               -  Low-risk disease - Histopathology score (Gleason sum): =<6, T-stage (per current\n",
      "                  AJCC staging criteria): T1c-T2a, and PSA: <10\n",
      "\n",
      "               -  Intermediate-risk disease as either:\n",
      "\n",
      "                    -  Histopathology score (Gleason sum) =< 6, T-stage (per current American Joint\n",
      "                       Committee on Cancer [AJCC] staging criteria): T1c-T2a, and prostate-specific\n",
      "                       antigen (PSA) > 10 but =< 20; or\n",
      "\n",
      "                    -  Histopathology score (Gleason sum) 7 with =< 50% of any cores positive,\n",
      "                       T-stage (per current AJCC staging criteria): T1c-T2a, and PSA < 10\n",
      "\n",
      "          -  Charlson index of comorbidity score =< 4\n",
      "\n",
      "          -  Ability to understand and the willingness to sign a written informed consent document\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with history of inflammatory bowel disease, or who require steroid or\n",
      "             cytotoxic therapy for collagen vascular disease\n",
      "\n",
      "          -  Patients with a history of cancer other than skin cancer within 5 years of the\n",
      "             initiation of protocol treatment\n",
      "\n",
      "          -  Patients with a history of pelvic irradiation for any reason\n",
      "\n",
      "          -  Life expectancy < 10 years - Prior treatment with an anti-androgen, luteinizing\n",
      "             hormone-releasing hormone (LHRH) agonist, or a combination of the two\n",
      "\n",
      "          -  Prior radiation therapy, brachytherapy, or cryotherapy\n",
      "\n",
      "          -  Prior surgical procedure involving peri-rectal and peri-prostatic area\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Youth between the ages of 13 and 17\n",
      "\n",
      "          -  Referred to ATP for residential substance abuse treatment in youth dual diagnosis\n",
      "             program\n",
      "\n",
      "          -  Dually diagnosed for substance abuse or dependence and at least one of the following\n",
      "             co-morbid conditions: major depressive disorder, bipolar disorder, I conduct disorder,\n",
      "             oppositional defiant disorder,\n",
      "\n",
      "          -  At least one parent or parent-figure can be located at the time of referral.\n",
      "\n",
      "          -  Obtain informed consent from a parent or formal guardian and assent from youth to\n",
      "             participate in the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Have any of the following disorders: Mental Retardation, Eating Disorders,\n",
      "             Schizophrenia, or Pervasive Developmental Disorders.\n",
      "\n",
      "          -  Current suicidality.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Forced expiratory volume in the 1st second (FEV1) > 70%.\n",
      "\n",
      "          -  No inhaled or systemic steroids.\n",
      "\n",
      "          -  No anti-inflammatory drugs, antileukotrienes and mast cell membrane stabilizers.\n",
      "\n",
      "          -  No serious organ involvement.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of pulmonary exacerbation or upper respiratory infection in the previous two\n",
      "             months.\n",
      "\n",
      "          -  Changes in medications in the past two months.\n",
      "\n",
      "          -  History of hemoptysis in the past two months.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Patient over the age of 21\n",
      "\n",
      "          2. Bladder tumor suspected or confirmed\n",
      "\n",
      "          3. ECOG status 0 to 2\n",
      "\n",
      "          4. Premedication Lab values:\n",
      "\n",
      "        Absolute Neutrophil Count >750 cells/m3 AST/ALT less than 1.5xN Amylase less than 1.5xN\n",
      "        Platelet Count > 125,000 PT/PTT > 1.3xN Hemoglobin > 8gm/dL Creatinine less than 1.5xN\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Allergy to valproic acid\n",
      "\n",
      "          2. Concurrent chemotherapy\n",
      "\n",
      "          3. Pre-menopausal women\n",
      "\n",
      "          4. Active systemic infection (HepatitisB,C)\n",
      "\n",
      "          5. Coagulation disorders\n",
      "\n",
      "          6. Concurrent medication: Tolbutamide, Warfarin, Zidovudine, Benzodiazepine, Clonazepam,\n",
      "             Diazepam, Any anti-convulsant therapy\n",
      "\n",
      "          7. Seizure disorder\n",
      "\n",
      "          8. Dementia\n",
      "\n",
      "          9. History of Pancreatitis\n",
      "\n",
      "         10. HIV diagnosis/treatment\n",
      "\n",
      "         11. Liver disease/dysfunction\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age > 18 years\n",
      "\n",
      "          -  Stable angina pectoris, electively referred for coronary angiography\n",
      "\n",
      "          -  Written informed consent to participate in the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Rest pain, ulceration or gangrene due to PAD (Rutherford 4-6)\n",
      "\n",
      "          -  Significant stenoses (>50%) or occlusion of superficial femoral or profunda femoral\n",
      "             artery\n",
      "\n",
      "          -  Aortoiliac occlusion or significant stenoses (>50%)\n",
      "\n",
      "          -  Aneurysm of abdominal aorta or iliac arteries\n",
      "\n",
      "          -  Acute coronary syndrome\n",
      "\n",
      "          -  Congestive heart failure NYHA III-IV\n",
      "\n",
      "          -  Severe pulmonary arterial hypertension\n",
      "\n",
      "          -  Severe hepatic or renal failure (creatinine clearance < 15ml/min)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        1. Patients diagnosed with MS in their inflammatory forms :\n",
      "\n",
      "          1. Course outbreaks ( relapsing- remitting ) , who have not responded to at least one\n",
      "             year of treatment with one or more of the approved therapies (beta - interferon,\n",
      "             glatiramer acetate, natalizumab , mitoxantrone, fingolimod ) , confirmed by one or\n",
      "             more of the following criteria:\n",
      "\n",
      "             ( ii ) At least one clinically documented outbreak in the past 12 months. ( iii ) At\n",
      "             least two clinically documented outbreaks in the last 24 months ( iv ) At least one\n",
      "             lesion with gadolinium on MRI performed in the last 12 months.\n",
      "\n",
      "             b . Secondary progressive forms that have not responded to at least one year of\n",
      "             treatment with one or more of the approved therapies ( interferon beta , glatiramer\n",
      "             acetate, natalizumab , mitoxantrone, fingolimod ) . That meet the following criteria:\n",
      "\n",
      "             ( i ) Increase of 1 point or more if baseline EDSS score is less than or equal to 5.0\n",
      "             , or 0.5 point increase if the baseline score is greater than or equal to 5.5, in the\n",
      "             last 12 months.\n",
      "\n",
      "             ( ii ) at least one clinically documented outbreak or at least one lesion with\n",
      "             gadolinium on MRI within the last 12 months.\n",
      "\n",
      "             c . Primary progressive forms that meet the following three criteria:\n",
      "\n",
      "             ( i ) Increase of 1 point or more if baseline EDSS score is less than or equal to 5.0\n",
      "             , or 0.5 point increase if the baseline score is greater than or equal to 5.5, in the\n",
      "             last 12 months.\n",
      "\n",
      "             ( ii ) At least 1 lesion with gadolinium on MRI within the last 12 months. ( iii )\n",
      "             oligoclonal bands in cerebrospinal fluid (CSF) .\n",
      "\n",
      "             2 . Normal laboratory parameters , defined by:\n",
      "\n",
      "               -  Leukocytes ≥ 3000\n",
      "\n",
      "               -  Neutrophils ≥ 1500\n",
      "\n",
      "               -  Platelets ≥ 100,000\n",
      "\n",
      "               -  Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) ≤ 2.5 standard\n",
      "                  range institution\n",
      "\n",
      "               -  Creatinine ≤ 2.5 mg / dl\n",
      "\n",
      "                  3 . Patients of both sexes aged between 18 and 50.\n",
      "\n",
      "                  4 . Disease duration ≥ 2 years and ≤ 10 years.\n",
      "\n",
      "                  5 . EDSS (Expanded Disability Status Scale) between 3.0 and 6.5 points.\n",
      "\n",
      "                  6. Patients give their informed consent for participation in the clinical trial\n",
      "                  consent.\n",
      "\n",
      "                  7. Women of childbearing potential must have negative results on a pregnancy test\n",
      "                  at the time of inclusion in the study and agree to use a medically approved\n",
      "                  method of contraception while on study\n",
      "\n",
      "             Exclusion Criteria:\n",
      "\n",
      "               1. Any active or chronic infection, including Hepatitis B virus (HBV), Hepatitis C\n",
      "                  virus (HCV) or HIV .\n",
      "\n",
      "               2. Immunosuppressive therapy in the 3 months prior to randomization (including\n",
      "                  natalizumab and fingolimod ).\n",
      "\n",
      "               3. Treatment with interferon beta or glatiramer acetate in the 30 days prior to\n",
      "                  randomization .\n",
      "\n",
      "               4. Corticosteroid therapy in the 30 days prior to randomization.\n",
      "\n",
      "               5. Time since last exceeding 60 days prior to randomization outbreak.\n",
      "\n",
      "               6. History of malignancy ( basal cell carcinoma of skin and carcinoma in situ are\n",
      "                  excluded in remission for over a year).\n",
      "\n",
      "               7. Life expectancy severely limited by other co - morbidities.\n",
      "\n",
      "               8. Previous history of myelodysplasia or hematological disease , or clinically\n",
      "                  relevant changes currently in the leukocyte count.\n",
      "\n",
      "               9. Pregnancy / risk of pregnancy (including refusal to use contraception)\n",
      "\n",
      "              10. Renal failure (eGFR <60 mL/min/1.37m2)\n",
      "\n",
      "              11. Inability to undergo MRI scans\n",
      "\n",
      "              12. Inability to give written informed consent.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Patients will be included in this study if they meet the following criteria (A+B+C):\n",
      "\n",
      "        A. Patients with the following conditions:\n",
      "\n",
      "          1. Abdominal cavity infection following emergency surgery.\n",
      "\n",
      "          2. Pneumonia, blood stream infection, urinary tract infection, or other infection, has\n",
      "             received adequate treatment and presents with an Endotoxin Activity Assay > 0.6 EAA\n",
      "             units.\n",
      "\n",
      "        B. SIRS, as defined by the presence of at least 2 of the following conditions (These\n",
      "        criteria should have occurred between 12 hours before or 6 hours after the onset of the\n",
      "        qualifying first organ dysfunction :\n",
      "\n",
      "          1. Fever or hypothermia (body temperature over 38 ℃ or under 36 ℃)\n",
      "\n",
      "          2. Tachycardia (heart rate > 90 bpm)\n",
      "\n",
      "          3. Tachypnea (respiratory rate over 20 breaths/min or under mechanical ventilation)\n",
      "\n",
      "          4. Leukocyte count more than 12,000 cells/mm3, less than 4,000 cells/mm3, or more than 10\n",
      "             % of immature form (band)\n",
      "\n",
      "        C. The presence of at least one of these symptoms of organ dysfunction or shock:\n",
      "\n",
      "          1. Cardiovascular system: an SBP of less than 90 mm Hg, a decrease in SBP of at least 40\n",
      "             mm Hg from baseline, a MAP of less than 65 mm Hg, or that requires treatments with\n",
      "             vasoactive medication at any dosage.\n",
      "\n",
      "          2. Acute lung injury: PaO2 / FiO2 ratio less than 300 (ratio in mm Hg)\n",
      "\n",
      "          3. Acute kidney injury: creatinine more than 2 mg/dL, an increase in creatinine of more\n",
      "             than 0.5 mg/dL, or diuresis of less than 0.5 mL/kg/h for 2 hours.\n",
      "\n",
      "          4. Acute liver injury: Total bilirubin level more than 4 mg/dL\n",
      "\n",
      "          5. Disseminated intravascular coagulation: platelet count less than 100,000 cells/mm3 or\n",
      "             a reduction of more than 50 % of baseline\n",
      "\n",
      "          6. INR > 1.5 or aPTT > 60 sec\n",
      "\n",
      "          7. Altered mental status: GCS under 13 or 9T under endotracheal tube\n",
      "\n",
      "          8. Lactic acidosis: Lactate level more than 2 mmol/L (accompany with pH < 7.3 or Base\n",
      "             excess < -5 mmol/L)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Patients will be excluded if they\n",
      "\n",
      "        A. are under 20 years old or older than 99 years old\n",
      "\n",
      "        B. have suffered from severe sepsis or septic shock more than 24 hours\n",
      "\n",
      "        C. are pregnant\n",
      "\n",
      "        D. were treated with another medicine or device in the trial less than 30 days prior to the\n",
      "        admission to this trial\n",
      "\n",
      "        E. have received organ transplantation less than 1 years prior to this trial\n",
      "\n",
      "        F. patients with hemophilia\n",
      "\n",
      "        G. have a allergic history of polymyxin B, heparin, or extracorporeal circulation\n",
      "\n",
      "        H. are terminally ill, for examples with metastasis, with a life expectancy of less than 30\n",
      "        days (certified by the attending physician)\n",
      "\n",
      "        I. have been diagnosed with HIV\n",
      "\n",
      "        J. present uncontrolled bleeding in the last 24 hours\n",
      "\n",
      "        K. were diagnosed with leukocytopenia (leukocyte count less than 500 cell/mm3) and/or\n",
      "        thrombocytopenia (platelet count less than 50,000 cells/mm3)\n",
      "\n",
      "        L. have already received other blood cleaning treatments, such as CVVH, HD, HF, and PE upon\n",
      "        entry into the trial\n",
      "\n",
      "        M. have a prior history of severe chronic organ failure\n",
      "\n",
      "          1. chronic respiratory failure ( COPD at last stage)\n",
      "\n",
      "          2. chronic heart failure (NYHA score = IV)\n",
      "\n",
      "          3. brain death\n",
      "\n",
      "          4. Chronic liver failure (Child Pugh score: C)\n",
      "\n",
      "        N. have evidence of infection by gram-positive bacteria, fungal infection, or mixed\n",
      "        infection\n",
      "\n",
      "        O. have chosen palliative care and signed Do Not Resuscitate sheet\n",
      "\n",
      "        P. an APACHE II score over 30 present on entry into the trial\n",
      "\n",
      "        Q. non-native speakers\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  ESD for gastric dysplasia or early gastric cancer\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Coagulopathy: liver cirrhosis, thrombocytopenia\n",
      "\n",
      "          -  Anti-platelet agents\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of adolescent idiopathic scoliosis made before age 18\n",
      "\n",
      "          -  Diagnosis of adolescent idiopathic scoliosis prior to 1994\n",
      "\n",
      "          -  Treatment with bracing, observation, or surgery prior to age 18 and 1994\n",
      "\n",
      "          -  Adequate radiographs/medical records available from time of diagnosis\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Neuromuscular scoliosis\n",
      "\n",
      "          -  Syrinx\n",
      "\n",
      "          -  Inadequate radiographs/medical records available from time of diagnosis\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 21 years or older with type 1 diabetes for at least one year\n",
      "\n",
      "          -  Stimulated C-peptide < 0.1 nmol/L at 90 minutes after liquid mixed meal by the DCCT\n",
      "             protocol\n",
      "\n",
      "          -  Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting\n",
      "             insulins including insulin aspart (NovoLog), insulin lispro (Humalog), and insulin\n",
      "             glulisine (Apidra) for at least three months prior to enrollment\n",
      "\n",
      "          -  Otherwise healthy (mild chronic disease such as asthma, hypertension, and depression\n",
      "             will be allowed if well controlled)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Unable to provide informed consent\n",
      "\n",
      "          -  Unable to comply with study procedures\n",
      "\n",
      "          -  Total daily dose (TDD) of insulin that is > 1.5 U/kg\n",
      "\n",
      "          -  Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the\n",
      "             immediate future, or sexually active without use of contraception.\n",
      "\n",
      "          -  Hypoglycemia unawareness (self-reported lack of hypoglycemia symptoms when BG is < 50\n",
      "             mg/dl)\n",
      "\n",
      "          -  End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).\n",
      "\n",
      "          -  Any known history of coronary artery disease (CAD)\n",
      "\n",
      "          -  Abnormal EKG suggestive of coronary artery disease or increased risk of malignant\n",
      "             arrhythmia\n",
      "\n",
      "          -  Congestive heart failure (established history of CHF, paroxysmal nocturnal dyspnea, or\n",
      "             orthopnea).\n",
      "\n",
      "          -  History of TIA or stroke.\n",
      "\n",
      "          -  History of pheochromocytoma. Fractionated metanephrines will be tested in patients\n",
      "             with history increasing the risk for a catecholamine secreting tumor\n",
      "\n",
      "          -  Untreated or inadequately treated mental illness\n",
      "\n",
      "          -  Current alcohol abuse or substance abuse\n",
      "\n",
      "          -  Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be\n",
      "             susceptible to RF interference.\n",
      "\n",
      "          -  Use non-insulin, injectable anti-diabetic medications or oral anti-diabetic\n",
      "             medications\n",
      "\n",
      "          -  History of adverse reaction to glucagon (including allergy) besides nausea and\n",
      "             vomiting\n",
      "\n",
      "          -  Unwilling or unable to completely avoid acetaminophen\n",
      "\n",
      "          -  ALT > 3-fold upper limit of normal\n",
      "\n",
      "          -  Albumin < 3 g/dl\n",
      "\n",
      "          -  Body mass index less than18 or greater than 35\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Group repeated miscarriages\n",
      "\n",
      "          -  Women aged 18 to 43 years\n",
      "\n",
      "          -  ≥ 2 miscarriages before 14 weeks of gestation\n",
      "\n",
      "          -  Genetic (karyotype x2), thrombophilic and endocrine assessment should be completed\n",
      "\n",
      "        Group of implantation failure in In-vitro fertilization\n",
      "\n",
      "          -  Women aged 18 to 45 years\n",
      "\n",
      "          -  Absence of pregnancy after 3 good quality embryos transferred in women under 35 years\n",
      "             and 4 embryos in the 35 years and over.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Positive pregnancy test\n",
      "\n",
      "          -  Unexplained bleeding\n",
      "\n",
      "          -  Incomplete miscarriage assessment\n",
      "\n",
      "          -  Uterine malformation\n",
      "\n",
      "          -  Antibiotic treatment during or within one month prior to the biopsy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects between the ages of 1 and 80,\n",
      "\n",
      "          -  Recruited from the eight (8) participating primary care sites,\n",
      "\n",
      "          -  Subjects newly identified with Kaposi sarcoma (KS) and HIV-1 infection.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  None Noted\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Provision of subject informed consent.\n",
      "\n",
      "          -  Diagnosis of Bipolar Disorder I or II (DSM-IV TR) in any phase of the disorder.\n",
      "\n",
      "          -  Patients who had at least one mood event( depression, mania, hypomania or mixed)\n",
      "             according to DSM-IV TR definition during the 3 and 12 months prior to the beginning of\n",
      "             the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Inability to complete Patient Reported Outcomes (PROs) questionnaires.\n",
      "\n",
      "          -  Participation in an interventional clinical study in last 12 months.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  General practices should use the information system MicroHIS X or Promedico ASP\n",
      "\n",
      "          -  NHGDoc should be available in the general practices\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  General practices that do not meet the inclusion criteria\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Board certified physicians with a certificate from the Swiss Medical Association\n",
      "             (Facharzttitel' General Internal Medicine, Subspecialities in Internal Medicine,\n",
      "             Paediatrics) with an own ZAHLSTELLENREGISTER NUMBER (Konkordatsnummer).\n",
      "\n",
      "          -  At least 100 patients enlisted with the specified social health insurance providers\n",
      "             (SANTÉSUISSE DATENPOOL AND TARIFPOOL). (to avoid classifying physicians as high\n",
      "             prescribers who only see a small number of patients and describe antibiotics to many\n",
      "             of them)\n",
      "\n",
      "          -  Prescription-rates of antibiotics (DDD per 100 consultations) - that are prescribed to\n",
      "             patients enlisted with the specified social health insurance providers (SANTÉSUISSE\n",
      "             TARIFPOOL)\n",
      "\n",
      "          -  are in the upper median of the prescription number distribution in the year prior to\n",
      "             the start of the trial.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Physicians with no own \"Zentralstellenregister\" (ZSR) number (practice fellows or\n",
      "             substitutes, medical trainees in general practices).\n",
      "\n",
      "          -  Physicians working in institutions without own but with institutional ZSR NUMBER\n",
      "             (ambulatory care facilities of University Hospitals, permanence, practices or Health\n",
      "             Maintenance Organisation (HMO) with group ZSR number).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Pathologically confirmed, newly diagnosed acute myelogenous leukemia\n",
      "\n",
      "          -  Agree to use an acceptable method for contraception during the entire study treatment\n",
      "             period through 4 months after the last dose of MLN8237\n",
      "\n",
      "          -  Able to take oral medication and to maintain a fast as required for 2 hours before and\n",
      "             1 hour after MLN8237 administration\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Have received systemic antineoplastic therapy, including radiotherapy within 14 days\n",
      "             of study treatment, with the exception of hydroxyurea or 6-mercaptopurine for the\n",
      "             purposes of cytoreduction\n",
      "\n",
      "          -  Pregnant or breastfeeding\n",
      "\n",
      "          -  Presence of \"favorable\" or \"better risk\" cytogenic prognosis\n",
      "\n",
      "          -  Prior allogeneic bone marrow or organ transplantation\n",
      "\n",
      "          -  Diagnosis of acute bilineal/biphenotypic leukemia\n",
      "\n",
      "          -  History of a different malignancy except if disease-free for at least 5 years and at\n",
      "             low risk or recurrence; or cervical cancer in situ, basal cell or squamous cell\n",
      "             carcinoma of the skin within the past 5 years\n",
      "\n",
      "          -  Uncontrolled intercurrent illness\n",
      "\n",
      "          -  HIV positive on combination antiretroviral therapy\n",
      "\n",
      "          -  Diagnosis of active hepatitis B or C\n",
      "\n",
      "          -  Current or history of congestive heart failure NYHA class 3 or 4, or documented\n",
      "             diastolic or systolic dysfunction\n",
      "\n",
      "          -  Current or history of ventricular or life threatening arrhythmias or diagnosis of long\n",
      "             QT syndrome\n",
      "\n",
      "          -  Known history of uncontrolled sleep apnea syndrome or other condition that could\n",
      "             result in excessive daytime sleepiness\n",
      "\n",
      "          -  Requirement for constant administration of proton pump inhibitor, H2 antagonist or\n",
      "             pancreatic enzymes\n",
      "\n",
      "          -  Systemic infection requiring IV antibiotic therapy within 14 days of first dose of\n",
      "             study drug\n",
      "\n",
      "          -  Treatment with clinically significant enzyme inducers\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must have a histologically confirmed, unresectable pancreatic adenocarcinoma\n",
      "\n",
      "          -  Patients must have already received or refused 1st-line treatment\n",
      "\n",
      "          -  Measurable disease will be required; biopsiable disease will be required\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1\n",
      "\n",
      "          -  Life expectancy of greater than 16 weeks\n",
      "\n",
      "          -  Leukocytes >= 3,000/mcL\n",
      "\n",
      "          -  Absolute neutrophil count >= 1,500/mcL\n",
      "\n",
      "          -  Platelets >= 100,000/mcL\n",
      "\n",
      "          -  Total bilirubin =< 1.5 institutional upper limit of normal (IULN)\n",
      "\n",
      "          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase\n",
      "             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT])\n",
      "             =< 2.5 X IULN if no liver metastasis or =< 5 X IULN if liver metastases are present\n",
      "\n",
      "          -  Creatinine not to be above IULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for\n",
      "             patients with creatinine levels above institutional normal\n",
      "\n",
      "          -  Women of child-bearing potential and men must agree to use adequate contraception\n",
      "             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\n",
      "             the duration of study participation; should a woman become pregnant or suspect she is\n",
      "             pregnant while she or her partner is participating in this study, she should inform\n",
      "             her treating physician immediately; men treated or enrolled on this protocol must also\n",
      "             agree to use adequate contraception prior to the study, for the duration of study\n",
      "             participation, and 4 months after completion of MK-2206 and dinaciclib administration\n",
      "\n",
      "          -  Patients must be able to swallow whole tablets (for MK-2206); nasogastric or\n",
      "             gastrostomy (G) tube administration is not allowed; tablets must not be crushed or\n",
      "             chewed\n",
      "\n",
      "          -  Ability to understand and the willingness to sign a written informed consent document\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n",
      "             nitrosoureas or mitomycin C) prior to entering the study or those who have not\n",
      "             recovered to =< grade 1 (or =< tolerable grade 2 for neuropathy) adverse events due to\n",
      "             agents administered more than 4 weeks earlier\n",
      "\n",
      "          -  Patients who are receiving any other investigational agents\n",
      "\n",
      "          -  Patients with known brain metastases should be excluded from this clinical trial\n",
      "\n",
      "          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n",
      "             composition to dinaciclib or to MK-2206\n",
      "\n",
      "          -  Patients receiving any medications or substances that are strong inhibitors/inducers,\n",
      "             sensitive substrates, or substrates with a narrow therapeutic index of cytochrome\n",
      "             P450, family 3, subfamily A, polypeptide 4 (CYP3A4) or permeability glycoprotein\n",
      "             (P-gp) are ineligible; caution should be exercised when dosing dinaciclib and/or\n",
      "             MK-2206 concurrently with CYP3A4 or P-gp substrates, inhibitors/inducers; if subjects\n",
      "             are taken off a forbidden medicine, a one-week washout is required for inhibitors and\n",
      "             two weeks for inducers; subjects on Coumadin are eligible but more frequent monitoring\n",
      "             of the international normalized ratio (INR) (weekly during the first cycle, then at\n",
      "             least each cycle thereafter) is recommended; as part of the enrollment/informed\n",
      "             consent procedures, the patient will be counseled on the risk of interactions with\n",
      "             other agents, and what to do if new medications need to be prescribed or if the\n",
      "             patient is considering a new over-the-counter medicine or herbal product\n",
      "\n",
      "          -  Patients with diabetes or in risk for hyperglycemia should not be excluded from trials\n",
      "             with MK-2206, but the hyperglycemia should be well controlled before the patient\n",
      "             enters the trial (glycosylated hemoglobin [Hba1c] < 7.5)\n",
      "\n",
      "          -  Concurrent medications associated with a risk of corrected QT (QTc) prolongation\n",
      "             and/or torsades de pointes are not allowed; those medications listed as reported but\n",
      "             lacking substantial evidence for causing QTc prolongation and torsades de pointes will\n",
      "             be allowed, although if an alternative medication can be substituted, that would be\n",
      "             preferable; for this study, a baseline electrocardiogram (EKG) will be performed and\n",
      "             will be repeated during cycle 1 and then every 3 cycles while on treatment\n",
      "\n",
      "          -  Patients with current evidence of significant cardiovascular disease (New York Heart\n",
      "             Association class III or IV cardiac disease), symptomatic congestive heart failure,\n",
      "             dilated/hypertrophic or restrictive cardiomyopathy, myocardial infarction (within the\n",
      "             past 6 months), unstable angina, unstable arrhythmia or a need for anti-arrhythmic\n",
      "             therapy (use of medications for rate control for atrial fibrillation is allowed such\n",
      "             as calcium channel blockers and beta-blockers, if stable medication for at least last\n",
      "             month prior to initiation of MK-2206 treatment and medication not listed as causing\n",
      "             torsades de pointes), or evidence of acute ischemia on electrocardiogram (ECG); marked\n",
      "             baseline prolongation of QT/QTc interval, e.g., repeated demonstration of a QTc\n",
      "             interval > 450 msec*; long QT syndrome; the required use of concomitant medication\n",
      "             that may cause torsades de pointes or may cause a significant prolongation of the QTc\n",
      "\n",
      "               -  Note: Due to difficulties assessing QTc in patients with heart block, they may be\n",
      "                  eligible if deemed safe by a cardiologist\n",
      "\n",
      "          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n",
      "             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n",
      "             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n",
      "             study requirements\n",
      "\n",
      "          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n",
      "             the mother is treated with MK-2206 and/or dinaciclib\n",
      "\n",
      "          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n",
      "             therapy are ineligible\n",
      "\n",
      "          -  Clinically significant ascites\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. A clinical diagnosis of laboratory-supported probable, probable, or definite ALS,\n",
      "             according to a modified El Escorial criteria, by the study investigator (Appendix IV).\n",
      "\n",
      "          2. 21 to 80 years of age inclusive.\n",
      "\n",
      "          3. VC greater or equal to 75% of predicted at screening and baseline.\n",
      "\n",
      "          4. Onset of weakness within 2 years prior to enrollment.\n",
      "\n",
      "          5. If patients are taking riluzole for ALS, they must be on a stable dose for at least\n",
      "             thirty days prior to the baseline visit.\n",
      "\n",
      "          6. Women of childbearing age must be non-lactating and surgically sterile or using an\n",
      "             effective method of birth control and have a negative pregnancy test.\n",
      "\n",
      "          7. Willing and able to give signed informed consent that has been approved by the\n",
      "             Institutional Review Board (IRB).\n",
      "\n",
      "        Exclusion criteria\n",
      "\n",
      "          1. Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per\n",
      "             day.\n",
      "\n",
      "          2. Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine,\n",
      "             phenylpropanolamine, and ephedrine.\n",
      "\n",
      "          3. Patients on analgesics with serotoninergic properties such as meperidine, tramadol,\n",
      "             methadone and propoxyphene, flexeril.\n",
      "\n",
      "          4. Patients on fluoxetine or fluvoxamine.\n",
      "\n",
      "          5. Patients taking amitriptyline > 50 mg/d, trazodone and sertraline > 100 mg/d,\n",
      "             citalogram > 20 mg/d or paroxetine > 30 mg/d.\n",
      "\n",
      "          6. Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease,\n",
      "             etc).\n",
      "\n",
      "          7. Clinically significant history of unstable medical illness (unstable angina, advanced\n",
      "             cancer, etc) over the last 30 days.\n",
      "\n",
      "          8. Has a diaphragm pacing device or plan on obtaining a diaphragm pacing device during\n",
      "             the course of the study.\n",
      "\n",
      "          9. History of renal disease.\n",
      "\n",
      "         10. History of liver disease.\n",
      "\n",
      "         11. Current pregnancy or lactation.\n",
      "\n",
      "         12. Limited mental capacity such that the patient cannot provide written informed consent\n",
      "             or comply with evaluation procedures.\n",
      "\n",
      "         13. History of recent alcohol or drug abuse or noncompliance with treatment or other\n",
      "             experimental protocols.\n",
      "\n",
      "         14. Vital Capacity (VC) < 75% of predicted.\n",
      "\n",
      "         15. Receipt of any investigational drug within the past 30 days.\n",
      "\n",
      "         16. Women with the potential to become pregnant who are not practicing effective birth\n",
      "             control.\n",
      "\n",
      "         17. Poorly controlled hypertensive subjects or resting blood pressure SBP > 160 mmHg\n",
      "             and/or DBP > 95 mmHg.\n",
      "\n",
      "         18. Use of BiPAP at screening.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Students will be screened for eligibility by testing their ability to perform a squat.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  a recent (within one month) ankle sprain\n",
      "\n",
      "          -  evidence of ankle instability\n",
      "\n",
      "          -  cardiac condition\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age (> 16 years of age) moderate to severe hallux valgus angle [HVA] of >30º with\n",
      "             increased intermetatarsal angles [IMA] of >13º\n",
      "\n",
      "          -  persistent incapacitating symptoms despite non-operative treatment (shoe wear\n",
      "             modification, orthoses, non-steroidal anti-inflammatory drugs and restricted activity)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  degenerative arthritis of 1st metatarsophalangeal (MTP) joint\n",
      "\n",
      "          -  neuropathic patients\n",
      "\n",
      "          -  diabetes mellitus\n",
      "\n",
      "          -  peripheral vascular disease\n",
      "\n",
      "          -  previous 1st metatarsal, hallux or MTP joint surgery\n",
      "\n",
      "          -  active or recent foot/toe infection\n",
      "\n",
      "          -  currently participation in a another clinical trial\n",
      "\n",
      "          -  Worker's Compensation Board patients.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All patients must fulfill the clinical criteria for diagnosis of CD as defined by\n",
      "             Lennard-Jones et al. (1976)\n",
      "\n",
      "          -  All patients must be in clinical remission for at least 1 month at study entry as\n",
      "             defined by a Crohn's Disease Activity Index (CDAI) of <150\n",
      "\n",
      "          -  18-65 years\n",
      "\n",
      "          -  Patients on stable drug therapies for at least 1 month pre-enrolment\n",
      "\n",
      "          -  Sufficient English language ability to carry out the study requirements\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Symptomatic CD at study entry including CDAI >150\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Previous extensive small bowel resection (less than 200 cm of viable small bowel or a\n",
      "             loss of 50% or more of the small intestine)\n",
      "\n",
      "          -  Presence of an ileostomy or colostomy\n",
      "\n",
      "          -  Known hypersensitivity to vitamin D\n",
      "\n",
      "          -  Hypercalcaemia (corrected serum calcium > 2.66 mmol/L)\n",
      "\n",
      "          -  Those currently using supplemental vitamin D >800 IU/D\n",
      "\n",
      "          -  Diagnosis of any of the following: active tuberculosis, sarcoidosis,\n",
      "             hyperparathyroidism, renal failure, pseudohyperparathyroidism, malignancy, active,\n",
      "             lymphoma, short bowel syndrome\n",
      "\n",
      "          -  Antibiotic use in the 4 weeks prior to enrolment\n",
      "\n",
      "          -  Current use of bisphosphonates\n",
      "\n",
      "          -  Renal Impairment, Diabetes Mellitus\n",
      "\n",
      "          -  Patients participating in a concurrent RCT\n",
      "\n",
      "          -  Alcohol dependency\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  UC\n",
      "\n",
      "          -  PSC\n",
      "\n",
      "          -  IPAA\n",
      "\n",
      "          -  IRA\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  non-UC\n",
      "\n",
      "          -  non-PSC\n",
      "\n",
      "          -  no consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All those who fulfil the diagnostic criteria of Depressive episode (F32) or Recurrent\n",
      "             depressive disorder (F33 except 33.4 ) using ICD10 RDC (based on interviews using SCAN\n",
      "             Urdu version),\n",
      "\n",
      "          -  Are between the ages of 19-60,\n",
      "\n",
      "          -  Score 8 or more on HADS, Depression Subscale, and\n",
      "\n",
      "          -  Who live within traveling distance of the psychiatry department will be approached\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Excessive use of alcohol or drugs (using ICD 10 RDC for alcohol or drug abuse or\n",
      "             dependence)\n",
      "\n",
      "          -  Significant cognitive impairment (for example learning disability or dementia) and\n",
      "\n",
      "          -  Active psychosis\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All adult patients between the ages of 18 and 89 that are having open surgical\n",
      "             resection of an AVM or clipping of an aneurysm will be included\n",
      "\n",
      "        Exclusion Criteria:\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Males 18 to 50 years of age\n",
      "\n",
      "          -  Non-smoker\n",
      "\n",
      "          -  Body mass index between 20.0 and 30.0 kg/m2\n",
      "\n",
      "          -  Plasma LDL-cholesterol levels between the 25th and 75th percentile for their age at\n",
      "             day -14\n",
      "\n",
      "          -  Plasma triglyceride levels < 1.7 mmol/L (150 mg/dl) at day -14\n",
      "\n",
      "          -  Plasma HDL-cholesterol levels between 0.9 (35 mg/dl) and 1.6 mmol/L (60 mg/dl) at day\n",
      "             -14\n",
      "\n",
      "          -  Subjects must be willing to give written informed consent and able to adhere to the\n",
      "             diet schedule and visit schedule\n",
      "\n",
      "          -  Patients should be otherwise healthy, without elevations in hepatic transaminases or\n",
      "             creatine kinase (CK) or abnormal renal function or coagulation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be\n",
      "             excluded\n",
      "\n",
      "          -  Subjects will be excluded if they have cardiovascular disease (CHD, cerebrovascular\n",
      "             disease or peripheral arterial disease) or if they are taking other medications known\n",
      "             to affect lipoprotein metabolism (eg. steroids, beta blockers, thiazide diuretics,\n",
      "             other lipid lowering agents, significant alcohol intake etc.)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Either having a T3 (the cancer has grown through the muscularis propria and into the\n",
      "             outermost layers of the colon or rectum but not through them) or higher, node\n",
      "             positivity or metastatic lesion in the context of rectal cancer or being studied for\n",
      "             colorectal cancer follow up, independent of the renal function\n",
      "\n",
      "          -  PET-CT should be requested by a referring physician; in the case of having an MR\n",
      "             requested as well, it will be reported from the MRI images generated in the PET-MRI\n",
      "\n",
      "          -  Stable physical medical conditions to undergo a MRI\n",
      "\n",
      "          -  Informed consent must be given and signed prior to study enrollment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Refuse to give and/or sign the informed consent\n",
      "\n",
      "          -  Subjects who do not meet the above mentioned inclusion criteria\n",
      "\n",
      "          -  Subjects who have a pacemaker\n",
      "\n",
      "          -  Subjects who have a metallic prostheses either in the pelvis or in the abdomen that\n",
      "             will interfere with the MR imaging of that anatomical area\n",
      "\n",
      "          -  Subjects who suffer from claustrophobia\n",
      "\n",
      "          -  Pregnant women\n",
      "\n",
      "          -  Cognitive impairment that affects the subject's ability to give consent\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Clinical diagnosis of FMD based on current guideline criteria and relevant imaging\n",
      "             results.\n",
      "\n",
      "          -  For ET-CAD (early onset CAD) = patients <50 years of age for males and <55 for females\n",
      "             with >60% stenosis in ≥2 coronary arteries or their branches, or SYNTAX score ≥12\n",
      "             (significant CAD), in the absence of acquired CAD risk factors.\n",
      "\n",
      "          -  Patients with >60% stenosis in ≥2 coronary arteries or their branches, or SYNTAX score\n",
      "             ≥12, will also be eligible for the ET-CAD group as follows: a) <40 years of age for\n",
      "             males and <45 for females in the presence of one acquired risk factor; b) <35 years of\n",
      "             age for males or females and two acquired risk factors.\n",
      "\n",
      "          -  Patients already having undergone revascularization will be eligible if other criteria\n",
      "             are fulfilled and an aggregate SYNTAX score of ≥12 would have been reached for all\n",
      "             treated lesions, or there was disease in ≥2 coronary arteries or their branches,\n",
      "             according to the criteria (1) and (2) above.\n",
      "\n",
      "          -  For Healthy Controls = age matched patients who have undergone angiography and who do\n",
      "             not have CAD ('normal coronary arteries'; SYNTAX score = 0) but with ≥2 acquired CAD\n",
      "             risk factors. Control subjects for the FMD studies will be unaffected family members,\n",
      "             or unrelated persons matched for age and gender.\n",
      "\n",
      "          -  For all subjects, other inclusion criteria are:\n",
      "\n",
      "          -  a. Age >18 years;\n",
      "\n",
      "          -  b. Fluency in English or Spanish (Spanish consent forms will be provided);\n",
      "\n",
      "          -  c. Freely willing to participate with signed informed consent.\n",
      "\n",
      "          -  Acquired Risk Factors are defined as:\n",
      "\n",
      "          -  (1) Diabetes for >2 years or HBA1C >10.0%;\n",
      "\n",
      "          -  (2) Smoker of >5 pack-years for entire lifetime;\n",
      "\n",
      "          -  (3) Obesity (BMI >30kg/m2);\n",
      "\n",
      "          -  (4) Dyslipidemia, defined by use of lipid lowering therapy, physician diagnosis of\n",
      "             dyslipidemia, serum total cholesterol >240 mg/dL or low-density\n",
      "             lipoprotein-cholesterol >100 mg/dL;\n",
      "\n",
      "          -  (5) Hypertension according to guidelines or requiring therapy.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Smoking >2 packets of cigarettes/day for >12 months;\n",
      "\n",
      "          -  Prior total cholesterol level of >400mg/dl;\n",
      "\n",
      "          -  BMI >40 kg/m2;\n",
      "\n",
      "          -  Uncontrolled or severe diabetes with prior hospitalization due to diabetic\n",
      "             complications other than at diagnosis;\n",
      "\n",
      "          -  For ET-CAD patients: Uncontrolled or severe hypertension causing hospitalization or\n",
      "             direct complications;\n",
      "\n",
      "          -  Serum creatinine ≥2.0 mg/dL;\n",
      "\n",
      "          -  Heart transplantation;\n",
      "\n",
      "          -  Active autoimmune disease;\n",
      "\n",
      "          -  Illicit drug use;\n",
      "\n",
      "          -  HIV positive;\n",
      "\n",
      "          -  Prior malignancy with mediastinal irradiation, bone marrow transplantation or\n",
      "             high-dose chemotherapy;\n",
      "\n",
      "          -  Adult congenital heart disease;\n",
      "\n",
      "          -  For healthy controls only, a positive family history of CAD or FMD.\n",
      "\n",
      "        Also, as an extension of this study, patients presenting with rare, undiagnosed or unusual\n",
      "        forms of CAD (e.g. unexplained dissection, fulminant calcification, aneurysms etc.) and FMD\n",
      "        and appropriate controls, will be recruited, particularly if there is a strong family\n",
      "        pedigree.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age between 16-40 years\n",
      "\n",
      "          -  axial topography consistent with keratoconus\n",
      "\n",
      "          -  minimum corneal thickness more than 400 µm and a progression of keratoconus in past 12\n",
      "             months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  history of ocular herpes or non-healing corneal ulcers\n",
      "\n",
      "          -  subjects with current ocular infection\n",
      "\n",
      "          -  severe preoperative corneal haze or scar\n",
      "\n",
      "          -  severe ocular surface disease\n",
      "\n",
      "          -  autoimmune diseases\n",
      "\n",
      "          -  pregnant women\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed prostate adenocarcinoma (within 365 days of randomization).\n",
      "\n",
      "          -  High-risk for recurrence as determined by evidence of at least one of the following:\n",
      "             Gleason Score 8-10 PSA 20 T stage T3\n",
      "\n",
      "          -  Histological evaluation of prostate biopsy with assignment of a Gleason score to the\n",
      "             biopsy material; Gleason score must be in the range 2-10. 6 cores are strongly\n",
      "             recommended.\n",
      "\n",
      "          -  Clinical stages T1a- T3 N0 M0 as staged by the treating investigator. (AJCC Criteria\n",
      "             7th Ed.-appendix III).\n",
      "\n",
      "          -  PSA values 50 ng/ml within 90 days prior to randomization. Must be completed prior to\n",
      "             biopsy or at least 21 days after prostate biopsy.\n",
      "\n",
      "          -  Absolute Neutrophil Count (ANC) 1,800 cells/mm³ within 90 days prior to randomization.\n",
      "\n",
      "          -  Platelets 100,000 cells/mm³ within 90 days prior to randomization.\n",
      "\n",
      "          -  Hemoglobin 10 g/dl within 90 days prior to randomization. 3.1.9 ALT, AST, and total\n",
      "             bilirubin within 1.5 X institutional upper normal limits within 90 days prior to\n",
      "             randomization.\n",
      "\n",
      "          -  ECOG status 0-1 (appendix II) documented within 90 days of randomization.\n",
      "\n",
      "          -  Patient must sign study specific informed consent prior to randomization. Note:\n",
      "             consent for legally authorized representative is not permitted.\n",
      "\n",
      "          -  Completed all requirements listed in section 4.0 within the specified time frames.\n",
      "\n",
      "          -  Able to start treatment within 56 days of randomization.\n",
      "\n",
      "          -  At least 18 years old and less than or equal to 75 years of age.\n",
      "\n",
      "          -  Men of child-producing potential must be willing to consent to use effective\n",
      "             contraception while on treatment and for at least 3 months afterwards.\n",
      "\n",
      "          -  Medical oncology consultation prior to randomization and medically approved for\n",
      "             chemotherapy treatment per protocol.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Evidence of distant metastasis.\n",
      "\n",
      "          -  Pelvic lymph nodes 1.5 cm in greatest dimension unless the enlarged lymph node is\n",
      "             biopsied and negative.\n",
      "\n",
      "          -  Prior prostate cancer surgery including but not limited to prostatectomy, hyperthermia\n",
      "             and cryosurgery.\n",
      "\n",
      "          -  Prior pelvic radiation for their prostate cancer.\n",
      "\n",
      "          -  Prior androgen suppression.\n",
      "\n",
      "          -  Severe, active co-morbidity, defined as follows:\n",
      "\n",
      "          -  Active rectal diverticulitis, Crohns disease affecting the rectum or ulcerative\n",
      "             colitis. (Non-active diverticulitis and Crohns disease not affecting the rectum are\n",
      "             allowed).\n",
      "\n",
      "          -  Unstable angina and/or congestive heart failure requiring hospitalization within the\n",
      "             last 6 months.\n",
      "\n",
      "          -  Myocardial infarction within the last 6 months.\n",
      "\n",
      "          -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time of\n",
      "             randomization.\n",
      "\n",
      "          -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note,\n",
      "             however, that HIV testing is not required for entry into this protocol. The need to\n",
      "             exclude patients with AIDS from this protocol is necessary because the treatments\n",
      "             involved in this protocol may be significantly immunosuppressive.\n",
      "\n",
      "          -  Prior allergic reaction to the drugs involved in this protocol.\n",
      "\n",
      "          -  Existing peripheral neuropathy grade 2.\n",
      "\n",
      "          -  Prior systemic chemotherapy for prostate cancer.\n",
      "\n",
      "          -  History of proximal urethral stricture requiring dilatation.\n",
      "\n",
      "          -  Major medical, addictive or psychiatric illness which in the investigators\n",
      "             opinion,will prevent the consent process, completion of the treatment and/or interfere\n",
      "             with follow-up.\n",
      "\n",
      "          -  Evidence of any other cancer within the past 5 years and 50% probability of a 5 year\n",
      "             survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell\n",
      "             cancer of the skin is allowed.)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Type 2 diabetes\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Atrial fibrillation\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patient must be female.\n",
      "\n",
      "          -  Patient must be at least 18 years of age.\n",
      "\n",
      "          -  Patient's clinical stage must be documented as tumor size less than 5 cm, with no\n",
      "             palpable nodes and no evidence of metastatic disease (T1 or T2 N0 M0). For patients\n",
      "             who will receive neoadjuvant systemic therapy, pre-treatment clinical stage should be\n",
      "             used.\n",
      "\n",
      "          -  Patient must have a negative (normal) axillary ultrasound performed at Siteman Cancer\n",
      "             Center. Lymph nodes will be evaluated based on morphologic features. AUS wil be\n",
      "             considered positive (abnormal)if lymph nodes are noted to be completely hypoechoic\n",
      "             (absent hilum) or have focal hypoechoic cortical thickening/lobulation greater than 4\n",
      "             mm.\n",
      "\n",
      "          -  Patient must have a tissue diagnosis of invasive breast carcinoma\n",
      "\n",
      "          -  Patient must have Eastern Cooperative Oncology Group (ECOG) status </= 2, as\n",
      "             documented in patient's medical record.\n",
      "\n",
      "          -  Patient must be available for follow-up.\n",
      "\n",
      "          -  A patient with a history of previous malignancy is eligible for this study as long as\n",
      "             the patient meets the following criteria for a cancer survivor. A cancer survivor is\n",
      "             eligible provided that the following criteria are met (1) The patient has undergone\n",
      "             potentially curative therapy for all prior malignancies; (2) There has been no\n",
      "             evidence of any prior malignancies for at least five years with no evidence of\n",
      "             recurrence (except for effectively treated basal cell or squamous carcinoma of the\n",
      "             skin, carcinoma in-situ of the cervix that has been effectively treated by surgery\n",
      "             alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated\n",
      "             by surgery alone); and (3) The patient is deemed by their treating physician to be at\n",
      "             low risks for recurrence from prior malignancies.\n",
      "\n",
      "          -  Patient, or the patient's legally acceptable representative, must provide a signed and\n",
      "             dated written informed consent prior to registration and any study-related procedures.\n",
      "\n",
      "          -  Patient must provide written authorization to allow the use and disclosure of their\n",
      "             protected health information. NOTE: This may be obtained in either the study-specific\n",
      "             informed consent or in a separate authorization form and must be obtained from the\n",
      "             patient prior to study registration.\n",
      "\n",
      "          -  Patient must be a candidate for sentinel lymph node biopsy (SLNB).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient in lactating (breast-feeding) or pregnant.\n",
      "\n",
      "          -  Patient has concurrent invasive bilateral breast malignancies or multicentric disease.\n",
      "\n",
      "          -  Patient has had previous ipsilateral axillary surgery such as excisional biopsy of\n",
      "             lymph nodes(s), treatment of hidradenitis.\n",
      "\n",
      "          -  Patient is considered poor candidate surgical candidate due to non-malignant systemic\n",
      "             disease.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of Conduct Disorder of Oppositional Defiant Disorder (for the child)\n",
      "\n",
      "          -  Residence in the state of CT\n",
      "\n",
      "          -  Access to a computer and high-speed Internet access\n",
      "\n",
      "          -  English fluency (at least one parent)\n",
      "\n",
      "          -  No history of significant developmental delay (for the child)\n",
      "\n",
      "          -  Parental consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Participation in another form of psychotherapy or counseling that is directed toward\n",
      "             the reduction of social, emotional, or behavioral problems\n",
      "\n",
      "          -  Evidence of recent suicidality (for the child)\n",
      "\n",
      "          -  Current or lifetime diagnosis of a Pervasive Developmental Disorder\n",
      "\n",
      "          -  Primary diagnoses of a mood or anxiety disorder\n",
      "\n",
      "          -  Acute family crisis\n",
      "\n",
      "          -  Parent or guardian who can participate in treatment shows current psychosis or an\n",
      "             uncontrolled medical condition\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 18 years or older,\n",
      "\n",
      "          -  Diagnosed with LEMS,\n",
      "\n",
      "          -  If female, have a negative pregnancy test, and\n",
      "\n",
      "          -  If premenopausal, be willing to practice an effective form of birth control during the\n",
      "             study,\n",
      "\n",
      "          -  Tested and found by ECG not to have a prolonged QT syndrome,\n",
      "\n",
      "          -  Agree to have a second ECG at the time of peak drug effect,\n",
      "\n",
      "          -  Has understood and signed the Informed Consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Is known to have a sensitivity to 3, 4-DAP,\n",
      "\n",
      "          -  Has a history of:\n",
      "\n",
      "               1. past or current seizures,\n",
      "\n",
      "               2. cardiac arrhythmia,\n",
      "\n",
      "               3. hepatic, renal or hematologic disease, or\n",
      "\n",
      "               4. severe asthma,\n",
      "\n",
      "          -  Is believed by the investigator to be unable to comply with the protocol.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All the following criteria must be met at enrollment:\n",
      "\n",
      "        Historical non-infectious intermediate, anterior and intermediate, posterior or panuveitis\n",
      "        in at least one eye\n",
      "\n",
      "        Active inflammation within the last 180 days, defined by the presence of any of the\n",
      "        following (in at least one eye) according to SUN criteria:\n",
      "\n",
      "          -  ≥ 2+ anterior chamber cells\n",
      "\n",
      "          -  ≥ 2+ vitreous haze\n",
      "\n",
      "          -  active retinal or choroidal lesions\n",
      "\n",
      "        Active inflammation at enrollment, defined by the presence of any of the following (in at\n",
      "        least one eye) according to SUN criteria:\n",
      "\n",
      "          -  ≥1+ anterior chamber cells and/or\n",
      "\n",
      "          -  ≥1+ vitreous haze and/or\n",
      "\n",
      "          -  active retinal/choroidal lesions\n",
      "\n",
      "        At least one of the following criteria must be met before or at enrollment:\n",
      "\n",
      "          -  Active inflammation after 4 weeks of high-dose (1mg/kg prednisone equivalent)\n",
      "             corticosteroid treatment or 4 weeks following a regional corticosteroid injection\n",
      "\n",
      "          -  Treatment with oral corticosteroids resulting in a reduction of inflammation, followed\n",
      "             by an increase in inflammation (of at least 1 grade in anterior chamber cells or\n",
      "             vitreous haze or a change of non-active to active lesions) when corticosteroid is\n",
      "             tapered, in the 180 weeks prior to enrollment\n",
      "\n",
      "          -  Active inflammation after long-acting corticosteroid injection 4 weeks to 180 days\n",
      "             prior to enrollment\n",
      "\n",
      "          -  Active inflammation after treatment with >10mg/day oral prednisone for at least the\n",
      "             past 90 days prior to enrollment\n",
      "\n",
      "          -  Known chronic condition necessitating corticosteroid-sparing immunosuppressive\n",
      "             treatment: Behcet's disease with posterior segment involvement, multifocal choroiditis\n",
      "             with panuveitis, serpiginous choroidopathy, birdshot retinochoroidopathy, diffuse\n",
      "             retinal vasculitis, Vogt-Koyanagi-Harada with bullous serous retinal detachments\n",
      "             and/or choroidal detachments, sympathetic ophthalmia. No prior therapy required for\n",
      "             these patients\n",
      "\n",
      "        Willingness to start corticosteroid treatment at 1mg/kg or 60mg a day of prednisone,\n",
      "        whichever is less\n",
      "\n",
      "        Willingness to limit alcohol consumption\n",
      "\n",
      "        Willingness to use an acceptable method of contraception during the study period (i.e.\n",
      "        pharmacologics, devices, barrier methods) or abstinence.\n",
      "\n",
      "          -  Exclusion Criteria: Any of the following\n",
      "\n",
      "        Any infectious cause of uveitis\n",
      "\n",
      "        Prior immunosuppressive therapy other than corticosteroids in the past 12 months\n",
      "\n",
      "        Prior intolerability or safety issues with methotrexate or mycophenolate mofetil\n",
      "\n",
      "        Prior failure to control ocular or other inflammation using methotrexate or mycophenolate\n",
      "        mofetil\n",
      "\n",
      "        Prior biologic therapy at any time\n",
      "\n",
      "        Media opacity (such as cataract and/or corneal scar) and/or extensive posterior synechiae\n",
      "        such that examination of the posterior segment is not possible in both eyes\n",
      "\n",
      "        Chronic hypotony (IOP < 5 mm Hg for > 3 months) in both eyes\n",
      "\n",
      "        Periocular or intravitreal corticosteroid injection in the past 4 weeks\n",
      "\n",
      "        Fluocinolone acetonide implant in either eye in < 3 years\n",
      "\n",
      "        Intraocular surgery in < 30 days, or planning on getting surgery within the next 6 months\n",
      "\n",
      "        Best spectacle-corrected visual acuity (BSCVA) of hand motions or worse in better eye\n",
      "\n",
      "        < 16 years of age at enrollment\n",
      "\n",
      "        Planning to conceive during the study period, pregnant or breast-feeding (blood or urine\n",
      "        pregnancy test for all females, excluding those who are post-menopausal is mandatory)*\n",
      "\n",
      "        Any history of cancer (If a patient has a history of non-melanoma skin cancer they can\n",
      "        still be considered for inclusion in this study, provided it is not currently active).\n",
      "\n",
      "        Systemic autoimmune disease anticipated to dictate treatment course\n",
      "\n",
      "        Abnormal Complete blood count (≤ 2,500 white blood cells and/or ≤ 75,000 platelets and/or\n",
      "        ≤9 hemoglobin) within 4 weeks prior to enrollment*\n",
      "\n",
      "        Abnormal alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 2 times\n",
      "        the upper limit of normal for the lab and/or creatinine ≥ 1.5 within 4 weeks prior to\n",
      "        enrollment*\n",
      "\n",
      "        Evidence of active tuberculosis, HIV infection, syphilis, or hepatitis B or C (patients\n",
      "        must have a tuberculin skin test, or interferon-gamma release assay, a chest radiograph,\n",
      "        RPR/VDRL, FTA-ABS, or other treponemal tests, Hepatitis B surface antigen, Hepatitis C\n",
      "        antibody tests, and HIV test within 90 days prior to enrollment)**\n",
      "\n",
      "        *Testing required within 4 weeks prior to enrollment; **Testing required within 90 days\n",
      "        prior to enrollment.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects included in this study will have completed the follow-up requirements of the\n",
      "             IDE G920035 or the IDE G000071 Clinical Trial;\n",
      "\n",
      "          -  Subjects must be willing to give a relevant medical history, undergo a focused\n",
      "             physical examination of their operative hip(s) and have an AP and lateral x-ray taken\n",
      "             of their operative hip(s);\n",
      "\n",
      "          -  Subjects must be willing to complete the Harris Hip Score, SF-12, WOMAC, UCLA Activity\n",
      "             Score, and VAS pain self-assessment questionnaires; and\n",
      "\n",
      "          -  Subjects must be willing to sign an informed consent document.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  There are no exclusion criteria.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Male and female patients older than 13 years of age\n",
      "\n",
      "          2. Presenting with 1 to 3 aphthous ulcers (less than 48 hours' duration) with a size no\n",
      "             greater than 5mm in diameter.\n",
      "\n",
      "          3. History of recurrent minor aphthous ulcer for at least one year with a frequency of at\n",
      "             least one outbreak every one month.\n",
      "\n",
      "          4. Normal sense of pain, without anesthesia or paresthesia.\n",
      "\n",
      "          5. Willingness to participate and sign the informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  1- Concurrent clinical conditions that could pose a health risk to the subjects\n",
      "             including serious heart, liver, or kidney dysfunctions.\n",
      "\n",
      "             2- Pregnancy and lactation. 3- Ulcers as a manifestation of systemic disorders such as\n",
      "             Ulcerative Colitis, Crohn's disease, Behçet's syndrome or serious anemia.\n",
      "\n",
      "             4- Treatment with systemic steroids, immunomodulatory agents, antibiotics,\n",
      "             non-steroidal anti-inflammatory drugs (except occasional use for headaches) one month\n",
      "             prior to the study entry.\n",
      "\n",
      "             5- Treatment of the current ulcer with any topical or systemic medication. 6-\n",
      "             Attendance of any other clinical trials prior to 3 months of study entry.\n",
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "               1. 30 to 60 years old\n",
      "\n",
      "               2. Physically healthy\n",
      "\n",
      "               3. Healthy volunteers only: Currently consuming 7 or less standard drinks per week\n",
      "                  if female; 14 or less drinks per week if male.\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "          1. Significant history of head trauma or cranial surgery,\n",
      "\n",
      "          2. History of diabetes or stroke which requires medical intervention,\n",
      "\n",
      "          3. Clinical or laboratory evidence of severe hepatic disease as determined by ALT or AST\n",
      "             greater than 5 times the upper normal limit, INR greater than 2.0, total bilirubin\n",
      "             greater than 2.5 mg/dL, and albumin lower than 3.0 g/dL.\n",
      "\n",
      "          4. Positive HIV test.\n",
      "\n",
      "          5. Healthy volunteers only: 5 or more binge drinking episodes in the past 30 days (5 or\n",
      "             more standard drinks on one occasion for males, 4 or more standard drinks on one\n",
      "             occasion for females within two hours)\n",
      "\n",
      "          6. Healthy volunteers only:\n",
      "\n",
      "             --Have fulfilled DSM-IV or DSM-5 criteria for current alcohol use disorder or\n",
      "             substance abuse disorder\n",
      "\n",
      "          7. Inpatient participants only: Currently experiencing symptoms of withdrawal from\n",
      "             alcohol (As determined by the most recent measurement within the past 30 days CIWA\n",
      "             score > 8)\n",
      "\n",
      "          8. Female participants only: Are currently pregnant\n",
      "\n",
      "          9. IPresence of any contraindication for fMRI as determined by the NIAAA MRI Safety\n",
      "             Screening Questionnaire\n",
      "\n",
      "         10. Have calustrophobia\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  first breast cancer without metastases\n",
      "\n",
      "          -  between 18 and 75-year-old\n",
      "\n",
      "          -  ability to read, write and speak French.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with a diagnosed psychiatric disorder or dementia\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Histologically documented squamous cell carcinoma of the thoracic esophagus;\n",
      "             undergoing radical esophagectomy; the pathological stage is T(primary tumor)1-4\n",
      "             N(regional lymph nodes)1-3 M(distant metastasis)0 (ESOPHAGUS, Union for International\n",
      "             Cancer Control(UICC) 2010) ;\n",
      "\n",
      "          2. Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy);\n",
      "\n",
      "          3. The expectation of life is more than 6 months;\n",
      "\n",
      "          4. Age: 18~70 years old;\n",
      "\n",
      "          5. Normal hemodynamic indices before the recruitment (including white blood cell\n",
      "             count>4.0×109/L, neutrophil count>1.5×109/L, platelet count >100×109/L,\n",
      "             hemoglobin≥90g/l, normal liver/kidney function);\n",
      "\n",
      "          6. ECOG (Eastern Cooperative Oncology Group) : 0-1;\n",
      "\n",
      "          7. Able to understand this study and have signed informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Have been treated with chemotherapy, radiotherapy and other anti tumor treatment\n",
      "             except surgery;\n",
      "\n",
      "          2. Known or suspected of allergy to paclitaxel or carboplatin;\n",
      "\n",
      "          3. Female in pregnancy or lactating;\n",
      "\n",
      "          4. With significant psychological, family, social and other factors which may affect the\n",
      "             ability to understand and sign the informed consent;\n",
      "\n",
      "          5. Patients with peripheral neuropathy(CTC grade≥2);\n",
      "\n",
      "          6. With other malignant tumors before the recruitment.\n",
      "\n",
      "          7. The researchers consider that the patient is not appropriate to enroll the study;\n",
      "\n",
      "          8. The patient can't be tolerant to postoperative adjuvant radiotherapy and chemotherapy\n",
      "             for serious heart/lung/liver/kidney function, the haematopoietic system diseases, the\n",
      "             immune system diseases, the nervous system diseases, cachexia and so on.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All patients undergoing a VATS lobectomy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Less than 18 year old, inability to consent, VATS lobectomy conversion to open\n",
      "             lobectomy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Adult patients (age> = 18 years) hospitalized in a facility selected during the\n",
      "        investigation period:\n",
      "\n",
      "        or in one of the three evaluated healthcare pathways: 1 / out patient surgery postoperative\n",
      "        period; 2 / downstream of hospital emergencies; 3 / downstream resuscitation (excluding\n",
      "        return home and external transfer), it is recognized or not USC.\n",
      "\n",
      "        USC is present during the investigation period. Patient who read the Circular.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  opposition to the data collection\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or non-pregnant female at least 18 years of age at the time of consent\n",
      "\n",
      "          -  One or both eyes having CME associated with non-infectious uveitis\n",
      "\n",
      "          -  Subject has the ability to understand and sign the Informed Consent Form\n",
      "\n",
      "          -  Subject is willing and able to comply with scheduled visits, treatment plan,\n",
      "             laboratory tests, and other study procedures\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Allergy to triamcinolone acetonide\n",
      "\n",
      "          -  History of any type of non-infectious uveitis without macular edema\n",
      "\n",
      "          -  Vitreous hemorrhage\n",
      "\n",
      "          -  Uveitis with infectious etiology\n",
      "\n",
      "          -  CME due to non-uveitis causes\n",
      "\n",
      "          -  Previous viral retinitis or uveitis\n",
      "\n",
      "          -  Toxoplasmosis scar in study eye or scar related to viral retinitis\n",
      "\n",
      "          -  Media opacity interfering with optical coherence tomography (OCT) or evaluation of the\n",
      "             retina and vitreous\n",
      "\n",
      "          -  Patient may not have had prior treatment for CME within the past 3 months including\n",
      "             anti-VEGF (vascular endothelial growth factor), periocular or intravitreal steroid\n",
      "\n",
      "          -  Pregnant or nursing women; females of childbearing potential who are unwilling or\n",
      "             unable to use an acceptable method of contraception\n",
      "\n",
      "          -  Subjects unwilling to comply with the study protocol or who are likely to be lost to\n",
      "             follow-up within 6 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Prostate adenocarcinoma, T3aN0M0, T3bN0M0\n",
      "\n",
      "          -  Previously untreated disease or undergone endocrine therapy without reaching to\n",
      "             castration resistant prostate cancer\n",
      "\n",
      "          -  Survival ≥ 12 months\n",
      "\n",
      "          -  WHO performance status 0-2\n",
      "\n",
      "          -  white blood cell ≥ 3.5 ×10*9/L\n",
      "\n",
      "          -  Platelets ≥ 5×10*9/L\n",
      "\n",
      "          -  Hemoglobin ≥ 10 g/dL\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of malignant disease\n",
      "\n",
      "          -  History of coronary artery disease\n",
      "\n",
      "          -  Uncontrolled infection\n",
      "\n",
      "          -  Other concurrent severe or uncontrolled medical disease that could compromise\n",
      "             participation in the study (i.e., uncontrolled diabetes mellitus, uncontrolled cardiac\n",
      "             disease, uncontrolled hypertension, congestive cardiac failure, ventricular\n",
      "             arrhythmias, active ischemic heart disease, myocardial infarction within the past six\n",
      "             months, chronic liver or renal disease, and active upper gastrointestinal tract\n",
      "             ulceration)\n",
      "\n",
      "          -  Psychological, familial, sociological, or geographical condition potentially hampering\n",
      "             compliance with the study treatment and follow-up schedule\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Main Inclusion Criteria:\n",
      "\n",
      "          1. Subjects must be approved for suitability by an Enrollment Approval Committee\n",
      "\n",
      "          2. Able and willing to give written (signed and dated) informed consent and adhere to\n",
      "             visit schedule and available to complete the study\n",
      "\n",
      "          3. Men or women 30 years of age and higher at initial screening assessment. (For the 100\n",
      "             subjects who enter the Gastroscopy sub study, the age limits are 30-80 years of age,\n",
      "             inclusive, at initial screening assessment)\n",
      "\n",
      "          4. Diagnosed with Parkinson's disease, consistent with UK brain bank criteria\n",
      "\n",
      "          5. Has a good response to Levodopa and is taking at least 4 doses of a Levodopa\n",
      "             containing medication (or 3 doses of Rytary) per day during waking hours (not\n",
      "             including nighttime long acting levodopa) at a stable dose for at least 28 days prior\n",
      "             to initial screening assessment\n",
      "\n",
      "          6. Other Anti-PD treatment (such as dopamine agonists, selective MAO-B inhibitors,\n",
      "             anticholinergic agents or Amantadine) are permitted if stable for at least 28 days\n",
      "             prior to study entry and provided they are not anticipated to be changed during the\n",
      "             course of the study\n",
      "\n",
      "          7. Total LD immediate release daily dose of 400 mg to 1300 mg or equivalent prior to\n",
      "             initial screening assessment. Specifically for Rytary, doses up to 1755 mg daily are\n",
      "             acceptable.\n",
      "\n",
      "          8. Able to complete a Hauser Home Diary and can tell the difference between \"On\" and\n",
      "             \"Off\" time\n",
      "\n",
      "               1. Achieved at least 75% diary concordance with an approved site rater in a 4-hour\n",
      "                  training session including at least one \"Off time\" assessment\n",
      "\n",
      "               2. Returned a valid 2-day practice diary after training has been completed.\n",
      "\n",
      "          9. At least 2.5 hours \"Off time\" per day during waking hours on Screening 2-day Practice\n",
      "             Hauser Home Diary (morning akinesia should be incorporated into the total \"Off time\"\n",
      "             assessment).\n",
      "\n",
      "         10. Other than PD, the subject is in satisfactory health, as assessed by physical\n",
      "             examination and screening tests. No clinically significant medical, psychiatric or\n",
      "             laboratory abnormality that could compromise safety or interfere with study procedures\n",
      "             in the opinion of either the investigator or the Enrollment Approval\n",
      "             Committee/Sponsor.\n",
      "\n",
      "         11. Living in an area that is within 3 hours driving distance from the study site or is\n",
      "             willing to stay in such a place the night before each study visit\n",
      "\n",
      "        Main Exclusion Criteria:\n",
      "\n",
      "          1. Participation in another drug clinical trial within 28 days prior to initial screening\n",
      "             assessment (calculated from the previous study's last dosing date)\n",
      "\n",
      "          2. Atypical Parkinsonism (subjects with Parkinsonian features caused by disorder such as\n",
      "             multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies or\n",
      "             multiple brain infarcts)\n",
      "\n",
      "          3. Clinically significant cardiac, pulmonary, hepatic or renal disease or other condition\n",
      "             or any major complication/illness which contraindicates his/her participation in the\n",
      "             opinion of either the investigator or the Enrollment Approval Committee/Sponsor.\n",
      "\n",
      "          4. Severe dyskinesia in the opinion of either the investigator or the Enrollment Approval\n",
      "             Committee.\n",
      "\n",
      "          5. Treatment with non-selective monoamine oxidase (MAO) inhibitors during the last 28\n",
      "             days prior to initial screening assessment or planning to take during study\n",
      "             participation\n",
      "\n",
      "          6. Previous or planned neurosurgical treatment for Parkinson's Disease (e.g., procedures\n",
      "             including ablation or deep brain stimulation) during the course of the study\n",
      "\n",
      "          7. Significant cognitive impairment as defined by the Mini-Mental State Examination\n",
      "             (MMSE) score < 26.\n",
      "\n",
      "          8. Clinically significant psychiatric illness, including major depression (Hamilton\n",
      "             Depression Rating Scale-17 ≥14). Subjects with a lifetime history of suicidal attempt\n",
      "             (including an active attempt, interrupted attempt or aborted attempt)\n",
      "\n",
      "          9. Current or previous treatment for more than 1 month within the past 2 years with any\n",
      "             neuroleptic drug (antipsychotic) or any other drug with anti-dopaminergic properties\n",
      "             (e.g. metoclopramide, domperidone)\n",
      "\n",
      "         10. Currently experiencing or any known history of psychosis or delusions within 2 years\n",
      "             prior to Screening.\n",
      "\n",
      "         11. Known history of substance abuse within the past 2 years\n",
      "\n",
      "         12. Moderate or greater level of alcohol consumption\n",
      "\n",
      "         13. Unable to swallow large pills (e.g., large vitamin pills)\n",
      "\n",
      "         14. History of Melanoma or suspicious skin lesion which could be a Melanoma\n",
      "\n",
      "         15. Narrow-angle Glaucoma\n",
      "\n",
      "         16. History of small bowel or gastric surgery (Including PEG-J placement for\n",
      "             Duopa/Duodopa) or bowel obstruction, diagnosis of small bowel narrowing, diagnosis of\n",
      "             Crohn's disease, or frequent nausea or emesis, regardless of etiology, (Previous\n",
      "             appendectomy or hernioplasty will not be exclusionary).\n",
      "\n",
      "         17. Active peptic ulcer disease or a history of peptic ulcer or upper GI bleeding\n",
      "\n",
      "         18. Regular use of opioids (Intermittent opioid use is not exclusionary)\n",
      "\n",
      "         19. Symptomatic gastroparesis with frequent vomiting (at least once a week)\n",
      "\n",
      "         20. Concomitant use of NSAIDs and oral steroids within the past 28 days\n",
      "\n",
      "         21. Allergy to the study drug or any of its excipients, or to Yellow Dye #5 (tartrazine)\n",
      "\n",
      "         22. Women who are pregnant or nursing. Women of childbearing potential who are not willing\n",
      "             to use a medically acceptable method of contraception.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients >18 years of age with malignant dysphagia due to locally advanced EAC (≥T3\n",
      "             and/or N1) who are undergoing upper endoscopic ultrasound or upper endoscopy for\n",
      "             pre-treatment staging or symptom evaluation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior esophageal or gastro-esophageal junction surgery.\n",
      "\n",
      "          -  Prior diagnosis of oropharyngeal dysphagia.\n",
      "\n",
      "          -  Prior diagnosis of esophageal achalasia.\n",
      "\n",
      "          -  Esophageal strictures unrelated to EAC\n",
      "\n",
      "          -  Distant metastasis\n",
      "\n",
      "          -  Dysphagia only to solid or semi-solid foods\n",
      "\n",
      "          -  Need for esophageal dilation in order to pass the diagnostic upper endoscope distal to\n",
      "             the tumor.\n",
      "\n",
      "          -  Coagulopathy (INR>2, platelets < 50,000)\n",
      "\n",
      "          -  Inability to provide informed consent.\n",
      "\n",
      "          -  Marfan's syndrome\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  written consent\n",
      "\n",
      "          -  indication for elective PCI of a de novo coronary stenosis in a native vessel\n",
      "\n",
      "          -  coronary multivessel disease with clinically proven indication for repeating coronary\n",
      "             angiography at 6-9 months (staged PCI strategy)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pregnancy, lactation, women of childbearing age w/o reliable contraception\n",
      "\n",
      "          -  life expectance < 50 % at 1 year\n",
      "\n",
      "          -  major surgery planned within 6 months\n",
      "\n",
      "          -  participation in other clinical trials or impossibility to give written consent\n",
      "\n",
      "          -  acute coronary syndrome or cardiogenic shock within the last 4 weeks\n",
      "\n",
      "          -  stent thrombosis, defined as \"probable\" or \"definite\" by ARC\n",
      "\n",
      "          -  contraindication against dual antiplatelet therapy\n",
      "\n",
      "          -  allergy against mTOR-inhibitors or taxol derivates\n",
      "\n",
      "          -  target lesion situated in the left main coronary artery, in a bypass graft or a\n",
      "             grafted vessel\n",
      "\n",
      "          -  reference luminal diameter of the target lesion > 3.75 mm or < 2.0 mm\n",
      "\n",
      "          -  lesion length > 30 mm, bifurcation lesion requiring intervention on a major side\n",
      "             branch\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  pre-hypertensive (systolic blood pressure 120-139 mmHg, or diastolic blood pressure\n",
      "             80-89 mmHg)\n",
      "\n",
      "          -  impaired fasting glucose (5.6-6.9 mmil/L)\n",
      "\n",
      "          -  not meeting the physical activity guidelines for adults (>=150 min/wk of\n",
      "             moderate-to-vigorous physical activity)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  smoking, pregnancy, known coronary heart disease, orthopedic limitations for\n",
      "             performing physical activity, taking medications to control high blood pressure or\n",
      "             high blood glucose, special dietary requirements, and being advised by a doctor to\n",
      "             avoid prolonged periods of sitting.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Symptomatic patients with a clinical indication for cardiac CT\n",
      "\n",
      "          2. Patients with a clinical indication for CT\n",
      "\n",
      "          3. Estimated GFR > 60 mL/min\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. No clinical indication for CT scanning\n",
      "\n",
      "          2. Contra-indication for CT scanning or for IV contrast administration\n",
      "\n",
      "          3. Pregnancy\n",
      "\n",
      "          4. Inability to give an informed consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of Crohn's disease confirmed by standard criteria\n",
      "\n",
      "          -  Active luminal Crohn's disease defined by an HBI score of >4 or with draining perianal\n",
      "             Crohn's disease a) Active perianal Crohn's disease defined a presence of draining\n",
      "             perianal fistula on physical exam19\n",
      "\n",
      "          -  Patients with active luminal Crohn's disease must be initiating treatment with an\n",
      "             anti-TNF agent (Remicade, Humira, Cimzia, or Simponi) or a steroid (prednisone,\n",
      "             Entocort, or Uceris).\n",
      "\n",
      "          -  Patients with active perianal disease must be initiating therapy with an anti-TNF\n",
      "             agent (Remicade, Humira, Cimzia, or Simponi).\n",
      "\n",
      "          -  Can understand written instructions in English\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Previous primary non-response to an anti-TNF\n",
      "\n",
      "          -  Uncontrolled medical or psychiatric disease (a. Degenerative neurologic condition,\n",
      "             b.Unstable angina, c.Class III/IV congestive heart failure, d.Severe asthma or chronic\n",
      "             obstructive pulmonary disease, e.Symptomatic peripheral vascular disease, f. Chronic\n",
      "             renal insufficiency (creatinine > 2.0), g. Malignancy within the last 3 years\n",
      "             (excluding squamous or basal cell cancers of the skin), h. Poorly controlled\n",
      "             depression, mania, and schizophrenia, i. Active infection, j. Acquired\n",
      "             immunodeficiency syndrome)\n",
      "\n",
      "          -  Inability to adhere to the protocol\n",
      "\n",
      "          -  Need for imminent surgery other than an exam under anesthesia\n",
      "\n",
      "          -  Under 18 years of age.\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Use of concurrent prednisone >30 mg per day in the anti-TNF groups\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Stable sickle cell disease patients\n",
      "\n",
      "          -  Patient hospitalized into the dermatology unit\n",
      "\n",
      "          -  Patient with an evolutive leg ulcer since more than 1 year\n",
      "\n",
      "          -  No infection at the time of surgery\n",
      "\n",
      "          -  Patient competent to give informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with a history of corticosteroids or on active therapy\n",
      "\n",
      "          -  infection at the limb affected by ulcer\n",
      "\n",
      "          -  Recurrent painful crises,\n",
      "\n",
      "          -  Immunosuppressive drug therapy,\n",
      "\n",
      "          -  Pregnancy,\n",
      "\n",
      "          -  Presence of neoplastic disease or any other clinical concurrent condition other than\n",
      "             sickle cell disease that predisposed them to the development of leg ulcer\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Inactivity during leisure time as assessed through the long version of the\n",
      "             International Physical Activity Questionnaire;\n",
      "\n",
      "          -  Apparent health defined as 1) no known CVD (coronary, cerebrovascular or peripheral\n",
      "             vascular disease), and 2) no known cardiovascular risk factors or cardiovascular\n",
      "             medications (hypertension, dyslipidemia, diabetes, active smoking within past year, or\n",
      "             clinical obesity defined as body mass index (BMI) ≥ 30kg/m2);\n",
      "\n",
      "          -  Signed consent form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Known dyslipidemia (participants receiving lipid-lowering medication, or in the\n",
      "             absence of such medication, having: a fasting total plasma cholesterol level > 6.2\n",
      "             mmol/L, a triglyceride level ≥ 1.7 mmol/L, and/or HDL-cholesterol level < 1.0 mmol/L\n",
      "             in men and < 1.3 mmol/L in women);\n",
      "\n",
      "          -  Hypertension (participants receiving antihypertensive medications or having blood\n",
      "             pressure ≥ 135/85 mmHg);\n",
      "\n",
      "          -  Diabetes (participants taking diabetes medication or having plasma HbA1c ≥ 6.5%);\n",
      "\n",
      "          -  Postmenopausal women;\n",
      "\n",
      "          -  Pregnancy or nursing in the past year or expected in the next two years;\n",
      "\n",
      "          -  Contraindications to MRI, as per the standardized IUCPQ MRI screening form;\n",
      "\n",
      "          -  Participation in another research study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  65-80 years of age\n",
      "\n",
      "          -  Right-handed\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Lifetime history of schizophrenia or psychosis. Any other Axis I diagnosis in the past\n",
      "             12 months.\n",
      "\n",
      "          2. Subjects must not endorse suicidality, homicidality or self-destructive acts or urges\n",
      "             as assessed through a structured clinical interview (SCID)\n",
      "\n",
      "          3. History of seizure or significant head trauma (i.e., extended loss of consciousness,\n",
      "             neurological sequelae, or known structural brain lesion).\n",
      "\n",
      "          4. Neurological or medical conditions that would interfere with study procedures or\n",
      "             confound results, such as conditions that alter cerebral blood flow or metabolism.\n",
      "\n",
      "          5. Use of psychotropic medications within 12 months prior to study.\n",
      "\n",
      "          6. Daily use of any medication that alters neural metabolism or blood flow.\n",
      "\n",
      "          7. Any concurrent psychotherapy.\n",
      "\n",
      "          8. Having taken no more than 8 meditation classes (or related practices such as yoga, Tai\n",
      "             Chi, or Chi Gong) of any kind in the past 6 months, or more than 15 classes in the\n",
      "             past 12 months.\n",
      "\n",
      "          9. Pregnancy.\n",
      "\n",
      "         10. Metallic implants or devices contraindicating magnetic resonance imaging.\n",
      "\n",
      "         11. Claustrophobia\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. between 4 and 9 days post-ischemic stroke;\n",
      "\n",
      "          2. admitted to inpatient rehabilitation;\n",
      "\n",
      "          3. cognitively able to provide consent or assent;\n",
      "\n",
      "          4. were living independently in the community prior to their stroke.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. hemorrhagic stroke or subarachnoid hemorrhage;\n",
      "\n",
      "          2. other neurological or psychiatric conditions deemed by the investigator to impair\n",
      "             participation;\n",
      "\n",
      "          3. no previous stroke on same side of brain unless that stroke was cerebellar\n",
      "\n",
      "          4. moribound or not expected to live 6 months;\n",
      "\n",
      "          5. contraindications to taking sildenafil in pill or syrup form;\n",
      "\n",
      "          6. other medical conditions that would limit ability to participate in the study,\n",
      "             specifically a) currently taking the P450 enzyme inhibitors (erythromycin,\n",
      "             ketoconazole, itraconazole, saquinavir), b) currently taking the protease inhibitor\n",
      "             ritonavir, c) currently taking nitrates or have a history of requiring nitrates\n",
      "             treatment, d) have left ventricular outflow obstruction (i.e., aortic stenosis,\n",
      "             idiopathic hypertrophic subaortic stenosis as confirmed by review of standard of care\n",
      "             echo received before admission to rehabilitation), e) have severely impaired autonomic\n",
      "             control of blood pressure, f) have previous history of symptomatic hypotension, g)\n",
      "             have severely impaired hepatic function, h) is pregnant or become pregnant during the\n",
      "             course of the study, i) Any medical condition which, in the opinion of the\n",
      "             investigator, may compromise compliance with the objectives and/or procedures of the\n",
      "             protocol.\n",
      "\n",
      "          7. scores > 50 on the upper extremity section of the Fugl-Meyer or no walking/gait\n",
      "             impairment\n",
      "\n",
      "             For the MRI portion of the study only:\n",
      "\n",
      "          8. contraindication to MRI: ferrous metal in body, lead included body art,\n",
      "             claustrophobia, pacemaker\n",
      "\n",
      "          9. allergic to or had previous reaction to gadolinium\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All consecutive ASA grade I-II- III patients undergoing elective unilateral\n",
      "             laparoscopic total extra peritoneal (TEP) Inguinal hernia repair\n",
      "\n",
      "          -  Age 18 - 80 yrs, including those who are having recurrent inguinal hernia repair.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  ASA grade IV, V\n",
      "\n",
      "          -  Bilateral inguinal hernia repair\n",
      "\n",
      "          -  BMI > 40 kg/m2\n",
      "\n",
      "          -  Converted to open procedures.\n",
      "\n",
      "          -  Conversion to Transabdominal preperitoneal (TAPP) repair\n",
      "\n",
      "          -  Coagulopathy.\n",
      "\n",
      "          -  Allergy to Bupivacaine.\n",
      "\n",
      "          -  Diagnosis of \"chronic pain syndrome\".\n",
      "\n",
      "          -  Known alcohol or substance abuse within the last 6 months.\n",
      "\n",
      "          -  Daily Opioid intake.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Recently prescribed varenicline (Chantix) with the intention to quit smoking in the\n",
      "             next 3 months\n",
      "\n",
      "          -  Has an Android smartphone (using v5.x.x or lollipop) or Apple smartphone (iPhone)\n",
      "             Operating System (iOS) (using v6.0)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Unwillingness to be randomized to either treatment condition\n",
      "\n",
      "          -  Use of only non-cigarette forms of tobacco (i.e., participant is not a cigarette\n",
      "             smoker but instead uses other tobacco products)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Women with a diagnosis of osteoporosis of at-Risk\n",
      "\n",
      "          -  Have a medical indication to receive Ibandronate+Vitamine D+Calcium\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Osteoporosis due to secondary causes\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Aged between 18 and 70 years old\n",
      "\n",
      "          -  Caucasian\n",
      "\n",
      "          -  Insulin resistance (based on HOMA single-value)\n",
      "\n",
      "          -  BMI between 25 and 50 kg/m²\n",
      "\n",
      "          -  Metabolic syndrome: presence of at least 3 of the following criteria\n",
      "\n",
      "               -  Hypertension (blood pressure ≥ 130/85 mm Hg or antihypertensive treatment)\n",
      "\n",
      "               -  Hypertriglyceridemia (triglyceridemia ≥ 150mg/dl)\n",
      "\n",
      "               -  Low HDL-cholesterol (HDL-cholesterol < 40mg/dl for males, 50mg/dl for females)\n",
      "\n",
      "               -  Visceral obesity (waist circumference > 102 cm for males, 88cm for females)\n",
      "\n",
      "               -  Fasting hyperglycemia (fasting glycemia ≥ 110mg/dl)\n",
      "\n",
      "          -  Informed consent signed by the patient\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Acute or chronic progressive or chronic unstabilized diseases\n",
      "\n",
      "          -  Alcohol consumption (more than 2 glasses per day)\n",
      "\n",
      "          -  Previous bariatric surgery\n",
      "\n",
      "          -  Surgery in the 3 months prior the study or surgery planned in the next 6 months\n",
      "\n",
      "          -  Pregnancy or pregnancy planned in the next 6 months\n",
      "\n",
      "          -  More than 30 minutes of sports 3 times per week\n",
      "\n",
      "          -  Consumption of dietary supplement (omega-3 fatty acids, probiotics, prebiotics, plant\n",
      "             stanols/sterols) in the month prior the study\n",
      "\n",
      "          -  Inflammatory bowel disease or irritable bowel syndrome\n",
      "\n",
      "          -  Diabetic gastrointestinal autonomic neuropathy (such as gastroparesis or reduced\n",
      "             gastrointestinal motility)\n",
      "\n",
      "          -  Consumption of more than 30g of dietary fibers per day\n",
      "\n",
      "          -  Vegetarian or unusual diet\n",
      "\n",
      "          -  Lactose intolerance or milk protein allergy\n",
      "\n",
      "          -  Gluten intolerance\n",
      "\n",
      "          -  Medications influencing parameters of interest (antidiabetic drugs such as metformin,\n",
      "             DPP-4 inhibitors, GLP-1 receptor agonists, acarbose, hypoglycemic\n",
      "             sulfonamides,glinides, thiazolidinediones, SGLT2 inhibitors, insulin,lactulose,\n",
      "             consumption of antibiotics in the 2 months prior the study, corticosteroids,\n",
      "             immunosuppressive agents, statins, fibrate, orlistat, cholestyramine, ezetimibe)\n",
      "\n",
      "          -  Glycated hemoglobin (HbA1c) > 7.5%\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  group 1: healthy female volunteers 18-35 y.o.\n",
      "\n",
      "          -  group 2: healthy male volunteers 18-35 y.o.\n",
      "\n",
      "          -  group 3: healthy female volunteers 36-60 y.o.\n",
      "\n",
      "          -  group 4: healthy male volunteers 36-60 y.o.\n",
      "\n",
      "          -  group 5: female volunteers 36-60 y.o., BMI 26-45\n",
      "\n",
      "          -  group 6: male volunteers 36-60 y.o., BMI 26-45\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  age below 18 years\n",
      "\n",
      "          -  age above 60 years\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  a seated systolic BP (SBP) ≥140 mmHg and <180 mmHg and/or a seated diastolic BP (DBP)\n",
      "             ≥90 mmHg and <110 mmHg;\n",
      "\n",
      "          -  an age ≥18 and ≤75 years;\n",
      "\n",
      "          -  those who had not taken any BP-lowering medications in 1 month before the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  a seated systolic BP (SBP) ≥180 mmHg and/or a seated diastolic BP ≥110 mmHg;\n",
      "\n",
      "          -  secondary hypertension;\n",
      "\n",
      "          -  diagnosed heart failure or stroke;\n",
      "\n",
      "          -  Any of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) was above\n",
      "             1.5 times of it's normal value upper limit, Serum creatinine >177 µmmol/L (2mg/dL), or\n",
      "             liver cirrhosis;\n",
      "\n",
      "          -  subjects with carotid stenosis or systolic murmur\n",
      "\n",
      "          -  subjects with a history of unstable angina pectoris, acute mycardial infarction,\n",
      "             percutaneous transluminal coronary angiography or coronary artery bypass grafting in\n",
      "             the past 6 months;\n",
      "\n",
      "          -  subjects who were within lactation period, pregnant, or planning to become pregnant\n",
      "             during the study;\n",
      "\n",
      "          -  hypersensitive to Nifedipine GITS or with SAE;\n",
      "\n",
      "          -  subjects who are participating in other clinical trials;\n",
      "\n",
      "          -  considered not fit for the study due to other reasons according to the researchers\n",
      "             (such as Malignant tumor, psyche or nervous system dysfunction, or special diseases).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        A person is eligible for inclusion in the study if he/she:\n",
      "\n",
      "          -  Oculo-visual examination in the last two years\n",
      "\n",
      "          -  Between 18 and 35 years of age and has full legal capacity to volunteer\n",
      "\n",
      "          -  Has read and understood the informed consent letter\n",
      "\n",
      "          -  Is willing and able to follow instructions and maintain the appointment schedule\n",
      "\n",
      "          -  Is correctable to a visual acuity of 20/25 or better (in each eye) with their habitual\n",
      "             correction or 20/20 best corrected\n",
      "\n",
      "          -  Currently wears, or has previously successfully worn, soft contact lenses between\n",
      "             -1.00D (Diopter) and -4.00D\n",
      "\n",
      "          -  Spherical Contact Lens Rx between -1.00 and -4.00 and spectacle cylinder <-0.75\n",
      "\n",
      "          -  Has not worn lenses for at least 12 hours before the initial visit\n",
      "\n",
      "          -  Has a subjective response at baseline, which indicates suitability for this study\n",
      "\n",
      "          -  Currently spends a minimum of 4 hours a day; 5 days a week on digital devices and can\n",
      "             replicate this time during the study period\n",
      "\n",
      "          -  Is willing and able to wear the study contact lenses a minimum of 10 hours per day; 5\n",
      "             days a week.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        A person will be excluded from the study if he/she:\n",
      "\n",
      "          -  Has never worn contact lenses before\n",
      "\n",
      "          -  Any systemic disease affecting ocular health\n",
      "\n",
      "          -  Is using any systemic or topical medications that will affect ocular health\n",
      "\n",
      "          -  Has known sensitivity to the diagnostic pharmaceuticals or study products used in this\n",
      "             study.\n",
      "\n",
      "          -  Has any ocular pathology or anomaly that would affect the wearing of the lenses\n",
      "\n",
      "          -  Has persistent, clinically significant corneal or conjunctival staining using sodium\n",
      "             fluorescein dye\n",
      "\n",
      "          -  Is aphakic\n",
      "\n",
      "          -  Has anisometropia of >1.00\n",
      "\n",
      "          -  Has undergone corneal refractive surgery\n",
      "\n",
      "          -  Has strabismus\n",
      "\n",
      "          -  Has any ocular amblyopia >= 1line of HC (High Contrast) Visual Acuity\n",
      "\n",
      "          -  Is participating in any other type of eye related clinical or research study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 18-70 years (male or female).\n",
      "\n",
      "          -  BMI >35 kg/m2 who meet the following criteria:\n",
      "\n",
      "               1. GFR 30-60 ml/min and proteinuria>1g/24 hours despite receiving maximally\n",
      "                  tolerated doses of blocking the renin-angiotensin system.\n",
      "\n",
      "               2. GFR >60 ml/min and proteinuria >(3.5) 2.5 g/24 hours despite receiving maximally\n",
      "                  tolerated doses of blocking the renin-angiotensin system.\n",
      "\n",
      "          -  Patients with BMI> 40 kg/m2 with a GFR> 30 ml/min and proteinuria >(1) 0.5 g/24 hours\n",
      "             despite receiving maximally tolerated doses of blocking the renin-angiotensin system.\n",
      "\n",
      "          -  Patients who are able to understand the purpose and risks of the study, which has been\n",
      "             fully informed and have finally given the written informed consent according to the\n",
      "             ICH-GCP. Patients who can not read or write but who properly understand the verbal\n",
      "             information provided by the investigator (or sub-investigator) the consent will be\n",
      "             granted orally before their inclusion and an independent witness will signing the\n",
      "             informed consent document.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects who are participating or have participated in another clinical trial and/or\n",
      "             who are taking or have taken an experimental drug (not registered) in the last 28\n",
      "             days.\n",
      "\n",
      "          -  Patients with chronic renal replacement therapy (hemodialysis and/or peritoneal\n",
      "             dialysis) and/or renal transplantation.\n",
      "\n",
      "          -  Patients with poorly controlled blood pressure (SBP> 170 mmHg or DBP> 110 mmHg).\n",
      "\n",
      "          -  Patients with a history of cardiovascular events (stroke, ischemic heart disease) in\n",
      "             the past six months.\n",
      "\n",
      "          -  Patients treated with steroids or other immunosuppressants.\n",
      "\n",
      "          -  Patients with a history of renovascular disease, obstructive uropathy, autoimmune\n",
      "             diseases, cancer, drug use.\n",
      "\n",
      "          -  Patients who are pregnant or lactating.\n",
      "\n",
      "          -  Patients who do not sign the informed consent.\n",
      "\n",
      "          -  A slight chance of compliance with visits scheduled in the protocol.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "        Subject Inclusion Criteria: AL Resistance Monitoring Study\n",
      "\n",
      "          -  Resident of Kenieroba\n",
      "\n",
      "          -  Age 2 to 17 years\n",
      "\n",
      "          -  Uncomplicated falciparum malaria, confirmed by the presence of asexual P. falciparum\n",
      "             parasites on blood film\n",
      "\n",
      "          -  Asexual P. falciparum count between 2,000 and 200,000/ microliters (inclusive) at\n",
      "             screening\n",
      "\n",
      "          -  Tympanic or axillary temperature greater than or equal to 37.5 (Infinite)C or history\n",
      "             of fever in the previous 24 hours\n",
      "\n",
      "          -  Written informed consent from the child s parent or guardian, and assent from children\n",
      "             aged 14-17 years\n",
      "\n",
      "        Subject Inclusion Criteria: Parasite Clearance Substudy\n",
      "\n",
      "          -  Enrolled in the AL Resistance Monitoring Study\n",
      "\n",
      "          -  Asexual P. falciparum count greater than or equal to 10,000/ microliters at screening\n",
      "\n",
      "          -  Hb level greater than or equal to 7 g/dL\n",
      "\n",
      "        Subject Inclusion Criteria: Blood Collection Study\n",
      "\n",
      "          -  Age 18 to 65 years or 5 to 65 years old for the mosquito infectivity study\n",
      "\n",
      "          -  Healthy-appearing\n",
      "\n",
      "          -  Hb level greater than or equal to 7 g/dL\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "        Subject Exclusion Criteria: AL Efficacy Study\n",
      "\n",
      "          -  Signs of severe malaria, defined as one or more of the following:\n",
      "\n",
      "               -  Blantyre Coma Scale less than or equal to 3/5 in children\n",
      "\n",
      "               -  Witnessed convulsions\n",
      "\n",
      "               -  Severe prostration\n",
      "\n",
      "               -  Shock (poor perfusion, cool peripheries)\n",
      "\n",
      "               -  Hb <5 g/dL\n",
      "\n",
      "               -  Jaundice\n",
      "\n",
      "               -  Respiratory distress (labored breathing, nasal flaring, intercostal retraction)\n",
      "\n",
      "               -  Anuria for 24 hours or more\n",
      "\n",
      "               -  Repetitive vomiting\n",
      "\n",
      "               -  Cessation of eating and drinking\n",
      "\n",
      "          -  Acute illness other than uncomplicated falciparum malaria requiring treatment\n",
      "\n",
      "          -  Presence of P. ovale or P. malariae parasites on blood film\n",
      "\n",
      "          -  Severe malnutrition: http://www.who.int/childgrowth/standards/Technical_report.pdf\n",
      "\n",
      "          -  Pregnancy or breastfeeding an infant\n",
      "\n",
      "          -  Planning to become pregnant in the next 1 month\n",
      "\n",
      "          -  History of taking an ACT in the previous 14 days\n",
      "\n",
      "          -  Known hypersensitivity to artemether or LF\n",
      "\n",
      "          -  Co-administration of strong inducers of CYP3A4 such as rifampin, carbamazepine,\n",
      "             phenytoin, and St. John s wort\n",
      "\n",
      "          -  Splenectomy\n",
      "\n",
      "          -  Any condition that in the opinion of the investigator would render the patient unable\n",
      "             to comply with the protocol (e.g., psychiatric disease)\n",
      "\n",
      "          -  Any health condition that in the opinion of the investigator would confound data\n",
      "             analysis (e.g., HIV infection) or pose unnecessary exposure risks to the subject\n",
      "\n",
      "        Subject Exclusion Criteria: Parasite Clearance Substudy\n",
      "\n",
      "        -Prior enrollment in the Parasite Clearance Substudy in current transmission season\n",
      "\n",
      "        Subject Exclusion Criteria: Blood Collection Study\n",
      "\n",
      "          -  P. falciparum infection, as determined by thick blood smear examination (unless the\n",
      "             subject is being screened for inclusion in the mosquito infectivity study, in which\n",
      "             case parasitemia, as detected by RDT or smear, is an inclusion criteria)\n",
      "\n",
      "          -  History of taking an ACT in the previous 28 days\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Joined the study voluntarily and signed informed consent form.\n",
      "\n",
      "          2. Age ＞75 or age 18-75 who are intolerant of or reject intravenous chemotherapy.\n",
      "\n",
      "          3. Both genders.\n",
      "\n",
      "          4. Esophageal squamous cell carcinoma confirmed by pathology.\n",
      "\n",
      "          5. Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a,TxN1M0-1a,TxNxM1a,\n",
      "             AJCC 6th).\n",
      "\n",
      "          6. No radiotherapy, chemotherapy or other treatments prior to enrollment.\n",
      "\n",
      "          7. PS ECOG 0-2，wight loss<30% during the latest 6 months.\n",
      "\n",
      "          8. Life expectancy of more than 3 months.\n",
      "\n",
      "          9. Hemoglobin（Hb）≥9 g/dL,WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L platelet count (Pt)\n",
      "             ≥100x 109/L.Hepatic function: ALAT and ASAT < 2.5 x ULN, TBIL<1.5 x ULN.Renal\n",
      "             function: creatinine < 1.5 x ULN.\n",
      "\n",
      "         10. No immuno-deficiency\n",
      "\n",
      "         11. No heart diseases that need cardiac glycoside\n",
      "\n",
      "         12. Use of an effective contraceptive for adults to prevent pregnancy.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Complete esophageal obstruction.\n",
      "\n",
      "          2. Deep esophageal ulcer.\n",
      "\n",
      "          3. Esophageal perforation.\n",
      "\n",
      "          4. Haematemesis.\n",
      "\n",
      "          5. After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting\n",
      "             therapy.\n",
      "\n",
      "          6. Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in\n",
      "             situ, who survived with no evidence disease for over 3 years.\n",
      "\n",
      "          7. Pregnant or breast-feeding women or people during the birth-period who refused to take\n",
      "             contraceptives.\n",
      "\n",
      "          8. Drug addiction,Alcoholism or AIDS.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Participants must be first year medical residents training in family medicine at the\n",
      "             University of Alberta. They will be recruited from the Obesity Management Workshop\n",
      "             that is a required component of their course on Doctor-Patient Relationships. All\n",
      "             participants must be over the age of 18 and be able to communicate effectively in\n",
      "             English.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  If participants are unable to communicate effectively in English, they will not be\n",
      "             able to participate in the study. The Obesity Management Workshop will be presented in\n",
      "             English and participants must be able to understand the presentation and written\n",
      "             documents that they are being asked to complete.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  women with PCOS in accordance with Rotterdam criteria\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pregnancy\n",
      "\n",
      "          -  past history of cardiovascular disease,\n",
      "\n",
      "          -  diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 g oral\n",
      "             glucose tolerance test),\n",
      "\n",
      "          -  hypertension,\n",
      "\n",
      "          -  significant liver or renal impairment,\n",
      "\n",
      "          -  other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for\n",
      "             the clinical signs),\n",
      "\n",
      "          -  neoplasms,\n",
      "\n",
      "          -  unstable mental illness.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Family with a child aged 0-60 months who enters care in the recruiting sites for\n",
      "             reasons associated with maltreatment during the study recruitment period.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Families will be excluded from the trial if the parent(s) is unavailable to take part\n",
      "             in intervention (e.g. because of death, unknown whereabouts or long term\n",
      "             imprisonment).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Sickle cell disease genotypes (HbSS, HbS/β-thalassemia\n",
      "\n",
      "          2. HbS/β+thalassemia, HbSC)\n",
      "\n",
      "          3. Patients with sickle cell disease aged 10 to 25 years old\n",
      "\n",
      "          4. Patients ages 10 through 17 years of age, whose parents have signed permission, and\n",
      "             who provide signed patient assent themselves\n",
      "\n",
      "          5. Patients 18 through 25 years of age who provide signed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Presence of any acute illness defined by fever >100.4°F within the past 48 hours\n",
      "\n",
      "          2. Presence of sickle cell pain crisis defined by the presence of pain requiring oral or\n",
      "             parental opioid therapy.\n",
      "\n",
      "          3. Presence of acute chest syndrome or presence of any other complication related to\n",
      "             sickle cell disease requiring hospitalization such as splenic sequestration, hepatic\n",
      "             sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, and\n",
      "             patients with diabetes etc.\n",
      "\n",
      "          4. Severe anemia (hemoglobin < 5g/dL)\n",
      "\n",
      "          5. History of red blood cell transfusion within the last 14 days\n",
      "\n",
      "          6. Systemic steroid therapy within the last 48 hours\n",
      "\n",
      "          7. Pregnant (as confirmed by a negative urine pregnancy test) or lactating female\n",
      "\n",
      "          8. Alanine/aspartate transferase >2x upper limit of normal laboratory range for age.\n",
      "\n",
      "          9. Elevated serum creatinine: Age 6 to 13 years > 0.9 mg/dL, Age 14-17 years 1.0 mg/dL,\n",
      "             Age >18 years >1.5mg/dL\n",
      "\n",
      "         10. Patients with an inability to give assent (ages 10 to 17 years) or consent (ages 18\n",
      "             through 25 years) will be excluded\n",
      "\n",
      "         11. History of diabetes due to risk of electrolyte imbalance\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult English speaking subjects able and willing to provide written informed consent\n",
      "\n",
      "          -  Active tobacco cigarette smoker\n",
      "\n",
      "          -  History of active smoking tobacco cigarettes for 3-10 years (at least 10 cigarettes\n",
      "             per day). The rational for inclusion of active smokers is based on prior data showing\n",
      "             that most e-cigarette users have smoked moderate to high amount of tobacco cigarettes\n",
      "             in the past\n",
      "\n",
      "          -  No other use of alternative tobacco or nicotine products\n",
      "\n",
      "          -  No history of hypertension, diabetes, cardiovascular disease, stroke, peripheral\n",
      "             arterial disease, asthma or other chronic lung disease.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Use of aspirin, clopidogrel, prasugrel, ticagrelor, warfarin, statins, colchicine,\n",
      "             nitrates, steroids, fish oil, omega-3 fatty acids, or any other anti-inflammatory,\n",
      "             antithrombotic or anticoagulant agent in the last week\n",
      "\n",
      "          -  History of adverse reactions to e-cigarettes\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Willing and able to give written informed consent.\n",
      "\n",
      "          2. Men and women ≥ 18 years of age.\n",
      "\n",
      "          3. Patient eligible to single dose Stereotactic Radiotherapy (Radiosurgery) as per the\n",
      "             pluridisciplinary committee.\n",
      "\n",
      "          4. Neurologically asymptomatic or pauci-symptomatic patients. Patients with moderated\n",
      "             neurological symptoms without systemic corticosteroids treatment can be included.\n",
      "\n",
      "          5. Less than 4 brain metastasis at the MRI. Brain metastasis should measure less than 3\n",
      "             cm in diameter. At least one brain metastasis > 5mm.\n",
      "\n",
      "          6. Maximum one prior systemic therapy for metastatic disease is allowed.\n",
      "\n",
      "          7. Prior treatment with INTERFERON in the adjuvant setting is authorized. Prior treatment\n",
      "             with anti-CTLA-4 is NOT authorized.\n",
      "\n",
      "          8. ECOG Performance Status 0 or 1\n",
      "\n",
      "          9. Within the last 2 weeks prior to study day 1 the following laboratory parameters,\n",
      "             which should be within the ranges specified:\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. The patient requires concomitant chronic treatment with systemic corticosteroids or\n",
      "             any other immunosuppressive agents 7 days prior to inclusion.\n",
      "\n",
      "          2. Neurological symptoms treated with systemic corticosteroids (whatever the dose of\n",
      "             corticoids).\n",
      "\n",
      "          3. The patient has concurrent severe medical problems, unrelated to the malignancy, that\n",
      "             would significantly limit full compliance with the study or expose the patient to\n",
      "             unacceptable risk such as but not limited to: Cardiac insufficiency (III or IV as per\n",
      "             NYHA classification), Renal insufficiency, ongoing infection.\n",
      "\n",
      "          4. Any symptom of concomitant tumour meningitis\n",
      "\n",
      "          5. History of immediate or delayed gadolinium hypersensitivity, or any contraindication\n",
      "             to undergo MRI examination (Pacemaker, brain aneurysms clips)\n",
      "\n",
      "          6. Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of\n",
      "             the cervix (Subjects with a previous malignancy but without evidence of disease for 5\n",
      "             years will be allowed to enter the study)\n",
      "\n",
      "          7. Uncontrolled infectious diseases - requires negative tests for clinically suspected\n",
      "             HIV, HBV and HCV. If positive results are not indicative of true active or chronic\n",
      "             infection, the subject may enter the study after discussion and agreement between the\n",
      "             Investigator and the Medical Monitor.\n",
      "\n",
      "          8. Active autoimmune disease. Autoimmune disease: subjects with a documented history of\n",
      "             inflammatory bowel disease, including ulcerative colitis and Crohn's disease are\n",
      "             excluded from this study as are subjects with a history of symptomatic disease (e.g.,\n",
      "             rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus\n",
      "             Erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]).\n",
      "\n",
      "          9. Subjects with motor neuropathy considered of autoimmune origin (e.g., Guillain Barré\n",
      "             Syndrome) are excluded from this study\n",
      "\n",
      "         10. Previous treatment with a CTLA-4 antagonist agent, including treatment in adjuvant\n",
      "             setting.\n",
      "\n",
      "         11. The patient has psychiatric or addictive disorders that may compromise his/her ability\n",
      "             to give informed consent or to comply with the trial procedures.\n",
      "\n",
      "         12. Lack of availability for clinical follow-up assessments.\n",
      "\n",
      "         13. For female patients: the patient is pregnant or lactating.\n",
      "\n",
      "         14. Women of childbearing potential: refusal or inability to use effective means of\n",
      "             contraception\n",
      "\n",
      "         15. Participation in another clinical trial protocol within 30 days prior to enrolment\n",
      "\n",
      "         16. Persons protected by a legal regime (guardianship, trusteeship)\n",
      "\n",
      "         17. Patients in emergency situations\n",
      "\n",
      "         18. Patients kept in detention\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Meet difficult had 1 month or more to heal the wound patients\n",
      "\n",
      "          2. Who signed the informed consent of men or women older than 17 (pregnancy)\n",
      "\n",
      "          3. Has the ability to care for, has the ability to self signed informed consent, 7 to 17\n",
      "             years old must be signed by the guardian informed consent\n",
      "\n",
      "          4. The process of mental stability, can finish the test\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Known allergic to bovine collagen or gao min physique\n",
      "\n",
      "          2. the wound is greater than the10cm×10cm\n",
      "\n",
      "          3. People with mental illness, drug abusers and or other items\n",
      "\n",
      "          4. Pregnant women,Prepare a pregnancy or breast feeding women 5.3 months participated in\n",
      "             other similar experiment\n",
      "\n",
      "        6.Serious infectious disease not controller 7.With surgery, such as severe trauma stress\n",
      "        situation 8.Can not meet the requirement of the long-term follow-up of patients\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  No individual patients will be randomized\n",
      "\n",
      "        Exclusion Criteria:\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  diagnosis of pancreatic cystic neoplasms\n",
      "\n",
      "          -  indication to surgery\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pregnancy, breastfeeding\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult (> 18 years) women\n",
      "\n",
      "          -  Uncomplicated pregnancy\n",
      "\n",
      "          -  English and Spanish speaking\n",
      "\n",
      "          -  Partners of pregnant women who have give birth.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Women younger than 18 years\n",
      "\n",
      "          -  Complicated pregnancy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  preterm infants with gestational age ≤ 34 weeks\n",
      "\n",
      "          -  postnatal age > 3 days\n",
      "\n",
      "          -  no previous enteral feeding, and\n",
      "\n",
      "          -  parental wish to use milk formula with no intention to use breast milk or breastfeed.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  infants with major chromosomal abnormalities\n",
      "\n",
      "          -  Infant with major congenital anomalies of the cardiovascular, pulmonary or central\n",
      "             nervous system; including neuromuscular disorders and neural tube defects\n",
      "\n",
      "          -  infants with intestinal atresia, tracheoesophageal fistulas, omphalocele,\n",
      "             gastroschisis, and other major congenital GI anomalies, and\n",
      "\n",
      "          -  infants with sepsis, either before or during enrollment\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects presenting to the ED will be screened in accordance with the Olive View\n",
      "             Medical Center Sepsis Waiver, and subjects meeting two of the following four criteria\n",
      "             will be eligible for inclusion in the study: Temperature >38/100.4 or <36/96.8, heart\n",
      "             rate >90, respiratory rate >20 or PaCO2<32, and WBC >12K or <4K or > 10% bands\n",
      "             (neutrophils). The clinical team will be contacted regarding patients identified based\n",
      "             on this initial screening, and if the patient is determined to have a suspected\n",
      "             infection and a fluid bolus is planned, the patient will be enrolled in the study if\n",
      "             they meet the following criteria:\n",
      "\n",
      "          -  Adult between the age of 18 to 90 years old;\n",
      "\n",
      "          -  Not pregnant;\n",
      "\n",
      "          -  Not using non-invasive positive pressure ventilation (CPAP or BiPAP);\n",
      "\n",
      "          -  No history of heart, lung, and/or liver transplant;\n",
      "\n",
      "          -  Not determined by the clinical team to be acutely unstable requiring immediate\n",
      "             intervention at the time of data collection, and;\n",
      "\n",
      "          -  No contraindications to a passive leg raise test (known or suspected cranio-cerebral\n",
      "             or C-spine injury, venous thrombosis, orthopedic injury requiring immobilization or\n",
      "             traction, or other contraindications as per clinical team).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant;\n",
      "\n",
      "          -  Using non-invasive positive pressure ventilation (CPAP or BiPAP);\n",
      "\n",
      "          -  Presence of or suspected elevated intracranial pressure;\n",
      "\n",
      "          -  Presence of central venous catheters or other medical devices that prevent the use of\n",
      "             bedside ultrasound;\n",
      "\n",
      "          -  History of heart, lung, and/or liver transplant;\n",
      "\n",
      "          -  History of critical aortic stenosis or severe aortic insufficiency;\n",
      "\n",
      "          -  Determined by the clinical team to be acutely unstable and requiring immediate\n",
      "             intervention at the time of study enrollment or data collection or;\n",
      "\n",
      "          -  Has a contraindication to passive leg raise maneuver, e.g. known cervical spinal\n",
      "             injury, deep venous thrombosis, orthopedic injury requiring immobilization or\n",
      "             traction.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All patients admitted to Peterborough City Hospital with a trochanteric hip fracture\n",
      "             (type A1 type A2) that is to be treated by internal fixation with an intramedullary\n",
      "             nail.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who decline to participate or in whom consent or assent is not available\n",
      "\n",
      "               -  Patients admitted when MJP is not available to supervise treatment\n",
      "\n",
      "               -  Patients with pathological fractures from Paget's disease of bone secondaries\n",
      "                  from tumour\n",
      "\n",
      "               -  Patients with a Subtrochanteric fracture and those of the reversed and transverse\n",
      "                  fracture type (A3 fractures)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age 18+, admitted for 8300 or 8400 medical ICU between 1/2016 and 12/2016 for\n",
      "             respiratory failure from pneumonia, requirement of > 24 hours of invasive mechanical\n",
      "             ventilatory support for pneumonia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Immunocompromised as defined by HIV/AIDS, known immunodeficiency, chronic steroids >\n",
      "             20mg/day Prednisone equivalent, other home immunosuppressants, solid organ or bone\n",
      "             marrow transplant patients, cystic fibrosis, bronchiectasis, active malignancy,\n",
      "             receiving chemotherapy or radiation therapy within the past 3 months, hematologic\n",
      "             malignancy\n",
      "\n",
      "          -  Chronic ventilator dependence\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  adult patients undergoing large endoscopic polypectomy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pregnancy\n",
      "\n",
      "          -  incapacity to give informed consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Female sex\n",
      "\n",
      "          2. Ability to give informed agreement and to carry out the whole study protocol during\n",
      "             the study period\n",
      "\n",
      "          3. The patient should be able to carry out the needs of the clinical trial and have\n",
      "             measurable disease\n",
      "\n",
      "          4. The patient should be 18-75 year-old\n",
      "\n",
      "          5. Triple negative breast cancer (ER<1%, Progesteron Receptor (PR)<1%, non-overexpressing\n",
      "             HER2). 1. Patients with oligometastatic disease (1-2 resectable metastases) could be\n",
      "             included\n",
      "\n",
      "          6. No previous systemic therapies\n",
      "\n",
      "          7. Patients who are going to benefit from neoadjuvant chemotherapy\n",
      "\n",
      "          8. Eastern Cooperative Oncology Group (ECOG)<2 or Karnofsky≥70%\n",
      "\n",
      "          9. Blood tests and biochemistry suitable: (absolute neutrophil count> 1500/uL;\n",
      "             haemoglobin>9 gr/dL; platelets>100000/uL (microliters); total bilirubin≤ 1.5 the upper\n",
      "             normal limit; GOT and GPT (transaminases)≤twice the upper normal limit; fasting\n",
      "             glucose≤150 gr/dL; HbA1c≤8%, serum creatinine≤2 mg/dL.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Severe diseases or infectious diseases or liver, kidney or bone marrow failure that\n",
      "             advise not to participate in the study according to investigator criteria\n",
      "\n",
      "          2. Pregnancy or breast feeding period or fertility women who are not agree with\n",
      "             contraception methods\n",
      "\n",
      "          3. Other primary tumors except for breast in situ carcinoma (CIS), cervical\n",
      "             neoplasia(CIN) or localized skin tumors\n",
      "\n",
      "          4. Inflammatory breast cancer or bilateral breast cancer\n",
      "\n",
      "          5. Bone fractures, peptic ulcus or healing disorders\n",
      "\n",
      "          6. Any local or systemic therapy for breast cancer\n",
      "\n",
      "          7. To be maintained on immunosuppressants (prednisone > 10 mgr daily or others), aspirin>\n",
      "             325 mgr per day or clopidogrel > 75 mgr daily\n",
      "\n",
      "          8. Cardiomyopathy by New York Heart Association (NYHA) class II-IV; heart stroke in the\n",
      "             previous 6 months; uncontrolled blood pressure (systolic > 150 mm Hg and /or diastolic\n",
      "             > 100 mm Hg), coagulopathy or hemorrhagic diseases\n",
      "\n",
      "          9. Previous lung diseases\n",
      "\n",
      "         10. Personal history of abdominal perforation, abdominal abscess, or abdominal fistula.\n",
      "\n",
      "         11. Inability to swallow pills\n",
      "\n",
      "         12. Intolerance to galactose, malabsorption to galactose or/and glucose, or primary\n",
      "             hypolactasia\n",
      "      \n",
      "\n",
      "        Inclusion Criteria: People who live or work in target villages, ages 12 and up -\n",
      "\n",
      "        Exclusion Criteria: People who do not live or work in the sample villages, and those who\n",
      "        are prisoners, mentally impaired, or under age 12 years.\n",
      "\n",
      "        -\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histological evidence of prostate cancer in the radical prostatectomy specimen\n",
      "\n",
      "          -  At least 2 rising PSA values, of which the last ≥ 0.15 ng/ml\n",
      "\n",
      "          -  Tumor, regional nodes, metastasis (TNM): any T, N0/x, M0/x\n",
      "\n",
      "          -  Age: 18 years or older\n",
      "\n",
      "          -  World Health Organization (WHO) performance status 0-1\n",
      "\n",
      "          -  Life expectancy > 10 years\n",
      "\n",
      "          -  Adequate laboratory findings: hematological: hemoglobin > 90 g/L (may be transfused to\n",
      "             maintain or exceed this level) absolute neutrophil count (ANC) ≥ 1,0 x 109/L,\n",
      "             platelets ≥ 75 x 109/L hepatic: bilirubin ≤ 1.5 x upper limit of normal (ULN), alanine\n",
      "             aminotransferase (ALAT) ≤ 5 x ULN renal: creatinine ≤ 1.5 x ULN\n",
      "\n",
      "          -  Signed written informed consent\n",
      "\n",
      "          -  The patient must be able to comply with the protocol\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Evidence of metastasis on imaging or in specimen (e.g. N1 at lymph-node dissection)\n",
      "\n",
      "          -  Prior or ongoing treatment with hormones (antiandrogens, GnRH)\n",
      "\n",
      "          -  Prior radiotherapy to the pelvis\n",
      "\n",
      "          -  Previous malignancy other than prostate cancer and basalioma the past 5 years.\n",
      "\n",
      "          -  Clinically significant (i.e. active) cardiovascular disease e.g. myocardial infarction\n",
      "             (≤ 6 months), unstable angina, New York Heart Association (NYHA) grade III-IV\n",
      "             congestive heart failure\n",
      "\n",
      "          -  Severe pulmonary disease e.g. pulmonary fibrosis\n",
      "\n",
      "          -  Any other serious or uncontrolled illness which in the opinion of the investigator\n",
      "             makes it undesirable for the patient to enter the trial\n",
      "      \n",
      "\n",
      "        Inclusion:\n",
      "\n",
      "          -  normal hematologic\n",
      "\n",
      "          -  normal hepatic\n",
      "\n",
      "          -  normal renal functions\n",
      "\n",
      "          -  non-smoking\n",
      "\n",
      "          -  non-alcoholic\n",
      "\n",
      "          -  non-obese\n",
      "\n",
      "        Exclusion:\n",
      "\n",
      "          -  pregnant or lactating women\n",
      "\n",
      "          -  any chronic medications\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adults (>18 years)\n",
      "\n",
      "          -  Previously diagnosed with diabetes mellitus.\n",
      "\n",
      "          -  Hospitalized but without intensive cares.\n",
      "\n",
      "          -  Have indication of total parenteral nutritional support (TPN, meaning the covering\n",
      "             over 70% of the estimated daily requirements intravenously) for a minimum of 5 days.\n",
      "\n",
      "          -  Signature of informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Diabetes mellitus type 1, diabetes secondary to total pancreatectomy.\n",
      "\n",
      "          -  Patients with intensive cares.\n",
      "\n",
      "          -  Patients who have been prescribed TPN in intensive cares unity more than 48 hours\n",
      "             before admission to hospitalization.\n",
      "\n",
      "          -  Intradialytic parenteral nutrition.\n",
      "\n",
      "          -  Patients under 18 or pregnant women.\n",
      "\n",
      "          -  Patients with renal insufficiency stage 3 B (glomerular filtration rate < 45 mL /\n",
      "             min).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        All patients with diagnosis of acute pancreatitis.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Refusal to sign informed consent\n",
      "\n",
      "          2. Age less than 18 years\n",
      "\n",
      "          3. Pregnancy\n",
      "\n",
      "          4. Patients with physical signs of heart failure,\n",
      "\n",
      "          5. Previously known congestive heart failure ( NYHA III - IV )\n",
      "\n",
      "          6. Severe kidney disease more than one month before the diagnosis of acute pancreatitis\n",
      "             (defined as severe reduction in eGFR less than 30 ml/min/1.73 m2) . Patients who\n",
      "             develop acute renal failure as a result of acute pancreatitis will be involved in\n",
      "             research .\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  infertility (12 months trying to conceive without success) and/or two previous\n",
      "             miscarriages\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  unknown pregnancy (ultrasound examination)\n",
      "\n",
      "          -  menopause\n",
      "\n",
      "          -  precancerous conditions and cancers of female genital tract\n",
      "\n",
      "          -  refused consent\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Participants aged between 18 and 55 years.\n",
      "\n",
      "          2. Judged as healthy and eligible for vaccination by the investigators through a\n",
      "             self-reported medical history and some physical examinations.\n",
      "\n",
      "          3. Written informed consent obtained from the participants.\n",
      "\n",
      "          4. Able to comply with the requests of the study.\n",
      "\n",
      "          5. Axillary temperature not higher than 37.0°C\n",
      "\n",
      "          6. Non-pregnancy verified by a urine pregnancy test.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Pregnant or breastfeeding or plan to be pregnant within 7 months.\n",
      "\n",
      "          2. Use of any investigational product or non-registered product (drug or vaccine) within\n",
      "             30 days preceding the first dose of the study vaccine or plan to use during the study\n",
      "             period.\n",
      "\n",
      "          3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy\n",
      "             for more than 14 days in the 6 months before entry, except local treatment.\n",
      "\n",
      "          4. Administration of any immunoglobulin or blood products within 3 months preceding the\n",
      "             first dose of the study vaccine.\n",
      "\n",
      "          5. Administration of any attenuated live vaccines within 30 days preceding the first dose\n",
      "             of the study vaccine or any subunit or inactivated vaccines within 14 days before\n",
      "             vaccination.\n",
      "\n",
      "          6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring\n",
      "             systemic antibiotics or antiviral treatment within 5 days before vaccination.\n",
      "\n",
      "          7. Having the plan to participate another clinical trial during the study period.\n",
      "\n",
      "          8. Received another HPV vaccine.\n",
      "\n",
      "          9. Immunodeficiency (such as HIV carriers), primary disease of important organs,\n",
      "             malignant tumor, .or any immune disease (such as systemic lupus erythematosus,\n",
      "             arthritis pauperum, splenectomy or functional asplenia or other disease which might\n",
      "             affect immune response).\n",
      "\n",
      "         10. History of allergic disease or history of serious adverse events occurring after\n",
      "             vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain.\n",
      "\n",
      "         11. Having serious disease of internal medicine, such as hypertension, cardiac disease,\n",
      "             diabetes, hyperthyroidism et al.\n",
      "\n",
      "         12. Asthma that required emergent treatment, hospitalization, oral or intravenous\n",
      "             corticosteroid for unstable condition within the past 2 years.\n",
      "\n",
      "         13. Diagnosed coagulant function abnormality (i.e., clotting factors absent, clotting\n",
      "             hemorrhagic disease, abnormal platelet function) or blood coagulation disorder.\n",
      "\n",
      "         14. Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3\n",
      "             years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3\n",
      "             years.\n",
      "\n",
      "         15. Past or current two-stage affective psychosis, not well controlled in the past 2 years\n",
      "             or requiring drugs, or h a tendency to commit suicide.\n",
      "\n",
      "         16. Other medical, psychological, social or occupational factors that, according to the\n",
      "             investigators' judgment, might affect the individual's ability to obey the protocol or\n",
      "             sign the informed consent.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Women with an abnormal Pap test, positive HPV test or any history of cervical\n",
      "             dysplasia\n",
      "\n",
      "          2. Women with an intact cervix (patients who have undergone previous LEEP, cone and/or\n",
      "             cryotherapy are eligible)\n",
      "\n",
      "          3. Women of childbearing potential must have a negative urine or serum pregnancy test\n",
      "\n",
      "          4. Women who are at least 21 years of age or older\n",
      "\n",
      "          5. Ability to understand and the willingness to provide informed consent and sign a\n",
      "             written Informed Consent Document (ICD)\n",
      "\n",
      "          6. For patients that present to clinic to have a cervical excisional procedure (LEEP) for\n",
      "             an already confirmed diagnosis of high grade cervical dysplasia, HRME imaging study\n",
      "             will be performed and cervical biopsies might be taken for research purposes only.\n",
      "             Since these patients have already the confirmed diagnosis of high-grade cervical\n",
      "             dysplasia, any extra biopsies taken will be for research purposes only and our\n",
      "             research fund will pay them\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Women < 21 years of age\n",
      "\n",
      "          2. Women who have undergone a hysterectomy with removal of the cervix\n",
      "\n",
      "          3. Women with a known allergy to proflavine, acriflavine, or iodine\n",
      "\n",
      "          4. Women who are pregnant or nursing\n",
      "\n",
      "          5. Patients unable or unwilling to provide informed consent or sign a written Informed\n",
      "             Consent Document (ICD)\n",
      "      \n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          -  provider willing to participate\n",
      "\n",
      "          -  an adult caregiver of a child between 7 and 11 years of age with a diagnosis of\n",
      "             Oppositional Defiant Disorder or Conduct Disorder\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  None\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Must be 18 years of age or above. All races and ethnicities are eligible and no upper\n",
      "             limit of age is specified.\n",
      "\n",
      "          -  Must have cytologically or histologically-confirmed unresectable melanoma that harbors\n",
      "             a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay\n",
      "             in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory, meeting\n",
      "             one of the following AJCC staging criteria: 1.) American Joint Committee on Cancer\n",
      "             (AJCC) stage IV (Tany, Nany, M1a, b, or c); 2.) AJCC stage IIIB or IIIC with\n",
      "             unresectable nodal/locoregional involvement.\n",
      "\n",
      "          -  Adequate hepatic, renal, and bone marrow function with parameters obtained within 4\n",
      "             weeks prior to initiation of study treatment.\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.\n",
      "\n",
      "          -  Willing to give written informed consent per institutional guidelines and must be able\n",
      "             to adhere to dose and visit schedules.\n",
      "\n",
      "          -  Negative serum pregnancy test within 7 days prior to commencement of dosing in\n",
      "             premenopausal women. Women of non-childbearing potential may be included without serum\n",
      "             pregnancy test if they are either surgically sterile or have been postmenopausal for\n",
      "             ≥1 year.\n",
      "\n",
      "          -  Fertile men and women must use an effective method of contraception during treatment\n",
      "             and for at least 6 months after completion of treatment as directed by their\n",
      "             physician.\n",
      "\n",
      "          -  Treatment-naïve and previously treated patients will be included; however, patients\n",
      "             may not have received a BRAF, Mitogen Activated Kinase (MEK) or HSP90 inhibitor in the\n",
      "             past.\n",
      "\n",
      "          -  May have received prior systemic and/or radiation therapy. All adverse events\n",
      "             associated with prior systemic therapy or radiation therapy must have resolved to ≤\n",
      "             Grade 1 prior to start of study.\n",
      "\n",
      "          -  Must have measurable disease as defined by Response Evaluation Criteria in Solid\n",
      "             Tumors (RECIST) 1.1.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Women who are pregnant, intend to become pregnant or are nursing.\n",
      "\n",
      "          -  Previously treated with BRAF, MEK or HSP90 inhibitor therapy.\n",
      "\n",
      "          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n",
      "             infection, or psychiatric illness/social situations that would limit compliance with\n",
      "             study requirements.\n",
      "\n",
      "          -  HIV-positive patients on combination antiretroviral therapy.\n",
      "\n",
      "          -  Potential participants with untreated or uncontrolled brain metastases or evidence of\n",
      "             leptomeningeal disease. Patients with asymptomatic brain metastases or previously\n",
      "             treated brain metastases that are stable (i.e., not requiring corticosteroids) at the\n",
      "             time of study start will be eligible.\n",
      "\n",
      "          -  Previous malignancy is not an exclusion provided that the other malignancy is\n",
      "             considered under control, patient is not on concomitant anti-cancer drug therapy, and\n",
      "             target lesions from melanoma are clearly defined for response assessment.\n",
      "\n",
      "          -  History of malabsorption or other condition that would interfere with absorption of\n",
      "             study drugs.\n",
      "\n",
      "          -  The following foods/supplements are prohibited at least 7 days prior to initiation of\n",
      "             and during study treatment: St. John's wort or hyperforin (potent cytochrome P450\n",
      "             CYP3A4 enzyme inducer); Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme\n",
      "             inhibitor).\n",
      "\n",
      "          -  Ocular: History of or evidence of retinal pathology on ophthalmologic examination that\n",
      "             is considered a risk factor for neurosensory retinal detachment, retinal vein\n",
      "             occlusion (RVO), or neovascular macular degeneration.\n",
      "\n",
      "          -  Cardiac: History of clinically significant cardiac dysfunction.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult current and former (within 2 years) collegiate athletes (football, rugby,\n",
      "             soccer, hockey, and volleyball)\n",
      "\n",
      "          -  Body mass index (estimated based on height and weight) from 23 to 37\n",
      "\n",
      "          -  Willing to provide informed consent, ingest test substance, and provide blood\n",
      "             specimens\n",
      "\n",
      "          -  Willing to comply with study instructions and maintain current level of physical\n",
      "             activity throughout the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of loss of consciousness of more than 5 minutes\n",
      "\n",
      "          -  Contraindications to Magnetic Resonance Imaging (MRI), such as implanted medical\n",
      "             devices, metal objects, or pacemakers\n",
      "\n",
      "          -  History of epilepsy\n",
      "\n",
      "          -  History of more than 3 concussions\n",
      "\n",
      "          -  History of headache preceding a concussion\n",
      "\n",
      "          -  History of depression preceding a concussion\n",
      "\n",
      "          -  History of developmental delays or Attention Deficit Hyperactivity Disorder (ADHD)\n",
      "\n",
      "          -  History of post-traumatic seizures\n",
      "\n",
      "          -  History of complex spine and/or skull trauma\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with confirmed diagnosis of diabetes mellitus\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        -\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All residents of the 4 Schlegel Villages: Glendale Crossing, St. Clair, Tansley Woods,\n",
      "             Winston Park\n",
      "\n",
      "          -  Both males and females\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Wheelchair bound residents\n",
      "\n",
      "          -  Residents who are blind or deaf without aids\n",
      "\n",
      "          -  Any residents who may not be able to participate due to health or behaviours in\n",
      "             collaboration and discretion of the Schlegel Villages staff.\n",
      "\n",
      "          -  Residents who have a diagnosis of dementia, have a score of greater than 3 on the\n",
      "             Cognitive Performance Scale (determined by each Schlegel Village) and advice from\n",
      "             Schlegel Villages staff will be excluded from specific assessments (dual-task gait;\n",
      "             oculomotor function; global cognitive functioning outcomes; Montreal Cognitive\n",
      "             Assessment; 2 cognitive questions).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult of age ≥19 years at the time of informed consent\n",
      "\n",
      "          -  Foot ulcers related to diabetes mellitus:\n",
      "\n",
      "               -  Present\n",
      "\n",
      "               -  Type I or II diabetes mellitus with HbA1c <10%, or serum creatinine ≤ 200 μmol/l\n",
      "\n",
      "               -  Wagner grade I-II (Partial- or full- thickness and not involving bone, tendon, or\n",
      "                  capsule (probing to tendon or capsule)\n",
      "\n",
      "               -  Post -debridement ulcer bed size ≥ 1*1cm2\n",
      "\n",
      "          -  No clinical signs of infection & necrosis\n",
      "\n",
      "          -  Site at anywhere below ankle\n",
      "\n",
      "          -  No vascular abnormalities of the foot by palpation (i.e. the dorsalis pedis should be\n",
      "             examined by the physician and characterized as present or absent)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant & lactating females\n",
      "\n",
      "          -  Known allergy to the dressing product including povidone iodine\n",
      "\n",
      "          -  Known hyperthyroidism or other acute thyroid diseases\n",
      "\n",
      "          -  Subject with clinical infection who should be administered antibiotics continuously\n",
      "             after enrolment\n",
      "\n",
      "          -  Subject has any condition(s) that seriously compromises the patient's ability to\n",
      "             complete this study.\n",
      "\n",
      "          -  Subject has participated in interventional study utilizing an investigational drug\n",
      "             within the previous 30 days\n",
      "\n",
      "          -  Subjects with known immune-suppressed state; who undergo chemotherapy or with\n",
      "             end-stage renal disease requiring haemodialysis or had kidney transplant surgery\n",
      "             previously and with immunosuppressant specifically\n",
      "\n",
      "          -  Subjects requiring skin grafting per physician's discretion\n",
      "\n",
      "          -  Vulnerable subjects as defined by Good Clinical Practice guidelines.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        - children living in study kindergartens\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  immune system deficiency, e.g. HIV-infection\n",
      "\n",
      "          -  a drug decreasing immune system response, e.g. oral corticosteroid\n",
      "\n",
      "          -  immune system disorder that affects immune response, e.g. rheumatoid\n",
      "\n",
      "          -  colitis ulcerosa, Crohn disease, diabetes\n",
      "\n",
      "          -  cancer\n",
      "\n",
      "          -  age less than 3 or more than 5\n",
      "\n",
      "          -  born outside Finland\n",
      "\n",
      "          -  intellectual disability\n",
      "      \n",
      "\n",
      "        Clinic Eligibility:\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  The presence of discrete primary care clinical services within the clinic (defined as\n",
      "             general internal medicine or family medicine clinical services);\n",
      "\n",
      "          -  At least three primary care clinician providers in the clinic (physicians or nurse\n",
      "             practitioners/physician assistants who see patients independently of a physician);\n",
      "\n",
      "          -  A total primary care clinical volume of at least 60 patients each week;\n",
      "\n",
      "          -  An existing EHR requirement for staff to document tobacco use status including smoking\n",
      "             status on all adult patients visiting the clinic at every visit;\n",
      "\n",
      "          -  A capacity to enumerate patient visit information including adult patients/month and\n",
      "             adult tobacco users/month by clinician and by clinic;\n",
      "\n",
      "          -  A willingness to participate in the proposed research;\n",
      "\n",
      "          -  A lead physician or a clinic manager on site who agree to serve as a clinic champion\n",
      "             for the project;\n",
      "\n",
      "          -  Prior use of the fax referral system to refer patients to the Wisconsin Tobacco Quit\n",
      "             Line with use data available for the 12 months prior to study launch;\n",
      "\n",
      "          -  A willingness to accept random assignment to either of the two experimental\n",
      "             conditions.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Those clinics not meeting the above criteria (e.g. too small, limited EHR capacity).\n",
      "\n",
      "        (Note: In this study, the clinics are the \"subjects\" under study. The patients that will be\n",
      "        referred by the clinic to the Wisconsin Tobacco Quit Line will be least 18 years old and\n",
      "        Cigarette smokers)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Clinical level of Insomnia (more than 10 on ISI)\n",
      "\n",
      "          -  Meets criteria for Insomnia Disorder according to DSM-V\n",
      "\n",
      "          -  Sufficient language skills\n",
      "\n",
      "          -  Having access to Internet to fill out forms and participating in treatment\n",
      "\n",
      "          -  Not foresee obstacles to participating in treatment during the coming 20 weeks, or\n",
      "             participating in measurements during the coming year.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Sleep disorders requiring other treatment\n",
      "\n",
      "          -  High consumption of alcohol/drugs that affect sleep\n",
      "\n",
      "          -  Somatic or psychiatric conditions counter-indicative of treatments given in the study,\n",
      "             requiring acute care, or with symptoms and level of functioning affecting the ability\n",
      "             to participate in the treatment programs.\n",
      "\n",
      "          -  Working (night) shifts\n",
      "\n",
      "          -  Ongoing psychological treatment for Insomnia with sleep restriction or sleep\n",
      "             compression as a treatment component - also previous such treatment can be excluding\n",
      "\n",
      "          -  Use of sleep medication in such a way that may hinder the implementation of the\n",
      "             methods in this treatment\n",
      "\n",
      "          -  Pre-treatment measurements not finished within the given time-frame.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Males + 18 years elite or amateur racing cyclists with more than 3 years of training\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  - Subjects with a previous history of acute coronary syndrome (including myocardial\n",
      "             infarction), stroke, transient ischaemic attack, cardiac surgery, other major\n",
      "             cardiovascular (CV) surgery, or percutaneous coronary intervention (PCI), carotid\n",
      "             surgery or carotid angioplasty, valvular heart, dysrhythmia\n",
      "\n",
      "          -  subjects treated with cardiovascular medication for blood pressure, or cholesterol\n",
      "\n",
      "          -  subjects with any clinical condition (diabetes, dyslipidaemia, obesity) that in the\n",
      "             opinion of the investigator, may have a possible unfavourable effect on patient risk\n",
      "             if included in the study, or is likely to interfere with the requirements of the study\n",
      "\n",
      "          -  subject with characteristics that may interfere with adherence to the study protocol,\n",
      "             such as dementia, substance abuse, history of non-compliance with prescribed\n",
      "             medications, or medical appointment\n",
      "\n",
      "          -  subject participating in another trial of an investigational drug or device within 30\n",
      "             days prior to screening will be excluded.\n",
      "\n",
      "          -  subject that previously underwent surgery for iliac EF\n",
      "\n",
      "          -  female subjects\n",
      "\n",
      "          -  smokers\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Overweight\n",
      "\n",
      "          -  Male\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Female\n",
      "\n",
      "          -  Obesity\n",
      "\n",
      "          -  Using any other drugs\n",
      "\n",
      "          -  < 18 years old\n",
      "\n",
      "          -  > 60 years old\n",
      "\n",
      "          -  Mental disorders\n",
      "\n",
      "          -  Surgery history for abdomen\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients will be selected from among those undergoing diagnostic work up for CTS in\n",
      "             the pre-treatment period. CTS diagnosis will be confirmed clinically and by nerve\n",
      "             conduction study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  The following disorders will be criteria for exclusion:\n",
      "\n",
      "               -  any history of cervical radiculopathy\n",
      "\n",
      "               -  rheumatoid arthritis\n",
      "\n",
      "               -  osteoarthritis\n",
      "\n",
      "               -  degenerative joint disease\n",
      "\n",
      "               -  flexor tendinitis\n",
      "\n",
      "               -  gout hemodialysis\n",
      "\n",
      "               -  sarcoidosis\n",
      "\n",
      "               -  peripheral nerve disease\n",
      "\n",
      "               -  amyloidosis\n",
      "\n",
      "               -  traumatic injuries to the ipsilateral arm\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subject is at least 18 years age\n",
      "\n",
      "          -  Subject has suffered from non-life threatening head trauma head trauma resulting in\n",
      "             current concussion-related symptoms\n",
      "\n",
      "          -  Subject is evaluated and diagnosed with a concussion\n",
      "\n",
      "          -  Subject has been cleared to participate in the study by the physician/neurologist\n",
      "             having excluded any potential emergent conditions\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  The subject has no absolute contraindications to osteopathic manipulative treatment,\n",
      "             such as skull fracture, cervical fracture, signs of intracranial bleeding, cervical\n",
      "             dissection, or stroke\n",
      "\n",
      "          -  The subject suffered from any of the following at the time of event leading to\n",
      "             concussion:\n",
      "\n",
      "               -  Loss of consciousness >2 minutes in the field\n",
      "\n",
      "               -  Seizures\n",
      "\n",
      "               -  Intractable vomiting\n",
      "\n",
      "               -  Paralysis\n",
      "\n",
      "          -  The subject has been diagnosed with an underlying neurodegenerative condition that may\n",
      "             confound test results (e.g.. Parkinson's Disease, Alzheimer's Disease)\n",
      "\n",
      "          -  The subject has a current or previous spinal cord injury\n",
      "\n",
      "          -  The subject is unable to complete the assessment tools\n",
      "\n",
      "          -  The subject is pregnant\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female, age between 40-90 years old.\n",
      "\n",
      "          -  Ankle-brachial index(ABI)<0.9.\n",
      "\n",
      "          -  Lower extremity arterial CT shows that the arterial stenosis>50%\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Type 2 diabetes with acute complications.\n",
      "\n",
      "          -  Type 1 diabetes.\n",
      "\n",
      "          -  Cerebrovascular diseases in the last 3 months.\n",
      "\n",
      "          -  Cardiovascular diseases (myocardial infarction, angina, cardiac failure) in the last 3\n",
      "             months.\n",
      "\n",
      "          -  Hemorrhagic disease.\n",
      "\n",
      "          -  Hypohepatia (AST or AST is twice higher than the upper limit) or cirrhosis, hepatic\n",
      "             encephalopathy.\n",
      "\n",
      "          -  History of dialysis.\n",
      "\n",
      "          -  Chronic obstructive pulmonary disease (COPD), chronic respiratory failure or\n",
      "             hypoxemia.\n",
      "\n",
      "          -  Acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine\n",
      "             addiction.\n",
      "\n",
      "          -  Fertile woman without contraceptives.\n",
      "\n",
      "          -  Allergic to iodine.\n",
      "\n",
      "          -  Unable to understanding and follow the study protocol orientations.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Disease severity: Participants with SCD who have 1 or more of the following (i-v).\n",
      "\n",
      "               -  Clinically significant neurologic event (stroke) or any neurological deficit\n",
      "                  lasting > 24 hours;\n",
      "\n",
      "               -  History of two or more episodes of acute chest syndrome (ACS) in the 2-year\n",
      "                  period preceding enrollment despite the institution of supportive care measures\n",
      "                  (i.e. asthma therapy and/or hydroxyurea);\n",
      "\n",
      "               -  History of three or more severe pain crises per year in the 2-year period\n",
      "                  preceding enrollment despite the institution of supportive care measures (i.e. a\n",
      "                  pain management plan and/or treatment with hydroxyurea);\n",
      "\n",
      "               -  Administration of regular red blood cell (RBC) transfusion therapy, defined as\n",
      "                  receiving 8 or more transfusions per year for ≥ 1 year to prevent vaso-occlusive\n",
      "                  clinical complications (i.e. pain, stroke, and ACS). Patients on chronic\n",
      "                  transfusion who have to discontinue transfusion because of allo-sensitization\n",
      "                  will be eligible.\n",
      "\n",
      "               -  An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥\n",
      "                  2.7 m/sec. Patients under the age of 18 years must have cardiac catheterization\n",
      "                  proven pulmonary arterial hypertension to qualify on this eligibility criterion.\n",
      "\n",
      "          2. Age: Patients must be 15 - 40 years of age inclusive OR if younger than 15 years must\n",
      "             be pubertal\n",
      "\n",
      "          3. Adequate physical function as measured by:\n",
      "\n",
      "               -  Karnofsky/Lansky performance score ≥ 60\n",
      "\n",
      "               -  Cardiac function: Left ventricular ejection fraction (LVEF) > 40% or LV\n",
      "                  shortening fraction > 26% by cardiac echocardiogram or by MUGA scan.\n",
      "\n",
      "               -  Pulmonary function: Pulse oximetry with a baseline O2 saturation of ≥ 85% and\n",
      "                  DLCO > 40% (corrected for hemoglobin).\n",
      "\n",
      "               -  Renal function: Serum creatinine ≤ 1.5 x the upper limit of normal for age as per\n",
      "                  local laboratory and 24 hour urine creatinine clearance > 70 mL/min/1.73 m2 or\n",
      "                  GFR > 70 mL/min/1.73 m2 by radionuclide GFR.\n",
      "\n",
      "               -  Hepatic function: Serum conjugated (direct) bilirubin < 2 x upper limit of normal\n",
      "                  for age as per local laboratory and ALT and AST < 5 x upper limit of normal as\n",
      "                  per local laboratory. Patients with hyperbilirubinemia as a consequence of\n",
      "                  hyperhemolysis, or who experience a sudden, profound change in the serum\n",
      "                  hemoglobin after a RBC transfusion, are not excluded.\n",
      "\n",
      "               -  For participants with a suitable donor who meet eligibility criteria and are\n",
      "                  willing to proceed to HCT, if they have received chronic transfusion therapy for\n",
      "                  ≥ 1 year and have clinical evidence of iron overload by serum ferritin or MRI, an\n",
      "                  evaluation by liver biopsy is required. Histological examination of the liver\n",
      "                  must document the absence of cirrhosis, bridging fibrosis, and active hepatitis.\n",
      "                  The absence of bridging fibrosis will be determined using the histological\n",
      "                  grading and staging scale\n",
      "\n",
      "          4. Suitable Donor: To undergo transplantation on this study, participants must have an\n",
      "             adult first degree relative who shares at least 1 human leukocyte antigen (HLA)\n",
      "             haplotype with the participant, does not have SCD or other hemoglobinopathy, and is in\n",
      "             good health; if these criteria are met, they will be allowed to serve as donors.\n",
      "             Relatives with sickle cell trait are not excluded as donors. When more than 1 donor is\n",
      "             available, the donor with the fewest HLA allele mismatches will be chosen, unless the\n",
      "             patient had donor anti-HLA antibodies or there was a medical reason to exclude the\n",
      "             donor. If donor anti-HLA antibodies are detected, the next best related match will be\n",
      "             chosen. Umbilical cord blood or peripheral blood stem cell donors will not be\n",
      "             accepted.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Availability of HLA matched sibling or 8 of 8 HLA-A, B, C and DRB1 matched unrelated\n",
      "             donor\n",
      "\n",
      "          -  Presence of donor specific antibodies in the patient\n",
      "\n",
      "          -  Histological examination of the liver must document the absence of cirrhosis, bridging\n",
      "             fibrosis and active hepatitis. The absence of bridging fibrosis will be determined\n",
      "             using the histological grading and staging scale as described by Ishak and colleagues\n",
      "             (1995). The presence of bridging fibrosis will be an exclusion criterion.\n",
      "\n",
      "          -  Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment\n",
      "\n",
      "          -  Seropositivity for HIV\n",
      "\n",
      "          -  Previous hematopoietic cell transplantation (HCT)\n",
      "\n",
      "          -  Participation in a clinical trial in which the patient received an investigational\n",
      "             drug or device or off-label use of a drug or device within 3 months of enrollment\n",
      "\n",
      "          -  Demonstrated lack of compliance with prior medical care\n",
      "\n",
      "          -  Unwilling to use approved contraception for at least 6 months after transplant\n",
      "\n",
      "          -  A history of substance abuse in the last 5 years that interferes with care\n",
      "\n",
      "          -  Pregnant or breast feeding females at the time of consideration for HCT\n",
      "\n",
      "        Donor Selection Criteria:\n",
      "\n",
      "        Preference will be given to related marrow donors who are 2-4 (out of 8) HLA antigen\n",
      "        mismatched and towards whom the recipient does not have donor specific antibodies. Donors\n",
      "        will sign an informed consent disclosing that the marrow donation will be used by a patient\n",
      "        participating in this study. The donor must be matched with the recipient for at least 4 of\n",
      "        8 HLA alleles (HLA -A, -B, -C and -DRB1 by allele-level DNA methodology). The target total\n",
      "        nucleated cell count (TNC) is 3.5-8.0 x 108/kg of recipient weight. Marrow will be\n",
      "        collected without mobilization. Mobilized peripheral blood stem cell (HPC-A) collections\n",
      "        will not be permitted. Donors must undergo hemoglobinopathy screening by electrophoresis;\n",
      "        donors who have a hemoglobinopathy will be excluded but trait condition is acceptable.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patient is a current patient in the Penn Medicine outpatient healthcare system\n",
      "\n",
      "          -  Patient's Primary Care Physician (PCP) or Endocrinologist is a Penn Medicine provider\n",
      "\n",
      "          -  Patient has a 12 month history of healthcare utilization in the Penn Medicine system\n",
      "             (in-office PCP/endocrinologist visits)\n",
      "\n",
      "          -  Patient has complete data (ICD-10 code for Type 2 diabetes diagnosis, date of\n",
      "             diagnosis, name and mailing address information) in the Penn Data Warehouse\n",
      "\n",
      "          -  Patient is diagnosed with Type II Diabetes as indicated by ICD-10 Codes: E11.**\n",
      "             (including any newly diagnosed)\n",
      "\n",
      "          -  Patients' HbA1c was ≥8.0% in last 6 months (if more than one A1c result present in\n",
      "             record, most recent measurement assessed)\n",
      "\n",
      "          -  Patient can read and understand English well enough to complete study tasks.\n",
      "\n",
      "          -  Patient has regular access to a telephone\n",
      "\n",
      "          -  Patient has at least bi-weekly access to internet and email\n",
      "\n",
      "          -  Patient agrees to release their medical record information to Children's Hospital of\n",
      "             Philadelphia research team\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient is deceased\n",
      "\n",
      "          -  Patient has indicated \"Do Not Solicit for Research\" in medical record\n",
      "\n",
      "          -  Patient is less than 18 years of age\n",
      "\n",
      "          -  Patient is older than 75 years old\n",
      "\n",
      "          -  Patient uses an insulin pump or injectable insulin to treat/manage their diabetes.\n",
      "\n",
      "          -  Patient is non-English speaking\n",
      "\n",
      "          -  Patient does not have HbA1c% in chart from last 6 months\n",
      "\n",
      "          -  Patients' HbA1c in last 6 months is <8.0%\n",
      "\n",
      "          -  Patient is currently taking medications that can raise glucose levels, such as\n",
      "             steroids\n",
      "\n",
      "          -  Patient has a history of cognitive disorders, mental illness, and/or cognitive\n",
      "             impairment that may impact their ability to use an online website, including,\n",
      "             dementia, Alzheimer's disease, Parkinson's disease, traumatic brain or head injury,\n",
      "             and psychosis\n",
      "\n",
      "          -  Patient has history of Heart Failure (included Chronic Heart Disease, Chronic Heart\n",
      "             Failure) and/or Chronic Kidney Disease, and has had other serious cardiovascular\n",
      "             conditions (e.g, heart attack or stroke) in the last 6 months\n",
      "\n",
      "          -  Patient has history of endocrine gland cancers or pancreatic cancers\n",
      "\n",
      "          -  Patient is undergoing chemotherapy or immunotherapy treatment in last 6 months\n",
      "\n",
      "          -  Patient's medical record contains ICD-10 Code for Type I diabetes diagnosis.\n",
      "\n",
      "          -  Patient's medical record contains ICD-10 Code for pregnancy-related diabetes:\n",
      "\n",
      "               -  024.419 (gestational diabetes)\n",
      "\n",
      "               -  024.419 (antepartum gestational diabetes)\n",
      "\n",
      "               -  Z79.4 (type II long term insulin use)\n",
      "\n",
      "               -  024.91x (pregnant women who are diabetic)\n",
      "\n",
      "          -  Patient is Pre-diabetic or borderline Type 2 diabetic\n",
      "\n",
      "          -  Patient is pregnant or lactating\n",
      "\n",
      "          -  Patient's electronic medical history data is not available through Penn Medicine's\n",
      "             electronic medical record and/or is not complete in Penn Data Store\n",
      "\n",
      "          -  Patients who, in the opinion of the Investigator, may be non-compliant with study\n",
      "             schedules or procedures\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18-40 years of age\n",
      "\n",
      "          -  regularly physically active\n",
      "\n",
      "          -  male\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  ex-smokers\n",
      "\n",
      "          -  pulmonary function <80% of predicted\n",
      "\n",
      "          -  contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma,\n",
      "             adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa\n",
      "             allergy or an electrolyte imbalance such as hyperchloremic acidosis)\n",
      "\n",
      "          -  Obese (BMI>30Kg/m2)\n",
      "\n",
      "          -  diuretic medication use\n",
      "\n",
      "          -  blood thinner use\n",
      "\n",
      "          -  anti-platelet drug use.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18 years old or more\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Age less than 18 years;\n",
      "\n",
      "          -  Liver transplantation living related donor;\n",
      "\n",
      "          -  Retransplantation;\n",
      "\n",
      "          -  combined transplantation;\n",
      "\n",
      "          -  fulminant hepatic failure;\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Histologic or cytologic diagnosis of malignant pleural Mesothelioma\n",
      "\n",
      "          2. No prior chemotherapy.\n",
      "\n",
      "          3. ECOG less than or equal to 2 .\n",
      "\n",
      "          4. Measurable disease according to the requirements of SWOG criteria.\n",
      "\n",
      "          5. Age ≥ 19 years .\n",
      "\n",
      "          6. Estimated life expectancy of at least 12 weeks .\n",
      "\n",
      "          7. Adequate bone marrow reserve (white blood cells [WBC] ≥ 3.5 × 109 /L, neutrophils ≥\n",
      "             1.5 × 109 /L, platelets ≥ 100 × 109 /L, and hemoglobin ≥ 9.0 gm/dL).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Presence of central nervous system metastases.\n",
      "\n",
      "          2. Inadequate liver function (bilirubin > 1.5 times upper normal limit [UNL] and alanine\n",
      "             transaminase [ALT] or aspartate transaminase [AST] > 3.0 UNL or up to 5.0 UNL in the\n",
      "             presence of hepatic metastases).\n",
      "\n",
      "          3. Inadequate renal function (creatinine > 1.25 times UNL, creatinine clearance <\n",
      "             50mL/min).\n",
      "\n",
      "          4. Serious concomitant systemic disorder incompatible with the study.\n",
      "\n",
      "          5. Second primary malignancy (except in situ carcinoma of the cervix, adequately treated\n",
      "             basal cell carcinoma of the skin, T1 vocal cord cancer in remission, or prior\n",
      "             malignancy treated more than 5 years prior to enrollment without recurrence).\n",
      "\n",
      "          6. Pregnancy\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 20-65 years of age.\n",
      "\n",
      "          -  Seen at Mayo Clinic Nutrition Clinic and have received authorization for RYGB surgery.\n",
      "\n",
      "          -  Type 2 Diabetes Mellitus or impaired fasting glucose with BMI >35 AND not interested\n",
      "             in surgery but are interested in supervised caloric restriction.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Previous treatment with thiazolidinediones.\n",
      "\n",
      "          -  Chronic antibiotic therapy.\n",
      "\n",
      "          -  Active microvascular or macrovascular complications of diabetes.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients without contraindications gastroscope，surgery and anesthesia;\n",
      "\n",
      "          -  Gastroscope found submucosal lesions, qualitative hard;Endoscopic ultrasonography\n",
      "             (EUS) confirmed the lesions come from the muscularis propria\n",
      "\n",
      "          -  Tumors diameter > 2 cm;Or tumors had < 2 cm, but the position is located in the\n",
      "             stomach wall, after nearly cardia and it is a difficult position for gastroscope ;\n",
      "\n",
      "          -  Tumors diameter < 5 cm, the tumors had complete, no broken feed and bleeding\n",
      "\n",
      "          -  Not found the tumor metastasis\n",
      "\n",
      "          -  There is no history of abdominal surgery, no severe abdominal cavity adhesion\n",
      "\n",
      "          -  Patients signed informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with preoperative assessment of distant metastasis;\n",
      "\n",
      "          -  Patients with preoperative radiation and chemotherapy or hormone therapy;\n",
      "\n",
      "          -  Patients with acute obstruction, bleeding or perforation of the emergency surgery\n",
      "\n",
      "          -  Patients with a history of abdominal trauma or abdominal surgery.\n",
      "\n",
      "          -  Patients with contraindications gastroscope，surgery and anesthesia;\n",
      "      \n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          -  All subjects were required to be at least 18 years old, able to read and sign the\n",
      "             informed consent document\n",
      "\n",
      "          -  Physically and psychologically able to tolerate conventional restorative procedures\n",
      "\n",
      "          -  Having no active periodontal or pulpal diseases\n",
      "\n",
      "          -  Having no primary caries\n",
      "\n",
      "          -  Not allergic to resin-based materials\n",
      "\n",
      "          -  Not pregnant or nursing\n",
      "\n",
      "          -  Having antagonist teeth opposing the FRC FDP to be restored\n",
      "\n",
      "          -  Willing to return for follow-up examinations as outlined by the investigators.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who had more absent teeth than the tooth to be replaced in the rest of the\n",
      "             dentition or those having diastemas were not excluded.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Diagnosis of T1DM within >3 and <24 months of day 0 according to the American Diabetes\n",
      "             Association standard criteria.\n",
      "\n",
      "          2. 18 to 45 years of age on day of screening visit.\n",
      "\n",
      "          3. Positive for at least one islet cell autoantibody (glutamate decarboxylase; insulin,\n",
      "             if obtained within 10 days of the onset of insulin therapy; ICA 512-antibody; and/or\n",
      "             ZnT8).\n",
      "\n",
      "          4. Peak stimulated C-peptide level >0.2 pmol/mL (0.6 ng/ml) following an MMTT.\n",
      "\n",
      "          5. Weight of >= 40 kg and <=90.7kg\n",
      "\n",
      "          6. Adequate venous access to support a blood draw of 5 mls/kg up to maximum of 400 ml\n",
      "             whole blood and later infusion of investigational therapy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Hemoglobin <10.0 g/dL; leukocytes <3,000/μL; neutrophils <1,500/μL; lymphocytes\n",
      "             <800μL; platelets <100,000/μL\n",
      "\n",
      "          2. Any sign of significant chronic active infection (e.g., hepatitis, tuberculosis, EBV,\n",
      "             or CMV), or screening laboratory evidence consistent with a significant chronic active\n",
      "             infection (such as positive for HIV, PPD, or HBsAg).\n",
      "\n",
      "          3. Anticipated ongoing use of diabetes medications other than insulin that affect glucose\n",
      "             homeostasis, such as metformin, sulfonylureas, thiazolidinediones, glucagon-like\n",
      "             peptide 1 (GLP-1) mimetics, dipeptidyl peptidase IV (DPP-IV) inhibitors, SGLT2\n",
      "             inhibitors, or amylin.\n",
      "\n",
      "          4. Chronic use of systemic glucocorticoids or other immunosuppressive agents, or biologic\n",
      "             immunomodulators within 6 months prior to study entry. Specifically, subjects who have\n",
      "             received over 7 days of treatment with 7.5 mg of prednisone (or the equivalent) within\n",
      "             6 months prior to study entry will be excluded.\n",
      "\n",
      "          5. History of malignancy (including squamous cell carcinoma of the skin or cervix) except\n",
      "             adequately treated basal cell carcinoma\n",
      "\n",
      "          6. Pregnant or breastfeeding women, or any female who is unwilling to use a reliable and\n",
      "             effective form of contraception for 1 year after Treg +/- IL-2 dosing, and any male\n",
      "             who is unwilling to use a reliable and effective form of contraception for 3 months\n",
      "             after Treg +/- IL-2 dosing\n",
      "\n",
      "          7. Any condition that, in the investigator's opinion, may compromise study participation\n",
      "             or may confound the interpretation of the study results.\n",
      "\n",
      "          8. Patients who are unwilling to agree to not participate in another clinical trial,\n",
      "             which in the opinion of the investigator may confound the results of this study, for\n",
      "             at least 1 year following Treg infusion.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Birthweight < 1500g and/or\n",
      "\n",
      "          -  Gestational age < 32 weeks\n",
      "\n",
      "          -  nCPAP treatment for > 24 h\n",
      "\n",
      "          -  Oxygen supply to keep SaO2 87-94% for a minimum of 1 h prior to initiation of the\n",
      "             study\n",
      "\n",
      "          -  Parents written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Active medical treatment for patent ductus arteriosus\n",
      "\n",
      "          -  culture proven sepsis\n",
      "\n",
      "          -  Major congenital malformations\n",
      "\n",
      "          -  Genetic syndromes\n",
      "\n",
      "          -  Postoperative recovery period of <24 h\n",
      "      \n",
      "\n",
      "        Household Inclusion Criteria:\n",
      "\n",
      "          -  At least one household member diagnosed and prescribed treatment for an NCD condition\n",
      "             targeted by Novartis Access (asthma; diabetes; breast cancer; hypertension)\n",
      "\n",
      "          -  Eligible household members must be at least 18 years of age to participate\n",
      "\n",
      "        Household Exclusion Criteria:\n",
      "\n",
      "          -  Households who are unwilling to provide informed consent\n",
      "\n",
      "          -  Households that plan to move from their location during the two year period of the\n",
      "             study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Measurable metastatic cancer that expresses NY ESO-1 as assessed by one of the\n",
      "             following methods: reverse transcriptase-polymerase chain reaction (RT-PCR) on tumor\n",
      "             tissue, or by immunohistochemistry of resected tissue, or serum antibody reactive with\n",
      "             ESO\n",
      "\n",
      "          -  Confirmation of diagnosis of metastatic cancer by the Laboratory of Pathology at the\n",
      "             Montefiore Medical Center\n",
      "\n",
      "          -  Patients must have previously received systemic standard care (or effective salvage\n",
      "             chemotherapy regimens) for metastatic disease, if known to be effective for that\n",
      "             disease, and have been either non-responders (progressive disease) or have recurred\n",
      "\n",
      "          -  3 or fewer brain metastases; Note: if lesions are symptomatic or greater than or equal\n",
      "             to 1 cm each, these lesions must have been treated and stable for 3 months for the\n",
      "             patient to be eligible\n",
      "\n",
      "          -  More than four weeks must have elapsed since any prior systemic therapy at the time\n",
      "             the patient receives the preparative regimen, and patients' toxicities must have\n",
      "             recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo);\n",
      "             Note: patients may have undergone minor surgical procedures within the past 3 weeks,\n",
      "             as long as all toxicities have recovered to grade 1 or less or as specified in the\n",
      "             eligibility criteria\n",
      "\n",
      "          -  Eight weeks must have elapsed from the time of any antibody therapy that could affect\n",
      "             an anti-cancer immune response, including anti-cytotoxic T-lymphocyte-associated\n",
      "             protein 4 (CTLA 4) therapy, at the time the patient receives the preparative regimen\n",
      "             to allow antibody levels to decline; Note: patients who have previously received\n",
      "             ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal\n",
      "             colonoscopy with normal colonic biopsies\n",
      "\n",
      "          -  Willing to sign a durable power of attorney\n",
      "\n",
      "          -  Able to understand and sign the informed consent document\n",
      "\n",
      "          -  Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1\n",
      "\n",
      "          -  Life expectancy of greater than three months\n",
      "\n",
      "          -  Patients must be HLA-A*0201 positive\n",
      "\n",
      "          -  Patients of both genders must be willing to practice birth control from the time of\n",
      "             enrollment on this study and for up to four months after cells are no longer detected\n",
      "             in the blood\n",
      "\n",
      "          -  Serology:\n",
      "\n",
      "               -  Seronegative for human immunodeficiency virus (HIV) antibody; (the experimental\n",
      "                  treatment being evaluated in this protocol depends on an intact immune system;\n",
      "                  patients who are HIV seropositive can have decreased immune-competence and thus\n",
      "                  be less responsive to the experimental treatment and more susceptible to its\n",
      "                  toxicities)\n",
      "\n",
      "               -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody;\n",
      "                  if hepatitis C antibody test is positive, then patient must be tested for the\n",
      "                  presence of antigen by RT-PCR and be hepatitis C virus (HCV) ribonucleic acid\n",
      "                  (RNA) negative\n",
      "\n",
      "          -  Women of child-bearing potential must have a negative pregnancy test because of the\n",
      "             potentially dangerous effects of the treatment on the fetus\n",
      "\n",
      "          -  Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim\n",
      "\n",
      "          -  White blood cell (WBC) >= 3000/mm^3\n",
      "\n",
      "          -  Platelet count >= 100,000/mm^3\n",
      "\n",
      "          -  Hemoglobin > 8.0 g/dl\n",
      "\n",
      "          -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times\n",
      "             the upper limit of normal\n",
      "\n",
      "          -  Serum creatinine =< to 1.6 mg/dl\n",
      "\n",
      "          -  Total bilirubin =< to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must\n",
      "             have a total bilirubin less than 3.0 mg/dl\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Women of child-bearing potential who are pregnant or breastfeeding because of the\n",
      "             potentially dangerous effects of the treatment on the fetus or infant\n",
      "\n",
      "          -  Any form of primary immunodeficiency (such as severe combined immunodeficiency\n",
      "             disease)\n",
      "\n",
      "          -  Active systemic infections, coagulation disorders or other major medical illnesses of\n",
      "             the cardiovascular, respiratory or immune system, myocardial infarction, cardiac\n",
      "             arrhythmias, obstructive or restrictive pulmonary disease\n",
      "\n",
      "          -  Concurrent opportunistic infections (the experimental treatment being evaluated in\n",
      "             this protocol depends on an intact immune system; patients who have decreased immune\n",
      "             competence may be less responsive to the experimental treatment and more susceptible\n",
      "             to its toxicities)\n",
      "\n",
      "          -  Concurrent systemic steroid therapy\n",
      "\n",
      "          -  History of severe immediate hypersensitivity reaction to any of the agents used in\n",
      "             this study\n",
      "\n",
      "          -  History of coronary revascularization or ischemic symptoms\n",
      "\n",
      "          -  History of or active central nervous system (CNS) or peripheral nerve stimulation\n",
      "             (PNS) involvement\n",
      "\n",
      "          -  Documented left ventricular ejection fraction (LVEF) of less than or equal to 45%;\n",
      "             testing is required in patients with:\n",
      "\n",
      "               -  Clinically significant atrial and/or ventricular arrhythmias including but not\n",
      "                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree\n",
      "                  heart block\n",
      "\n",
      "               -  Age >= 60 years old\n",
      "\n",
      "          -  Pulmonary function testing in patients with:\n",
      "\n",
      "               -  A prolonged history of cigarette smoking (20 pk/yr of smoking within the past two\n",
      "                  years)\n",
      "\n",
      "               -  Symptoms of respiratory dysfunction\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Diagnosed with Stage I-II endometrial cancer\n",
      "\n",
      "          2. Six to 36 months post treatment\n",
      "\n",
      "          3. Body mass index (BMI) 30-<45 kg/m2\n",
      "\n",
      "          4. Age of at least 18 years\n",
      "\n",
      "          5. Access to a telephone for coaching sessions and access to a computer, smartphone, or\n",
      "             tablet for syncing Fitbit devices\n",
      "\n",
      "          6. Can speak and read English\n",
      "\n",
      "          7. Can provide informed consent\n",
      "\n",
      "          8. Willing to travel to MD Anderson's main campus for 2 visits (baseline and 6 months\n",
      "             post-baseline)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Unmanaged lymphedema\n",
      "\n",
      "          2. Medical contraindications to home-based exercise or low-fat, high fruit and vegetable\n",
      "             diet\n",
      "\n",
      "          3. Functional limitations requiring a walker/scooter/wheelchair for daily activities\n",
      "\n",
      "          4. Recurrent disease\n",
      "\n",
      "          5. Vigorous exercise > or = 60 min/week or moderate exercise > or = 150 min/week. If a\n",
      "             combination of moderate and vigorous exercise are preformed, the minutes of moderate\n",
      "             exercise/week plus 2 x minutes of vigorous exercise/week > or = 150 min/week.\n",
      "\n",
      "          6. Resistance training on > or = 2 days/week accounting for more than 30 minutes of\n",
      "             strength training per week\n",
      "\n",
      "          7. Enrollment in a structured weight loss program in the past 6 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. T1b and above adenocarcinoma of gall bladder\n",
      "\n",
      "          2. Patients undergoing curative resection\n",
      "\n",
      "          3. Incidentally diagnosed carcinoma who have undergone curative completion radical\n",
      "             cholecystectomy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. T1a tumors\n",
      "\n",
      "          2. Patients with metastatic disease\n",
      "\n",
      "          3. Patients unfit to undergo chemotherapy\n",
      "\n",
      "          4. Patients unwilling to undergo the trial\n",
      "\n",
      "          5. Patients with double cancers\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. The subjects should be 65 years old and above.\n",
      "\n",
      "          2. The participants should be able to walk independently for a minimum of 10 meter.\n",
      "\n",
      "          3. The participants should be able to do their daily activities such as eating, going to\n",
      "             bathroom, and taking a shower.\n",
      "\n",
      "          4. The participants should be able to do low-level balance exercise\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. The participants who had cognitive problems.\n",
      "\n",
      "          2. The participants who could not walk and do their daily activities independently.\n",
      "\n",
      "          3. The participants who have knee fracture or joint replacement.\n",
      "\n",
      "          4. The participant who had regular balance exercise or resistance training in lower body\n",
      "             in past 3 months.\n",
      "\n",
      "          5. The participant who had neurological and cardiovascular problem\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  At least one child aged 0-59 months living in the home\n",
      "\n",
      "          -  And non model health extension household.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  A household was excluded if the household graduated model health extension households.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Internal carotid artery or middle cerebral artery occlusion\n",
      "\n",
      "          -  Transient ischemic attack (TIA) or ischemic stroke in the ipsilateral hemisphere\n",
      "             within 30 days in patients who are either\n",
      "\n",
      "               -  hospitalized unstable patients with crescendo or postural TIA's, OR\n",
      "\n",
      "               -  Multiple TIA's, limb-shaking TIA's, and/or cognitive decline despite medical\n",
      "                  therapy*\n",
      "\n",
      "          -  Evidence of ipsilateral impaired cerebrovascular reserve on physiological testing\n",
      "             (e.g. Diamox challenge SPECT)\n",
      "\n",
      "          -  Modified Rankin Score (mRS) >3\n",
      "\n",
      "          -  Language comprehension intact\n",
      "\n",
      "          -  Age 18-85 years * failure of medical therapy must include at least failure on a\n",
      "             regimen of antiplatelets and statins.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Moya-moya syndrome\n",
      "\n",
      "          -  Known heart disease likely to cause cerebral ischemia\n",
      "\n",
      "               -  Prosthetic Valves\n",
      "\n",
      "               -  Atrial Fibrillation\n",
      "\n",
      "               -  Infective endocarditis\n",
      "\n",
      "               -  Left atrial or ventricular thrombus\n",
      "\n",
      "               -  Sick sinus syndrome\n",
      "\n",
      "               -  Cardiac myxoma\n",
      "\n",
      "               -  Cardiomyopathy with ejection fraction < 25%\n",
      "\n",
      "          -  Any condition likely to lead to death within 2 years\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Allergy or contraindication to aspirin\n",
      "\n",
      "          -  Uncontrolled diabetes mellitus (FBS > 300 mg%/16.7 mmol/L)\n",
      "\n",
      "          -  Uncontrolled hypertension (systolic BP>180, diastolic BP >110), other than induced for\n",
      "             control of pressure dependent symptoms\n",
      "\n",
      "          -  Uncontrolled hypotension (diastolic BP <65)\n",
      "\n",
      "          -  Unstable angina\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Completion of the written informed consent process.\n",
      "\n",
      "          2. Men or WNCBP age 18 to 55 years, in good health as determined by past medical history,\n",
      "             physical examination, vital signs, electrocardiogram, and laboratory tests at\n",
      "             screening.\n",
      "\n",
      "          3. Male subjects agree to use acceptable methods of contraception if the male subject's\n",
      "             partner could become pregnant from the time of the first administration of study\n",
      "             medication until 130 (90+40) days following administration of the investigational\n",
      "             medicinal product. One of the following acceptable methods of contraception must be\n",
      "             utilized:\n",
      "\n",
      "               -  Condom and occlusive cap (diaphragm or cervical/vault caps)\n",
      "\n",
      "               -  Surgical sterilization (vasectomy with documentation of azoospermia) and a\n",
      "                  barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].\n",
      "\n",
      "               -  The subject's female partner uses oral contraceptives (combination\n",
      "                  estrogen/progesterone pills), injectable progesterone or subdermal implants and a\n",
      "                  barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].\n",
      "\n",
      "               -  The subject's female partner uses medically prescribed topically-applied\n",
      "                  transdermal contraceptive patch and a barrier method (condom or occlusive cap\n",
      "                  [diaphragm or cervical/vault caps].\n",
      "\n",
      "               -  The subject's female partner has undergone documented tubal ligation (female\n",
      "                  sterilization). In addition, a barrier method (condom or occlusive cap [diaphragm\n",
      "                  or cervical/vault caps].\n",
      "\n",
      "               -  The subject's female partner has undergone documented placement of an\n",
      "                  intrauterine device or intrauterine system. In addition, a barrier method (condom\n",
      "                  or occlusive cap [diaphragm or cervical/vault caps].\n",
      "\n",
      "               -  True abstinence: when this is in line with the preferred and usual lifestyle of\n",
      "                  the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal,\n",
      "                  post-ovulation methods) and withdrawal are not acceptable methods of\n",
      "                  contraception. Abstinent subjects have to agree to use 1 of the above-mentioned\n",
      "                  contraceptive methods, if they start sexual relationships during the study and\n",
      "                  for up to 100 days after the last dose of study drug.\n",
      "\n",
      "          4. Women subjects must be of non-childbearing potential (WNCBP) as per one of the\n",
      "             following definitions:\n",
      "\n",
      "               -  Natural (spontaneous) post-menopausal defined as being amenorrhoeic for at least\n",
      "                  12 months without an alternative medical cause with a screening follicle\n",
      "                  stimulating hormone level consistent with local laboratory levels for\n",
      "                  post-menopause.\n",
      "\n",
      "               -  Premenopausal with irreversible surgical sterilization by hysterectomy and/or\n",
      "                  bilateral oophorectomy or salpingectomy at least 6 months before screening (as\n",
      "                  determined by subject medical history).\n",
      "\n",
      "          5. Haematology, clinical chemistry and urinalysis results at screening that are within\n",
      "             the local laboratory reference range or, if outside the range, not clinically\n",
      "             significant as judged by the Investigator. More specifically, serum creatinine,\n",
      "             hepatic transaminase enzymes (AST ALT), and total bilirubin (unless the subject has\n",
      "             documented Gilbert syndrome) should not exceed the upper laboratory norm and\n",
      "             haemoglobin must be equal to or higher than the lower limit of the normal range.\n",
      "\n",
      "          6. Total body weight greater than 50 kg and a body mass index (BMI) within the range of\n",
      "             18 to 32 kg/m2 (inclusive).\n",
      "\n",
      "          7. Non-smoker or ex-smoker for more than 90 days prior to screening, or smoke no more\n",
      "             than 5 cigarettes per day as determined by history. Must be able to abstain from\n",
      "             smoking during the inpatient stay.\n",
      "\n",
      "          8. Willing and able to comply with all scheduled visits, treatment plan, laboratory\n",
      "             tests, and other study procedures.\n",
      "\n",
      "          9. Agree to stay in contact with the study site for the duration of the study and up to 2\n",
      "             weeks following the end of study visit, provide updated contact information as\n",
      "             necessary, and have no current plans to move away from the study area for the duration\n",
      "             of the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Male subjects with a female partner(s) who is (are) pregnant or lactating from the\n",
      "             time of the administration of study medication.\n",
      "\n",
      "          2. Women of childbearing potential, defined as all women physiologically capable of\n",
      "             becoming pregnant, including women whose career, lifestyle, or sexual orientation\n",
      "             precludes intercourse with a male partner and women whose partners have been\n",
      "             sterilized by vasectomy or other means.\n",
      "\n",
      "          3. Evidence or history of clinically significant haematological, renal, endocrine,\n",
      "             pulmonary, gastrointestinal (including gallbladder), cardiovascular (including a\n",
      "             family history of long QT syndrome or sudden death), hepatic, psychiatric, neurologic,\n",
      "             or allergic disease (including drug or food allergies, anaphylaxis or other severe\n",
      "             allergic reactions but excluding untreated, asymptomatic, seasonal allergies at the\n",
      "             time of dosing).\n",
      "\n",
      "          4. History of malignancy of any organ system (other than localised basal cell carcinoma\n",
      "             of the skin), treated or untreated, within the past five years, regardless of whether\n",
      "             there is evidence of local recurrence or metastases.\n",
      "\n",
      "          5. Other severe acute or chronic medical or psychiatric condition or laboratory\n",
      "             abnormality that may increase the risk associated with study participation or\n",
      "             investigational product administration or may interfere with the interpretation of\n",
      "             study results and, in the judgment of the Investigator, would make the subject\n",
      "             inappropriate for entry into this study.\n",
      "\n",
      "          6. Any surgical or medical condition possibly affecting drug absorption (e.g.\n",
      "             cholecystectomy, gastrectomy, bowel disease, etc.), distribution, metabolism or\n",
      "             excretion.\n",
      "\n",
      "          7. Previous splenectomy.\n",
      "\n",
      "          8. A history of photosensitivity.\n",
      "\n",
      "          9. Subject positive for any of the following\n",
      "\n",
      "               -  Anti-human immunodeficiency virus 1 or 2 antibodies (anti-HIV1 or anti-HIV2 Ab)\n",
      "                  (ELISA)\n",
      "\n",
      "               -  Hepatitis B surface antigen (HBsAg)\n",
      "\n",
      "               -  Anti-hepatitis B core antibodies (anti-HBcAb)\n",
      "\n",
      "               -  Anti-hepatitis C antibodies (anti-HCV)\n",
      "\n",
      "         10. Resting vital signs (measured after 5 minutes in the supine position) at screening,\n",
      "             pre-dose (Part A) or pre-inoculation (Part B) outside of the following study-specific\n",
      "             normal ranges:\n",
      "\n",
      "               -  tympanic body temperature < 38.0 °C\n",
      "\n",
      "               -  90 < SBP < 140 mmHg\n",
      "\n",
      "               -  50 < DBP < 90 mmHg\n",
      "\n",
      "               -  40 < pulse rate < 100 bpm\n",
      "\n",
      "         11. Symptomatic postural hypotension at screening, irrespective of the decrease in blood\n",
      "             pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood\n",
      "             pressure ≥20 mmHg 2 minutes after changing from a supine to standing position.\n",
      "\n",
      "         12. A history of clinically significant ECG abnormalities, or any of the following ECG\n",
      "             abnormalities at screening, pre-dose (Part A and B) or pre-inoculation (Part B):\n",
      "\n",
      "               -  PR >210 ms\n",
      "\n",
      "               -  QRS complex >120 ms\n",
      "\n",
      "               -  QTcF >450 ms\n",
      "\n",
      "               -  Second or third degree atrioventricular block\n",
      "\n",
      "               -  Incomplete, complete or intermittent bundle branch block\n",
      "\n",
      "               -  Abnormal T wave morphology\n",
      "\n",
      "               -  Left ventricular hypertrophy with repolarisation abnormalities\n",
      "\n",
      "               -  Right ventricular hypertrophy.\n",
      "\n",
      "         13. Presence of acute infectious disease or fever (i.e. tympanic body temperature ≥38.5\n",
      "             ºC) within five days prior to the first dose of study medication (Part A) or the\n",
      "             inoculation administration (Part B).\n",
      "\n",
      "         14. Use of prescription or non-prescription drugs, herbal and dietary supplements within\n",
      "             14 days or 5 half-lives (whichever is the longer) prior to the first dose of study\n",
      "             medication (Part A) or the inoculation administration (Part B). [As an exception,\n",
      "             paracetamol may be used at doses of up to 1 g/day (Part A) or 2 g/day (Part B), or\n",
      "             ibuprofen up to 1.2 g/day (Part B). Limited use of other non-prescription medications\n",
      "             not believed to affect subject safety or the overall results of the study, may be\n",
      "             permitted on a case-by-case basis following approval by the sponsor.]\n",
      "\n",
      "         15. Recipient of any vaccination within 28 days prior to the first dose of study\n",
      "             medication (Part A) or the inoculation administration (Part B).\n",
      "\n",
      "         16. Urine drug screen at screening, pre-dose (Part A) or pre-inoculation (Part B) positive\n",
      "             for any drug as listed in Section 9.2.4 unless there is an explanation acceptable to\n",
      "             the medical Investigator (e.g. the subject has stated in advance that they consumed a\n",
      "             prescription or over the counter product which contained the detected drug) and/or the\n",
      "             subject has a negative urine drug screen on retest by the pathology laboratory.\n",
      "\n",
      "         17. Ingestion of any poppy seeds within the 24 hours prior to the screening blood test.\n",
      "\n",
      "         18. A positive alcohol breath test at screening, pre-dose (Part A) or pre-inoculation\n",
      "             (Part B).\n",
      "\n",
      "         19. History of regular alcohol consumption exceeding a weekly intake of more than 21 units\n",
      "             for males and more than 14 units for females (one unit is equivalent to 8-10 g of\n",
      "             ethanol, 285 ml of beer or lager, one glass [125 ml] of wine, or 25 ml of spirits)\n",
      "             within 6 months of screening.\n",
      "\n",
      "         20. History of drug habituation, or any prior intravenous usage of an illicit substance.\n",
      "\n",
      "         21. Participation in any investigational product study within 12 weeks or five half-lives\n",
      "             (whichever is longer) prior to the first dose of the study medication.\n",
      "\n",
      "         22. Intake of grapefruit, grapefruit juice or grapefruit-related citrus fruits (e.g.\n",
      "             Seville oranges, pomelos) within 28 days prior to the first dose of the study\n",
      "             medication.\n",
      "\n",
      "         23. Excessive consumption of beverages containing xanthine bases (e.g. more than 400 mg of\n",
      "             caffeine per day, equivalent to approximately 4 cups of coffee).\n",
      "\n",
      "         24. Pregnant or nursing (lactating) women.\n",
      "\n",
      "         25. Participation in any research study involving blood sampling (more than 450 ml/ unit\n",
      "             of blood), or blood donation to the Australian Red Cross Blood Service (ARCBS) or\n",
      "             other blood bank during the 8 weeks prior to IMP administration (Part A) or\n",
      "             inoculation (Part B).\n",
      "\n",
      "         26. Blood donation (excluding plasma donation) of any volume, within 1 month prior to\n",
      "             screening.\n",
      "\n",
      "         27. Medical requirement for intravenous immunoglobulin or blood transfusions.\n",
      "\n",
      "         28. Subject with poor peripheral venous access.\n",
      "\n",
      "         29. Subject unwilling or unable to comply with the restrictions described in this\n",
      "             protocol.\n",
      "\n",
      "         30. Any subject who, in the judgment of the Investigator, is likely to be noncompliant\n",
      "             during the study, or unable to cooperate because of a language problem or poor mental\n",
      "             development.\n",
      "\n",
      "         31. Any subject who is the Investigator or any sub-investigator, research assistant,\n",
      "             pharmacist, study coordinator, or other staff thereof, directly involved in conducting\n",
      "             the study.\n",
      "\n",
      "         32. Recent (within the last three years) and/or recurrent history of autonomic dysfunction\n",
      "             (e.g. recurrent episodes of fainting, palpitations, etc.).\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  aged between 6 and 12 y\n",
      "\n",
      "          -  referred to the HFME for a suspicion of sleep apnea\n",
      "\n",
      "          -  narcolepsy\n",
      "\n",
      "          -  centro-temporal epilepsy\n",
      "\n",
      "          -  high intellectual potential\n",
      "\n",
      "          -  children without sleep disorders will be included in the healthy control group.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with hematologic malignancy receiving care (chemotherapy, immunotherapy,\n",
      "             targeted agents, bone marrow transplant, or other) for their hematologic malignancy at\n",
      "             the Ohio State University\n",
      "\n",
      "          -  Impairments in physical function, as defined by a score < 9 on the SPPB pre-screen\n",
      "\n",
      "          -  Medical clearance from an oncologist or primary care physician stating the participant\n",
      "             is able to participate in an unsupervised, moderate-intensity physical activity\n",
      "             program\n",
      "\n",
      "          -  Ability to understand and the willingness to sign a written informed consent document\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prisoners\n",
      "\n",
      "          -  Any medical condition including, but not limited to, symptomatic congestive heart\n",
      "             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that\n",
      "             would limit compliance with study procedures\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must have a history of a premalignant lesion of the stomach, atrophic\n",
      "             gastritis or intestinal metaplasia\n",
      "\n",
      "          -  Patients must have a pure tone audiometry evaluation to document air conduction within\n",
      "             60 days prior to randomization.\n",
      "\n",
      "          -  Patients must have adequate blood counts as evidenced by the following results\n",
      "             (obtained within 60 days):\n",
      "\n",
      "               -  Blood counts: WBC ≥4.0 /mcL, platelets ≥100,000 /mcL and hemoglobin ≥11.0 g/dL\n",
      "\n",
      "               -  Kidney function: Creatinine <1.6 x IULN (institutional upper limit of normal)\n",
      "\n",
      "               -  Liver function tests: Bilirubin ≤2.0 mg/dL and AST (SGOT) or ALT (SGPT) ≤2 x IULN\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects with dysplasia (indeterminate, low grade, high grade) are not eligible for\n",
      "             participation\n",
      "\n",
      "          -  Patients must not have a significant medical or psychiatric condition that would\n",
      "             preclude study completion.\n",
      "\n",
      "          -  Patients with hearing loss ≥30 dB in any of the tested frequencies (250 Hz, 500 Hz,\n",
      "             1,000 Hz, 2,000 Hz, 4,000 Hz, 8,000 Hz) are not eligible.\n",
      "\n",
      "          -  Patients must not have known hypersensitivity to eflornithine or the excipients.\n",
      "\n",
      "          -  Patients must not be receiving corticosteroids, nonsteroidal anti-inflammatory drugs\n",
      "             (NSAIDs), or anticoagulants on a regular or intermittent basis.\n",
      "\n",
      "          -  Patients must not have a significant cardiovascular disease history, including\n",
      "             uncontrolled blood pressure (sBP > 150 mmHg), myocardial infarction, cerebrovascular\n",
      "             accident, or heart failure (New York Heart Association Class III, or IV).\n",
      "\n",
      "          -  Patients must not have a history of gastric or esophageal cancer, gastric resection or\n",
      "             surgery, peptic ulcer disease (within 6 months), H. pylori treatment (within 6\n",
      "             months), or inflammatory bowel disease.\n",
      "\n",
      "          -  No prior malignancy is allowed except for adequately treated basal cell or squamous\n",
      "             cell skin cancer, in situ cervical cancer, or other cancer for which the patient has\n",
      "             been disease-free for >5 years.\n",
      "\n",
      "          -  Patients must not be receiving corticosteroids, nonsteroidal anti-inflammatory drugs\n",
      "             (NSAIDs), or anticoagulants on a regular or intermittent basis.\n",
      "\n",
      "          -  Patients must not be pregnant or nursing (due to eflornithine pregnancy class C).\n",
      "             Women and men of reproductive potential must have agreed to use an effective\n",
      "             contraceptive method.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Signed and dated informed consent form (ICF) to participate before any study related\n",
      "             procedures are performed\n",
      "\n",
      "          -  Adult over the age of 18\n",
      "\n",
      "          -  Both males and females\n",
      "\n",
      "          -  Clinically stable for at least 4 weeks with no acute medical co-morbidities\n",
      "\n",
      "          -  Patients on a stable Intralipid HPN regimen for 6 months and expected to require\n",
      "             long-term PN for at least 13 more months\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Subjects not already on Intralipid PN Inability to give informed consent Alcohol or drug\n",
      "        abuse Pregnant and lactating women\n",
      "\n",
      "        Clinical instability such as the following:\n",
      "\n",
      "          -  Acute pulmonary edema\n",
      "\n",
      "          -  Decompensated heart failure\n",
      "\n",
      "          -  Decompensated chronic liver disease\n",
      "\n",
      "          -  Severe post-traumatic conditions\n",
      "\n",
      "          -  Uncontrolled diabetes mellitus\n",
      "\n",
      "          -  Acute myocardial infarction\n",
      "\n",
      "          -  Acute stroke\n",
      "\n",
      "          -  Acute thromboembolism\n",
      "\n",
      "          -  Metabolic acidosis\n",
      "\n",
      "          -  Sepsis\n",
      "\n",
      "          -  Hypotonic dehydration\n",
      "\n",
      "          -  Coagulopathy with prolonged aPTT or INR Elevated triglyceride level: more than 4.5\n",
      "             mmol/L Active malignancy with life expectancy less than one year Subjects who are\n",
      "             hypersensitive or allergic to the product ingredients of SMOF or Intralipid, including\n",
      "             soybean oil, peanuts, fish oil, and egg as well as allergy to peanuts.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age between 20-80 year-old.\n",
      "\n",
      "          2. Typical symptoms and signs of CTS, such as positive Tinel's sign or Phalen's test,\n",
      "             numbness/tingling in at least two of the first, second, or third digits, and in whom\n",
      "             the diagnosis was confirmed using an electrophysiological study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Cancer\n",
      "\n",
      "          2. Coagulopathy\n",
      "\n",
      "          3. Pregnancy\n",
      "\n",
      "          4. Inflammation status\n",
      "\n",
      "          5. Patients who had conditions mimicking CTS, such as cervical radiculopathy,\n",
      "             polyneuropathy, brachial plexopathy, thoracic outlet syndrome or who had previously\n",
      "             undergone wrist surgery or steroid injection for CTS.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Written informed-consent before any evaluation\n",
      "\n",
      "          -  Visual impairment due to active CNV,including predominantly classic CNV,minimally\n",
      "             classic CNV,occult CNV with no classic component and PCV.\n",
      "\n",
      "          -  50 years old and older\n",
      "\n",
      "          -  Chinese\n",
      "\n",
      "          -  For study eye: BCVA between 20/30 and 20/320 on electronic visual acuity texting at\n",
      "             the time point of both screening and baseline.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Have Stroke and myocardial infarction within 3 months before screening\n",
      "\n",
      "          -  Any active periocular and ocular infection and inflammation (including blepharitis,\n",
      "             conjunctivitis, keratitis, scleritis, uveitis, intraocular inflammation) while\n",
      "             screening and baseline.\n",
      "\n",
      "          -  Uncontrolled glaucoma (under treatment [IOP] ≥ 30 mm Hg or depend on researchers)\n",
      "             while screening and baseline\n",
      "\n",
      "          -  Neovascularization of iris and neovascular glaucoma while screening and baseline\n",
      "\n",
      "          -  Any causes led to choroidal neovascularization except Wet AMD (including ICNV,central\n",
      "             serous chorioretinopathy,ocular histoplazmoza and pathologic myopia) while screening\n",
      "             and baseline\n",
      "\n",
      "          -  With structure injury (including vitreous macular traction,epiretinal membrane\n",
      "             involving in central fovea,subretinal fibroplasia,laser scar and central fovea\n",
      "             atrophy) within 0.5 optic disc diameter to the central of macula while screening and\n",
      "             baseline, which may harm the improvement of vision by treatment according to\n",
      "             researchers\n",
      "\n",
      "          -  Any systemic anti-VEGF medication(as Avastin) use within 3 months before screening\n",
      "\n",
      "          -  Any medication systemic use toxic to lens, retina and optic nerve,including iron\n",
      "             amine, chloroquine/chloroquine (Plaquenil ®), tamoxifen, phenothiazine and ethambutol\n",
      "\n",
      "          -  For study eye：Used to accept following treatments for wet AMD within 3 months or\n",
      "             accept following treatments more than three times before baseline: a)Anti-angiogenesis\n",
      "             drugs(pegaptanib （Macugen®），ranibizumab\n",
      "             ,bevacizumab（Avastin®),VEGF-Trap，KH902；b）Anecortave acetate corticosteroids；c）Protein\n",
      "             kinase C inhibitors，squalamine，siRNA; d)PDT （Visudyne®）treatment,external beam\n",
      "             radiotherapy, local laser photocoagulation, vitrectomy, submacular surgery and\n",
      "             transpupillary thermotherapy\n",
      "\n",
      "          -  Any intraocular surgery(including YAG laser) within 3 months before baseline or\n",
      "             predicated within 6 months after baseline\n",
      "\n",
      "          -  Intraocular or periocular treatment of corticosteroids within 3 months before baseline\n",
      "\n",
      "          -  For follow eye:Any anti-angiogenesis treatment(including anti-VEGF,like\n",
      "             Lucentis,Avastin® and KH902 ) within 3 months before baseline\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  English and Spanish speaking pregnant women\n",
      "\n",
      "          -  Any order pregnancy (singleton, twin gestation, etc)\n",
      "\n",
      "          -  Suspected accreta based on ultrasound or MRI imaging studies\n",
      "\n",
      "          -  All women evaluated for placenta accreta and deemed to be high risk for this disease\n",
      "             (≥40% risk), meaning women diagnosed with a placenta previa and greater than or equal\n",
      "             to 2 prior c-sections\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Women less than 18 years of age\n",
      "\n",
      "          -  Women with a personal history of venous or arterial thrombosis (deep vein thrombosis,\n",
      "             pulmonary embolism, myocardial infarction, or stroke\n",
      "\n",
      "          -  Women with a personal history of a high risk clotting disorder, such as\n",
      "             anti-phospholipid syndrome\n",
      "\n",
      "          -  Women who do not have a good understanding of either English or Spanish will be\n",
      "             excluded.\n",
      "\n",
      "          -  Women with defective color vision (color-blindness)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult patients (age 18 years or older) in a state of delirium (hyperactive ore mixed\n",
      "             type) upon detection in the ICU (i.e., ICDSC >3).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Hypersensitivity to the active substance\n",
      "\n",
      "          -  Advanced heart block (grade 2 or 3) unless implanted pacemaker\n",
      "\n",
      "          -  Uncontrolled hypotension\n",
      "\n",
      "          -  Acute cerebrovascular conditions\n",
      "\n",
      "          -  Severe cardiac dysfunction\n",
      "\n",
      "          -  Bradycardia\n",
      "\n",
      "          -  Egg allergy\n",
      "\n",
      "          -  Soybean/soy allergy\n",
      "\n",
      "          -  Age below 18 years\n",
      "\n",
      "          -  Terminal state\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Active psychosis (of non organic origin = functional disturbances)\n",
      "\n",
      "          -  Status epilepticus or postictal states following seizures on EEG\n",
      "\n",
      "          -  Delirium due to alcohol withdrawal\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Male and female aged 18-65 years old;\n",
      "\n",
      "          2. Histopathologically confirmed Peripheral T -cell Lymphoma (PTCL) including:\n",
      "\n",
      "               -  PTCL-unspecified;\n",
      "\n",
      "               -  Angioimmunoblastic T-cell lymphoma;\n",
      "\n",
      "               -  Anaplastic large cell lymphoma, ALK positive or negative;\n",
      "\n",
      "               -  Subcutaneous panniculitis T-cell lymphoma;\n",
      "\n",
      "               -  Cutaneous / T-cell lymphoma;\n",
      "\n",
      "               -  Other T-cell lymphoma that investigators consider to be appropriate to be\n",
      "                  enrolled;\n",
      "\n",
      "          3. Patients have not received anti-tumor therapy;\n",
      "\n",
      "          4. In any Ann Arbor disease stage;\n",
      "\n",
      "          5. ECOG performance status 0-1;\n",
      "\n",
      "          6. Patients without bone marrow involvement. The absolute number of neutrophile is no\n",
      "             less then 2.0 * 10^9/L, platelet no less then 100 * 10^9/L. And the concentration of\n",
      "             hemoglobin is no less than 110 g/L;\n",
      "\n",
      "          7. Life expectancy is no less than 6 months;\n",
      "\n",
      "          8. Patients who have signed the Informed Consent Form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Patients who have central nervous system or meninges involvements;\n",
      "\n",
      "          2. Patients have been treated by radiotherapy, chemotherapy or immunotherapy for PTCL;\n",
      "\n",
      "          3. Patients have uncontrollable or significant cardiovascular disease including:\n",
      "\n",
      "               -  history of myocardial infarction;\n",
      "\n",
      "               -  uncontrollable angina within the 6 months before screening, or taking anti-angina\n",
      "                  drugs at the time of screening;\n",
      "\n",
      "               -  history of congestive heart failure, or the left ventricular ejection fraction\n",
      "                  (LVEF) is < 50% at the time of screening;\n",
      "\n",
      "               -  clinically significant ventricular arrhythmia such as ventricular tachycardia,\n",
      "                  ventricular fibrillation or torsades de pointes;\n",
      "\n",
      "               -  History of supraventricular arrhythmia or nodal arrhythmia that could not been\n",
      "                  controlled by drug or need a pacemaker;\n",
      "\n",
      "               -  History of cardiomyopathy;\n",
      "\n",
      "               -  History of clinically significant QTc interval prolongation, or QTc interval >\n",
      "                  450 ms at screening;\n",
      "\n",
      "               -  Coronary disease which is with symptoms and needs drug therapy;\n",
      "\n",
      "          4. Patients have undergone organ transplantation;\n",
      "\n",
      "          5. Patients with thromboembolic disease, hematencephalon or cerebral infraction within 4\n",
      "             weeks before screening, or patients who are under anticoagulant therapy;\n",
      "\n",
      "          6. Patients with clinically significant abnormalities in gastrointestinal tract, such as\n",
      "             dysphagia, chronic diarrhea and intestinal obstruction which may affect the\n",
      "             uptake,transformation and absorption of the drug;\n",
      "\n",
      "          7. Patients with active infections, including active bacterial,viral,fungoid,\n",
      "             mycobacterium, parasite infections (but not including hyponychium fungoid infection),\n",
      "             or infections which need not be treated by intravenous antibody therapies, or\n",
      "             antiviral therapies, or any serious infection need to be treated by hospitalization;\n",
      "\n",
      "          8. Patients who have been conducted the surgery on a major organ in less than 6 weeks;\n",
      "\n",
      "          9. Hepatic function: Serum total bilirubin > 1.5 fold of normal range; ALT/AST > 2.5\n",
      "             folds of normal range or 5 folds for liver metastasis; Renal function: Serum creatine\n",
      "             > 1.5 folds of normal range;\n",
      "\n",
      "         10. Patients with other malignancies in the past or now (except basal cell carcinoma,\n",
      "             squamous-cell carcinoma or carcinoma in situs of cervix that has been adequately\n",
      "             treated),unless the malignancy has been radically treated and there has been no\n",
      "             evidence of recurrence for 5 years;\n",
      "\n",
      "         11. Pregnant or lactating women and patients in childbearing age who will not carry out\n",
      "             birth control;\n",
      "\n",
      "         12. Patients with mental disorders, which may affect understanding and execution of\n",
      "             informed consent or the compliance of the study;\n",
      "\n",
      "         13. Drug abuse or long term alcoholism that could affect the evaluation for the study\n",
      "             results;\n",
      "\n",
      "         14. Patients considered by investigators not suitable for the study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria for amnestic MCI cohort:\n",
      "\n",
      "          1. Participants will be at least 65 years of age\n",
      "\n",
      "          2. Positive brain amyloid PET/CT scan within 6 months of study screening\n",
      "\n",
      "          3. Mini-mental status examination (MMSE) score ≥ 24 at screening visit\n",
      "\n",
      "          4. A brain MRI is required. If a brain MRI has been performed within 6 months of\n",
      "             11C-Acetate PET/CT and of adequate quality that scan may be used for the study\n",
      "             analysis, subjects who do not have a brain MRI will undergo a brain MRI as a part of\n",
      "             this study\n",
      "\n",
      "          5. Participants must identify a study partner who is willing to accompany the patient to\n",
      "             study visits\n",
      "\n",
      "          6. Participants must be informed of the investigational nature of this study and provide\n",
      "             written informed consent in accordance with institutional and federal guidelines prior\n",
      "             to study-specific procedures. If the patient is unable to provide informed consent,\n",
      "             the patient's legal representative may consent on behalf of the patient but the\n",
      "             patient will be asked to confirm assent.\n",
      "\n",
      "        Inclusion Criteria for Control cohort:\n",
      "\n",
      "          1. Participants will be at least 65 years of age\n",
      "\n",
      "          2. History of negative brain amyloid PET/CT scan within 6 months of study screening OR\n",
      "             negative CSF analysis for AD biomarkers within 6 months of study screening\n",
      "\n",
      "          3. Mini-mental status examination (MMSE) > 27 at screening visit\n",
      "\n",
      "          4. A brain MRI is required. If a brain MRI has been performed within 6 months of\n",
      "             enrollment to this study and of adequate quality that scan may be used for the study\n",
      "             analysis, subjects who do not have a brain MRI will undergo a brain MRI as a part of\n",
      "             this study\n",
      "\n",
      "          5. Participants must be informed of the investigational nature of this study and provide\n",
      "             written informed consent in accordance with institutional and federal guidelines prior\n",
      "             to study-specific procedures.\n",
      "\n",
      "        Exclusion Criteria for both cohorts:\n",
      "\n",
      "          1. Inability to tolerate or contraindication to imaging procedures (PET/CT or MRI) in the\n",
      "             opinion of an investigator or treating physician\n",
      "\n",
      "          2. History of stroke or other neurological disease that in the opinion of the\n",
      "             investigator might interfere with evaluation of the 11C-Acetate scan\n",
      "\n",
      "          3. Any medical or psychological conditions that, in the opinion of the investigator,\n",
      "             would compromise the subject's safety or successful participation in the study.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Informed consent obtained from parent or legally authorized representative (LAR)\n",
      "\n",
      "          -  Live-born ELBW infant\n",
      "\n",
      "          -  Less than 6 hours of life\n",
      "\n",
      "          -  Birth weight 401 to 1000g\n",
      "\n",
      "          -  Admitted to Texas Children's Hospital (TCH) Pavilion for Women (PFW) Neonatal\n",
      "             Intensive Care Unit (NICU)\n",
      "\n",
      "          -  Umbilical arterial catheter (UAC) in place\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Complex congenital anomalies of central nervous system (CNS)\n",
      "\n",
      "          -  Complex chromosomal congenital anomalies\n",
      "\n",
      "          -  Hydrops fetalis\n",
      "\n",
      "          -  Poor skin integrity\n",
      "\n",
      "          -  Live-born but receiving only comfort care\n",
      "\n",
      "          -  Grade 3-4 IVH by head ultrasound (HUS) at the first ultrasound completed at or before\n",
      "             6 hours of life\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Healthy Caucasian (no acute or chronic diseases)\n",
      "\n",
      "          -  Normal weight or slightly overweight (BMI: 18.5 - 27.5 kg/m²)\n",
      "\n",
      "          -  Regularly working in sedentary office environments\n",
      "\n",
      "          -  Regular computer users\n",
      "\n",
      "          -  Fluent German speakers\n",
      "\n",
      "          -  Consented to participate\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Heavily overweight & Obesity (BMI > 27.5 kg/m²)\n",
      "\n",
      "          -  Short office stay duration (< 8 h / day or < 20 h / week)\n",
      "\n",
      "          -  Experience in sit-to-stand workstations\n",
      "\n",
      "          -  Acute or chronic diseases\n",
      "\n",
      "          -  Inability to stand\n",
      "\n",
      "          -  Visual impairments that had not been corrected\n",
      "\n",
      "          -  Color blindness\n",
      "\n",
      "          -  People planning to change their physical activity level\n",
      "\n",
      "          -  Regular smokers (> 1 cigarette /day)\n",
      "\n",
      "          -  Not consented to participate\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Self-identification as African American\n",
      "\n",
      "          2. Self-report pre-pregnancy BMI between 25-49.9 kg/m2\n",
      "\n",
      "          3. Measured BMI at baseline between 25-49.9 kg/m2\n",
      "\n",
      "          4. Philadelphia WIC participant\n",
      "\n",
      "          5. Singleton birth\n",
      "\n",
      "          6. Between 1 and 6 months postpartum\n",
      "\n",
      "          7. Own a cell phone with an unlimited text messaging plan\n",
      "\n",
      "          8. Able to participate in light physical activity (walking)\n",
      "\n",
      "          9. Participants must be willing to comply with all study-related procedures\n",
      "\n",
      "         10. Participants must be able to read and write fluently in English\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. BMI ≤ 24.9 or ≥ 50.0 kg/m2\n",
      "\n",
      "          2. Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >\n",
      "             95 mmHg). Participants with controlled hypertension on medication for at least three\n",
      "             months are allowable.\n",
      "\n",
      "          3. Known atherosclerotic cardiovascular disease\n",
      "\n",
      "          4. Known congestive heart failure\n",
      "\n",
      "          5. Known diabetes mellitus (type 1 or type 2)\n",
      "\n",
      "          6. Known thyroid disease\n",
      "\n",
      "          7. Any major active rheumatologic, pulmonary, hepatic, dermatologic disease or\n",
      "             inflammatory condition requiring steroids or immune modulating medications\n",
      "\n",
      "          8. History of testing HIV positive\n",
      "\n",
      "          9. Current smoker or tobacco user. Participants with < 5 cigarettes daily are allowable\n",
      "\n",
      "         10. Current or recent history (past 6 months) of drug or alcohol abuse or dependence\n",
      "\n",
      "         11. Participation in any weight control or investigational drug study within 6 weeks of\n",
      "             screening\n",
      "\n",
      "         12. Current consumption of any of the following medications: appetite suppressants,\n",
      "             anti-psychotics, lipase inhibitors\n",
      "\n",
      "         13. Serious or unstable medical or psychological conditions that, in the opinion of the\n",
      "             investigator, would compromise the subject's safety for successful participation in\n",
      "             the study\n",
      "\n",
      "         14. Gastrointestinal Disorders (gallbladder disease, Crohn's disease, etc)\n",
      "\n",
      "         15. Previous weight loss surgery\n",
      "\n",
      "         16. History of bulimia or anorexia\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  American Society of Anesthesiology (ASA) class 1,2, and 3\n",
      "\n",
      "          -  English speaking women at a gestational age > 37 weeks\n",
      "\n",
      "          -  scheduled for cesarean delivery under spinal or combined spinal epidural anesthesia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  BMI > 50 kg/m2\n",
      "\n",
      "          -  history of intravenous drug or opioid abuse\n",
      "\n",
      "          -  previous history of chronic pain syndrome\n",
      "\n",
      "          -  history of opioid use in the past week\n",
      "\n",
      "          -  allergy or contraindication to any of the study medications\n",
      "\n",
      "          -  non-English speaking\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Child or young person aged 5 to 17 years of age.\n",
      "\n",
      "          -  Child under the care of the paediatric rheumatology team at Alder Hey Children's NHS\n",
      "             Foundation Trust.\n",
      "\n",
      "          -  Child must be expected to require at least 2 blood tests during the study period of 16\n",
      "             weeks as part of their routine care. All decisions regarding requirement for blood\n",
      "             tests and/or procedures will be made solely on clinical grounds and not determined in\n",
      "             any way by the study team.\n",
      "\n",
      "          -  Sufficient time for assessment visit and preparation prior to first procedure.\n",
      "\n",
      "          -  The parent or child if aged above 16 years of age has provided written, informed\n",
      "             consent to participate in the study.\n",
      "\n",
      "          -  The child aged less than 16 years has provided assent appropriate to their age.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Child unable to understand and complete Visual Analogue Scale (VAS) with support.\n",
      "\n",
      "          -  Family unwilling to take part in study.\n",
      "\n",
      "          -  Patient has previously received regular play therapy.\n",
      "\n",
      "          -  Patient receiving psychology input for procedure-related anxiety or anxiety disorder.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or Female, aged 18 years or above.\n",
      "\n",
      "          -  An ESD is attempted for clinical indications approved by MDT.\n",
      "\n",
      "          -  Oesophageal or colonic lesion 2-5cm in size\n",
      "\n",
      "          -  Participant is willing and able to give informed consent for participation in the\n",
      "             study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Known coagulopathy likely to affect risk of bleeding\n",
      "\n",
      "          -  Submucosal tumour\n",
      "\n",
      "          -  Anticoagulation or anti-platelet therapy (apart from single modality aspirin or\n",
      "             clopidogrel) which cannot be stopped for clinical reasons\n",
      "\n",
      "          -  Patient preference\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Stable HIV participants (CD4+ lymphocyte count > 350 cells/mm3) for at least two years\n",
      "\n",
      "          -  prescribed their current cART regimen for at least six months) with mild to moderate\n",
      "             cognitive impairment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Drug/alcohol abuse\n",
      "\n",
      "          -  History of Parkinsons\n",
      "\n",
      "          -  Alzheimers, stroke or traumatic brain injury\n",
      "\n",
      "          -  diabetes mellitus\n",
      "\n",
      "          -  renal insufficiency\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Willing and able to provide written informed consent/assent for the trial\n",
      "\n",
      "          -  Be >/= 18 years of age on day of signing consent.\n",
      "\n",
      "          -  Have a diagnosis of histologically confirmed metastatic colorectal cancer to the liver\n",
      "             (no other sites of metastatic disease)\n",
      "\n",
      "             * Histologic confirmation of a colorectal primary tumor is acceptable if accompanied\n",
      "             by radiographic evidence of metastatic disease\n",
      "\n",
      "          -  Tumor must be mismatch repair (MMR) proficient as determined by microsatellite\n",
      "             instability or immunohistochemistry for for MMR proteins\n",
      "\n",
      "               -  Microsatellite instability testing must be MSI-stable or MSI-low\n",
      "\n",
      "               -  Or IHC for MMR proteins must demonstrate intact MMR proteins\n",
      "\n",
      "          -  Participant must be candidate for SBRT to at least one intrahepatic lesion. There is\n",
      "             no limit on the number of intrahepatic lesions the patient may have\n",
      "\n",
      "          -  Participant must be a surgical candidate with therapeutic goal of eradicating all\n",
      "             known disease with one additional surgery. Portal venous embolization is permitted to\n",
      "             ensure resectability.\n",
      "\n",
      "          -  Prior resection of extra-hepatic metastatic disease allowed if completed more than 12\n",
      "             months previous to study enrollment and now new extra-hepatic disease has been found\n",
      "\n",
      "          -  Have measurable disease based on RECIST 1.1\n",
      "\n",
      "          -  Fresh or archived colorectal cancer tissue, preferably from a hepatic metastatic site.\n",
      "             Archival tissue is acceptable for enrolled into this study. Participants who have no\n",
      "             archival tissue available do not need to undergo a new biopsy solely for the purpose\n",
      "             of this study\n",
      "\n",
      "          -  Participants must have received at least one prior line or chemotherapy including an\n",
      "             irinotecan or oxaliplatin-fluoropyrimidine-based systemic treatment for colorectal\n",
      "             cancer\n",
      "\n",
      "          -  Have performance status of 0 or 1 on the ECOG Performance Scale\n",
      "\n",
      "          -  Demonstrate an adequate organ function as defined in Table 1. These labs should be\n",
      "             repeated if not completed within 10 days of SBRT treatment initiation\n",
      "\n",
      "          -  Female participants of childbearing potential should have a negative urine or serum\n",
      "             pregnancy test within 10 days of initiating SBRT. If the urine test is positive or\n",
      "             cannot be confirmed as negative, a serum pregnancy test will be required\n",
      "\n",
      "          -  Female participants of childbearing potential should be willing to use 2 methods of\n",
      "             birth control or be surgically sterile, or abstain from heterosexual activity for the\n",
      "             course of the study through 120 days after the last dose of study medication\n",
      "             (Reference Section 5.7.2). Participants of childbearing potential are those who have\n",
      "             not been surgically sterilized or have not been free from menses for >1 year\n",
      "\n",
      "          -  Male participant should agree to use an adequate method of contraception starting with\n",
      "             the first dose of study therapy through 120 days after the last dose of study therapy\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Current participation and receiving study therapy or previous participation in a study\n",
      "             of an investigational agent and received study therapy or used an investigational\n",
      "             device within 4 weeks of the initiation of SBRT\n",
      "\n",
      "          -  Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 (first\n",
      "             day of SBRT treatment) or who has not recovered (i.e. < Grade 1 or at baseline) from\n",
      "             adverse events due to agents administered more than 4 weeks earlier\n",
      "\n",
      "          -  Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2\n",
      "             weeks prior to study Day 1 or who has not recovered (i.e. < Grade 1 or at baseline)\n",
      "             from adverse events due to a previously administered agent. Prior radiotherapy to the\n",
      "             liver is not allowed\n",
      "\n",
      "               -  Participants with < Grade 2 neuropathy are an exception to this criterion and may\n",
      "                  qualify for the study\n",
      "\n",
      "               -  If the participant received major surgery, they must have recovered adequately\n",
      "                  from the toxicity and/or complications from the intervention prior to starting\n",
      "                  therapy\n",
      "\n",
      "          -  Participant has a diagnosis of immunodeficiency or is receiving systemic steroid\n",
      "             therapy or any other form of immunosuppressive therapy within 7 days prior to the\n",
      "             initiation of SBRT\n",
      "\n",
      "          -  Participant has a known history of active TB (Bacillus Tuberculosis)\n",
      "\n",
      "          -  Hypersensitivity to pembrolizumab or any of its excipients\n",
      "\n",
      "          -  Participant has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior\n",
      "             to study Day 1 (first day or SBRT treatment) or who has not recovered (i.e., ≤ Grade 1\n",
      "             or at baseline) from adverse events due to agents administered more than 4 weeks\n",
      "             earlier\n",
      "\n",
      "          -  Participant has had prior chemotherapy, targeted small molecule therapy, or radiation\n",
      "             therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1\n",
      "             or at baseline) from adverse events due to a previously administered agent. Prior\n",
      "             radiotherapy to the liver is not allowed. (Notes: Participants with ≤ Grade 2\n",
      "             neuropathy are an exception to this criterion and may qualify for the study. If\n",
      "             participant received major surgery, they must have recovered adequately from the\n",
      "             toxicity and/or complications from the intervention prior to starting therapy.)\n",
      "\n",
      "          -  Participant has a known additional malignancy that is progressing or requires active\n",
      "             treatment. Exceptions include basal cell carcinoma of the skin or squamous cell\n",
      "             carcinoma of the skin that has undergone potentially curative therapy or in situ\n",
      "             cervical cancer.\n",
      "\n",
      "          -  Participant has known active central nervous system (CNS) metastases and/or\n",
      "             carcinomatous meningitis. Participants with previously resected brain metastases may\n",
      "             participate provided it has been at least 6 months and no CNS progression has been\n",
      "             identified.\n",
      "\n",
      "          -  Participant has active autoimmune disease that has required systemic treatment in the\n",
      "             past 2 years (i.e. with use of disease modifying agents, corticosteroids or\n",
      "             immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic\n",
      "             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is\n",
      "             not considered a form of systemic treatment.\n",
      "\n",
      "          -  Participant has known history of, or any evidence of active, non-infectious\n",
      "             pneumonitis.\n",
      "\n",
      "          -  Participant has an active infection requiring systemic therapy.\n",
      "\n",
      "          -  Participant has a history or current evidence of any condition, therapy, or laboratory\n",
      "             abnormality that might confound the results of the trial, interfere with the\n",
      "             participant's participation for the full duration of the trial, or is not in the best\n",
      "             interest of the participant to participate, in the opinion of the treating\n",
      "             investigator.\n",
      "\n",
      "          -  Participant has known psychiatric or substance abuse disorders that would interfere\n",
      "             with cooperation with the requirements of the trial.\n",
      "\n",
      "          -  Participant is pregnant or breastfeeding, or expecting to conceive or father children\n",
      "             within the projected duration of the trial, starting with the pre-screening or\n",
      "             screening visit through 120 days after the last dose of trial treatment.\n",
      "\n",
      "          -  Participant has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2\n",
      "             agent.\n",
      "\n",
      "          -  Participant has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2\n",
      "             antibodies).\n",
      "\n",
      "          -  Participant has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g.,\n",
      "             HCV RNA [qualitative or quantitative] is detected).\n",
      "\n",
      "          -  Participant has received a live vaccine within 30 days of planned start of study\n",
      "             therapy.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All confirmed cases of retinitis pigmentosa\n",
      "\n",
      "          -  VA of 20/400 or better\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Advanced stages of retinitis pigmentosa with poor best corrected visual acuity (less\n",
      "             than 20/400)\n",
      "\n",
      "          -  co-existing eye morbidities interfering with retinitis pigmentosa (glaucoma, retinal\n",
      "             detachment...)\n",
      "\n",
      "          -  Flat electroretinogram\n",
      "\n",
      "          -  Intolerance or counterindication to drug\n",
      "\n",
      "          -  Unability for long-term follow-up\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Men with bone-metastatic CRPC before starting the first dose of radium 223 therapy\n",
      "\n",
      "          -  Laboratory requirements:\n",
      "\n",
      "          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L\n",
      "\n",
      "          -  Platelet count ≥ 100 x109/L\n",
      "\n",
      "          -  Hemoglobin ≥ 10.0 g/dL (100 g/L; 6.2 mmol/L)\n",
      "\n",
      "          -  Total bilirubin level ≤ 1.5 institutional upper limit of normal (ULN)\n",
      "\n",
      "          -  ASAT and ALAT ≤ 2.5 ULN\n",
      "\n",
      "          -  • Creatinine ≤ 1.5 ULN\n",
      "\n",
      "          -  Albumin >25 g/L\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group Status of 0 or 1\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Unable to give valid informed consent\n",
      "\n",
      "          -  Contraindication for MRI as per Sunnybrook MRI questionnaire (Appendix 1).\n",
      "\n",
      "          -  Claustrophobia\n",
      "\n",
      "          -  Body mass index of less than 18.5 or greater than 32\n",
      "\n",
      "          -  Congestive heart failure, a past or present medical history of clinically significant\n",
      "             electrocardiogram (EKG) abnormalities, which may include QT prolongation, a family\n",
      "             history of prolonged QT interval syndrome, or a myocardial infarction (MI) within the\n",
      "             past 12 months with ensuing unstable EKG, or ongoing acute or chronic pulmonary\n",
      "             bronchospastic disease, including a history of chronic obstructive pulmonary disease\n",
      "             or asthma, with an exacerbation within the past year\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Male and female subjects, ages over 18.\n",
      "\n",
      "          2. Subjects with at least one implant with initial peri-implantitis: PPD of 4-6mm\n",
      "             combined with BOP+, bone loss of 0.5-2mm on peri-apical radiographs compared to the\n",
      "             time point of restoration placement.\n",
      "\n",
      "          3. Availability for the 12 month duration of the study.\n",
      "\n",
      "          4. Good general health (ASA classification I-II).\n",
      "\n",
      "          5. Signed Informed Consent Form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Medically compromised subjects (ASA classification III-V)\n",
      "\n",
      "          2. Pregnant or lactating females.\n",
      "\n",
      "          3. Peri-implant mucositis defined as the absence of radiographic marginal bone loss\n",
      "             between restoration placement and pre-screening review.\n",
      "\n",
      "          4. Subjects treated for >2 weeks with any medication known to affect soft tissue\n",
      "             condition (e.g. phenytoin, calcium antagonists, cyclosporin, Coumadin and\n",
      "             non-steroidal anti-inflammatory drugs) within 1 month of the baseline examination.\n",
      "\n",
      "          5. Unwilling to participate in the study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with an upper gastrointestinal metastatic cancer: pancreatic, biliary tract\n",
      "             or gastric (including junctional Siewert 2 and 3 cancers) cancers.\n",
      "\n",
      "        NB: gastrooesophageal junctional cancers with dysphagia and/or gastric/gastrooesophageal\n",
      "        cancers with unknown or positive HER2 status are not eligible.\n",
      "\n",
      "          -  Patients planed to be treated with first-line chemotherapy for metastatic disease.\n",
      "\n",
      "          -  Age ≥ 18 years\n",
      "\n",
      "          -  Life expectancy ≥ 1 month\n",
      "\n",
      "          -  Performance status (OMS) ≤ 2\n",
      "\n",
      "          -  Good understanding of French language\n",
      "\n",
      "          -  Signed and dated informed consent\n",
      "\n",
      "          -  Patients covered by government health insurance\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Locally advanced cancer\n",
      "\n",
      "          -  Junctional Siewert 1 gastrooesophageal cancer\n",
      "\n",
      "          -  Gastric or junctional gastrooesophageal cancer with dysphagia\n",
      "\n",
      "          -  Gastric or junctional gastrooesophageal cancer with unknown or positive HER2 status\n",
      "             (IHC: +++ or IHC ++ and FISH/SISH +)\n",
      "\n",
      "          -  Compression of the biliary tract requiring a bypass\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Weight:18≦ BMI≦25\n",
      "\n",
      "          2. Written informed consent from the patient or the relatives of the participating\n",
      "             patient.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. A previous history of intolerance to the study drug or related compounds and\n",
      "             additives.\n",
      "\n",
      "          2. Existing significant haematological, endocrine, metabolic or gastrointestinal disease.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subject refractory to conventional treatments (tricyclic antidepressants and\n",
      "             benzodiazepines at analgesic doses, biofeedback physical therapy)\n",
      "\n",
      "          -  Negative screening test results\n",
      "\n",
      "          -  Notified associated factors\n",
      "\n",
      "          -  Menopause, surgically sterilized women or women using effective contraceptive method\n",
      "\n",
      "          -  Good understanding and predictable adherence to the protocol\n",
      "\n",
      "          -  beneficiary/affiliated to French social security/social healthcare\n",
      "\n",
      "          -  signed Informed Consent Form\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Predictable poor adherence\n",
      "\n",
      "          -  Pregnant or breastfeeding women\n",
      "\n",
      "          -  Myasthenia\n",
      "\n",
      "          -  Treatment with aminoglycosides\n",
      "\n",
      "          -  Major mental disorders\n",
      "\n",
      "          -  Underlying etiology\n",
      "\n",
      "          -  Vulnerable subjects (particularly adults under guardianship)\n",
      "\n",
      "          -  Any reason deemed relevant by the investigator\n",
      "\n",
      "          -  Current or former (in the last 3 months) participation to another clinical trial\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  21 to 74 years of age\n",
      "\n",
      "          -  BMI≥ 25 kg/m2\n",
      "\n",
      "          -  Self-reported being diagnosed with type 2 diabetes for at least 6 months\n",
      "\n",
      "          -  Currently monitor blood glucose and has a blood glucose meter\n",
      "\n",
      "          -  Be able to read and write in English\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Previously participated in a structured lifestyle intervention, such as Look AHEAD in\n",
      "             the last 12 months\n",
      "\n",
      "          -  Current pregnant /nursing or plan to become pregnant in the next 6 months\n",
      "\n",
      "          -  In addition to their diabetes condition, presence of a current serious illness or\n",
      "             unstable condition requiring supervision on a special diet and limiting their ability\n",
      "             to perform physical activity level.\n",
      "\n",
      "          -  Current treatment for a severe psychological disorder\n",
      "\n",
      "          -  Planned vacation, absences, or relocation in the next 6 months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age range: 18-45. The participant should be a woman of reproductive age, i.e.,\n",
      "             premenopausal who is healthy.\n",
      "\n",
      "          2. Body mass index: 19-35 kg/m2\n",
      "\n",
      "          3. Diagnosis of infertility: inability to conceive with unprotected intercourse after 1\n",
      "             year for women aged < 35 and after 6 months for women aged > 35.\n",
      "\n",
      "          4. Pap smear within 1 year should be normal.\n",
      "\n",
      "          5. Endometrial cavity will be evaluated and should be normal using hysteroscopy or saline\n",
      "             ultrasound\n",
      "\n",
      "          6. Fallopian tubes will be assessed by hysterosalpingogram in women who have normal\n",
      "             ovarian reserve, regular menstrual cycles with a partner who has normal semen\n",
      "             analysis. Unless there is a clear diagnosis of a reason for infertility, such as poor\n",
      "             sperm, poor ovarian reserve, fallopian tube patency will not be performed because it\n",
      "             would not change the treatment.\n",
      "\n",
      "          7. Semen analysis will be performed on every male partner to ensure that there are sperm\n",
      "             to be used for IVF/ICSI.\n",
      "\n",
      "          8. All assessment will be performed at baseline and before initiation of any treatment.\n",
      "\n",
      "          9. The investigators will obtain at screening Pap smear, hysteroscopy or saline\n",
      "             ultrasound, hysterosalpingography, and semen analysis if they have not been done\n",
      "             within one year of baseline.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Any medical condition that interferes with the health of the participant such as\n",
      "             uncontrolled diabetes, uncontrolled hypertension, cardiac disease, or renal disease.\n",
      "\n",
      "          2. Any type of malignancy.\n",
      "\n",
      "          3. Mental problems that could interfere with the patient's ability to conceive and take\n",
      "             care of her baby.\n",
      "\n",
      "          4. Abnormal endometrial cavity that could interfere with implantation and/or carrying the\n",
      "             pregnancy.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Fagerström score ≥ 5\n",
      "\n",
      "          -  Q-MAT score ≥ 6\n",
      "\n",
      "          -  smoking subjects from 10 to 30 cigarettes a day\n",
      "\n",
      "          -  right-handed subjects\n",
      "\n",
      "          -  w/o severe progressive somatic pathology (especially tumor diseases, degenerative\n",
      "             diseases)\n",
      "\n",
      "          -  Hamilton Depression Rating Scale-17 score <18\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  pregnancy and/or lactation\n",
      "\n",
      "          -  presence of a specific contraindication for tDCS (e.g. personal history of epilepsy,\n",
      "             metallic head implant, cardiac pacemaker...)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Signed informed consent\n",
      "\n",
      "          -  Age ≥18 years\n",
      "\n",
      "          -  Histologically or cytologically confirmed salivary glands cancer\n",
      "\n",
      "          -  At least, one target lesion defined as RECIST 1.1 (clear progression of disease is\n",
      "             required in the presence of one target lesion previously treated with radiotherapy\n",
      "\n",
      "          -  Clinical and/or radiological progression of disease on ADT\n",
      "\n",
      "          -  Ongoing androgen deprivation with a serum testosterone level of less than 50 ng per\n",
      "             deciliter (1.7 nmol per liter)\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2\n",
      "\n",
      "          -  Adequate bone marrow function: Neutrophils > 1.5 x 109/L; Hemoglobin ≥ 9.0 g/dL\n",
      "             independent of transfusion and platelet count ≥ 100,000/μL\n",
      "\n",
      "          -  No limits are required for the number of previous chemotherapy lines\n",
      "\n",
      "          -  Serum albumin ≥ 3.0 g/dL\n",
      "\n",
      "          -  Serum creatinine <1.5 x upper limit of normal (ULN) or a calculated creatinine\n",
      "             clearance ≥ 60 mL/min\n",
      "\n",
      "          -  Serum potassium ≥3.5 mmol/L\n",
      "\n",
      "          -  Able to swallow the study drug whole as a tablet\n",
      "\n",
      "          -  Patients with treated brain metastases, stable within the last three months, are\n",
      "             allowed\n",
      "\n",
      "          -  Subjects who have partners of childbearing potential must use a method of birth\n",
      "             control with adequate barrier protection as determined to be acceptable by the\n",
      "             investigator and for 13 weeks after last study drug administration\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Received abiraterone acetate within the last 5 years\n",
      "\n",
      "          -  Serious or uncontrolled co-existent non-malignant disease, including active and\n",
      "             uncontrolled infection\n",
      "\n",
      "          -  Abnormal liver functions consisting of any of the following:\n",
      "\n",
      "          -  Serum bilirubin ≥ 1.5 x ULN (except for subjects with documented Gilbert's disease,\n",
      "             for whom the upper limit of serum bilirubin is 3 mg/dL)\n",
      "\n",
      "          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2.5 x ULN\n",
      "\n",
      "          -  Patients with ALT and/or AST not exceeding 5 x ULN due to liver mets can be enrolled\n",
      "\n",
      "          -  Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood\n",
      "             pressure ≥95 mmHg); subjects with a history of hypertension are allowed provided blood\n",
      "             pressure is controlled by anti-hypertensive therapy\n",
      "\n",
      "          -  Active or symptomatic viral hepatitis or chronic liver disease\n",
      "\n",
      "          -  History of pituitary or adrenal dysfunction\n",
      "\n",
      "          -  Clinically significant heart disease as evidenced by myocardial infarction, or\n",
      "             arterial thrombotic events in the past 6 months, severe or unstable angina, or New\n",
      "             York Heart Association (NYHA) Class III or IV heart disease or left ventricular\n",
      "             ejection fraction (LVEF) of <50% at baseline\n",
      "\n",
      "          -  History of gastrointestinal disorders (medical disorders or extensive surgery) that\n",
      "             may interfere with the absorption of the study drug\n",
      "\n",
      "          -  Any acute toxicities due to prior chemotherapy or radiotherapy that have not resolved\n",
      "             to a NCI-CTCAE (Version 4.0) Grade of ≤1\n",
      "\n",
      "          -  Participation in clinical trials with other experimental agents within 30 days of\n",
      "             study entry or concomitant treatment with other experimental drug\n",
      "\n",
      "          -  Previous or concurrent cancer that is distinct in primary site or histology from the\n",
      "             cancer being evaluated in this study except cervical carcinoma in situ, treated basal\n",
      "             cell carcinoma, superficial bladder tumors (Ta, Tis and T1) or any cancer curatively\n",
      "             treated > 3 years prior to study entry\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Low-risk and intermediate-risk AML Subjects (or their legally acceptable representatives)\n",
      "        must have signed an informed consent document indicating that they understand the purpose\n",
      "        of and procedures required for the study and are willing to participate in the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n",
      "        Patients with any conditions not suitable for the trial (investigators' decision)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        - Chest indrawing pneumonia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Convulsions\n",
      "\n",
      "          -  Cough for 14 days or more\n",
      "\n",
      "          -  Blood in stool\n",
      "\n",
      "          -  Fever for last 7 days or more\n",
      "\n",
      "          -  Diarrhoea for 14 days or more\n",
      "\n",
      "          -  Not able to drink or feed anything\n",
      "\n",
      "          -  Unusually sleepy or unconscious\n",
      "\n",
      "          -  Vomits everything\n",
      "\n",
      "          -  Swelling of both feet\n",
      "\n",
      "          -  Red on MUAC strap (severe acute malnutrition)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Active SLE disease，and at least according with 4 of the 11 items of the American\n",
      "             College of Rheumatology (ACR) criteria 1997.\n",
      "\n",
      "          -  Age & Gender: Male or female between 18 and 65 years of age inclusive，and the sex\n",
      "             ratio is not limited\n",
      "\n",
      "          -  Signed informed consent form，willing or able to participate in all required study\n",
      "             evaluations and procedures.\n",
      "\n",
      "          -  SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE\n",
      "             Disease Activity Index) score ≥ 8 during the screening period.and if there is\n",
      "             hypocomlement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be\n",
      "             at least 6 at screening .\n",
      "\n",
      "          -  Autoantibody-positive\n",
      "\n",
      "          -  on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted\n",
      "             of any of the following (alone or in combination): cortical\n",
      "             hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any\n",
      "             immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate\n",
      "             ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin ).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Severe lupus nephritis within two months(designed as:Urine protein>6g/24h or serum\n",
      "             creatinine ( SCr）>2.5mg/dL or 221umol/L ) or needing for hemodialysis or recepting\n",
      "             high dose cortical hormone ≥14 days( metacortandracin>100mg/d or equivalent)\n",
      "\n",
      "          -  Central nervous system disease caused by SLE or non SLE within two months (including\n",
      "             epilepsy， mental disease，organic encephalopathy syndrome，cerebrovascular accident,\n",
      "             encephalitis, central nervous system vasculitis）;\n",
      "\n",
      "          -  there are serious heart, liver, kidney and other important organs and blood, endocrine\n",
      "             system diseases and medical history;\n",
      "\n",
      "        Evaluation criteria for severity :\n",
      "\n",
      "          1. Alanine aminotransferase（ALT）or aspartate aminotransferase (AST) ≥2 upper limit of\n",
      "             normal (ULN);\n",
      "\n",
      "          2. Creatinine Clearance (Ccr)<30ml/min;\n",
      "\n",
      "          3. White Blood Cell Count(WBCs)<2.5x 10(9)/L;\n",
      "\n",
      "          4. hemoglobin<85g/L;\n",
      "\n",
      "          5. Platelets<50x 10(9)/L.\n",
      "\n",
      "               -  Have a historically active hepatitis or active hepatitis or medical\n",
      "                  history,hepatitis B :Patients with positive HBsAg are excluded.;Hepatitis C:\n",
      "                  Patients with hepatitis C antibody positive are excluded;\n",
      "\n",
      "               -  Immune deficiency, uncontrolled severe infection and patients with active or\n",
      "                  recurrent peptic ulcer;\n",
      "\n",
      "               -  Pregnant , lactating women and men or women who have birth plans in the past 12\n",
      "                  months ;\n",
      "\n",
      "               -  Have a history of allergic reaction to human biological medicines.\n",
      "\n",
      "               -  Receipt of live vaccine within 1 month;\n",
      "\n",
      "               -  Have participated in any clinical trial in the first 28 days of the initial\n",
      "                  screening or 5 times half-life period of the study compound (taking the time for\n",
      "                  the elderly).\n",
      "\n",
      "               -  Have received treatment with B cell targeted therapy such as Rituximab or\n",
      "                  Epratuzumab etc.\n",
      "\n",
      "               -  Receipt of anti-tumor necrosis factor、interleukin receptor antagonist；\n",
      "\n",
      "               -  Receipt of IV immunoglobulin（IVIG）,prednisone>100mg/d more than 14 days or plasma\n",
      "                  exchange;\n",
      "\n",
      "               -  There are active infections (such as herpes zoster, human immunodeficiency virus\n",
      "                  (HIV) virus infection, active tuberculosis, etc.) during the screening period;\n",
      "\n",
      "               -  Patients have depression or the significant suicide ideation;\n",
      "\n",
      "               -  Investigator considers candidates not appropriating for the study.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age 18 years or older\n",
      "\n",
      "          2. Smoke at least five cigarettes per day\n",
      "\n",
      "          3. Have an expired carbon monoxide level of more than 8 ppm or a urinary cotinine level\n",
      "             of more than 100 ng per milliliter\n",
      "\n",
      "          4. Have a Fagerström Test for Nicotine Dependence score of at least 5 upon screening\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. The intention to quit smoking in the next 30 days\n",
      "\n",
      "          2. The use of other tobacco products in addition to machine-manufactured cigarettes on\n",
      "             more than 9 of the previous 30 days\n",
      "\n",
      "          3. Use of \"roll your own\" cigarettes as an exclusive form of smoking\n",
      "\n",
      "          4. A serious medical or psychiatric disorder or unstable condition\n",
      "\n",
      "          5. Any positive toxicological screening for illicit drugs other than cannabis will be\n",
      "             excluded\n",
      "\n",
      "          6. Women who are pregnant, plan to become pregnant or are breast-feeding\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  age older than 18 years\n",
      "\n",
      "          -  requirement of invasive mechanical ventilation for more than 4 hours and less than 12\n",
      "             hours\n",
      "\n",
      "          -  severe hypoxemia (PAFI < 200) secondary to ARDS or post-operatory atelectasis\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        -requirement of invasive mechanical ventilation prior to enrollment in this study\n",
      "      \n",
      "\n",
      "        Wards\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  ≥20% of oncology patients\n",
      "\n",
      "          -  pre-selection by nursing director and clinical nurse specialists\n",
      "\n",
      "          -  willing to participate\n",
      "\n",
      "        Patients\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  admission to one of the participating wards\n",
      "\n",
      "          -  cancer-related pain ≥3 on 11-point numeric rating scale within the last week or\n",
      "\n",
      "          -  have regular pain medication because of cancer-related pain\n",
      "\n",
      "          -  are able to read and write German\n",
      "\n",
      "          -  likely to be discharged with pain self-management\n",
      "\n",
      "          -  willing to participate\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  if patients are showing signs of disorientation that may limit their ability to\n",
      "             perform pain self-management at home as assessed by staff nurse\n",
      "      \n",
      "\n",
      "        Patients with Parkinsons disease and dry eye attributed to meibomian gland dysfunction\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Medical diagnosis of Parkinsons disease\n",
      "\n",
      "          -  > 18 years-old\n",
      "\n",
      "          -  Reported dry eye symptoms within 3 months of baseline examination with a Standard\n",
      "             Patient Evaluation for Eye Dryness (SPEED) score ≥ 6 at baseline visit\n",
      "\n",
      "          -  Evidence of meibomian gland obstruction (based on a total meibomian gland secretion\n",
      "             score of ≤ 12 for 15 glands of the lower lid)\n",
      "\n",
      "          -  Willingness to stop dry eye medications including antibiotics, non-steroidal and\n",
      "             anti-inflammatory drugs, and corticosteroids for 2 weeks prior to treatment and during\n",
      "             the duration of the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Active intraocular inflammation\n",
      "\n",
      "          -  Ocular surface abnormality that could potentially compromise corneal integrity in\n",
      "             either eye\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  pediatric patient for scheduled surgery\n",
      "\n",
      "          -  from 8 to 30 kg of weight\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  denied from the child or their parents\n",
      "\n",
      "          -  congenital cardiopathy\n",
      "\n",
      "          -  cardiovascular shunt\n",
      "\n",
      "          -  respiratory dysfunction\n",
      "\n",
      "          -  hepatic dysfunction\n",
      "\n",
      "          -  renal dysfunction\n",
      "\n",
      "          -  intracranial hypertension\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  women\n",
      "\n",
      "          -  age ≥ 18 and <80 years old\n",
      "\n",
      "          -  invasive or in situ breast carcinoma\n",
      "\n",
      "          -  non-metastatic disease.\n",
      "\n",
      "          -  postoperative radiotherapy completed since at least 6 months\n",
      "\n",
      "          -  unilateral breast radiotherapy\n",
      "\n",
      "          -  grade > 2 dermal and/or soft tissue toxicity (CTCAE v4.0)\n",
      "\n",
      "          -  no inflammatory ou infectious flare on the breast at the time of inclusion\n",
      "\n",
      "          -  ability to provide an informed written consent form\n",
      "\n",
      "          -  affiliation to a social security system\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  age <18 or ≥ 80 years old\n",
      "\n",
      "          -  evolutive cancer\n",
      "\n",
      "          -  Metastatic Disease\n",
      "\n",
      "          -  Patient undergoing specific treatment for breast cancer (except adjuvant endocrine\n",
      "             therapy and / or adjuvant Herceptin) at the time of inclusion\n",
      "\n",
      "          -  bilateral Breast/chest wall Radiotherapy\n",
      "\n",
      "          -  breast prosthesis bearer\n",
      "\n",
      "          -  Body Mass Index > 40 or <18.5\n",
      "\n",
      "          -  chronic skin ulceration within the treated breast at the time of inclusion\n",
      "\n",
      "          -  contraindications to spa care :\n",
      "\n",
      "               -  inflammatory disease in flare at the time of inclusion\n",
      "\n",
      "               -  active infections\n",
      "\n",
      "               -  heart failure (NYHA class> 1)\n",
      "\n",
      "               -  chronic respiratory failure\n",
      "\n",
      "               -  labile blood pressure\n",
      "\n",
      "               -  bullous dermatitis\n",
      "\n",
      "          -  evolutive chronic skin disease\n",
      "\n",
      "          -  hypersensitivity to pentoxifylline or any of the excipients\n",
      "\n",
      "          -  acute myocardial infarction\n",
      "\n",
      "          -  ongoing hemorrhage or major bleeding risk\n",
      "\n",
      "          -  use of oral anticoagulants\n",
      "\n",
      "          -  pregnant or likely to be in 6 months or breastfeeding\n",
      "\n",
      "          -  patients deprived of liberty or under supervision\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Children aged 2-17 years old\n",
      "\n",
      "          2. Receiving oral voriconazole as standard of care and at steady-state concentrations\n",
      "             (defined as 72 hours from first-dose or 72 hours with no dose change)\n",
      "\n",
      "          3. Informed Consent/Assent when appropriate\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Allergy or inability to receive the slushy solution, which will be prepared using\n",
      "             commercially available frozen grapefruit juice concentrate, cherry syrup, and Sprite.\n",
      "\n",
      "          2. Receiving tacrolimus and/or cyclosporine, which are affected by the furanocoumarins,\n",
      "             during study period\n",
      "\n",
      "          3. Suspected or known hepatic dysfunction (defined as liver function tests measured at 3x\n",
      "             upper limit of normal within the past 1 month, when measured as standard of care)\n",
      "\n",
      "          4. Receiving renal replacement therapy (example peritoneal dialysis, hemodialysis,\n",
      "             continuous veno-venous hemofiltration, continuous veno-venous hemodialysis)\n",
      "\n",
      "          5. Receiving therapy with extracorporeal membrane oxygenation (ECMO)\n",
      "\n",
      "          6. Patients with documented pancytopenia, diarrhea, mucositis, or active infection\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with pre-existing paroxysmal, persistent or chronic atrial fibrillation,\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with pre-existing inflammatory state: sepsis undergoing treatment, acute\n",
      "             kidney injury within 5 days, chronic inflammatory disease, congestive heart failure.\n",
      "\n",
      "          -  Emergency or salvage procedure.\n",
      "\n",
      "          -  Ejection fraction <30 %.\n",
      "\n",
      "          -  Patient in a critical preoperative state (Kidney Disease: Improving Global Outcomes\n",
      "             (KDIGO) Stage 3 AKI [20] or requiring inotropes, ventilation or intra-aortic balloon\n",
      "             pump).\n",
      "\n",
      "          -  Pregnancy.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subject was included in the CS-03 study\n",
      "\n",
      "          -  Subject indicated for a de novo pulse generator implant\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subject was excluded from the CS-03 study\n",
      "\n",
      "          -  Subject is not 100% dependent on RV pacing\n",
      "\n",
      "          -  Subject receiving a pacemaker pulse generator exchange\n",
      "\n",
      "          -  Subject is unwilling or cannot provide Informed Consent for this sub study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  known bicuspid aortic valve\n",
      "\n",
      "          -  calcified mild to moderate aortic valve stenosis on prior echocardiography\n",
      "\n",
      "          -  informed consent provided\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  absence of calcified aortic valve stenosis on echocardiography\n",
      "\n",
      "          -  presence of severe aortic valve stenosis\n",
      "\n",
      "          -  history of aortic valve repair or replacement\n",
      "\n",
      "          -  accepted atrial fibrillation\n",
      "\n",
      "          -  use of oral anticoagulants\n",
      "\n",
      "          -  claustrophobia\n",
      "\n",
      "          -  presence of a pacemaker, ICD or ferromagnetic materials in the body\n",
      "\n",
      "          -  life expectancy <2 years\n",
      "\n",
      "          -  Pregnancy (current or wish for near future)\n",
      "\n",
      "          -  soy allergy\n",
      "\n",
      "          -  use of vitamin K-containing supplements\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Up to diagnostic criteria for relapsed or refractory neuroblastoma or high-risk\n",
      "             patients，including:\n",
      "\n",
      "               -  Relapsed neuroblastoma : Children diagnosed with neuroblastoma who after standard\n",
      "                  treatment and remission, present lesions again and cannot reach complete\n",
      "                  remission with surgery.\n",
      "\n",
      "               -  Refractory neuroblastoma : ① Untreated patients that do not have to reach\n",
      "                  completes remission after 4 courses of chemotherapy in accordance with standard\n",
      "                  regimens nor reach complete remission with surgery. ② High-risk patients : Who\n",
      "                  have cell genetic variation, such as MYCN amplification or bone marrow\n",
      "                  metastasis.\n",
      "\n",
      "          2. Relapsed or Refractory Neuroblastoma: Target, of which expression may be intervened ,\n",
      "             discovered with Immunohistochemistry can be selected (GD2 +) (more than 50% of tumor\n",
      "             cells is at least 2+ , adopting anti-GD2-mAb14G2a ).\n",
      "\n",
      "          3. Age: 1~14 years old of age at the time of enrollment, male or female.\n",
      "\n",
      "          4. Physical condition is good: ECOG score reaches 0 to 2 points.\n",
      "\n",
      "          5. Body weights greater than or equal to 10 kg.\n",
      "\n",
      "          6. White blood cell counts acuity≥ 1.0 x10^9 / L.\n",
      "\n",
      "          7. Estimated survival times > 90 days.\n",
      "\n",
      "          8. Voluntary participation, good compliance, can cooperate with the experimental\n",
      "             observation and signed an informed consent form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Positive pregnancy tests.\n",
      "\n",
      "          2. Uncontrolled infection.\n",
      "\n",
      "          3. HIV infection, hepatitis B or C activity period.\n",
      "\n",
      "          4. Patients who need long-term immunosuppressive therapy (Such as allergies, autoimmune\n",
      "             diseases, GVHD, etc.)\n",
      "\n",
      "          5. Combined activity of the central nervous system malignant tumor invasion.\n",
      "\n",
      "          6. Abnormal coagulation function, patients with severe thrombosis.\n",
      "\n",
      "          7. Organ failure\n",
      "\n",
      "               1. Heart：class Ⅱ or above.\n",
      "\n",
      "               2. Liver：class Ⅱ or above( Refer to Classification of Wuhan Conference (1983)).\n",
      "\n",
      "               3. Kidney: The second stage of renal insufficiency or above.\n",
      "\n",
      "               4. Lung: class Ⅱdecreased slightly or above.\n",
      "\n",
      "               5. Brain: The central nervous system transfer or have active lesions.\n",
      "\n",
      "          8. Patients who have participated in other clinical trials or other clinical trials in\n",
      "             the past 30 days.\n",
      "\n",
      "          9. The researchers believe that the patient is not suitable to participate in the study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        All subjects meet the standards of sepsis 3.0 diagnostic criteria for the diagnosis of\n",
      "        sepsis.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        The following situations can not occur when all subjects are enrolled\n",
      "\n",
      "          1. Age> 80 years or <18 years\n",
      "\n",
      "          2. Chronic renal insufficiency, renal transplantation\n",
      "\n",
      "          3. Blood purification treatment\n",
      "\n",
      "          4. AKI has occurred\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients who give informed consent\n",
      "\n",
      "          -  Patients on the community nurses caseload\n",
      "\n",
      "          -  Patients with long-term conditions\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any inclusion criteria not met\n",
      "\n",
      "          -  Patients who are not expected to be seen more than three times\n",
      "\n",
      "          -  Less than 18 years old.\n",
      "\n",
      "          -  Patients who are unable to complete the questionnaire in English.\n",
      "\n",
      "          -  Patients who through physical or psychological conditions do not have the potential to\n",
      "             contribute to their own care, as decided by the community nurse.\n",
      "\n",
      "          -  Patients who are unable to give informed consent.\n",
      "\n",
      "          -  Those who hold their own health budget or are part of the proactive care programme\n",
      "\n",
      "          -  Patients who are at the end of life.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Exposure to at least one traumatic event and endorsement of any trauma symptoms on the\n",
      "             UCLA PTSD Reaction Index for DSM-V\n",
      "\n",
      "          2. Ages 7-18\n",
      "\n",
      "          3. Willingness to participate in therapy and fNIRs imaging\n",
      "\n",
      "          4. Caregiver willing to participate in the study\n",
      "\n",
      "          5. Perpetrator of the traumatic event is not living in the home with the child\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Low cognitive functioning (IQ less than 70)\n",
      "\n",
      "          2. Substance dependence as defined by DSM criteria\n",
      "\n",
      "          3. Autism/Schizophrenia\n",
      "\n",
      "          4. Clinically significant medical illness\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 18 years or older\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Use of a cardiac pacemaker, an implantable cardioverter-defibrillator (ICD) or any\n",
      "             other active implants\n",
      "      \n",
      "\n",
      "        Inclusion criteria\n",
      "\n",
      "          1. Aged 18-75 years, male and female;\n",
      "\n",
      "          2. Patients diagnosed as coronary disease, scheduled to receive CABG;\n",
      "\n",
      "          3. BMI: 18.5kg/m2<BMI≤30kg/m2；\n",
      "\n",
      "          4. Graded as I-III by American Standards Association(ASA);\n",
      "\n",
      "          5. Patients firstly receiving CABG under extracorporeal circulation.\n",
      "\n",
      "        Exclusion Criteria\n",
      "\n",
      "          1. Presence of surgical incision or scar at Zusanli acupoint (ST36) /Shenshu (BL23)\n",
      "             acupoint;\n",
      "\n",
      "          2. Patients with local skin infection at acupoint;\n",
      "\n",
      "          3. Patients with nerve injury on upper or lower limbs;\n",
      "\n",
      "          4. Patients with history of spinal surgery;\n",
      "\n",
      "          5. Patients who have participated in other clinical trial in recent 4 weeks;\n",
      "\n",
      "          6. Patients using pacemaker;\n",
      "\n",
      "          7. Patients combined with pain before surgery who are using central analgesic drug or\n",
      "             drug abuser (e.g., opioid) and dependent user;\n",
      "\n",
      "          8. Patients combined with severe central nervous system disease or severe mental disease;\n",
      "\n",
      "          9. Patients with alcoholic history;\n",
      "\n",
      "         10. Patients who have received emergent coronary bypass operation due to acute myocardial\n",
      "             infarction.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  All patient at Lindesbergs hospital that get bariatric surgery (a limit to get the\n",
      "             surgery is BMI above 35)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Not understanding Swedish or English\n",
      "\n",
      "          -  Not the first bariatric surgery\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  within one month of acute stroke\n",
      "\n",
      "          -  receive total hip/knee replacement within two to four weeks before\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  cannot perform from sitting to standing\n",
      "\n",
      "          -  Body Mass Index > 30\n",
      "\n",
      "          -  Lower limbs fracture history\n",
      "\n",
      "          -  Diabetic polyneuropathy\n",
      "\n",
      "          -  Cardiopulmonary diseases that impede exercise prescription\n",
      "\n",
      "          -  Impaired cognitive function\n",
      "\n",
      "          -  Infectious disease during the study period that may cause cytokine changes\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must show no signs of spontaneous dental pain.\n",
      "\n",
      "          -  Male or female patients between the ages of 18 to 40.\n",
      "\n",
      "          -  Patients with good general and oral health.\n",
      "\n",
      "          -  Patients having six caries-free maxillaryanterior teeth without restorations on the\n",
      "             labial surfaces.\n",
      "\n",
      "          -  Patients should have central incisors determined to be shade C2 or darker\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patient with spontaneous dental pain.\n",
      "\n",
      "          -  Patient with anterior restorations or non carious cervical lesion.\n",
      "\n",
      "          -  Patient having severe internal tooth discoloration (tetracycline stains, fluorosis,\n",
      "             pulpless teeth), and bruxism habits.\n",
      "\n",
      "          -  Tempro-mandibular joint problems involving symptomatic pain.\n",
      "\n",
      "          -  Patients taking analgesics that could alter their normal pain perception level.\n",
      "\n",
      "          -  Pregnant or breast feeding women.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Single pregnancies with once cesarean section history\n",
      "\n",
      "          -  see a doctor before gestational 8 weeks in our study center\n",
      "\n",
      "          -  will continue to pregnancy, high patient compliance\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  twins or multiple pregnancies\n",
      "\n",
      "          -  hysteromyoma or adenomyoma stripping history\n",
      "\n",
      "          -  history of intrauterine adhesions\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  history of smoking\n",
      "\n",
      "          -  Do not currently smoke and no one currently smokes inside the home\n",
      "\n",
      "          -  history of exacerbation or development of respiratory symptoms (e.g.cough, sputum\n",
      "             production, chest tightness, exertional dyspnea, etc.) with periods of high outdoor\n",
      "             air pollution (\"inversions\")\n",
      "\n",
      "          -  Age 40 or older\n",
      "\n",
      "          -  Access to Wi-Fi\n",
      "\n",
      "          -  Access to a cell phone, tablet or personal computer\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  active tobacco use of subject\n",
      "\n",
      "          -  active tobacco use in the home\n",
      "\n",
      "          -  pre-existing use of a HEPA filter in the subject's bedroom\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Group 1 Non CRRT\n",
      "\n",
      "          -  Diagnosis of systemic infection known or suspected to be caused by an organism\n",
      "             susceptible to ceftolozane-tazobactam\n",
      "\n",
      "          -  Age more than 18 years\n",
      "\n",
      "          -  The treating clinician considers Ceftolozane-tazobactam to be an appropriate agent to\n",
      "             treat the infection Group 2 CRRT\n",
      "\n",
      "          -  Diagnosis of systemic infection known or suspected to be caused by an organism\n",
      "             susceptible to ceftolozane-tazobactam\n",
      "\n",
      "          -  Age more than18 years\n",
      "\n",
      "          -  Prescribed to receive CRRT\n",
      "\n",
      "          -  The treating clinician considers Ceftolozane-tazobactam to be an appropriate agent to\n",
      "             treat the infection\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Group 1 Non CRRT\n",
      "\n",
      "          -  Renal dysfunction that necessitates the use of renal replacement therapy\n",
      "\n",
      "          -  Known or suspected allergy to cephalosporins\n",
      "\n",
      "          -  Receipt of any Pipercillin-Tazobactam for the treatment of this current infection.\n",
      "\n",
      "          -  Pregnancy Group 2 CRRT\n",
      "\n",
      "          -  Known or suspected allergy to cephalosporins\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Receipt of any Pipercillin-Tazobactam for the treatment of this current infection\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of Congenital Dyserythropoietic Anemia (CDA), whether a genetic mutation is\n",
      "             identified or not\n",
      "\n",
      "          -  Evidence of congenital anemia/jaundice or a positive family history\n",
      "\n",
      "          -  Evidence of ineffective erythropoiesis\n",
      "\n",
      "          -  Typical morphological appearance of bone marrow erythroblasts\n",
      "\n",
      "          -  All ages (ages 0-99)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of cancer\n",
      "\n",
      "          -  Myelodysplasia\n",
      "\n",
      "          -  Secondary dyserythropoiesis: e.g.; vitamin B12 deficiency or drug-related.\n",
      "\n",
      "        Note1: Patients with rare band 3 (SLC4A1) mutations recently described to be associated\n",
      "        with dyserythropoiesis will be eligible since the mechanisms appear to involve direct\n",
      "        participation of band 3 in the erythroblast mitosis and cytokinesis.\n",
      "\n",
      "        Note2: Siblings, parents, and family members of patients with confirmed CDA diagnosis are\n",
      "        encouraged to participate in the study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Children between 5-11 years of age, inclusive, at enrollment.\n",
      "\n",
      "          -  Participant must have a current diagnosis of persistent asthma.\n",
      "\n",
      "          -  Parent/legal guardian must provide written informed consent and subject must provide\n",
      "             assent as appropriate for age prior to initiation of study procedures and according to\n",
      "             local Institutional Review Board (IRB) requirement.\n",
      "\n",
      "          -  Parent/legal guardian and subject must be willing and able to comply with planned\n",
      "             study procedures and be available for all study visits.\n",
      "\n",
      "          -  Children aged 5-8 years must have received at least 2 doses of seasonal trivalent or\n",
      "             quadrivalent influenza vaccine prior to the current influenza season. Children 9-11\n",
      "             years must have received at least 1 dose of seasonal trivalent or quadrivalent\n",
      "             influenza vaccine prior to the current influenza season.\n",
      "\n",
      "          -  Is in good health, other than their asthma, as determined by medical history and\n",
      "             targeted physical examination based on medical history.\n",
      "\n",
      "          -  English or Spanish literate.\n",
      "\n",
      "          -  Intention of being available for entire study period and complete all relevant study\n",
      "             procedures, including follow-up phone calls and collection of information.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Acute illness and/or a reported oral temperature of ≥ 100.4°F within 72 hours prior to\n",
      "             enrollment (this may result in a temporary delay of vaccination.\n",
      "\n",
      "          -  Use of antipyretic medication during the preceding 24 hours that might mask a fever\n",
      "             (temporary deferral).\n",
      "\n",
      "          -  History of a severe allergic reaction (e.g., anaphylaxis) to any component of study\n",
      "             influenza vaccines or a known allergy to eggs.\n",
      "\n",
      "          -  Receipt of any licensed vaccine within 14 days (for inactivated vaccines) or 28 days\n",
      "             (for live vaccines) prior to vaccination or planned receipt of any licensed vaccine\n",
      "             within 42 days after vaccination.\n",
      "\n",
      "          -  Receipt of current year's licensed influenza vaccine.\n",
      "\n",
      "          -  Received an investigational agent (licensed or unlicensed vaccine, drug, biologic,\n",
      "             device, blood product, or medication) in the 28 days prior to enrollment or planned\n",
      "             receipt before 42 days after vaccination.\n",
      "\n",
      "          -  Has immunosuppression as a result of an underlying illness or treatment, or use of\n",
      "             anticancer chemotherapy or radiation therapy within the preceding 36 months.\n",
      "\n",
      "          -  Has taken ≥ 20mg/day of prednisone or its equivalent, for 14 days or more within the\n",
      "             past 28 days.\n",
      "\n",
      "          -  Has know active neoplasm or a history of any hematologic malignancy.\n",
      "\n",
      "          -  Has had a previous exacerbation of their asthma symptoms requiring systemic steroids\n",
      "             within the prior 28 days, or has had a life-threatening exacerbation of asthma in the\n",
      "             past two years (e.g. hypoxic seizure, mechanical ventilation).\n",
      "\n",
      "          -  History of Guillian-Barre syndrome within 6 weeks of previous influenza vaccination.\n",
      "\n",
      "          -  Has any condition that, in the opinion of the investigator, would interfere with the\n",
      "             evaluation of the responses or would place the participant at unacceptable risk of\n",
      "             injury.\n",
      "\n",
      "          -  Has any diagnosis, current or past, of schizophrenia, bipolar disease, or other major\n",
      "             psychiatric disorder.\n",
      "\n",
      "          -  Currently taking aspirin or aspirin-containing products.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  class 1-3 per American Society Anesthesiologists Physical Status Classification\n",
      "\n",
      "          -  Subject signed Informed Concent Form\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Unresolved pulmonary infection requiring active treatment\n",
      "\n",
      "          -  Chronic pulmonary disease\n",
      "\n",
      "          -  Any othe medical condition, that treating physician determines participating in the\n",
      "             study is unadvisable\n",
      "      \n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          -  Aged between 21 and 50 years\n",
      "\n",
      "          -  BMI < 30 kg/m2\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  Individuals whose body weight has changed more than 5 kilograms in the last 12 months\n",
      "\n",
      "          -  People who are taking insulin or medications known to affect glucose metabolism,\n",
      "             appetite or energy metabolism\n",
      "\n",
      "          -  Individuals who are currently dieting\n",
      "\n",
      "          -  People with intolerances or allergies to study foods or test products, e.g. soya,\n",
      "             wheat, gluten, cereal, fruits, biscuits, dairy products, rice, vegetable, meat,\n",
      "             seafood, sugar and sweetener, gelatin, natural food colourings or flavourings, etc\n",
      "\n",
      "          -  Pregnant women\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Be willing and able to provide written informed consent/assent for the trial.\n",
      "\n",
      "          2. Be > or = 21 years of age on day of signing informed consent.\n",
      "\n",
      "          3. Histologically proven invasive breast carcinoma with triple negative receptor status\n",
      "             (Estrogen receptor, Progesterone receptor and HER2 negative by IHC and FISH). Patients\n",
      "             who are weekly positive for the estrogen or progesterone receptor (i.e., < or = 10%)\n",
      "             are eligible.\n",
      "\n",
      "          4. Clinically ≤ 3 cm unifocal lesion by imaging or physical examination.\n",
      "\n",
      "          5. Clinically node negative, no evidence of metastatic disease.\n",
      "\n",
      "          6. No prior chemotherapy, radiation therapy, or breast resection within 6 months of study\n",
      "             entry.\n",
      "\n",
      "          7. Breast size B cup or larger, to allow for IORT procedure.\n",
      "\n",
      "          8. Have a performance status of 0 or 1 on the ECOG Performance Scale.\n",
      "\n",
      "          9. Demonstrate adequate organ function.\n",
      "\n",
      "         10. Female subject of childbearing potential should have a negative urine or serum\n",
      "             pregnancy within 72 hours prior to receiving the first dose of study medication. If\n",
      "             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test\n",
      "             will be required.\n",
      "\n",
      "         11. Female subjects of childbearing potential must be willing to use an adequate method of\n",
      "             contraception for the course of the study through 120 days after the last dose of\n",
      "             study medication.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Multifocal disease within the breast.\n",
      "\n",
      "          2. Has primary lesion > 3 cm in size radiographically or by physical examination.\n",
      "             Pathologically proven nodal disease at diagnosis is not allowed.\n",
      "\n",
      "          3. Has metastatic disease.\n",
      "\n",
      "          4. Has a known additional malignancy that is progressing or requires active treatment in\n",
      "             the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell\n",
      "             carcinoma of the skin, DCIS of the breast, or in situ cervical cancer that has\n",
      "             undergone potentially curative therapy.\n",
      "\n",
      "          5. Patients for whom radiotherapy for breast cancer is contraindicated because of medical\n",
      "             reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation).\n",
      "\n",
      "          6. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any\n",
      "             other form of immunosuppressive therapy within 7 days prior to the first dose of trial\n",
      "             treatment.\n",
      "\n",
      "          7. Has a known history of active TB (Bacillus Tuberculosis).\n",
      "\n",
      "          8. Hypersensitivity to pembrolizumab or any of its excipients.\n",
      "\n",
      "          9. Has active autoimmune disease that has required systemic treatment in the past 2 years\n",
      "             (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive\n",
      "             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid\n",
      "             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a\n",
      "             form of systemic treatment.\n",
      "\n",
      "         10. Has a History of (non-infectious) pneumonitis that required steroids or current\n",
      "             pneumonitis.\n",
      "\n",
      "         11. Has an active infection requiring systemic therapy.\n",
      "\n",
      "         12. Has known psychiatric or substance abuse disorders that would interfere with\n",
      "             cooperation with the requirements of the trial.\n",
      "\n",
      "         13. Is pregnant or breastfeeding.\n",
      "\n",
      "         14. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n",
      "\n",
      "         15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\n",
      "\n",
      "         16. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA\n",
      "             [qualitative] is detected).\n",
      "\n",
      "         17. Has received a live vaccine within 30 days of planned start of study therapy.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with PSMA-positive tumors including prostate cancer, breast cancer, lung\n",
      "             cancer, and other tumor types know to express PSMA\n",
      "\n",
      "          -  Patients able to tolerate PET/MRI scans\n",
      "\n",
      "          -  Informed consent must be given and signed\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects who do not meet the above mentioned inclusion criteria\n",
      "\n",
      "          -  Subjects who refuse to give and/or sign the informed consent\n",
      "\n",
      "          -  Patients who have a history of serious adverse events related to a previous MRI or\n",
      "             PET/CT\n",
      "\n",
      "          -  Patients who are unable to undergo MRI scanning due to exclusion by institutional MRI\n",
      "             restriction policies as mentioned in the standard institutional MRI informed consent\n",
      "             form\n",
      "\n",
      "          -  Patients who are currently pregnant or breast feeding. A pregnancy test within 72\n",
      "             hours of the first PET/MRI will be performed.\n",
      "\n",
      "          -  Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks.\n",
      "\n",
      "          -  Renal insufficiency: elevated Creatinine and/or Glomerular Filtration Rate\n",
      "             (GFR)<40ml/min/1.7sqm (exclusion criterion only for contrast enhanced MRI)\n",
      "\n",
      "          -  Patients with a known allergy against any component of the contrast enhancing MR agent\n",
      "             will not receive MR contrast agents. (exclusion criterion only for contrast enhanced\n",
      "             MRI)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:The following are requirements for entry into the study:\n",
      "\n",
      "          1. Female, age 40 or older at the time of enrollment\n",
      "\n",
      "          2. Most recent MBI examination, performed within 3 years of enrollment, showed moderate\n",
      "             or marked background parenchymal uptake\n",
      "\n",
      "          3. Mammogram performed within 12 months prior to enrollment that is available for\n",
      "             comparison\n",
      "\n",
      "          4. Willing and able to return for MBI following 30 days of low-dose tamoxifen\n",
      "\n",
      "          5. If able to become pregnant\n",
      "\n",
      "               1. Negative pregnancy test within 48 hours prior to study MBI exam(s)\n",
      "\n",
      "               2. Agrees to avoid pregnancy during the study and for at least 2 months after study\n",
      "                  participation ends, by abstinence, barrier method, or nonhormonal contraception.\n",
      "\n",
      "          6. Understands and signs the consent form\n",
      "\n",
      "             -\n",
      "\n",
      "        Exclusion Criteria:Subjects will be excluded if any of the following characteristics are\n",
      "        present:\n",
      "\n",
      "        1) Evidence of suspected breast disease as defined by positive findings or recommendation\n",
      "        for short-interval follow-up on most recent breast imaging (including mammography, MBI,\n",
      "        MRI, ultrasound, etc.) not yet resolved prior to enrollment 2) Breast biopsy or breast\n",
      "        surgery performed 6 months prior to enrollment 3) Bilateral breast implants or status\n",
      "        post-bilateral prophylactic mastectomy 4) Pregnant or lactating 5) Current or recent use\n",
      "        (within 6 months prior to enrollment) of any of the following drugs:\n",
      "\n",
      "          1. Systemic hormonal therapy (oral or transdermal patch formulations)\n",
      "\n",
      "          2. Hormonal contraception (oral, transdermal, implanted, or injected formulations)\n",
      "\n",
      "          3. Selective estrogen receptor modulators (tamoxifen, raloxifene, or toremifene)\n",
      "\n",
      "          4. Aromatase inhibitors (anastrazole, letrozole, or exemestane)\n",
      "\n",
      "          5. GnRH analogs\n",
      "\n",
      "          6. Prolactin inhibitors\n",
      "\n",
      "          7. Androgens or antiandrogens\n",
      "\n",
      "          8. Anticoagulants or \"blood thinners\" (warfarin, heparin, rivaroxaban and other novel\n",
      "             anticoagulants)\n",
      "\n",
      "          9. Drugs known to be strong inhibitors of CYP2D6, the major P450 enzyme that metabolizes\n",
      "             tamoxifen, including:\n",
      "\n",
      "               -  bupropion (Wellbutrin)\n",
      "\n",
      "               -  fluoxetine (Prozac)\n",
      "\n",
      "               -  paroxetine (Paxil)\n",
      "\n",
      "               -  quinidine (Quinidex) 6) Personal history of any type of malignancy, with the\n",
      "                  exclusion of non-melanoma skin cancer, diagnosed prior to enrollment 7) Personal\n",
      "                  history or strong family history of blood clots in legs or lungs (also known as\n",
      "                  deep vein thrombosis or pulmonary embolism) 8) Personal history of transient\n",
      "                  ischemic attack (TIA) or cerebrovascular accident (CVA) 9) Active proliferative\n",
      "                  disorders of the endometrium such as atypical hyperplasia, history of active\n",
      "                  endometriosis, unresected polyps 10) Any type of retinal disorders or severe\n",
      "                  cataract 11) Current or former smoker 12) Known carrier of BRCA1 or BRCA2 genetic\n",
      "                  mutation or known DNA repair defect.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age 6 months to < 8 years\n",
      "\n",
      "          -  Presentation to one of the study sites with signs and symptoms of influenza-like\n",
      "             illness (temperature of >37.8⁰C and at least one of the following: cough, sore throat,\n",
      "             runny nose or nasal congestion)\n",
      "\n",
      "          -  Parents or guardians agreeing and consenting to medical information release,\n",
      "             respiratory specimen collection and testing, email/phone call follow up and collection\n",
      "             of leftover blood samples obtained during routine clinical care\n",
      "\n",
      "          -  Patients seen during the 2016-2017 influenza season\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Respiratory symptom duration > 14 days\n",
      "\n",
      "          -  Nurse only visit\n",
      "\n",
      "          -  Enrollment in the study within prior 14 days\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Male or female patients > 18 years old who have full legal capacity to volunteer on\n",
      "             the date the informed consent is signed.\n",
      "\n",
      "          2. Subjects who can follow the instructions by the clinical staff at the clinical site,\n",
      "             and can attend examinations on the scheduled examination date.\n",
      "\n",
      "          3. Subjects who agree to participate in the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. History of cataract or ocular surgical procedures that render the cornea opaque or\n",
      "             otherwise impact its ability to be imaged using the investigational device.\n",
      "\n",
      "          2. Fixation problems which may prevent obtaining good quality images in either eye.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Diagnosed with a chronic pain condition (> 3 months) other conventional medical\n",
      "             therapies (anticonvulsants, tricyclics etc), have not been effective.\n",
      "\n",
      "          2. American Society of Anesthesiologists class 1 or 2\n",
      "\n",
      "          3. Age 8-18 years\n",
      "\n",
      "          4. Ability to understand and use the numeric rating scale to rate their pain and to\n",
      "             understand and answer other questionnaires\n",
      "\n",
      "          5. Negative pregnancy test in participants of child-bearing potential (Females 12 years\n",
      "             of age and older, or menarchal if under 12)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. History of seizures\n",
      "\n",
      "          2. Known liver or renal disease\n",
      "\n",
      "          3. Patient taking CYP1A2 substrate or inhibitors (eg. Ciprofloxacin, fluvoxamine,\n",
      "             clozapine, duloxetine, melatonin, propranolol, tizanidine)\n",
      "\n",
      "          4. Allergy or sensitivity to lidocaine or other local anesthetic\n",
      "\n",
      "          5. Cardiac conduction anomalies (eg. Heart block, Wolff-Parkinson-White)\n",
      "\n",
      "          6. Serum electrolytes (potassium, sodium, magnesium or calcium) outside of reference\n",
      "             ranges\n",
      "\n",
      "          7. Pregnancy\n",
      "\n",
      "        Withdrawal Criteria\n",
      "\n",
      "          1. Patient or parent/guardian request\n",
      "\n",
      "          2. Refusal to have intravenous access and serum levels drawn\n",
      "\n",
      "          3. Inability to complete pain scores on the questionnaires (paper or electronic) at the\n",
      "             first infusion and weekly for 2 weeks and at one month following infusion\n",
      "\n",
      "          4. Baseline free carnitine concentration < 26 micromoles/L or total carnitine < 32\n",
      "             micromoles/L (reference values from SickKids Department of Pediatric Laboratory\n",
      "             Medicine \"Guide to Laboratory Services\")\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. 19 years old or older\n",
      "\n",
      "          2. ① Systolic blood pressure is less than 90mmHg for more than 30 minutes despite the\n",
      "             fluid therapy, or Use of pressure boosting agents is necessary.\n",
      "\n",
      "             ② Peripheral hypopnea (cold skin, urine less than 30 cc per hour, impaired\n",
      "             consciousness, lactate ≥2.0 mmol / l) or a person with pulmonary edema.\n",
      "\n",
      "          3. Causes of cardiogenic shock include acute myocardial infarction (including in coronary\n",
      "             intervention), cardiomyopathy, myocarditis, pulmonary embolism, refractory ventricular\n",
      "             tachycardia, shock during coronary intervention.\n",
      "\n",
      "          4. Those voluntarily consenting to the medical records and the data necessary for the\n",
      "             study during the entire study period.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Other causes except for cardiogenic shock (low blood pressure, septic, obstructive\n",
      "             shock)\n",
      "\n",
      "          2. Shock with cardiac arrest outside the hospital\n",
      "\n",
      "          3. People with allergic reactions to anticoagulants such as heparin.\n",
      "\n",
      "          4. Those who refused active treatment.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  hair parameters obtained before the start of chemotherapy\n",
      "\n",
      "          -  Patients who participated in VOLUME\n",
      "\n",
      "          -  Able to keep their hair style\n",
      "\n",
      "          -  Able to use the study treatment in compliance with the protocol.\n",
      "\n",
      "          -  Physical (ECOG≤1) and psychological ability to participate\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Concomitant use of other anti-hair-loss treatment or hair growth treatment.\n",
      "\n",
      "          -  Patients with recent hair transplants or who plan to have transplants.\n",
      "\n",
      "          -  Known allergy or hypersensitivity to some components of CG428 (including allium cepa\n",
      "             (onion), citrus, caffeine, theobromine)\n",
      "\n",
      "          -  Pre-existing alopecia or significant scalp disease, which may alter study treatment\n",
      "             administration or absorption.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female fetuses from 18 weeks and 0/7 days to 25 weeks 0/7 days gestation with\n",
      "             a diagnosis of alpha-thalassemia major by chorionic villus sampling (CVS),\n",
      "             amniocentesis, cordocentesis or by identification of parents as genetic carriers, and\n",
      "             identification of fetal anemia or signs of impending hydrops, for whom parents elect\n",
      "             to pursue in utero transfusion, and are willing to undergo subsequent IUT for the\n",
      "             remainder of gestation.\n",
      "\n",
      "          -  parents must consent to fetal autopsy in the event of a fetal demise\n",
      "\n",
      "          -  adequate bone marrow harvest from maternal participant is a condition for inclusion\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Fetal Subject Exclusion Criteria: Fetal participants will be excluded if they have a\n",
      "             second major anatomic anomaly (not related to the underlying thalassemia) that\n",
      "             contributes a significant morbidity or mortality risk, or echocardiogram or ultrasound\n",
      "             findings that indicate a high risk of fetal demise after fetal intervention.\n",
      "\n",
      "          -  Maternal Subject Exclusion Criteria: Maternal participants will be excluded if they\n",
      "             have one or more morbidities that would preclude bone marrow harvest and fetal\n",
      "             intervention including, but not limited to, morbid obesity with BMI > 35, maternal\n",
      "             cardiac disease, mirror syndrome, symptomatic maternal anemia, or if they develop\n",
      "             preterm premature rupture of membranes (PPROM) or active preterm labor (PTL).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Follow up at the Gastroenterology Unit at TLVMC\n",
      "\n",
      "          -  Diagnosis of cirrhosis\n",
      "\n",
      "          -  Abnormal coagulation test results: INR > 1.5 and/or a PLT count < 50x10^9/L\n",
      "\n",
      "          -  Planned to undergo an invasive procedure\n",
      "\n",
      "          -  Hospitalization in one of the following units at TLVMC: Internal Medicine D, Internal\n",
      "             Medicine T, Internal Medicine Consultations, Intensive Care Unit, Surgical Intensive\n",
      "             Care Unit, General Surgery Division and the Gastroenterology unit.\n",
      "\n",
      "          -  Invasive procedures: central venous catheter placement, drainage of ascitic fluid,\n",
      "             endoscopic procedures (variceal ligation or polypectomy) or any surgical procedure\n",
      "             (excluding liver transplantation).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Ongoing bleeding\n",
      "\n",
      "          -  Current/recent (past 7 days) antiplatelet/anticoagulant therapy\n",
      "\n",
      "          -  Hemodialysis in the previous 7 days.\n",
      "\n",
      "          -  planned procedure is liver transplantation.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Pathologically confirmed metastatic lung (NSCLC), pancreatic, gastric and biliary\n",
      "             tract cancer, diagnosed within the previous 8 weeks; an Eastern Cooperative Oncology\n",
      "             Group (ECOG) performance status (PS) of 0, 1, or 2; age ± 18 years; metastatic or\n",
      "             locally advanced disease (but not susceptible of loco-regional treatments);\n",
      "             eligibility to first-line chemotherapy ± biological agents; life expectancy more than\n",
      "             three months; written informed consent provided; FACT-G questionnaire filled in at\n",
      "             enrollment, before the randomization.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients already receiving care from the PC service or pretreated with chemotherapy ±\n",
      "             biological\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosed with diabetes mellitus according to definitions outlined by the American\n",
      "             Diabetes Association\n",
      "\n",
      "          -  Presenting with a localized mild infection of the ulcer as listed in the IDSA Clinical\n",
      "             Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections (Table\n",
      "             1); exceeding 0.5 cm2 in area after appropriate debridement\n",
      "\n",
      "          -  Diagnosis of mild infection must be confirmed immediately following debridement at\n",
      "             Baseline\n",
      "\n",
      "          -  Subject must agree to adhere to all protocol procedures and must be willing and able\n",
      "             to provide written informed consent.\n",
      "\n",
      "          -  Correction or optimization of underlying medical problems (e.g. diabetes or systemic\n",
      "             infection).\n",
      "\n",
      "          -  Wound has been identified as stalled or persistent non-healing under current\n",
      "             standard-of-care; showing no progression in 2 weeks as per IDSA guidelines\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Use of systemic antibiotics within the previous 2 weeks\n",
      "\n",
      "          -  Known silver sensitivity\n",
      "\n",
      "          -  Current use of enzymatic debridement\n",
      "\n",
      "          -  Wounds where best practice wound bed preparation is not available or applicable (eg,\n",
      "             wound with diminutive oxygen supply would be contraindicated for debridement.\n",
      "\n",
      "          -  No palpable dorsalis pedis or posterior tibial pulse or a pedal systolic pressure\n",
      "             (Doppler) of ≤ 40 mm Hg\n",
      "\n",
      "          -  Evidence of systemic infection (fever, chills, hypotension)/sepsis\n",
      "\n",
      "          -  Non-study systemic or anti-infective topical agents\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Minimum age of 20 years(range from 20 year to 25 years)\n",
      "\n",
      "          -  The value of OSDI is over 12\n",
      "\n",
      "          -  NBUT is less 5 seconds\n",
      "\n",
      "          -  Schirmer 1 test is less 10mm\n",
      "\n",
      "          -  The basical lipid layer grade is 1-2\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any corneal,conjunctival, or eyelid abnormalities; conjunctivitis; current ocular\n",
      "             infection; photophobia that may cause reflex tearing or difficulty in evaluating the\n",
      "             patient's lipid layer;\n",
      "\n",
      "          -  Known allergic sensitivity to any of the ingredients in Liposic or Tears Naturale\n",
      "             Forte\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of cubital tunnel syndrome confirmed with Electromyography (EMG) testing or\n",
      "             Ultrasound imaging\n",
      "\n",
      "          -  Ability to comprehend English and complete health related quality of life\n",
      "             questionnaires\n",
      "\n",
      "          -  Willing to provide informed consent\n",
      "\n",
      "          -  Age > 18 years\n",
      "\n",
      "          -  Not pregnant\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Prior ipsilateral cubital tunnel release\n",
      "\n",
      "          -  Evidence of symptomatic clinical double crush syndrome confirmed by EMG/Nerve\n",
      "             Conduction Study (NCS)\n",
      "\n",
      "          -  Patients with rheumatoid arthritis, connective tissue disorder, tenosynovitis, or\n",
      "             diagnosed neurological condition that could confound the assessment of health-related\n",
      "             quality of life with regard to the affected arm and hand\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Laypeople who have not received any BLS training or practice in the 6 months leading\n",
      "             up to the date of their participation will be recruited.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Under 18 years old;\n",
      "\n",
      "          -  Non layperson and Basic Life Training in less than 6 months.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age: 22-65 years\n",
      "\n",
      "          2. If the patient is taking medications, it must take on a stable dose for at least a\n",
      "             month\n",
      "\n",
      "          3. Obesity: ≤ 30 BMI ≤ 45\n",
      "\n",
      "          4. Ability to follow verbal or written instructions.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Axis-I and II psychiatric disorders according to DSM criteria 5 (such as Major\n",
      "             Depression, Bipolar Disorder, or Attention Deficit Disorder)\n",
      "\n",
      "          2. IQ score < 85\n",
      "\n",
      "          3. Organic brain disorders: history of stroke, brain major surgery or head trauma\n",
      "\n",
      "          4. Pregnancy or lactation, absence of medically approved contraceptive methods in females\n",
      "             of childbearing potential\n",
      "\n",
      "          5. Serious or poorly controlled diseases (hepatic, renal or hearth failure, atrial\n",
      "             fibrillation or other heart rhythm disorders)\n",
      "\n",
      "          6. H yperglycemia - Fasting glucose level > 170 mg/dl\n",
      "\n",
      "          7. Urine drug screen positive for amphetamines, barbiturates, cannabinoids, cocaine\n",
      "             metabolites, opiates and phencyclidine\n",
      "\n",
      "          8. Positivity to blood alcohol test\n",
      "\n",
      "          9. Metal in any part of the head, except for dental fillings\n",
      "\n",
      "         10. Implanted infusion pumps\n",
      "\n",
      "         11. Intracardiac devices (pacemakers, heart valves ...)\n",
      "\n",
      "         12. History of diseases whose exacerbation could be fatal (e.g. cardiovascular disease,\n",
      "             increased intracranial pressure)\n",
      "\n",
      "         13. History of epilepsy or a family history of epilepsy among first-degree relatives\n",
      "\n",
      "         14. Medications associated with lowered seizure threshold (such as antidepressants,\n",
      "             anxiolytics…)\n",
      "\n",
      "         15. Treatment with anti-obesity medications or other medications influencing body weight\n",
      "             within 3 month prior to Screening Visit\n",
      "\n",
      "         16. Starting a weight loss plan at any time during data collection for the subject\n",
      "\n",
      "         17. Patients affected by galactosemia, priapism and terminal illness\n",
      "\n",
      "         18. Patients on fluid restriction for SIADH or other conditions\n",
      "\n",
      "         19. Contraindications to perform the Magnetic Resonance Imaging (MRI).\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  a group of children (n=90) suffering from CRS (fulfilling the EPOS criteria, European\n",
      "             Position Paper on Rhinosinusitis and Nasal Polyps) and asthma (fulfilling the API\n",
      "             criteria, Asthma Predictive Index), including a 30-person subgroup diagnosed with\n",
      "             clinically significant IgE-dependent hypersensitivity (accordance between symptoms and\n",
      "             current exposure to sensitizing allergen),\n",
      "\n",
      "          -  a group of children (n=30) suffering from CRS (fulfilling the EPOS criteria) but\n",
      "             without asthma symptoms (negative API criteria), including a 15-person subgroup\n",
      "             diagnosed with clinically significant IgE-dependent hypersensitivity (accordance\n",
      "             between symptoms and current exposure to sensitizing allergen),\n",
      "\n",
      "          -  a group of children (n=30) without symptoms of CRS (negative EPOS criteria) and\n",
      "             without asthma symptoms (negative API criteria).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  food allergy with symptoms affecting the respiratory tract\n",
      "\n",
      "          -  contraindication to nasal endoscopy or contraindication to nasal mucosa biopsy\n",
      "\n",
      "          -  hypertrophy of the third tonsil exceeding 60% of the nasopharynx (the criterion of\n",
      "             obstruction being an indication for adenoidectomy). In these patients, the anatomical\n",
      "             nasal obstruction may be the single cause of chronic inflammation in the airways, and\n",
      "             hence verification of the hypotheses is impossible\n",
      "\n",
      "          -  confirmed immunodeficiency\n",
      "\n",
      "          -  exacerbation of asthma requiring systemic administration of glucocorticosteroids\n",
      "\n",
      "          -  obesity, exposure to tobacco smoke\n",
      "\n",
      "          -  other chronic illnesses and clinical conditions, which in the opinion of the\n",
      "             researcher may influence the evaluation and the course of the study.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Gluten-free diet for at least 1 year\n",
      "\n",
      "          2. Clinical endoscopy within the past month\n",
      "\n",
      "          3. Biopsies must show no villous atrophy or villous blunting\n",
      "\n",
      "          4. Villous height to crypt depth (VHCD) ratio measurement should be 2.5:1 or greater\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. 1st degree relative with Celiac Disease\n",
      "\n",
      "          2. Positive tTG IgA, already on simvastatin or statin agent\n",
      "\n",
      "          3. Unable to stop non-steroidal or anti-inflammatory drugs\n",
      "\n",
      "          4. Prior history of GI surgery other than appendectomy or cholecystectomy\n",
      "\n",
      "          5. Taking drugs know to inhibit or activate CYP3A4\n",
      "\n",
      "          6. Unable to avoid food known to inhibit CYP3A4\n",
      "\n",
      "          7. History of a reaction to statin drugs in the past\n",
      "\n",
      "          8. Pregnant or nursing women\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Patients age: ≥ 18 years\n",
      "\n",
      "          2. Patients should have a history of Barrett's associated esophageal dysplasia (either\n",
      "             low or high-grade) confirmed on histology\n",
      "\n",
      "          3. Willingness to undergo both WATS3D and random forceps biopsies while undergoing\n",
      "             conventional EGD with sedation\n",
      "\n",
      "          4. Ability to provide written, informed consent (approved by IRB) and understand the\n",
      "             responsibilities of trial participation\n",
      "\n",
      "          5. Only patients who no visible mucosal abnormalities at the time that they undergo both\n",
      "             random forceps biopsies and WATS3D testing of the esophagus will be included in this\n",
      "             study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Coagulopathy with INR > 2.0, thrombocytopenia with platelet counts < 50,000\n",
      "\n",
      "          2. The subject is pregnant or planning a pregnancy during the study period\n",
      "\n",
      "          3. History of esophageal or gastric surgery other than Endoscopic Mucosal Resection (EMR)\n",
      "\n",
      "          4. Patients who have undergone endoscopic ablative therapies\n",
      "\n",
      "          5. Subject has a known history of unresolved drug or alcohol dependency that would limit\n",
      "             ability to comprehend or follow instructions related to informed consent,\n",
      "             post-treatment instructions, or follow-up guidelines\n",
      "\n",
      "          6. Study patients with inadequate WATS3D specimens will not undergo a repeat brush biopsy\n",
      "             test and will be excluded from the study\n",
      "\n",
      "          7. BE length < 1 cm or > 10 cm\n",
      "\n",
      "          8. Patients within six weeks of receiving targeted forceps biopsies and/or EMR\n",
      "\n",
      "          9. Patients with visible mucosal abnormality at the time of the WATS3D and random biopsy\n",
      "             testing\n",
      "\n",
      "         10. Patients with visible lesions that are either submucosal or covered with a clinically\n",
      "             intact epithelium\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patient with histologically proven CD20+ diffuse large B cell lymphoma (WHO\n",
      "             Classification),\n",
      "\n",
      "          -  aaIPI>1,\n",
      "\n",
      "          -  Age >18 and < 61 years,\n",
      "\n",
      "          -  Negative HIV serologies 4 weeks\n",
      "\n",
      "          -  Ability to understand and willingness to sign a written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any other histological type of lymphoma. Any history of treated or non-treated\n",
      "             indolent lymphoma.\n",
      "\n",
      "          -  Central nervous system or meningeal involvement by lymphoma.\n",
      "\n",
      "          -  Contraindication to any drug contained in the chemotherapy regimens.\n",
      "\n",
      "          -  Any serious active disease (according to the investigator's decision).\n",
      "\n",
      "          -  Poor renal function (creatinin level>150µmol/l), poor hepatic function (total\n",
      "             bilirubin level>30mmol/l, transaminases>2.5 maximum normal level) unless these\n",
      "             abnormalities are related to the lymphoma.\n",
      "\n",
      "          -  Poor bone marrow reserve as defined by neutrophils <1.5 G/l or platelets <100 G/l,\n",
      "             unless related to bone marrow infiltration.\n",
      "\n",
      "          -  Treatment with any investigational drug within 30 days before planned first cycle of\n",
      "             chemotherapy and during the study.\n",
      "\n",
      "          -  Pregnant or lactating women.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients scheduled for percutaneous nephtolithotomy, ureteroscopy lithotripsy,\n",
      "             transurethral resection of bladder tumor or transurethral resection of the prostate\n",
      "\n",
      "          -  American Society of Anesthesiologists physical statusⅠ-Ⅲ\n",
      "\n",
      "          -  Informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Coagulopathy, on anticoagulants\n",
      "\n",
      "          -  History of surgery on spine\n",
      "\n",
      "          -  Spine deformity\n",
      "\n",
      "          -  A known allergy to the drugs being used\n",
      "\n",
      "          -  Tumer or infection at the site of puncture\n",
      "\n",
      "          -  refusal to participate in the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Newly diagnosed (< 1 year) diabetes patients clinically classified as type-2 diabetes\n",
      "             patients of both sex.\n",
      "\n",
      "          -  Age 18 +.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Type 1 diabetes (or have age<30 years and C-peptid<300pmol/l and GAD-ab titer> 20\n",
      "             IU/ml).\n",
      "\n",
      "          -  Renal insufficiency (GFR < 45 or se-creatinine >140 micromol/l).\n",
      "\n",
      "          -  BMI > 35.\n",
      "\n",
      "          -  Atrial fibrillation.\n",
      "\n",
      "          -  Life expectancy below 2 years.\n",
      "\n",
      "          -  Mental disease and/or misuse of alcohol or drugs that affects patient's ability to\n",
      "             give informed consent.\n",
      "\n",
      "          -  Pregnancy at time of or planned at inclusion.\n",
      "\n",
      "          -  Patients with a history of prior atherothrombotic disease (including acute coronary\n",
      "             syndromes, prior revascularization, ischemic stroke or peripheral arterial disease).\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  A diagnosis of Sjogren's syndrome according to the revised American-European Consensus\n",
      "             Group (AECG) criteria\n",
      "\n",
      "          -  Positive dry eyes and (or) dry mouth symptoms\n",
      "\n",
      "          -  Hyperglobulinemia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Complicated with other systemic autoimmune diseases\n",
      "\n",
      "          -  Severe complications of Sjogren's syndrome\n",
      "\n",
      "          -  Glucocorticosteroid therapy, systemic immunosuppressant therapy, or biological agents\n",
      "             therapy within 3 months prior to the screening visit\n",
      "\n",
      "          -  Active infections or chronic infectious diseases\n",
      "\n",
      "          -  A history of malignancies\n",
      "\n",
      "          -  Pregnancy or breathfeeding\n",
      "\n",
      "          -  Inability to comply with the study protocol for any other reason\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Receives services or lives within one of the communities selected for the study\n",
      "\n",
      "          -  Main shopper for the household\n",
      "\n",
      "          -  Intends to use Veggie Van if it comes to their community\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Under 18\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  In order to be eligible to participate in this study, an individual must meet all of\n",
      "             the following criteria:\n",
      "\n",
      "               -  Age 18 or older\n",
      "\n",
      "               -  Able and willing to access the internet on a regular basis\n",
      "\n",
      "               -  Able to read and speak English\n",
      "\n",
      "               -  Be willing to comply with all study procedures:\n",
      "\n",
      "                    1. Randomly assigned to either arm of the study\n",
      "\n",
      "                    2. Be available for the duration of the study\n",
      "\n",
      "                    3. Complete study data collection forms\n",
      "\n",
      "                    4. Reachable by phone and able to participate in weekly phone coaching calls if\n",
      "                       randomized to the PACT arm\n",
      "\n",
      "               -  Have a diagnosis of TMD pain using a self-report screener. These questions\n",
      "                  include;\n",
      "\n",
      "                    1. In the last 30 days, which of the following best describes any pain in your\n",
      "                       jaw or temple area on either side?\n",
      "\n",
      "                    2. In the last 30 days, have you had pain or stiffness in your jaw on\n",
      "                       awakening?\n",
      "\n",
      "                    3. In the last 30 days, did the following activities change any pain (that is,\n",
      "                       make it better or make it worse) in your jaw or temple area on either side?\n",
      "                       Chewing hard or tough food, Opening your mouth or moving your jaw forward or\n",
      "                       to the side, Jaw habits such as holding teeth together, clenching/grinding,\n",
      "                       or chewing gum, or other jaw activities such as talking, kissing, or yawning\n",
      "\n",
      "               -  Frequency of TMD pain more than once a week with pain in the past 6 months\n",
      "\n",
      "               -  Electronically sign an informed consent form\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  An individual who meets any of the following criteria will be excluded from\n",
      "             participation in this study:\n",
      "\n",
      "               -  Currently participating in any other TMD and temporomandibular joint (TMJ)\n",
      "                  related studies\n",
      "\n",
      "               -  Major disk disorder that requires opioids or surgery for TMD pain\n",
      "\n",
      "               -  Serious medical condition that might interfere with or prohibit participation in\n",
      "                  an online program or pregnancy\n",
      "\n",
      "               -  Treatment for a mental health disorder or substance abuse in the past six months\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age 18 years or more at the time of consent\n",
      "\n",
      "          2. Histologically confirmed cT0-4, N1 breast cancer\n",
      "\n",
      "          3. Axillary lymph node metastasis with pathologic confirmation by needle biopsy\n",
      "\n",
      "          4. Clip placed in the sampled axillary lymph node at the time of the biopsy\n",
      "\n",
      "          5. Received neoadjuvant chemotherapy prior to surgical resection\n",
      "\n",
      "          6. Scheduled for targeted axillary dissection (defined as selective localization and\n",
      "             removal of the clipped node and SLND)\n",
      "\n",
      "          7. ECOG performance status 0-2\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Distant metastases\n",
      "\n",
      "          2. Inflammatory breast cancer\n",
      "\n",
      "          3. Prior surgical axillary procedure including SLND or axillary node excision\n",
      "\n",
      "          4. Prior history of breast cancer in the ipsilateral breast\n",
      "\n",
      "          5. History of lymphoma\n",
      "\n",
      "          6. The subject is pregnant\n",
      "\n",
      "          7. Previous radiation to the breast or axilla\n",
      "\n",
      "          8. Pacemaker of other implantable device in the chest wall\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Able to provide informed consent\n",
      "\n",
      "          -  English speaking\n",
      "\n",
      "          -  Women age 18 years old or greater\n",
      "\n",
      "          -  Nulliparous\n",
      "\n",
      "          -  Pregnant with a singleton gestation that is greater than or equal to 37 weeks\n",
      "\n",
      "          -  Undergoing induction of labor with Foley catheter\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Women not meeting above criteria\n",
      "\n",
      "          -  Fetus in non-cephalic position\n",
      "\n",
      "          -  Intrauterine fetal demise\n",
      "\n",
      "          -  Fetus with major anomalies\n",
      "\n",
      "          -  HIV, hepatitis B or C infection\n",
      "\n",
      "          -  Planned use of oxytocin during the Foley catheter ripening\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Women with pelvic cancer and indication for pelvic radiation therapy who have\n",
      "             fertility sparing desire.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Previously documented infertility, ovarian failure or gynecologic cancer.\n",
      "\n",
      "          -  More than 40 yo.\n",
      "\n",
      "          -  Previous oophorectomy\n",
      "\n",
      "          -  Tumor infiltrating uterus or adnexes\n",
      "\n",
      "          -  Presence of peritoneal metastasis\n",
      "\n",
      "          -  Presence of systemic metastasis\n",
      "\n",
      "          -  Previous retroperitoneal radiotherapy\n",
      "\n",
      "          -  Retroperitoneal radiotherapy planned\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        Patients with active IBD, and endoscopic and histological diagnosis of CD or UC that attend\n",
      "        a colonoscopy with sedation performed by medical criteria.\n",
      "\n",
      "        Patients without an IBD diagnosis, or other types of inflammatory, allergic, malignant or\n",
      "        autoimmune diseases, prior to their inclusion in this project. All patients will attend a\n",
      "        colonoscopy with sedation at medical judgment with biopsy indication for histopathological\n",
      "        study as in cases of diarrhea but also due to changes in the bowel transit, rectal bleeding\n",
      "        or screening for gastrointestinal diseases. Patients will be paired in age and gender with\n",
      "        the IBD groups. All patients will have no signs of macroscopic or microscopic inflammation\n",
      "        hence excluding the presence of microscopic colitis.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Age less than 18 years\n",
      "\n",
      "          2. Chronic disease or any other advanced clinically significant pathology, uncontrolled\n",
      "             by investigator judgment.\n",
      "\n",
      "          3. Should be with medication, this will be unchanged in the 3 months prior to\n",
      "             colonoscopy.\n",
      "\n",
      "          4. Alcohol or drugs.\n",
      "\n",
      "          5. Pregnancy or lactation\n",
      "\n",
      "          6. Do not sign the informed consent form (see \"Ethical Issues\") In any case NO\n",
      "             colonoscopies exclusively targeted for sampling for this project will be made\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  stroke with hemiplegia\n",
      "\n",
      "          -  age between 18-80\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  recurrent stoke patient\n",
      "\n",
      "          -  previous history of shoulder pain, any injuries and operation in shoulder joint,\n",
      "             frozen shoulder, tendinitis in shoulder joint,\n",
      "\n",
      "          -  any other systemic neuromuscular disease\n",
      "\n",
      "          -  cognition or language impairment leading to communication difficulty\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  The patients who were diagnosed of primary gastric adenocarcinoma and drew up\n",
      "             agreement for understanding and enrollment of this study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Being treated (surgery, endoscopic resection and chemoradiation) after the diagnosis\n",
      "             of gastric cancer; metastatic gastric cancer; refusal to participation of this study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  OSA diagnosis and CPAP prescription\n",
      "\n",
      "          -  No use of internet or mobile devices\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Unstable diseases and severe comorbidities\n",
      "\n",
      "          -  Previous CPAP treatment\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Ulcerative Colitis in clinical remission (partial Mayo score 0-1)\n",
      "\n",
      "          -  Taking oral 5-ASA, methotrexate, azathioprine or 6-mecaptopurine as long as there have\n",
      "             been no changes in dosage for 2 months prior to the start of the study\n",
      "\n",
      "          -  Generally healthy besides having UC\n",
      "\n",
      "          -  Agree not to use any dietary supplements, herbal treatments, prebiotics, probiotics or\n",
      "             diet therapies within three weeks of the onset of the trial or during the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Using prednisone (or steroid equivalent) or biologics (i.e., infliximab, adalimumab,\n",
      "             vedolizumab) at the time of enrollment\n",
      "\n",
      "          -  Using antibiotics two weeks prior to or anytime during the study period\n",
      "\n",
      "          -  Pregnancy, lactation or desire to become pregnant during the study period because we\n",
      "             do not know if or how an unborn baby/fetus could be harmed\n",
      "\n",
      "          -  History of colectomy or extensive colonic resection or disease is limited to the\n",
      "             rectum\n",
      "\n",
      "          -  Significant chronic disorders such as severe cardiac disease, significant renal\n",
      "             failure, severe pulmonary disease (need for oxygen)\n",
      "\n",
      "          -  Active gastrointestinal infection (e.g., C. difficile infection)\n",
      "\n",
      "          -  Severe psychiatric disorder\n",
      "\n",
      "          -  Unable or unwilling to consent\n",
      "\n",
      "          -  Unable to comply with study requirements\n",
      "\n",
      "          -  Presence of alcohol or drug abuse\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Documented stable refraction for at least 1 year(within 0.5D)\n",
      "\n",
      "          -  Best spectacle-corrected visual acuity (BCVA) of 20/40 or better\n",
      "\n",
      "          -  Clear central cornea\n",
      "\n",
      "          -  -0.5D to -18.0D of myopic refractive error\n",
      "\n",
      "          -  Normal anterior chamber depth at least 2.8 mm to endothelium\n",
      "\n",
      "          -  Endothelial cell density (ECD) more than 2000 cell/mm2\n",
      "\n",
      "          -  Pupil diameter smaller than 7.0 mm under mesopic condition\n",
      "\n",
      "          -  Discontinued 3 weeks for hard contact lens and 1 week for soft contact lens wear\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Preexisting ocular diseases or conditions other than myopia, evidence of progressive\n",
      "             or acute ocular disease\n",
      "\n",
      "          -  Evidence of connective tissue disease or other systemic diseases that may confound the\n",
      "             results of the study;\n",
      "\n",
      "          -  Narrow angle of anterior chamber\n",
      "\n",
      "          -  Pregnant, lactating, or planning to become pregnant during the course of the trial\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Consenting patients with spondylarthropathies or ankolysiing spondylitis, according to\n",
      "             European Ppondyloarthropathy Study Group criteria or New York Criteria:\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients having been or are currently exposed to an anti-tumour necrotic factor\n",
      "             treatment (Adalimumab or Infliximab). Patients treated with anti-tumour necrotic\n",
      "             factor receptor antibodies (Etanercept) are not excluded.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Females with age between 18 and 75 years old\n",
      "\n",
      "          2. ECOG: 0～2\n",
      "\n",
      "          3. Life expectancy longer than 3 months\n",
      "\n",
      "          4. Histological proven unresectable recurrent or metastatic HR positive/HER2 negative\n",
      "             breast cancer\n",
      "\n",
      "          5. Primary endocrine resistance is defined as: a relapse while on the first 2 years of\n",
      "             adjuvant ET, or PD within first 6 months of first-line ET for MBC, while on ET\n",
      "\n",
      "          6. At least one measurable disease according to RECIST 1.1(except for bone metastasis\n",
      "             only)\n",
      "\n",
      "          7. LVEF ≥ 55%\n",
      "\n",
      "          8. No radiation therapy within 4 weeks prior to enrollment\n",
      "\n",
      "          9. Normal function of major organs: Hb ≥ 90 g/L (no blood transfusion within 14 days)\n",
      "             ;ANC ≥1.5×109 /L；PLT ≥75×109 /L；TBIL≤1. 5×ULN; ALT、 AST≤ 3×ULN（ALT、 AST≤ 5×ULN with\n",
      "             hepatic metastases）; serum Cr ≤ 1×ULN\n",
      "\n",
      "         10. Be willing to participate in the study, sign informed consent and cooperate with the\n",
      "             follow-up\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Previous accumulated or equivalent dose of doxorubicin ≥300mg/m2\n",
      "\n",
      "          2. Intervals of anthracycline-based adjuvant chemotherapy ≤1 year (time between\n",
      "             anthracycline-based adjuvant or neoadjuvant chemotherapy and disease relapse)\n",
      "\n",
      "          3. Patients with symptomatic central nervous system metastases. Except for patients with\n",
      "             stable and asymptomatic brain metastases for at least 8 weeks and no need for\n",
      "             glucocorticoids or mannitol treatment before the trial and at least one measurable\n",
      "             lesion outside the brain. Radiotherapy for brain metastases should be completed at\n",
      "             least 4 weeks before the registration\n",
      "\n",
      "          4. Pregnant or lactating women and gestational age women who are unable to use effective\n",
      "             contraception\n",
      "\n",
      "          5. Treatment with investigational products within 4 weeks before the study\n",
      "\n",
      "          6. Severe cardiopulmonary insufficiency, severe hepatic and renal dysfunction\n",
      "\n",
      "          7. Severe or uncontrolled infection\n",
      "\n",
      "          8. Psychiatric drugs abuse and unable to withdrawal or mental disorders\n",
      "\n",
      "          9. Other malignancies, except for cured skin basal cell carcinoma and cervical\n",
      "             intraepithelial neoplasia.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Female with OI who has delivered an infant of at least 24 weeks' gestation\n",
      "\n",
      "          -  Participant in the BBD Contact Registry\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Inability to provide informed consent and complete survey\n",
      "\n",
      "          -  Males\n",
      "\n",
      "          -  Women with OI who have not delivered children and gestations associated with higher\n",
      "             order multiples\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Physician diagnosis of COPD\n",
      "\n",
      "          -  Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) ≤70%\n",
      "\n",
      "          -  FEV1 (% predicted) ≥40 % AND ≤ 70%,\n",
      "\n",
      "          -  Tobacco exposure ≥ 10 pack-years,\n",
      "\n",
      "          -  Chronic cough and sputum production\n",
      "\n",
      "          -  At least one COPD exacerbation requiring systemic glucocorticosteroids or treatment in\n",
      "             hospital, or both, in the previous year\n",
      "\n",
      "          -  Not suffering from any concomitant disease that might interfere with study procedures\n",
      "             or evaluations.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or\n",
      "             antibiotics not stopped at least 4 weeks prior to the baseline visit V0\n",
      "\n",
      "          -  Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0\n",
      "\n",
      "          -  Diagnosis of asthma and/or other relevant lung disease (e.g. history of\n",
      "             bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer,\n",
      "             interstitial lung disease [e.g. fibrosis, silicosis, sarcoidosis], and active\n",
      "             tuberculosis\n",
      "\n",
      "          -  Known alpha-1-antitrypsin deficiency\n",
      "\n",
      "          -  Known infection with HIV and/or active hepatitis\n",
      "\n",
      "          -  Pregnancy or women of childbearing potential not using or willing to continue using a\n",
      "             medically reliable method of contraception for the entire study period\n",
      "\n",
      "          -  Suspected hypersensitivity to the study medication (roflumilast).\n",
      "\n",
      "          -  Use of mucolytics within the last 4 weeks.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        - Patients scheduled for elective surgery requiring general anesthesia\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Age less than 18 years\n",
      "\n",
      "          -  Adults unable to give primary consent\n",
      "\n",
      "          -  Pregnancy\n",
      "\n",
      "          -  Prisoners\n",
      "\n",
      "          -  Unable to access pericardial 6 acupressure point bilaterally post procedure\n",
      "\n",
      "          -  Allergy to Ondansetron\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age between 21 and 65 years;\n",
      "\n",
      "          2. Chronic (more than 12 months since injury) incomplete SCI between levels C2-C8 or\n",
      "             diagnosis of definite or probable ALS;\n",
      "\n",
      "          3. Incomplete weakness of left or right hand muscles: score of 2, 3, or 4 (out of 5) on\n",
      "             manual muscle testing of finger extension, finger flexion, or finger abduction;\n",
      "\n",
      "          4. Detectable F-wave responses of the left or right abductor pollicis brevis muscle to\n",
      "             median nerve stimulation.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Multiple spinal cord lesions;\n",
      "\n",
      "          2. History of seizures;\n",
      "\n",
      "          3. Ventilator dependence or patent tracheostomy site;\n",
      "\n",
      "          4. Use of medications that significantly lower seizure threshold, such as tricyclic\n",
      "             antidepressants, amphetamines, neuroleptics, dalfampridine, and bupropion;\n",
      "\n",
      "          5. History of stroke, brain tumor, brain abscess, or multiple sclerosis;\n",
      "\n",
      "          6. History of moderate or severe head trauma (loss of consciousness for greater than one\n",
      "             hour or evidence of brain contusion or hemorrhage or depressed skull fracture on prior\n",
      "             imaging);\n",
      "\n",
      "          7. History of implanted brain/spine/nerve stimulators, aneurysm clips, ferromagnetic\n",
      "             metallic implants, or cardiac pacemaker/defibrillator;\n",
      "\n",
      "          8. Significant coronary artery or cardiac conduction disease;\n",
      "\n",
      "          9. Recent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a\n",
      "             syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic\n",
      "             pressure greater than 10 mm Hg, without rise in heart rate, accompanied by symptoms\n",
      "             such as headache, facial flushing, sweating, nasal congestion, and blurry vision (this\n",
      "             will be closely monitored during all screening and testing procedures);\n",
      "\n",
      "         10. History of bipolar disorder;\n",
      "\n",
      "         11. History of suicide attempt;\n",
      "\n",
      "         12. Active psychosis;\n",
      "\n",
      "         13. Heavy alcohol consumption (greater than equivalent of 5 oz of liquor) within previous\n",
      "             48 hours;\n",
      "\n",
      "         14. Open skin lesions over the face, neck, shoulders, or arms;\n",
      "\n",
      "         15. Pregnancy\n",
      "\n",
      "         16. Unsuitable for study participation as determined by study physician.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria von Willebrand Patients:\n",
      "\n",
      "          -  18 - 80 years old\n",
      "\n",
      "          -  no other bleeding disorder except 2 and 3 von Willebrand disease\n",
      "\n",
      "        Inclusion Criteria healthy controls:\n",
      "\n",
      "          -  no bleeding disorder\n",
      "\n",
      "          -  no anticoagulative medication\n",
      "\n",
      "        Exclusion Criteria von Willebrand Patients:\n",
      "\n",
      "        - requirement of systemic antibiotics for measures that may cause transitory bacteraemia\n",
      "\n",
      "        Exclusion Criteria healthy controls:\n",
      "\n",
      "        - bleeding disorder\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  0 till16 years of age\n",
      "\n",
      "          -  Any primary wound repair treatment of a laceration caused by trauma and involving the\n",
      "             skin of the head area\n",
      "\n",
      "          -  Patient or caregiver must be able to understand and sign an informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pre-existing conditions that affect wound healing adversely\n",
      "\n",
      "          -  Patients who demonstrate severe or life-threatening injuries\n",
      "\n",
      "          -  Patients / caregivers with communication / logistic barriers that would make them\n",
      "             unfit to provide informed consent or to attend the follow-up visits\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Individuals with an index episode of self-poisoning or self-injury with or without\n",
      "             suicide intent, based on the ICD-10 codes for self-harm with and without suicide\n",
      "             intent (i.e., X60 to X84 and R45.8)\n",
      "\n",
      "          -  Admission to the AEDs at the 4 collaborating public hospitals in Hong Kong (United\n",
      "             Christian Hospital, North District Hospital, Queen Mary Hospital, and Pamela Youde\n",
      "             Nethersole Eastern Hospital)\n",
      "\n",
      "          -  Mentally well assessed by a psychiatrist or Consultation Liaison Nurses (CLNs)\n",
      "\n",
      "          -  Capable of providing written Informed Consent Form\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Individuals with DSM-IV-TR Axis II disorder; or\n",
      "\n",
      "          -  Individuals with severe psychotic mental illness or bipolar disorder\n",
      "      \n",
      "\n",
      "        INCLUSION CRITERIA:\n",
      "\n",
      "          1. Patients age 55 and older;\n",
      "\n",
      "          2. Owns and uses a smartphone;\n",
      "\n",
      "          3. Any ONE of the following guideline-related needs in the past 18 months:\n",
      "\n",
      "               1. Most recent encounter LDL >= 100 mg/dl\n",
      "\n",
      "               2. Most recent encounter BP > 140/90 mmHg (or > 150/90 for persons age 60+)\n",
      "\n",
      "               3. Most recent encounter not taking recommended post-stroke medications\n",
      "\n",
      "               4. Most recent encounter not taking recommended post-MI medications\n",
      "\n",
      "               5. Diabetics with most recent encounter not on ACE inhibitor or ARB blocker\n",
      "\n",
      "               6. Any patient with most recent A1c > 8.0%\n",
      "\n",
      "               7. Diabetics with no urine microalbumin screening, past 18 months\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "          1. Non-English speaking (app available only in English for this study)\n",
      "\n",
      "          2. No encounter in the past 18 months (they may be receiving care elsewhere and\n",
      "             guideline-related needs may not be reliably assessed) at the clinic itself\n",
      "\n",
      "          3. Most recent systolic BP >200 or diastolic BP > 110 mm Hg\n",
      "\n",
      "          4. Any history of significant hepatic disease, including cirrhosis, Hepatitis B or C\n",
      "             infection, or laboratory abnormalities (serum ALT or AST > 3 times normal (either AST\n",
      "             above 96 U/L or ALT above 99 U/L or total bilirubin > 2.0 mg/dl))\n",
      "\n",
      "          5. History of hemorrhagic stroke\n",
      "\n",
      "          6. Pulmonary hypertension\n",
      "\n",
      "          7. Stage 4 or metastatic cancer\n",
      "\n",
      "          8. Current nursing home residence or has plans to move to one within the next 12 months\n",
      "\n",
      "          9. Has plans to transfer care from the current clinic within the next 6 months\n",
      "\n",
      "         10. Inability to give informed consent or impaired cognitive function\n",
      "\n",
      "         11. Currently pregnant (females only)\n",
      "\n",
      "         12. Currently a prisoner\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Community-dwelling, English-speaking women, over 18 years, who are currently\n",
      "             undergoing chemotherapy for Stage 1-3 BC and have been cleared by their oncologist to\n",
      "             participate in moderate intensity aerobic exercise\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Participants will be excluded from the study if they have another chronic disease,\n",
      "             cognitive impairment or injury that prevents them from participating independently in\n",
      "             moderate intensity exercise\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Palliative care professionals (medical, nursing and social worker) affiliated to a\n",
      "             hospice in the West Midlands.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Medical, nursing or social worker not working in a hospice in the West Midlands.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Willingness to provide informed consent\n",
      "\n",
      "          2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least\n",
      "             one year and using insulin for at least 1 year\n",
      "\n",
      "          3. Using basal and meal insulin (NovoLog® [insulin aspart], Humalog® [insulin lispro] or\n",
      "             Apidra® [insulin glulisine]) for Intensive Insulin Therapy including carbohydrate\n",
      "             counting and use of pre-defined parameters for glucose goal, carbohydrate ratio, and\n",
      "             insulin sensitivity factor for at least 1 month.\n",
      "\n",
      "             a. Acceptable basal insulin regimens include: i. Lantus® (insulin glargine) 100U/mL\n",
      "             once or twice daily ii. Levemir® (insulin detemir) 100U/mL once or twice daily iii.\n",
      "             Tresiba® (insulin degludec) 100U/mL once daily\n",
      "\n",
      "          4. Age ≥15.0 years old\n",
      "\n",
      "          5. Willingness to use the study basal insulin (Tresiba® [insulin degludec]) and meal\n",
      "             insulin (NovoLog® [insulin aspart]) for the duration of the study.\n",
      "\n",
      "          6. Willingness to use the home or DSS-optimized carbohydrate counting parameters for all\n",
      "             meal dosing and enter the information into the inControl APP (for CGM+DSS group).\n",
      "\n",
      "          7. For females, not currently known to be pregnant\n",
      "\n",
      "          8. If female and sexually active, must agree to use a highly effective form of\n",
      "             contraception to prevent pregnancy while a participant in the study. A negative serum\n",
      "             or urine pregnancy test will be required for all premenopausal women who are not\n",
      "             surgically sterile. Subjects who become pregnant will be discontinued from the study.\n",
      "             Also, subjects who during the study develop and express the intention to become\n",
      "             pregnant within the timespan of the study will be discontinued.\n",
      "\n",
      "          9. Ability to access the Internet to provide data to the clinical team or to travel to\n",
      "             the research center so that the study equipment can be downloaded.\n",
      "\n",
      "         10. Ability to have 3G or Wi-Fi to be able to use the DSS smart bolus calculator and\n",
      "             advice given (i.e. sleep, exercise).\n",
      "\n",
      "         11. Demonstration of proper mental status and cognition for the study\n",
      "\n",
      "         12. Investigator has confidence that the subject can successfully operate all study\n",
      "             devices and is capable of adhering to the protocol\n",
      "\n",
      "         13. If on a non-insulin hyperglycemic therapy, stability on that therapy for the prior 3\n",
      "             months and willingness not to alter the therapy for the study duration.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Medical need for chronic acetaminophen\n",
      "\n",
      "          2. Use of any medication that at the discretion of the clinical protocol chair is deemed\n",
      "             to interfere with the trial.\n",
      "\n",
      "          3. Current treatment of a seizure disorder.\n",
      "\n",
      "          4. Coronary artery disease or heart failure, unless written clearance is received from a\n",
      "             cardiologist.\n",
      "\n",
      "          5. Hemophilia or any other bleeding disorder\n",
      "\n",
      "          6. A known medical condition, which in the opinion of the investigator or designee, would\n",
      "             put the participant or study at risk such as the following examples:\n",
      "\n",
      "               1. Inpatient psychiatric treatment in the past 6 months\n",
      "\n",
      "               2. Presence of a known adrenal disorder\n",
      "\n",
      "               3. Abnormal liver function test results (Transaminase >3 times the upper limit of\n",
      "                  normal)\n",
      "\n",
      "               4. Abnormal renal function test results (calculated GFR <60 mL/min/1.73m2).\n",
      "\n",
      "               5. Active gastroparesis requiring medical therapy\n",
      "\n",
      "               6. Uncontrolled thyroid disease (TSH undetectable or >10 mlU/L).\n",
      "\n",
      "               7. Abuse of alcohol or recreational drugs\n",
      "\n",
      "               8. Infectious process not anticipated to be resolved prior to study procedures (e.g.\n",
      "                  meningitis, pneumonia, osteomyelitis, deep tissue infection).\n",
      "\n",
      "               9. Uncontrolled arterial hypertension (Resting diastolic blood pressure >100 mmHg\n",
      "                  and/or systolic blood pressure >180 mmHg).\n",
      "\n",
      "              10. Uncontrolled microvascular complications such as current active proliferative\n",
      "                  diabetic retinopathy defined as proliferative retinopathy requiring treatment\n",
      "                  (e.g. laser therapy or VEGF inhibitor injections) in the past 12 months.\n",
      "\n",
      "          7. A recent injury to body or limb, muscular disorder, use of any medication, any\n",
      "             carcinogenic disease, or other significant medical disorder if that injury, medication\n",
      "             or disease in the judgment of the investigator will affect the completion of the\n",
      "             protocol.\n",
      "\n",
      "          8. Current use of the following drugs and supplements:\n",
      "\n",
      "             k. Regular acetaminophen user, or not willing to suspend acetaminophen 24 hours before\n",
      "             and during the entire length of the trial l. Oral steroids m. Any other medication\n",
      "             that the investigator believes is a contraindication to the subject's participation\n",
      "\n",
      "          9. Participation in another pharmaceutical or device trial at the time of enrollment or\n",
      "             during the study\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically proven squamous cell carcinoma of the intrathoracic esophagus.\n",
      "\n",
      "          -  Surgical resectable (T1b-3, N0-2, M0)\n",
      "\n",
      "          -  Age ≥ 18 and ≤ 75 years\n",
      "\n",
      "          -  European Clinical Oncology Group performance status 0, 1 or 2\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Carcinoma of the cervical esophagus\n",
      "\n",
      "          -  Histologically proven adenocarcinoma or undifferentiated carcinoma.\n",
      "\n",
      "          -  Prior thoracic surgery at the right hemithorax or thorax trauma.\n",
      "\n",
      "          -  Infectious disease with systemic therapy indicated.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Subjects must be undergoing autologous or allogeneic hematopoietic cell transplant\n",
      "             (HSCT) with the BEAM conditioning regimen prior to HSCT\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n",
      "\n",
      "          -  Able to swallow oral medications\n",
      "\n",
      "          -  Ability to understand and the willingness to sign a written informed consent document\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects with known hypersensitivity or other allergic reactions attributed to\n",
      "             compounds of similar biologic composition to netupitant, palonosetron, dexamethasone,\n",
      "             or other agents used in the study\n",
      "\n",
      "          -  Subjects who are receiving any other investigational agents or have received another\n",
      "             investigational drug in the last 30 days\n",
      "\n",
      "          -  Subjects who have had emesis or required antiemetics in the 48 hours prior to starting\n",
      "             the BEAM conditioning regimen; also patients required to take antipsychotics, appetite\n",
      "             stimulants, or other medications with antiemetic effects will be excluded if those\n",
      "             medications cannot be replaced by therapeutic equivalents\n",
      "\n",
      "          -  Female subjects who are pregnant, have a positive serum human chorionic gonadotrophin\n",
      "             (hCG), or are lactating and intend to breast feed a child; pregnant women are excluded\n",
      "             from this study; breastfeeding should be discontinued if the mother is treated with\n",
      "             NEPA\n",
      "\n",
      "          -  Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral\n",
      "             therapy are ineligible\n",
      "\n",
      "          -  Subjects who have taken a neurokinin antagonist within 14 days prior to beginning the\n",
      "             BEAM regimen\n",
      "\n",
      "          -  Subjects who have a serum creatinine > 2 x upper limit of normal (ULN)\n",
      "\n",
      "          -  Subjects with severe renal failure or end stage renal disease (estimated GFR\n",
      "             [glomerular filtration rate] of < 30 mL/min) as estimated by the Cockcroft-Gault\n",
      "             formula\n",
      "\n",
      "          -  Subjects with severe hepatic insufficiency (Child Pugh score > 9)\n",
      "\n",
      "          -  Subjects who have been drinking > 5 alcoholic drinks daily for the last year\n",
      "\n",
      "          -  Subjects who have concurrent illness requiring systemic corticosteroid use other than\n",
      "             the planned dexamethasone during conditioning therapy\n",
      "\n",
      "          -  Subjects with gastrointestinal conditions which might result in malabsorption of the\n",
      "             study drug\n",
      "\n",
      "          -  Subjects with a history of anxiety-induced (\"anticipatory\") nausea and vomiting\n",
      "\n",
      "          -  Subjects on strong CYP 3A4 inducers or inhibitors who are unable to have those agents\n",
      "             replaced with clinical alternatives prior to beginning the study; length of washout\n",
      "             period will be 7 days; notably, in the case of allogeneic transplant recipients\n",
      "             requiring cyclosporine or tacrolimus, no empiric dose adjustments will be required due\n",
      "             to close level monitoring and adjustments, which are standard in Oregon Health &\n",
      "             Science University (OHSU) protocols\n",
      "\n",
      "          -  Subjects unable to discontinue benzodiazepines will not be allowed as hypnotics;\n",
      "             additional antiemetics will be allowed for rescue but not for prophylaxis\n",
      "\n",
      "          -  Subjects with personal or family history of QT prolongation, uncorrected electrolyte\n",
      "             abnormalities, congestive heart failure, bradyarrhythmia, conduction disturbances and\n",
      "             those taking antiarrhythmic medicinal products or other medicinal products that lead\n",
      "             to QT prolongation or electrolyte abnormalities; relevant information will be\n",
      "             collected during medical history taking\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age greater than or equal to 18 years old.\n",
      "\n",
      "          -  At least three months status post heart transplantation.\n",
      "\n",
      "          -  Heart-transplant patients with normal graft function (left ventricular ejection\n",
      "             fraction equal to or greater than 55%) and no prior history of clinically significant\n",
      "             acute rejection episodes that required modification of the immunosuppressive regimen\n",
      "             or cardiac allograft vasculopathy.\n",
      "\n",
      "          -  Heart-transplant patients with nonspecific allograft dysfunction (left ventricular\n",
      "             ejection fraction equal to or less than 50% AND decrease from post-transplant baseline\n",
      "             ejection fraction by an absolute difference of 10% or greater, no formal diagnosis of\n",
      "             allograft vasculopathy by coronary angiogram or coronary vascular ultrasonography, and\n",
      "             no history of prior acute rejection episodes known to have decreased left ventricular\n",
      "             ejection fraction to or less than 50%).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Biopsy proven acute rejection episode in the past 3 months.\n",
      "\n",
      "          -  Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary\n",
      "             syndrome in the past 3 months.\n",
      "\n",
      "          -  Uncontrolled obstructive ventilatory disease including asthma and COPD.\n",
      "\n",
      "          -  Second or third degree AV nodal block.\n",
      "\n",
      "          -  Sinus node dysfunction.\n",
      "\n",
      "          -  Contraindications to MRI including pacemakers or implantable\n",
      "             cardioverter-defibrillators.\n",
      "\n",
      "          -  Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m2.\n",
      "\n",
      "          -  Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse\n",
      "             reaction to adenosine will be assessed on a case-by-case basis.\n",
      "\n",
      "          -  Any invasive procedure, including endomyocardial biopsy and left coronary angiogram,\n",
      "             performed within one week.\n",
      "\n",
      "          -  Systolic blood pressure greater than 180 or less than 85 mmHg.\n",
      "\n",
      "          -  Diastolic blood pressure greater than 120 or less than 40 mmHg.\n",
      "\n",
      "          -  Resting heart rate greater than 120 or less than 45 beats per minute.\n",
      "\n",
      "          -  Severe claustrophobia.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  gestational age <32 weeks\n",
      "\n",
      "          -  birth weight <1500 g.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  congenital abnormalities\n",
      "\n",
      "          -  hypoxic-ischemic encephalopathy\n",
      "\n",
      "          -  intraventricular haemorrhage grade 3-4\n",
      "\n",
      "          -  post-haemorrhagic ventricular dilatation\n",
      "\n",
      "          -  periventricular leukomalacia and/or porencephalic cysts\n",
      "\n",
      "          -  general anaesthesia\n",
      "      \n",
      "\n",
      "        Inclusion criteria\n",
      "\n",
      "          -  Provision of informed consent prior to any study specific procedures\n",
      "\n",
      "          -  Female patients ≥18 years of age, with histologically diagnosed relapsed non-mucinous\n",
      "             epithelial ovarian cancer (EOC) (including primary peritoneal and/or fallopian tube\n",
      "             cancer) (Non-mucinous EOC includes patients with serous, endometrioid, and\n",
      "             transitional cell tumours, and those with mixed histology where one of these subtypes\n",
      "             is predominant (>50%). Inclusion of other subtypes should first be discussed with the\n",
      "             Medical Monitor).\n",
      "\n",
      "          -  Documented BRCA1/2 status.\n",
      "\n",
      "          -  Patients must have received one prior PARPi therapy PARPi therapy includes any agent\n",
      "             (including Olaparib) used in a maintenance setting For the BRCA1/2 (+ve) cohort, the\n",
      "             duration of first PARPi exposure must have been ≥18 months following a first line of\n",
      "             chemotherapy or ≥12 months following a second or subsequent line of chemotherapy For\n",
      "             the BRCA1/2 (-ve) cohort, the duration of first PARPi exposure must have been ≥12\n",
      "             months following a first line of chemotherapy or ≥6 months following a second or\n",
      "             subsequent line of chemotherapy For the last chemotherapy course immediately prior to\n",
      "             randomisation on the study Patients must have received a platinum-based chemotherapy\n",
      "             regimen (carboplatin, cisplatin or oxaliplatin) and have received at least 4 cycles of\n",
      "             treatment Patients must be, in the opinion of the investigator, in response (partial\n",
      "             or complete radiological response) or may have no evidence of disease (if optimal\n",
      "             cytoreductive surgery was conducted prior to chemotherapy) and no evidence of a rising\n",
      "             CA-125, as defined below, following completion of this chemotherapy course\n",
      "             Pre-treatment CA-125 measurements must meet criterion specified below\n",
      "\n",
      "          -  If the first value is within upper limit of normal (ULN) the patient is eligible to be\n",
      "             randomised and a second sample is not required\n",
      "\n",
      "          -  If the first value is greater than ULN a second assessment must be performed at least\n",
      "             7 days after the first. If the second assessment is ≥ 15% more than the first the\n",
      "             patient is not eligible.\n",
      "\n",
      "        Patients must not have received bevacizumab during this course of treatment. Bevacizumab\n",
      "        use as part of an earlier line of chemotherapy is permitted Patients must not have received\n",
      "        any investigational agent during this course of treatment Patients must be randomised\n",
      "        within 8 weeks of their last dose of chemotherapy (last dose is the day of the last\n",
      "        infusion)\n",
      "\n",
      "          -  Patients must have normal organ and bone marrow function measured within 28 days of\n",
      "             randomization.\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group performance status 0-1\n",
      "\n",
      "          -  Patients must have a life expectancy ≥16 weeks.\n",
      "\n",
      "          -  Postmenopausal or evidence of non-childbearing status for women of childbearing\n",
      "             potential: negative urine or serum pregnancy test within 28 days of study treatment\n",
      "             and confirmed prior to treatment on day 1\n",
      "\n",
      "          -  At least one lesion (measurable and/or non-measurable) that can be accurately assessed\n",
      "             at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and is\n",
      "             suitable for repeated assessment. or No measurable disease following a complete\n",
      "             response to most recent chemotherapy (+/- surgery)\n",
      "\n",
      "          -  A formalin fixed, paraffin embedded (FFPE) tumour sample from the cancer of sufficient\n",
      "             quantity and quality (as specified in the Covance Central Laboratory Services Manual)\n",
      "             must be available for future central testing of tumour genetic status.\n",
      "\n",
      "          -  For inclusion in the optional biomarker research, patients must sign an informed\n",
      "             consent for biomarker research.\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca\n",
      "             staff and/or staff at the study site).\n",
      "\n",
      "          -  Participation in another clinical study with an investigational product during the\n",
      "             chemotherapy course immediately prior to randomisation.\n",
      "\n",
      "          -  Other malignancy within the last 5 years except the ones detailed in the exclusion\n",
      "             criteria section of study protocol.\n",
      "\n",
      "          -  Resting electrocardiogram (ECG) with corrected QT interval (QTc) >470 msec on 2 or\n",
      "             more time points within a 24 hour period or family history of long QT syndrome6.\n",
      "             Patients receiving any systemic chemotherapy or radiotherapy (except for palliative\n",
      "             radiotherapy) within 3 weeks prior to study treatment.\n",
      "\n",
      "          -  Concomitant use of known strong cytochrome P450 (CYP) subfamily 3A (CYP3A) inhibitors\n",
      "             or moderate CYP3A inhibitors.\n",
      "\n",
      "          -  Concomitant use of known strong or moderate CYP3A inducers.\n",
      "\n",
      "          -  Persistent toxicities (Common Terminology Criteria for Adverse Event [CTCAE] grade 2\n",
      "             or higher) caused by previous cancer therapy, excluding alopecia and stable Grade 2\n",
      "             peripheral neuropathy .\n",
      "\n",
      "          -  Patients with current or previous myelodysplastic syndrome (MDS)/acute myeloid\n",
      "             leukaemia (AML) or with features suggestive of MDS/AML.\n",
      "\n",
      "          -  Patients with symptomatic uncontrolled brain metastases.\n",
      "\n",
      "          -  Immunocompromised patients, e.g., patients who are known to be serologically positive\n",
      "             for human immunodeficiency virus (HIV).\n",
      "\n",
      "          -  Patients with a known hypersensitivity to Olaparib or any of the excipients of the\n",
      "             product.\n",
      "\n",
      "          -  Patients with a known active hepatitis (i.e..Hepatitis B or C).\n",
      "\n",
      "          -  Patient who have received a whole blood transfusion within 30 days prior to screening\n",
      "             tests (packed red blood cells and platelet transfusions are acceptable).\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Completed 2 years in the FUNCTION (WA19926) trial\n",
      "\n",
      "          -  Patient has provided written informed consent and is willing to comply with the\n",
      "             requirements of this study protocol\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Requirement for immediate treatment with a biologic therapy following completion of\n",
      "             the FUNCTION (WA19926) trial as per treating physician judgement.\n",
      "\n",
      "          -  Presence of any condition that, in the opinion of the treating physician, prohibits\n",
      "             the patient from participating in the study or obscures the assessment of the\n",
      "             treatment of RA\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients suffering from paresis or plegia after trauma\n",
      "\n",
      "          -  First ASCIS assessment possible within the first 3 days after incidence\n",
      "\n",
      "          -  Patient capable and willing of giving written informed consent\n",
      "\n",
      "          -  No cognitive impairment which would preclude an informed consent (including severe\n",
      "             traumatic brain injury)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Nontraumatic paresis or plegia (e.g. disc-herniation, tumor, AV-malformation,\n",
      "             myelitis)\n",
      "\n",
      "          -  Previously known dementia or severe reduction of intelligence, leading to reduced\n",
      "             capabilities of cooperation or giving consent\n",
      "\n",
      "          -  Peripheral nerve lesion above the level of lesion (e.g. Plexus brachialis impairment)\n",
      "\n",
      "          -  Previously known polyneuropathy\n",
      "\n",
      "          -  Severe craniocerebral injury\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Received solid organ transplant\n",
      "\n",
      "          -  3-24 months post-transplant (any number of transplant)\n",
      "\n",
      "          -  Time interval of at least 6 days duration where complications such as rejection\n",
      "             episodes, viral infections, surgical interventions and therapies with mono or\n",
      "             polyclonal antibodies are ruled out by the transplant team.\n",
      "\n",
      "          -  No prior history of NMSC in the treatment fields\n",
      "\n",
      "          -  No AK/Bowen's disease in the treatment fields within the last 3 months.\n",
      "\n",
      "          -  Moderate to severe sun damage\n",
      "\n",
      "          -  Be willing to forego other interventions in the treatment fields than the ones\n",
      "             approved by the investigator that would interfere with the protocol or evaluation of\n",
      "             the study medication\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients with Fitzpatrick's scale skin type IV-VI\n",
      "\n",
      "          -  Cutaneous photosensitivity to wavelengths of 400-450 nm, porphyria or known allergies\n",
      "             to porphyrins\n",
      "\n",
      "          -  Known sensitivity to any of the components of the Levulan® Kerastick® for Topical\n",
      "             Solution\n",
      "\n",
      "          -  Prior use of topical or systemic therapies that might interfere with the evaluation of\n",
      "             the study medication during the study, within a 3 month washout period from the time\n",
      "             of the screening visit\n",
      "\n",
      "          -  Unable to return for follow-up visits and tests\n",
      "\n",
      "          -  Any condition or situation which in the Investigator's opinion may put the subject at\n",
      "             significant risk, could confound the study results, or could interfere significantly\n",
      "             with the subject's participation in the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Individuals in accordance with indications for YXSF Capsule, including xerasia, itchy\n",
      "             scalp, alopecia areata, seborrheic dermatitis and alopecia;\n",
      "\n",
      "          2. The age range of 18 to 70 years；\n",
      "\n",
      "          3. Individuals taking YXSF Capsule over 2 weeks;\n",
      "\n",
      "          4. Abnormalities of serum liver biochemistry achieving one of the criteria as follows:\n",
      "\n",
      "             (i) alanine aminotransaminase (ALT) or aspartate transaminase (AST) ≥2 folds of upper\n",
      "             limit of normal (ULN); (ii) total bilirubin (TBiL) ≥ 2 ULN; (iii) alkaline phosphatase\n",
      "             (ALP) ≥ 2 ULN;\n",
      "\n",
      "          5. Individuals can provide informed consent form.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Individuals without indications for YXSF Capsule;\n",
      "\n",
      "          2. Inconformity to the YXSF Capsule drug label;\n",
      "\n",
      "          3. Individual taking YXSF Capsule less than 2 weeks;\n",
      "\n",
      "          4. Individuals taking other hepatotoxic drugs combined with YXSF Capsule, simultaneously;\n",
      "\n",
      "          5. Inconformity to the diagnostic standard for herb-induced liver injury (the Guideline\n",
      "             for Diagnosis and Treatment of Herb-induced Liver Injury, RPGIP-2016CN003）.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Women undergoing minimally invasive surgery (MIS) hysterectomy with Bilateral Salpingo\n",
      "             Oophorectomy (BSO) for either a benign or malignant condition.\n",
      "\n",
      "          -  Performance Status of 0-1\n",
      "\n",
      "          -  Must have the ability to understand and willingness to sign a written informed consent\n",
      "             document\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of radical pelvic surgery.\n",
      "\n",
      "          -  History of stage IV-V uterine prolapse or hysteropexy\n",
      "\n",
      "          -  History of prior ureteral injury or retroperitoneal dissection\n",
      "\n",
      "          -  Known hydronephrosis.\n",
      "\n",
      "          -  Known congenital genitourinary or gynaecologic anomaly\n",
      "\n",
      "          -  Any known obstructing mass along any portion of the pelvic ureter\n",
      "\n",
      "          -  Known American Society for Reproductive Medicine (ASRM) stage III/IV endometriosis\n",
      "             (obliteration of the cul-de-sac)\n",
      "      \n",
      "\n",
      "        Retrospective study 1. Adults (age > 20 year old) with linezolid treatment (oral or\n",
      "        intravenous) in National Taiwan University hospital medical charts record from 2011 to\n",
      "        2016. 2. Patients with linezolid treatment for 3 days or above Prospective study\n",
      "\n",
      "          1. Adults (age > 20 year old) are going to start with linezolid treatment (oral or\n",
      "             intravenous) due to gram positive infection, multidrug resistant - tuberculosis\n",
      "             (MDR-TB) or nontuberculous mycobacterium (NTM) infection.\n",
      "\n",
      "          2. Keeping follow up in National Taiwan University Hospital\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        Retrospective study 1. Patients without baseline complete blood count (CBC) data (RBC or\n",
      "        Hb, WBC, platelet) before linezolid treatment. Prospective study\n",
      "\n",
      "        1. Patients with severe disease status (assess by clinicians) might die within 2 days or\n",
      "        treatment duration less than 2 days\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must have a minimum head circumference of 44 cm\n",
      "\n",
      "          -  Patients must have a histologically- or cytologically-confirmed supratentorial\n",
      "             high-grade glioma or supratentorial ependemoma.\n",
      "\n",
      "          -  Eligible pathologic diagnoses include:\n",
      "\n",
      "        High-grade Glioma (WHO Grade III or IV): Anaplastic Astrocytoma, Astroblastoma, Diffuse\n",
      "        Midline Glioma, Glioblastoma, Gliosarcoma Ependymoma (WHO Grade II or III):Ependymoma,\n",
      "        Anaplastic Ependymoma\n",
      "\n",
      "          -  Patients must have a tumor that is progressive or recurrent following standard\n",
      "             treatment.\n",
      "\n",
      "          -  Patients must have received the maximal feasible resection of their tumor and\n",
      "             radiation therapy (unless contraindicated due to patient age) as part of their initial\n",
      "             treatment prior to study enrollment.\n",
      "\n",
      "          -  Patients must be enrolled before treatment begins. Treatment must start within 14 days\n",
      "             of study enrollment.\n",
      "\n",
      "          -  All clinical and laboratory studies to determine eligibility must be performed within\n",
      "             7 days prior to enrollment unless otherwise indicated in the eligibility section.\n",
      "\n",
      "          -  Recurrent high-grade glioma patients must begin therapy within four weeks of\n",
      "             documented tumor progression by MRI scan.\n",
      "\n",
      "          -  Patients must have a Lansky or Karnofsky performance status score of ≥ 50%,\n",
      "             corresponding to ECOG categories of 0, 1 or 2. Use Karnofsky for patients > 16 years\n",
      "             of age and Lansky for patients ≤ 16 years of age. Patients who are unable to walk\n",
      "             because of paralysis, but who are up in a wheelchair will be considered ambulatory for\n",
      "             the purpose of assessing the performance score.\n",
      "\n",
      "          -  Able to undergo adequate tumor imaging, via magnetic resonance imaging (MRI) scan to\n",
      "             evaluate disease evolution.\n",
      "\n",
      "          -  Adequate hematologic, renal, liver function as demonstrated by laboratory values: ANC\n",
      "             ≥ 1,000/ul Hemoglobin ≥8.0 gm/dl Platelet count ≥ 100,000/ul\n",
      "\n",
      "        Adequate Liver Function Defined As:\n",
      "\n",
      "          -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and\n",
      "\n",
      "          -  SGPT (ALT) < 2.5 x upper limit of normal (ULN) for age. Adequate Renal Function\n",
      "             Defined As Either\n",
      "\n",
      "          -  Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73m2\n",
      "\n",
      "          -  or a serum creatinine less than or equal to the institutional normal for age\n",
      "\n",
      "               -  Negative pregnancy test in women of childbearing potential within 7 days of\n",
      "                  initiating investigational therapy\n",
      "\n",
      "               -  Recent mothers must agree not to breast feed while receiving medications on study\n",
      "\n",
      "               -  Patient or legal guardian must give written, informed consent or assent (when\n",
      "                  applicable).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Age less than 5 or greater than or equal to 18 years\n",
      "\n",
      "          -  Head circumference < 44 cm\n",
      "\n",
      "          -  Infra-tentorial or spinal primary tumor\n",
      "\n",
      "          -  Metastatic disease outside of the Optune treatment field (infra-tentorial or spinal\n",
      "             metastatic disease).\n",
      "\n",
      "          -  Use of any other investigational drug within five half-lives of that drug prior to the\n",
      "             initiation of protocol therapy\n",
      "\n",
      "          -  Anti-cancer therapy within 4 weeks prior to the initiation of protocol therapy (6\n",
      "             weeks for mitomycin and nitrosureas, 4 weeks for curative-intent radiotherapy, and 2\n",
      "             weeks for palliative radiotherapy)\n",
      "\n",
      "          -  Any National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE\n",
      "             version 4.0) >Grade 1 toxicities from prior chemotherapy or radiotherapy that could\n",
      "             impact on safety outcome assessment\n",
      "\n",
      "          -  Any surgery within 14 days prior to initiation of protocol therapy (excluding shunt or\n",
      "             line insertion)\n",
      "\n",
      "          -  Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other\n",
      "             implanted electronic devices in the brain, or documented clinically significant\n",
      "             arrhythmias.\n",
      "\n",
      "          -  Evidence of increased intracranial pressure (midline shift > 5mm, clinically\n",
      "             significant papilledema, vomiting and nausea or reduced level of consciousness)\n",
      "             Patients receiving escalating doses of corticosteroids to control symptoms of\n",
      "             increased intracranial pressure (e.g., require a stable or decreasing dose of\n",
      "             corticosteroids for at least 7 days prior to enrollment) will also be excluded.\n",
      "\n",
      "          -  Known > Grade 1 intracranial or intratumoral hemorrhage either by CT or MRI scan\n",
      "             within the last 1 month. Patients with resolving hemorrhage changes, punctuate\n",
      "             hemorrhage or hemosiderin may enter the study\n",
      "\n",
      "          -  Pregnant female patients, Pregnancy tests with a negative result must be obtained in\n",
      "             all post-menarchal females.\n",
      "\n",
      "          -  Lactating females must agree they will not breastfeed a child while on this study.\n",
      "\n",
      "          -  Males and females of reproductive potential may not participate unless they agree to\n",
      "             use an effective contraceptive method and continue to do so for at least 6 months\n",
      "             after the completion of therapy.\n",
      "\n",
      "          -  Any serious and/or unstable pre-existing medical, psychiatric or other condition which\n",
      "             in the Investigator's opinion could interfere with subject safety, obtaining written\n",
      "             informed consent, or compliance with the study protocol\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Ages 18-35\n",
      "\n",
      "          -  Elevated anxiety sensitivity (ASI-3 score >=23)\n",
      "\n",
      "          -  Able to safely participate in moderate-intensity physical activity as assessed by the\n",
      "             Physical Activity Readiness Questionnaire (PAR-Q), which will be administered during\n",
      "             screening\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Current aerobic exercise routine - Measured using the L-CAT with an established cut\n",
      "             point of >2 (assessed at screening)\n",
      "\n",
      "          -  Receiving ongoing psychotherapy or counseling (Self-report at screening)\n",
      "\n",
      "          -  Recent change in psychotropic medication for anxiety (Self-report at screening)\n",
      "\n",
      "          -  Psychiatric hospitalization in past 6 months (Self-report at screening)\n",
      "\n",
      "          -  Current pregnancy (Self-report at screening)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. surgical indication for lobectomy;\n",
      "\n",
      "          2. minimal invasive surgery;\n",
      "\n",
      "          3. ASA (American Society of Anesthesiologists) stage: I-III;\n",
      "\n",
      "          4. sign the informed consent. -\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. benign tumor or nodule;\n",
      "\n",
      "          2. present of other malignancy;\n",
      "\n",
      "          3. preoperative chemotherapy, radiotherapy, targeted therapy. -\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  18 years of age or older\n",
      "\n",
      "          -  Cardiac surgery using COVA™+ CARD\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  In accordance with the instruction for use (IFU) of the medical device.\n",
      "\n",
      "          -  Refusal of participation to the study\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  males or females with their age of 30 years or older at screening\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  subjects with a neurological disorder, a first degree relative with idiopathic PD,\n",
      "             Montreal Cognitive Assessment score of 26 or less, medications that might interfere\n",
      "             with DAT SPECT scans, anticoagulants that might preclude safe completion of the lumbar\n",
      "             puncture, or investigational drugs, and a condition that precludes the safe\n",
      "             performance of routine lumbar puncture\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients must be able to understand and willing to sign a written informed consent\n",
      "             document.\n",
      "\n",
      "          -  Patients with advanced triple-negative breast cancer (histologically or cytologically\n",
      "             confirmed invasive breast carcinoma with estrogen receptor negative, progesterone\n",
      "             receptor negative, human epidermal growth factor receptor 2 negative).\n",
      "\n",
      "          -  Patients must have progressed on or been intolerant of at least prior first-line\n",
      "             systemic treatment with anthracycline and/or taxane drugs for metastatic disease.\n",
      "             There are no any routine regimens.\n",
      "\n",
      "          -  At least 5-8 pieces of pathological tissue can be provided (for the detection of PD-L1\n",
      "             expression and the infiltrating lymphocytes).\n",
      "\n",
      "          -  Patients must have at least one metastatic lesion with diameter> 1 cm that is amenable\n",
      "             to SBRT, as determined by radiation oncologist.\n",
      "\n",
      "          -  Patients must be able to withstand the radiotherapy process, such as maintaining the\n",
      "             position, etc.\n",
      "\n",
      "          -  Patients must have at least 2 measurable lesions (based on RECIST V1.1);\n",
      "\n",
      "          -  Female aged 18 to 75 years old are eligible.\n",
      "\n",
      "          -  Weight ≥40kg\n",
      "\n",
      "          -  Life expectancy ≥6 months\n",
      "\n",
      "          -  ECOG performance status score of 0 or 1\n",
      "\n",
      "          -  There must be at least 4 weeks since the last radiotherapy, chemotherapy, hormone\n",
      "             therapy and molecular targeted therapy. Patients must have recovered from any toxicity\n",
      "             related to prior therapy and the toxicity should be less than or equal to grade 1\n",
      "             (according to CTCAE 4.03) or returned to baseline.\n",
      "\n",
      "          -  A systemic medication (such as corticosteroids) with an immunosuppressive dose\n",
      "             (prednisone> 10 mg/d or equivalent dose) must have been discontinued for at least 2\n",
      "             weeks before the initiation of the study drug.\n",
      "\n",
      "          -  Surgeries requiring general anesthesia must have been completed for at least 4 weeks\n",
      "             before the initiation of the study drug. Surgeries requiring local anesthesia or\n",
      "             epidural anesthesia must have been completed for at least 72 hours and the patients\n",
      "             have recovered from these surgeries. Skin biopsy that needs local anesthesia must have\n",
      "             been completed for at least 1 hour.\n",
      "\n",
      "          -  The Laboratory test results must meet the following criteria:\n",
      "\n",
      "               1. neutrophils ≥1.5×109/L\n",
      "\n",
      "               2. Platelets ≥100×109/L\n",
      "\n",
      "               3. Hemoglobin ≥90g/L (no blood transfusion within past 14 days)\n",
      "\n",
      "               4. Serum Cr ≤1×ULN, endogenous creatinine clearance rate >50ml/min (Cockcroft-Gault\n",
      "                  formula)\n",
      "\n",
      "               5. AST ≤2.5×ULN, ALT ≤2.5×ULN; both ALT and AST ≤5×ULN if there are liver metastasis\n",
      "\n",
      "               6. Total bilirubin ≤ 1.5 × ULN (except for patients with Gilbert syndrome, the total\n",
      "                  bilirubin of those patients must be <51.3μmol/L)\n",
      "\n",
      "               7. TSH, FT3, FT4 are within ± 10% of the normal range.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Evidence with active central nervous system (CNS) metastases. Patients can be included\n",
      "             if the CNS metastasis can be treated and the neurological symptoms can be restored to\n",
      "             a level of ≤1 degree of CTCAE (except for residual signs or symptoms associated with\n",
      "             CNS treatment) for at least 2 weeks before the enrollment. In addition, patients must\n",
      "             have not be treated with a corticosteroid, or just be treated with a stable dose of ≤\n",
      "             10 mg prednisone/day (or equivalent dose) or with a dose reduced to 10 mg\n",
      "             prednisone/day;\n",
      "\n",
      "          -  Patients with cancerous meningitis\n",
      "\n",
      "          -  The same part of body has been irradiated previously;\n",
      "\n",
      "          -  Patients with active, known or suspected autoimmune diseases. Patients with the\n",
      "             following conditions can be selected: vitiligo, type I diabetes, residual thyroid\n",
      "             dysfunction caused by autoimmune thyroiditis that just need hormone replacement\n",
      "             therapy, or diseases that will not relapse without external stimulating factors;\n",
      "\n",
      "          -  Any prior immune checkpoint inhibition treatment with anti-PD-1/PD-L1 /PD-L2 antibody\n",
      "             or anti-CTLA-4 antibody (or any other antibody acting on the T cell co-stimulus or\n",
      "             checkpoint pathway)\n",
      "\n",
      "          -  Evidence of active pulmonary tuberculosis (TB). Patients diagnosed with active\n",
      "             tuberculosis infection within 1 year should be excluded even if they have been\n",
      "             treated. Patients diagnosed with active tuberculosis infection for more than 1 year\n",
      "             must be excluded unless previous anti-tuberculosis treatment is effective;\n",
      "\n",
      "          -  Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome\n",
      "             (AIDS);\n",
      "\n",
      "          -  Complications that require immunosuppressive drugs or systemic or topical\n",
      "             corticosteroids with immunosuppressive doses;\n",
      "\n",
      "          -  Prior treatment of other study drug within past 28 days, or though the internal is\n",
      "             more than 28 days, precious study drug is still in the 5 half-life periods;\n",
      "\n",
      "          -  Inoculation of any anti-infective vaccine (such as influenza vaccine, varicella\n",
      "             vaccine, etc.) within past 4 weeks;\n",
      "\n",
      "          -  Pregnancy and breastfeeding\n",
      "\n",
      "          -  Patients that can't receive intravenous puncture and/or venous access;\n",
      "\n",
      "          -  History of other medical, psychological or social reasons as determined by the\n",
      "             investigator;\n",
      "\n",
      "          -  History of symptomatic interstitial lung disease or other conditions that may cause\n",
      "             confusion when discovering or managing suspicious drug-related lung toxicity;\n",
      "\n",
      "          -  Prior traditional Chinese medicine therapy with antitumor activity within past 2\n",
      "             weeks;\n",
      "\n",
      "          -  Prior therapy with monoclonal antibodies within past 3 months (except for locally\n",
      "             administration);\n",
      "\n",
      "          -  History of other malignant tumors. (Except for non-melanoma skin cancer and the\n",
      "             following carcinomas in situ: bladder, stomach, colon, endometrium, cervical /\n",
      "             dysplasia, melanoma or breast cancer). Patients who have obtained complete response\n",
      "             for at least 2 years prior to enrollment and don't need receive other treatment should\n",
      "             be included;\n",
      "\n",
      "          -  Underlying medical conditions, according to the investigator, that would increase the\n",
      "             risks of study drug administration or obscure the interpretation of adverse events;\n",
      "\n",
      "          -  Chronic hepatitis B (HBs Ag positive) or chronic hepatitis C (HCV antibody positive);\n",
      "\n",
      "          -  Patients with known sensitivity or allergy to any components of humanized anti-PD-1\n",
      "             antibody.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age between 18 and 85 years of age\n",
      "\n",
      "          -  Participants must have undergone implantation of DBS electrodes.\n",
      "\n",
      "          -  Participants must be able to understand the purpose of this research and must sign the\n",
      "             informed consent form.\n",
      "\n",
      "          -  Participants must understand that the role of this research is to enhance our\n",
      "             understanding of brain functioning and that he/she will not directly or indirectly\n",
      "             benefit from the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Participants who have serious cognitive or psychological impairments and cannot give\n",
      "             informed consent.\n",
      "\n",
      "          -  Participants who are unable to effectively or efficiently communicate, for example\n",
      "             patients suffering from speech deficits (dysarthria, aphasia) or are non-English\n",
      "             speaking.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age 18-40 years\n",
      "\n",
      "          2. Documented HIV-infected status\n",
      "\n",
      "          3. Current use of EFV\n",
      "\n",
      "          4. Fluency in English or Chichewa (the most commonly-spoken language in Malawi)\n",
      "\n",
      "          5. Not currently pregnant (to be confirmed by urine pregnancy test)\n",
      "\n",
      "          6. Initiation of DMPA or the LNG implant within the past 28 days (to be confirmed by\n",
      "             verification in the woman's Health Passport and palpation of the implant if\n",
      "             applicable)\n",
      "\n",
      "          7. No use of their current contraceptive during the 3 months before they recently\n",
      "             initiated it (i.e., they must be newly starting and not just continuing their chosen\n",
      "             contraceptive)\n",
      "\n",
      "          8. No desire for pregnancy in the next 4 years\n",
      "\n",
      "          9. Most recent HIV VL <1,000 copies/mL (as per Malawi guidelines, women who have VL\n",
      "             ≥1,000 copies/mL will need to be referred for possible 2nd-line ART without EFV)\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        -\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Male or female adult subjects over 18 years of age\n",
      "\n",
      "          2. Able to provide written informed consent and able to understand and willing to comply\n",
      "             with the requirements of the study\n",
      "\n",
      "          3. Clinical/imaging-diagnosed or biopsy-proven liver cirrhosis of any aetiology\n",
      "\n",
      "          4. Not previously enrolled in this study on a previous admission\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        1) Those patients who do not have capacity to consent\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  between 18 and 89 years old willing to commit to two days of testing\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  severe musculoskeletal impairment,\n",
      "\n",
      "          -  neurological impairment that would affect balance,\n",
      "\n",
      "          -  severe cognitive impairment (Mini-mental 19 or below),\n",
      "\n",
      "          -  unstable chronic disease state,\n",
      "\n",
      "          -  severe vestibular problems\n",
      "\n",
      "          -  severe orthostatic hypotension,\n",
      "\n",
      "          -  Simultaneous use of cardiovascular, psychotropic and antidepressant drugs.\n",
      "\n",
      "          -  Adults unable to consent\n",
      "\n",
      "          -  Prisoners\n",
      "\n",
      "          -  Pregnant females\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  hospitalized patients who underwent endoscopic swallowing evaluation at Showa Inan\n",
      "             General Hospital\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  an age less than 65 years old or the presence of an acute infection.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "        In order to be eligible for participation in this trial, the subject must:\n",
      "\n",
      "          1. Be willing and able to provide written informed consent for the trial and comply with\n",
      "             the protocol scheduled follow-up visits and examinations for the duration of the\n",
      "             study.\n",
      "\n",
      "          2. Be ≥ 18 years of age on day of signing informed consent.\n",
      "\n",
      "          3. Have recurrent NMIBC for which adjuvant treatment post TURBT would be a reasonable\n",
      "             treatment option.\n",
      "\n",
      "          4. Main study only: a. Have recurrent, multiple (minimum 2) tumours consistent with\n",
      "             NMIBC.\n",
      "\n",
      "             b. Have at least one lesion of between 5-10mm in size clinically that can be left\n",
      "             un-resected at TURBT as the marker lesion.\n",
      "\n",
      "             c. Have histologically confirmed low grade transitional cell NMIBC at original and any\n",
      "             subsequent diagnosis.\n",
      "\n",
      "          5. Have a normal upper urinary tract (as evidenced by ultrasound or CT urography within 2\n",
      "             years prior to randomisation) and no evidence of tumour in prostatic urethra at\n",
      "             flexible cystoscopy.\n",
      "\n",
      "          6. Have a performance status of 0 or 1 on the ECOG Performance Scale.\n",
      "\n",
      "          7. Have adequate organ function as defined below:\n",
      "\n",
      "             Haemoglobin (Hb) ≥ 9 g/dL without transfusion or EPO dependency Absolute neutrophil\n",
      "             count (ANC) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Total bilirubin ≤ 1.5 times the\n",
      "             upper limit of normal (ULN) or direct bilirubin < ULN for subjects with total\n",
      "             bilirubin levels > 1.5 x ULN Serum alanine aminotransferase (ALT) and/or serum\n",
      "             aspartate aminotransferase (AST) ≤ 2.5 x ULN Serum creatinine OR Measured or\n",
      "             calculated creatinine clearance ≤ 1.5 x ULN OR\n",
      "\n",
      "             ≥ 60ml/min for subject with creatinine levels > 1.5 x institutional ULN Albumin ≥\n",
      "             25g/L International Normalized Ratio (INR) or Prothrombin Time (PT) and Activated\n",
      "             Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN unless subject is receiving\n",
      "             anticoagulant therapy as long as PT or APTT is within therapeutic range of intended\n",
      "             use of anticoagulants a Creatinine clearance should be calculated as per institutional\n",
      "             standard\n",
      "\n",
      "          8. Female subjects of childbearing potential should have a negative urine or serum\n",
      "             pregnancy test within 72 hours prior to receiving the first dose of study medication.\n",
      "             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy\n",
      "             test will be required.\n",
      "\n",
      "          9. Both male and female subjects of childbearing potential must be willing to use an\n",
      "             adequate method of contraception as outlined in section 5.1 for the course of the\n",
      "             study and until 120 days after the last dose of the study medication.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        The subject must be excluded from participating in the trial if the subject:\n",
      "\n",
      "          1. Has received prior radiotherapy to the pelvis.\n",
      "\n",
      "          2. Has significant urinary incontinence or known bladder instability.\n",
      "\n",
      "          3. Main study only:\n",
      "\n",
      "               1. Has more than 2 out of 3 of the following present at the current time: i. ≥8\n",
      "                  tumours ii. Tumour ≥3cm in size iii. Frequent recurrence (>1/year)\n",
      "\n",
      "               2. Has a previous history of any of the following: T1 tumour, high grade/G3 tumour,\n",
      "                  carcinoma in situ, multiple recurrent large (>3cm) Ta, G1 or G2 tumours.\n",
      "\n",
      "               3. Had a primary tumour of unknown pathological stage or grade.\n",
      "\n",
      "               4. Has disease for which resection of all visible tumours is not possible.\n",
      "\n",
      "          4. Is currently participating and receiving study therapy or has participated in a study\n",
      "             of an investigational agent and received study therapy or used an investigational\n",
      "             device within 28 days of the first dose of trial treatment.\n",
      "\n",
      "          5. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any\n",
      "             other form of immunosuppressive therapy within 7 days prior to the first dose of trial\n",
      "             treatment. Subjects requiring use of inhaled or intranasal corticosteroids or local\n",
      "             steroid injections would not be excluded.\n",
      "\n",
      "          6. Has a known history of active TB.\n",
      "\n",
      "          7. Has received intravesical BCG treatment within 30 days prior to the first dose of\n",
      "             trial treatment.\n",
      "\n",
      "          8. Has hypersensitivity to pembrolizumab or any of its excipients.\n",
      "\n",
      "          9. Has had treatment with any other anti-cancer monoclonal antibody within 28 days prior\n",
      "             to enrolment or who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse\n",
      "             events due to agents administered more than 4 weeks earlier.\n",
      "\n",
      "         10. Has had treatment with prior chemotherapy, targeted small molecule therapy, or\n",
      "             radiation therapy within 2 weeks of administration of study drug or who has not\n",
      "             recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to a previously\n",
      "             administered agent.\n",
      "\n",
      "         11. Has a known additional malignancy that is progressing or requires active treatment.\n",
      "             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the\n",
      "             skin that has undergone potentially curative therapy or in situ cervical cancer.\n",
      "\n",
      "         12. Has known active central nervous system (CNS) metastases and/or carcinomatous\n",
      "             meningitis. Subjects with previously treated brain metastases may participate provided\n",
      "             they are stable (without evidence of progression by imaging for at least four weeks\n",
      "             prior to the first dose of trial treatment and any neurological symptoms have returned\n",
      "             to baseline), have no evidence of new or enlarging brain metastases, and are not using\n",
      "             steroids for a t least 7 days prior to trial treatment. This exception does not\n",
      "             include carcinomatous meningitis which is excluded regardless of clinical stability.\n",
      "\n",
      "         13. Has active autoimmune disease that has required systemic treatment in the past 2 years\n",
      "             (i.e. with use of disease modifying agents or immunosuppressive drugs). Replacement\n",
      "             therapy (e.g. thyroxine, insulin or physiologic corticosteroids replacement therapy\n",
      "             for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic\n",
      "             treatment.\n",
      "\n",
      "         14. Has a known history of, or any evidence of active, non-infectious pneumonitis.\n",
      "\n",
      "         15. Has an active or intractable infection requiring systemic therapy.\n",
      "\n",
      "         16. Has a history or current evidence of any condition, therapy, or laboratory abnormality\n",
      "             that might confound the results of the trial, interfere with the subject's\n",
      "             participation for the full duration of the trial, or is not in the best interest of\n",
      "             the subject to participate, in the opinion of the treating Investigator.\n",
      "\n",
      "         17. Has a known psychiatric or substance abuse disorder that would interfere with\n",
      "             cooperation with the requirements of the trial.\n",
      "\n",
      "         18. Is pregnant or breastfeeding, or expecting to conceive or father children within the\n",
      "             projected duration of the trial, starting with the pre-screening or screening visit\n",
      "             through to 120 days after the last dose of trial treatment.\n",
      "\n",
      "         19. Has received prior therapy with an anti-PD-1, anti PD-L1, or anti-PD-L2 agent.\n",
      "\n",
      "         20. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\n",
      "\n",
      "         21. Has known active Hepatitis B (e.g. HBsAg reactive) or Hepatitis C (e.g. HCV RNA\n",
      "             [qualitative] is detected).\n",
      "\n",
      "         22. Has received a live vaccine within 30 days prior to the first dose of trial treatment.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Age ≥40 (to reduce the likelihood of enrolling patients with obstruction due to\n",
      "             primary sclerosing cholangitis)\n",
      "\n",
      "          2. Cholestatic liver function tests, including serum alkaline phosphatase level ≥ 300\n",
      "             IU/L and bilirubin level ≥ 3.7 mg/dL\n",
      "\n",
      "          3. Radiographic evidence of a biliary hilar stricture OR intrahepatic but no extrahepatic\n",
      "             biliary ductal dilation\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Known radiographic evidence of a Bismuth-Corlette type 1 biliary stricture\n",
      "\n",
      "          2. Known diagnosis of primary sclerosing cholangitis without suspicion of dominant hilar\n",
      "             stricture\n",
      "\n",
      "          3. Recent gallbladder/biliary surgery within 12 months\n",
      "\n",
      "          4. Known Mirizzi syndrome\n",
      "\n",
      "          5. Known IgG4-mediated cholangiopathy\n",
      "\n",
      "          6. Significant liver metastatic disease interfering with safe/effective PTBD\n",
      "\n",
      "          7. Significant ascites interfering with safe/effective PTBD\n",
      "\n",
      "          8. Known regional malignant-appearing adenopathy or extra-biliary mass, indicating the\n",
      "             need for concurrent EUS-FNA\n",
      "\n",
      "          9. Prior ERCP or PTBD for hilar obstruction\n",
      "\n",
      "         10. Surgically altered luminal anatomy other than prior Billroth reconstruction or Whipple\n",
      "             resection\n",
      "\n",
      "         11. Standard general contraindications to ERCP or PTBD (e.g. hemodynamic instability,\n",
      "             uncorrected coagulopathy, etc.)\n",
      "\n",
      "         12. Inability or unwillingness to follow study protocol\n",
      "      \n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          -  Patients with esophageal cancer\n",
      "\n",
      "          -  Patients will undergo video-assisted thoracic surgical (VATS) esophagectomy and\n",
      "             laparoscopic gastric tube reconstruction\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          -  History of arrhythmia\n",
      "\n",
      "          -  History of chronic obstructive pulmonary disease (COPD)\n",
      "\n",
      "          -  With poor lung function test (FEV1 < 70% or FEV1/ forced vital capacity (FVC) < 70% of\n",
      "             predicted)\n",
      "\n",
      "          -  Preoperative creatinine more than 1.5 mg/dl\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  child aged 4.0 to 6.11 years\n",
      "\n",
      "          -  child diagnosed with ASD (Autism Diagnostic Observation Schedule; ADOS-2)\n",
      "\n",
      "          -  child without intellectual disability (Stanford Binet Intelligence Scales; SB-5)\n",
      "\n",
      "          -  parent able to consistently participate in parent training sessions and complete study\n",
      "             measures\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  child with other severe psychiatric disorder\n",
      "\n",
      "          -  child with known genetic condition (e.g., Fragile X, Retts)\n",
      "\n",
      "          -  child with unstable medical condition (e.g., active seizures)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Any patient with suspected malignant brain tumor on diagnostic MR imaging who will\n",
      "             undergo a resection\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Informed consent cannot be obtained either from the patient or legal representative\n",
      "\n",
      "          -  Severe coexisting or terminal systemic disease that may interfere with the conduct of\n",
      "             the study\n",
      "\n",
      "          -  Contraindication to MRI (metal implants)\n",
      "\n",
      "          -  Hemosiderosis/hemochromatosis\n",
      "\n",
      "          -  Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if\n",
      "             secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or\n",
      "             parenteral iron, or any other etiology\n",
      "\n",
      "          -  Known hypersensitivity to ferumoxytol or any of its components\n",
      "\n",
      "          -  Pregnant patients\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Male or female > 18 years of age.\n",
      "\n",
      "          -  Patient indicated for a first EUS-FNA for a pancreatic cyst or\n",
      "\n",
      "          -  Patients who had previous non-diagnostic tissue sampling taken during a previous\n",
      "             EUS-FNA for pancreatic cyst more than three months ago.\n",
      "\n",
      "          -  Patient with known pancreatic cyst detected at cross-sectional imaging\n",
      "\n",
      "          -  Willing and able to comply with study procedures and provide written informed consent\n",
      "             to participate in the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Subjects for whom EUS-FNA procedures are contraindicated\n",
      "\n",
      "          -  Known allergy to fluorescein dye\n",
      "\n",
      "          -  If female, pregnant based on a positive hCG serum or an in vitro diagnostic test\n",
      "             result or breast-feeding\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Osteoporotic patients who want to take oral ibandronate\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who are allergic to oral ibandronate or vitamin D Patients who have not taken\n",
      "             oral ibandronate for the last 2 years\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  HIV-positive\n",
      "\n",
      "          -  Pregnant and currently in 3rd trimester\n",
      "\n",
      "          -  Must reside in Nkoldongo district or Djoungolo district\n",
      "\n",
      "          -  Willing to be followed up for up to 21 months (pregnancy + postpartum periods)\n",
      "\n",
      "          -  Agrees to voluntary participation\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Age between 18 and 65 years old\n",
      "\n",
      "          -  VPSG within the last three months\n",
      "\n",
      "          -  Diagnosis of mild-to-moderate OSAS (AHI 5-30/h)\n",
      "\n",
      "          -  At least 4 teeth present in the lower and upper arch\n",
      "\n",
      "          -  Ability to protrude the mandible for at least 6 mm\n",
      "\n",
      "          -  Informed Consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Significant ENT disease\n",
      "\n",
      "               -  Tonsillar hypertrophy\n",
      "\n",
      "               -  Uvulopalatopharyngoplasty (UPPP)\n",
      "\n",
      "               -  Palatoschisis\n",
      "\n",
      "               -  Neoplastic lesions\n",
      "\n",
      "          -  Other neurological disorders\n",
      "\n",
      "               -  Trigeminal neuralgia\n",
      "\n",
      "               -  Myofacial pain dysfunction (MPD)\n",
      "\n",
      "               -  Central Sleep Apnea\n",
      "\n",
      "               -  Limited mental capacity\n",
      "\n",
      "          -  Obesity (BMI > 30 kg/m2)\n",
      "\n",
      "          -  Concomitant sleep-disordered breathing treatment (CPAP and/or positional therapy)\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Symptomatic posterior circulation ischemia（Vertebral basilar artery system TIA or\n",
      "             non-disabling ischemic stroke）result from the stenosis in the extracranial proximal\n",
      "             vertebral artery stenosis.\n",
      "\n",
      "          -  Atherosclerotic extracranial proximal vertebral artery stenosis demonstrated by\n",
      "             angiography(any of the following): 1) bilateral vertebral artery stenosis ≥70%, or\n",
      "             vertebral artery stenosis ≥70% concomitant occlusion of contralateral vertebral\n",
      "             artery; 2) superior lateral vertebral artery stenosis ≥70%; 3) non-superior lateral\n",
      "             vertebral artery stenosis ≥50%, but the vertebral artery was directly extended to the\n",
      "             posterior inferior cerebellar artery on this side and symptoms were related to\n",
      "             insufficiency of the ipsilateral posterior inferior cerebellar artery.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  1) lesions characteristics (such as diffuse lesions) which was not suitable for\n",
      "             interventional treatment, or unstable condition that cannot tolerate the\n",
      "             interventional therapy;\n",
      "\n",
      "          -  2) vertebral artery stenosis caused by non atherosclerosis disease: Takayasu arteritis\n",
      "             or other diseases;\n",
      "\n",
      "          -  3) severe stroke within 3 months;\n",
      "\n",
      "          -  4) contraindicated using contrast agents: such as chronic renal insufficiency or had\n",
      "             serious contrast agents allergy history;\n",
      "\n",
      "          -  5) malignant tumor;\n",
      "\n",
      "          -  6) with Alzheimer's disease or mental illness previously or currently ;\n",
      "\n",
      "          -  7) patients or family members refuse the operation.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  ARDS diagnosis within 72h after intubation\n",
      "\n",
      "          -  Severe to moderate ARDS (PaO2 / FiO2 < 200 mmHg)\n",
      "\n",
      "          -  Presence of an arterial line\n",
      "\n",
      "          -  Between 18 and 85 years old\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Persistent systolic blood pressure < 90 mmHg and/or >180 mmHg despite the use of\n",
      "             vasopressor or vasodilators\n",
      "\n",
      "          -  Increment in vasopressors over the past two hour just before enrollment of: more than\n",
      "             15 mcg/min for norepinephrine and dopamine, more than 10 mcg/min in epinephrine; and\n",
      "             more than 50 mcg/ min for phenylephrine.\n",
      "\n",
      "          -  Advanced lung disease confirmed by computed tomography findings\n",
      "\n",
      "          -  Presence or history of pneumothorax\n",
      "\n",
      "          -  Severe coagulopathy (INR ≥ 4)\n",
      "\n",
      "          -  Severe thrombocytopenia (Platelets count ≤ 5,000/mm3)\n",
      "\n",
      "          -  Usage of any devices with electric current generation such as pacemaker or internal\n",
      "             cardiac defibrillator\n",
      "\n",
      "          -  Recent esophageal trauma or surgery\n",
      "\n",
      "          -  Known presence of esophageal varices\n",
      "\n",
      "          -  Pregnancy\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  HIV-uninfected women, aged 15-24 years, being sexually active and having engaged in\n",
      "             any form of transactional sex at least once in the last 3 months, agreeing to\n",
      "             participate in all intervention sessions and to all study procedures and interviews\n",
      "             planned over 18 months of follow-up.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  presence of any physical or mental condition likely to cause inability to provide\n",
      "             consent or hinder study participation; HIV infection\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patient is scheduled for a bronchoscopic lung volume treatment using one-way valves\n",
      "\n",
      "          -  Patient has provided signed informed consent.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        For safety reasons patients that meet the following criteria will not be included in this\n",
      "        study:\n",
      "\n",
      "          1. FEV1 <20%\n",
      "\n",
      "          2. RV/TLC>70%\n",
      "\n",
      "          3. pCO2 >6.5\n",
      "\n",
      "          4. RVSP>40mmHg\n",
      "\n",
      "          5. 6MWT<200m\n",
      "\n",
      "          6. Known intolerance to Lidocaine\n",
      "\n",
      "          7. Any other medical reason/condition that warrants a short procedure (physician\n",
      "             judgement )\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Breast cancer patients treated with radiotherapy in UMC Utrecht, Erasmus Medical\n",
      "             Center or Radboudumc between 2004-16\n",
      "\n",
      "          -  Planning CT scan available\n",
      "\n",
      "          -  Age: ≥18 years\n",
      "\n",
      "          -  Gender: both genders\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Not applicable\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Type 2 diabetes\n",
      "\n",
      "          -  Between the ages of 21 and 80\n",
      "\n",
      "          -  Failed on an oral medication regimen (HbA1c > 7.5%).\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Takes insulin\n",
      "\n",
      "          -  Took medications in the last 3 months that impede weight loss (e.g., prednisone)\n",
      "\n",
      "          -  Pregnant or contemplating pregnancy in the next 12 months\n",
      "\n",
      "          -  Conditions that preclude increasing physical activity (e.g. severe neuropathy,\n",
      "             cardiovascular disease, chronic obstructive pulmonary disease/emphysema,\n",
      "             osteoarthritis, stroke)\n",
      "\n",
      "          -  Severe mental disease (e.g. manic depressive illness, severe depression, or active\n",
      "             substance abuse)\n",
      "\n",
      "          -  Undergoing treatment for cancer\n",
      "\n",
      "          -  History of lactic acidosis\n",
      "\n",
      "          -  Marked renal impairment (eGFR < 45; stage 3b chronic kidney disease)\n",
      "\n",
      "          -  Takes psychotropic medications that raise blood glucose (e.g. atypical antipsychotics)\n",
      "\n",
      "          -  Cannot read English.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with benign lesions (hemangioma, focal nodular hyperplasia [FNH],\n",
      "             hepatocellular adenoma, biliary cystadenoma, hydatid echinococcosis [only with total\n",
      "             pericystectomy]) and malignant tumors (colorectal cancer metastases in the liver\n",
      "             [CRLM], hepatocellular carcinoma [HCC], intrahepatic cholangiocellular carcinoma,\n",
      "             gallbladder cancer T1b-3NxMo without invasion into bile ducts and adjacent organs),\n",
      "             which involves laparoscopic segmental or major resection of the liver.\n",
      "\n",
      "          -  Gender: both, male and female\n",
      "\n",
      "          -  Minimum age 18 years\n",
      "\n",
      "          -  Maximum age: 80 years\n",
      "\n",
      "          -  ASA physical status I-IV\n",
      "\n",
      "          -  BMI up to 40 kg/m2\n",
      "\n",
      "          -  No simultaneous extrahepatic intra-abdominal procedures (bile duct resection, colon\n",
      "             resection, partial duodenum resection)\n",
      "\n",
      "          -  Total bilirubin up to 100mmol/l if jaundice presents in non-cirrhotic patients\n",
      "\n",
      "          -  If cirrhosis is present, class A and B according to CTP score\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  • Difficulty index > 12 points (see below)\n",
      "\n",
      "               -  Tumor invasion of IVC or portal trunk (necessity of vascular reconstruction)\n",
      "\n",
      "               -  Repeated liver resection before laparoscopic resection (the single resection\n",
      "                  before is not a contraindication)\n",
      "\n",
      "               -  Simultaneous extra-hepatic intra-abdominal procedures (bile duct resection, colon\n",
      "                  resection etc.)\n",
      "\n",
      "               -  Age under 18 years\n",
      "\n",
      "               -  Age above 80 years\n",
      "\n",
      "               -  ASA physical status >IV\n",
      "\n",
      "               -  BMI > 40 kg/m2\n",
      "\n",
      "               -  Total bilirubin >100mmol/l if jaundice presents in non-cirrhotic patients\n",
      "\n",
      "               -  If cirrhosis is present, class C according to CTP score\n",
      "\n",
      "               -  Persons who are incapable of giving consent\n",
      "\n",
      "               -  Pregnant or breast-feeding women\n",
      "\n",
      "               -  Patients enlisted in other studies\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Successfully CTO revascularization by PCI with immediate post-PCI OFDI analysis\n",
      "\n",
      "          -  3 months follow-up with OFDI analysis of the recanalized coronary artery\n",
      "\n",
      "          -  Aged 18 or over\n",
      "\n",
      "          -  Written informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Contraindication or impossibility to realize a safety coronary OFDI (severe\n",
      "             tortuosities)\n",
      "\n",
      "          -  Severe renal insufficiency (creatinine clearance < 30 ml/min)\n",
      "\n",
      "          -  Pregnancy or women with child-bearing potential\n",
      "\n",
      "          -  Bacteriemia or septicemia\n",
      "\n",
      "          -  Severe hemodynamic instability\n",
      "\n",
      "          -  Severe coagulation disorders\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Vitamin D deficient females undergoing first ICSI trial\n",
      "\n",
      "          -  Age from 20 to 35 years\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Women undergoing ICSI trials whose serum vitamin D level more than 20 nano-gram per\n",
      "             milliliter\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients with Multiple Sclerosis (PwMS)\n",
      "\n",
      "          -  Age range 18-65\n",
      "\n",
      "          -  Expanded disability status scale comprised between 1.5 and 6.5 with relapsing\n",
      "             remitting MS (RRMS) in remitting phase\n",
      "\n",
      "          -  Presenting with chronic, drug-resistant, neuropathic pain\n",
      "\n",
      "          -  Patients must score at or above a 0 on the Neuropathic Pain Questionnaire (NPQ).\n",
      "\n",
      "          -  Patients must score at least a 40 mm on the visual analog scale (VAS) for pain\n",
      "             perception at baseline\n",
      "\n",
      "          -  All analgesic medications discontinued at least 24 hours before entering the study\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Any change in:\n",
      "\n",
      "               -  disease-modifying medications, or\n",
      "\n",
      "               -  a relapse of disease symptoms within the last 60 days\n",
      "\n",
      "          -  History of seizures\n",
      "\n",
      "          -  History of traumatic brain injury\n",
      "\n",
      "          -  History of claustrophobia\n",
      "\n",
      "          -  Presence of:\n",
      "\n",
      "               -  pacemakers,\n",
      "\n",
      "               -  aneurysm clips,\n",
      "\n",
      "               -  artificial heart valves,\n",
      "\n",
      "               -  metallic prostheses, or\n",
      "\n",
      "               -  pregnancy.\n",
      "\n",
      "          -  Recent hospitalization (within the last 3 months)\n",
      "\n",
      "          -  Enforced bed rest/sedentary state\n",
      "\n",
      "          -  Resting plasma glucose greater than 200 mg/dl\n",
      "\n",
      "          -  Presence of other neurological disorders.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. HCV antibody and HCV RNA positive\n",
      "\n",
      "          2. HCV Genotype 1a, 1b, or 4\n",
      "\n",
      "          3. Liver staging assessment:\n",
      "\n",
      "             a. Cirrhosis will be defined by any of the following: i. A liver biopsy prior to day 1\n",
      "             of this study showing cirrhosis (F4) ii. Fibroscan within 12 calendar months of day 1\n",
      "             of this study showing cirrhosis with result > 12.5 kPa iii. FibroSURE performed during\n",
      "             screening with a score > 0.75 and APRI > 2 b. Absence of cirrhosis will be defined by\n",
      "             any of the following: i. Liver biopsy performed within 24 months of day 1 of this\n",
      "             study showing absence of cirrhosis ii. Fibroscan performed within 12 months of day 1\n",
      "             of this study with a result of ≤ 12.5 kPa iii. FibroSURE score ≤ 0.48 and APRI ≤ 1\n",
      "             during screening\n",
      "\n",
      "          4. If HIV co-infected, HAART regimen will consist of two NRTIs (abacavir, tenofovir\n",
      "             disoproxil fumarate or tenofovir alafenamide, each in combination with lamivudine or\n",
      "             emtricitabine) with one of the following 3rd agents:\n",
      "\n",
      "               1. raltegravir\n",
      "\n",
      "               2. dolutegravir\n",
      "\n",
      "               3. rilpivirine HIV co-infected patients must be on their stable HAART regimen for at\n",
      "                  least 6 months, with HIV viral load < 50 c/mL at screening\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Hepatitis B surface antigen positivity\n",
      "\n",
      "          2. Decompensated cirrhosis (Child Pugh B or C)\n",
      "\n",
      "          3. Any prior hepatitis C treatment\n",
      "\n",
      "          4. Pregnant or nursing\n",
      "\n",
      "          5. Treatment with any medication specifically contraindicated with EBR/GZR or not\n",
      "             recommended for concomitant use as per the prescribing label (Table 2)\n",
      "\n",
      "          6. Age less than 18\n",
      "\n",
      "          7. Prisoners or subjects otherwise involuntarily incarcerated\n",
      "\n",
      "          8. Absence of signed informed consent by patient or appropriate surrogate\n",
      "\n",
      "          9. Known hypersensitivity to elbasvir or grazoprevir\n",
      "\n",
      "         10. For patients with genotype 1a, one more of the following mutations on baseline NS5A\n",
      "             genotype: M28, Q30, L31, or Y93\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "      \n",
      "\n",
      "        -  INCLUSION CRITERIA:\n",
      "\n",
      "          -  Ages between 18-70 years.\n",
      "\n",
      "          -  Right-handed (tested by the Edinburg handedness inventory).\n",
      "\n",
      "          -  Able to give informed consent and able to comply with all study procedures.\n",
      "\n",
      "        EXCLUSION CRITERIA:\n",
      "\n",
      "          -  Self-reported consumption of >14 alcoholic drinks/week for a man and >7 alcoholic\n",
      "             drinks/week for a woman.\n",
      "\n",
      "          -  Abnormal findings on neurological examination.\n",
      "\n",
      "          -  History of brain tumor, stroke, head trauma with loss of consciousness, epilepsy or\n",
      "             seizures.\n",
      "\n",
      "          -  Current episode of any major psychiatric illness.\n",
      "\n",
      "          -  Use of medications that act directly on the CNS.\n",
      "\n",
      "          -  Hearing loss reported in the history or detected in the routine physical examination\n",
      "\n",
      "          -  Having permanent tattooed makeup (eyeliner, lip, etc.) or general tattoos. Subjects\n",
      "             with tattoos will be excluded if those are in a dangerous location in the body or made\n",
      "             with colors (e.g. dark blue and dark green) whose content in iron cannot be definitely\n",
      "             ruled out by the investigators.\n",
      "\n",
      "          -  Having non-organic implant or any other device such as: cardiac pacemaker, insulin\n",
      "             infusion pump, implanted drug infusion device, cochlear, otologic, or ear implant,\n",
      "             transdermal medication patch, any metallic implants or objects, body piercing(s),\n",
      "             bone/joint pin, screw, nail, plate, wire sutures or surgical staples, shunt.\n",
      "\n",
      "          -  Having cerebral or other aneurysm clips.\n",
      "\n",
      "          -  Having shrapnel or other metal imbedded in the body (such as from war wounds or\n",
      "             accidents).\n",
      "\n",
      "          -  Had severe accidents in the past that may possibly have left metal in the body.\n",
      "\n",
      "          -  Previously worked in metal fields or with machines that may have left any metallic\n",
      "             fragments in or near eyes.\n",
      "\n",
      "          -  Having any psychological contraindications for MRI (e.g., suffer from claustrophobia,\n",
      "             unable to lie comfortably on your back for 2 hours).\n",
      "\n",
      "          -  Discomfort being in a small space for the expected length of the experiment, up to 2\n",
      "             hours.\n",
      "\n",
      "          -  Pregnancy.\n",
      "\n",
      "          -  NIH staff from HMCS in NINDS, Section on Quantitative Imaging and Tissue Sciences in\n",
      "             NICHD or MEG Core facility in NIMH involved in the protocol.\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Post-menopausal - at least 12 months since last menstruation and/or hysterectomy,\n",
      "             oophorectomy or hormonal contraceptive use\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Existing knee, hip or back injury.\n",
      "\n",
      "          -  Any medical conditions or injuries which exclude participation in an exercise\n",
      "             intervention e.g. heart conditions, hypertension\n",
      "\n",
      "          -  BMI > 30 kg/m2\n",
      "\n",
      "          -  Participation in a study involving ionising radiation in the previous 12 months.\n",
      "\n",
      "          -  Exercise involving ground reaction forces greater than that of jogging more than once\n",
      "             a week.\n",
      "\n",
      "          -  Contraindications to MRI or DXA\n",
      "\n",
      "          -  Osteoporotic (FRAX score requiring the participant is advised to seek treatment)\n",
      "\n",
      "          -  Medication affecting bone metabolism or density\n",
      "      \n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Adult patients (age 18 and older)\n",
      "\n",
      "          -  Newly diagnosed with cancer referred from Massachusetts General Hospital (MGH)\n",
      "             community health centers in\n",
      "\n",
      "               -  Revere\n",
      "\n",
      "               -  Chelsea\n",
      "\n",
      "               -  Charlestown\n",
      "\n",
      "               -  surrounding communities referred to receive cancer treatment at the MGH Cancer\n",
      "                  Center\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "        -Patients that primary care providers exclude\n",
      "      \n",
      "\n",
      "        Inclusion Criteria for Childhood Survivors:\n",
      "\n",
      "          -  St. Jude childhood cancer survivors who have consented to SJLIFE;\n",
      "\n",
      "          -  Age at assessment: 8-18.9 years at T1 (toward 20.9 years at T3);\n",
      "\n",
      "          -  2 years off therapy and > 5 years since diagnosis; and\n",
      "\n",
      "          -  Agrees to complete three annual assessments during routinely scheduled ACT clinic\n",
      "             appointments.\n",
      "\n",
      "        Exclusion Criteria for Childhood Survivors:\n",
      "\n",
      "          -  Cancer-related or unrelated (e.g., genetic disorders) neurocognitive injuries that\n",
      "             requires parents/proxies to complete the survey [e.g. intelligence quotient (IQ) <70];\n",
      "\n",
      "          -  Inability to read and speak English; or\n",
      "\n",
      "          -  Parent doesn't agree to participate in the parent part of the study.\n",
      "\n",
      "        Inclusion Criteria for Parents/Legal Guardians:\n",
      "\n",
      "          -  Parent/legal guardian of St. Jude childhood cancer survivor aged 8-18.9 who is\n",
      "             eligible to participate and has agreed to do so;\n",
      "\n",
      "          -  Participant is not developmentally delayed, intellectually disabled or\n",
      "             non-communicative; and\n",
      "\n",
      "          -  Participant speaks and understands the English language.\n",
      "\n",
      "        Exclusion Criteria for Parents/Legal Guardians:\n",
      "\n",
      "          -  Developmentally delayed, intellectually disabled or non-communicative;\n",
      "\n",
      "          -  Unable to speak or understand the English language; and\n",
      "\n",
      "          -  Child doesn't agree to participate in child part of the study.\n",
      "      \n",
      "1138\n"
     ]
    }
   ],
   "source": [
    "lista = df['CT'].tolist()\n",
    "abstracts = []\n",
    "\n",
    "count = 0\n",
    "for i in range(len(lista)):\n",
    "    if lista[i].clinical_trial.eligibility.criteria is not None:\n",
    "        count +=1\n",
    "        #print(lista[i].clinical_trial.find('nct_id'))\n",
    "        print(lista[i].clinical_trial.eligibility.criteria.textblock.text)\n",
    "        \n",
    "print(count)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Emergency Medicine\n",
      "trends\n",
      "\n",
      "\n",
      "Famous Persons\n",
      "\n",
      "\n",
      "Humans\n",
      "\n",
      "0\n"
     ]
    }
   ],
   "source": [
    "lista = df['PubMed'].tolist()\n",
    "abstracts = []\n",
    "\n",
    "count = 0\n",
    "for i in range(len(lista)):\n",
    "    coso = lista[i].article.findAll('MeshHeading')\n",
    "    if len(coso) == 2:\n",
    "        print(coso[0].text)\n",
    "        \n",
    "print(count)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "last_names = df['ct_last_name'].tolist()\n",
    "first_initial = df['ct_first_name_initial'].tolist()\n",
    "\n",
    "names_array = []\n",
    "for i in range(len(last_names)):\n",
    "    string = last_names[i] + '+' + first_initial[i] + '[author]'\n",
    "    names_array.append(string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'England', 'Czech Republic', 'Indonesia', 'Denmark', 'Poland', 'Brazil', 'New Zealand', 'Slovakia', 'Uganda', 'Spain', 'Austria', 'Lebanon', 'France', 'Canada', 'Argentina', 'Korea (South)', 'Saudi Arabia', 'South Africa', 'Turkey', 'Pakistan', 'China', 'Iran', 'Sweden', 'Greece', 'Japan', 'United States', 'Ireland', 'India', 'Italy', 'Netherlands', 'Costa Rica', 'Singapore', 'Switzerland', 'Germany', 'Thailand', 'Ukraine', 'Bulgaria', 'Australia', 'United Arab Emirates'}\n"
     ]
    }
   ],
   "source": [
    "lista = df['PubMed'].tolist()\n",
    "roba = []\n",
    "\n",
    "for i in range(len(lista)):\n",
    "    med = lista[i].article.MedlineJournalInfo.Country\n",
    "    roba.append(med.text)\n",
    "    \n",
    "coso = set(roba)\n",
    "print(coso)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Egypt', 'Jordan', 'Denmark', 'Poland', 'Serbia', 'Indonesia', 'Belgium', 'Portugal', 'Colombia', 'Brazil', 'Czechia', 'Vietnam', 'United Kingdom', 'Spain', 'Lithuania', 'Iran, Islamic Republic of', 'Uganda', 'Burkina Faso', 'Austria', 'Zambia', 'Lebanon', 'Mexico', 'Zimbabwe', 'Iraq', 'Hong Kong', 'France', 'Canada', 'Argentina', 'Korea, Republic of', 'Kuwait', 'Russian Federation', 'Saudi Arabia', 'Israel', 'Bangladesh', 'Slovenia', 'Turkey', 'Pakistan', 'Malawi', 'Hungary', 'Chile', 'Cameroon', 'China', 'Nigeria', 'Finland', 'Sweden', 'Japan', 'Greece', 'Burundi', 'Taiwan', 'United States', 'Ireland', 'India', 'Tanzania', 'Italy', 'Netherlands', 'Ghana', 'Singapore', 'Switzerland', 'Germany', 'Thailand', 'Ukraine', 'Croatia', 'Norway', 'Kenya', 'Australia', 'Mali'}\n",
      "87\n"
     ]
    }
   ],
   "source": [
    "lista = df['CT'].tolist()\n",
    "roba = []\n",
    "count = 0\n",
    "\n",
    "for i in range(len(lista)):\n",
    "    country = lista[i].clinical_trial.find('location')\n",
    "    if country is None:\n",
    "        count += 1\n",
    "        continue\n",
    "    roba.append(country.country.text)\n",
    "    \n",
    "coso = set(roba)\n",
    "print(coso)\n",
    "print(count)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CT</th>\n",
       "      <th>PubMed</th>\n",
       "      <th>common_answer</th>\n",
       "      <th>ct_last_name</th>\n",
       "      <th>ct_first_name_initial</th>\n",
       "      <th>ct_first_name</th>\n",
       "      <th>ct_organization</th>\n",
       "      <th>ct_mail</th>\n",
       "      <th>ct_year</th>\n",
       "      <th>ct_initials</th>\n",
       "      <th>...</th>\n",
       "      <th>email_equality</th>\n",
       "      <th>year_difference</th>\n",
       "      <th>last_name_length</th>\n",
       "      <th>initials_equality</th>\n",
       "      <th>namespace_size</th>\n",
       "      <th>country_equality</th>\n",
       "      <th>city_equality</th>\n",
       "      <th>organization_type_equality</th>\n",
       "      <th>jds_similarity</th>\n",
       "      <th>sts_similarity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>abdulkarim</td>\n",
       "      <td>b</td>\n",
       "      <td>bassam</td>\n",
       "      <td>AHS Cancer Control Alberta</td>\n",
       "      <td>None</td>\n",
       "      <td>2008</td>\n",
       "      <td>b</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.470588</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000627</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.516345</td>\n",
       "      <td>0.415668</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>gawin</td>\n",
       "      <td>f</td>\n",
       "      <td>frank</td>\n",
       "      <td>Friends Research Institute, Inc.</td>\n",
       "      <td>None</td>\n",
       "      <td>1999</td>\n",
       "      <td>f</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000534</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.205678</td>\n",
       "      <td>0.099415</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>deutsch</td>\n",
       "      <td>s</td>\n",
       "      <td>steven</td>\n",
       "      <td>Washington D.C. Veterans Affairs Medical Center</td>\n",
       "      <td>None</td>\n",
       "      <td>1999</td>\n",
       "      <td>s</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.181818</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.005065</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.011458</td>\n",
       "      <td>0.035696</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>maisiak</td>\n",
       "      <td>r</td>\n",
       "      <td>richard s</td>\n",
       "      <td>University of Alabama at Birmingham</td>\n",
       "      <td>None</td>\n",
       "      <td>1999</td>\n",
       "      <td>rs</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000421</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.042765</td>\n",
       "      <td>0.032953</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>gorden</td>\n",
       "      <td>p</td>\n",
       "      <td>phillip</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>gordenp@extra.niddk.nih.gov</td>\n",
       "      <td>1999</td>\n",
       "      <td>p</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.196970</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.003333</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.583667</td>\n",
       "      <td>0.398814</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>hochster</td>\n",
       "      <td>h</td>\n",
       "      <td>howard</td>\n",
       "      <td>Eastern Cooperative Oncology Group</td>\n",
       "      <td>None</td>\n",
       "      <td>2000</td>\n",
       "      <td>h</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.121212</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001638</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.242221</td>\n",
       "      <td>0.352993</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>fabian</td>\n",
       "      <td>c</td>\n",
       "      <td>carol j</td>\n",
       "      <td>University of Kansas Medical Center</td>\n",
       "      <td>bkimler@kumc.edu</td>\n",
       "      <td>2000</td>\n",
       "      <td>cj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>0</td>\n",
       "      <td>0.002163</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.363632</td>\n",
       "      <td>0.353336</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>dematteo</td>\n",
       "      <td>r</td>\n",
       "      <td>ronald</td>\n",
       "      <td>American College of Surgeons</td>\n",
       "      <td>None</td>\n",
       "      <td>2001</td>\n",
       "      <td>r</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.227273</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.004512</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.147187</td>\n",
       "      <td>0.324725</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>klein</td>\n",
       "      <td>j</td>\n",
       "      <td>jonathan d</td>\n",
       "      <td>University of Rochester</td>\n",
       "      <td>None</td>\n",
       "      <td>2002</td>\n",
       "      <td>jd</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.181818</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>0</td>\n",
       "      <td>0.042269</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.043593</td>\n",
       "      <td>0.036725</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>dispenzieri</td>\n",
       "      <td>a</td>\n",
       "      <td>angela</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>None</td>\n",
       "      <td>2002</td>\n",
       "      <td>a</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.529412</td>\n",
       "      <td>1</td>\n",
       "      <td>0.006422</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.469777</td>\n",
       "      <td>0.256853</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>fine</td>\n",
       "      <td>h</td>\n",
       "      <td>howard a</td>\n",
       "      <td>NCI, NIH</td>\n",
       "      <td>hfine@mail.nih.gov</td>\n",
       "      <td>2006</td>\n",
       "      <td>ha</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.003323</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.317896</td>\n",
       "      <td>0.369992</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>orban</td>\n",
       "      <td>t</td>\n",
       "      <td>tihamer</td>\n",
       "      <td>Joslin Diabetes Center</td>\n",
       "      <td>None</td>\n",
       "      <td>2003</td>\n",
       "      <td>t</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.075758</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001554</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.460329</td>\n",
       "      <td>0.283797</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>griffin</td>\n",
       "      <td>t</td>\n",
       "      <td>timothy</td>\n",
       "      <td>Children's Oncology Group</td>\n",
       "      <td>None</td>\n",
       "      <td>2003</td>\n",
       "      <td>t</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.007321</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.059046</td>\n",
       "      <td>0.028094</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>palmer</td>\n",
       "      <td>j</td>\n",
       "      <td>jerry p</td>\n",
       "      <td>University of Washington</td>\n",
       "      <td>None</td>\n",
       "      <td>2003</td>\n",
       "      <td>jp</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.035013</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.564146</td>\n",
       "      <td>0.319692</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>grossi</td>\n",
       "      <td>s</td>\n",
       "      <td>sara g</td>\n",
       "      <td>University at Buffalo</td>\n",
       "      <td>None</td>\n",
       "      <td>2003</td>\n",
       "      <td>sg</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001826</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.234871</td>\n",
       "      <td>0.082533</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>goldbach-mansky</td>\n",
       "      <td>r</td>\n",
       "      <td>raphaela t</td>\n",
       "      <td>National Institute of Arthritis and Musculoske...</td>\n",
       "      <td>goldbacr@mail.nih.gov</td>\n",
       "      <td>2003</td>\n",
       "      <td>rt</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.764706</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001264</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.488722</td>\n",
       "      <td>0.139726</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>saltz</td>\n",
       "      <td>l</td>\n",
       "      <td>leonard</td>\n",
       "      <td>Memorial Sloan Kettering Cancer Center</td>\n",
       "      <td>None</td>\n",
       "      <td>2004</td>\n",
       "      <td>l</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.121212</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.003932</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.453016</td>\n",
       "      <td>0.356721</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>abrams</td>\n",
       "      <td>d</td>\n",
       "      <td>donald</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>None</td>\n",
       "      <td>2004</td>\n",
       "      <td>d</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.196970</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.007826</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.319381</td>\n",
       "      <td>0.241797</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>reid</td>\n",
       "      <td>t</td>\n",
       "      <td>tony</td>\n",
       "      <td>University of California, San Diego</td>\n",
       "      <td>None</td>\n",
       "      <td>2004</td>\n",
       "      <td>t</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.006750</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.231587</td>\n",
       "      <td>0.299354</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>hahn</td>\n",
       "      <td>s</td>\n",
       "      <td>stephen michael</td>\n",
       "      <td>Abramson Cancer Center of the University of Pe...</td>\n",
       "      <td>None</td>\n",
       "      <td>2004</td>\n",
       "      <td>sm</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.121212</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>0</td>\n",
       "      <td>0.021747</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.022815</td>\n",
       "      <td>0.042106</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>penzak</td>\n",
       "      <td>s</td>\n",
       "      <td>scott r</td>\n",
       "      <td>National Institutes of Health (NIH)</td>\n",
       "      <td>spenzak@cc.nih.gov</td>\n",
       "      <td>2005</td>\n",
       "      <td>sr</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000964</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.322597</td>\n",
       "      <td>0.233166</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>shulan</td>\n",
       "      <td>m</td>\n",
       "      <td>mollie</td>\n",
       "      <td>Albany VA Medical Center Samuel S. Stratton, A...</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000047</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.272492</td>\n",
       "      <td>0.077240</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>nakayama</td>\n",
       "      <td>e</td>\n",
       "      <td>eiichi</td>\n",
       "      <td>Dept. of Immunology, Okayama University Schhol...</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>e</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.004615</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.430412</td>\n",
       "      <td>0.296263</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>butler</td>\n",
       "      <td>s</td>\n",
       "      <td>stephen f</td>\n",
       "      <td>Inflexxion, Inc.</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>sf</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.010551</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.261118</td>\n",
       "      <td>0.120846</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>blum</td>\n",
       "      <td>k</td>\n",
       "      <td>kristie</td>\n",
       "      <td>Ohio State University</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>k</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>0</td>\n",
       "      <td>0.005598</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.405291</td>\n",
       "      <td>0.371039</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>salmon</td>\n",
       "      <td>d</td>\n",
       "      <td>dominique</td>\n",
       "      <td>Hopital Cochin Paris. Centre des essais vaccin...</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>d</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.008491</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.300441</td>\n",
       "      <td>0.347303</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>braun</td>\n",
       "      <td>u</td>\n",
       "      <td>ursula k</td>\n",
       "      <td>Michael E DeBakey VA Medical Center</td>\n",
       "      <td>ubraun@bcm.edu</td>\n",
       "      <td>2005</td>\n",
       "      <td>uk</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.006450</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0.019052</td>\n",
       "      <td>0.066381</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>piketty</td>\n",
       "      <td>c</td>\n",
       "      <td>christophe</td>\n",
       "      <td>Hopital Européen Georges Pompidou Paris, servi...</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>c</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000871</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.129597</td>\n",
       "      <td>0.057230</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>perlis</td>\n",
       "      <td>m</td>\n",
       "      <td>michael</td>\n",
       "      <td>University of Rochester Sleep Research Lab</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.151515</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001283</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.331523</td>\n",
       "      <td>0.113088</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>kane</td>\n",
       "      <td>m</td>\n",
       "      <td>madeleine</td>\n",
       "      <td>Southwest Oncology Group</td>\n",
       "      <td>None</td>\n",
       "      <td>2005</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.075758</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.009624</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.342847</td>\n",
       "      <td>0.363237</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1109</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>guo</td>\n",
       "      <td>x</td>\n",
       "      <td>xiaomao</td>\n",
       "      <td>Fudan University</td>\n",
       "      <td>guoxm1800@126.com</td>\n",
       "      <td>2017</td>\n",
       "      <td>x</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.058824</td>\n",
       "      <td>0</td>\n",
       "      <td>0.141167</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.036093</td>\n",
       "      <td>0.047501</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1110</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>lozano</td>\n",
       "      <td>a</td>\n",
       "      <td>andres m</td>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>am</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.008369</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.303210</td>\n",
       "      <td>0.258016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1111</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>tang</td>\n",
       "      <td>j</td>\n",
       "      <td>jennifer</td>\n",
       "      <td>UNC-CH</td>\n",
       "      <td>jennifer_tang@med.unc.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>j</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.113409</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.018004</td>\n",
       "      <td>0.046952</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1112</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>fallowfield</td>\n",
       "      <td>j</td>\n",
       "      <td>jonathan a</td>\n",
       "      <td>MRC Centre for Inflammation Research, Queens M...</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>ja</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.529412</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000889</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.069859</td>\n",
       "      <td>0.315856</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1113</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>signorile</td>\n",
       "      <td>j</td>\n",
       "      <td>joseph f</td>\n",
       "      <td>University of Miami</td>\n",
       "      <td>jsignorile@miami.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>jf</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.411765</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000899</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.052423</td>\n",
       "      <td>0.052678</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1114</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>horiuchi</td>\n",
       "      <td>a</td>\n",
       "      <td>akira</td>\n",
       "      <td>Showa Inan General Hospital</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>a</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.004980</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.142655</td>\n",
       "      <td>0.070999</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1115</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>protheroe</td>\n",
       "      <td>a</td>\n",
       "      <td>andrew s</td>\n",
       "      <td>Oxford University Hospitals NHS Trust</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>as</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.106061</td>\n",
       "      <td>0.411765</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000861</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.080336</td>\n",
       "      <td>0.062233</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1116</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>elmunzer</td>\n",
       "      <td>b</td>\n",
       "      <td>b joseph</td>\n",
       "      <td>Medical University of South Carolina</td>\n",
       "      <td>elmunzer@musc.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>bj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001105</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.269334</td>\n",
       "      <td>0.295984</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1117</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>cheng</td>\n",
       "      <td>y</td>\n",
       "      <td>ya-jung</td>\n",
       "      <td>Anesthesiology Department, NTUH</td>\n",
       "      <td>chengyj@ntu.edu.tw</td>\n",
       "      <td>2017</td>\n",
       "      <td>yj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>0</td>\n",
       "      <td>0.134389</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.020727</td>\n",
       "      <td>0.029074</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1118</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>gengoux</td>\n",
       "      <td>g</td>\n",
       "      <td>grace w</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>ggengoux@stanford.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>gw</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000084</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.359807</td>\n",
       "      <td>0.387530</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1119</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>iv</td>\n",
       "      <td>m</td>\n",
       "      <td>michael</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.212121</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000337</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.021843</td>\n",
       "      <td>0.056887</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1120</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>yang</td>\n",
       "      <td>a</td>\n",
       "      <td>aiming</td>\n",
       "      <td>Peking Union Medical College Hospital</td>\n",
       "      <td>yangaiming@medmail.com.cn</td>\n",
       "      <td>2017</td>\n",
       "      <td>a</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.212121</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>1</td>\n",
       "      <td>0.027486</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.051676</td>\n",
       "      <td>0.047034</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1121</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>nakamura</td>\n",
       "      <td>y</td>\n",
       "      <td>yukio</td>\n",
       "      <td>Shinshu University</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>y</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>0</td>\n",
       "      <td>0.107530</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.040390</td>\n",
       "      <td>0.057942</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1122</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>baumgartner</td>\n",
       "      <td>j</td>\n",
       "      <td>joy n</td>\n",
       "      <td>Duke University</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>jn</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.529412</td>\n",
       "      <td>0</td>\n",
       "      <td>0.006020</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.053935</td>\n",
       "      <td>0.089332</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1123</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>manconi</td>\n",
       "      <td>m</td>\n",
       "      <td>mauro</td>\n",
       "      <td>Ente Ospedaliero Cantonale, Bellinzona</td>\n",
       "      <td>mauro.manconi@eoc.ch</td>\n",
       "      <td>2017</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.151515</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.002078</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.127418</td>\n",
       "      <td>0.128917</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1124</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>jiang</td>\n",
       "      <td>x</td>\n",
       "      <td>xiongjing</td>\n",
       "      <td>Chinese Academy of Medical Sciences, Fuwai Hos...</td>\n",
       "      <td>None</td>\n",
       "      <td>2016</td>\n",
       "      <td>x</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.130316</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.207291</td>\n",
       "      <td>0.207314</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1125</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>berra</td>\n",
       "      <td>l</td>\n",
       "      <td>lorenzo</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>lberra@partners.org</td>\n",
       "      <td>2017</td>\n",
       "      <td>l</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000833</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.043021</td>\n",
       "      <td>0.034778</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1126</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>king</td>\n",
       "      <td>r</td>\n",
       "      <td>rachel</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>rachel.king@ucsf.edu</td>\n",
       "      <td>2017</td>\n",
       "      <td>r</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>0</td>\n",
       "      <td>0.035678</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.424220</td>\n",
       "      <td>0.191339</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1127</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>slebos</td>\n",
       "      <td>d</td>\n",
       "      <td>dirk-jan</td>\n",
       "      <td>University Medical Center Groningen</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>dj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.121212</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001133</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.130993</td>\n",
       "      <td>0.027481</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1128</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>verkooijen</td>\n",
       "      <td>h</td>\n",
       "      <td>helena m</td>\n",
       "      <td>UMC Utrecht</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>hm</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.470588</td>\n",
       "      <td>1</td>\n",
       "      <td>0.002060</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0.123197</td>\n",
       "      <td>0.158898</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1129</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>0</td>\n",
       "      <td>cox</td>\n",
       "      <td>d</td>\n",
       "      <td>daniel j</td>\n",
       "      <td>University of Virginia</td>\n",
       "      <td>None</td>\n",
       "      <td>2016</td>\n",
       "      <td>dj</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.058824</td>\n",
       "      <td>0</td>\n",
       "      <td>0.025314</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.011749</td>\n",
       "      <td>0.036847</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1130</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>kazakov</td>\n",
       "      <td>i</td>\n",
       "      <td>ivan</td>\n",
       "      <td>Moscow Clinical Scientific Center</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>i</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000964</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.366493</td>\n",
       "      <td>0.364507</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1131</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>levesque</td>\n",
       "      <td>s</td>\n",
       "      <td>sebastien</td>\n",
       "      <td>University Hospital of Poitiers, Department of...</td>\n",
       "      <td>sebastien.levesque@chu-poitiers.fr</td>\n",
       "      <td>2017</td>\n",
       "      <td>s</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>1</td>\n",
       "      <td>0.001994</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.469401</td>\n",
       "      <td>0.409564</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1132</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>omran</td>\n",
       "      <td>e</td>\n",
       "      <td>eman</td>\n",
       "      <td>Cairo University</td>\n",
       "      <td>eman.omran@kasralaini.edu.eg</td>\n",
       "      <td>2017</td>\n",
       "      <td>e</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.015152</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000243</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.031556</td>\n",
       "      <td>0.036602</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1133</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>rudroff</td>\n",
       "      <td>t</td>\n",
       "      <td>thorsten</td>\n",
       "      <td>University of Colorado, Denver</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>t</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.045455</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000384</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.092798</td>\n",
       "      <td>0.093753</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1134</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>bedimo</td>\n",
       "      <td>r</td>\n",
       "      <td>roger</td>\n",
       "      <td>Dallas VAMC</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>r</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.196970</td>\n",
       "      <td>0.235294</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000730</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.228434</td>\n",
       "      <td>0.291385</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1135</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>hallett</td>\n",
       "      <td>m</td>\n",
       "      <td>mark</td>\n",
       "      <td>National Institute of Neurological Disorders a...</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>m</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.075758</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>1</td>\n",
       "      <td>0.012517</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.227339</td>\n",
       "      <td>0.231806</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1136</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>brooke-wavell</td>\n",
       "      <td>k</td>\n",
       "      <td>katherine</td>\n",
       "      <td>Loughborough University</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>k</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.030303</td>\n",
       "      <td>0.647059</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000374</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0.513921</td>\n",
       "      <td>0.337498</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1137</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>percac-lima</td>\n",
       "      <td>s</td>\n",
       "      <td>sanja</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>None</td>\n",
       "      <td>2017</td>\n",
       "      <td>s</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.136364</td>\n",
       "      <td>0.529412</td>\n",
       "      <td>1</td>\n",
       "      <td>0.000431</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.124253</td>\n",
       "      <td>0.185858</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1138</th>\n",
       "      <td>&lt;clinical_trials.clinical_trial.ClinicalTrial ...</td>\n",
       "      <td>&lt;articles.article.Article object at 0x0000014F...</td>\n",
       "      <td>1</td>\n",
       "      <td>huang</td>\n",
       "      <td>i</td>\n",
       "      <td>i-chan</td>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>referralinfo@stjude.org</td>\n",
       "      <td>2017</td>\n",
       "      <td>ic</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0.060606</td>\n",
       "      <td>0.176471</td>\n",
       "      <td>1</td>\n",
       "      <td>0.005140</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0.234911</td>\n",
       "      <td>0.207093</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1139 rows × 34 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                     CT  \\\n",
       "0     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "2     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "3     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "4     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "5     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "6     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "7     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "8     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "9     <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "10    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "11    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "12    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "13    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "14    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "15    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "16    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "17    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "18    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "19    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "20    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "21    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "22    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "23    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "24    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "25    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "26    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "27    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "28    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "29    <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "...                                                 ...   \n",
       "1109  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1110  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1111  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1112  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1113  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1114  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1115  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1116  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1117  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1118  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1119  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1120  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1121  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1122  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1123  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1124  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1125  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1126  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1127  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1128  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1129  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1130  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1131  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1132  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1133  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1134  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1135  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1136  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1137  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "1138  <clinical_trials.clinical_trial.ClinicalTrial ...   \n",
       "\n",
       "                                                 PubMed  common_answer  \\\n",
       "0     <articles.article.Article object at 0x0000014F...              1   \n",
       "1     <articles.article.Article object at 0x0000014F...              1   \n",
       "2     <articles.article.Article object at 0x0000014F...              1   \n",
       "3     <articles.article.Article object at 0x0000014F...              1   \n",
       "4     <articles.article.Article object at 0x0000014F...              1   \n",
       "5     <articles.article.Article object at 0x0000014F...              1   \n",
       "6     <articles.article.Article object at 0x0000014F...              1   \n",
       "7     <articles.article.Article object at 0x0000014F...              1   \n",
       "8     <articles.article.Article object at 0x0000014F...              0   \n",
       "9     <articles.article.Article object at 0x0000014F...              1   \n",
       "10    <articles.article.Article object at 0x0000014F...              1   \n",
       "11    <articles.article.Article object at 0x0000014F...              1   \n",
       "12    <articles.article.Article object at 0x0000014F...              0   \n",
       "13    <articles.article.Article object at 0x0000014F...              1   \n",
       "14    <articles.article.Article object at 0x0000014F...              1   \n",
       "15    <articles.article.Article object at 0x0000014F...              1   \n",
       "16    <articles.article.Article object at 0x0000014F...              1   \n",
       "17    <articles.article.Article object at 0x0000014F...              1   \n",
       "18    <articles.article.Article object at 0x0000014F...              1   \n",
       "19    <articles.article.Article object at 0x0000014F...              0   \n",
       "20    <articles.article.Article object at 0x0000014F...              1   \n",
       "21    <articles.article.Article object at 0x0000014F...              1   \n",
       "22    <articles.article.Article object at 0x0000014F...              1   \n",
       "23    <articles.article.Article object at 0x0000014F...              1   \n",
       "24    <articles.article.Article object at 0x0000014F...              1   \n",
       "25    <articles.article.Article object at 0x0000014F...              1   \n",
       "26    <articles.article.Article object at 0x0000014F...              1   \n",
       "27    <articles.article.Article object at 0x0000014F...              1   \n",
       "28    <articles.article.Article object at 0x0000014F...              1   \n",
       "29    <articles.article.Article object at 0x0000014F...              1   \n",
       "...                                                 ...            ...   \n",
       "1109  <articles.article.Article object at 0x0000014F...              0   \n",
       "1110  <articles.article.Article object at 0x0000014F...              1   \n",
       "1111  <articles.article.Article object at 0x0000014F...              0   \n",
       "1112  <articles.article.Article object at 0x0000014F...              1   \n",
       "1113  <articles.article.Article object at 0x0000014F...              1   \n",
       "1114  <articles.article.Article object at 0x0000014F...              1   \n",
       "1115  <articles.article.Article object at 0x0000014F...              1   \n",
       "1116  <articles.article.Article object at 0x0000014F...              1   \n",
       "1117  <articles.article.Article object at 0x0000014F...              0   \n",
       "1118  <articles.article.Article object at 0x0000014F...              1   \n",
       "1119  <articles.article.Article object at 0x0000014F...              1   \n",
       "1120  <articles.article.Article object at 0x0000014F...              0   \n",
       "1121  <articles.article.Article object at 0x0000014F...              0   \n",
       "1122  <articles.article.Article object at 0x0000014F...              1   \n",
       "1123  <articles.article.Article object at 0x0000014F...              1   \n",
       "1124  <articles.article.Article object at 0x0000014F...              1   \n",
       "1125  <articles.article.Article object at 0x0000014F...              1   \n",
       "1126  <articles.article.Article object at 0x0000014F...              1   \n",
       "1127  <articles.article.Article object at 0x0000014F...              1   \n",
       "1128  <articles.article.Article object at 0x0000014F...              1   \n",
       "1129  <articles.article.Article object at 0x0000014F...              0   \n",
       "1130  <articles.article.Article object at 0x0000014F...              1   \n",
       "1131  <articles.article.Article object at 0x0000014F...              1   \n",
       "1132  <articles.article.Article object at 0x0000014F...              1   \n",
       "1133  <articles.article.Article object at 0x0000014F...              1   \n",
       "1134  <articles.article.Article object at 0x0000014F...              1   \n",
       "1135  <articles.article.Article object at 0x0000014F...              1   \n",
       "1136  <articles.article.Article object at 0x0000014F...              1   \n",
       "1137  <articles.article.Article object at 0x0000014F...              1   \n",
       "1138  <articles.article.Article object at 0x0000014F...              1   \n",
       "\n",
       "         ct_last_name ct_first_name_initial    ct_first_name  \\\n",
       "0          abdulkarim                     b           bassam   \n",
       "1               gawin                     f            frank   \n",
       "2             deutsch                     s           steven   \n",
       "3             maisiak                     r        richard s   \n",
       "4              gorden                     p          phillip   \n",
       "5            hochster                     h           howard   \n",
       "6              fabian                     c          carol j   \n",
       "7            dematteo                     r           ronald   \n",
       "8               klein                     j       jonathan d   \n",
       "9         dispenzieri                     a           angela   \n",
       "10               fine                     h         howard a   \n",
       "11              orban                     t          tihamer   \n",
       "12            griffin                     t          timothy   \n",
       "13             palmer                     j          jerry p   \n",
       "14             grossi                     s           sara g   \n",
       "15    goldbach-mansky                     r       raphaela t   \n",
       "16              saltz                     l          leonard   \n",
       "17             abrams                     d           donald   \n",
       "18               reid                     t             tony   \n",
       "19               hahn                     s  stephen michael   \n",
       "20             penzak                     s          scott r   \n",
       "21             shulan                     m           mollie   \n",
       "22           nakayama                     e           eiichi   \n",
       "23             butler                     s        stephen f   \n",
       "24               blum                     k          kristie   \n",
       "25             salmon                     d        dominique   \n",
       "26              braun                     u         ursula k   \n",
       "27            piketty                     c       christophe   \n",
       "28             perlis                     m          michael   \n",
       "29               kane                     m        madeleine   \n",
       "...               ...                   ...              ...   \n",
       "1109              guo                     x          xiaomao   \n",
       "1110           lozano                     a         andres m   \n",
       "1111             tang                     j         jennifer   \n",
       "1112      fallowfield                     j       jonathan a   \n",
       "1113        signorile                     j         joseph f   \n",
       "1114         horiuchi                     a            akira   \n",
       "1115        protheroe                     a         andrew s   \n",
       "1116         elmunzer                     b         b joseph   \n",
       "1117            cheng                     y          ya-jung   \n",
       "1118          gengoux                     g          grace w   \n",
       "1119               iv                     m          michael   \n",
       "1120             yang                     a           aiming   \n",
       "1121         nakamura                     y            yukio   \n",
       "1122      baumgartner                     j            joy n   \n",
       "1123          manconi                     m            mauro   \n",
       "1124            jiang                     x        xiongjing   \n",
       "1125            berra                     l          lorenzo   \n",
       "1126             king                     r           rachel   \n",
       "1127           slebos                     d         dirk-jan   \n",
       "1128       verkooijen                     h         helena m   \n",
       "1129              cox                     d         daniel j   \n",
       "1130          kazakov                     i             ivan   \n",
       "1131         levesque                     s        sebastien   \n",
       "1132            omran                     e             eman   \n",
       "1133          rudroff                     t         thorsten   \n",
       "1134           bedimo                     r            roger   \n",
       "1135          hallett                     m             mark   \n",
       "1136    brooke-wavell                     k        katherine   \n",
       "1137      percac-lima                     s            sanja   \n",
       "1138            huang                     i           i-chan   \n",
       "\n",
       "                                        ct_organization  \\\n",
       "0                            AHS Cancer Control Alberta   \n",
       "1                      Friends Research Institute, Inc.   \n",
       "2       Washington D.C. Veterans Affairs Medical Center   \n",
       "3                   University of Alabama at Birmingham   \n",
       "4     National Institute of Diabetes and Digestive a...   \n",
       "5                    Eastern Cooperative Oncology Group   \n",
       "6                   University of Kansas Medical Center   \n",
       "7                          American College of Surgeons   \n",
       "8                               University of Rochester   \n",
       "9                                           Mayo Clinic   \n",
       "10                                             NCI, NIH   \n",
       "11                               Joslin Diabetes Center   \n",
       "12                            Children's Oncology Group   \n",
       "13                             University of Washington   \n",
       "14                                University at Buffalo   \n",
       "15    National Institute of Arthritis and Musculoske...   \n",
       "16               Memorial Sloan Kettering Cancer Center   \n",
       "17              University of California, San Francisco   \n",
       "18                  University of California, San Diego   \n",
       "19    Abramson Cancer Center of the University of Pe...   \n",
       "20                  National Institutes of Health (NIH)   \n",
       "21    Albany VA Medical Center Samuel S. Stratton, A...   \n",
       "22    Dept. of Immunology, Okayama University Schhol...   \n",
       "23                                     Inflexxion, Inc.   \n",
       "24                                Ohio State University   \n",
       "25    Hopital Cochin Paris. Centre des essais vaccin...   \n",
       "26                  Michael E DeBakey VA Medical Center   \n",
       "27    Hopital Européen Georges Pompidou Paris, servi...   \n",
       "28           University of Rochester Sleep Research Lab   \n",
       "29                             Southwest Oncology Group   \n",
       "...                                                 ...   \n",
       "1109                                   Fudan University   \n",
       "1110                 University Health Network, Toronto   \n",
       "1111                                             UNC-CH   \n",
       "1112  MRC Centre for Inflammation Research, Queens M...   \n",
       "1113                                University of Miami   \n",
       "1114                        Showa Inan General Hospital   \n",
       "1115              Oxford University Hospitals NHS Trust   \n",
       "1116               Medical University of South Carolina   \n",
       "1117                    Anesthesiology Department, NTUH   \n",
       "1118                                Stanford University   \n",
       "1119                                Stanford University   \n",
       "1120              Peking Union Medical College Hospital   \n",
       "1121                                 Shinshu University   \n",
       "1122                                    Duke University   \n",
       "1123             Ente Ospedaliero Cantonale, Bellinzona   \n",
       "1124  Chinese Academy of Medical Sciences, Fuwai Hos...   \n",
       "1125                     Massachusetts General Hospital   \n",
       "1126            University of California, San Francisco   \n",
       "1127                University Medical Center Groningen   \n",
       "1128                                        UMC Utrecht   \n",
       "1129                             University of Virginia   \n",
       "1130                  Moscow Clinical Scientific Center   \n",
       "1131  University Hospital of Poitiers, Department of...   \n",
       "1132                                   Cairo University   \n",
       "1133                     University of Colorado, Denver   \n",
       "1134                                        Dallas VAMC   \n",
       "1135  National Institute of Neurological Disorders a...   \n",
       "1136                            Loughborough University   \n",
       "1137                     Massachusetts General Hospital   \n",
       "1138              St. Jude Children's Research Hospital   \n",
       "\n",
       "                                 ct_mail  ct_year ct_initials      ...        \\\n",
       "0                                   None     2008           b      ...         \n",
       "1                                   None     1999           f      ...         \n",
       "2                                   None     1999           s      ...         \n",
       "3                                   None     1999          rs      ...         \n",
       "4            gordenp@extra.niddk.nih.gov     1999           p      ...         \n",
       "5                                   None     2000           h      ...         \n",
       "6                       bkimler@kumc.edu     2000          cj      ...         \n",
       "7                                   None     2001           r      ...         \n",
       "8                                   None     2002          jd      ...         \n",
       "9                                   None     2002           a      ...         \n",
       "10                    hfine@mail.nih.gov     2006          ha      ...         \n",
       "11                                  None     2003           t      ...         \n",
       "12                                  None     2003           t      ...         \n",
       "13                                  None     2003          jp      ...         \n",
       "14                                  None     2003          sg      ...         \n",
       "15                 goldbacr@mail.nih.gov     2003          rt      ...         \n",
       "16                                  None     2004           l      ...         \n",
       "17                                  None     2004           d      ...         \n",
       "18                                  None     2004           t      ...         \n",
       "19                                  None     2004          sm      ...         \n",
       "20                    spenzak@cc.nih.gov     2005          sr      ...         \n",
       "21                                  None     2005           m      ...         \n",
       "22                                  None     2005           e      ...         \n",
       "23                                  None     2005          sf      ...         \n",
       "24                                  None     2005           k      ...         \n",
       "25                                  None     2005           d      ...         \n",
       "26                        ubraun@bcm.edu     2005          uk      ...         \n",
       "27                                  None     2005           c      ...         \n",
       "28                                  None     2005           m      ...         \n",
       "29                                  None     2005           m      ...         \n",
       "...                                  ...      ...         ...      ...         \n",
       "1109                   guoxm1800@126.com     2017           x      ...         \n",
       "1110                                None     2017          am      ...         \n",
       "1111           jennifer_tang@med.unc.edu     2017           j      ...         \n",
       "1112                                None     2017          ja      ...         \n",
       "1113                jsignorile@miami.edu     2017          jf      ...         \n",
       "1114                                None     2017           a      ...         \n",
       "1115                                None     2017          as      ...         \n",
       "1116                   elmunzer@musc.edu     2017          bj      ...         \n",
       "1117                  chengyj@ntu.edu.tw     2017          yj      ...         \n",
       "1118               ggengoux@stanford.edu     2017          gw      ...         \n",
       "1119                                None     2017           m      ...         \n",
       "1120           yangaiming@medmail.com.cn     2017           a      ...         \n",
       "1121                                None     2017           y      ...         \n",
       "1122                                None     2017          jn      ...         \n",
       "1123                mauro.manconi@eoc.ch     2017           m      ...         \n",
       "1124                                None     2016           x      ...         \n",
       "1125                 lberra@partners.org     2017           l      ...         \n",
       "1126                rachel.king@ucsf.edu     2017           r      ...         \n",
       "1127                                None     2017          dj      ...         \n",
       "1128                                None     2017          hm      ...         \n",
       "1129                                None     2016          dj      ...         \n",
       "1130                                None     2017           i      ...         \n",
       "1131  sebastien.levesque@chu-poitiers.fr     2017           s      ...         \n",
       "1132        eman.omran@kasralaini.edu.eg     2017           e      ...         \n",
       "1133                                None     2017           t      ...         \n",
       "1134                                None     2017           r      ...         \n",
       "1135                                None     2017           m      ...         \n",
       "1136                                None     2017           k      ...         \n",
       "1137                                None     2017           s      ...         \n",
       "1138             referralinfo@stjude.org     2017          ic      ...         \n",
       "\n",
       "     email_equality year_difference last_name_length initials_equality  \\\n",
       "0                 0        0.000000         0.470588                 1   \n",
       "1                 0        0.045455         0.176471                 1   \n",
       "2                 0        0.181818         0.294118                 1   \n",
       "3                 0        0.106061         0.294118                 1   \n",
       "4                 0        0.196970         0.235294                 1   \n",
       "5                 0        0.121212         0.352941                 1   \n",
       "6                 0        0.106061         0.235294                 0   \n",
       "7                 0        0.227273         0.352941                 1   \n",
       "8                 0        0.181818         0.176471                 0   \n",
       "9                 0        0.015152         0.529412                 1   \n",
       "10                0        0.060606         0.117647                 1   \n",
       "11                0        0.075758         0.176471                 1   \n",
       "12                0        0.030303         0.294118                 1   \n",
       "13                0        0.136364         0.235294                 1   \n",
       "14                0        0.030303         0.235294                 1   \n",
       "15                0        0.166667         0.764706                 1   \n",
       "16                0        0.121212         0.176471                 1   \n",
       "17                0        0.196970         0.235294                 1   \n",
       "18                0        0.136364         0.117647                 1   \n",
       "19                0        0.121212         0.117647                 0   \n",
       "20                0        0.045455         0.235294                 1   \n",
       "21                0        0.106061         0.235294                 1   \n",
       "22                0        0.136364         0.352941                 1   \n",
       "23                0        0.015152         0.235294                 1   \n",
       "24                0        0.136364         0.117647                 0   \n",
       "25                0        0.030303         0.235294                 1   \n",
       "26                1        0.090909         0.176471                 1   \n",
       "27                0        0.106061         0.294118                 1   \n",
       "28                0        0.151515         0.235294                 1   \n",
       "29                0        0.075758         0.117647                 1   \n",
       "...             ...             ...              ...               ...   \n",
       "1109              0        0.090909         0.058824                 0   \n",
       "1110              0        0.060606         0.235294                 1   \n",
       "1111              0        0.045455         0.117647                 1   \n",
       "1112              0        0.045455         0.529412                 1   \n",
       "1113              1        0.000000         0.411765                 0   \n",
       "1114              0        0.090909         0.352941                 1   \n",
       "1115              0        0.106061         0.411765                 1   \n",
       "1116              0        0.030303         0.352941                 1   \n",
       "1117              0        0.045455         0.176471                 0   \n",
       "1118              0        0.030303         0.294118                 0   \n",
       "1119              0        0.212121         0.000000                 1   \n",
       "1120              0        0.212121         0.117647                 1   \n",
       "1121              0        0.090909         0.352941                 0   \n",
       "1122              0        0.015152         0.529412                 0   \n",
       "1123              0        0.151515         0.294118                 1   \n",
       "1124              0        0.045455         0.176471                 1   \n",
       "1125              0        0.060606         0.176471                 1   \n",
       "1126              0        0.045455         0.117647                 0   \n",
       "1127              0        0.121212         0.235294                 1   \n",
       "1128              0        0.030303         0.470588                 1   \n",
       "1129              0        0.060606         0.058824                 0   \n",
       "1130              0        0.000000         0.294118                 1   \n",
       "1131              0        0.015152         0.352941                 1   \n",
       "1132              0        0.015152         0.176471                 1   \n",
       "1133              0        0.045455         0.294118                 1   \n",
       "1134              0        0.196970         0.235294                 1   \n",
       "1135              0        0.075758         0.294118                 1   \n",
       "1136              0        0.030303         0.647059                 1   \n",
       "1137              0        0.136364         0.529412                 1   \n",
       "1138              0        0.060606         0.176471                 1   \n",
       "\n",
       "     namespace_size country_equality city_equality organization_type_equality  \\\n",
       "0          0.000627                0             0                          0   \n",
       "1          0.000534                0             0                          0   \n",
       "2          0.005065                0             0                          0   \n",
       "3          0.000421                0             0                          0   \n",
       "4          0.003333                1             1                          1   \n",
       "5          0.001638                1             0                          0   \n",
       "6          0.002163                0             0                          0   \n",
       "7          0.004512                0             0                          0   \n",
       "8          0.042269                1             0                          1   \n",
       "9          0.006422                0             0                          0   \n",
       "10         0.003323                0             0                          0   \n",
       "11         0.001554                0             0                          0   \n",
       "12         0.007321                0             0                          0   \n",
       "13         0.035013                0             0                          0   \n",
       "14         0.001826                0             0                          0   \n",
       "15         0.001264                0             0                          0   \n",
       "16         0.003932                0             0                          0   \n",
       "17         0.007826                0             0                          0   \n",
       "18         0.006750                0             0                          0   \n",
       "19         0.021747                0             0                          0   \n",
       "20         0.000964                0             0                          0   \n",
       "21         0.000047                0             0                          0   \n",
       "22         0.004615                1             1                          1   \n",
       "23         0.010551                1             0                          1   \n",
       "24         0.005598                1             1                          1   \n",
       "25         0.008491                0             0                          0   \n",
       "26         0.006450                1             1                          0   \n",
       "27         0.000871                0             0                          0   \n",
       "28         0.001283                1             0                          1   \n",
       "29         0.009624                0             0                          0   \n",
       "...             ...              ...           ...                        ...   \n",
       "1109       0.141167                0             0                          0   \n",
       "1110       0.008369                0             0                          0   \n",
       "1111       0.113409                0             0                          0   \n",
       "1112       0.000889                0             0                          0   \n",
       "1113       0.000899                1             0                          1   \n",
       "1114       0.004980                1             1                          1   \n",
       "1115       0.000861                0             0                          0   \n",
       "1116       0.001105                1             1                          1   \n",
       "1117       0.134389                0             0                          0   \n",
       "1118       0.000084                0             0                          0   \n",
       "1119       0.000337                0             0                          0   \n",
       "1120       0.027486                0             0                          0   \n",
       "1121       0.107530                0             0                          0   \n",
       "1122       0.006020                0             0                          1   \n",
       "1123       0.002078                0             0                          0   \n",
       "1124       0.130316                0             0                          0   \n",
       "1125       0.000833                0             0                          0   \n",
       "1126       0.035678                0             0                          0   \n",
       "1127       0.001133                0             0                          0   \n",
       "1128       0.002060                1             1                          0   \n",
       "1129       0.025314                0             0                          0   \n",
       "1130       0.000964                1             1                          1   \n",
       "1131       0.001994                1             0                          0   \n",
       "1132       0.000243                0             0                          0   \n",
       "1133       0.000384                1             0                          1   \n",
       "1134       0.000730                1             0                          0   \n",
       "1135       0.012517                0             0                          0   \n",
       "1136       0.000374                1             0                          1   \n",
       "1137       0.000431                0             0                          0   \n",
       "1138       0.005140                1             1                          1   \n",
       "\n",
       "      jds_similarity sts_similarity  \n",
       "0           0.516345       0.415668  \n",
       "1           0.205678       0.099415  \n",
       "2           0.011458       0.035696  \n",
       "3           0.042765       0.032953  \n",
       "4           0.583667       0.398814  \n",
       "5           0.242221       0.352993  \n",
       "6           0.363632       0.353336  \n",
       "7           0.147187       0.324725  \n",
       "8           0.043593       0.036725  \n",
       "9           0.469777       0.256853  \n",
       "10          0.317896       0.369992  \n",
       "11          0.460329       0.283797  \n",
       "12          0.059046       0.028094  \n",
       "13          0.564146       0.319692  \n",
       "14          0.234871       0.082533  \n",
       "15          0.488722       0.139726  \n",
       "16          0.453016       0.356721  \n",
       "17          0.319381       0.241797  \n",
       "18          0.231587       0.299354  \n",
       "19          0.022815       0.042106  \n",
       "20          0.322597       0.233166  \n",
       "21          0.272492       0.077240  \n",
       "22          0.430412       0.296263  \n",
       "23          0.261118       0.120846  \n",
       "24          0.405291       0.371039  \n",
       "25          0.300441       0.347303  \n",
       "26          0.019052       0.066381  \n",
       "27          0.129597       0.057230  \n",
       "28          0.331523       0.113088  \n",
       "29          0.342847       0.363237  \n",
       "...              ...            ...  \n",
       "1109        0.036093       0.047501  \n",
       "1110        0.303210       0.258016  \n",
       "1111        0.018004       0.046952  \n",
       "1112        0.069859       0.315856  \n",
       "1113        0.052423       0.052678  \n",
       "1114        0.142655       0.070999  \n",
       "1115        0.080336       0.062233  \n",
       "1116        0.269334       0.295984  \n",
       "1117        0.020727       0.029074  \n",
       "1118        0.359807       0.387530  \n",
       "1119        0.021843       0.056887  \n",
       "1120        0.051676       0.047034  \n",
       "1121        0.040390       0.057942  \n",
       "1122        0.053935       0.089332  \n",
       "1123        0.127418       0.128917  \n",
       "1124        0.207291       0.207314  \n",
       "1125        0.043021       0.034778  \n",
       "1126        0.424220       0.191339  \n",
       "1127        0.130993       0.027481  \n",
       "1128        0.123197       0.158898  \n",
       "1129        0.011749       0.036847  \n",
       "1130        0.366493       0.364507  \n",
       "1131        0.469401       0.409564  \n",
       "1132        0.031556       0.036602  \n",
       "1133        0.092798       0.093753  \n",
       "1134        0.228434       0.291385  \n",
       "1135        0.227339       0.231806  \n",
       "1136        0.513921       0.337498  \n",
       "1137        0.124253       0.185858  \n",
       "1138        0.234911       0.207093  \n",
       "\n",
       "[1139 rows x 34 columns]"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['United States'] ['Bethesda'] ['Bethesda', 'Maryland', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Durham'] ['Surgeons', 'New York', 'NY'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Rochester'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['Japan'] ['Okayama'] ['Okayama', 'Japan'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['La Puente', 'Athol', 'Ann Arbor', 'Detroit', 'Brooklyn', 'New York', 'Montpelier'] ['Newton', 'MA', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Columbus'] ['Columbus'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Houston'] ['Houston', 'Texas', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Rochester'] ['Philadelphia', 'PA', 'USA', 'Philadelphia', 'Philadelphia', 'PA', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Brazil'] ['Porto Alegre'] ['RS', 'Brazil'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['Boston', 'MA', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['New Brunswick'] ['Boston', 'Massachusetts', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Taipei', 'Taiwan'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Pittsburgh'] ['Bochum', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Rochester'] ['Rochester', 'New York', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['USA'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Berlin', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Taiwan'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Stanford'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['France'] ['Nantes'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Wynnewood'] ['Wynnewood', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['Boston', 'United States'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Toronto'] ['Münster', 'Deutschland'] 0 0 \n",
      "\n",
      "\n",
      "['Israel'] ['Ramat-Gan'] ['Ramat-Gan', 'Israel', 'Israel'] 1 1 \n",
      "\n",
      "\n",
      "['Germany'] ['Berlin'] ['Berlin', 'Germany'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Toronto'] ['Toronto', 'Ontario', 'Canada', 'Toronto', 'Ontario', 'Canada', 'Toronto', 'Ontario', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Stony Brook'] ['New York'] 0 0 \n",
      "\n",
      "\n",
      "['France'] ['Angers'] ['France'] 1 0 \n",
      "\n",
      "\n",
      "['Denmark'] ['Frederiksberg'] ['Frederiksberg', 'Denmark'] 1 1 \n",
      "\n",
      "\n",
      "['Belgium'] ['Leuven'] ['Leuven', 'Belgium'] 1 1 \n",
      "\n",
      "\n",
      "['Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan'] ['Nagoya', 'Hirosaki', 'Hirosaki', 'Misawa', 'Matsuyama', 'Iizuka', 'Kitakyusyu', 'Kitakyusyu', 'Kurume', 'Ibi', 'Maehashi', 'Oota', 'Fukuyama', 'Kure', 'Asahikawa', 'Asahikawa', 'Hakodate', 'Kushiro', 'Sapporo', 'Sapporo', 'Itan', 'Kobe', 'Nishimiya', 'Hitachi', 'Kanazawa', 'Kanazawa', 'Kawakita', 'Nanao', 'Morioka', 'Morioka', 'Isehara', 'Kawasaki', 'Sagamihara', 'Yokohama', 'Yokohama', 'Yokohama', 'Yokohama', 'Yokohama', 'Sendai', 'Sendai', 'Nakano', 'Oomura', 'Kashihara', 'Maniwa', 'Chutougun', 'Izumisano', 'Kimen', 'Sakai', 'Sayama', 'Toyonaka', 'Yao', 'Otsu', 'Ritto', 'Izumo', 'Hyogo', 'Shimono', 'Shimotsuga', 'Komatsushima', 'Bunkyo-ku', 'Bunkyo-ku', 'Chiyoda-ku', 'Hachioji', 'Itabashi-ku', 'Itabashi-ku', 'Koto-ku', 'Koto-ku', 'Koto-ku', 'Meguro-ku', 'Meguro-ku', 'Minato-ku', 'Minato-ku', 'Minato-ku', 'Mitaka', 'Shinagawa-ku', 'Shinjuku-ku', 'Shinjuku-ku', 'Shinjuku-ku', 'Shinjuku-ku', 'Yonago', 'Takaoka', 'Kohfu', 'Aichi', 'Akita', 'Akita', 'Aomori', 'Chiba', 'Ehime', 'Fukui', 'Fukui', 'Fukui', 'Fukuoka', 'Fukuoka', 'Fukuoka', 'Fukuoka', 'Fukushima', 'Gifu', 'Gifu', 'Gifu', 'Hiroshima', 'Hiroshima', 'Hiroshima', 'Kagoshima', 'Kochi', 'Kumamoto', 'Kyoto', 'Kyoto', 'Nagano', 'Nagasaki', 'Nagoya', 'Niigata', 'Oita', 'Osaka', 'Osaka', 'Osaka', 'Saga', 'Yamagata'] ['Japan'] 1 0 \n",
      "\n",
      "\n",
      "['Canada', 'Canada', 'Canada', 'Canada'] ['Edmonton', 'London', 'Toronto', 'Saskatoon'] ['Livermore', 'California', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Birmingham', 'Indianapolis', 'Baltimore', 'Cumberland', 'Boston', 'Detroit', 'University Park'] ['Mt. Freedom'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['San Francisco'] ['San Francisco', 'California', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Fort Worth'] ['Chicago', 'Chicago', 'Illinois', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Albuquerque'] ['New York', 'NY', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['Cleveland', 'Philadelphia', 'Pittsburgh'] ['Philadelphia'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Peoria'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada'] ['Calgary', 'Edmonton', 'Vancouver', 'Winnipeg', 'Halifax', 'Hamilton', 'London', 'Toronto', 'Montreal', 'Montreal'] ['Ajman'] 0 0 \n",
      "\n",
      "\n",
      "['Denmark'] ['Sønderborg'] ['Aarhus', 'Denmark'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'Korea, Republic of'] ['Bethesda', 'Seoul'] ['Bethesda', 'MD', 'Detroit', 'Ann Arbor', 'East Lansing'] 1 1 \n",
      "\n",
      "\n",
      "['Singapore'] ['Singapore'] ['Singapore'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Baltimore', 'Pittsburgh'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Seattle'] ['South Africa', 'Durban, South Africa'] 0 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Toronto'] ['Montreal', 'Quebec', 'Canada'] 1 0 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['London'] ['London', 'UK'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Toronto', 'Ontario', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Nashville'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Canada', 'Canada', 'Canada'] ['La Jolla', 'La Jolla', 'Washington', 'Atlanta', 'Boston', 'Boston', 'Royal Oak', 'Kansas City', 'New York', 'Charlotte', 'Durham', 'Elyria', 'Austin', 'Vancouver', 'Toronto', 'Toronto'] ['India'] 0 0 \n",
      "\n",
      "\n",
      "['Germany'] ['Magdeburg'] ['Magdeburg', 'Germany'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['La Jolla'] ['La Jolla', 'California, USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Stanford'] ['Palo Alto', 'Los Angeles', 'Fremont', 'Indianapolis', 'New York', 'NY', 'Omaha', 'Baltimore', 'MD', 'Vancouver', 'British Columbia', 'Toronto', 'Ontario', 'Edmonton', 'Alberta', 'Canada', 'St Louis', 'Portland', 'Chicago', 'Iowa City', 'Rochester', 'MN', 'Boston', 'MA', 'Denver'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Baltimore', 'Maryland', 'USA', 'Amsterdam', 'Netherlands', 'Baltimore', 'Maryland', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Los Angeles'] ['Los Angeles VA', 'Sepulveda', 'United States of America', 'Los Angeles', 'United States of America', 'Santa Monica', 'United States of America'] 1 1 \n",
      "\n",
      "\n",
      "['Denmark', 'Denmark', 'Norway', 'Norway', 'Sweden', 'Sweden', 'Sweden', 'Sweden'] ['Aarhus N', 'Copenhagen', 'Bergen', 'Oslo', 'Göteborg', 'Lund', 'Stockholm', 'Uppsala'] ['Tucson', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Philadelphia'] ['Minneapolis', 'Minn.'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Boston', 'Boston'] ['Aarhus', 'Denmark'] 0 0 \n",
      "\n",
      "\n",
      "['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom'] ['Belfast', 'Birmingham', 'East Grinstead', 'Newcastle Upon Tyne', 'Preston', 'Salisbury'] ['East Grinstead', 'United Kingdom'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Toronto', 'Ontario', 'Canada', 'Toronto', 'Ontario', 'Canada'] 0 0 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['San Diego', 'Washington', 'Palm Beach', 'Tampa', 'Chicago', 'Lexington', 'Silver Spring', 'Pascagoula', 'Rochester', 'Cleveland', 'Lancaster', 'Knoxville', 'Holladay', 'Falls Church'] ['Salt Lake City', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Hamilton'] ['Canada', 'Canada', 'Canada'] 1 0 \n",
      "\n",
      "\n",
      "['Belgium', 'Belgium', 'Belgium'] ['Antwerpen', 'Edegem', 'Wilrijk'] ['Belgium'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Milwaukee'] ['Milwaukee', 'Wis.'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Atlanta'] ['Atlanta', 'Atlanta', 'Ga.'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['Boston', 'Ann Arbor', 'St. Louis'] ['Boston'] 1 1 \n",
      "\n",
      "\n",
      "[] [] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Baltimore', 'Maryland', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Baltimore', 'Maryland', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Columbus'] ['Columbus', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Houston'] ['La Jolla', 'CA', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Iraq'] ['Baghdad'] [] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Brazil'] 0 0 \n",
      "\n",
      "\n",
      "['Canada'] ['London'] ['NC', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Ann Arbor'] ['Ann Arbor', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['USA'] 1 0 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada'] ['Mobile', 'Mobile', 'Phoenix', 'Scottsdale', 'Tucson', 'Tucson', 'Auburn', 'Burbank', 'Cameron Park', 'Carmichael', 'Chico', 'Concord', 'Duarte', 'Glendale', 'La Jolla', 'Los Angeles', 'Los Angeles', 'Orange', 'Roseville', 'Sacramento', 'Sacramento', 'Sacramento', 'Stanford', 'Turlock', 'Vacaville', 'Walnut Creek', 'Aurora', 'Colorado Springs', 'Fort Collins', 'New Haven', 'Newark', 'Washington, D.C.', 'Gainesville', 'Jacksonville Beach', 'Jacksonville', 'Jacksonville', 'Jacksonville', 'Orange Park', 'Orlando', 'Palatka', 'Saint Augustine', 'Atlanta', 'Columbus', 'Decatur', 'Gainesville', 'Arlington Heights', 'Chicago', 'Springfield', 'Urbana', 'Anderson', 'Bloomington', 'Fort Wayne', 'Fort Wayne', 'Goshen', 'Indianapolis', 'Indianapolis', 'Indianapolis', 'Indianapolis', 'Indianapolis', 'Muncie', 'South Bend', 'Iowa City', 'Overland Park', 'Lexington', 'Louisville', 'Baltimore', 'Baltimore', 'Baltimore', 'Baltimore', 'Columbia', 'Glen Burnie', 'Towson', 'Boston', 'Commerce', 'Detroit', 'Detroit', 'Flint', 'Grand Rapids', 'Livonia', 'Royal Oak', 'Albert Lea', 'Burnsville', 'Coon Rapids', 'Edina', 'Fridley', 'Mankato', 'Maplewood', 'Minneapolis', 'Robbinsdale', 'Rochester', 'Saint Cloud', 'Saint Louis Park', 'Saint Paul', 'Waconia', 'Pascagoula', 'Kansas City', 'Kansas City', 'Saint Louis', 'Springfield', 'Billings', 'Billings', 'Billings', 'Omaha', 'Omaha', 'Las Vegas', 'Reno', 'Concord', 'Manchester', 'Bricktown', 'Camden', 'Elizabeth', 'Jamesburg', 'New Brunswick', 'Princeton', 'Toms River', 'Voorhees', 'Albuquerque', 'Albuquerque', 'Albuquerque', 'Albany', 'Albany', 'Brooklyn', 'Buffalo', 'Canandaigua', 'Manhasset', 'New Hyde Park', 'Rochester', 'Rochester', 'Rochester', 'Rochester', 'Asheville', 'Wilmington', 'Minot', 'Akron', 'Akron', 'Barberton', 'Cincinnati', 'Cleveland', 'Cleveland', 'Columbus', 'Independence', 'Maumee', 'Mayfield Heights', 'Oregon', 'Salem', 'Sandusky', 'Sylvania', 'Toledo', 'Toledo', 'Toledo', 'West Chester', 'Wooster', 'Wooster', 'Oklahoma City', 'Eugene', 'Grants Pass', 'Medford', 'Medford', 'Abington', 'Beaver', 'Bethlehem', 'Bryn Mawr', 'Clairton', 'Clarion', 'Danville', 'Drexel Hill', 'Dunmore', 'Gettysburg', 'Greensburg', 'Hanover', 'Hershey', 'Johnstown', 'McKeesport', 'Moon', 'Natrona Heights', 'New Castle', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Pittsburgh', 'Pittsburgh', 'Pittsburgh', 'Pittsburgh', 'Pittsburgh', 'Seneca', 'Uniontown', 'Washington', 'Wynnewood', 'York', 'Charleston', 'Spartanburg', 'Rapid City', 'Arlington', 'Bedford', 'Dallas', 'Dallas', 'Dallas', 'Denton', 'Fort Worth', 'Longview', 'Odessa', 'San Antonio', 'San Antonio', 'Sherman', 'Sugar Land', 'Tyler', 'Murray', 'Ogden', 'Saint George', 'Salt Lake City', 'Salt Lake City', 'Burlington', 'Charlottesville', 'Norfolk', 'Seattle', 'Spokane', 'Yakima', 'Wheeling', 'Appleton', 'Green Bay', 'La Crosse', 'Madison', 'Marinette', 'Menomonee Falls', 'Milwaukee', 'Milwaukee', 'Racine', 'Wausau', 'West Allis', 'Halifax', 'London', 'Montreal', 'Montreal', 'Montreal', 'Quebec City'] ['Houston', 'Texas'] 0 0 \n",
      "\n",
      "\n",
      "['Germany'] ['Neuss'] ['41460 Neuss, Germany'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['Boston', 'Massachusetts'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Los Angeles'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['San Diego'] ['San Diego', 'USA', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Birmingham'] ['Birmingham', 'Birmingham', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Germany'] ['Berlin'] ['Germany'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Naples'] ['Baltimore', 'MD, USA'] 0 0 \n",
      "\n",
      "\n",
      "['United Kingdom', 'United Kingdom'] ['Gloucester', 'London'] ['Sacramento', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['San Francisco', 'W.S.S.', 'Cleveland'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Houston'] ['Houston', 'Texas', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Washington'] ['Washington,', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Spain'] ['Barcelona'] ['Denmark Hill', 'London', 'London', 'UK'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Singapore'] ['Palo Alto', 'San Diego', 'Chicago', 'Boston', 'Detroit', 'Memphis', 'Fort Worth', 'Singapore'] ['Memphis', 'TN', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['San Francisco'] ['Los Angeles County', 'Los Angeles', 'USA'] 1 0 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['United States', 'United States'] ['Louisville', 'Louisville'] ['Louisville', 'KY'] 1 1 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['China'] 0 0 \n",
      "\n",
      "\n",
      "['Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy'] ['Alessandria', 'Ancona', 'Arezzo', 'Aviano', 'Brescia', 'Brescia', 'Brindisi', 'Caltanissetta', 'Carrara', 'Cecina', 'Cremona', 'Cuneo', 'Empoli', 'Fabriano', 'Firenze', 'Genova', 'Lecce', 'Legnano', 'Lido di Camaiore', 'Livorno', 'Lucca', 'Milano', 'Milano', 'Monza', 'Napoli', 'Novara', 'Parma', 'Perugia', 'Perugia', 'Pesaro', 'Pescia', 'Piombino', 'Pisa', 'Pisa', 'Pisa', 'Pistoia', 'Prato', 'Reggio Emilia', 'Rome', 'Rome', 'Rome', 'Siena', 'Sondrio', 'Torino'] ['Italy'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada'] ['Phoenix', 'Stanford', 'Portland', 'Calgary', 'Edmonton', 'Halifax', 'Hamilton', 'London', 'Ottawa', 'Toronto', 'Toronto', 'Montréal', 'Quebec City', 'Saskatoon'] ['Oxford', 'UK'] 0 0 \n",
      "\n",
      "\n",
      "['Denmark'] ['Aalborg'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Santa Rosa'] ['Fulton', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Australia'] ['Sydney'] ['Sydney', 'New South Wales', 'Australia'] 1 1 \n",
      "\n",
      "\n",
      "['Japan'] ['Osaka-city'] ['Fukuoka', 'Japan'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['New Hyde Park'] ['Hempstead', 'NY'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Washington'] ['Hempstead', 'NY'] 0 0 \n",
      "\n",
      "\n",
      "['Israel'] ['Jerusalem'] ['Jerusalem', 'Israel', 'Jerusalem', 'Israel'] 1 1 \n",
      "\n",
      "\n",
      "['Norway', 'Sweden', 'Sweden'] ['Oslo', 'Stockholm', 'Uppsala'] ['Uppsala', 'Sweden'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Durham'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Springfield'] ['Springfield', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Thailand'] ['Mae Sot, 63110'] ['Thailand', 'Bangkok', 'Thailand', 'Oxford', 'United Kingdom'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Minneapolis'] ['Pittsburgh'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Chicago'] ['Chicago', 'Illinois'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Berkeley'] ['Oakland', 'California', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Jacksonville'] ['Philadelphia'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'Belgium', 'Belgium', 'Germany', 'Germany', 'Germany', 'Germany', 'Italy', 'Spain', 'Switzerland', 'Switzerland', 'Switzerland', 'Switzerland', 'Switzerland', 'Switzerland', 'Switzerland'] ['Boston', 'Springfield', 'Tyler', 'Gent', 'Leuven', 'Essen', 'Essen', 'Westerstede', 'Worms', 'Reggio Emilia', 'Girona', 'Aarau', 'Basel', 'Bern', 'Geneva', 'Lausanne', 'Zürich', 'Zürich'] ['Aarau', 'Switzerland'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Southfield'] ['Detroit', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Richmond'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['Australia', 'Australia', 'Australia'] ['Melbourne', 'Melbourne', 'Perth'] ['St Louis', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Z.-G.W.', 'W.-Z.S.', 'Taipei', 'Taiwan', 'Republic of China', 'New Taipei', 'Taiwan', 'Republic of China', 'New Taipei', 'Taiwan', 'Republic of China'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Bethesda'] ['Bethesda', 'MD', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['Toronto', 'ON', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['New York'] ['New York', 'New York'] 1 1 \n",
      "\n",
      "\n",
      "['Hungary', 'Hungary', 'Hungary', 'Hungary', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain'] ['Budapest', 'Budapest', 'Komárom', 'Mosonmagyaróvár', 'Avila', 'Badajoz', 'Burgos', 'Caceres', 'Caceres', 'Ciudad Real', 'Leon', 'Leon', 'Logroño', 'Madrid', 'Merida', 'Navarra', 'Palencia', 'Ponferrada', 'Puertollano', 'Soria', 'Valladolid', 'Zaragoza', 'Zaragoza'] ['Spain', 'Spain'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Madison'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "[] [] [] 0 0 \n",
      "\n",
      "\n",
      "['Portugal'] ['S. Mamede do Coronado'] ['Madrid', 'Spain'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Atlanta', 'Atlanta'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['United Kingdom', 'United Kingdom'] ['Oxford', 'Oxford'] ['Kenya'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Denver'] ['Colorado'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Palo Alto', 'Los Angeles', 'Fremont', 'Indianapolis', 'New York', 'NY', 'Omaha', 'Baltimore', 'MD', 'Vancouver', 'British Columbia', 'Toronto', 'Ontario', 'Edmonton', 'Alberta', 'Canada', 'St Louis', 'Portland', 'Chicago', 'Iowa City', 'Rochester', 'MN', 'Boston', 'MA', 'Denver'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Portland'] ['4144 Arlesheim', 'Switzerland', '58313 Herdecke', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['Brooksville', 'Casselberry', 'Melbourne'] ['Washington', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Phoenix'] ['Arizona', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Bethesda', 'Falls Church'] ['Bethesda', 'MD', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Malawi'] ['Blantyre'] ['St Louis', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Taipei', 'Taiwan'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Bronx'] ['Bronx', 'New York', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['China', 'China', 'China', 'China', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Korea, Republic of', 'Philippines', 'Philippines', 'Philippines', 'Philippines'] ['Hong Kong', 'Hong Kong', 'Hong Kong', 'Shatin, NT', 'Cheongju', 'Cheonan', 'Wonju', 'Gyeonggi-do', 'Jinju', 'Ansan', 'Bucheon', 'Goyang-si', 'Goyang', 'Guri', 'Seongnam-si', 'Uijeongbu', 'Changwon', 'Iksan', 'Jeonju-si', 'Chuncheon', 'Changwon', 'Goyang', 'Anyang', 'Seongnam', 'Suwon', 'Busan', 'Busan', 'Busan', 'Busan', 'Daegu', 'Daegu', 'Daejon', 'Deagu', 'Deagu', 'Deagu', 'Deagu', 'Deajeon', 'Deajeon', 'GwangJu', 'Gwangju', 'Incheon', 'Inchon', 'Pusan', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Seoul', 'Ulsan', 'Manila', 'Manila', 'Pasig', 'Quezon City'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Hartford'] ['Morristown', 'NJ, USA'] 0 0 \n",
      "\n",
      "\n",
      "['India'] ['Chandigarh'] ['India'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Saint Louis'] ['Missouri'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Hampton', 'VA', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Jordan'] ['Amman'] ['Kuwait'] 0 0 \n",
      "\n",
      "\n",
      "['Kuwait'] ['Ahmadi'] ['Abbassia', 'Cairo', 'Egypt'] 0 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei, Taiwan'] ['São Paulo', 'Brazil'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['Newport Beach', 'Orange', 'Westminster'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "[] [] ['Gainesville', 'USA'] 0 0 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Australia', 'Germany', 'Germany', 'Germany', 'Sweden', 'Sweden', 'Sweden', 'Sweden', 'Sweden', 'Switzerland', 'Switzerland', 'Switzerland', 'Switzerland', 'Switzerland', 'Switzerland', 'Switzerland', 'Turkey', 'Turkey', 'Turkey', 'Turkey'] ['Epping', 'Berlin', 'Marburg', 'München', 'Falun', 'Lund', 'Stockholm', 'Stockholm', 'Uppsala', 'Basel', 'Bern', 'Bern', 'Genève', 'Lausanne', 'Lugano', 'Zürich', 'Adana', 'Istanbul', 'Istanbul', 'Istanbul'] [] 0 0 \n",
      "\n",
      "\n",
      "['Denmark'] ['Hvidovre'] ['Denmark'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Durham'] ['Durham', 'NC', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['London', 'London', 'United Kingdom'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['San Francisco'] ['San Francisco General Hospital', 'San Francisco', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Ann Arbor'] ['Ann Arbor', 'Michigan'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['San Francisco'] ['San Francisco', 'San Francisco', 'Peter.Rechmann@ucsf.edu'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Houston'] ['Houston', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Dallas'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Charleston'] ['Charleston', 'SC', 'United States'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['San Francisco', 'Columbus'] ['Seattle'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Jackson'] ['Jackson', 'Mississippi'] 1 1 \n",
      "\n",
      "\n",
      "['Sweden', 'Sweden', 'Sweden', 'Sweden', 'Sweden', 'Sweden'] ['Falun', 'Gävle', 'Linköping', 'Stockholm', 'Uppsala', 'Örebro'] ['Uppsala', 'Sweden', 'Uppsala', 'Sweden'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Ft. Sam Houston'] ['Houston', 'Texas', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Germany'] ['Hannover'] ['Hannover', 'Germany'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['Toronto', 'ON', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada'] ['Chicago', 'Montreal', 'Montreal', 'Montreal', 'Montreal', 'Montreal', 'Montreal', 'Quebec'] ['Montreal', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States'] ['Boston', 'Cleveland', 'Portland', 'Pittsburgh'] ['Cleveland', 'United Arab Emirates'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Palo Alto', 'Los Angeles', 'Fremont', 'Indianapolis', 'New York', 'NY', 'Omaha', 'Baltimore', 'MD', 'Vancouver', 'British Columbia', 'Toronto', 'Ontario', 'Edmonton', 'Alberta', 'Canada', 'St Louis', 'Portland', 'Chicago', 'Iowa City', 'Rochester', 'MN', 'Boston', 'MA', 'Denver'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Cullman', 'Scottsdale', 'Tucson', 'Encinitas', 'Fountain Valley', 'La Jolla', 'Los Angeles', 'Los Gatos', 'Newport Beach', 'Sacramento', 'New Haven', 'Washington', 'Boca Raton', 'North Palm Beach', 'Saint Petersburg', 'Sarasota', 'Chicago', 'Glenview', 'Lake Bluff', 'Winfield', 'Munster', 'Overland Park', 'Baton Rouge', 'Baltimore', 'Boston', 'Roseville', 'Warren', 'Bloomington', 'Eagan', 'Minneapolis', 'Des Peres', 'St. Louis', 'Las Vegas', 'Reno', 'Toms River', 'Kingston', 'New York', 'New York', 'New York', 'North Syracuse', 'Syracuse', 'Durham', 'Bellevue', 'Cleveland', 'Columbus', 'Tulsa', 'Bend', 'Medford', 'Collegeville', 'Philadelphia', 'Wynnewood', 'Spartanburg', 'Chattanooga', 'Columbia', 'Memphis', 'Nashville', 'Bedford', 'Bedford', 'Bedford', 'Dallas', 'Dallas', 'Houston', 'Houston', 'Houston', 'Tyler', 'Alexandria', 'Fishersville', 'Virginia Beach', 'Kirkland', 'Spokane'] ['Cleveland', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Iowa City'] ['India'] 0 0 \n",
      "\n",
      "\n",
      "['Germany'] ['Hamburg'] ['Berlin', 'Germany'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Newton'] ['Lausanne', 'Switzerland'] 0 0 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['Leicester'] ['Pittsburgh', 'Pittsburgh'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Fairfield', 'Lynbrook', 'Manhasset', 'Port Jefferson', 'Rockville Centre', 'Valley Stream'] ['New York', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Argentina'] ['Buenos Aires'] ['Argentina'] 1 0 \n",
      "\n",
      "\n",
      "['Korea, Republic of'] ['Seoul'] ['Houston, USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Denver'] ['Denver', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Korea, Republic of'] ['Seoul'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Spokane'] ['Houston', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Puerto Rico'] ['Duarte', 'Oakland', 'Santa Ana', 'Denver', 'Fort Lauderdale', 'Honolulu', 'Glenview', 'Rockford', 'Indianapolis', 'Leawood', 'Boston', 'Grand Rapids', 'Oradell', 'Brooklyn', 'New York', 'Charlotte', 'Cleveland', 'Oklahoma City', 'Philadelphia', 'Providence', 'Chattanooga', 'Knoxville', 'Dallas', 'El Paso', 'Houston', 'San Antonio', 'Temple', 'Appleton', 'Guaynabo'] ['Bochum', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Hamilton'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['New York'] ['Toronto', 'ON', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Vancouver'] ['Vancouver', 'BC', 'Canada', 'Vancouver', 'BC', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['2nd Floor', 'Boston', 'MA', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Toronto'] ['Boston', 'MA', 'United States'] 0 0 \n",
      "\n",
      "\n",
      "['Chile'] ['Santiago'] ['Baltimore', 'MD', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['San Diego', 'Memphis'] ['Hiroto Inaba', 'Memphis', 'TN', 'Fort Worth'] 1 1 \n",
      "\n",
      "\n",
      "['Japan'] ['Yokohama'] ['Tokyo', 'Japan', 'Yokohama', 'Kanagawa Prefecture', 'Japan', 'Kawaguchi', 'Saitama Prefecture', 'Japan'] 1 1 \n",
      "\n",
      "\n",
      "['China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China'] ['Changsha', 'Chengdu', 'Hangzhou', 'Huhehaote', 'Nanchang', 'Nanjing', 'Qingdao', 'Shanghai', 'Shanghai', 'Shenyang', \"Xi'an\", 'Yangzhou'] ['Shanghai'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Lebanon'] ['Columbus'] 0 0 \n",
      "\n",
      "\n",
      "['Denmark'] ['Esbjerg'] ['San Francisco', 'San Francisco', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Palo Alto'] ['Palo Alto', 'California'] 1 1 \n",
      "\n",
      "\n",
      "['China', 'China', 'China', 'China', 'China'] ['Beijing', 'Beijing', \"Xi'an\", \"Xi'an\", 'Tianjin'] ['Beijing', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['Netherlands', 'Netherlands'] ['Groningen', 'Groningen'] ['The Netherlands'] 0 0 \n",
      "\n",
      "\n",
      "['Germany'] ['Jena'] ['Jena', 'Germany'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['McAllen'] ['Logan', 'Utah', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Québec City'] [] 0 0 \n",
      "\n",
      "\n",
      "['Belgium', 'Belgium'] ['Genk', 'Leuven'] ['Leuven', 'Belgium'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Quebec City'] ['Halifax', 'Canada'] 1 0 \n",
      "\n",
      "\n",
      "['France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France'] ['Brest', 'Grenoble', 'La Rochelle', 'Marseille', 'Marseille', 'Nantes', 'Nantes', 'Rennes', 'Rouen', 'Strasbourg', 'Toulouse', 'Tours', 'Tours', 'Trelaze', 'Valenciennes'] ['Montpellier', 'France'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Denver', 'Seattle'] ['Seattle', 'USA', 'Seattle'] 1 1 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['United States', 'Denmark'] ['Greenville', 'Copenhagen'] ['Denmark'] 1 0 \n",
      "\n",
      "\n",
      "['Lithuania'] ['Kaunas'] ['Kaunas', 'Lithuania'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Bethesda'] ['Bethesda', 'MD', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Japan'] ['Komagane'] ['Komagane', 'Matsumoto', 'Japan'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Lyons'] ['Lyons', 'New Jersey', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada'] ['Calgary', 'Nanaimo', 'Vancouver', 'Saint John', \"St. John's\", 'Dartmouth', 'Sudbury', 'Toronto'] [] 0 0 \n",
      "\n",
      "\n",
      "['China'] ['Guangzhou'] ['Guangzhou', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Baltimore', 'Maryland', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Mishawaka'] ['M.E.W.', 'R.H.', 'S.H.', 'D.S.', 'Cambridge', 'Norfolk', 'E.M.S.', 'the United Kingdom'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Denver'] ['Argentina', 'Argentina'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Halle', 'Germany', 'Addis Ababa', 'Ethiopia', 'Boston', 'Massachusetts', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['Iran, Islamic Republic of'] ['Tehran'] ['Tehran', 'Iran'] 1 1 \n",
      "\n",
      "\n",
      "['Singapore'] ['Singapore'] ['Singapore', 'Singapore'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Chicago', 'Houston'] ['Cleveland', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Indianapolis', 'Indianapolis'] ['Boston', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['New Haven'] ['New Haven', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Bethesda', 'MD, USA'] 0 0 \n",
      "\n",
      "\n",
      "['United Kingdom', 'United Kingdom'] ['Leicester', 'London'] ['UK'] 1 0 \n",
      "\n",
      "\n",
      "['China'] ['Beijing'] ['Beijing', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'Netherlands'] ['Baltimore', 'Amsterdam'] ['Hampton', 'VA', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "[] [] [] 0 0 \n",
      "\n",
      "\n",
      "['Thailand'] ['Bangkok'] ['Bangkok', 'Thailand'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Seongnam', 'Korea'] 0 0 \n",
      "\n",
      "\n",
      "['China'] ['Beijing'] ['Beijing', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['Kenya'] ['Nairobi'] ['London', 'UK'] 0 0 \n",
      "\n",
      "\n",
      "['Germany'] ['Frankfurt/Main'] ['Germany'] 1 0 \n",
      "\n",
      "\n",
      "['Vietnam'] ['ThaiNguyen'] ['Atlanta', 'Georgia', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Loveland'] ['Toronto', 'ON', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'New Zealand'] ['Buffalo', 'Hamilton'] ['Kansas City', 'Kansas'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Atlanta', 'Georgia', 'Atlanta', 'Georgia'] 0 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Kaohsiung'] ['Taiwan'] 1 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Atlanta', 'Georgia'] 0 0 \n",
      "\n",
      "\n",
      "['Germany'] ['Heidelberg'] ['Heidelberg', 'Germany'] 1 1 \n",
      "\n",
      "\n",
      "['China'] ['Hong Kong'] ['Beijing', \"People's Republic of China\"] 0 0 \n",
      "\n",
      "\n",
      "['Spain'] ['Elche'] ['Elche', 'Alicante', 'Spain'] 1 1 \n",
      "\n",
      "\n",
      "['Spain'] ['Barcelona'] ['Barcelona', 'Spain'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Munich', 'Munich', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['France'] ['Paris'] ['New York', 'NY', 'K.I.', 'J.A.', 'J.G.O.', 'N.H.', 'L.F.', 'L.L.', 'B.P.', 'C.G.S.G.', 'K.F.'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Norfolk', 'UK'] 0 0 \n",
      "\n",
      "\n",
      "['Brazil', 'Brazil'] ['Sao Paulo', 'São Paulo'] ['Brazil', 'Brazil'] 1 0 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['London'] ['Seattle'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Williamsville'] ['Kaleida Health', 'Buffalo', 'New York', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Columbus'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Houston'] ['Urbana', 'Illinois'] 0 0 \n",
      "\n",
      "\n",
      "['Italy'] ['Roma'] ['Rome', 'RM', 'Italy'] 1 0 \n",
      "\n",
      "\n",
      "['Spain', 'Spain', 'Spain'] ['Córdoba', 'Málaga', 'Sevilla'] ['Sevilla', 'Spain'] 1 1 \n",
      "\n",
      "\n",
      "['Taiwan', 'Taiwan', 'Taiwan'] ['New Taipei', 'Taipei', 'Taipei'] ['Z.-G.W.', 'W.-Z.S.', 'Taipei', 'Taiwan', 'Republic of China', 'New Taipei', 'Taiwan', 'Republic of China', 'New Taipei', 'Taiwan', 'Republic of China'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['Boston', 'MA', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Montreal'] ['Angers', 'France'] 0 0 \n",
      "\n",
      "\n",
      "['China', 'China', 'China', 'China', 'China', 'China'] ['Beijing', 'Shenzhen', 'Shanghai', \"Xi'an\", 'Kunming', 'Hangzhou'] ['New York', 'NY', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['Boston', 'Boston', 'Boston'] ['Milwaukee', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'Canada'] ['Aurora', 'Denver', 'Baltimore', 'Madison', 'Toronto'] ['Hampton', 'VA', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Halifax'] ['Halifax', 'Nova Scotia', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "['Sweden'] ['Göteborg'] ['Gothenburg', 'Sweden'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Cleveland'] ['Cleveland', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['New York'] ['New York', 'NY'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Philadelphia'] [] 0 0 \n",
      "\n",
      "\n",
      "['Denmark'] ['Silkeborg'] ['USA'] 0 0 \n",
      "\n",
      "\n",
      "['Egypt'] ['Cairo'] ['Cairo', 'Egypt'] 1 1 \n",
      "\n",
      "\n",
      "['Sweden'] ['Helsingborg'] ['Lund', 'Sweden'] 1 0 \n",
      "\n",
      "\n",
      "['Netherlands'] ['Amsterdam'] ['Amsterdam', 'The Netherlands'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Sherbrooke'] ['Quebec', 'Canada', 'Sherbrooke', 'Sherbrooke', 'Quebec', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Montréal'] ['Stockholm', 'Sweden'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['USA', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['China', 'China'] ['Hong Kong', 'Hong Kong'] ['Toronto', 'ON', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria'] ['Feldkirch', 'Graz', 'Graz', 'Innsbruck', 'Linz', 'Linz', 'Salzburg', 'Steyr'] ['Salzburg', 'Austria'] 1 1 \n",
      "\n",
      "\n",
      "['China'] ['Changchun'] ['Brisbane', 'Australia'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Boston', 'Boston'] ['Alyn Hospital', 'Jerusalem', 'Israel'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Seattle'] ['Seattle', 'Washington, USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['New York'] ['Bochum', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Tucson'] ['Tucson', 'Arizona'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['India'] ['Chandigarh'] ['India'] 1 0 \n",
      "\n",
      "\n",
      "['Korea, Republic of'] ['Seongnam'] [] 0 0 \n",
      "\n",
      "\n",
      "['Canada', 'Canada', 'Canada', 'Canada'] ['Mississauga', 'Thunder Bay', 'Toronto', 'Whitby'] ['Toronto', 'ON', 'Canada', 'Toronto', 'ON', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Kayseri', 'Turkey'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Gainesville'] ['Gainesville', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Denmark'] ['Copenhagen N'] ['Denmark'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['La Jolla'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['Vietnam'] ['Hanoi'] ['New York', 'New York'] 0 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Paris', 'France'] 0 0 \n",
      "\n",
      "\n",
      "['Canada', 'Canada', 'Canada'] ['Ottawa', 'Ottawa', 'Toronto'] ['Ottawa'] 1 1 \n",
      "\n",
      "\n",
      "['Netherlands'] ['Maastricht'] ['The Netherlands'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Rochester'] ['Rochester', 'Minnesota'] 1 1 \n",
      "\n",
      "\n",
      "['Netherlands'] ['Amsterdam'] ['Duesseldorf', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['Korea, Republic of'] ['Seongnam-si'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Kansas City'] ['South Africa', 'Durban, South Africa'] 0 0 \n",
      "\n",
      "\n",
      "['Norway'] ['Trondheim'] ['Trondheim', 'Norway', 'Trondheim', 'Norway', 'Spinal Disorders', 'Trondheim', 'Norway', 'Trondheim', 'Norway'] 1 1 \n",
      "\n",
      "\n",
      "['China'] ['Beijing'] ['Taipei', 'Taiwan', 'Taipei', 'Taiwan'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'Germany'] ['Boston', 'New York', 'New York', 'Cologne'] ['New York'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Salt Lake City'] ['Salt Lake City', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Denmark'] ['Copenhagen NV'] ['Denmark'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Dallas'] ['New York', 'New York', 'C.P.N.', 'E.P.', 'New York', 'New York', 'J.R.', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'C.C.', 'New York', 'New York', 'New York', 'New York', 'Cambridge', 'Massachusetts', 'K.S.', 'D.Z.', 'K.Y.', 'Miami', 'Florida', 'C.D.', 'Dallas', 'Texas', 'E.M.', 'C.C.', 'Berlin', 'Germany', 'New York', 'New York'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Sherbrooke'] ['Québec', 'Canada'] 1 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Santa Monica', 'Jacksonville', 'Chicago', 'Iowa City', 'Minneapolis', 'Rochester', 'Saint Louis'] ['Toronto', 'Ontario', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Ottawa'] ['Ottawa', 'Ontario', 'Canada', 'Ottawa', 'Ontario', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "['Zambia'] ['Lusaka'] ['Pittsburgh', 'Pittsburgh'] 0 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Taipei', 'Taiwan'] 1 1 \n",
      "\n",
      "\n",
      "['Hong Kong'] ['Hong Kong'] ['Australia'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['New Brunswick'] ['Newark', 'New Brunswick', 'N.J.', 'Trenton', 'N.J.'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['Gatineau'] ['Toronto', 'ON', 'Canada'] 1 0 \n",
      "\n",
      "\n",
      "['Egypt'] ['Cairo,'] ['Cairo', 'Egypt'] 1 0 \n",
      "\n",
      "\n",
      "['Uganda'] ['Masindi'] ['Uganda'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Little Rock'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['Sweden'] ['Umeå'] ['Umeå', 'Sweden'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['La Jolla'] ['La Jolla', 'California'] 1 1 \n",
      "\n",
      "\n",
      "['Mexico'] ['Guadalajara'] ['Jalisco', 'Mexico'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['London', 'London', 'United Kingdom'] 0 0 \n",
      "\n",
      "\n",
      "['Ghana'] ['Kumasi'] ['Kumasi', 'Ghana'] 1 1 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['United States'] ['Birmingham'] ['Indianapolis', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Taipei', 'Taiwan'] 1 1 \n",
      "\n",
      "\n",
      "['China'] ['Nanning'] ['Nanning', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom'] ['Bournemouth', 'Cardiff', 'Oswestry', 'Southampton'] ['Australia'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Mesa', 'Phoenix', 'Carlsbad', 'Castro Valley', 'Fresno', 'Laguna Hills', 'Los Angeles', 'San Francisco', 'Sylmar', 'Hialeah', 'Miami', 'South Miami', 'Chicago', 'Oak Park', 'Indianapolis', 'Baltimore', 'Boston', 'Las Vegas', 'Emerson', 'Summit', \"Tom's River\", 'New York', 'Chapel Hill', 'Willoughby', 'Wyomissing', 'Dallas', 'Lewisville', 'McAllen'] ['Florida'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Australia', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'China', 'China', 'China', 'Hong Kong', 'Singapore', 'Taiwan', 'Taiwan'] ['Birmingham', 'Birmingham', 'Tucson', 'Auburn', 'Berkeley', 'Burlingame', 'Cameron Park', 'Duarte', 'Fresno', 'La Jolla', 'Modesto', 'Oakland', 'Orange', 'Palo Alto', 'Palo Alto', 'Rancho Cordova', 'Rohnert Park', 'Roseville', 'Roseville', 'Sacramento', 'Sacramento', 'Sacramento', 'San Francisco', 'San Francisco', 'Santa Clara', 'South Pasadena', 'South San Francisco', 'Sunnyvale', 'Vacaville', 'Greeley', 'Loveland', 'Parker', 'Wheat Ridge', 'New Haven', 'Newark', 'Newark', 'Tampa', 'Atlanta', 'Atlanta', 'Atlanta', \"'Aiea\", 'Honolulu', 'Honolulu', 'Boise', 'Chicago', 'Chicago', 'Decatur', 'Decatur', 'Effingham', 'Springfield', 'Urbana', 'South Bend', 'Des Moines', 'Iowa City', 'Wichita', 'Wichita', 'Baltimore', 'Baltimore', 'Boston', 'Boston', 'Boston', 'Ann Arbor', 'Ann Arbor', 'Brownstown', 'Clinton Township', 'Detroit', 'Livonia', 'Pontiac', 'West Bloomfield', 'Rochester', 'Cape Girardeau', 'Creve Coeur', 'Rolla', 'Saint Louis', 'Saint Louis', 'Saint Louis', 'Saint Peters', 'Springfield', 'Omaha', 'Reno', 'Reno', 'Basking Ridge', 'Middletown', 'Bronx', 'Bronx', 'Brooklyn', 'Brooklyn', 'Commack', 'Harrison', 'New York', 'New York', 'New York', 'Rochester', 'Rockville Centre', 'Sleepy Hollow', 'Akron', 'Chardon', 'Cincinnati', 'Cleveland', 'Cleveland', 'Cleveland', 'Columbus', 'Elyria', 'Mansfield', 'Sandusky', 'Strongsville', 'Sylvania', 'West Chester', 'Wooster', 'Oklahoma City', 'Oklahoma City', 'Gresham', 'Portland', 'Chadds Ford', 'Danville', 'Lewisburg', 'West Reading', 'Wilkes-Barre', 'Greenville', 'Greenville', 'Greenville', 'Greer', 'Greer', 'Seneca', 'Spartanburg', 'Spartanburg', 'Dallas', 'American Fork', 'Murray', 'Riverton', 'Saint George', 'Salt Lake City', 'Vancouver', 'Eau Claire', 'La Crosse', 'Madison', 'Marshfield', 'Milwaukee', 'Minocqua', 'Rice Lake', 'Stevens Point', 'Weston', 'Melbourne', 'Calgary', 'Edmonton', 'London', 'Toronto', 'Montreal', 'Montreal', 'Montreal', 'Shatin', 'Guangdong Province', 'Guangzhou', 'Chai Wan', 'Singapore', 'Taipei', 'Taoyuan'] [] 0 0 \n",
      "\n",
      "\n",
      "['Brazil'] ['São Paulo'] ['Orlando', 'Orlando', 'Fl, United States of America'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['San Francisco', 'Gainesville', 'Rochester'] ['Rochester', 'New York', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Sweden'] ['Lund'] ['Huddinge', 'Sweden'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Winston-Salem'] ['Winston Salem', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['China'] ['Changsha'] ['Changsha', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China'] ['Beijing', 'Beijing', 'BeiJing', 'Beijing', 'Beijing', 'Guangzhou', 'GuangZhou', 'Wuhan', 'ChangSha', 'ChangChun', 'ShenYang', 'ShangHai', 'ShangHai', 'HangZhou'] ['Guangzhou', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['Burundi'] ['Bujumbura'] ['Box D23', 'Konstanz', 'Germany', 'Bujumbura', 'Burundi'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['New York'] ['Baltimore', 'MD', 'USA', 'Baltimore', 'MD, USA'] 1 0 \n",
      "\n",
      "\n",
      "['Netherlands'] ['Nijmegen'] ['The Netherlands'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Boulder'] ['Colorado', 'U.S.A.'] 0 0 \n",
      "\n",
      "\n",
      "['Denmark'] ['Horsens'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Chapel Hill'] [] 0 0 \n",
      "\n",
      "\n",
      "['Germany'] ['Dresden'] ['Duesseldorf', 'Germany'] 1 0 \n",
      "\n",
      "\n",
      "['China'] ['Tianjin'] ['Beijing', \"People's Republic of China\"] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['Chicago', 'Cincinnati', 'Pittsburgh'] ['Pittsburgh', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Argentina'] ['Caba'] ['Argentina'] 1 0 \n",
      "\n",
      "\n",
      "['China'] [\"Xi'an\"] [\"Xi'an\", 'Shaanxi', 'China', \"Xi'an\", 'Shaanxi', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Zhong-Zheng District', 'Taipei', 'Taiwan'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Rochester'] ['Rochester', 'Minnesota', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Canada'] ['London'] ['Windermere Road', 'London', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Portland'] ['Portland', 'Portland', 'OR', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Denmark'] ['Herlev'] ['Denmark'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Boston'] ['New Haven', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Italy'] ['Milan'] ['Milan', 'Italy'] 1 1 \n",
      "\n",
      "\n",
      "['Denmark'] ['Copenhagen'] [] 0 0 \n",
      "\n",
      "\n",
      "['Germany', 'Germany', 'Germany'] ['Aachen', 'Köln', 'Düsseldorf'] ['Aachen', 'Germany'] 1 1 \n",
      "\n",
      "\n",
      "['Turkey', 'Turkey'] ['Istanbul', 'Istanbul'] ['Fatih', 'Istanbul', 'Turkey'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Scottsdale', 'Scottsdale'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['Burkina Faso'] ['Bobo Dioulasso'] ['Boston', 'Massachusetts'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Gainesville'] ['Gainesville', 'Florida', 'United States of America'] 1 1 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['China', 'Germany', 'Switzerland'] ['Fuzhou', 'Herzogenaurach', 'Rheinfelden'] ['Fujian', 'China'] 1 0 \n",
      "\n",
      "\n",
      "['France'] ['Caen'] ['Caen', 'France'] 1 1 \n",
      "\n",
      "\n",
      "['Korea, Republic of'] ['Gangnam-Gu'] ['Bochum', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['France'] ['Caen'] ['France'] 1 0 \n",
      "\n",
      "\n",
      "['China'] ['Beijing'] ['Gainesville', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Cairo', 'Egypt'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Saint Louis'] ['Fujian', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Irvine', 'San Diego', 'Jacksonville', 'Atlanta', 'Chicago', 'Charlestown', 'Saddle Brook', 'New York', 'White Plains', 'Cleveland', 'Charleston', 'Seattle'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Nashville'] ['Nashville'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States'] ['Tempe', 'San Diego', 'Plano', 'San Antonio', 'North Chesterfield'] ['North Chesterfield', 'VA'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Jacksonville', 'Maywood', 'Boston', 'New York', 'Cincinnati', 'Nashville'] [\"St. Joseph's\", 'ON', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Columbus'] ['Kalamazoo', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Las Vegas'] ['Reno', 'Nevada', 'Las Vegas', 'Nevada'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Gainesville'] ['Gainesville', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Ann Arbor'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Loma Linda'] ['Baltimore', 'Maryland'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Old Westbury'] ['NY', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands'] ['Enschede', 'Leiden', 'Amsterdam', 'Amsterdam', 'Arnhem', 'Den Haag', 'Groningen', 'Maastricht', 'NIjmegen', 'Rotterdam', 'Tilburg'] ['The Netherlands'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Vancouver', 'BC', 'Canada', 'Vancouver', 'BC', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China', 'China'] ['Beijing', 'Beijing', 'Chongqing', 'Fuzhou', 'Guangzhou', 'Tianjing', 'Shiyan', 'Wuhan', 'Changsha', 'Changchun', 'Jinan', 'Shanghai', 'Shanghai', 'Chengdu', 'Wulumuqi'] ['Beijing', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['Canada', 'Canada'] ['Toronto', 'Toronto'] ['Toronto', 'Ontario', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['New York', 'NY'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Durham'] ['Durham', 'NC', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Switzerland'] ['Winterthur'] ['Zürich', 'Switzerland'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['San Francisco'] ['Seattle'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Aurora', 'Washington', 'Chicago', 'Boston', 'Detroit', 'Saint Louis', 'New York', 'Cincinnati', 'Dallas'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['Brazil'] ['São Paulo'] ['São Paulo', 'Brazil'] 1 1 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['Glasgow'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Minneapolis'] ['Minneapolis', 'Minnesota'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Bronx'] ['Bronx', 'New York'] 1 1 \n",
      "\n",
      "\n",
      "['Slovenia'] ['Celje'] ['Celje', 'Slovenia'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['N. West Drive', 'Indianapolis', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada'] ['Calgary', 'Winnipeg', 'Hamilton', 'London', 'London', 'Toronto', 'Toronto'] ['North Adelaide', 'SA', 'Australia'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Birmingham', 'Phoenix', 'Tucson', 'Jonesboro', 'Carmichael', 'Castro Valley', 'Long Beach', 'Los Angeles', 'Los Angeles', 'San Francisco', 'Sylmar', 'Miami', 'Miami', 'Chicago', 'Worcester', 'Saint Louis', 'Las Vegas', 'Eugene', 'El Paso', 'Fort Worth', 'Houston', 'McAllen'] ['Houston', 'Texas'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Bethesda'] ['San Francisco', 'San Francisco', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Montréal'] ['Stockholm', 'Sweden'] 0 0 \n",
      "\n",
      "\n",
      "['France'] ['Paris'] ['Garches', 'France'] 1 0 \n",
      "\n",
      "\n",
      "[] [] ['L647Ad', 'Portland', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['China'] ['Tianjin'] ['Tianjin', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Bulgaria', 'Bulgaria', 'Bulgaria', 'Bulgaria', 'Bulgaria', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Israel', 'Israel', 'Israel', 'Israel', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Poland', 'Poland', 'Poland', 'Poland', 'Poland', 'Poland', 'Poland', 'Poland', 'Slovakia', 'Slovakia', 'Slovakia', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Ukraine', 'Ukraine', 'Ukraine', 'Ukraine', 'Ukraine', 'Ukraine', 'Ukraine', 'Ukraine', 'Ukraine', 'Ukraine', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom'] ['Birmingham', 'Phoenix', 'Fountain Valley', 'Loma Linda', 'Los Angeles', 'Pasadena', 'Reseda', 'Sacramento', 'Aurora', 'Vernon', 'Boca Raton', 'Naples', 'Orlando', 'Tampa', 'Chicago', 'Kansas City', 'Boston', 'East Lansing', 'Farmington Hills', 'West Bloomfield', 'Lebanon', 'Summit', 'Commack', 'New York', 'New York', 'Asheville', 'Cincinnati', 'Toledo', 'Tulsa', 'Hershey', 'Charleston', 'Nashville', 'Bedford', 'Houston', 'Charlottesville', 'Kirkland', 'Pleven', 'Plovdiv', 'Sofia', 'Sofia', 'Varna', 'Aschaffenburg', 'Berlin', 'Dresden', 'Munchen', 'Westerstede', 'Haifa', 'Petah Tiqva', 'Ramat Gan', 'Tel Aviv', 'Acquaviva delle Fonti', 'Ancona', 'Brescia', 'Napoli', 'Pavia', 'Pisa', 'Roma', 'Roma', 'Salerno', 'Varese', 'Venezia', 'Vicenza', 'Warszawa', 'Bydgoszcz', 'Czestochowa', 'Katowice', 'Katowice', 'Krakow', 'Lodz', 'Warszawa', 'Bratislava', 'Považská Bystrica', 'Zilina', 'Mostoles', 'Barcelona', 'Barcelona', 'Barcelona', 'Madrid', 'Madrid', 'Madrid', 'Majadahonda', 'San Sebastian de los Reyes', 'Sant Cugat del Valles', 'Cherkasy', \"Dnipropetrovs'k\", 'Kharkiv', 'Kyiv', \"L'viv\", 'Poltava', 'Zaporizhzhya', 'Zaporizhzhya', \"Zaporozh'ye\", \"Zaporozh'ye\", 'Bury', 'Newcastle upon Tyne', 'Nottingham', 'Stoke-on-Trent'] ['Detroit', 'Michigan', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Saint Louis'] ['Ukraine'] 0 0 \n",
      "\n",
      "\n",
      "['Israel'] ['Haifa'] ['Rochester', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States'] ['Baltimore', 'Baltimore', 'Hershey', 'Nashville'] ['Baltimore', 'Maryland'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Salvador', 'Brazil'] 0 0 \n",
      "\n",
      "\n",
      "['Ireland'] ['Castlebar'] ['Reading', 'UK'] 0 0 \n",
      "\n",
      "\n",
      "['Argentina'] ['Buenos Aires'] ['Argentina'] 1 0 \n",
      "\n",
      "\n",
      "['Belgium'] ['Brussels'] ['Brussels', 'Belgium', 'Wavre', 'Belgium'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Indianapolis'] ['Bloomington', 'Indiana', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Spain'] ['Madrid'] ['Madrid', 'Spain'] 1 1 \n",
      "\n",
      "\n",
      "['Mali'] ['Bamako'] ['Malaria', 'Bethesda', 'Maryland', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['Canada'] ['Edmonton'] ['Edmonton', 'Alberta', 'Canada'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Rome', 'Italy'] 0 0 \n",
      "\n",
      "\n",
      "['United Kingdom', 'United Kingdom'] ['Glasgow', 'London'] ['Glasgow', 'UK'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Jackson'] ['USA'] 1 0 \n",
      "\n",
      "\n",
      "['China'] ['Beijing'] ['Beijing', 'China'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Salt Lake City', 'Utah'] 0 0 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['Peterborough'] ['Houston', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['Sweden'] ['Lund'] ['Lund', 'Sweden'] 1 1 \n",
      "\n",
      "\n",
      "['Croatia'] ['Rijeka'] ['Croatia'] 1 0 \n",
      "\n",
      "\n",
      "[] [] ['Guangzhou', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['New York'] ['New York', 'St. Louis', 'St. Louis'] 1 1 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['United States'] ['Tampa'] ['Tampa', 'FL', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Mexico'] ['Leon'] ['San Carlos la Roncha', 'Mexico'] 1 0 \n",
      "\n",
      "\n",
      "['Korea, Republic of'] ['Seoul'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['Finland'] ['Lahti'] ['Finland'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Madison'] [] 0 0 \n",
      "\n",
      "\n",
      "['China'] ['Wuhan'] ['Wuhan', 'Hubei Province', 'China'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['Rochester', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Old Westbury'] ['NY', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "[] [] [] 0 0 \n",
      "\n",
      "\n",
      "['Italy'] ['Udine'] ['Italy'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Rochester'] ['Toronto', 'ON', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['China'] [\"Xi'an\"] [\"Xi'an\", 'China'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Bronx'] ['Bronx', 'NY', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['Miami', 'Chicago', 'Burlington'] ['Burlington', 'Massachusetts'] 1 1 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['China'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Fresno'] ['07743 Jena', 'Germany'] 0 0 \n",
      "\n",
      "\n",
      "['Switzerland'] ['Basel'] ['Basel', 'Switzerland'] 1 1 \n",
      "\n",
      "\n",
      "['China'] ['Beijing'] ['Beijing', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States'] ['Houston', 'Houston', 'Houston'] ['Houston', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Philadelphia'] ['Philadelphia', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['Liverpool'] ['UK'] 1 0 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['Portsmouth'] ['Dublin', 'Ireland'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Madison'] [] 0 0 \n",
      "\n",
      "\n",
      "['Lebanon'] ['Beirut'] ['Beirut', 'Lebanon', 'Dubai', 'United Arab Emirates'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['New York'] ['New York'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Baltimore'] ['Salt Lake City'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Argentina'] 0 0 \n",
      "\n",
      "\n",
      "['Austria', 'Austria', 'Austria'] ['Vienna', 'Vienna', 'Vienna'] ['Switzerland'] 0 0 \n",
      "\n",
      "\n",
      "['Czechia'] ['Prague'] ['Prague', 'Czech Republic'] 1 1 \n",
      "\n",
      "\n",
      "['China', 'China'] ['Nanjing', 'Shanghai'] ['China'] 1 0 \n",
      "\n",
      "\n",
      "[] [] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Sacramento', 'San Francisco'] ['California', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Ann Arbor'] ['Paris'] 0 0 \n",
      "\n",
      "\n",
      "['Sweden'] ['Örebro'] ['Gothenburg', 'Sweden'] 1 0 \n",
      "\n",
      "\n",
      "[] [] ['Paris', 'France'] 0 0 \n",
      "\n",
      "\n",
      "['Australia'] ['Brisbane'] ['Beijing', 'China'] 0 0 \n",
      "\n",
      "\n",
      "['Singapore'] ['Singapore'] ['Singapore', 'Singapore'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Aurora', 'Broomfield'] ['Baltimore', 'MD', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Oakland'] ['Taiwan'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Ontario', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['Belgium'] ['Leuven'] ['Amsterdam', 'The Netherlands'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Houston'] ['Houston', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Chicago'] ['Sacramento', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Brazil'] ['Curitiba'] ['Brazil'] 1 0 \n",
      "\n",
      "\n",
      "[] [] ['Madrid', 'Spain'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Beijing', \"People's Republic of China\"] 0 0 \n",
      "\n",
      "\n",
      "['Korea, Republic of'] ['Daegu'] ['MD', 'Busan', 'South Korea'] 0 0 \n",
      "\n",
      "\n",
      "['China'] ['Shanghai'] ['Shanghai', 'China'] 1 1 \n",
      "\n",
      "\n",
      "['United States'] ['Tampa'] ['Tampa', 'Florida', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['New York', 'NY', 'USA'] 0 0 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Iowa City', 'Sioux City'] ['Iowa City', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['Wolverhampton'] ['Wednesfield Road', 'UK'] 1 0 \n",
      "\n",
      "\n",
      "['China', 'China', 'China', 'China', 'China'] ['Nanchang', 'Shanghai', 'Shanghai', 'Shanghai', 'Shanghai'] ['Baltimore', 'MD, USA'] 0 0 \n",
      "\n",
      "\n",
      "['Italy'] ['Bologna'] ['Bologna', 'Italy'] 1 1 \n",
      "\n",
      "\n",
      "[] [] ['London', 'Canada'] 0 0 \n",
      "\n",
      "\n",
      "['Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria', 'Austria'] ['Amstetten', 'Eisenstadt', 'Feldkirch', 'Graz', 'Graz', 'Horn', 'Klagenfurt', 'Klagenfurt', 'Linz', 'Linz', 'Linz', 'Salzburg', 'Salzburg', 'St. Pölten', 'Vienna', 'Vienna', 'Vienna', 'Wiener Neustadt'] ['Wiederherstellungschirurgie'] 0 0 \n",
      "\n",
      "\n",
      "[] [] ['Cleveland', 'United States'] 0 0 \n",
      "\n",
      "\n",
      "['Taiwan'] ['Taipei'] ['Taipei', 'Taiwan', 'Taipei', 'Taiwan'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States'] ['Orlando', 'Hackensack'] ['Philadelphia', 'Pennsylvania', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "[] [] ['Busan', 'South Korea'] 0 0 \n",
      "\n",
      "\n",
      "['Malawi'] ['Lilongwe'] ['Los Angeles', 'California'] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Coral Gables'] ['USA', 'Miami', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['Japan'] ['Komagane'] ['Komagane', 'Matsumoto', 'Japan'] 1 1 \n",
      "\n",
      "\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States'] ['Los Angeles', 'Los Angeles', 'New Haven', 'Washington', 'Gainesville', 'Jacksonville', 'Jacksonville', 'Atlanta', 'Chicago', 'Baltimore', 'Boston', 'Ann Arbor', 'Saint Louis', 'Saint Louis', 'Lebanon', 'Stony Brook', 'Cleveland', 'Columbus', 'Philadelphia', 'Charleston', 'Nashville', 'Dallas', 'Charlottesville', 'Richmond', 'Milwaukee'] ['Ann Arbor', 'USA'] 1 1 \n",
      "\n",
      "\n",
      "['Cameroon'] ['Yaoundé'] ['South Africa', 'Durban, South Africa'] 0 0 \n",
      "\n",
      "\n",
      "['Netherlands', 'Netherlands', 'Netherlands'] ['Nijmegen', 'Rotterdam', 'Utrecht'] ['Utrecht', 'The Netherlands'] 1 1 \n",
      "\n",
      "\n",
      "['Russian Federation'] ['Moscow'] ['Moscow', 'Russia'] 1 1 \n",
      "\n",
      "\n",
      "['France', 'France', 'France', 'France', 'France', 'France', 'France'] ['Clermont-Ferrand', 'Grenoble', 'Nantes', 'Nimes', 'Poitiers', 'Saint Laurent Du Var', 'Toulouse'] ['France'] 1 0 \n",
      "\n",
      "\n",
      "['Egypt'] ['Cairo'] [] 0 0 \n",
      "\n",
      "\n",
      "['United States'] ['Aurora'] ['Fort Collins', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Dallas'] ['Birmingham', 'USA'] 1 0 \n",
      "\n",
      "\n",
      "['United Kingdom'] ['Loughborough'] ['UK'] 1 0 \n",
      "\n",
      "\n",
      "['United States'] ['Memphis'] ['Gainesville', 'FL', 'Memphis', 'TN'] 1 1 \n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "lista = df['ct_country'].tolist()\n",
    "lista1 = df['ct_city'].tolist()\n",
    "lista2 = df['ar_location'].tolist()\n",
    "lista3 = df['country_equality'].tolist()\n",
    "lista4 = df['city_equality'].tolist()\n",
    "\n",
    "for i in range(len(lista)):\n",
    "    if(lista2[i] is not None):\n",
    "        print(lista[i], lista1[i], lista2[i], lista3[i], lista4[i], '\\n\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ['Obesity Branch', 'National Institute of Diabetes and Digestive', 'National Institutes of Health'] 1 \n",
      "\n",
      "\n",
      "Eastern Cooperative Oncology Group ['Division of Medical Oncology', 'New York University School of Medicine', 'NYU Cancer Institute'] 0 \n",
      "\n",
      "\n",
      "American College of Surgeons ['Columbia University College of Physicians and', 'Weill Cornell Medical College'] 0 \n",
      "\n",
      "\n",
      "University of Rochester ['University of California, Irvine', 'CA'] 1 \n",
      "\n",
      "\n",
      "Dept. of Immunology, Okayama University Schhol of Medicine and Dentistry ['Faculty of Health and Welfare', 'Kawasaki University of Medical Welfare', 'Kurashiki'] 1 \n",
      "\n",
      "\n",
      "Inflexxion, Inc. ['Pain and Opioid Division', 'Inflexxion Inc.'] 1 \n",
      "\n",
      "\n",
      "Ohio State University ['Division of Hematology', 'The Ohio State University-James Comprehensive Cancer Center'] 1 \n",
      "\n",
      "\n",
      "Michael E DeBakey VA Medical Center ['Health Services Research and Development Center of Excellence'] 0 \n",
      "\n",
      "\n",
      "University of Rochester Sleep Research Lab ['Behavioral Sleep Medicine Program', 'Department of Psychiatry, University of Pennsylvania', 'Center for Sleep', 'Circadian Neurobiology', 'Department of Medicine', 'University of Pennsylvania', 'PA, USA,', 'School', 'Nursing, University of Pennsylvania'] 1 \n",
      "\n",
      "\n",
      "Universidade Federal do Rio Grande do Sul-Hospital de Clínicas de Porto Alegre ['Department of Pediatrics', 'Universidade Federal'] 0 \n",
      "\n",
      "\n",
      "Boston Children’s Hospital [\"Division of Endocrinology, Boston Children's Hospital\"] 1 \n",
      "\n",
      "\n",
      "Rutgers, The State University of New Jersey ['Department of Dermatology', 'Tufts University School of Medicine'] 1 \n",
      "\n",
      "\n",
      "National Taiwan University Hospital ['Department of Urology', 'National Taiwan University College of Medicine'] 1 \n",
      "\n",
      "\n",
      "University of Pittsburgh ['Fakultät für Physik & Astronomie'] 0 \n",
      "\n",
      "\n",
      "University of Rochester ['Department of Pediatrics, University of Rochester School of Medicine and Dentistry'] 1 \n",
      "\n",
      "\n",
      "Massachusetts General Hospital ['Mount Sinai School of Medicine'] 0 \n",
      "\n",
      "\n",
      "Charite University, Berlin, Germany ['Department of Gynecology', 'Charité - University Medicine Berlin'] 1 \n",
      "\n",
      "\n",
      "National Taiwan University Hospital ['Department of Parasitology, College of Medicine', 'Chang Gung University', 'Tao-Yuan 33332'] 1 \n",
      "\n",
      "\n",
      "Stanford University ['Stanford University School of Medicine', 'Department of Psychiatry and Behavioral Sciences', 'Stanford'] 1 \n",
      "\n",
      "\n",
      "CHU de Nantes ['Hôtel-Dieu'] 0 \n",
      "\n",
      "\n",
      "Main Line Health ['Lankenau Institute for Medical Research'] 0 \n",
      "\n",
      "\n",
      "Shriners Hospitals for Children ['Shriners Hospital for Children'] 1 \n",
      "\n",
      "\n",
      "Sunnybrook Health Sciences Centre ['Department', 'Gebäude\\xa0A1'] 0 \n",
      "\n",
      "\n",
      "Tel Aviv University ['Division of Psychiatry', 'The State of Israel Ministry of Health', 'The Chaim Sheba Medical Center', 'Sackler Medical School', 'Tel-Aviv University'] 1 \n",
      "\n",
      "\n",
      "Charité Campus Benjamin-Franklin, Rheumatology ['Medical Department I, Rheumatology', 'Charité University Medicine Berlin'] 0 \n",
      "\n",
      "\n",
      "Sunnybrook Health Sciences Centre ['University of Toronto', 'Brain Sciences Research Program', 'Sunnybrook Health Sciences Center', 'Department of Psychiatry'] 1 \n",
      "\n",
      "\n",
      "Dept. Orthopaedics, SUNY@Stony Brook, NY 11794 ['Department of Orthopaedics, Health Science Center', 'Stony Brook University Medical Center', 'Stony Brook'] 0 \n",
      "\n",
      "\n",
      "CHU Angers, Service d'hépato-gastroentérologie, 49933 Angers Cedex 09 ['Department of Hepatology', 'University Hospital of Angers'] 0 \n",
      "\n",
      "\n",
      "Department of Human Nutrition, Royal Veterinary and Agricultural University, Denmark ['Department of Nutrition', 'Exercise', 'University of Copenhagen'] 1 \n",
      "\n",
      "\n",
      "Universitaire Ziekenhuizen Leuven ['Department of Ophthalmology, University Hospitals Leuven'] 0 \n",
      "\n",
      "\n",
      "Surugadai Nihon University Hospital ['Department of Anesthesia', 'Intensive Care', 'Osaka Medical Center and Research Institute', 'Maternal and', 'Child Health'] 0 \n",
      "\n",
      "\n",
      "University of Alberta ['Lawrence Livermore National Laboratory', 'L-481,'] 0 \n",
      "\n",
      "\n",
      "University of Alabama at Birmingham ['Sturge-Weber Foundation', 'NJ'] 0 \n",
      "\n",
      "\n",
      "University of California, San Francisco ['Division of Endocrinology, Department of Medicine', 'University of California'] 1 \n",
      "\n",
      "\n",
      "Investigator / Contact ['University of Illinois at Peoria', 'University of Illinois'] 0 \n",
      "\n",
      "\n",
      "University of New Mexico [\"Department of Obstetrics and Gynecology and Women's Health\"] 0 \n",
      "\n",
      "\n",
      "VA Medical Center, Philadelphia ['University of Pennsylvania Perelman School of Medicine'] 0 \n",
      "\n",
      "\n",
      "OSF Stroke Center ['Nuclear Physics and Technology', 'Peking University'] 0 \n",
      "\n",
      "\n",
      "Université de Montréal ['Gulf Medical University', 'UAE'] 0 \n",
      "\n",
      "\n",
      "Aarhus University, Perinatal Epidemiological Unit ['Perinatal Epidemiology Research Unit', 'Aarhus University Hospital'] 1 \n",
      "\n",
      "\n",
      "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) ['Perinatology Research Branch', 'Program for Perinatal Research and Obstetrics, Division of Intramural Research', 'Eunice Kennedy Shriver National Institute of Child Health and Human Development', 'National Institutes of Health', 'MI', 'Department of Obstetrics and Gynecology', 'University of Michigan', 'MI', 'Department of Epidemiology and Biostatistics', 'Michigan State University', 'MI'] 1 \n",
      "\n",
      "\n",
      "Singapore National Eye Centre ['Singapore Eye Research Institute', 'Singapore National Eye Centre'] 1 \n",
      "\n",
      "\n",
      "University of Maryland Greenebaum Cancer Center ['Bakewell Veterinary Clinic', 'Milford Farm', 'Mill Street'] 0 \n",
      "\n",
      "\n",
      "University of Washington and Children's Hospital and Regional Medical Center ['University of KwaZulu-Natal', 'Nelson R. Mandela School of Medicine', 'KwaZulu-Natal Department of Health'] 1 \n",
      "\n",
      "\n",
      "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) ['Department of Pediatrics'] 0 \n",
      "\n",
      "\n",
      "London School of Hygiene and Tropical Medicine ['Clinical Trials Unit', 'London School of Hygiene & Tropical Medicine'] 1 \n",
      "\n",
      "\n",
      "Center for Immunization Research, Johns Hopkins School of Public Health ['Institute of Health Policy, Management and Evaluation, University of Toronto'] 0 \n",
      "\n",
      "\n",
      "VUMC ['the Department of Radiology and Research Institute of Radiology', 'N.J.L.', 'M.S.C.', 'S.C.J.', 'C.-G.C.', 'S.J.K.', 'D.H.L.'] 0 \n",
      "\n",
      "\n",
      "Duke University ['Division of Radiation Biology and Toxicology, School of Life Sciences', 'Manipal University', 'Manipal', 'Karnataka'] 1 \n",
      "\n",
      "\n",
      "University of Magdeburg, Department of Hematology and Oncology ['Klinik', 'Hämatologie/Onkologie'] 0 \n",
      "\n",
      "\n",
      "The Scripps Research Institute ['Pearson Center', 'Alcoholism and Addiction Research', 'The Scripps Research Institute'] 1 \n",
      "\n",
      "\n",
      "Stanford University ['Stanford University Medical Center', 'University of California Los Angeles Medical Center', 'CA', 'Indiana University Medical Center', 'Weill Medical College of Cornell University', 'University of Nebraska Medical Center', 'NE', 'Johns Hopkins University Oncology Center', 'British Columbia Cancer Agency Centre for Lymphoid Cancer', 'Toronto-Sunnybrook Regional Cancer Centre', 'Cross Cancer Institute', 'Washington University School of Medicine', 'MO', 'Oregon Health Science University', 'Rush University Medical Center', 'IL', 'University of Iowa Hospitals and Clinics', 'IA', 'Mayo Clinic', 'Dana-Farber Cancer Institute', 'Rocky Mountain Cancer Centers'] 1 \n",
      "\n",
      "\n",
      "Johns Hopkins University ['Oncology', 'Sidney Kimmel Comprehensive Cancer Center', 'Johns Hopkins University School of Medicine', 'Netherlands Cancer Institute', 'Department of Obstetrics and Gynecology', 'Johns Hopkins University School of Medicine'] 1 \n",
      "\n",
      "\n",
      "University of California, Los Angeles ['CA', 'UCLA School of Medicine', 'CA', 'RAND Corp', 'CA'] 0 \n",
      "\n",
      "\n",
      "Rigshospitalet, Denmark ['University of Arizona', 'AZ 85721'] 0 \n",
      "\n",
      "\n",
      "Thomas Jefferson University ['Department of Pediatric Bone Marrow Transplantation', 'University of Minnesota'] 1 \n",
      "\n",
      "\n",
      "Boston University ['Clinical Neurophysiology', 'Aarhus University Hospital'] 1 \n",
      "\n",
      "\n",
      "Queen Victoria Hospital, East Grinstead ['The Burns Centre', 'Queen Victoria Hospital'] 1 \n",
      "\n",
      "\n",
      "University of Toronto ['Bloorview Research Institute', 'Holland Bloorview Kids Rehabilitation Hospital', 'Departments of Occupational Science', 'Occupational Therapy', 'University of Toronto'] 1 \n",
      "\n",
      "\n",
      "Patient-centered Education and Research ['Intermountain Healthcare', 'Institute for Healthcare Delivery Research', 'UT'] 0 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "McMaster University ['Department of Family Medicine', 'McMaster University', 'Kingston Community Health Centres', 'Department of Family Medicine', \"Queen's University\"] 1 \n",
      "\n",
      "\n",
      "Universiteit Antwerpen ['University of Ghent'] 0 \n",
      "\n",
      "\n",
      "Medical College of Wisconsin ['Division of Critical Care Medicine', 'Department of Pediatrics', \"Children's Hospital of Wisconsin\"] 0 \n",
      "\n",
      "\n",
      "Children's Healthcare of Atlanta ['Sibley Heart Center Cardiology', \"Children's Healthcare\"] 0 \n",
      "\n",
      "\n",
      "Dana-Farber Cancer Institute ['Department of Medical Oncology', 'Dana-Farber Cancer Institute', 'Harvard Medical School'] 1 \n",
      "\n",
      "\n",
      "Mayo Graduate School of Medicine ['Gastroenterology & Hepatology'] 0 \n",
      "\n",
      "\n",
      "Johns Hopkins University ['Johns Hopkins University School of Medicine'] 1 \n",
      "\n",
      "\n",
      "Johns Hopkins University ['Johns Hopkins University School of Medicine'] 1 \n",
      "\n",
      "\n",
      "Ohio State University ['Department of Neurology', 'Ohio State University'] 1 \n",
      "\n",
      "\n",
      "M.D. Anderson Cancer Center ['The Center for Personalized Cancer Therapy', 'University of California San Diego Moores Cancer Center'] 0 \n",
      "\n",
      "\n",
      "US Army Institute of Surgical Research ['U.S. Army Institute of Surgical Research', 'Chambers Pass', 'JBSA'] 1 \n",
      "\n",
      "\n",
      "Botucatu School of Medicine - Unesp ['Department of Tropical Diseases', 'Botucatu Medical School', 'UNESP', 'Botucatu-SP'] 1 \n",
      "\n",
      "\n",
      "Lawson Health Research Institute ['Department of Chemistry, Division of Chemical Biology', 'Medicinal Chemistry', 'Department of Pharmacology, University of North Carolina', 'Chapel Hill'] 0 \n",
      "\n",
      "\n",
      "University of Michigan ['Department of Surgery', \"CS Mott Children's Hospital\", 'University of Michigan'] 1 \n",
      "\n",
      "\n",
      "Massachusetts General Hospital ['Mount Sinai School of Medicine'] 0 \n",
      "\n",
      "\n",
      "Mayo Clinic ['Department of Clinical Cancer Prevention', 'MD Anderson Cancer Center'] 0 \n",
      "\n",
      "\n",
      "Profil Institute for Metabolic Research [] 0 \n",
      "\n",
      "\n",
      "Brigham and Women's Hospital ['Diabetes Unit', 'Massachusetts General Hospital'] 1 \n",
      "\n",
      "\n",
      "University of California, Los Angeles ['Nuclear Physics and Technology', 'Peking University'] 1 \n",
      "\n",
      "\n",
      "UCSD ['University of California', 'CA', 'National Center for PTSD,'] 0 \n",
      "\n",
      "\n",
      "University of Alabama at Birmingham ['Division of Clinical Immunology and Rheumatology, Department of Medicine', 'University of Alabama', 'AL 35294'] 1 \n",
      "\n",
      "\n",
      "St. Joseph-Krankenhaus Berlin ['Department of Medicine II'] 0 \n",
      "\n",
      "\n",
      "NEMA Research, Inc. ['Department of Medicine', 'Johns Hopkins University School of Medicine'] 0 \n",
      "\n",
      "\n",
      "Public Health England ['Department of Pediatrics', 'UC Davis School of Medicine'] 0 \n",
      "\n",
      "\n",
      "Department of Neurology; the Cleveland Clinic Foundation ['the Department of Neurology', 'University of California', 'Department of Neurology', 'Neurological Institute', 'University Hospitals Case Medical Center', 'Case Western Reserve University'] 0 \n",
      "\n",
      "\n",
      "Baylor College of Medicine ['Department of Pediatrics, Baylor College of Medicine', 'Lille Frank Abercrombie Section of Cardiology', \"Texas Children's Hospital\"] 0 \n",
      "\n",
      "\n",
      "George Washington University ['Pediatrics', 'Division of Newborn Service', 'George Washington University Medical Center', \"Children's National Medical Center\"] 1 \n",
      "\n",
      "\n",
      "Hospital Clinic of Barcelona ['Institute of Liver Studies', \"King's College Hospital\", \"King's College\"] 1 \n",
      "\n",
      "\n",
      "St. Jude Children's Research Hospital [\"St Jude Children's Research Hospital\"] 1 \n",
      "\n",
      "\n",
      "University of California, San Francisco ['Department of Health Services', 'CA'] 0 \n",
      "\n",
      "\n",
      "University of Louisville ['Department of Surgery, University of Louisville'] 1 \n",
      "\n",
      "\n",
      "NTUH ['Department of Epidemiology and Biostatistics, Xiangya School of Public Health', 'Central South University', 'Changsha 410008'] 0 \n",
      "\n",
      "\n",
      "Presidio Ospedaliero di Livorno ['Oncology', 'Pisa University Hospital'] 0 \n",
      "\n",
      "\n",
      "Foothills Medical Centre, University of Calgary ['Clinical Trial Service Unit', 'Epidemiological Studies Unit,', 'University of Oxford'] 1 \n",
      "\n",
      "\n",
      "Northern Orthopaedic Division ['Aalborg Sygehus'] 0 \n",
      "\n",
      "\n",
      "Soul Medicine Institute ['Foundation for Epigenetic Medicine'] 0 \n",
      "\n",
      "\n",
      "University of NSW ['School of Psychiatry,University of New South Wales'] 1 \n",
      "\n",
      "\n",
      "Kyushu Clinical Pharmacology Research Clinic ['Sugioka Memorial Hospital Clinical Research Center'] 0 \n",
      "\n",
      "\n",
      "Northwell Health ['Hofstra University'] 0 \n",
      "\n",
      "\n",
      "George Washington University ['Hofstra University'] 1 \n",
      "\n",
      "\n",
      "Herzog Hospital ['Herzog Hospital', 'Faculty of Medicine', 'Hebrew University'] 1 \n",
      "\n",
      "\n",
      "Uppsala University Hospital, Sweden ['Department of Immunology, Genetics', 'Uppsala University'] 1 \n",
      "\n",
      "\n",
      "Duke University ['Department of Gastroenterology', 'General Surgery', 'Mayo Clinic'] 0 \n",
      "\n",
      "\n",
      "National Pediatric Neuroinflammation Organization, Inc. ['Southern Illinois University School of Medicine', 'IL'] 0 \n",
      "\n",
      "\n",
      "Malaria Research Unit, Thailand ['Shoklo Malaria Research Unit', 'Faculty of Tropical Medicine', 'Mahidol University', 'Nuffield Department of Clinical Medicine', 'Centre for Clinical Vaccinology and Tropical Medicine', 'University of Oxford'] 0 \n",
      "\n",
      "\n",
      "International Diabetes Center at Park Nicollet ['Department of Emergency Medicine', 'Allegheny Health Network', 'PA'] 0 \n",
      "\n",
      "\n",
      "Northwestern University ['Northwestern University Feinberg School of Medicine', 'Northwestern Memorial Hospital', 'Department of Surgery'] 1 \n",
      "\n",
      "\n",
      "Children's Hospital & Research Center Oakland ['Department of Atherosclerosis Research', \"Children's Hospital Oakland Research Institute\"] 1 \n",
      "\n",
      "\n",
      "Jacksonville Orthopedic Institute ['Department of Radiology, Hospital of', 'the University of Pennsylvania', 'PA'] 0 \n",
      "\n",
      "\n",
      "Kantonsspital Aarau ['Department of Neurology', 'Cantonal Hospital of Aarau'] 0 \n",
      "\n",
      "\n",
      "Wayne State University ['Department of Psychology', 'Wayne State University', 'MI'] 1 \n",
      "\n",
      "\n",
      "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) ['Nuclear Physics and Technology', 'Peking University'] 0 \n",
      "\n",
      "\n",
      "Bayside Health ['Division of Gastroenterology', 'Washington University School of Medicine', 'MO'] 0 \n",
      "\n",
      "\n",
      "National Taiwan University Hospital ['the Department of Anesthesiology', 'National Taiwan University Hospital', 'Y.-C.Y.', 'C.-Y.W.', 'Y.-J.C.', 'C.-M.L.', 'the Graduate Institutes of Physiology, College of Medicine', 'National Taiwan University', 'Department of Medical Imaging', 'Taipei Buddhist Tzu Chi General Hospital', 'Department of Anesthesiology, Far Eastern Memorial Hospital'] 1 \n",
      "\n",
      "\n",
      "National Institute of Nursing Research (NINR) ['National Institute of Nursing Research', 'National Institutes of Health'] 1 \n",
      "\n",
      "\n",
      "Boston Children’s Hospital ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] 1 \n",
      "\n",
      "\n",
      "Mt Sinai School of Medicine, Dept Obstetrics and Gynecology ['Icahn School of Medicine'] 1 \n",
      "\n",
      "\n",
      "Hospital Río Carrión ['Department of Pharmacy and Pharmaceutical Technology', 'Faculty of Pharmacy', 'Universidade de Santiago de Compostela', 'Santiago de Compostela', 'Genetics and Biology of the Development of Kidney Diseases Unit', 'Sanitary Research Institute (IDIS', 'the University Hospital Complex of Santiago de Compostela', 'CHUS', 's/n', 'Santiago de Compostela'] 1 \n",
      "\n",
      "\n",
      "University of Wisconsin, Madison ['Department of Medicine', 'University of Wisconsin', 'WI'] 1 \n",
      "\n",
      "\n",
      "Seoul National University Hospital ['the Department of Radiology and Research Institute of Radiology', 'N.J.L.', 'M.S.C.', 'S.C.J.', 'C.-G.C.', 'S.J.K.', 'D.H.L.'] 0 \n",
      "\n",
      "\n",
      "Hospital Ruber Internacional La Masó 38, Mirasierra 28034 Madrid, Spain ['Department of Neurology'] 0 \n",
      "\n",
      "\n",
      "Emory University ['Nuclear Physics and Technology', 'Peking University'] 1 \n",
      "\n",
      "\n",
      "Oxford Radcliffe Hospitals Trust ['Kenya Medical Research Institute', 'Centre for Geographical Medical Research (Coast', 'Kilifi'] 0 \n",
      "\n",
      "\n",
      "University of Colorado, Denver ['School of Medicine', 'Internal Medicine', 'University of Colorado', 'Aurora'] 1 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Johns Hopkins University ['Stanford University Medical Center', 'University of California Los Angeles Medical Center', 'CA', 'Indiana University Medical Center', 'Weill Medical College of Cornell University', 'University of Nebraska Medical Center', 'NE', 'Johns Hopkins University Oncology Center', 'British Columbia Cancer Agency Centre for Lymphoid Cancer', 'Toronto-Sunnybrook Regional Cancer Centre', 'Cross Cancer Institute', 'Washington University School of Medicine', 'MO', 'Oregon Health Science University', 'Rush University Medical Center', 'IL', 'University of Iowa Hospitals and Clinics', 'IA', 'Mayo Clinic', 'Dana-Farber Cancer Institute', 'Rocky Mountain Cancer Centers'] 1 \n",
      "\n",
      "\n",
      "Oregon Health and Science University ['Neurology and Research', 'Institute of Integrative Medicine', 'Chair for Theory of Medicine', 'Integrative', 'Anthroposophic Medicine', 'Witten/Herdecke University'] 1 \n",
      "\n",
      "\n",
      "Synergy Health Solutions ['Research and Development Division of the National Association of County'] 0 \n",
      "\n",
      "\n",
      "Banner Alzheimer's Institute [\"Banner Alzheimer's Institute\"] 1 \n",
      "\n",
      "\n",
      "National Heart, Lung, and Blood Institute (NHLBI) ['Pulmonary-Critical Care Medicine Branch', 'National Heart, Lung', 'Blood Institute', 'National Institutes of Health'] 1 \n",
      "\n",
      "\n",
      "Washington University School of Medicine ['Department of Pediatrics', 'Washington University School of Medicine'] 1 \n",
      "\n",
      "\n",
      "National Taiwan University Hospital ['Department of Urology', 'National Taiwan University College of Medicine'] 1 \n",
      "\n",
      "\n",
      "Montefiore Medical Center ['Albert Einstein College of Medicine', \"Children's Hospital\", 'Montefiore'] 0 \n",
      "\n",
      "\n",
      "Asan Medical Center ['the Department of Radiology and Research Institute of Radiology', 'N.J.L.', 'M.S.C.', 'S.C.J.', 'C.-G.C.', 'S.J.K.', 'D.H.L.'] 0 \n",
      "\n",
      "\n",
      "Hartford Hospital ['Division of Cardiology', 'Morristown Medical Center'] 0 \n",
      "\n",
      "\n",
      "Postgraduate Institute of Medical Education and Research ['Department of Endocrinology', 'Post Graduate Institute of Medical Education and Research', 'Chandigarh'] 1 \n",
      "\n",
      "\n",
      "Washington University School of Medicine ['Department of Neurology', 'Washington University School of Medicine St. Louis'] 1 \n",
      "\n",
      "\n",
      "Johns Hopkins University/Sidney Kimmel Cancer Center ['Department of Pharmaceutical Sciences', 'Hampton University'] 1 \n",
      "\n",
      "\n",
      "University of Jordan/ Faculty of Pharmacy ['Department of Paediatrics'] 0 \n",
      "\n",
      "\n",
      "Professor of Surgery, Faculty of Medicine, Alexandria University ['Department of Tropical Medicine', 'Faculty of Medicine', 'Ain Shams University'] 1 \n",
      "\n",
      "\n",
      "National Taiwan University Hospital ['Department of Gastroenterology, University of São Paulo'] 1 \n",
      "\n",
      "\n",
      "University of California, Irvine ['Center for Health Policy Research and Department of Medicine', 'University of California, Irvine', 'CA'] 1 \n",
      "\n",
      "\n",
      "University of North Carolina ['Department of Neurology', 'University of Florida College of Medicine'] 1 \n",
      "\n",
      "\n",
      "University of Zurich [] 0 \n",
      "\n",
      "\n",
      "Rigshospitalet, Denmark ['University of Copenhagen'] 0 \n",
      "\n",
      "\n",
      "Duke University ['Carolinas Cord Blood Bank', 'Translational Therapy Program', 'Duke Translational Research Institute', 'Duke University Medical Center'] 1 \n",
      "\n",
      "\n",
      "Albert Einstein College of Medicine ['Department of Epidemiology and Biostatistics, School of Public Health', 'Imperial College'] 0 \n",
      "\n",
      "\n",
      "University of California, San Francisco ['HIV/AIDS Division', 'University of California', 'CA'] 1 \n",
      "\n",
      "\n",
      "University of Michigan ['Division of Metabolism, Endocrinology and Diabetes,', 'Department of Internal Medicine', 'University of Michigan Health System', 'University of Michigan'] 1 \n",
      "\n",
      "\n",
      "University of California, San Francisco ['Department of Preventive and Restorative Dental Sciences', 'School of Dentistry, University of California', 'Department of Preventive and Restorative Dental Sciences', 'Dean, School of Dentistry, University of California'] 1 \n",
      "\n",
      "\n",
      "Hugo W. Moser Research Institute at Kennedy Krieger, Inc. ['Kennedy Krieger Institute'] 1 \n",
      "\n",
      "\n",
      "UT MD Anderson Cancer Center ['Department of Interventional Radiology', 'The University of Texas MD Anderson Cancer Center', 'PO'] 0 \n",
      "\n",
      "\n",
      "Baylor Health Care System ['Nuclear Physics and Technology', 'Peking University'] 0 \n",
      "\n",
      "\n",
      "Medical University of South Carolina ['Department of Psychiatry and Behavioral Sciences', 'Medical University of South Carolina'] 1 \n",
      "\n",
      "\n",
      "UCSF-Mount Zion ['Department of Neurological Surgery, University of Washington School of Medicine', 'WA, USA'] 0 \n",
      "\n",
      "\n",
      "University of Mississippi Medical Center ['Department of Orthopedic Surgery', 'University of Mississippi Medical Center'] 1 \n",
      "\n",
      "\n",
      "Uppsala University ['Department of Medical Sciences', 'Uppsala University', 'Clinical Research Centre', 'Uppsala University'] 1 \n",
      "\n",
      "\n",
      "Boston Children’s Hospital ['Department of Surgery, Center for Advanced Intestinal Rehabilitation (CAIR', \"Boston Children's Hospital\", 'Harvard Medical School'] 1 \n",
      "\n",
      "\n",
      "US Army Institute of Surgical Research ['United States Army Institute of Surgical Research'] 1 \n",
      "\n",
      "\n",
      "Hannover Medical School ['Department of Plastic', 'Reconstructive Surgery', 'Hannover Medical School'] 1 \n",
      "\n",
      "\n",
      "Boston Children’s Hospital ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] 1 \n",
      "\n",
      "\n",
      "Jewish General Hospital ['Lady Davis Institute for Medical Research', 'Jewish General Hospital', 'Côte-Ste-Catherine', 'Quebec H3T 1E2'] 1 \n",
      "\n",
      "\n",
      "The Cleveland Clinic [] 0 \n",
      "\n",
      "\n",
      "Johns Hopkins University ['Stanford University Medical Center', 'University of California Los Angeles Medical Center', 'CA', 'Indiana University Medical Center', 'Weill Medical College of Cornell University', 'University of Nebraska Medical Center', 'NE', 'Johns Hopkins University Oncology Center', 'British Columbia Cancer Agency Centre for Lymphoid Cancer', 'Toronto-Sunnybrook Regional Cancer Centre', 'Cross Cancer Institute', 'Washington University School of Medicine', 'MO', 'Oregon Health Science University', 'Rush University Medical Center', 'IL', 'University of Iowa Hospitals and Clinics', 'IA', 'Mayo Clinic', 'Dana-Farber Cancer Institute', 'Rocky Mountain Cancer Centers'] 1 \n",
      "\n",
      "\n",
      "Center for Neurological Restoration ['Cleveland Clinic'] 0 \n",
      "\n",
      "\n",
      "Augusta University ['Division of Radiation Biology and Toxicology, School of Life Sciences', 'Manipal University', 'Manipal', 'Karnataka'] 1 \n",
      "\n",
      "\n",
      "University Medical Center Hamburg-Eppendorf, Department of Gynecology ['Department of Gynecology', 'Charité - University Medicine Berlin'] 1 \n",
      "\n",
      "\n",
      "New England School of Acupuncture ['Laboratory of Behavioral Genetics', 'Brain Mind Institute', 'Ecole Polytechnique Federale de Lausanne'] 0 \n",
      "\n",
      "\n",
      "University of Nottingham ['Department of Psychology, University of Pittsburgh', 'PA', 'PA'] 1 \n",
      "\n",
      "\n",
      "Ophthalmic Consultants of Long Island [] 0 \n",
      "\n",
      "\n",
      "Hospital Italiano de Buenos Aires ['Department of Health Informatics'] 0 \n",
      "\n",
      "\n",
      "Severance Hospital ['The University of Texas MD Anderson Cancer Center'] 0 \n",
      "\n",
      "\n",
      "Denver Nephrologists, P.C. [] 0 \n",
      "\n",
      "\n",
      "Seoul National University Hospital ['Nuclear Physics and Technology', 'Peking University'] 1 \n",
      "\n",
      "\n",
      "Spokane Joint Replacement Center ['Department of Molecular and Human Genetics', 'Baylor College of Medicine', 'TX 77030'] 0 \n",
      "\n",
      "\n",
      "National Marrow Donor Program ['Fakultät für Physik & Astronomie'] 0 \n",
      "\n",
      "\n",
      "St. Joseph's Healthcare Hamilton ['Department of Medicine'] 0 \n",
      "\n",
      "\n",
      "Weill Medical College of Cornell University ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] 0 \n",
      "\n",
      "\n",
      "University of British Columbia ['Centre for Health Evaluation and Outcome Sciences', \"St Paul's Hospital\", 'Department of Medicine and Sleep Disorders Program', 'University of British Columbia'] 1 \n",
      "\n",
      "\n",
      "Boston Medical Center ['Department of Medicine', 'Boston University', 'Massachusetts Ave'] 0 \n",
      "\n",
      "\n",
      "Baycrest ['Department of Medicine/Diabetes Unit', 'Massachusetts General Hospital'] 0 \n",
      "\n",
      "\n",
      "Pontificia Universidad Catolica de Chile. Hospital Sotero del Rio. [] 0 \n",
      "\n",
      "\n",
      "St. Jude Children's Research Hospital ['Ching-Hon Pui', \"St Jude Children's Research Hospital\", 'University of Tennessee Health Sciences Center', \"Cook Children's Medical Center\"] 1 \n",
      "\n",
      "\n",
      "Showa University ['Department of Psychiatry', 'Tokyo Metropolitan Police Hospital', 'Department of Psychiatry', 'Showa University Northern Yokohama Hospital'] 1 \n",
      "\n",
      "\n",
      "Shanghai Changzheng Hospital [] 0 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Dartmouth-Hitchcock Medical Center ['Division of Hematology', 'The Ohio State University-James Comprehensive Cancer Center'] 0 \n",
      "\n",
      "\n",
      "Region Syddanmark ['Department of Neurology', 'University of California', 'CA'] 0 \n",
      "\n",
      "\n",
      "Stanford University ['Department of Obstetrics and Gynecology', 'Stanford University School of Medicine'] 1 \n",
      "\n",
      "\n",
      "Beijing Chao Yang Hospital ['Nuclear Physics and Technology', 'Peking University'] 0 \n",
      "\n",
      "\n",
      "University Medical Center Groningen ['University of Groningen, Department of Pharmacy, Division of Pharmacoepidemiology and Pharmacoeconomics'] 1 \n",
      "\n",
      "\n",
      "University of Jena ['Department of Nutritional Physiology, Institute of Nutrition', 'Friedrich Schiller University', 'Dornburger Straße'] 1 \n",
      "\n",
      "\n",
      "Valley Retina Institute ['USDA', 'Bee Biology & Systematics Laboratory', 'Utah State University'] 0 \n",
      "\n",
      "\n",
      "PharmaNet ['Université Laval', 'Association'] 0 \n",
      "\n",
      "\n",
      "Universitaire Ziekenhuizen Leuven ['Department of Vascular and Endovascular Surgery', 'Department of Interventional Radiology', 'University Hospital Leuven'] 0 \n",
      "\n",
      "\n",
      "Laval University ['Department of Physiology and Biophysics', 'Dalhousie University'] 1 \n",
      "\n",
      "\n",
      "University Hospital, Rouen [] 0 \n",
      "\n",
      "\n",
      "Fred Hutch/University of Washington Cancer Consortium ['Fred Hutchinson Cancer Research Center', 'WA', 'University of Washington', 'WA, USA'] 1 \n",
      "\n",
      "\n",
      "Frederiksberg University Hospital ['The Parker Institute', 'Department of Rheumatology', 'Copenhagen University Hospitals', 'Bispebjerg'] 1 \n",
      "\n",
      "\n",
      "Lithuanian University of Health Sciences ['Department of Skin', 'Lithuanian University of Health Sciences', 'Medical Academy'] 1 \n",
      "\n",
      "\n",
      "National Eye Institute (NEI) ['Neuron–Glia Interactions', 'National Eye Institute', 'National Institutes of Health'] 1 \n",
      "\n",
      "\n",
      "Showa Inan General Hospital ['Digestive Disease Center', 'Showa Inan General Hospital', 'Shinshu University Graduate School of Medicine'] 1 \n",
      "\n",
      "\n",
      "Department of Veterans Affairs, New Jersey ['Mental Health and Behavioral Sciences Service', 'Veterans Affairs', 'New Jersey Healthcare System'] 0 \n",
      "\n",
      "\n",
      "University of British Columbia ['Emergency Medicine', 'University of British Columbia Vancouver'] 1 \n",
      "\n",
      "\n",
      "Sun Yat-sen University ['Division of Gastrointestinal Surgery & Gastric Cancer Center', 'The First Affiliated Hospital'] 0 \n",
      "\n",
      "\n",
      "Wilmer Eye Institute - Johns Hopkins University School of Medicine ['Wilmer Eye Institute', 'Johns Hopkins University School of Medicine'] 1 \n",
      "\n",
      "\n",
      "Ascensia Diabetes Care ['the Wellcome Trust-Medical Research Council Institute of Metabolic Science', 'University of Cambridge', 'H.R.M.', 'Wolfson Diabetes', 'Cambridge University Hospitals NHS Foundation Trust', 'H.R.M.', 'the Elsie Bertram Diabetes Centre', 'R.C.T.', 'H.R.M.', 'the Department of Obstetrics and Gynaecology', 'K.P.S.', 'Norwich University Hospitals NHS Foundation Trust', 'the Norwich Medical School', 'University of East Anglia', 'H.R.M.', 'Ipswich Hospital NHS Trust', 'the Division of Epidemiology and Biostatistics, Leeds Institute of Cardiovascular', 'Metabolic Medicine', 'University of Leeds, Leeds', 'G.R.L.'] 0 \n",
      "\n",
      "\n",
      "Exempla Saint Joseph Hospital ['Department of Biological Sciences', 'School of Pharmacy and Biochemistry, University of Buenos Aires', 'IQUIFIB-CONICET'] 0 \n",
      "\n",
      "\n",
      "Martin-Luther-Universität Halle-Wittenberg ['Department of Gynaecology and Institute of Clinical Epidemiology', 'Martin Luther University', 'School of Public Health', 'Departments of Pathology and Gynaecology', 'Radiotherapy Center', 'School of Medicine', 'Addis Ababa University', 'Department of Epidemiology, School of Public Health', 'Boston University'] 0 \n",
      "\n",
      "\n",
      "Tehran University of Medical Sciences ['Endocrinology and Metabolism Research Center', 'Vali-Asr Hospital', 'School of Medicine', 'Tehran University of Medical Sciences'] 1 \n",
      "\n",
      "\n",
      "Singapore General Hospital ['Department of Respiratory and Critical Care Medicine', 'Singapore General Hospital'] 1 \n",
      "\n",
      "\n",
      "CleveMed Inc. also dba Great Lakes NeuroTechnologies ['Great Lakes NeuroTechnologies'] 0 \n",
      "\n",
      "\n",
      "Indiana University ['Department of Medicine', \"Women's Hospital\"] 0 \n",
      "\n",
      "\n",
      "Yale University ['Yale School of Medicine', 'Department of Psychiatry', 'CMHC', 'CT 06519'] 0 \n",
      "\n",
      "\n",
      "National Cancer Institute (NCI) ['Molecular Imaging Program', 'National Cancer Institute'] 1 \n",
      "\n",
      "\n",
      "University of Leicester ['Leicester Diabetes Centre', 'University of Leicester', 'Leicester'] 1 \n",
      "\n",
      "\n",
      "Cancer Institute and Hospital, Chinese Academy of Medical Sciences ['Department of Medical Oncology', 'Cancer Institute Hospital', 'Chinese Academy of Medical Sciences', 'Peking Union Medical College', 'National Center', 'Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs'] 1 \n",
      "\n",
      "\n",
      "SKCCC at JHMI ['Department of Pharmaceutical Sciences', 'Hampton University'] 0 \n",
      "\n",
      "\n",
      "Lawson Health Research Institute ['Curtin Health Innovation Research Institute', 'Curtin University'] 1 \n",
      "\n",
      "\n",
      "Mahidol University ['Department of Anesthesiology, Faculty of Medicine Siriraj Hospital', 'Mahidol University'] 1 \n",
      "\n",
      "\n",
      "National Medical Center, Seoul ['Department of Anesthesiology and Pain Medicine', 'Seoul National University Bundang Hospital'] 0 \n",
      "\n",
      "\n",
      "Peking University Third Hospital ['Nuclear Physics and Technology', 'Peking University'] 1 \n",
      "\n",
      "\n",
      "London School of Hygiene and Tropical Medicine ['London School of Hygiene and Tropical Medicine'] 1 \n",
      "\n",
      "\n",
      "Johann Wolfgang Goethe University Hospital ['Division of Vascular Medicine', 'Department of Internal Medicine', 'Goethe University Hospital', 'Frankfurt/Main'] 1 \n",
      "\n",
      "\n",
      "Emory University ['Rollins School of Public Health, Emory University'] 1 \n",
      "\n",
      "\n",
      "Poudre Valley Health System ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] 0 \n",
      "\n",
      "\n",
      "Roswell Park Cancer Institute ['Division of Hematology and Oncology, University of Kansas Medical Center']1 \n",
      "\n",
      "\n",
      "Catholic University of the Sacred Heart ['Department of Obstetrics and Gynecology'] 0 \n",
      "\n",
      "\n",
      "University of Glasgow ['Faculty of Medicine', 'University of Glasgow', 'Yorkhill Hospital'] 1 \n",
      "\n",
      "\n",
      "University of Mississippi Medical Center ['Department of Pediatrics, University of Mississippi Medical Center', 'MS'] 1 \n",
      "\n",
      "\n",
      "Chinese PLA General Hospital ['Institute of Basic Medicine Science, College of Life Science'] 0 \n",
      "\n",
      "\n",
      "University of Utah ['University of Utah'] 1 \n",
      "\n",
      "\n",
      "Peterborough and Stamford Hospitals NHS Foundation Trust ['Department of Molecular and Human Genetics', 'Baylor College of Medicine', 'TX 77030'] 0 \n",
      "\n",
      "\n",
      "Lund University Hospital, Department of Oncology ['Department of Oncology and Radiation Physics', 'Skåne University Hospital', 'Lund University'] 1 \n",
      "\n",
      "\n",
      "University Hospital Rijeka ['Department of Internal', 'Division of Gastroenterology', 'University Hospital Center Rijeka'] 1 \n",
      "\n",
      "\n",
      "Xiamen University ['Division of Gastrointestinal Surgery & Gastric Cancer Center', 'The First Affiliated Hospital'] 0 \n",
      "\n",
      "\n",
      "NYU Silver School of Social Work ['Silver School of Social Work', 'New York University', 'NY 10003', 'The Brown School', 'Washington University'] 1 \n",
      "\n",
      "\n",
      "H. Lee Moffitt Cancer Center and Research Institute ['Moffitt Cancer Center'] 0 \n",
      "\n",
      "\n",
      "Hospital Regional de Alta Especialidad del Bajio ['Pediatric Endocrinology Department Research Department', 'Hospital Regional de Alta Especialidad del Bajío'] 1 \n",
      "\n",
      "\n",
      "Inje University Sangye Paik Hospital, ['Nuclear Physics and Technology', 'Peking University'] 1 \n",
      "\n",
      "\n",
      "Helsinki University ['Department of Ecological and Environmental Sciences', 'University of Helsinki'] 1 \n",
      "\n",
      "\n",
      "University of Wisconsin, Madison ['the Center for Tobacco Research and Intervention', 'the Department of Medicine', 'University of Wisconsin School of Medicine and Public Health'] 1 \n",
      "\n",
      "\n",
      "Wuhan General Hospital of Guangzhou Military Command ['Department of Endocrinology, Wuhan General Hospital of Guangzhou Command'] 1 \n",
      "\n",
      "\n",
      "Mayo Clinic ['Mayo Clinic', 'MN 55905'] 1 \n",
      "\n",
      "\n",
      "New York Institute of Technology ['Department of Osteopathic Medicine', 'College of Osteopathic Medicine', 'New York Institute of Technology', 'NYITCOM'] 1 \n",
      "\n",
      "\n",
      "Children's Hospital of Philadelphia [\"Children's Hospital of Philadelphia, USA\", 'Fox Chase', 'Center/Temple University Health System'] 1 \n",
      "\n",
      "\n",
      "Azienda Ospedaliera S. Maria della Misericordia ['Department of Anesthesia', 'Intensive Care', 'the University of Udine'] 0 \n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Mayo Clinic ['Prosserman Centre for Health Research', 'Lunenfeld-Tanenbaum Research Institute', 'Mount Sinai Hospital'] 0 \n",
      "\n",
      "\n",
      "First Affiliated Hospital Xi'an Jiaotong University ['Department of General Surgery', 'First Affiliated Hospital of Medical College', \"Xi'an Jiao-Tong University\"] 1 \n",
      "\n",
      "\n",
      "Albert Einstein College of Medicine ['Department of Oncology', 'Montefiore Medical Center/Albert Einstein College of Medicine'] 0 \n",
      "\n",
      "\n",
      "Lahey Hospital & Medical Center ['Department of Neurosurgery, Lahey Clinic Medical Center'] 0 \n",
      "\n",
      "\n",
      "Tri-Service General Hospital ['Department of Central Laboratory', 'Xuan Wu Hospital of Capital Medical University'] 1 \n",
      "\n",
      "\n",
      "University of California, San Francisco ['Institut', 'Abbe School of Photonics', 'Max-Wien'] 0 \n",
      "\n",
      "\n",
      "University Hospital, Basel, Switzerland ['Department for Anesthesia, Surgical Intensive Care', 'Prehospital Emergency Medicine', 'Pain Therapy', 'University Hospital Basel'] 1 \n",
      "\n",
      "\n",
      "Cancer Institute and Hospital, Chinese Academy of Medical Sciences ['Chinese Academy of Medical Sciences & Peking Union Medical College', 'Cancer Hospital'] 1 \n",
      "\n",
      "\n",
      "Baylor College of Medicine ['Department of Pediatrics, Section of Neonatology', \"Texas Children's Hospital\", 'Baylor College of Medicine'] 1 \n",
      "\n",
      "\n",
      "Temple University ['Department of Medicine, Center for Obesity Research and Education', 'Temple University School of Medicine', 'PA'] 1 \n",
      "\n",
      "\n",
      "Alder Hey Children's NHS Foundation Trust ['Mount Vernon Cancer Centre', 'Northwood', 'Middlesex'] 0 \n",
      "\n",
      "\n",
      "Portsmouth Hospitals NHS Trust ['Department of Pharmacognosy, School of Pharmacy', 'Trinity College Dublin'] 0 \n",
      "\n",
      "\n",
      "University of Wisconsin, Madison ['University of Wisconsin Carbone Cancer Center', 'WI'] 1 \n",
      "\n",
      "\n",
      "Beirut Eye Specialist Hospital ['Beirut Eye Specialist Hospital'] 1 \n",
      "\n",
      "\n",
      "New Hope Fertility Center ['Department of Obstetrics and Gynecology, Division of Reproductive Biology', 'New York University School of Medicine'] 0 \n",
      "\n",
      "\n",
      "Johns Hopkins University ['Division of Pediatric Emergency Medicine', 'University of Utah', 'UT'] 1 \n",
      "\n",
      "\n",
      "Hospital Italiano de Buenos Aires ['Unidad de Terapia Intensiva de Adultos'] 0 \n",
      "\n",
      "\n",
      "University of Vienna ['University of Basel'] 1 \n",
      "\n",
      "\n",
      "Na Homolce Hospital ['Cardiology Department', 'Na Homolce Hospital'] 1 \n",
      "\n",
      "\n",
      "Nanjing Children's Hospital ['Rubber Research Institute', 'Chinese Academy of Tropical Agricultural Sciences', 'CATAS'] 0 \n",
      "\n",
      "\n",
      "Chinese PLA General Hospital ['Department of Respiratory Medicine', \"Chinese People's Liberation Army General Hospital\"] 1 \n",
      "\n",
      "\n",
      "Stanford University ['Department of Psychiatry and Behavioral Sciences', 'Stanford University School of Medicine', 'Stanford'] 1 \n",
      "\n",
      "\n",
      "University of Michigan [] 0 \n",
      "\n",
      "\n",
      "Region Örebro County ['the Institute of Biomedicine, Department of Infectious Diseases , University of Gothenburg'] 0 \n",
      "\n",
      "\n",
      "Cairo University ['rue Henri Huchard'] 0 \n",
      "\n",
      "\n",
      "Royal Brisbane and Women's Hospital ['Nuclear Physics and Technology', 'Peking University'] 0 \n",
      "\n",
      "\n",
      "Clinical Nutrition Research Centre, Singapore ['Clinical Nutrition Research Centre', 'Centre for Translational Medicine', 'Yong Loo Lin School of Medicine', 'Singapore Institute for Clinical Sciences', 'Science, Technology and Research', 'A*STAR'] 0 \n",
      "\n",
      "\n",
      "University of Colorado, Denver ['Department of International Health', 'Johns Hopkins Bloomberg School of Public Health'] 0 \n",
      "\n",
      "\n",
      "Topcon Medical Systems, Inc. ['Division of Hematology, Department of Internal Medicine', 'Chang Gung Memorial Hospital-Kaohsiung Medical Center', 'Chang Gung University College of Medicine Kaohsiung'] 0 \n",
      "\n",
      "\n",
      "McMaster University ['Department of Kinesiology', 'Brock University'] 1 \n",
      "\n",
      "\n",
      "University Hospitals Leuven, Dept. of Gastroenterology ['Department of Gastroenterology, Academic Medical Center'] 0 \n",
      "\n",
      "\n",
      "M.D. Anderson Cancer Center ['The University of Texas MD Anderson Cancer Center'] 0 \n",
      "\n",
      "\n",
      "Northwestern University ['Department of Pediatrics', 'UC Davis School of Medicine'] 0 \n",
      "\n",
      "\n",
      "Hospital Erasto Gaertner ['Department of Gynecology, Vita Batel Hospital', 'Curitiba, Paraná'] 1 \n",
      "\n",
      "\n",
      "Fundación de Investigación Biomédica - Hospital Universitario de La Princesa ['Department of Gastroenterology, Hospital Universitario de La Princesa', 'Instituto de Investigación'] 1 \n",
      "\n",
      "\n",
      "Study Principal Investigator ChangGungMH ['Chinese Academy of Medical Sciences'] 0 \n",
      "\n",
      "\n",
      "Kyungpook National University ['Sang Yoon Jeon', 'Department of Anesthesiology and Pain Medicine', 'Haeundae Paik Hospital', 'Inje University'] 1 \n",
      "\n",
      "\n",
      "Fudan University ['Department of Medical Oncology', 'Fudan University Shanghai Cancer Center', 'Department of Oncology', 'Shanghai Medical College', 'Fudan University'] 1 \n",
      "\n",
      "\n",
      "University of South Florida ['College of Medicine', 'University of South Florida'] 1 \n",
      "\n",
      "\n",
      "Bronx VA Medical Center ['Icahn School of Medicine at Mount Sinai', 'Department of Rehabilitation Medicine'] 0 \n",
      "\n",
      "\n",
      "University of Iowa ['Department of Epidemiology, University of Iowa'] 1 \n",
      "\n",
      "\n",
      "The Royal Wolverhampton NHS Trust ['Deansley Centre', 'Royal Wolverhampton Hospital'] 0 \n",
      "\n",
      "\n",
      "Shanghai Chest Hospital ['Department of Medicine', 'Johns Hopkins University School of Medicine'] 0 \n",
      "\n",
      "\n",
      "Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi ['Division of Neonatology, Department of Pediatrics'] 0 \n",
      "\n",
      "\n",
      "Pope Research Corp. ['Division of Rheumatology, Department of Medicine', 'The University of Western Ontario'] 0 \n",
      "\n",
      "\n",
      "Paracelsus Medical University ['Klinik'] 0 \n",
      "\n",
      "\n",
      "Cleveland Clinic, Case Comprehensive Cancer Center ['Cleveland Clinic Foundation'] 0 \n",
      "\n",
      "\n",
      "National Taiwan University Hospital ['Department of Pharmacy', 'National Taiwan University Hospital', 'Graduate Institute of Clinical Pharmacy', 'National Taiwan University'] 1 \n",
      "\n",
      "\n",
      "Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center ['Thomas Jefferson University Medical College'] 1 \n",
      "\n",
      "\n",
      "Pusan National University Hospital ['Department of Nuclear Medicine', 'Department of Internal Medicine Medical Research Institute', 'Pusan National University Hospital', 'Pusan National University'] 1 \n",
      "\n",
      "\n",
      "UNC-CH ['Center for Health Services and Society', 'University of California', 'Los Angeles Institute for Neuroscience and Human Behavior'] 0 \n",
      "\n",
      "\n",
      "University of Miami ['Department of Kinesiology and Sport Sciences', 'School of Education & Human Development', 'University of Miami', 'Coral Gables', 'Center on Aging, Miller School of Medicine', 'N.W. 9th Avenue', 'Suite 3204'] 1 \n",
      "\n",
      "\n",
      "Showa Inan General Hospital ['Digestive Disease Center', 'Showa Inan General Hospital', 'Shinshu University Graduate School of Medicine'] 1 \n",
      "\n",
      "\n",
      "Medical University of South Carolina ['Division of Gastroenterology, Department of Internal Medicine', 'University of Michigan Health System', 'Taubman Center', 'MI'] 1 \n",
      "\n",
      "\n",
      "Duke University ['University of KwaZulu-Natal', 'Nelson R. Mandela School of Medicine', 'KwaZulu-Natal Department of Health'] 1 \n",
      "\n",
      "\n",
      "UMC Utrecht ['Imaging Division', 'University Medical Centre Utrecht'] 0 \n",
      "\n",
      "\n",
      "Moscow Clinical Scientific Center ['Moscow Clinical Scientific Centre', 'Central Scientific Research Institute of Gastroenterology'] 1 \n",
      "\n",
      "\n",
      "University Hospital of Poitiers, Department of Cardiology ['Cardiology Department', 'CHU Poitiers', 'Poitiers'] 0 \n",
      "\n",
      "\n",
      "Cairo University ['Department of Obstetrics & Gynecology'] 0 \n",
      "\n",
      "\n",
      "University of Colorado, Denver ['Department of Health and Exercise Science', 'Colorado State University'] 1 \n",
      "\n",
      "\n",
      "Dallas VAMC ['University of Alabama'] 0 \n",
      "\n",
      "\n",
      "Loughborough University ['Health Sciences', 'Loughborough University', 'Loughborough'] 1 \n",
      "\n",
      "\n",
      "St. Jude Children's Research Hospital ['University of Florida', 'Kirsten K. Ness', \"St Jude Children's Research Hospital\"] 1 \n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "lista = df['ct_organization'].tolist()\n",
    "lista1 = df['ar_organization'].tolist()\n",
    "lista2 = df['organization_type_equality'].tolist()\n",
    "\n",
    "for i in range(len(lista)):\n",
    "    if lista1[i] is not None:\n",
    "        print(lista[i], lista1[i], lista2[i], '\\n\\n')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
